(12) STANDARD PATENT (11) Application No. **AU 2018358051 B2**
(19) AUSTRALIAN PATENT OFFICE

(54) Title
CasZ compositions and methods of use

(51) International Patent Classification(s)
C12N 9/22 (2006.01) ***C12Q 1/6816*** (2018.01)
C12Q 1/6809 (2018.01)

(21) Application No: **2018358051** (22) Date of Filing: **2018.10.31**

(87) WIPO No: **WO19/089820**

(30) Priority Data

(31) Number	(32) Date	(33) Country
62/580,395	**2017.11.01**	**US**

(43) Publication Date: **2019.05.09**
(44) Accepted Journal Date: **2025.01.09**

(71) Applicant(s)
The Regents of The University of California

(72) Inventor(s)
DOUDNA, Jennifer A.;BURSTEIN, David;CHEN, Janice S.;HARRINGTON, Lucas B.;PAEZ-ESPINO, David;BANFIELD, Jillian F.

(74) Agent / Attorney
FB Rice Pty Ltd, L 33 477 Collins Street, Melbourne, VIC, 3000, AU

(56) Related Art
SERGEY SHMAKOV ET AL: "Diversity and evolution of class 2 CRISPR-Cas systems", NATURE REVIEWS MICROBIOLOGY, vol. 15, no. 3, 30 March 2017 (2017-03-30), GB, pages 169 - 182, XP055718298, ISSN: 1740-1526, DOI: 10.1038/nrmicro.2016.184

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
09 May 2019 (09.05.2019)

WIPO | PCT

(10) International Publication Number
WO 2019/089820 A1

(51) International Patent Classification:
C12N 9/22 (2006.01) *C12Q 1/6816* (2018.01)
C12Q 1/6809 (2018.01)

(21) International Application Number:
PCT/US2018/058545

(22) International Filing Date:
31 October 2018 (31.10.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/580,395 01 November 2017 (01.11.2017) US

(71) Applicant: **THE REGENTS OF THE UNIVERSITY OF CALIFORNIA** [US/US]; 1111 Franklin Street, 12th Floor, Oakland, California 94607 (US).

(72) Inventors: **DOUDNA, Jennifer A.**; 164 Vicente Road, Berkeley, California 94705 (US). **BURSTEIN, David**; 2151 Berkeley Way, Berkeley, California 94720 (US). **CHEN, Janice S.**; 731 Stanley Hall, MS # 3220, Berkeley, California 94720 (US). **HARRINGTON, Lucas B.**; 731 Stanley Hall, MS # 3220, Berkeley, California 94720 (US). **PAEZ-ESPINO, David**; 2800 Mitchell Drive, Walnut Creek, California 94598 (US). **BANFIELD, Jillian F.**; 160 Hill Road, Berkeley, California 94708 (US).

(74) Agent: **BORDEN, Paula A.**; 201 Redwood Shores Parkway, Suite 200, Redwood City, California 94065 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

(54) Title: CASZ COMPOSITIONS AND METHODS OF USE

FIG. 2

	#	Cas1	Organism	Locus example
Za	5	I-B	DPANN	508aa Cas1 2 4 CasZa
Zb	7	I-B	DPANN	538aa Cas1 2 4 CasZb
Zc	5	I-B	DPANN	614aa CasZc Cas1 2 4
Zd	1	I-B	DPANN	518aa Cas1 2 4 CasZd
Ze	4	III-D*	CPR	650aa CasZe Cas1
Zf	3	III-D	CPR	415aa CasZf Cas1
Zg	1	I-E	Phage?	712aa CasZg Cas1 2
Zh	1	II-C	MGE	401aa CasZh Tmsp Cas1 2
Zi	1	I-U	Plancto	744aa Cas4+1 2 CasZi

(57) Abstract: Provided are compositions and methods that include one or more of: (1) a "CasZ" protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a "CasZ trancRNA"), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

WO 2019/089820 A1

[Continued on next page]

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

CASZ COMPOSITIONS AND METHODS OF USE

CROSS-REFERENCE

[0001] This application claims the benefit of U.S. Provisional Patent Application No. 62/580,395, filed November 1, 2017, which application is incorporated herein by reference in its entirety.

INCORPORATION BY REFERENCE OF SEQUENCE LISTING PROVIDED AS A TEXT FILE

[0002] A Sequence Listing is provided herewith as a text file, "BERK-374WO_SEQ_LISTING_ST25.txt" created on October 30, 2018 and having a size of 536 KB. The contents of the text file are incorporated by reference herein in their entirety.

INTRODUCTION

[0003] The CRISPR-Cas system, an example of a pathway that was unknown to science prior to the DNA sequencing era, is now understood to confer bacteria and archaea with acquired immunity against phage and viruses. Intensive research has uncovered the biochemistry of this system. CRISPR-Cas systems consist of Cas proteins, which are involved in acquisition, targeting and cleavage of foreign DNA or RNA, and a CRISPR array, which includes direct repeats flanking short spacer sequences that guide Cas proteins to their targets. Class 2 CRISPR-Cas are streamlined versions in which a single Cas protein bound to RNA is responsible for binding to and cleavage of a targeted sequence. The programmable nature of these minimal systems has facilitated their use as a versatile technology that is revolutionizing the field of genome manipulation.

SUMMARY

[0004] The present disclosure provides compositions and methods that include one or more of: (1) a "CasZ" protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a "CasZ trancRNA"), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

[0004A] In one embodiment the present disclosure provides a method of modifying a target nucleic acid, the method comprising contacting the target nucleic acid with:

(a) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, wherein the guide RNA comprises (i) a guide sequence that hybridizes to a target sequence of the target nucleic acid, and (ii) a region that is bound by the polypeptide.

[0004B] In another embodiment the present disclosure provides a composition comprising an engineered and/or non-naturally occurring complex comprising:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, or a nucleic acid encoding said guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide.

[0004C] In another embodiment the present disclosure provides a kit comprising an engineered and/or non-naturally occurring complex comprising:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27;

(b) a guide RNA, or a nucleic acid encoding said CasZ guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide.

[0004D] In another embodiment the present disclosure provides a genetically modified eukaryotic cell, comprising at least one of:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, or a nucleic acid encoding said guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide; and optionally

(c) a transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said trancRNA.

[0004E] In another embodiment the present disclosure provides a method of detecting a target DNA in a sample, the method comprising:

(a) contacting the sample with:

(i) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27;

(ii) a guide RNA comprising: a region that is bound by polypeptide, and a guide sequence that hybridizes with the target DNA; and

(iii) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA; and

(b) measuring a detectable signal produced by cleavage of the single stranded detector DNA by the , thereby detecting the target DNA.

[0004F] In another embodiment the present disclosure provides a kit for detecting a target DNA in a sample, the kit comprising:

(a) a guide RNA, or a nucleic acid encoding the guide RNA; wherein the guide RNA comprises: a region that is bound by a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27, and a guide sequence that is complementary to a target DNA; and

(b) a labeled detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA.

[0004G] In another embodiment the present disclosure provides a method of cleaving single stranded DNAs (ssDNAs), the method comprising:

contacting a population of nucleic acids, wherein said population comprises a target DNA and a plurality of non-target ssDNAs, with:

(i) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(ii) a guide RNA comprising: a region that is bound by the polypeptide, and a guide sequence that hybridizes with the target DNA,

wherein the polypeptide cleaves non-target ssDNAs of said plurality.

[0004H] Throughout this specification, except where the context implies or requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be understood to imply the inclusion of a stated element or feature, but not to preclude the presence of any further element or feature.

BRIEF DESCRIPTION OF THE DRAWINGS

[0005] **Figure 1** depicts examples of naturally occurring CasZ protein sequences.

[0006] **Figure 2** depicts schematic representations of CasZ loci, which include a Cas1 protein in addition to the CasZ protein.

[0007] **Figure 3** depicts a phylogenetic tree of CasZ sequences in relation to other Class 2 CRISPR/Cas effector protein sequences.

[0008] **Figure 4** depicts a phylogenetic tree of Cas1 sequences from CasZ loci in relation to Cas1 sequences from other Class 2 CRISPR/Cas loci.

[0009] **Figure 5** depicts transcriptomic RNA mapping data demonstrating expression of trancRNA from CasZ loci. The trancRNAs are adjacent to the CasZ repeat array, but do not include the repeat sequence and are not complementary to the repeat sequence. Shown are RNA mapping data for the following loci: CasZa3, CasZb4, CasZc5, CasZd1, and CasZe3. Small repeating aligned arrows represent the repeats of the CRISPR array (indicating the presence of guide RNA-encoding sequence); The peaks outside and adjacent to the repeat arrays represent highly transcribed trancRNAs. Figure 5 (Cont. 1) nucleotide sequences (Top to Bottom: SEQ ID NOs.:312-331). Figure 5 (Cont. 3) nucleotide sequences (Top to Bottom: SEQ ID Nos.:161-177).

[0010] **Figure 6** depicts results for PAM preferences as assayed using PAM depletion assays for CasZc (top) and CasZb (bottom).

[0011] **Figure 7** depict the sequences of Cas14 proteins described herein.

[0012] **Figure 8, Panels A-D** depict the architecture and phylogeny of CRISPR-Cas14 genomic loci.

[0013] **Figure 9** depicts a phylogenetic analysis of Cas14 orthologs.

[0014] **Figure 10** depicts a maximum likelihood tree for Cas1 from known CRISPR systems.

[0015] **Figure 11, Panels A-B** depict the acquisition of new spacers by CRISPR-Cas14 systems.

[0016] **Figure 12, Panels A-D** depict that CRISPR-Cas14a actively adapts and encodes a tracrRNA.

[0017] **Figure 13, Panels A-B** depict metatranscriptomics for CRISPR-Cas14 loci.

[0018] **Figure 14, Panels A-B** depict RNA processing and heterologous expression by CRISPR-Cas14.

[0019] **Figure 15, Panels A-D** depict plasmid depletion by Cas14a1 and SpCas9.

[0020] **Figure 16, Panels A-D** depict CRISPR-Cas14a is an RNA-guided DNA-endonuclease.

[0021] **Figure 17, Panels A-E** depict degradation of ssDNA by Cas14a1.

[0022] **Figure 18** depicts kinetics of Cas14a1 cleavage of ssDNA with various guide RNA components.

[0023] **Figure 19, Panels A-F** depict optimization of Cas14a1 guide RNA components.

[0024] **Figure 20, Panels A-E** depict high fidelity ssDNA DNP detection by CRISPR-Cas14a. Figure 20, panel C provides nucleotide sequences (Top to Bottom: SEQ ID NOs:367-370)

[0025] **Figure 21, Panels A-F** depict the impact of various activators on Cas14a1 cleavage rate.

[0026] **Figure 22, Panels A-B** depict diversity of CRISPR-Cas14 systems.

[0027] **Figure 23, Panels A-C** depict a test of Cas14a1 mediated interference in a heterologous host. Diagram of Cas14a1 and LbCas12a constructs to test interference in *E. coli*.

[0028] **Figure 24** depicts Cas14 nucleotide sequences of plasmids used in the present invention.

[0029] **Figure 25, Panels A-E** depict a sequence map of each of the plasmids disclosed in Figure 24.

DEFINITIONS

[0030] "Heterologous," as used herein, means a nucleotide or polypeptide sequence that is not found in the native nucleic acid or protein, respectively. For example, relative to a CasZ polypeptide, a heterologous polypeptide comprises an amino acid sequence from a protein other than the CasZ polypeptide. In some cases, a portion of a CasZ protein from one species is fused to a portion of a CasZ protein from a different species. The CasZ sequence from each species could therefore be considered heterologous relative to one another. As another example, a CasZ protein (e.g., a dCasZ protein) can be fused to an active domain from a non-CasZ protein (e.g., a histone deacetylase), and the sequence of the active domain could be considered a heterologous polypeptide (it is heterologous to the CasZ protein).

[0031] The terms "polynucleotide" and "nucleic acid," used interchangeably herein, refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxynucleotides. Thus, this term includes, but is not limited to, single-, double-, or multi-stranded DNA or RNA, genomic DNA, cDNA, DNA-RNA hybrids, or a polymer comprising purine and pyrimidine bases or other natural, chemically or biochemically modified, non-natural, or derivatized nucleotide bases. The terms "polynucleotide" and "nucleic acid" should be understood to include, as applicable to the embodiment being described, single-stranded (such as sense or antisense) and double-stranded polynucleotides.

[0032] The terms "polypeptide," "peptide," and "protein", are used interchangeably herein, refer to a polymeric form of amino acids of any length, which can include genetically coded and non-genetically coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides having modified peptide backbones. The term includes fusion proteins, including, but not limited to, fusion proteins with a heterologous amino acid sequence, fusions with heterologous and

homologous leader sequences, with or without N-terminal methionine residues; immunologically tagged proteins; and the like.

[0033] The term "naturally-occurring" as used herein as applied to a nucleic acid, a protein, a cell, or an organism, refers to a nucleic acid, cell, protein, or organism that is found in nature.

[0034] As used herein the term "isolated" is meant to describe a polynucleotide, a polypeptide, or a cell that is in an environment different from that in which the polynucleotide, the polypeptide, or the cell naturally occurs. An isolated genetically modified host cell may be present in a mixed population of genetically modified host cells.

[0035] As used herein, the term "exogenous nucleic acid" refers to a nucleic acid that is not normally or naturally found in and/or produced by a given bacterium, organism, or cell in nature. As used herein, the term "endogenous nucleic acid" refers to a nucleic acid that is normally found in and/or produced by a given bacterium, organism, or cell in nature. An "endogenous nucleic acid" is also referred to as a "native nucleic acid" or a nucleic acid that is "native" to a given bacterium, organism, or cell.

[0036] "Recombinant," as used herein, means that a particular nucleic acid (DNA or RNA) is the product of various combinations of cloning, restriction, and/or ligation steps resulting in a construct having a structural coding or non-coding sequence distinguishable from endogenous nucleic acids found in natural systems. Generally, DNA sequences encoding the structural coding sequence can be assembled from cDNA fragments and short oligonucleotide linkers, or from a series of synthetic oligonucleotides, to provide a synthetic nucleic acid which is capable of being expressed from a recombinant transcriptional unit contained in a cell or in a cell-free transcription and translation system. Such sequences can be provided in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, which are typically present in eukaryotic genes. Genomic DNA comprising the relevant sequences can also be used in the formation of a recombinant gene or transcriptional unit. Sequences of non-translated DNA may be present 5' or 3' from the open reading frame, where such sequences do not interfere with manipulation or expression of the coding regions, and may indeed act to modulate production of a desired product by various mechanisms (see "DNA regulatory sequences", below).

[0037] Thus, e.g., the term "recombinant" polynucleotide or "recombinant" nucleic acid refers to one which is not naturally occurring, e.g., is made by the artificial combination of two otherwise separated segments of sequence through human intervention. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. Such is usually done to replace a codon with a redundant codon encoding the same or a conservative amino acid, while typically introducing or

removing a sequence recognition site. Alternatively, it is performed to join together nucleic acid segments of desired functions to generate a desired combination of functions. This artificial combination is often accomplished by either chemical synthesis means, or by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques.

[0038] Similarly, the term "recombinant" polypeptide refers to a polypeptide which is not naturally occurring, e.g., is made by the artificial combination of two otherwise separated segments of amino sequence through human intervention. Thus, e.g., a polypeptide that comprises a heterologous amino acid sequence is recombinant.

[0039] By "construct" or "vector" is meant a recombinant nucleic acid, generally recombinant DNA, which has been generated for the purpose of the expression and/or propagation of a specific nucleotide sequence(s), or is to be used in the construction of other recombinant nucleotide sequences.

[0040] The terms "DNA regulatory sequences," "control elements," and "regulatory elements," used interchangeably herein, refer to transcriptional and translational control sequences, such as promoters, enhancers, polyadenylation signals, terminators, protein degradation signals, and the like, that provide for and/or regulate expression of a coding sequence and/or production of an encoded polypeptide in a host cell.

[0041] The term "transformation" is used interchangeably herein with "genetic modification" and refers to a permanent or transient genetic change induced in a cell following introduction of new nucleic acid (e.g., DNA exogenous to the cell) into the cell. Genetic change ("modification") can be accomplished either by incorporation of the new nucleic acid into the genome of the host cell, or by transient or stable maintenance of the new nucleic acid as an episomal element. Where the cell is a eukaryotic cell, a permanent genetic change is generally achieved by introduction of new DNA into the genome of the cell. In prokaryotic cells, permanent changes can be introduced into the chromosome or via extrachromosomal elements such as plasmids and expression vectors, which may contain one or more selectable markers to aid in their maintenance in the recombinant host cell. Suitable methods of genetic modification include viral infection, transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate precipitation, direct microinjection, and the like. The choice of method is generally dependent on the type of cell being transformed and the circumstances under which the transformation is taking place (i.e. *in vitro, ex vivo,* or *in vivo*). A general discussion of these methods can be found in Ausubel, et al, Short Protocols in Molecular Biology, 3rd ed., Wiley & Sons, 1995.

[0042] "Operably linked" refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. As used herein, the

terms "heterologous promoter" and "heterologous control regions" refer to promoters and other control regions that are not normally associated with a particular nucleic acid in nature. For example, a "transcriptional control region heterologous to a coding region" is a transcriptional control region that is not normally associated with the coding region in nature.

[0043] A "host cell," as used herein, denotes an *in vivo* or *in vitro* eukaryotic cell, a prokaryotic cell, or a cell from a multicellular organism (e.g., a cell line) cultured as a unicellular entity, which eukaryotic or prokaryotic cells can be, or have been, used as recipients for a nucleic acid (e.g., an expression vector), and include the progeny of the original cell which has been genetically modified by the nucleic acid. It is understood that the progeny of a single cell may not necessarily be completely identical in morphology or in genomic or total DNA complement as the original parent, due to natural, accidental, or deliberate mutation. A "recombinant host cell" (also referred to as a "genetically modified host cell") is a host cell into which has been introduced a heterologous nucleic acid, e.g., an expression vector. For example, a subject prokaryotic host cell is a genetically modified prokaryotic host cell (e.g., a bacterium), by virtue of introduction into a suitable prokaryotic host cell of a heterologous nucleic acid, e.g., an exogenous nucleic acid that is foreign to (not normally found in nature in) the prokaryotic host cell, or a recombinant nucleic acid that is not normally found in the prokaryotic host cell; and a subject eukaryotic host cell is a genetically modified eukaryotic host cell, by virtue of introduction into a suitable eukaryotic host cell of a heterologous nucleic acid, e.g., an exogenous nucleic acid that is foreign to the eukaryotic host cell, or a recombinant nucleic acid that is not normally found in the eukaryotic host cell.

[0044] The term "conservative amino acid substitution" refers to the interchangeability in proteins of amino acid residues having similar side chains. For example, a group of amino acids having aliphatic side chains consists of glycine, alanine, valine, leucine, and isoleucine; a group of amino acids having aliphatic-hydroxyl side chains consists of serine and threonine; a group of amino acids having amide-containing side chains consists of asparagine and glutamine; a group of amino acids having aromatic side chains consists of phenylalanine, tyrosine, and tryptophan; a group of amino acids having basic side chains consists of lysine, arginine, and histidine; and a group of amino acids having sulfur-containing side chains consists of cysteine and methionine. Exemplary conservative amino acid substitution groups are: valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, and asparagine-glutamine.

[0045] A polynucleotide or polypeptide has a certain percent "sequence identity" to another polynucleotide or polypeptide, meaning that, when aligned, that percentage of bases or amino acids are the same, and in the same relative position, when comparing the two sequences. Sequence similarity can be determined in a number of different manners. To determine sequence identity, sequences can be aligned using the methods and computer programs, including BLAST, available over the world wide web at ncbi.nlm.nih.gov/BLAST. See, e.g., Altschul *et al.* (1990), *J. Mol. Biol.* 215:403-10. Another

alignment algorithm is FASTA, available in the Genetics Computing Group (GCG) package, from Madison, Wisconsin, USA, a wholly owned subsidiary of Oxford Molecular Group, Inc. Other techniques for alignment are described in Methods in Enzymology, vol. 266: Computer Methods for Macromolecular Sequence Analysis (1996), ed. Doolittle, Academic Press, Inc., a division of Harcourt Brace & Co., San Diego, California, USA. Of particular interest are alignment programs that permit gaps in the sequence. The Smith-Waterman is one type of algorithm that permits gaps in sequence alignments. See *Meth. Mol. Biol.* 70: 173-187 (1997). Also, the GAP program using the Needleman and Wunsch alignment method can be utilized to align sequences. See *J. Mol. Biol.* 48: 443-453 (1970).

[0046] As used herein, the terms "treatment," "treating," and the like, refer to obtaining a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or symptom thereof and/or may be therapeutic in terms of a partial or complete cure for a disease and/or adverse effect attributable to the disease. "Treatment," as used herein, covers any treatment of a disease in a mammal, e.g., in a human, and includes: (a) preventing the disease from occurring in a subject which may be predisposed to the disease but has not yet been diagnosed as having it; (b) inhibiting the disease, i.e., arresting its development; and (c) relieving the disease, i.e., causing regression of the disease.

[0047] The terms "individual," "subject," "host," and "patient," used interchangeably herein, refer to an individual organism, e.g., a mammal, including, but not limited to, murines, simians, non-human primates, humans, mammalian farm animals, mammalian sport animals, and mammalian pets.

[0048] Before the present invention is further described, it is to be understood that this invention is not limited to particular embodiments described, as such may, of course, vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0049] Where a range of values is provided, it is understood that each intervening value, to the tenth of the unit of the lower limit unless the context clearly dictates otherwise, between the upper and lower limit of that range and any other stated or intervening value in that stated range, is encompassed within the invention. The upper and lower limits of these smaller ranges may independently be included in the smaller ranges, and are also encompassed within the invention, subject to any specifically excluded limit in the stated range. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.

[0050] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

Although any methods and materials similar or equivalent to those described herein can also be used in the practice or testing of the present invention, the preferred methods and materials are now described. All publications mentioned herein are incorporated herein by reference to disclose and describe the methods and/or materials in connection with which the publications are cited.

[0051] It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a CasZ polypeptide" includes a plurality of such polypeptides and reference to "the guide RNA" includes reference to one or more guide RNAs and equivalents thereof known to those skilled in the art, and so forth. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as "solely," "only" and the like in connection with the recitation of claim elements, or use of a "negative" limitation.

[0052] It is appreciated that certain features of the invention, which are, for clarity, described in the context of separate embodiments, may also be provided in combination in a single embodiment. Conversely, various features of the invention, which are, for brevity, described in the context of a single embodiment, may also be provided separately or in any suitable sub-combination. All combinations of the embodiments pertaining to the invention are specifically embraced by the present invention and are disclosed herein just as if each and every combination was individually and explicitly disclosed. In addition, all sub-combinations of the various embodiments and elements thereof are also specifically embraced by the present invention and are disclosed herein just as if each and every such sub-combination was individually and explicitly disclosed herein.

[0053] The publications discussed herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein is to be construed as an admission that the present invention is not entitled to antedate such publication by virtue of prior invention. Further, the dates of publication provided may be different from the actual publication dates which may need to be independently confirmed.

DETAILED DESCRIPTION

[0054] The present disclosure provides compositions and methods that include one or more of: (1) a "CasZ" protein (also referred to as a CasZ polypeptide), a nucleic acid encoding the CasZ protein, and/or a modified host cell comprising the CasZ protein (and/or a nucleic acid encoding the same); (2) a CasZ guide RNA that binds to and provides sequence specificity to the CasZ protein, a nucleic acid encoding the CasZ guide RNA, and/or a modified host cell comprising the CasZ guide RNA (and/or a nucleic acid encoding the same); and (3) a CasZ transactivating noncoding RNA (trancRNA) (referred to

herein as a "CasZ trancRNA"), a nucleic acid encoding the CasZ trancRNA, and/or a modified host cell comprising the CasZ trancRNA (and/or a nucleic acid encoding the same).

COMPOSITIONS

CRISPR/CASZ PROTEINS, GUIDE RNAS, AND TRANCRNAS

[0055] Class 2 CRISPR–Cas systems are characterized by effector modules that include a single multidomain protein. In the CasZ system, a CRISPR/Cas endonuclease (e.g., a CasZ protein) interacts with (binds to) a corresponding guide RNA (e.g., a CasZ guide RNA) to form a ribonucleoprotein (RNP) complex that is targeted to a particular site in a target nucleic acid via base pairing between the guide RNA and a target sequence within the target nucleic acid molecule. A guide RNA includes a nucleotide sequence (a guide sequence) that is complementary to a sequence (the target site) of a target nucleic acid. Thus, a CasZ protein forms a complex with a CasZ guide RNA and the guide RNA provides sequence specificity to the RNP complex via the guide sequence. The CasZ protein of the complex provides the site-specific activity. In other words, the CasZ protein is guided to a target site (e.g., stabilized at a target site) within a target nucleic acid (e.g. a target nucleotide sequence within a target chromosomal nucleic acid; or a target nucleotide sequence within a target extrachromosomal nucleic acid , e.g., an episomal nucleic acid, a minicircle nucleic acid, a mitochondrial nucleic acid, a chloroplast nucleic acid, etc.) by virtue of its association with the guide RNA.

[0056] The present disclosure provides compositions comprising a CasZ polypeptide (and/or a nucleic acid encoding the CasZ polypeptide) (e.g., where the CasZ polypeptide can be a naturally existing CasZ protein, a nickase CasZ protein, a dCasZ protein, a chimeric CasZ protein, etc.)(a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein). The present disclosure provides compositions comprising a CasZ guide RNA (and/or a nucleic acid encoding the CasZ guide RNA). For example, the present disclosure provides compositions comprising (a) a CasZ polypeptide (and/or a nucleic acid encoding the CasZ polypeptide) and (b) a CasZ guide RNA (and/or a nucleic acid encoding the CasZ guide RNA). The present disclosure provides a nucleic acid/protein complex (RNP complex) comprising: (a) a CasZ polypeptide; and (b) a CasZ guide RNA. The present disclosure provides compositions comprising a CasZ trancRNA. The present disclosure provides compositions comprising a CasZ trancRNA and one or more of: (a) a CasZ protein, and (b) a CasZ guide RNA (e.g., comprising a CasZ trancRNA and a CasZ protein, a CasZ trancRNA and a CasZ guide RNA, or a CasZ trancRNA and a CasZ protein and a CasZ guide RNA. The present disclosure provides a nucleic acid/protein complex (RNP complex) comprising: (a) a CasZ polypeptide; (b) a CasZ guide RNA; and (c) a CasZ trancRNA. The present disclosure provides compositions comprising a CasZ protein and one or more of: (a) a CasZ trancRNA, and (b) a CasZ guide RNA.

CasZ protein

[0057] A CasZ polypeptide (this term is used interchangeably with the term "CasZ protein", "Cas14", "Cas14 polypeptide", or "Cas14 protein") can bind and/or modify (e.g., cleave, nick, methylate, demethylate, etc.) a target nucleic acid and/or a polypeptide associated with target nucleic acid (e.g., methylation or acetylation of a histone tail) (e.g., in some cases the CasZ protein includes a fusion partner with an activity, and in some cases the CasZ protein provides nuclease activity). In some cases, the CasZ protein is a naturally-occurring protein (e.g., naturally occurs in prokaryotic cells). In other cases, the CasZ protein is not a naturally-occurring polypeptide (e.g., the CasZ protein is a variant CasZ protein, a chimeric protein, and the like). A CasZ protein includes 3 partial RuvC domains (RuvC-I, RuvC-II, and RuvC-III, also referred to herein as subdomains) that are not contiguous with respect to the primary amino acid sequence of the CasZ protein, but form a RuvC domain once the protein is produced and folds. A naturally occurring CasZ protein functions as an endonuclease that catalyzes cleavage at a specific sequence in a targeted nucleic acid (e.g., a double stranded DNA (dsDNA)). The sequence specificity is provided by the associated guide RNA, which hybridizes to a target sequence within the target DNA. The naturally occurring CasZ guide RNA is a crRNA, where the crRNA includes (i) a guide sequence that hybridizes to a target sequence in the target DNA and (ii) a protein binding segment that binds to the CasZ protein.

[0058] In some embodiments, the CasZ protein of the subject methods and/or compositions is (or is derived from) a naturally occurring (wild type) protein. Examples of naturally occurring CasZ proteins (e.g., CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZk, CasZl) are depicted in Figure 1. In some cases, a subject CasZ protein is a CasZa protein. In some cases, a subject CasZ protein is a CasZb protein. In some cases, a subject CasZ protein is a CasZc protein. In some cases, a subject CasZ protein is a CasZd protein. In some cases, a subject CasZ protein is a CasZe protein. In some cases, a subject CasZ protein is a CasZf protein. In some cases, a subject CasZ protein is a CasZg protein. In some cases, a subject CasZ protein is a CasZh protein. In some cases, a subject CasZ protein is a CasZi protein. In some cases, a subject CasZ protein is a CasZj protein. In some cases, a subject CasZ protein is a CasZk protein. In some cases, a subject CasZ protein is a CasZl protein. In some cases, a subject CasZ protein is a CasZe, CasZf, CasZg, or CasZh protein. In some cases, a subject CasZ protein is a CasZj, CasZk, or CasZl protein.

[0059] It is important to note that this newly discovered protein (CasZ) is short compared to previously identified CRISPR-Cas endonucleases, and thus use of this protein as an alternative provides the advantage that the nucleotide sequence encoding the protein is relatively short. This is useful, for example, in cases where a nucleic acid encoding the CasZ protein is desirable, e.g., in situations that employ a viral vector (e.g., an AAV vector), for delivery to a cell such as a eukaryotic cell (e.g.., mammalian cell, human cell, mouse cell, in vitro, ex vivo, in vivo) for research and/or clinical

applications. In addition, in their natural context, the CasZ-encoding DNA sequences are present in loci that also have a Cas1 protein.

[0060] In some cases, a subject CasZ protein has a length of 900 amino acids or less (e.g., 850 amino acids or less, 800 amino acids or less, 750 amino acids or less, or 700 amino acids or less). In some cases, a subject CasZ protein has a length of 850 amino acids or less (e.g., 850 amino acids or less). In some cases, a subject CasZ protein length of 800 amino acids or less (e.g., 750 amino acids or less). In some cases, a subject CasZ protein has a length of 700 amino acids or less. In some cases, a subject CasZ protein has a length of 650 amino acids or less.

[0061] In some cases, a subject CasZ protein has a length in a range of from 350-900 amino acids (e.g., 350-850, 350-800, 350-750, 350-700, 400-900, 400-850, 400-800, 400-750, or 400-700 amino acids).

[0062] In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 350-750 amino acids (e.g., 350-700, 350-550, 450-550, 450-750, 450-650, or 450-550 amino acids). In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 450-750 amino acids (e.g., 500-700 amino acids). In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 350-700 amino acids (e.g., 350-650, 350-600, or 350-550 amino acids). In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 500-700 amino acids. In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 450-550 amino acids. In some cases, a subject CasZ protein (e.g., CasZa) has a length in a range of from 350-550 amino acids.

[0063] In some cases, a subject CasZ protein (e.g., CasZb) has a length in a range of from 350-700 amino acids (e.g., 350-650, or 350-620 amino acids). In some cases, a subject CasZ protein (e.g., CasZb) has a length in a range of from 450-700 amino acids (e.g., 450-650, 500-650 or 500-620 amino acids). In some cases, a subject CasZ protein (e.g., CasZb) has a length in a range of from 500-650 amino acids (e.g., 500-620 amino acids). In some cases, a subject CasZ protein (e.g., CasZb) has a length in a range of from 500-620 amino acids.

[0064] In some cases, a subject CasZ protein (e.g., CasZc) has a length in a range of from 600-800 amino acids (e.g., 600-650 or 700-800 amino acids). In some cases, a subject CasZ protein (e.g., CasZc) has a length in a range of from 600-650 amino acids. In some cases, a subject CasZ protein (e.g., CasZc) has a length in a range of from 700-800 amino acids.

[0065] In some cases, a subject CasZ protein (e.g., CasZd) has a length in a range of from 400-650 amino acids (e.g., 400-600, 400-550, 500-650, 500-600 or 500-550 amino acids). In some cases, a subject CasZ protein (e.g., CasZd) has a length in a range of from 500-600 amino acids. In some cases, a subject CasZ protein (e.g., CasZd) has a length in a range of from 500-550 amino acids. In some cases, a subject CasZ protein (e.g., CasZd) has a length in a range of from 400-550 amino acids.

[0066] In some cases, a subject CasZ protein (e.g., CasZe) has a length in a range of from 450-700 amino acids (e.g., 450--650, 450-615, 475-700, 475-650, or 475-615 amino acids). In some cases, a subject CasZ protein (e.g., CasZe) has a length in a range of from 450-675 amino acids. In some cases, a subject CasZ protein (e.g., CasZe) has a length in a range of from 475-675 amino acids.

[0067] In some cases, a subject CasZ protein (e.g., CasZf) has a length in a range of from 400-550 amino acids (e.g., 400-520, 400-500, 400-475, 415-550, 415-520, 415-500, or 415-475 amino acids). In some cases, a subject CasZ protein (e.g., CasZf) has a length in a range of from 400-475 amino acids (e.g., 400-450 amino acids).

[0068] In some cases, a subject CasZ protein (e.g., CasZg) has a length in a range of from 500-750 amino acids (e.g., 550-750 or 500-700 amino acids). In some cases, a subject CasZ protein (e.g., CasZg) has a length in a range of from 700-750 amino acids. In some cases, a subject CasZ protein (e.g., CasZg) has a length in a range of from 550-600 amino acids.

[0069] In some cases, a subject CasZ protein (e.g., CasZh) has a length in a range of from 380-450 amino acids (e.g., 380-420, 400-450, or 400-420 amino acids). In some cases, a subject CasZ protein (e.g., CasZh) has a length in a range of from 400-420 amino acids.

[0070] In some cases, a subject CasZ protein (e.g., CasZi) has a length in a range of from 700-800 amino acids (e.g., 700-750, 720-800, or 720-750 amino acids). In some cases, a subject CasZ protein (e.g., CasZi) has a length in a range of from 720-780 amino acids.

[0071] In some cases, a subject CasZ protein (e.g., CasZj) has a length in a range of from 600-750 amino acids (e.g., 600-700 or 650-700 amino acids). In some cases, a subject CasZ protein (e.g., CasZj) has a length in a range of from 400-420 amino acids.

[0072] In some cases, a subject CasZ protein (e.g., CasZk) has a length in a range of from 450-600 amino acids (e.g., 450-580, 480-600, 480-580, or 500-600 amino acids). In some cases, a subject CasZ protein (e.g., CasZk) has a length in a range of from 480-580 amino acids.

[0073] In some cases, a subject CasZ protein (e.g., CasZl) has a length in a range of from 350-500 amino acids (e.g., 350-450, 380-450, 350-420, or 380-420 amino acids). In some cases a subject CasZ protein (e.g., CasZl) has a length in a range of from 380-420 amino acids.

[0074] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity)

with a CasZa protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZa amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZa amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes one or more amino acid substitutions (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa protein of Figure 1 or Figure 7 and has a length in a range of from 350-800 amino acids (e.g., 350-800, 350-750, 350-700, 350-550, 450-550, 450-750, 450-650, or 450-550 amino acids).

[0075] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZb protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZb protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZb protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZb protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZb amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZb amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more,

99% or more, or 100% sequence identity) with a CasZb protein of Figure 1 or Figure 7 and has a length in a range of from 350-700 amino acids (e.g., 350-650, or 350-620 amino acids).

[0076] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZc protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZc protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZc protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZc protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZc amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZc amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZc protein of Figure 1 or Figure 7 and has a length in a range of from 600-800 amino acids (e.g., 600-650 or 700-800 amino acids).

[0077] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZd protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZd protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZd protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence

identity) with a CasZd protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZd amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZd amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZd protein of Figure 1 or Figure 7 and has a length in a range of from 400-650 amino acids (e.g., 400-600, 400-550, 500-650, 500-600 or 500-550 amino acids).

[0078] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZe amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZe amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe protein of Figure 1 or Figure 7 and has a length in a range of from 450-700 amino acids (e.g., 450--650, 450-615, 475-700, 475-650, or 475-615 amino acids).

[0079] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or

more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZf protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZf protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZf protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZf protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZf amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZf amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZf protein of Figure 1 or Figure 7 and has a length in a range of from 400-750 amino acids (e.g., 400-700, 700-650, 400-620, 400-600, 400-550, 400-520, 400-500, 400-475, 415-550, 415-520, 415-500, or 415-475 amino acids).

[0080] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZg protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZg protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZg protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZg protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZg amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZg amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring

catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZg protein of Figure 1 or Figure 7 and has a length in a range of from 500-750 amino acids (e.g., 500-750 amino acids (e.g., 550-750 amino acids)).

[0081] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZh protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZh amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZh amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZh protein of Figure 1 or Figure 7 and has a length in a range of from 380-450 amino acids (e.g., 380-420, 400-450, or 400-420 amino acids).

[0082] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZi protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZi protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more,

97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZi protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZi protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZi amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZi amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZi protein of Figure 1 or Figure 7 and has a length in a range of from 700-800 amino acids (e.g., 700-750, 720-800, or 720-750 amino acids).

[0083] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZj protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZj protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZj protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZj protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZj amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZj amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZj protein of Figure 1 or Figure 7 and has a length in a range of from 600-750 amino acids (e.g., 600-700 or 650-700 amino acids).

[0084] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or

more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZk protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZk protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZk protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZk protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZk amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZk amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZk protein of Figure 1 or Figure 7 and has a length in a range of from 450-600 amino acids (e.g., 450-580, 480-600, 480-580, or 500-600 amino acids).

[0085] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZl protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZl amino acid sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes a CasZl amino acid sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring

catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions)(e.g., in some cases such that the CasZ protein is a dCasZ). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZl protein of Figure 1 or Figure 7 and has a length in a range of from 450-600 amino acids (e.g., 450-580, 480-600, 480-580, or 500-600 amino acids).

[0086] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe, CasZf, CasZg, or CasZh protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe, CasZf, CasZg, or CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe, CasZf, CasZg, or CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe, CasZf, CasZg, or CasZh protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having a CasZe, CasZf, CasZg, or CasZh protein sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having a CasZe, CasZf, CasZg, or CasZh protein sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZe, CasZf, CasZg, or CasZh protein of Figure 1 or Figure 7 and has a length in a range of from 350-900 amino acids (e.g., 350-850, 350-800, 400-900, 400-850, or 400-800 amino acids).

[0087] In some cases, a subject CasZ protein (of the subject compositions and/or methods) includes an amino acid sequence having 20% or more sequence identity (e.g., 30% or more, 40% or more, 50% or more, 60% or more, 70% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein of Figure 1 or Figure 7. For example, in some cases, a subject CasZ protein includes an amino acid sequence having 50% or more sequence identity (e.g., 60% or more, 70% or more, 80% or more, 85% or more, 90% or

more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 80% or more sequence identity (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein sequence of Figure 1 or Figure 7. In some cases, a subject CasZ protein includes an amino acid sequence having a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein sequence of Figure 1 or Figure 7, with the exception that the sequence includes an amino acid substitution (e.g., 1, 2, or 3 amino acid substitutions) that reduces the naturally occurring catalytic activity of the protein (e.g., such as at one or more catalytic amino acid positions). In some cases, a subject CasZ protein includes an amino acid sequence having 90% or more sequence identity (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100% sequence identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, CasZi, CasZj, CasZK, or CasZl protein of Figure 1 or Figure 7 and has a length in a range of from 350-900 amino acids (e.g., 350-850, 350-800, 400-900, 400-850, or 400-800 amino acids).

CasZ Variants

[0088] A variant CasZ protein has an amino acid sequence that is different by at least one amino acid (e.g., has a deletion, insertion, substitution, fusion) when compared to the amino acid sequence of the corresponding wild type CasZ protein. A CasZ protein that cleaves one strand but not the other of a double stranded target nucleic acid is referred to herein as a "nickase" (e.g., a "nickase CasZ"). A CasZ protein that has substantially no nuclease activity is referred to herein as a dead CasZ protein ("dCasZ") (with the caveat that nuclease activity can be provided by a heterologous polypeptide – a fusion partner – in the case of a chimeric CasZ protein, which is described in more detail below). For any of the CasZ variant proteins described herein (e.g., nickase CasZ, dCasZ, chimeric CasZ), the CasZ variant can include a CasZ protein sequence with the same parameters described above (e.g., domains that are present, percent identity, length, and the like).

Variants – catalytic activity

[0089] In some cases, the CasZ protein is a variant CasZ protein, e.g., mutated relative to the naturally occurring catalytically active sequence, and exhibits reduced cleavage activity (e.g., exhibits 90%, or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, or 30% or less cleavage

activity) when compared to the corresponding naturally occurring sequence. In some cases, such a variant CasZ protein is a catalytically 'dead' protein (has substantially no cleavage activity) and can be referred to as a 'dCasZ.' In some cases, the variant CasZ protein is a nickase (cleaves only one strand of a double stranded target nucleic acid, e.g., a double stranded target DNA). As described in more detail herein, in some cases, a CasZ protein (in some case a CasZ protein with wild type cleavage activity and in some cases a variant CasZ with reduced cleavage activity, e.g., a dCasZ or a nickase CasZ) is fused (conjugated) to a heterologous polypeptide that has an activity of interest (e.g., a catalytic activity of interest) to form a fusion protein (a chimeric CasZ protein).

[0090] Catalytic residues of CasZ include D405, E586 and D684 when numbered according to CasZi.1 (e.g., see Figure 1). Thus, in some cases, the CasZ protein has reduced activity and one or more of the above described amino acids (or one or more corresponding amino acids of any CasZ protein) are mutated (e.g., substituted with an alanine). In some cases, the variant CasZ protein is a catalytically 'dead' protein (is catalytically inactive) and is referred to as 'dCasZ.' A dCasZ protein can be fused to a fusion partner that provides an activity, and in some cases, the dCasZ (e.g., one without a fusion partner that provides catalytic activity – but which can have an NLS when expressed in a eukaryotic cell) can bind to target DNA and can be used for imaging (e.g., the protein can be tagged/labeled) and/or can block RNA polymerase from transcribing from a target DNA. In some cases, the variant CasZ protein is a nickase (cleaves only one strand of a double stranded target nucleic acid, e.g., a double stranded target DNA).

Variants – chimeric CasZ (i.e., fusion proteins)

[0091] As noted above, in some cases, a CasZ protein (in some cases a CasZ protein with wild type cleavage activity and in some cases a variant CasZ with reduced cleavage activity, e.g., a dCasZ or a nickase CasZ) is fused (conjugated) to a heterologous polypeptide that has an activity of interest (e.g., a catalytic activity of interest) to form a fusion protein (a chimeric CasZ protein). A heterologous polypeptide to which a CasZ protein can be fused is referred to herein as a 'fusion partner.'

[0092] In some cases, the fusion partner can modulate transcription (e.g., inhibit transcription, increase transcription) of a target DNA. For example, in some cases the fusion partner is a protein (or a domain from a protein) that inhibits transcription (e.g., a transcriptional repressor, a protein that functions via recruitment of transcription inhibitor proteins, modification of target DNA such as methylation, recruitment of a DNA modifier, modulation of histones associated with target DNA, recruitment of a histone modifier such as those that modify acetylation and/or methylation of histones, and the like). In some cases the fusion partner is a protein (or a domain from a protein) that increases transcription (e.g., a transcription activator, a protein that acts via recruitment of transcription activator proteins, modification of target DNA such as demethylation, recruitment of a DNA modifier, modulation

of histones associated with target DNA, recruitment of a histone modifier such as those that modify acetylation and/or methylation of histones, and the like).

[0093] In some cases, a chimeric CasZ protein includes a heterologous polypeptide that has enzymatic activity that modifies a target nucleic acid (e.g., nuclease activity such as FokI nuclease activity, methyltransferase activity, demethylase activity, DNA repair activity, DNA damage activity, deamination activity, dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity, transposase activity, recombinase activity, polymerase activity, ligase activity, helicase activity, photolyase activity or glycosylase activity).

[0094] In some cases, a chimeric CasZ protein includes a heterologous polypeptide that has enzymatic activity that modifies a polypeptide (e.g., a histone) associated with a target nucleic acid (e.g., methyltransferase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity or demyristoylation activity).

[0095] Examples of proteins (or fragments thereof) that can be used in increase transcription include but are not limited to: transcriptional activators such as VP16, VP64, VP48, VP160, p65 subdomain (e.g., from NFkB), and activation domain of EDLL and/or TAL acitvation domain (e.g., for activity in plants); histone lysine methyltransferases such as SET1A, SET1B, MLL1 to 5, ASH1, SYMD2, NSD1, and the like; histone lysine demethylases such as JHDM2a/b, UTX, JMJD3, and the like; histone acetyltransferases such as GCN5, PCAF, CBP, p300, TAF1, TIP60/PLIP, MOZ/MYST3, MORF/MYST4, SRC1, ACTR, P160, CLOCK, and the like; and DNA demethylases such as Ten-Eleven Translocation (TET) dioxygenase 1 (TET1CD), TET1, DME, DML1, DML2, ROS1, and the like.

[0096] Examples of proteins (or fragments thereof) that can be used in decrease transcription include but are not limited to: transcriptional repressors such as the Krüppel associated box (KRAB or SKD); KOX1 repression domain; the Mad mSIN3 interaction domain (SID); the ERF repressor domain (ERD), the SRDX repression domain (e.g., for repression in plants), and the like; histone lysine methyltransferases such as Pr-SET7/8, SUV4-20H1, RIZ1, and the like; histone lysine demethylases such as JMJD2A/JHDM3A, JMJD2B, JMJD2C/GASC1, JMJD2D, JARID1A/RBP2, JARID1B/PLU-1, JARID1C/SMCX, JARID1D/SMCY, and the like; histone lysine deacetylases such as HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, and the like; DNA methylases such as HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), and the like; and periphery recruitment elements such as Lamin A, Lamin B, and the like.

[0097] In some cases, the fusion partner has enzymatic activity that modifies the target nucleic acid (e.g., ssRNA, dsRNA, ssDNA, dsDNA). Examples of enzymatic activity that can be provided by the fusion partner include but are not limited to: nuclease activity such as that provided by a restriction enzyme (e.g., FokI nuclease), methyltransferase activity such as that provided by a methyltransferase (e.g., HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3 (plants), ZMET2, CMT1, CMT2 (plants), and the like); demethylase activity such as that provided by a demethylase (e.g., Ten-Eleven Translocation (TET) dioxygenase 1 (TET1CD), TET1, DME, DML1, DML2, ROS1, and the like) , DNA repair activity, DNA damage activity, deamination activity such as that provided by a deaminase (e.g., a cytosine deaminase enzyme such as rat APOBEC1), dismutase activity, alkylation activity, depurination activity, oxidation activity, pyrimidine dimer forming activity, integrase activity such as that provided by an integrase and/or resolvase (e.g., Gin invertase such as the hyperactive mutant of the Gin invertase, GinH106Y; human immunodeficiency virus type 1 integrase (IN); Tn3 resolvase; and the like), transposase activity, recombinase activity such as that provided by a recombinase (e.g., catalytic domain of Gin recombinase), polymerase activity, ligase activity, helicase activity, photolyase activity, and glycosylase activity).

[0098] In some cases, the fusion partner has enzymatic activity that modifies a protein associated with the target nucleic acid (e.g., ssRNA, dsRNA, ssDNA, dsDNA) (e.g., a histone, an RNA binding protein, a DNA binding protein, and the like). Examples of enzymatic activity (that modifyies a protein associated with a target nucleic acid) that can be provided by the fusion partner include but are not limited to: methyltransferase activity such as that provided by a histone methyltransferase (HMT) (e.g., suppressor of variegation 3-9 homolog 1 (SUV39H1, also known as KMT1A), euchromatic histone lysine methyltransferase 2 (G9A, also known as KMT1C and EHMT2), SUV39H2, ESET/SETDB1, and the like, SET1A, SET1B, MLL1 to 5, ASH1, SYMD2, NSD1, DOT1L, Pr-SET7/8, SUV4-20H1, EZH2, RIZ1), demethylase activity such as that provided by a histone demethylase (e.g., Lysine Demethylase 1A (KDM1A also known as LSD1), JHDM2a/b, JMJD2A/JHDM3A, JMJD2B, JMJD2C/GASC1, JMJD2D, JARID1A/RBP2, JARID1B/PLU-1, JARID1C/SMCX, JARID1D/SMCY, UTX, JMJD3, and the like), acetyltransferase activity such as that provided by a histone acetylase transferase (e.g., catalytic core/fragement of the human acetyltransferase p300, GCN5, PCAF, CBP, TAF1, TIP60/PLIP, MOZ/MYST3, MORF/MYST4, HBO1/MYST2, HMOF/MYST1, SRC1, ACTR, P160, CLOCK, and the like), deacetylase activity such as that provided by a histone deacetylase (e.g., HDAC1, HDAC2, HDAC3, HDAC8, HDAC4, HDAC5, HDAC7, HDAC9, SIRT1, SIRT2, HDAC11, and the like), kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylating activity, deSUMOylating activity, ribosylation activity, deribosylation activity, myristoylation activity, and demyristoylation activity.

[0099] Additional examples of a suitable fusion partners are dihydrofolate reductase (DHFR) destabilization domain (e.g., to generate a chemically controllable chimeric CasZ protein), and a chloroplast transit peptide. Suitable chloroplast transit peptides include, but are not limited to:

[00100] MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGR VKCMQVWPPIGKKKFETLSYLPPLTRDSRA (SEQ ID NO: 101);
MASMISSSAVTTVSRASRGQSAAMAPFGGLKSMTGFPVRKVNTDITSITSNGGRVKS (SEQ ID NO: 102);
MASSMLSSATMVASPAQATMVAPFNGLKSSAAFPATRKANNDITSITSNGGRVNCMQVWPPIE KKKFETLSYLPDLTDSGGRVNC (SEQ ID NO: 103);
MAQVSRICNGVQNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIGSELRPL KVMSSVSTAC (SEQ ID NO: 104);
MAQVSRICNGVWNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIGSELRP LKVMSSVSTAC (SEQ ID NO: 105);
MAQINNMAQGIQTLNPNSNFHKPQVPKSSSFLVFGSKKLKNSANSMLVLKKDSIFMQLFCSFRIS ASVATAC (SEQ ID NO: 106);
MAALVTSQLATSGTVLSVTDRFRRPGFQGLRPRNPADAALGMRTVGASAAPKQSRKPHRFDRR CLSMVV (SEQ ID NO: 107);
MAALTTSQLATSATGFGIADRSAPSSLLRHGFQGLKPRSPAGGDATSLSVTTSARATPKQQRSV QRGSRRFPSVVVC (SEQ ID NO: 108);
MASSVLSSAAVATRSNVAQANMVAPFTGLKSAASFPVSRKQNLDITSIASNGGRVQC (SEQ ID NO: 109);
MESLAATSVFAPSRVAVPAARALVRAGTVVPTRRTSSTSGTSGVKCSAAVTPQASPVISRSAAA A (SEQ ID NO: 110); and
MGAAATSMQSLKFSNRLVPPSRRLSPVPNNVTCNNLPKSAAPVRTVKCCASSWNSTINGAAAT TNGASAASS (SEQ ID NO: 111).

[00101] In some case, a CasZ fusion polypeptide of the present disclosure comprises: a) a CasZ polypeptide of the present disclosure; and b) a chloroplast transit peptide. Thus, for example, a CRISPR-CasZ complex can be targeted to the chloroplast. In some cases, this targeting may be achieved by the presence of an N-terminal extension, called a chloroplast transit peptide (CTP) or plastid transit peptide. Chromosomal transgenes from bacterial sources must have a sequence encoding a CTP sequence fused to a sequence encoding an expressed polypeptide if the expressed polypeptide is to be compartmentalized in the plant plastid (e.g. chloroplast). Accordingly, localization of an exogenous polypeptide to a chloroplast is often 1 accomplished by means of operably linking a polynucleotide sequence encoding a CTP sequence to the 5' region of a polynucleotide encoding the exogenous polypeptide. The CTP is removed in a processing step during translocation into the plastid. Processing efficiency may, however,

be affected by the amino acid sequence of the CTP and nearby sequences at the NH 2 terminus of the peptide. Other options for targeting to the chloroplast which have been described are the maize cab-m7 signal sequence (U.S. Pat. No. 7,022,896, WO 97/41228) a pea glutathione reductase signal sequence (WO 97/41228) and the CTP described in US2009029861.

[00102] In some cases, a CasZ fusion polypeptide of the present disclosure can comprise: a) a CasZ polypeptide of the present disclosure; and b) an endosomal escape peptide. In some cases, an endosomal escape polypeptide comprises the amino acid sequence GLFXALLXLLXSLWXLLLXA (SEQ ID NO: 112), wherein each X is independently selected from lysine, histidine, and arginine. In some cases, an endosomal escape polypeptide comprises the amino acid sequence GLFHALLHLLHSLWHLLLHA (SEQ ID NO: 113).

[00103] For examples of some of the above fusion partners (and more) used in the context of fusions with Cas9, Zinc Finger, and/or TALE proteins (for site specific target nucleic modification, modulation of transcription, and/or target protein modification, e.g., histone modification), see, e.g.: Nomura et al, J Am Chem Soc. 2007 Jul 18;129(28):8676-7; Rivenbark et al., Epigenetics. 2012 Apr;7(4):350-60; Nucleic Acids Res. 2016 Jul 8;44(12):5615-28; Gilbert et al., Cell. 2013 Jul 18;154(2):442-51; Kearns et al., Nat Methods. 2015 May;12(5):401-3; Mendenhall et al., Nat Biotechnol. 2013 Dec;31(12):1133-6; Hilton et al., Nat Biotechnol. 2015 May;33(5):510-7; Gordley et al., Proc Natl Acad Sci U S A. 2009 Mar 31;106(13):5053-8; Akopian et al., Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8688-91; Tan et., al., J Virol. 2006 Feb;80(4):1939-48; Tan et al., Proc Natl Acad Sci U S A. 2003 Oct 14;100(21):11997-2002; Papworth et al., Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):1621-6; Sanjana et al., Nat Protoc. 2012 Jan 5;7(1):171-92; Beerli et al., Proc Natl Acad Sci U S A. 1998 Dec 8;95(25):14628-33; Snowden et al., Curr Biol. 2002 Dec 23;12(24):2159-66; Xu et.al., Xu et al., Cell Discov. 2016 May 3;2:16009; Komor et al., Nature. 2016 Apr 20;533(7603):420-4; Chaikind et al., Nucleic Acids Res. 2016 Aug 11; Choudhury at. al., Oncotarget. 2016 Jun 23; Du et al., Cold Spring Harb Protoc. 2016 Jan 4; Pham et al., Methods Mol Biol. 2016;1358:43-57; Balboa et al., Stem Cell Reports. 2015 Sep 8;5(3):448-59; Hara et al., Sci Rep. 2015 Jun 9;5:11221; Piatek et al., Plant Biotechnol J. 2015 May;13(4):578-89; Hu et al., Nucleic Acids Res. 2014 Apr;42(7):4375-90; Cheng et al., Cell Res. 2013 Oct;23(10):1163-71; and Maeder et al., Nat Methods. 2013 Oct;10(10):977-9.

[00104] Additional suitable heterologous polypeptides include, but are not limited to, a polypeptide that directly and/or indirectly provides for increased transcription and/or translation of a target nucleic acid (e.g., a transcription activator or a fragment thereof, a protein or fragment thereof that recruits a transcription activator, a small molecule/drug-responsive transcription and/or translation regulator, a translation-regulating protein, etc.). Non-limiting examples of heterologous polypeptides to accomplish increased or decreased transcription include transcription activator and transcription repressor domains. In some such cases, a chimeric CasZ polypeptide is targeted by the guide nucleic acid

(guide RNA) to a specific location (i.e., sequence) in the target nucleic acid and exerts locus-specific regulation such as blocking RNA polymerase binding to a promoter (which selectively inhibits transcription activator function), and/or modifying the local chromatin status (e.g., when a fusion sequence is used that modifies the target nucleic acid or modifies a polypeptide associated with the target nucleic acid). In some cases, the changes are transient (e.g., transcription repression or activation). In some cases, the changes are inheritable (e.g., when epigenetic modifications are made to the target nucleic acid or to proteins associated with the target nucleic acid, e.g., nucleosomal histones).

[00105] Non-limiting examples of heterologous polypeptides for use when targeting ssRNA target nucleic acids include (but are not limited to): splicing factors (e.g., RS domains); protein translation components (e.g., translation initiation, elongation, and/or release factors; e.g., eIF4G); RNA methylases; RNA editing enzymes (e.g., RNA deaminases, e.g., adenosine deaminase acting on RNA (ADAR), including A to I and/or C to U editing enzymes); helicases; RNA-binding proteins; and the like. It is understood that a heterologous polypeptide can include the entire protein or in some cases can include a fragment of the protein (e.g., a functional domain).

[00106] The heterologous polypeptide of a subject chimeric CasZ polypeptide can be any domain capable of interacting with ssRNA (which, for the purposes of this disclosure, includes intramolecular and/or intermolecular secondary structures, e.g., double-stranded RNA duplexes such as hairpins, stem-loops, etc.), whether transiently or irreversibly, directly or indirectly, including but not limited to an effector domain selected from the group comprising; Endonucleases (for example RNase III, the CRR22 DYW domain, Dicer, and PIN (PilT N-terminus) domains from proteins such as SMG5 and SMG6); proteins and protein domains responsible for stimulating RNA cleavage (for example CPSF, CstF, CFIm and CFIIm); Exonucleases (for example XRN-1 or Exonuclease T) ; Deadenylases (for example HNT3); proteins and protein domains responsible for nonsense mediated RNA decay (for example UPF1, UPF2, UPF3, UPF3b, RNP S1, Y14, DEK, REF2, and SRm160); proteins and protein domains responsible for stabilizing RNA (for example PABP) ; proteins and protein domains responsible for repressing translation (for example Ago2 and Ago4); proteins and protein domains responsible for stimulating translation (for example Staufen); proteins and protein domains responsible for (e.g., capable of) modulating translation (e.g., translation factors such as initiation factors, elongation factors, release factors, etc., e.g., eIF4G); proteins and protein domains responsible for polyadenylation of RNA (for example PAP1, GLD-2, and Star- PAP) ; proteins and protein domains responsible for polyuridinylation of RNA (for example CI D1 and terminal uridylate transferase) ; proteins and protein domains responsible for RNA localization (for example from IMP1, ZBP1, She2p, She3p, and Bicaudal-D); proteins and protein domains responsible for nuclear retention of RNA (for example Rrp6); proteins and protein domains responsible for nuclear export of RNA (for example TAP, NXF1, THO, TREX, REF, and Aly) ; proteins and protein domains responsible for repression of RNA splicing (for example PTB,

Sam68, and hnRNP A1) ; proteins and protein domains responsible for stimulation of RNA splicing (for example Serine/Arginine-rich (SR) domains) ; proteins and protein domains responsible for reducing the efficiency of transcription (for example FUS (TLS)); and proteins and protein domains responsible for stimulating transcription (for example CDK7 and HIV Tat). Alternatively, the effector domain may be selected from the group comprising Endonucleases; proteins and protein domains capable of stimulating RNA cleavage; Exonucleases; Deadenylases; proteins and protein domains having nonsense mediated RNA decay activity; proteins and protein domains capable of stabilizing RNA; proteins and protein domains capable of repressing translation; proteins and protein domains capable of stimulating translation; proteins and protein domains capable of modulating translation (e.g., translation factors such as initiation factors, elongation factors, release factors, etc., e.g., eIF4G); proteins and protein domains capable of polyadenylation of RNA; proteins and protein domains capable of polyuridinylation of RNA; proteins and protein domains having RNA localization activity; proteins and protein domains capable of nuclear retention of RNA; proteins and protein domains having RNA nuclear export activity; proteins and protein domains capable of repression of RNA splicing; proteins and protein domains capable of stimulation of RNA splicing; proteins and protein domains capable of reducing the efficiency of transcription ; and proteins and protein domains capable of stimulating transcription. Another suitable heterologous polypeptide is a PUF RNA-binding domain, which is described in more detail in WO2012068627, which is hereby incorporated by reference in its entirety.

[00107] Some RNA splicing factors that can be used (in whole or as fragments thereof) as heterologous polypeptides for a chimeric CasZ polypeptide have modular organization, with separate sequence-specific RNA binding modules and splicing effector domains. For example, members of the Serine/ Arginine-rich (SR) protein family contain N-terminal RNA recognition motifs (RRMs) that bind to exonic splicing enhancers (ESEs) in pre-mRNAs and C-terminal RS domains that promote exon inclusion. As another example, the hnRNP protein hnRNP Al binds to exonic splicing silencers (ESSs) through its RRM domains and inhibits exon inclusion through a C-terminal Glycine-rich domain. Some splicing factors can regulate alternative use of splice site (ss) by binding to regulatory sequences between the two alternative sites. For example, ASF/SF2 can recognize ESEs and promote the use of intron proximal sites, whereas hnRNP Al can bind to ESSs and shift splicing towards the use of intron distal sites. One application for such factors is to generate ESFs that modulate alternative splicing of endogenous genes, particularly disease associated genes. For example, Bcl-x pre-mRNA produces two splicing isoforms with two alternative 5' splice sites to encode proteins of opposite functions. The long splicing isoform Bcl-xL is a potent apoptosis inhibitor expressed in long-lived postmitotic cells and is up-regulated in many cancer cells, protecting cells against apoptotic signals. The short isoform Bcl-xS is a pro-apoptotic isoform and expressed at high levels in cells with a high turnover rate (e.g., developing lymphocytes). The ratio of the two Bcl-x splicing isoforms is regulated by multiple cώ-elements that are

located in either the core exon region or the exon extension region (i.e., between the two alternative 5' splice sites). For more examples, see WO2010075303, which is hereby incorporated by reference in its entirety.

[00108] Further suitable fusion partners include, but are not limited to, proteins (or fragments thereof) that are boundary elements (e.g., CTCF), proteins and fragments thereof that provide periphery recruitment (e.g., Lamin A, Lamin B, etc.), protein docking elements (e.g., FKBP/FRB, Pil1/Aby1, etc.).

[00109] Examples of various additional suitable heterologous polypeptide (or fragments thereof) for a subject chimeric CasZ polypeptide include, but are not limited to those described in the following applications (which publications are related to other CRISPR endonucleases such as Cas9, but the described fusion partners can also be used with CasZ instead): PCT patent applications: WO2010075303, WO2012068627, and WO2013155555, and can be found, for example, in U.S. patents and patent applications: 8,906,616; 8,895,308; 8,889,418; 8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945; 8,697,359; 20140068797; 20140170753; 20140179006; 20140179770; 20140186843; 20140186919; 20140186958; 20140189896; 20140227787; 20140234972; 20140242664; 20140242699; 20140242700; 20140242702; 20140248702; 20140256046; 20140273037; 20140273226; 20140273230; 20140273231; 20140273232; 20140273233; 20140273234; 20140273235; 20140287938; 20140295556; 20140295557; 20140298547; 20140304853; 20140309487; 20140310828; 20140310830; 20140315985; 20140335063; 20140335620; 20140342456; 20140342457; 20140342458; 20140349400; 20140349405; 20140356867; 20140356956; 20140356958; 20140356959; 20140357523; 20140357530; 20140364333; and 20140377868; all of which are hereby incorporated by reference in their entirety.

[00110] In some cases, a heterologous polypeptide (a fusion partner) provides for subcellular localization, i.e., the heterologous polypeptide contains a subcellular localization sequence (e.g., a nuclear localization signal (NLS) for targeting to the nucleus, a sequence to keep the fusion protein out of the nucleus, e.g., a nuclear export sequence (NES), a sequence to keep the fusion protein retained in the cytoplasm, a mitochondrial localization signal for targeting to the mitochondria, a chloroplast localization signal for targeting to a chloroplast, an ER retention signal, and the like). In some embodiments, a CasZ fusion polypeptide does not include a NLS so that the protein is not targeted to the nucleus (which can be advantageous, e.g., when the target nucleic acid is an RNA that is present in the cyosol). In some embodiments, the heterologous polypeptide can provide a tag (i.e., the heterologous polypeptide is a detectable label) for ease of tracking and/or purification (e.g., a fluorescent protein, e.g., green fluorescent protein (GFP), YFP, RFP, CFP, mCherry, tdTomato, and the like; a histidine tag, e.g., a 6XHis tag; a hemagglutinin (HA) tag; a FLAG tag; a Myc tag; and the like).

[00111] In some cases a CasZ protein (e.g., a wild type CasZ protein, a variant CasZ protein, a chimeric CasZ protein, a dCasZ protein, a chimeric CasZ protein where the CasZ portion has reduced nuclease activity - such as a dCasZ protein fused to a fusion partner, and the like) includes (is fused to) a

nuclear localization signal (NLS) (e.g, in some cases 2 or more, 3 or more, 4 or more, or 5 or more NLSs). Thus, in some cases, a CasZ polypeptide includes one or more NLSs (e.g., 2 or more, 3 or more, 4 or more, or 5 or more NLSs). In some cases, one or more NLSs (2 or more, 3 or more, 4 or more, or 5 or more NLSs) are positioned at or near (e.g., within 50 amino acids of) the N-terminus and/or the C-terminus. In some cases, one or more NLSs (2 or more, 3 or more, 4 or more, or 5 or more NLSs) are positioned at or near (e.g., within 50 amino acids of) the N-terminus. In some cases, one or more NLSs (2 or more, 3 or more, 4 or more, or 5 or more NLSs) are positioned at or near (e.g., within 50 amino acids of) the C-terminus. In some cases, one or more NLSs (3 or more, 4 or more, or 5 or more NLSs) are positioned at or near (e.g., within 50 amino acids of) both the N-terminus and the C-terminus. In some cases, an NLS is positioned at the N-terminus and an NLS is positioned at the C-terminus.

[00112] In some cases a CasZ protein (e.g., a wild type CasZ protein, a variant CasZ protein, a chimeric CasZ protein, a dCasZ protein, a chimeric CasZ protein where the CasZ portion has reduced nuclease activity - such as a dCasZ protein fused to a fusion partner, and the like) includes (is fused to) between 1 and 10 NLSs (e.g., 1-9, 1-8, 1-7, 1-6, 1-5, 2-10, 2-9, 2-8, 2-7, 2-6, or 2-5 NLSs). In some cases a CasZ protein (e.g., a wild type CasZ protein, a variant CasZ protein, a chimeric CasZ protein, a dCasZ protein, a chimeric CasZ protein where the CasZ portion has reduced nuclease activity - such as a dCasZ protein fused to a fusion partner, and the like) includes (is fused to) between 2 and 5 NLSs (e.g., 2-4, or 2-3 NLSs).

[00113] Non-limiting examples of NLSs include an NLS sequence derived from: the NLS of the SV40 virus large T-antigen, having the amino acid sequence PKKKRKV (SEQ ID NO: 114); the NLS from nucleoplasmin (e.g., the nucleoplasmin bipartite NLS with the sequence KRPAATKKAGQAKKKK (SEQ ID NO: 115)); the c-myc NLS having the amino acid sequence PAAKRVKLD (SEQ ID NO: 116) or RQRRNELKRSP (SEQ ID NO: 117); the hRNPA1 M9 NLS having the sequence NQSSNFGPMKGGNFGGRSSGPYGGGGQYFAKPRNQGGY (SEQ ID NO: 118); the sequence RMRIZFKNKGKDTAELRRRRVEVSVELRKAKKDEQILKRRNV (SEQ ID NO: 119) of the IBB domain from importin-alpha; the sequences VSRKRPRP (SEQ ID NO: 120) and PPKKARED (SEQ ID NO: 121) of the myoma T protein; the sequence PQPKKKPL (SEQ ID NO: 122) of human p53; the sequence SALIKKKKKMAP (SEQ ID NO: 123) of mouse c-abl IV; the sequences DRLRR (SEQ ID NO: 124) and PKQKKRK (SEQ ID NO: 125) of the influenza virus NS1; the sequence RKLKKKIKKL (SEQ ID NO: 126) of the Hepatitis virus delta antigen; the sequence REKKKFLKRR (SEQ ID NO: 127) of the mouse Mx1 protein; the sequence KRKGDEVDGVDEVAKKKSKK (SEQ ID NO: 128) of the human poly(ADP-ribose) polymerase; and the sequence RKCLQAGMNLEARKTKK (SEQ ID NO: 129) of the steroid hormone receptors (human) glucocorticoid. In general, NLS (or multiple NLSs) are of sufficient strength to drive accumulation of the CasZ protein in a detectable amount in the nucleus of a eukaryotic cell. Detection of accumulation in the

nucleus may be performed by any suitable technique. For example, a detectable marker may be fused to the CasZ protein such that location within a cell may be visualized. Cell nuclei may also be isolated from cells, the contents of which may then be analyzed by any suitable process for detecting protein, such as immunohistochemistry, Western blot, or enzyme activity assay. Accumulation in the nucleus may also be determined indirectly.

[00114] In some cases, a CasZ fusion polypeptide includes a "Protein Transduction Domain" or PTD (also known as a CPP – cell penetrating peptide), which refers to a polypeptide, polynucleotide, carbohydrate, or organic or inorganic compound that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD attached to another molecule, which can range from a small polar molecule to a large macromolecule and/or a nanoparticle, facilitates the molecule traversing a membrane, for example going from extracellular space to intracellular space, or cytosol to within an organelle. In some embodiments, a PTD is covalently linked to the amino terminus a polypeptide (e.g., linked to a wild type CasZ to generate a fusino protein, or linked to a variant CasZ protein such as a dCasZ, nickase CasZ, or chimeric CasZ protein to generate a fusion protein). In some embodiments, a PTD is covalently linked to the carboxyl terminus of a polypeptide (e.g., linked to a wild type CasZ to generate a fusino protein, or linked to a variant CasZ protein such as a dCasZ, nickase CasZ, or chimeric CasZ protein to generate a fusion protein). In some cases, the PTD is inserted interally in the CasZ fusion polypeptide (i.e., is not at the N- or C-terminus of the CasZ fusion polypeptide) at a suitable insertion site. In some cases, a subject CasZ fusion polypeptide includes (is conjugated to, is fused to) one or more PTDs (e.g., two or more, three or more, four or more PTDs). In some cases, a PTD includes a nuclear localization signal (NLS) (e.g, in some cases 2 or more, 3 or more, 4 or more, or 5 or more NLSs). Thus, in some cases, a CasZ fusion polypeptide includes one or more NLSs (e.g., 2 or more, 3 or more, 4 or more, or 5 or more NLSs). In some cases, a PTD is covalently linked to a nucleic acid (e.g., a CasZ guide nucleic acid, a polynucleotide encoding a CasZ guide nucleic acid, a polynucleotide encoding a CasZ fusion polypeptide, a donor polynucleotide, etc.). Examples of PTDs include but are not limited to a minimal undecapeptide protein transduction domain (corresponding to residues 47-57 of HIV-1 TAT comprising YGRKKRRQRRR; SEQ ID NO: 130); a polyarginine sequence comprising a number of arginines sufficient to direct entry into a cell (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines); a VP22 domain (Zender et al. (2002) *Cancer Gene Ther.* 9(6):489-96); an Drosophila Antennapedia protein transduction domain (Noguchi et al. (2003) *Diabetes* 52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al. (2004) *Pharm. Research* 21:1248-1256); polylysine (Wender et al. (2000) *Proc. Natl. Acad. Sci. USA* 97:13003-13008); RRQRRTSKLMKR (SEQ ID NO: 131); Transportan GWTLNSAGYLLGKINLKALAALAKKIL (SEQ ID NO: 132); KALAWEAKLAKALAKALAKHLAKALAKALKCEA (SEQ ID NO: 133); and RQIKIWFQNRRMKWKK (SEQ ID NO: 134). Exemplary PTDs include but are not limited to,

YGRKKRRQRRR (SEQ ID NO: 130), RKKRRQRRR (SEQ ID NO: 135); an arginine homopolymer of from 3 arginine residues to 50 arginine residues; Exemplary PTD domain amino acid sequences include, but are not limited to, any of the following: YGRKKRRQRRR (SEQ ID NO: 130); RKKRRQRR (SEQ ID NO: 136); YARAAARQARA (SEQ ID NO: 137); THRLPRRRRRR (SEQ ID NO: 138); and GGRRARRRRRR (SEQ ID NO: 139). In some embodiments, the PTD is an activatable CPP (ACPP) (Aguilera et al. (2009) *Integr Biol (Camb)* June; 1(5-6): 371-381). ACPPs comprise a polycationic CPP (e.g., Arg9 or "R9") connected via a cleavable linker to a matching polyanion (e.g., Glu9 or "E9"), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells. Upon cleavage of the linker, the polyanion is released, locally unmasking the polyarginine and its inherent adhesiveness, thus "activating" the ACPP to traverse the membrane.

Linkers (e.g., for fusion partners)

[00115] In some instances, a subject CasZ protein is fused to a fusion partner via a linker polypeptide (e.g., one or more linker polypeptides). The linker polypeptide may have any of a variety of amino acid sequences. Proteins can be joined by a spacer peptide, generally of a flexible nature, although other chemical linkages are not excluded. Suitable linkers include polypeptides of between 4 amino acids and 40 amino acids in length, or between 4 amino acids and 25 amino acids in length. These linkers can be produced by using synthetic, linker-encoding oligonucleotides to couple the proteins, or can be encoded by a nucleic acid sequence encoding the fusion protein. Peptide linkers with a degree of flexibility can be used. The linking peptides may have virtually any amino acid sequence, bearing in mind that the preferred linkers will have a sequence that results in a generally flexible peptide. The use of small amino acids, such as glycine and alanine, are of use in creating a flexible peptide. The creation of such sequences is routine to those of skill in the art. A variety of different linkers are commercially available and are considered suitable for use.

[00116] Examples of linker polypeptides include glycine polymers $(G)_n$, glycine-serine polymers (including, for example, $(GS)_n$, $GSGGS_n$ (SEQ ID NO: 140), $GGSGGS_n$ (SEQ ID NO: 141), and $GGGS_n$ (SEQ ID NO: 142), where n is an integer of at least one), glycine-alanine polymers, alanine-serine polymers. Exemplary linkers can comprise amino acid sequences including, but not limited to, GGSG (SEQ ID NO: 143), GGSGG (SEQ ID NO: 144), GSGSG (SEQ ID NO: 145), GSGGG (SEQ ID NO: 146), GGGSG (SEQ ID NO: 147), GSSSG (SEQ ID NO: 148), and the like. The ordinarily skilled artisan will recognize that design of a peptide conjugated to any desired element can include linkers that are all or partially flexible, such that the linker can include a flexible linker as well as one or more portions that confer less flexible structure.

Detectable labels

[00117] In some cases, a CasZ polypeptide of the present disclosure comprises (e.g., can be attached/fused to) a detectable label. Suitable detectable labels and/or moieties that can provide a

detectable signal can include, but are not limited to, an enzyme, a radioisotope, a member of a specific binding pair; a fluorophore; a fluorescent protein; a quantum dot; and the like.

[00118] Suitable fluorescent proteins include, but are not limited to, green fluorescent protein (GFP) or variants thereof, blue fluorescent variant of GFP (BFP), cyan fluorescent variant of GFP (CFP), yellow fluorescent variant of GFP (YFP), enhanced GFP (EGFP), enhanced CFP (ECFP), enhanced YFP (EYFP), GFPS65T, Emerald, Topaz (TYFP), Venus, Citrine, mCitrine, GFPuv, destabilised EGFP (dEGFP), destabilised ECFP (dECFP), destabilised EYFP (dEYFP), mCFPm, Cerulean, T-Sapphire, CyPet, YPet, mKO, HcRed, t-HcRed, DsRed, DsRed2, DsRed-monomer, J-Red, dimer2, t-dimer2(12), mRFP1, pocilloporin, Renilla GFP, Monster GFP, paGFP, Kaede protein and kindling protein, Phycobiliproteins and Phycobiliprotein conjugates including B-Phycoerythrin, R-Phycoerythrin and Allophycocyanin. Other examples of fluorescent proteins include mHoneydew, mBanana, mOrange, dTomato, tdTomato, mTangerine, mStrawberry, mCherry, mGrape1, mRaspberry, mGrape2, mPlum (Shaner et al. (2005) *Nat. Methods* 2:905-909), and the like. Any of a variety of fluorescent and colored proteins from Anthozoan species, as described in, e.g., Matz et al. (1999) *Nature Biotechnol.* 17:969-973, is suitable for use.

[00119] Suitable enzymes include, but are not limited to, horse radish peroxidase (HRP), alkaline phosphatase (AP), beta-galactosidase (GAL), glucose-6-phosphate dehydrogenase, beta-N-acetylglucosaminidase, β-glucuronidase, invertase, Xanthine Oxidase, firefly luciferase, glucose oxidase (GO), and the like.

Protospacer Adjacent Motif (PAM)

[00120] A natural CasZ protein binds to target DNA at a target sequence defined by the region of complementarity between the DNA-targeting RNA and the target DNA. As is the case for many CRISPR endonucleases, site-specific binding (and/or cleavage) of a double stranded target DNA occurs at locations determined by both (i) base-pairing complementarity between the guide RNA and the target DNA; and (ii) a short motif [referred to as the protospacer adjacent motif (PAM)] in the target DNA.

[00121] In some cases, the PAM for a CasZ protein is immediately 5' of the target sequence of the non-complementary strand of the target DNA (also referred to as the non-target strand; the complementary strand hybridizes to the guide sequence of the guide RNA while the non-complementary strand does not directly hybridize with the guide RNA and is the reverse complement of the non-complementary strand). In some cases (e.g., for CasZc), the PAM sequence of the non-complementary strand is 5'-TTA-3'. In some cases (e.g., for CasZb), the PAM sequence of the non-complementary strand is 5'-TTTN-3'. In some cases (e.g., for CasZb), the PAM sequence of the non-complementary strand is 5'-TTTA-3'.

[00122] In some cases, different CasZ proteins (i.e., CasZ proteins from various species) may be advantageous to use in the various provided methods in order to capitalize on various enzymatic characteristics of the different CasZ proteins (e.g., for different PAM sequence preferences; for increased or decreased enzymatic activity; for an increased or decreased level of cellular toxicity; to change the balance between NHEJ, homology-directed repair, single strand breaks, double strand breaks, etc.; to take advantage of a short total sequence; and the like). CasZ proteins from different species may require different PAM sequences in the target DNA. Thus, for a particular CasZ protein of choice, the PAM sequence preference may be different than the sequence(s) described above. Various methods (including in silico and/or wet lab methods) for identification of the appropriate PAM sequence are known in the art and are routine, and any convenient method can be used.

CasZ Guide RNA

[00123] A nucleic acid molecule that binds to a CasZ protein, forming a ribonucleoprotein complex (RNP), and targets the complex to a specific location within a target nucleic acid (e.g., a target DNA) is referred to herein as a "CasZ guide RNA" or simply as a "guide RNA." It is to be understood that in some cases, a hybrid DNA/RNA can be made such that a CasZ guide RNA includes DNA bases in addition to RNA bases, but the term "CasZ guide RNA" is still used to encompass such a molecule herein.

[00124] A CasZ guide RNA can be said to include two segments, a targeting segment and a protein-binding segment. The targeting segment of a CasZ guide RNA includes a nucleotide sequence (a guide sequence) that is complementary to (and therefore hybridizes with) a specific sequence (a target site) within a target nucleic acid (e.g., a target ssRNA, a target ssDNA, the complementary strand of a double stranded target DNA, etc.). The protein-binding segment (or "protein-binding sequence") interacts with (binds to) a CasZ polypeptide. The protein-binding segment of a subject CasZ guide RNA includes two complementary stretches of nucleotides that hybridize to one another to form a double stranded RNA duplex (dsRNA duplex). Site-specific binding and/or cleavage of a target nucleic acid (e.g., genomic DNA) can occur at locations (e.g., target sequence of a target locus) determined by base-pairing complementarity between the CasZ guide RNA (the guide sequence of the CasZ guide RNA) and the target nucleic acid.

[00125] A CasZ guide RNA and a CasZ protein, e.g., a fusion CasZ polypeptide, form a complex (e.g., bind via non-covalent interactions). The CasZ guide RNA provides target specificity to the complex by including a targeting segment, which includes a guide sequence (a nucleotide sequence that is complementary to a sequence of a target nucleic acid). The CasZ protein of the complex provides the site-specific activity (e.g., cleavage activity provided by the CasZ protein and/or an activity provided by the fusion partner in the case of a chimeric CasZ protein). In other words, the CasZ protein is guided to a

target nucleic acid sequence (e.g. a target sequence) by virtue of its association with the CasZ guide RNA.

[00126] The "guide sequence" also referred to as the "targeting sequence" of a CasZ guide RNA can be modified so that the CasZ guide RNA can target a CasZ protein (e.g., a naturally occurring CasZ protein, a fusion CasZ polypeptide (chimeric CasZ), and the like) to any desired sequence of any desired target nucleic acid, with the exception (e.g., as described herein) that the PAM sequence can be taken into account. Thus, for example, a CasZ guide RNA can have a guide sequence with complementarity to (e.g., can hybridize to) a sequence in a nucleic acid in a eukaryotic cell, e.g., a viral nucleic acid, a eukaryotic nucleic acid (e.g., a eukaryotic chromosome, chromosomal sequence, a eukaryotic RNA, etc.), and the like.

[00127] In some cases, a CasZ guide RNA has a length of 30 nucleotides (nt) or more (e.g., 35 nt or more, 40 nt or more, 45 nt or more, 50 nt or more, 55 nt or more, or 60 nt or more). In some embodiments, a CasZ guide RNA has a length of 40 nucleotides (nt) or more (e.g., 45 nt or more, 50 nt or more, 55 nt or more, or 60 nt or more). In some cases, a CasZ guide RNA has a length of from 30 nucleotides (nt) to 100 nt (e.g., 30-90, 30-80, 30-75, 30-70, 30-65, 40-100, 40-90, 40-80, 40-75, 40-70, or 40-65 nt). In some cases, a CasZ guide RNA has a length of from 40 nucleotides (nt) to 100 nt (e.g., 40-90, 40-80, 40-75, 40-70, or 40-65 nt).

Guide sequence of a CasZ guide RNA

[00128] A subject CasZ guide RNA includes a guide sequence (i.e., a targeting sequence), which is a nucleotide sequence that is complementary to a sequence (a target site) in a target nucleic acid. In other words, the guide sequence of a CasZ guide RNA can interact with a target nucleic acid (e.g., double stranded DNA (dsDNA), single stranded DNA (ssDNA), single stranded RNA (ssRNA), or double stranded RNA (dsRNA)) in a sequence-specific manner via hybridization (i.e., base pairing). The guide sequence of a CasZ guide RNA can be modified (e.g., by genetic engineering)/designed to hybridize to any desired target sequence (e.g., while taking the PAM into account, e.g., when targeting a dsDNA target) within a target nucleic acid (e.g., a eukaryotic target nucleic acid such as genomic DNA).

[00129] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 60% or more (e.g., 65% or more, 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%). In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 80% or more (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%). In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 90% or more (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100%). In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100%.

[00130] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100% over the seven contiguous 3'-most nucleotides of the target site of the target nucleic acid.

[00131] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 60% or more (e.g., 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17 or more (e.g., 18 or more, 19 or more, 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 80% or more (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17 or more (e.g., 18 or more, 19 or more, 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 90% or more (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17 or more (e.g., 18 or more, 19 or more, 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100% over 17 or more (e.g., 18 or more, 19 or more, 20 or more, 21 or more, 22 or more) contiguous nucleotides.

[00132] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 60% or more (e.g., 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19 or more (e.g., 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 80% or more (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19 or more (e.g., 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 90% or more (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19 or more (e.g., 20 or more, 21 or more, 22 or more) contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100% over 19 or more (e.g., 20 or more, 21 or more, 22 or more) contiguous nucleotides.

[00133] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 60% or more (e.g., 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 80% or more (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 90%

or more (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 17-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100% over 17-25 contiguous nucleotides.

[00134] In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 60% or more (e.g., 70% or more, 75% or more, 80% or more, 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 80% or more (e.g., 85% or more, 90% or more, 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 90% or more (e.g., 95% or more, 97% or more, 98% or more, 99% or more, or 100%) over 19-25 contiguous nucleotides. In some cases, the percent complementarity between the guide sequence and the target site of the target nucleic acid is 100% over 19-25 contiguous nucleotides.

[00135] In some cases, the guide sequence has a length in a range of from 17-30 nucleotides (nt) (e.g., from 17-25, 17-22, 17-20, 19-30, 19-25, 19-22, 19-20, 20-30, 20-25, or 20-22 nt). In some cases, the guide sequence has a length in a range of from 17-25 nucleotides (nt) (e.g., from 17-22, 17-20, 19-25, 19-22, 19-20, 20-25, or 20-22 nt). In some cases, the guide sequence has a length of 17 or more nt (e.g., 18 or more, 19 or more, 20 or more, 21 or more, or 22 or more nt; 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, etc.). In some cases, the guide sequence has a length of 19 or more nt (e.g., 20 or more, 21 or more, or 22 or more nt; 19 nt, 20 nt, 21 nt, 22 nt, 23 nt, 24 nt, 25 nt, etc.). In some cases, the guide sequence has a length of 17 nt. In some cases, the guide sequence has a length of 18 nt. In some cases, the guide sequence has a length of 19 nt. In some cases, the guide sequence has a length of 20 nt. In some cases, the guide sequence has a length of 21 nt. In some cases, the guide sequence has a length of 22 nt. In some cases, the guide sequence has a length of 23 nt.

Protein-binding segment of a CasZ guide RNA

[00136] The protein-binding segment of a subject CasZ guide RNA interacts with a CasZ protein. The CasZ guide RNA guides the bound CasZ protein to a specific nucleotide sequence within target nucleic acid via the above-mentioned guide sequence. The protein-binding segment of a CasZ guide RNA comprises two stretches of nucleotides that are complementary to one another and hybridize to form a double stranded RNA duplex (dsRNA duplex). Thus, the protein-binding segment includes a dsRNA duplex.

[00137] In some cases, the dsRNA duplex region includes a range of from 5-25 base pairs (bp) (e.g., from 5-22, 5-20, 5-18, 5-15, 5-12, 5-10, 5-8, 8-25, 8-22, 8-18, 8-15, 8-12, 12-25, 12-22, 12-18, 12-15, 13-25, 13-22, 13-18, 13-15, 14-25, 14-22, 14-18, 14-15, 15-25, 15-22, 15-18, 17-25, 17-22, or 17-18 bp, e.g., 5 bp, 6 bp, 7 bp, 8 bp, 9 bp, 10 bp, etc.). In some cases, the dsRNA duplex region includes a

range of from 6-15 base pairs (bp) (e.g., from 6-12, 6-10, or 6-8 bp, e.g., 6 bp, 7 bp, 8 bp, 9 bp, 10 bp, etc.). In some cases, the duplex region includes 5 or more bp (e.g., 6 or more, 7 or more, or 8 or more bp). In some cases, the duplex region includes 6 or more bp (e.g., 7 or more, or 8 or more bp). In some cases, not all nucleotides of the duplex region are paired, and therefore the duplex forming region can include a bulge. The term "bulge" herein is used to mean a stretch of nucleotides (which can be one nucleotide or multiple nucleotides) that do not contribute to a double stranded duplex, but which are surround 5' and 3' by nucleotides that do contribute, and as such a bulge is considered part of the duplex region. In some cases, the dsRNA includes 1 or more bulges (e.g., 2 or more, 3 or more, 4 or more bulges). In some cases, the dsRNA duplex includes 2 or more bulges (e.g., 3 or more, 4 or more bulges). In some cases, the dsRNA duplex includes 1-5 bulges (e.g., 1-4, 1-3, 2-5, 2-4, or 2-3 bulges).

[00138] Thus, in some cases, the stretches of nucleotides that hybridize to one another to form the dsRNA duplex have 70%-100% complementarity (e.g., 75%-100%, 80%-10%, 85%-100%, 90%-100%, 95%-100% complementarity) with one another. In some cases, the stretches of nucleotides that hybridize to one another to form the dsRNA duplex have 70%-100% complementarity (e.g., 75%-100%, 80%-10%, 85%-100%, 90%-100%, 95%-100% complementarity) with one another. In some cases, the stretches of nucleotides that hybridize to one another to form the dsRNA duplex have 85%-100% complementarity (e.g., 90%-100%, 95%-100% complementarity) with one another. In some cases, the stretches of nucleotides that hybridize to one another to form the dsRNA duplex have 70%-95% complementarity (e.g., 75%-95%, 80%-95%, 85%-95%, 90%-95% complementarity) with one another.

[00139] In other words, in some embodiments, the dsRNA duplex includes two stretches of nucleotides that have 70%-100% complementarity (e.g., 75%-100%, 80%-10%, 85%-100%, 90%-100%, 95%-100% complementarity) with one another. In some cases, the dsRNA duplex includes two stretches of nucleotides that have 85%-100% complementarity (e.g., 90%-100%, 95%-100% complementarity) with one another. In some cases, the dsRNA duplex includes two stretches of nucleotides that have 70%-95% complementarity (e.g., 75%-95%, 80%-95%, 85%-95%, 90%-95% complementarity) with one another.

[00140] The duplex region of a subject CasZ guide RNA can include one or more (1, 2, 3, 4, 5, etc) mutations relative to a naturally occurring duplex region. For example, in some cases a base pair can be maintained while the nucleotides contributing to the base pair from each segment can be different. In some cases, the duplex region of a subject CasZ guide RNA includes more paired bases, less paired bases, a smaller bulge, a larger bulge, fewer bulges, more bulges, or any convenient combination thereof, as compared to a naturally occurring duplex region (of a naturally occurring CasZ guide RNA).

[00141] Examples of various Cas9 guide RNAs and cpf1 guide RNAs can be found in the art, and in some cases variations similar to those introduced into Cas9 guide RNAs can also be introduced into CasZ guide RNAs of the present disclosure (e.g., mutations to the dsRNA duplex region, extension

of the 5' or 3' end for added stability for to provide for interaction with another protein, and the like). For example, see Jinek et al., Science. 2012 Aug 17;337(6096):816-21; Chylinski et al., RNA Biol. 2013 May;10(5):726-37; Ma et al., Biomed Res Int. 2013;2013:270805; Hou et al., Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15644-9; Jinek et al., Elife. 2013;2:e00471; Pattanayak et al., Nat Biotechnol. 2013 Sep;31(9):839-43; Qi et al, Cell. 2013 Feb 28;152(5):1173-83; Wang et al., Cell. 2013 May 9;153(4):910-8; Auer et al., Genome Res. 2013 Oct 31; Chen et al., Nucleic Acids Res. 2013 Nov 1;41(20):e19; Cheng et al., Cell Res. 2013 Oct;23(10):1163-71; Cho et al., Genetics. 2013 Nov;195(3):1177-80; DiCarlo et al., Nucleic Acids Res. 2013 Apr;41(7):4336-43; Dickinson et al., Nat Methods. 2013 Oct;10(10):1028-34; Ebina et al., Sci Rep. 2013;3:2510; Fujii et. al, Nucleic Acids Res. 2013 Nov 1;41(20):e187; Hu et al., Cell Res. 2013 Nov;23(11):1322-5; Jiang et al., Nucleic Acids Res. 2013 Nov 1;41(20):e188; Larson et al., Nat Protoc. 2013 Nov;8(11):2180-96; Mali et. at., Nat Methods. 2013 Oct;10(10):957-63; Nakayama et al., Genesis. 2013 Dec;51(12):835-43; Ran et al., Nat Protoc. 2013 Nov;8(11):2281-308; Ran et al., Cell. 2013 Sep 12;154(6):1380-9; Upadhyay et al., G3 (Bethesda). 2013 Dec 9;3(12):2233-8; Walsh et al., Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15514-5; Xie et al., Mol Plant. 2013 Oct 9; Yang et al., Cell. 2013 Sep 12;154(6):1370-9; Briner et al., Mol Cell. 2014 Oct 23;56(2):333-9; and U.S. patents and patent applications: 8,906,616; 8,895,308; 8,889,418; 8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945; 8,697,359; 20140068797; 20140170753; 20140179006; 20140179770; 20140186843; 20140186919; 20140186958; 20140189896; 20140227787; 20140234972; 20140242664; 20140242699; 20140242700; 20140242702; 20140248702; 20140256046; 20140273037; 20140273226; 20140273230; 20140273231; 20140273232; 20140273233; 20140273234; 20140273235; 20140287938; 20140295556; 20140295557; 20140298547; 20140304853; 20140309487; 20140310828; 20140310830; 20140315985; 20140335063; 20140335620; 20140342456; 20140342457; 20140342458; 20140349400; 20140349405; 20140356867; 20140356956; 20140356958; 20140356959; 20140357523; 20140357530; 20140364333; and 20140377868; all of which are hereby incorporated by reference in their entirety.

[00142] A CasZ guide RNA comprises both the guide sequence and two stretches ("duplex-forming segments") of nucleotides that hybridize to form the dsRNA duplex of the protein-binding segment. The particular sequence of a given CasZ guide RNA can be characteristic of the species in which a crRNA is found. Examples of suitable CasZ guide RNAs are provided herein.

Example Guide RNA sequences

[00143] Repeat sequences (non-guide sequence portion of a CasZ guide RNA) of crRNAs for naturally existing CasZ proteins (e.g., see Figure 1 and Figure 7) are shown in Table 1 and Table 3.

[00144] **Table 1.** crRNA repeat sequences for CasZ proteins

CasZ Protein	Repeat sequence	SEQ ID NO:
Za.1	GTTGCATTCCTTCATTCGTCTATTCGGGTTCTGCAAC	51
Za.2	GTTGCATTCCTTCATTCGTCTATCCGGGTTCTGCAAG	52
Za.3	GTTGCAGAACCCGAATAGACGAATGAAGGAATGCAAC	53
Za.4	CTATCATATTCAGAACAAAGGGATTAAGGAATGCAAC	54
Za.5	CTTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	55
Za.6	GTCTACAACTCATTGATAGAAATCAATGAGTTAGACA	56
Za.7	GTTATAAAGGCGGGGATCGCGACCGAGCGATTGAAAG	57
Zb.1	GTTGCATTCCTTAATTCATTTTCTCAATATCGGAAAC	58
Zb.2	GTTGCAGAAATAGAATAAAGGAATTAAGGAATGCAAC	59
Zb.3	CTTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	55
Zb.4	ATTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	61
Zb.5	GTTTCAGCGCACGAATTAACGAGATGAGAGATGCAACT	62
Zb.6	CTTGCAGAAGCTGAATAGACGAATCAAGGAATGCAAC	63
Zb.7	CACTTGCAGGCCTTGAATAGAGGAGTTAAGGAATGCAAC	64
Zb.8	GTCTCCATGACTGAAAAGTCGTGGCCGAATTGAAAC	65
Zb.9	GTTGCAGCGCCCGAACTGACGAGACGAGAGATGCAAC	66
Zb.10	GTTGCGCGAATAGAATAAAGGAATTAAGGAATGCAAC	67
Zb.11	AGTTGCATTCCTTAATCCCTCTGTTCAGTTTGTGCAAT	68
Zc.1	GTTGCATTCCTAGTTTCTCTAATTAGCACTGTGCAAC	69
Zc.2	GTTGCGGCGCGCGAATAAACGAGACTAGGAATGCAAC	70
Zc.3	ACTAGTTGCATTCCTTAATCCCTTTGTTCTGAATATGCTAG	71
Zc.4	CTTTCATATTCAGAACAAAGGGATTAAGGAATGCAAC	72
Zc.5	GTTGCAGTCCTTAACCCCTAGTTTCTGAATATGAAAGAT	73
Zc.6	GTTGCAGCCCCCGAACTAACGAGATGAGAGATGCAAC	74
Zc.7	CTTGCAGAACAATCATATATGACTAATCAGACTGCAAC	75
Zd.1	GTTGCACTCACCGGTGCTCACGACGTAGGGATGCAAC	76
Zd.2	GTCCCTACTCGCTAGGGAAACTAATTGAATGGAAAC	77
Ze.1	GTTGCATTCGGGTGCAAAACAGGGAGTAGAGTGTAAC	78
Ze.2	CTTCCAAACTCGAGCCAGTGGGGAGAGAAGTGGCA	79
Ze.3	CCTGTAGACCGGTCTCATTCTGAGAGGGGTATGCAACT	80
Ze.4	GTCTCGAGACCCTACAGATTTTGGAGAGGGGTGGGAC	81
Ze.4b	GTCCCACCCCTCTCCAAAATCTGTAGGGTCTCGAGAC	82
Zf.1	GTAGCAGGACTCTCCTCGAGAGAAACAGGGGTATGCT	83
Zf.2	GTACAATACCTCTCCTTTAAGAGAGGGAGGGGTACGCTAC	84
Zf.3	CCCCCTCGTTTCCTTCAGGGGATTCCTTTCC	85
Zg.1	GGTTCCCCCGGGCGCGGGTGGGGTGGCG	86
Zg.2	GGCTGCTCCGGGTGCGCGTGGAGCGAGG	87

CasZ Protein	Repeat sequence	SEQ ID NO:
Zh.1	GTTTTATACCCTTTAGAATTTAAACTGTCTAAAAG	88
Zi.1	ATTGCACCGGCCAACGCAAATCTGATTGATGGACAC	89
Zi.2	GCCGCAGCGGCCGACGCGGCCCTGATCGATGGACAC	90
Zj.1	GTCGAAATGCCCGCGCGGGGGCGTCGTACCCGCGAC	91
Zk.1	GGCTAGCCCGTGCGCGCAGGGACGAGTGG	92
Zk.2	GCCCGTGCGCGCAGGGACGAGTGG	93
Zk.3	GTTGCAGCGGCCGACGGAGCGCGAGCGTGGATGCCAC	94
Zk.4	CCATCGCCCCGCGCGCACGTGGATGAGCC	95
Zl.1	CTTTAGACTTCTCCGGAAGTCGAATTAATGGAAAC	96
Zl.2	GGGCGCCCCGCGCGAGCGGGGGTTGAAG	97
Za.8	CTTGCAGAACCCGGATAGACGAATGAAGGAATGCAAC	295
Zb.12	CTTGCAGGCCTTGAATAGAGGAGTTAAGGAATGCAAC	296
Zb.13	GTTGCACAGTGCTAATTAGAGAAACTAGGAATGCAAC	297
Zb.14	CTAGCATATTCAGAACAAAGGGATTAAGGAATGCAAC	298
Zb.15	CTTTCATATTCAGAAACTAGGGGTTAAGGACTGCAAC	299
Zc.8	GTTGCATCCCTACGTCGTGAGCACCGGTGAGTGCAAC	300
Ze.5	GGAAAGGAATCCCCTGAAGGAAACGAGGGGG	301
Zg.3	GTGTCCATCAATCAGATTTGCGTTGGCCGGTGCAAT	302
Zb.16	GTTTCAGCGCACGAATTAACGAGATGAGAGATGCAAC	303
Zj.2	CTTTTAGACAGTTTAAATTCTAAAGGGTATAAAAC	307

[00145] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a crRNA sequence of Table 1 or Table 3.

[00146] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, or CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity)

with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, or CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, or CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, CasZc, CasZd, CasZe, CasZf, CasZg, CasZh, or CasZi crRNA sequence of Table 1 or Table 3.

[00147] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZa crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa crRNA sequence of Table 1 or Table 3.

[00148] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZb crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb crRNA sequence of Table 1 or Table 3.

[00149] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZc crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a

CasZc crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc crRNA sequence of Table 1 or Table 3.

[00150] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZd crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZd crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZd crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZd crRNA sequence of Table 1 or Table 3.

[00151] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZe crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZe crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZe crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZe crRNA sequence of Table 1 or Table 3.

[00152] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZf crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZf crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZf crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZf crRNA sequence of Table 1 or Table 3.

[00153] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZg crRNA sequence of Table 1 or Table 3. In

some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZg crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZg crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZg crRNA sequence of Table 1 or Table 3.

[00154] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZh crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZh crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZh crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZh crRNA sequence of Table 1 or Table 3.

[00155] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZi crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZi crRNA sequence of Table 1 or Table 3.

[00156] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZj crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZj crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a

CasZj crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZj crRNA sequence of Table 1 or Table 3.

[00157] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZk crRNA sequence of Table 1 or Table 3.

[00158] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZl crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZl crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZl crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZl crRNA sequence of Table 1 or Table 3.

[00159] In some cases, a subject CasZ guide RNA comprises (e.g., in addition to a guide sequence, e.g., as part of the protein-binding region) a CasZj, CasZl, or CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZj, CasZl, or CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZj, CasZl, or CasZk crRNA sequence of Table 1 or Table 3. In some cases, a subject CasZ guide RNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZj, CasZl, or CasZk crRNA sequence of Table 1 or Table 3.

CasZ transactivating noncoding RNA (trancRNA)

[00160] Composisions and methods of the present disclosure include a CasZ transactivating noncoding RNA ("trancRNA"; also referred to herein as a "CasZ trancRNA"). In some cases, a trancRNA forms a complex with a CasZ polypeptide of the present disclosure and a CasZ guide RNA. A trancRNA can be identified as a highly transcribed RNA encoded by a nucleotide sequence present in a CasZ locus. The sequence encoding a trancRNA is usually located between the *cas* genes and the array of the CasZ locus (the repeats) (e.g., can be located adjacent to the repeat sequences). Examples below demonstrate detection of a CasZ trancRNA. In some cases, a CasZ trancRNA co-immunoprecipitates (forms a complex with) with a CasZ polypeptide. In some cases, the presence of a CasZ trancRNA is required for function of the system. Data related to trancRNAs (e.g., their expression and their location on naturally occurring arrays) is presented in the examples section below.

[00161] In some cases, a CasZ trancRNA has a length of from 60 nucleotides (nt) to 270 nt (e.g., 60-260, 70-270, 70-260, or 75-255 nt). In some cases, a CasZ trancRNA (e.g., a CasZa trancRNA) has a length of from 60-150 nt (e.g., 60-140, 60-130, 65-150, 65-140, 65-130, 70-150, 70-140, or 70-130 nt). In some cases, a CasZ trancRNA (e.g., a CasZa trancRNA) has a length of from 70-130 nt. In some cases, a CasZ trancRNA (e.g., a CasZa trancRNA) has a length of about 80 nt. In some cases, a CasZ trancRNA (e.g., a CasZa trancRNA) has a length of about 90 nt. In some cases, a CasZ trancRNA (e.g., a CasZa trancRNA) has a length of about 120 nt.

[00162] In some cases, a CasZ trancRNA (e.g., a CasZb trancRNA) has a length of from 85-240 nt (e.g., 85-230, 85-220, 85-150, 85-130, 95-240, 95-230, 95-220, 95-150, or 95-130 nt). In some cases, a CasZ trancRNA (e.g., a CasZb trancRNA) has a length of from 95-120 nt. In some cases, a CasZ trancRNA (e.g., a CasZb trancRNA) has a length of about 105 nt. In some cases, a CasZ trancRNA (e.g., a CasZb trancRNA) has a length of about 115 nt. In some cases, a CasZ trancRNA (e.g., a CasZb trancRNA) has a length of about 215 nt.

[00163] In some cases, a CasZ trancRNA (e.g., a CasZc trancRNA) has a length of from 80-275 nt (e.g., 85-260 nt). In some cases, a CasZ trancRNA (e.g., a CasZc trancRNA) has a length of from 80-110 nt (e.g., 85-105 nt). In some cases, a CasZ trancRNA (e.g., a CasZc trancRNA) has a length of from 235-270 nt (e.g., 240-260 nt). In some cases, a CasZ trancRNA (e.g., a CasZc trancRNA) has a length of about 95 nt. In some cases, a CasZ trancRNA (e.g., a CasZc trancRNA) has a length of about 250 nt.

Example trancRNA sequences

[00164] Examples of trancRNA sequences for naturally existing CasZ proteins are shown in Table 2.

[00165] **Table 2. CasZ trancRNA sequences**

CasZ Protein	trancRNA sequence	SEQ ID NO

CasZ Protein	trancRNA sequence	SEQ ID NO
Za.1	CGATTCCTCCCTACAGTAGTTAGGTATAGCCGAAAGGTAG AGACTAAATCTGTAGTTGGAGTGGGCCGCTTGCATCGGCC	151
Za.2	TCGTCTCGAGGGTTACCAAAATTGGCACTTCTCGACTTTAG GCCGATGCAAGCGGCCCACTCCACTACAGATTTAGTCTCTA CCTTGCGGCTATACCTAACTTACTGTAGGGAGGAATCGTG	152
Za.3	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGT CCCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTG CATCAGCCTAA	153
Zb.2	CAGAATAATACTGACTTACTAAGATATCTTGAGGGTATACC CGAAAAGATTGGCGTTGTTGCAACGCAATAAGATGTAAAT CTGAAAAGGTTTGGAATCATATAAATAATTTTA	154
Zb.4	AAGCCAAGATATGGAATGCCATTGTAATATTATGGTGTTG ACTTAGTTTAGATTTAAACAATCTTCGATGGCTATATGCGG AAGGTTTGGCGTCGTTGTAACGC	155
Zb.6	CAGTGTGCATAGCTATAACACTACGCAAAGACTGCTAAAG AGCGATGTGCTCTATCGCAGTCTCACCTTTAATGGACTTAC GGATCTTTTGGAGCACTAAGCTCCGCTGCGGTGCAACACC GCCCTTTTCTTGCCTCTGCTTGCCCTTTCCGGTTATTATAGC CGGGAGAGTGCGGAAGATTACCGCTCTAGCTCGCAGCATG TTACTGAGTC	156
Zc.3	GCAAGTCATTCGGGGACACTTTTTGTTATTTAAAGTGTTTT AGATAAATCAGTGTCATGCTGAATAACGACCCGACCTATA AATAACATAATCC	157
Zc.5	GTCCTTAAGGTACTACACATTACATGTGAACGTGGAGCTA ATAATAGAAATATTATTAGACTACACCTTATTAATAACGGT AGGAGATCTATATGGTCTTGAATGGAATAGTAATTGTGAA ATTATAATTTCTGTTCTTAGCTACTTAAGATGGCTCGTTGC AAGCCACTCGGGGGCTCTCTTGAAGTCAAAGAGCTTTAGA CAAATCAGTGTCAAACTGAATAACGACCCGACCATGACTT CATAATCCCG	158

[00166] In some cases, a subject CasZ trancRNA comprises a CasZa trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa trancRNA sequence above, and has a length of from 60-150 nt (e.g., 60-140, 60-130, 65-150, 65-140, 65-130, 70-150, 70-140, or 70-130 nt).

[00167] In some cases, a subject CasZ trancRNA comprises a CasZb trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZb trancRNA sequence above, and has a length of from 85-240 nt (e.g., 85-230, 85-220, 85-150, 85-130, 95-240, 95-230, 95-220, 95-150, or 95-130 nt).

[00168] In some cases, a subject CasZ trancRNA comprises a CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZc trancRNA sequence above, and has a length of from 80-110 nt (e.g., 85-105 nt) or from 235-270 nt (e.g., 240-260 nt).

[00169] In some cases, a subject CasZ trancRNA comprises a CasZa, CasZb, or CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 70% or more identity (e.g., 75% or more, 80% or more, 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, or CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, or CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide sequence having 90% or more identity (e.g., 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, or CasZc trancRNA sequence above. In some cases, a subject CasZ trancRNA comprises a nucleotide

sequence having 80% or more identity (e.g., 85% or more, 90% or more, 93% or more, 95% or more, 97% or more, 98% or more, or 100% identity) with a CasZa, CasZb, or CasZc trancRNA sequence above, and has a length of from 60 nucleotides (nt) to 270 nt (e.g., 60-260, 70-270, 70-260, or 75-255 nt).

[00170] In some cases, a CasZ trancRNA comprises a modified nucleotide (e.g., methylated). In some cases, a CasZ trancRNA comprises one or more of: i) a base modification or substitution; ii) a backbone modification; iii) a modified internucleoside linkage; and iv) a modified sugar moiety. Possible nucleic acid modifications are described below.

CASZ SYSTEMS

[00171] The present disclosure provides a CasZ system. A CasZ system of the present disclosure can comprise one or more of: (1) a CasZ transactivating noncoding RNA (trancRNA) (referred to herein as a "CasZ trancRNA") or a nucleic acid encoding the CasZ trancRNA (e.g., an expression vector); (2) a CasZ protein (e.g., a wild type protein, a variant, a catalytically compromised variant, a CasZ fusion protein, and the like) or a nucleic acid encoding the CasZ protein (e.g., an RNA, an expression vector, and the like); and (3) a CasZ guide RNA (that binds to and provides sequence specificity to the CasZ protein, e.g., a guide RNA that can bind to a target sequence of a eukaryotic genome) or a nucleic acid encoding the CasZ guide RNA)(e.g., an expression vector). A CasZ system can include a host cell (e.g., a eukaryotic cell, a plant cell, a mammalian cell, a human cell) that comprises one or more of (1), (2), and (3) (in any combination), e.g., in some cases the host cell comprises a trancRNA and/or a nucleic acid encoding the trancRNA. In some cases, a CasZ system includes (e.g., in addition to the above) a donor template nucleic acid. In some cases, the CasZ system is a system of one or more nucleic acids (e.g., one or more expression vectors encoding any combination of the above).

NUCLEIC ACIDS

[00172] The present disclosure provides one or more nucleic acids comprising one or more of: a CasZ trancRNA sequence, a nucleotide sequence encoding a CasZ trancRNA, a nucleotide sequence encoding a CasZ polypeptide (e.g., a wild type CasZ protein, a nickase CasZ protein, a dCasZ protein, chimeric CasZ protein/CasZ fusion protein, and the like), a CasZ guide RNA sequence, a nucleotide sequence encoding a CasZ guide RNA, and a donor polynucleotide (donor template, donor DNA) sequence. In some cases, a subject nucleic acid (e.g., the one or more nucleic acids) is a recombinant expression vector (e.g., plasmid, viral vector, minicircle DNA, and the like). In some cases, the nucleotide sequence encoding the CasZ trancRNA, the nucleotide sequence encoding the CasZ protein, and/or the nucleotide sequence encoding the CasZ guide RNA is (are) operably linked to a promoter (e.g., an inducible promoter), e.g., one that is operable in a cell type of choice (e.g., a prokaryotic cell, a eukaryotic cell, a plant cell, an animal cell, a mammalian cell, a primate cell, a rodent cell, a human cell, etc.).

[00173] In some cases, a nucleotide sequence encoding a CasZ polypeptide of the present disclosure is codon optimized. This type of optimization can entail a mutation of a CasZ-encoding nucleotide sequence to mimic the codon preferences of the intended host organism or cell while encoding the same protein. Thus, the codons can be changed, but the encoded protein remains unchanged. For example, if the intended target cell was a human cell, a human codon-optimized CasZ-encoding nucleotide sequence could be used. As another non-limiting example, if the intended host cell were a mouse cell, then a mouse codon-optimized CasZ-encoding nucleotide sequence could be generated. As another non-limiting example, if the intended host cell were a plant cell, then a plant codon-optimized CasZ-encoding nucleotide sequence could be generated. As another non-limiting example, if the intended host cell were an insect cell, then an insect codon-optimized CasZ-encoding nucleotide sequence could be generated.

[00174] The present disclosure provides one or more recombinant expression vectors that include (in different recombinant expression vectors in some cases, and in the same recombinant expression vector in some cases): a CasZ trancRNA sequence, a nucleotide sequence encoding a CasZ trancRNA, a nucleotide sequence encoding a CasZ polypeptide (e.g., a wild type CasZ protein, a nickase CasZ protein, a dCasZ protein, chimeric CasZ protein/CasZ fusion protein, and the like), a CasZ guide RNA sequence, a nucleotide sequence encoding a CasZ guide RNA, and a donor polynucleotide (donor template, donor DNA) sequence. In some cases, a subject nucleic acid (e.g., the one or more nucleic acids) is a recombinant expression vector (e.g., plasmid, viral vector, minicircle DNA, and the like). In some cases, the nucleotide sequence encoding the CasZ trancRNA, the nucleotide sequence encoding the CasZ protein, and/or the nucleotide sequence encoding the CasZ guide RNA is (are) operably linked to a promoter (e.g., an inducible promoter), e.g., one that is operable in a cell type of choice (e.g., a prokarytoic cell, a eukaryotic cell, a plant cell, an animal cell, a mammalian cell, a primate cell, a rodent cell, a human cell, etc.).

[00175] Suitable expression vectors include viral expression vectors (e.g. viral vectors based on vaccinia virus; poliovirus; adenovirus (see, e.g., Li et al., Invest Opthalmol Vis Sci 35:2543 2549, 1994; Borras et al., Gene Ther 6:515 524, 1999; Li and Davidson, PNAS 92:7700 7704, 1995; Sakamoto et al., H Gene Ther 5:1088 1097, 1999; WO 94/12649, WO 93/03769; WO 93/19191; WO 94/28938; WO 95/11984 and WO 95/00655); adeno-associated virus (AAV) (see, e.g., Ali et al., Hum Gene Ther 9:81 86, 1998, Flannery et al., PNAS 94:6916 6921, 1997; Bennett et al., Invest Opthalmol Vis Sci 38:2857 2863, 1997; Jomary et al., Gene Ther 4:683 690, 1997, Rolling et al., Hum Gene Ther 10:641 648, 1999; Ali et al., Hum Mol Genet 5:591 594, 1996; Srivastava in WO 93/09239, Samulski et al., J. Vir. (1989) 63:3822-3828; Mendelson et al., Virol. (1988) 166:154-165; and Flotte et al., PNAS (1993) 90:10613-10617); SV40; herpes simplex virus; human immunodeficiency virus (see, e.g., Miyoshi et al., PNAS 94:10319 23, 1997; Takahashi et al., J Virol 73:7812 7816, 1999); a retroviral vector (e.g., Murine

Leukemia Virus, spleen necrosis virus, and vectors derived from retroviruses such as Rous Sarcoma Virus, Harvey Sarcoma Virus, avian leukosis virus, a lentivirus, human immunodeficiency virus, myeloproliferative sarcoma virus, and mammary tumor virus); and the like. In some cases, a recombinant expression vector of the present disclosure is a recombinant adeno-associated virus (AAV) vector. In some cases, a recombinant expression vector of the present disclosure is a recombinant lentivirus vector. In some cases, a recombinant expression vector of the present disclosure is a recombinant retroviral vector.

[00176] Depending on the host/vector system utilized, any of a number of suitable transcription and translation control elements, including constitutive and inducible promoters, transcription enhancer elements, transcription terminators, etc. may be used in the expression vector.

[00177] In some embodiments, a nucleotide sequence encoding a CasZ guide RNA is operably linked to a control element, e.g., a transcriptional control element, such as a promoter. In some embodiments, a nucleotide sequence encoding a CasZ protein or a CasZ fusion polypeptide is operably linked to a control element, e.g., a transcriptional control element, such as a promoter.

[00178] The transcriptional control element can be a promoter. In some cases, the promoter is a constitutively active promoter. In some cases, the promoter is a regulatable promoter. In some cases, the promoter is an inducible promoter. In some cases, the promoter is a tissue-specific promoter. In some cases, the promoter is a cell type-specific promoter. In some cases, the transcriptional control element (e.g., the promoter) is functional in a targeted cell type or targeted cell population. For example, in some cases, the transcriptional control element can be functional in eukaryotic cells, e.g., hematopoietic stem cells (e.g., mobilized peripheral blood (mPB) CD34(+) cell, bone marrow (BM) CD34(+) cell, etc.).

[00179] Non-limiting examples of eukaryotic promoters (promoters functional in a eukaryotic cell) include EF1α, those from cytomegalovirus (CMV) immediate early, herpes simplex virus (HSV) thymidine kinase, early and late SV40, long terminal repeats (LTRs) from retrovirus, and mouse metallothionein-I. Selection of the appropriate vector and promoter is well within the level of ordinary skill in the art. The expression vector may also contain a ribosome binding site for translation initiation and a transcription terminator. The expression vector may also include appropriate sequences for amplifying expression. The expression vector may also include nucleotide sequences encoding protein tags (e.g., 6xHis tag, hemagglutinin tag, fluorescent protein, etc.) that can be fused to the CasZ protein, thus resulting in a chimeric CasZ polypeptide.

[00180] In some cases, a nucleotide sequence encoding a CasZ guide RNA and/or a CasZ fusion polypeptide is operably linked to an inducible promoter. In some cases, a nucleotide sequence encoding a CasZ guide RNA and/or a CasZ fusion protein is operably linked to a constitutive promoter.

[00181] A promoter can be a constitutively active promoter (i.e., a promoter that is constitutively in an active/"ON" state), it may be an inducible promoter (i.e., a promoter whose state, active/"ON" or inactive/"OFF", is controlled by an external stimulus, e.g., the presence of a particular temperature, compound, or protein.), it may be a spatially restricted promoter (i.e., transcriptional control element, enhancer, etc.)(e.g., tissue specific promoter, cell type specific promoter, etc.), and it may be a temporally restricted promoter (i.e., the promoter is in the "ON" state or "OFF" state during specific stages of embryonic development or during specific stages of a biological process, e.g., hair follicle cycle in mice).

[00182] Suitable promoters can be derived from viruses and can therefore be referred to as viral promoters, or they can be derived from any organism, including prokaryotic or eukaryotic organisms. Suitable promoters can be used to drive expression by any RNA polymerase (e.g., pol I, pol II, pol III). Exemplary promoters include, but are not limited to the SV40 early promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), a rous sarcoma virus (RSV) promoter, a human U6 small nuclear promoter (U6) (Miyagishi et al., Nature Biotechnology 20, 497 - 500 (2002)), an enhanced U6 promoter (e.g., Xia et al., Nucleic Acids Res. 2003 Sep 1;31(17)), a human H1 promoter (H1), and the like.

[00183] In some cases, a nucleotide sequence encoding a CasZ guide RNA is operably linked to (under the control of) a promoter operable in a eukaryotic cell (e.g., a U6 promoter, an enhanced U6 promoter, an H1 promoter, and the like). As would be understood by one of ordinary skill in the art, when expressing an RNA (e.g., a guide RNA) from a nucleic acid (e.g., an expression vector) using a U6 promoter (e.g., in a eukaryotic cell), or another PolIII promoter, the RNA may need to be mutated if there are several Ts in a row (coding for Us in the RNA). This is because a string of Ts (e.g., 5 Ts) in DNA can act as a terminator for polymerase III (PolIII). Thus, in order to ensure transcription of a guide RNA in a eukaryotic cell it may sometimes be necessary to modify the sequence encoding the guide RNA to eliminate runs of Ts. In some cases, a nucleotide sequence encoding a CasZ protein (e.g., a wild type CasZ protein, a nickase CasZ protein, a dCasZ protein, a chimeric CasZ protein and the like) is operably linked to a promoter operable in a eukaryotic cell (e.g., a CMV promoter, an EF1α promoter, an estrogen receptor-regulated promoter, and the like).

[00184] Examples of inducible promoters include, but are not limited toT7 RNA polymerase promoter, T3 RNA polymerase promoter, Isopropyl-beta-D-thiogalactopyranoside (IPTG)-regulated promoter, lactose induced promoter, heat shock promoter, Tetracycline-regulated promoter, Steroid-regulated promoter, Metal-regulated promoter, estrogen receptor-regulated promoter, etc. Inducible promoters can therefore be regulated by molecules including, but not limited to, doxycycline; estrogen and/or an estrogen analog; IPTG; etc.

[00185] Inducible promoters suitable for use include any inducible promoter described herein or known to one of ordinary skill in the art. Examples of inducible promoters include, without limitation, chemically/biochemically-regulated and physically-regulated promoters such as alcohol-regulated promoters, tetracycline-regulated promoters (e.g., anhydrotetracycline (aTc)-responsive promoters and other tetracycline-responsive promoter systems, which include a tetracycline repressor protein (tetR), a tetracycline operator sequence (tetO) and a tetracycline transactivator fusion protein (tTA)), steroid-regulated promoters (e.g., promoters based on the rat glucocorticoid receptor, human estrogen receptor, moth ecdysone receptors, and promoters from the steroid/retinoid/thyroid receptor superfamily), metal-regulated promoters (e.g., promoters derived from metallothionein (proteins that bind and sequester metal ions) genes from yeast, mouse and human), pathogenesis-regulated promoters (e.g., induced by salicylic acid, ethylene or benzothiadiazole (BTH)), temperature/heat-inducible promoters (e.g., heat shock promoters), and light-regulated promoters (e.g., light responsive promoters from plant cells).

[00186] In some cases, the promoter is a spatially restricted promoter (i.e., cell type specific promoter, tissue specific promoter, etc.) such that in a multi-cellular organism, the promoter is active (i.e., "ON") in a subset of specific cells. Spatially restricted promoters may also be referred to as enhancers, transcriptional control elements, control sequences, etc. Any convenient spatially restricted promoter may be used as long as the promoter is functional in the targeted host cell (e.g., eukaryotic cell; prokaryotic cell).

[00187] In some cases, the promoter is a reversible promoter. Suitable reversible promoters, including reversible inducible promoters are known in the art. Such reversible promoters may be isolated and derived from many organisms, e.g., eukaryotes and prokaryotes. Modification of reversible promoters derived from a first organism for use in a second organism, e.g., a first prokaryote and a second a eukaryote, a first eukaryote and a second a prokaryote, etc., is well known in the art. Such reversible promoters, and systems based on such reversible promoters but also comprising additional control proteins, include, but are not limited to, alcohol regulated promoters (e.g., alcohol dehydrogenase I (alcA) gene promoter, promoters responsive to alcohol transactivator proteins (AlcR), etc.), tetracycline regulated promoters, (e.g., promoter systems including TetActivators, TetON, TetOFF, etc.), steroid regulated promoters (e.g., rat glucocorticoid receptor promoter systems, human estrogen receptor promoter systems, retinoid promoter systems, thyroid promoter systems, ecdysone promoter systems, mifepristone promoter systems, etc.), metal regulated promoters (e.g., metallothionein promoter systems, etc.), pathogenesis-related regulated promoters (e.g., salicylic acid regulated promoters, ethylene regulated promoters, benzothiadiazole regulated promoters, etc.), temperature regulated promoters (e.g., heat shock inducible promoters (e.g., HSP-70, HSP-90, soybean heat shock promoter, etc.), light regulated promoters, synthetic inducible promoters, and the like.

[00188] Methods of introducing a nucleic acid (e.g., DNA or RNA) (e.g., a nucleic acid comprising a donor polynucleotide sequence, one or more nucleic acids encoding a CasZ protein and/or a CasZ guide RNA and/or a CasZ trancRNA, and the like) into a host cell are known in the art, and any convenient method can be used to introduce a nucleic acid (e.g., an expression construct) into a cell. Suitable methods include e.g., viral infection, transfection, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct microinjection, nanoparticle-mediated nucleic acid delivery, and the like.

[00189] Introducing the recombinant expression vector into cells can occur in any culture media and under any culture conditions that promote the survival of the cells. Introducing the recombinant expression vector into a target cell can be carried out *in vivo* or *ex vivo*. Introducing the recombinant expression vector into a target cell can be carried out *in vitro*.

[00190] In some cases, a CasZ protein can be provided as RNA. The RNA can be provided by direct chemical synthesis or may be transcribed in vitro from a DNA (e.g., encoding the CasZ protein). Once synthesized, the RNA may be introduced into a cell by any of the well-known techniques for introducing nucleic acids into cells (e.g., microinjection, electroporation, transfection, etc.).

[00191] Nucleic acids may be provided to the cells using well-developed transfection techniques; see, e.g. Angel and Yanik (2010) PLoS ONE 5(7): e11756, and the commercially available TransMessenger® reagents from Qiagen, Stemfect™ RNA Transfection Kit from Stemgent, and TransIT®-mRNA Transfection Kit from Mirus Bio LLC. See also Beumer et al. (2008) PNAS 105(50):19821-19826.

[00192] Vectors may be provided directly to a target host cell. In other words, the cells are contacted with vectors comprising the subject nucleic acids (e.g., recombinant expression vectors having the donor template sequence and encoding the CasZ guide RNA; recombinant expression vectors encoding the CasZ protein; etc.) such that the vectors are taken up by the cells. Methods for contacting cells with nucleic acid vectors that are plasmids, include electroporation, calcium chloride transfection, microinjection, and lipofection are well known in the art. For viral vector delivery, cells can be contacted with viral particles comprising the subject viral expression vectors.

[00193] Retroviruses, for example, lentiviruses, are suitable for use in methods of the present disclosure. Commonly used retroviral vectors are "defective", i.e. unable to produce viral proteins required for productive infection. Rather, replication of the vector requires growth in a packaging cell line. To generate viral particles comprising nucleic acids of interest, the retroviral nucleic acids comprising the nucleic acid are packaged into viral capsids by a packaging cell line. Different packaging cell lines provide a different envelope protein (ecotropic, amphotropic or xenotropic) to be incorporated

into the capsid, this envelope protein determining the specificity of the viral particle for the cells (ecotropic for murine and rat; amphotropic for most mammalian cell types including human, dog and mouse; and xenotropic for most mammalian cell types except murine cells). The appropriate packaging cell line may be used to ensure that the cells are targeted by the packaged viral particles. Methods of introducing subject vector expression vectors into packaging cell lines and of collecting the viral particles that are generated by the packaging lines are well known in the art. Nucleic acids can also introduced by direct micro-injection (e.g., injection of RNA).

[00194] Vectors used for providing the nucleic acids encoding CasZ guide RNA and/or a CasZ polypeptide to a target host cell can include suitable promoters for driving the expression, that is, transcriptional activation, of the nucleic acid of interest. In other words, in some cases, the nucleic acid of interest will be operably linked to a promoter. This may include ubiquitously acting promoters, for example, the CMV-β-actin promoter, or inducible promoters, such as promoters that are active in particular cell populations or that respond to the presence of drugs such as tetracycline. By transcriptional activation, it is intended that transcription will be increased above basal levels in the target cell by 10 fold, by 100 fold, more usually by 1000 fold. In addition, vectors used for providing a nucleic acid encoding a CasZ guide RNA and/or a CasZ protein to a cell may include nucleic acid sequences that encode for selectable markers in the target cells, so as to identify cells that have taken up the CasZ guide RNA and/or CasZ protein.

[00195] A nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide, or a CasZ fusion polypeptide, is in some cases an RNA. Thus, a CasZ fusion protein can be introduced into cells as RNA. Methods of introducing RNA into cells are known in the art and may include, for example, direct injection, transfection, or any other method used for the introduction of DNA. A CasZ protein may instead be provided to cells as a polypeptide. Such a polypeptide may optionally be fused to a polypeptide domain that increases solubility of the product. The domain may be linked to the polypeptide through a defined protease cleavage site, e.g. a TEV sequence, which is cleaved by TEV protease. The linker may also include one or more flexible sequences, e.g. from 1 to 10 glycine residues. In some embodiments, the cleavage of the fusion protein is performed in a buffer that maintains solubility of the product, e.g. in the presence of from 0.5 to 2 M urea, in the presence of polypeptides and/or polynucleotides that increase solubility, and the like. Domains of interest include endosomolytic domains, e.g. influenza HA domain; and other polypeptides that aid in production, e.g. IF2 domain, GST domain, GRPE domain, and the like. The polypeptide may be formulated for improved stability. For example, the peptides may be PEGylated, where the polyethyleneoxy group provides for enhanced lifetime in the blood stream.

[00196] Additionally, or alternatively, a CasZ polypeptide of the present disclosure may be fused to a polypeptide permeant domain to promote uptake by the cell. A number of permeant domains are

known in the art and may be used in the non-integrating polypeptides of the present disclosure, including peptides, peptidomimetics, and non-peptide carriers. For example, a permeant peptide may be derived from the third alpha helix of *Drosophila melanogaster* transcription factor Antennapaedia, referred to as penetratin, which comprises the amino acid sequence RQIKIWFQNRRMKWKK (SEQ ID NO: 134). As another example, the permeant peptide comprises the HIV-1 tat basic region amino acid sequence, which may include, for example, amino acids 49-57 of naturally-occurring tat protein. Other permeant domains include poly-arginine motifs, for example, the region of amino acids 34-56 of HIV-1 rev protein, nona-arginine, octa-arginine, and the like. (See, for example, Futaki et al. (2003) Curr Protein Pept Sci. 2003 Apr; 4(2): 87-9 and 446; and Wender et al. (2000) Proc. Natl. Acad. Sci. U.S.A 2000 Nov. 21; 97(24):13003-8; published U.S. Patent applications 20030220334; 20030083256; 20030032593; and 20030022831, herein specifically incorporated by reference for the teachings of translocation peptides and peptoids). The nona-arginine (R9) sequence is one of the more efficient PTDs that have been characterized (Wender et al. 2000; Uemura et al. 2002). The site at which the fusion is made may be selected in order to optimize the biological activity, secretion or binding characteristics of the polypeptide. The optimal site will be determined by routine experimentation.

[00197] A CasZ polypeptide of the present disclosure may be produced *in vitro* or by eukaryotic cells or by prokaryotic cells, and it may be further processed by unfolding, e.g. heat denaturation, dithiothreitol reduction, etc. and may be further refolded, using methods known in the art.

[00198] Modifications of interest that do not alter primary sequence include chemical derivatization of polypeptides, e.g., acylation, acetylation, carboxylation, amidation, etc. Also included are modifications of glycosylation, e.g. those made by modifying the glycosylation patterns of a polypeptide during its synthesis and processing or in further processing steps; e.g. by exposing the polypeptide to enzymes which affect glycosylation, such as mammalian glycosylating or deglycosylating enzymes. Also embraced are sequences that have phosphorylated amino acid residues, e.g. phosphotyrosine, phosphoserine, or phosphothreonine.

[00199] Also suitable for inclusion in embodiments of the present disclosure are nucleic acids (e.g., encoding a CasZ guide RNA, encoding a CasZ fusion protein, etc.) and proteins (e.g., a CasZ fusion protein derived from a wild type protein or a variant protein) that have been modified using ordinary molecular biological techniques and synthetic chemistry so as to improve their resistance to proteolytic degradation, to change the target sequence specificity, to optimize solubility properties, to alter protein activity (e.g., transcription modulatory activity, enzymatic activity, etc.) or to render them more suitable. Analogs of such polypeptides include those containing residues other than naturally occurring L-amino acids, e.g. D-amino acids or non-naturally occurring synthetic amino acids. D-amino acids may be substituted for some or all of the amino acid residues.

[00200] A CasZ polypeptide of the present disclosure may be prepared by *in vitro* synthesis, using conventional methods as known in the art. Various commercial synthetic apparatuses are available, for example, automated synthesizers by Applied Biosystems, Inc., Beckman, etc. By using synthesizers, naturally occurring amino acids may be substituted with unnatural amino acids. The particular sequence and the manner of preparation will be determined by convenience, economics, purity required, and the like.

[00201] If desired, various groups may be introduced into the peptide during synthesis or during expression, which allow for linking to other molecules or to a surface. Thus cysteines can be used to make thioethers, histidines for linking to a metal ion complex, carboxyl groups for forming amides or esters, amino groups for forming amides, and the like.

[00202] A CasZ polypeptide of the present disclosure may also be isolated and purified in accordance with conventional methods of recombinant synthesis. A lysate may be prepared of the expression host and the lysate purified using high performance liquid chromatography (HPLC), exclusion chromatography, gel electrophoresis, affinity chromatography, or other purification technique. For the most part, the compositions which are used will comprise 20% or more by weight of the desired product, more usually 75% or more by weight, preferably 95% or more by weight, and for therapeutic purposes, usually 99.5% or more by weight, in relation to contaminants related to the method of preparation of the product and its purification. Usually, the percentages will be based upon total protein. Thus, in some cases, a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure is at least 80% pure, at least 85% pure, at least 90% pure, at least 95% pure, at least 98% pure, or at least 99% pure (e.g., free of contaminants, non-CasZ proteins or other macromolecules, etc.).

[00203] To induce cleavage or any desired modification to a target nucleic acid (e.g., genomic DNA), or any desired modification to a polypeptide associated with target nucleic acid, the CasZ guide RNA and/or the CasZ polypeptide and/or the CasZ trancRNA, and/or the donor template sequence, whether they be introduced as nucleic acids or polypeptides, can be provided to the cells for about 30 minutes to about 24 hours, e.g., 1 hour, 1.5 hours, 2 hours, 2.5 hours, 3 hours, 3.5 hours 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 12 hours, 16 hours, 18 hours, 20 hours, or any other period from about 30 minutes to about 24 hours, which may be repeated with a frequency of about every day to about every 4 days, e.g., every 1.5 days, every 2 days, every 3 days, or any other frequency from about every day to about every four days. The agent(s) may be provided to the subject cells one or more times, e.g. one time, twice, three times, or more than three times, and the cells allowed to incubate with the agent(s) for some amount of time following each contacting event e.g. 16-24 hours, after which time the media is replaced with fresh media and the cells are cultured further.

[00204] In cases in which two or more different targeting complexes are provided to the cell (e.g., two different CasZ guide RNAs that are complementary to different sequences within the same or different target nucleic acid), the complexes may be provided simultaneously (e.g. as two polypeptides and/or nucleic acids), or delivered simultaneously. Alternatively, they may be provided consecutively, e.g. the targeting complex being provided first, followed by the second targeting complex, etc. or vice versa.

[00205] To improve the delivery of a DNA vector into a target cell, the DNA can be protected from damage and its entry into the cell facilitated, for example, by using lipoplexes and polyplexes. Thus, in some cases, a nucleic acid of the present disclosure (e.g., a recombinant expression vector of the present disclosure) can be covered with lipids in an organized structure like a micelle or a liposome. When the organized structure is complexed with DNA it is called a lipoplex. There are three types of lipids, anionic (negatively-charged), neutral, or cationic (positively-charged). Lipoplexes that utilize cationic lipids have proven utility for gene transfer. Cationic lipids, due to their positive charge, naturally complex with the negatively charged DNA. Also as a result of their charge, they interact with the cell membrane. Endocytosis of the lipoplex then occurs, and the DNA is released into the cytoplasm. The cationic lipids also protect against degradation of the DNA by the cell.

[00206] Complexes of polymers with DNA are called polyplexes. Most polyplexes consist of cationic polymers and their production is regulated by ionic interactions. One large difference between the methods of action of polyplexes and lipoplexes is that polyplexes cannot release their DNA load into the cytoplasm, so to this end, co-transfection with endosome-lytic agents (to lyse the endosome that is made during endocytosis) such as inactivated adenovirus must occur. However, this is not always the case; polymers such as polyethylenimine have their own method of endosome disruption as does chitosan and trimethylchitosan.

[00207] Dendrimers, a highly branched macromolecule with a spherical shape, may be also be used to genetically modify stem cells. The surface of the dendrimer particle may be functionalized to alter its properties. In particular, it is possible to construct a cationic dendrimer (i.e., one with a positive surface charge). When in the presence of genetic material such as a DNA plasmid, charge complementarity leads to a temporary association of the nucleic acid with the cationic dendrimer. On reaching its destination, the dendrimer-nucleic acid complex can be taken up into a cell by endocytosis.

[00208] In some cases, a nucleic acid of the disclosure (e.g., an expression vector) includes an insertion site for a guide sequence of interest. For example, a nucleic acid can include an insertion site for a guide sequence of interest, where the insertion site is immediately adjacent to a nucleotide sequence encoding the portion of a CasZ guide RNA that does not change when the guide sequence is changed to hybrized to a desired target sequence (e.g., sequences that contribute to the CasZ binding aspect of the

guide RNA, e.g, the sequences that contribute to the dsRNA duplex(es) of the CasZ guide RNA – this portion of the guide RNA can also be referred to as the 'scaffold' or 'constant region' of the guide RNA). Thus, in some cases, a subject nucleic acid (e.g., an expression vector) includes a nucleotide sequence encoding a CasZ guide RNA, except that the portion encoding the guide sequence portion of the guide RNA is an insertion sequence (an insertion site). An insertion site is any nucleotide sequence used for the insertion of a desired sequence. "Insertion sites" for use with various technologies are known to those of ordinary skill in the art and any convenient insertion site can be used. An insertion site can be for any method for manipulating nucleic acid sequences. For example, in some cases the insertion site is a multiple cloning site (MCS) (e.g., a site including one or more restriction enzyme recognition sequences), a site for ligation independent cloning, a site for recombination-based cloning (e.g., recombination based on *att* sites), a nucleotide sequence recognized by a CRISPR/Cas (e.g. Cas9) based technology, and the like.

[00209] An insertion site can be any desirable length, and can depend on the type of insertion site (e.g., can depend on whether (and how many) the site includes one or more restriction enzyme recognition sequences, whether the site includes a target site for a CRISPR/Cas protein, etc.). In some cases, an insertion site of a subject nucleic acid is 3 or more nucleotides (nt) in length (e.g., 5 or more, 8 or more, 10 or more, 15 or more, 17 or more, 18 or more, 19 or more, 20 or more or 25 or more, or 30 or more nt in length). In some cases, the length of an insertion site of a subject nucleic acid has a length in a range of from 2 to 50 nucleotides (nt) (e.g., from 2 to 40 nt, from 2 to 30 nt, from 2 to 25 nt, from 2 to 20 nt, from 5 to 50 nt, from 5 to 40 nt, from 5 to 30 nt, from 5 to 25 nt, from 5 to 20 nt, from 10 to 50 nt, from 10 to 40 nt, from 10 to 30 nt, from 10 to 25 nt, from 10 to 20 nt, from 17 to 50 nt, from 17 to 40 nt, from 17 to 30 nt, from 17 to 25 nt). In some cases, the length of an insertion site of a subject nucleic acid has a length in a range of from 5 to 40 nt.

Nucleic acid modifications

[00210] In some embodiments, a subject nucleic acid (e.g., a CasZ guide RNA or trancRNA) has one or more modifications, e.g., a base modification, a backbone modification, etc., to provide the nucleic acid with a new or enhanced feature (e.g., improved stability). A nucleoside is a base-sugar combination. The base portion of the nucleoside is normally a heterocyclic base. The two most common classes of such heterocyclic bases are the purines and the pyrimidines. Nucleotides are nucleosides that further include a phosphate group covalently linked to the sugar portion of the nucleoside. For those nucleosides that include a pentofuranosyl sugar, the phosphate group can be linked to the 2', the 3', or the 5' hydroxyl moiety of the sugar. In forming oligonucleotides, the phosphate groups covalently link adjacent nucleosides to one another to form a linear polymeric compound. In turn, the respective ends of this linear polymeric compound can be further joined to form a circular compound, however, linear compounds are suitable. In addition, linear compounds may have internal nucleotide base

complementarity and may therefore fold in a manner as to produce a fully or partially double-stranded compound. Within oligonucleotides, the phosphate groups are commonly referred to as forming the internucleoside backbone of the oligonucleotide. The normal linkage or backbone of RNA and DNA is a 3' to 5' phosphodiester linkage.

[00211] Suitable nucleic acid modifications include, but are not limited to: 2'Omethyl modified nucleotides, 2' Fluoro modified nucleotides, locked nucleic acid (LNA) modified nucleotides, peptide nucleic acid (PNA) modified nucleotides, nucleotides with phosphorothioate linkages, and a 5' cap (e.g., a 7-methylguanylate cap (m7G)). Additional details and additional modifications are described below.

[00212] A 2'-O-Methyl modified nucleotide (also referred to as 2'-O-Methyl RNA) is a naturally occurring modification of RNA found in tRNA and other small RNAs that arises as a post-transcriptional modification. Oligonucleotides can be directly synthesized that contain 2'-O-Methyl RNA. This modification increases Tm of RNA:RNA duplexes but results in only small changes in RNA:DNA stability. It is stabile with respect to attack by single-stranded ribonucleases and is typically 5 to 10-fold less susceptible to DNases than DNA. It is commonly used in antisense oligos as a means to increase stability and binding affinity to the target message.

[00213] 2' Fluoro modified nucleotides (e.g., 2' Fluoro bases) have a fluorine modified ribose which increases binding affinity (Tm) and also confers some relative nuclease resistance when compared to native RNA. These modifications are commonly employed in ribozymes and siRNAs to improve stability in serum or other biological fluids.

[00214] LNA bases have a modification to the ribose backbone that locks the base in the C3'-endo position, which favors RNA A-type helix duplex geometry. This modification significantly increases Tm and is also very nuclease resistant. Multiple LNA insertions can be placed in an oligo at any position except the 3'-end. Applications have been described ranging from antisense oligos to hybridization probes to SNP detection and allele specific PCR. Due to the large increase in Tm conferred by LNAs, they also can cause an increase in primer dimer formation as well as self-hairpin formation. In some cases, the number of LNAs incorporated into a single oligo is 10 bases or less.

[00215] The phosphorothioate (PS) bond (i.e., a phosphorothioate linkage) substitutes a sulfur atom for a non-bridging oxygen in the phosphate backbone of a nucleic acid (e.g., an oligo). This modification renders the internucleotide linkage resistant to nuclease degradation. Phosphorothioate bonds can be introduced between the last 3-5 nucleotides at the 5'- or 3'-end of the oligo to inhibit exonuclease degradation. Including phosphorothioate bonds within the oligo (e.g., throughout the entire oligo) can help reduce attack by endonucleases as well.

[00216] In some embodiments, a subject nucleic acid has one or more nucleotides that are 2'-O-Methyl modified nucleotides. In some embodiments, a subject nucleic acid (e.g., a guide RNA, a tranc

RNA, etc.) has one or more 2' Fluoro modified nucleotides. In some embodiments, a subject nucleic acid (e.g., a dsRNA, a siNA, etc.) has one or more LNA bases. In some embodiments, a subject nucleic acid (e.g., a dsRNA, a siNA, etc.) has one or more nucleotides that are linked by a phosphorothioate bond (i.e., the subject nucleic acid has one or more phosphorothioate linkages). In some embodiments, a subject nucleic acid (e.g., a dsRNA, a siNA, etc.) has a 5' cap (e.g., a 7-methylguanylate cap (m7G)). In some embodiments, a subject nucleic acid (e.g., a guide RNA, a tranc RNA, etc.) has a combination of modified nucleotides. For example, a subject nucleic acid (e.g., a guide RNA, a tranc RNA, etc.) can have a 5' cap (e.g., a 7-methylguanylate cap (m7G)) in addition to having one or more nucleotides with other modifications (e.g., a 2'-O-Methyl nucleotide and/or a 2' Fluoro modified nucleotide and/or a LNA base and/or a phosphorothioate linkage).

Modified backbones and modified internucleoside linkages

[00217] Examples of suitable nucleic acids (e.g., a CasZ guide RNA and/or CasZ trancRNA) containing modifications include nucleic acids containing modified backbones or non-natural internucleoside linkages. Nucleic acids having modified backbones include those that retain a phosphorus atom in the backbone and those that do not have a phosphorus atom in the backbone.

[00218] Suitable modified oligonucleotide backbones containing a phosphorus atom therein include, for example, phosphorothioates, chiral phosphorothioates, phosphorodithioates, phosphotriesters, aminoalkylphosphotriesters, methyl and other alkyl phosphonates including 3'-alkylene phosphonates, 5'-alkylene phosphonates and chiral phosphonates, phosphinates, phosphoramidates including 3'-amino phosphoramidate and aminoalkylphosphoramidates, phosphorodiamidates, thionophosphoramidates, thionoalkylphosphonates, thionoalkylphosphotriesters, selenophosphates and boranophosphates having normal 3'-5' linkages, 2'-5' linked analogs of these, and those having inverted polarity wherein one or more internucleotide linkages is a 3' to 3', 5' to 5' or 2' to 2' linkage. Suitable oligonucleotides having inverted polarity comprise a single 3' to 3' linkage at the 3'-most internucleotide linkage i.e. a single inverted nucleoside residue which may be a basic (the nucleobase is missing or has a hydroxyl group in place thereof). Various salts (such as, for example, potassium or sodium), mixed salts and free acid forms are also included.

[00219] In some embodiments, a subject nucleic acid comprises one or more phosphorothioate and/or heteroatom internucleoside linkages, in particular $-CH_2-NH-O-CH_2-$, $-CH_2-N(CH_3)-O-CH_2-$ (known as a methylene (methylimino) or MMI backbone), $-CH_2-O-N(CH_3)-CH_2-$, $-CH_2-N(CH_3)-N(CH_3)-CH_2-$ and $-O-N(CH_3)-CH_2-CH_2-$ (wherein the native phosphodiester internucleotide linkage is represented as $-O-P(=O)(OH)-O-CH_2-$). MMI type internucleoside linkages are disclosed in the above referenced U.S. Pat. No. 5,489,677, the disclosure of which is incorporated herein by reference in its entirety. Suitable amide internucleoside linkages are disclosed in U.S. Pat. No. 5,602,240, the disclosure of which is incorporated herein by reference in its entirety.

[00220] Also suitable are nucleic acids having morpholino backbone structures as described in, e.g., U.S. Pat. No. 5,034,506. For example, in some embodiments, a subject nucleic acid comprises a 6-membered morpholino ring in place of a ribose ring. In some of these embodiments, a phosphorodiamidate or other non-phosphodiester internucleoside linkage replaces a phosphodiester linkage.

[00221] Suitable modified polynucleotide backbones that do not include a phosphorus atom therein have backbones that are formed by short chain alkyl or cycloalkyl internucleoside linkages, mixed heteroatom and alkyl or cycloalkyl internucleoside linkages, or one or more short chain heteroatomic or heterocyclic internucleoside linkages. These include those having morpholino linkages (formed in part from the sugar portion of a nucleoside); siloxane backbones; sulfide, sulfoxide and sulfone backbones; formacetyl and thioformacetyl backbones; methylene formacetyl and thioformacetyl backbones; riboacetyl backbones; alkene containing backbones; sulfamate backbones; methyleneimino and methylenehydrazino backbones; sulfonate and sulfonamide backbones; amide backbones; and others having mixed N, O, S and CH_2 component parts.

Mimetics

[00222] A subject nucleic acid can be a nucleic acid mimetic. The term "mimetic" as it is applied to polynucleotides is intended to include polynucleotides wherein only the furanose ring or both the furanose ring and the internucleotide linkage are replaced with non-furanose groups, replacement of only the furanose ring is also referred to in the art as being a sugar surrogate. The heterocyclic base moiety or a modified heterocyclic base moiety is maintained for hybridization with an appropriate target nucleic acid. One such nucleic acid, a polynucleotide mimetic that has been shown to have excellent hybridization properties, is referred to as a peptide nucleic acid (PNA). In PNA, the sugar-backbone of a polynucleotide is replaced with an amide containing backbone, in particular an aminoethylglycine backbone. The nucleotides are retained and are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone.

[00223] One polynucleotide mimetic that has been reported to have excellent hybridization properties is a peptide nucleic acid (PNA). The backbone in PNA compounds is two or more linked aminoethylglycine units which gives PNA an amide containing backbone. The heterocyclic base moieties are bound directly or indirectly to aza nitrogen atoms of the amide portion of the backbone. Representative U.S. patents that describe the preparation of PNA compounds include, but are not limited to: U.S. Pat. Nos. 5,539,082; 5,714,331; and 5,719,262, the disclosures of which are incorporated herein by reference in their entirety.

[00224] Another class of polynucleotide mimetic that has been studied is based on linked morpholino units (morpholino nucleic acid) having heterocyclic bases attached to the morpholino ring. A number of

linking groups have been reported that link the morpholino monomeric units in a morpholino nucleic acid. One class of linking groups has been selected to give a non-ionic oligomeric compound. The non-ionic morpholino-based oligomeric compounds are less likely to have undesired interactions with cellular proteins. Morpholino-based polynucleotides are non-ionic mimics of oligonucleotides which are less likely to form undesired interactions with cellular proteins (Dwaine A. Braasch and David R. Corey, *Biochemistry*, 2002, 41(14), 4503-4510). Morpholino-based polynucleotides are disclosed in U.S. Pat. No. 5,034,506, the disclosure of which is incorporated herein by reference in its entirety. A variety of compounds within the morpholino class of polynucleotides have been prepared, having a variety of different linking groups joining the monomeric subunits.

[00225] A further class of polynucleotide mimetic is referred to as cyclohexenyl nucleic acids (CeNA). The furanose ring normally present in a DNA/RNA molecule is replaced with a cyclohexenyl ring. CeNA DMT protected phosphoramidite monomers have been prepared and used for oligomeric compound synthesis following classical phosphoramidite chemistry. Fully modified CeNA oligomeric compounds and oligonucleotides having specific positions modified with CeNA have been prepared and studied (see Wang et al., *J. Am. Chem. Soc.*, 2000, 122, 8595-8602, the disclosure of which is incorporated herein by reference in its entirety). In general, the incorporation of CeNA monomers into a DNA chain increases its stability of a DNA/RNA hybrid. CeNA oligoadenylates formed complexes with RNA and DNA complements with similar stability to the native complexes. The study of incorporating CeNA structures into natural nucleic acid structures was shown by NMR and circular dichroism to proceed with easy conformational adaptation.

[00226] A further modification includes Locked Nucleic Acids (LNAs) in which the 2'-hydroxyl group is linked to the 4' carbon atom of the sugar ring thereby forming a 2'-C,4'-C-oxymethylene linkage thereby forming a bicyclic sugar moiety. The linkage can be a methylene (-CH_2-), group bridging the 2' oxygen atom and the 4' carbon atom wherein n is 1 or 2 (Singh et al., *Chem. Commun.*, 1998, 4, 455-456, the disclosure of which is incorporated herein by reference in its entirety). LNA and LNA analogs display very high duplex thermal stabilities with complementary DNA and RNA (Tm=+3 to +10° C), stability towards 3'-exonucleolytic degradation and good solubility properties. Potent and nontoxic antisense oligonucleotides containing LNAs have been described (e.g., Wahlestedt et al., *Proc. Natl. Acad. Sci.* U.S.A., 2000, 97, 5633-5638, the disclosure of which is incorporated herein by reference in its entirety).

[00227] The synthesis and preparation of the LNA monomers adenine, cytosine, guanine, 5-methyl-cytosine, thymine and uracil, along with their oligomerization, and nucleic acid recognition properties have been described (e.g., Koshkin et al., *Tetrahedron*, 1998, 54, 3607-3630, the disclosure of which is incorporated herein by reference in its entirety). LNAs and preparation thereof are also described in WO 98/39352 and WO 99/14226, as well as U.S. applications 20120165514, 20100216983, 20090041809,

20060117410, 20040014959, 20020094555, and 20020086998, the disclosures of which are incorporated herein by reference in their entirety.

Modified sugar moieties

[00228] A subject nucleic acid can also include one or more substituted sugar moieties. Suitable polynucleotides comprise a sugar substituent group selected from: OH; F; O-, S-, or N-alkyl; O-, S-, or N-alkenyl; O-, S- or N-alkynyl; or O-alkyl-O-alkyl, wherein the alkyl, alkenyl and alkynyl may be substituted or unsubstituted C.sub.1 to C_{10} alkyl or C_2 to C_{10} alkenyl and alkynyl. Particularly suitable are $O((CH_2)_nO)_mCH_3$, $O(CH_2)_nOCH_3$, $O(CH_2)_nNH_2$, $O(CH_2)_nCH_3$, $O(CH_2)_nONH_2$, and $O(CH_2)_nON((CH_2)_nCH_3)_2$, where n and m are from 1 to about 10. Other suitable polynucleotides comprise a sugar substituent group selected from: C_1 to C_{10} lower alkyl, substituted lower alkyl, alkenyl, alkynyl, alkaryl, aralkyl, O-alkaryl or O-aralkyl, SH, SCH_3, OCN, Cl, Br, CN, CF_3, OCF_3, $SOCH_3$, SO_2CH_3, ONO_2, NO_2, N_3, NH_2, heterocycloalkyl, heterocycloalkaryl, aminoalkylamino, polyalkylamino, substituted silyl, an RNA cleaving group, a reporter group, an intercalator, a group for improving the pharmacokinetic properties of an oligonucleotide, or a group for improving the pharmacodynamic properties of an oligonucleotide, and other substituents having similar properties. A suitable modification includes 2'-methoxyethoxy (2'-O-CH_2 CH_2OCH_3, also known as 2'-O-(2-methoxyethyl) or 2'-MOE) (Martin et al., *Helv. Chim. Acta*, 1995, 78, 486-504, the disclosure of which is incorporated herein by reference in its entirety) i.e., an alkoxyalkoxy group. A further suitable modification includes 2'-dimethylaminooxyethoxy, i.e., a $O(CH_2)_2ON(CH_3)_2$ group, also known as 2'-DMAOE, as described in examples hereinbelow, and 2'-dimethylaminoethoxyethoxy (also known in the art as 2'-O-dimethyl-amino-ethoxy-ethyl or 2'-DMAEOE), i.e., 2'-O-CH_2-O-CH_2-$N(CH_3)_2$.

[00229] Other suitable sugar substituent groups include methoxy (-O-CH_3), aminopropoxy (--O CH_2 CH_2 CH_2NH_2), allyl (-CH_2-CH=CH_2), -O-allyl (--O-- CH_2—CH=CH_2) and fluoro (F). 2'-sugar substituent groups may be in the arabino (up) position or ribo (down) position. A suitable 2'-arabino modification is 2'-F. Similar modifications may also be made at other positions on the oligomeric compound, particularly the 3' position of the sugar on the 3' terminal nucleoside or in 2'-5' linked oligonucleotides and the 5' position of 5' terminal nucleotide. Oligomeric compounds may also have sugar mimetics such as cyclobutyl moieties in place of the pentofuranosyl sugar.

Base modifications and substitutions

[00230] A subject nucleic acid may also include nucleobase (often referred to in the art simply as "base") modifications or substitutions. As used herein, "unmodified" or "natural" nucleobases include the purine bases adenine (A) and guanine (G), and the pyrimidine bases thymine (T), cytosine (C) and uracil (U). Modified nucleobases include other synthetic and natural nucleobases such as 5-methylcytosine (5-me-C), 5-hydroxymethyl cytosine, xanthine, hypoxanthine, 2-aminoadenine, 6-methyl and other alkyl derivatives of adenine and guanine, 2-propyl and other alkyl derivatives of adenine and guanine, 2-

thiouracil, 2-thiothymine and 2-thiocytosine, 5-halouracil and cytosine, 5-propynyl (-C=C-CH_3) uracil and cytosine and other alkynyl derivatives of pyrimidine bases, 6-azo uracil, cytosine and thymine, 5-uracil (pseudouracil), 4-thiouracil, 8-halo, 8-amino, 8-thiol, 8-thioalkyl, 8-hydroxyl and other 8-substituted adenines and guanines, 5-halo particularly 5-bromo, 5-trifluoromethyl and other 5-substituted uracils and cytosines, 7-methylguanine and 7-methyladenine, 2-F-adenine, 2-amino-adenine, 8-azaguanine and 8-azaadenine, 7-deazaguanine and 7-deazaadenine and 3-deazaguanine and 3-deazaadenine. Further modified nucleobases include tricyclic pyrimidines such as phenoxazine cytidine(1H-pyrimido(5,4-b)(1,4)benzoxazin-2(3H)-one), phenothiazine cytidine (1H-pyrimido(5,4-b)(1,4)benzothiazin-2(3H)-one), G-clamps such as a substituted phenoxazine cytidine (e.g. 9-(2-aminoethoxy)-H-pyrimido(5,4-(b) (1,4)benzoxazin-2(3H)-one), carbazole cytidine (2H-pyrimido(4,5-b)indol-2-one), pyridoindole cytidine (H-pyrido(3',2':4,5)pyrrolo(2,3-d)pyrimidin-2-one).

[00231] Heterocyclic base moieties may also include those in which the purine or pyrimidine base is replaced with other heterocycles, for example 7-deaza-adenine, 7-deazaguanosine, 2-aminopyridine and 2-pyridone. Further nucleobases include those disclosed in U.S. Pat. No. 3,687,808, those disclosed in *The Concise Encyclopedia Of Polymer Science And Engineering*, pages 858-859, Kroschwitz, J. I., ed. John Wiley & Sons, 1990, those disclosed by Englisch et al., *Angewandte Chemie, International Edition*, 1991, 30, 613, and those disclosed by Sanghvi, Y. S., *Chapter 15, Antisense Research and Applications*, pages 289-302, Crooke, S. T. and Lebleu, B., ed., CRC Press, 1993; the disclosures of which are incorporated herein by reference in their entirety. Certain of these nucleobases are useful for increasing the binding affinity of an oligomeric compound. These include 5-substituted pyrimidines, 6-azapyrimidines and N-2, N-6 and O-6 substituted purines, including 2-aminopropyladenine, 5-propynyluracil and 5-propynylcytosine. 5-methylcytosine substitutions have been shown to increase nucleic acid duplex stability by 0.6-1.2° C. (Sanghvi et al., eds., *Antisense Research and Applications*, CRC Press, Boca Raton, 1993, pp. 276-278; the disclosure of which is incorporated herein by reference in its entirety) and are suitable base substitutions, e.g., when combined with 2'-O-methoxyethyl sugar modifications.

Conjugates

[00232] Another possible modification of a subject nucleic acid involves chemically linking to the polynucleotide one or more moieties or conjugates which enhance the activity, cellular distribution or cellular uptake of the oligonucleotide. These moieties or conjugates can include conjugate groups covalently bound to functional groups such as primary or secondary hydroxyl groups. Conjugate groups include, but are not limited to, intercalators, reporter molecules, polyamines, polyamides, polyethylene glycols, polyethers, groups that enhance the pharmacodynamic properties of oligomers, and groups that enhance the pharmacokinetic properties of oligomers. Suitable conjugate groups include, but are not limited to, cholesterols, lipids, phospholipids, biotin, phenazine, folate, phenanthridine, anthraquinone,

acridine, fluoresceins, rhodamines, coumarins, and dyes. Groups that enhance the pharmacodynamic properties include groups that improve uptake, enhance resistance to degradation, and/or strengthen sequence-specific hybridization with the target nucleic acid. Groups that enhance the pharmacokinetic properties include groups that improve uptake, distribution, metabolism or excretion of a subject nucleic acid.

[00233] Conjugate moieties include but are not limited to lipid moieties such as a cholesterol moiety (Letsinger et al., *Proc. Natl. Acad. Sci.* USA, 1989, 86, 6553-6556), cholic acid (Manoharan et al., *Bioorg. Med. Chem. Let.*, 1994, 4, 1053-1060), a thioether, e.g., hexyl-S-tritylthiol (Manoharan et al., *Ann. N.Y. Acad. Sci.*, 1992, 660, 306-309; Manoharan et al., Bioorg. *Med. Chem. Let.*, 1993, 3, 2765-2770), a thiocholesterol (Oberhauser et al., *Nucl. Acids Res.*, 1992, 20, 533-538), an aliphatic chain, e.g., dodecandiol or undecyl residues (Saison-Behmoaras et al., *EMBO J.*, 1991, 10, 1111-1118; Kabanov et al., *FEBS Lett.*, 1990, 259, 327-330; Svinarchuk et al., *Biochimie*, 1993, 75, 49-54), a phospholipid, e.g., di-hexadecyl-rac-glycerol or triethylammonium 1,2-di-O-hexadecyl-rac-glycero-3-H-phosphonate (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654; Shea et al., *Nucl. Acids Res.*, 1990, 18, 3777-3783), a polyamine or a polyethylene glycol chain (Manoharan et al., *Nucleosides & Nucleotides*, 1995, 14, 969-973), or adamantane acetic acid (Manoharan et al., *Tetrahedron Lett.*, 1995, 36, 3651-3654), a palmityl moiety (Mishra et al., *Biochim. Biophys. Acta*, 1995, 1264, 229-237), or an octadecylamine or hexylamino-carbonyl-oxycholesterol moiety (Crooke et al., *J. Pharmacol. Exp. Ther.*, 1996, 277, 923-937).

[00234] A conjugate may include a "Protein Transduction Domain" or PTD (also known as a CPP – cell penetrating peptide), which may refer to a polypeptide, polynucleotide, carbohydrate, or organic or inorganic compound that facilitates traversing a lipid bilayer, micelle, cell membrane, organelle membrane, or vesicle membrane. A PTD attached to another molecule, which can range from a small polar molecule to a large macromolecule and/or a nanoparticle, facilitates the molecule traversing a membrane, for example going from extracellular space to intracellular space, or cytosol to within an organelle (e.g., the nucleus). In some cases, a PTD is covalently linked to the 3' end of an exogenous polynucleotide. In some cases, a PTD is covalently linked to the 5' end of an exogenous polynucleotide. Exemplary PTDs include but are not limited to a minimal undecapeptide protein transduction domain (corresponding to residues 47-57 of HIV-1 TAT comprising YGRKKRRQRRR; SEQ ID NO: 130); a polyarginine sequence comprising a number of arginines sufficient to direct entry into a cell (e.g., 3, 4, 5, 6, 7, 8, 9, 10, or 10-50 arginines); a VP22 domain (Zender et al. (2002) *Cancer Gene Ther.* 9(6):489-96); an Drosophila Antennapedia protein transduction domain (Noguchi et al. (2003) *Diabetes* 52(7):1732-1737); a truncated human calcitonin peptide (Trehin et al. (2004) *Pharm. Research* 21:1248-1256); polylysine (Wender et al. (2000) *Proc. Natl. Acad. Sci. USA* 97:13003-13008); RRQRRTSKLMKR SEQ ID NO: 131); Transportan GWTLNSAGYLLGKINLKALAALAKKIL SEQ ID NO: 132);

KALAWEAKLAKALAKALAKHLAKALAKALKCEA SEQ ID NO: 133); and RQIKIWFQNRRMKWKK SEQ ID NO: 134). Exemplary PTDs include but are not limited to, YGRKKRRQRRR SEQ ID NO: 130), RKKRRQRRR SEQ ID NO: 135); an arginine homopolymer of from 3 arginine residues to 50 arginine residues; Exemplary PTD domain amino acid sequences include, but are not limited to, any of the following: YGRKKRRQRRR SEQ ID NO: 130); RKKRRQRR SEQ ID NO: 136); YARAAARQARA SEQ ID NO: 137); THRLPRRRRRR SEQ ID NO: 138); and GGRRARRRRRR SEQ ID NO: 139). In some cases, the PTD is an activatable CPP (ACPP) (Aguilera et al. (2009) *Integr Biol (Camb)* June; 1(5-6): 371-381). ACPPs comprise a polycationic CPP (e.g., Arg9 or "R9") connected via a cleavable linker to a matching polyanion (e.g., Glu9 or "E9"), which reduces the net charge to nearly zero and thereby inhibits adhesion and uptake into cells. Upon cleavage of the linker, the polyanion is released, locally unmasking the polyarginine and its inherent adhesiveness, thus "activating" the ACPP to traverse the membrane.

Introducing components into a target cell

[00235] A CasZ guide RNA (or a nucleic acid comprising a nucleotide sequence encoding same) and/or a CasZ polypeptide (or a nucleic acid comprising a nucleotide sequence encoding same) and/or a CasZ trancRNA (or a nucleic acid that includes a nucleotide sequence encoding same) and/or a donor polynucleotide (donor template) can be introduced into a host cell by any of a variety of well-known methods.

[00236] Any of a variety of compounds and methods can be used to deliver to a target cell a CasZ system of the present disclosure. As a non-limiting example, a CasZ system of the present disclosure can be combined with a lipid. As another non-limiting example, a CasZ system of the present disclosure can be combined with a particle, or formulated into a particle.

[00237] Methods of introducing a nucleic acid into a host cell are known in the art, and any convenient method can be used to introduce a subject nucleic acid (e.g., an expression construct/vector) into a target cell (e.g., prokaryotic cell, eukaryotic cell, plant cell, animal cell, mammalian cell, human cell, and the like). Suitable methods include, e.g., viral infection, transfection, conjugation, protoplast fusion, lipofection, electroporation, calcium phosphate precipitation, polyethyleneimine (PEI)-mediated transfection, DEAE-dextran mediated transfection, liposome-mediated transfection, particle gun technology, calcium phosphate precipitation, direct micro injection, nanoparticle-mediated nucleic acid delivery (see, e.g., Panyam et., al Adv Drug Deliv Rev. 2012 Sep 13. pii: S0169-409X(12)00283-9. doi: 10.1016/j.addr.2012.09.023), and the like.

[00238] In some cases, a CasZ polypeptide of the present disclosure (e.g., wild type protein, variant protein, chimeric/fusion protein, dCasZ, etc.) is provided as a nucleic acid (e.g., an mRNA, a DNA, a plasmid, an expression vector, a viral vector, etc.) that encodes the CasZ polypeptide. In some cases, the CasZ polypeptide of the present disclosure is provided directly as a protein (e.g., without an

associated guide RNA or with an associate guide RNA, i.e., as a ribonucleoprotein complex). A CasZ polypeptide of the present disclosure can be introduced into a cell (provided to the cell) by any convenient method; such methods are known to those of ordinary skill in the art. As an illustrative example, a CasZ polypeptide of the present disclosure can be injected directly into a cell (e.g., with or without a CasZ guide RNA or nucleic acid encoding a CasZ guide RNA, and with or without a donor polynucleotide and with or without a CasZ trancRNA). As another example, a preformed complex of a CasZ polypeptide of the present disclosure and a CasZ guide RNA (an RNP) can be introduced into a cell (e.g, eukaryotic cell) (e.g., via injection, via nucleofection; via a protein transduction domain (PTD) conjugated to one or more components, e.g., conjugated to the CasZ protein, conjugated to a guide RNA, conjugated to a CasZ trancRNA, conjugated to a CasZ polypeptide of the present disclosure and a guide RNA; etc.).

[00239] In some cases, a nucleic acid (e.g., a CasZ guide RNA and/or a nucleic acid encoding it, a nucleic acid encoding a CasZ protein, a CasZ trancRNA and/or a nucleic acid encoding it, and the like) and/or a polypeptide (e.g., a CasZ polypeptide; a CasZ fusion polypeptide) is delivered to a cell (e.g., a target host cell) in a particle, or associated with a particle. In some cases, a CasZ system of the present disclosure is delivered to a cell in a particle, or associated with a particle. The terms "particle" and nanoparticle" can be used interchangeable, as appropriate. For example, a recombinant expression vector comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure and/or a CasZ guide RNA, an mRNA comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure, and guide RNA may be delivered simultaneously using particles or lipid envelopes; for instance, a CasZ polypeptide and/or a CasZ guide RNA and/or a trancRNA, e.g., as a complex (e.g., a ribonucleoprotein (RNP) complex), can be delivered via a particle, e.g., a delivery particle comprising lipid or lipidoid and hydrophilic polymer, e.g., a cationic lipid and a hydrophilic polymer, for instance wherein the cationic lipid comprises 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) or 1,2-ditetradecanoyl-sn-glycero-3-phosphocholine (DMPC) and/or wherein the hydrophilic polymer comprises ethylene glycol or polyethylene glycol (PEG); and/or wherein the particle further comprises cholesterol (e.g., particle from formulation 1=DOTAP 100, DMPC 0, PEG 0, Cholesterol 0; formulation number 2=DOTAP 90, DMPC 0, PEG 10, Cholesterol 0; formulation number 3=DOTAP 90, DMPC 0, PEG 5, Cholesterol 5). For example, a particle can be formed using a multistep process in which a CasZ polypepide and a CasZ guideRNA are mixed together, e.g., at a 1:1 molar ratio, e.g., at room temperature, e.g., for 30 minutes, e.g., in sterile, nuclease free 1 x phosphate-buffered saline (PBS); and separately, DOTAP, DMPC, PEG, and cholesterol as applicable for the formulation are dissolved in alcohol, e.g., 100% ethanol; and, the two solutions are mixed together to form particles containing the complexes).

[00240] A CasZ polypeptide of the present disclosure (or an mRNA comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure; or a recombinant expression vector comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure) and/or CasZ guide RNA (or a nucleic acid such as one or more expression vectors encoding the CasZ guide RNA) may be delivered simultaneously using particles or lipid envelopes. For example, a biodegradable core-shell structured nanoparticle with a poly (β-amino ester) (PBAE) core enveloped by a phospholipid bilayer shell can be used. In some cases, particles/nanoparticles based on self assembling bioadhesive polymers are used; such particles/nanoparticles may be applied to oral delivery of peptides, intravenous delivery of peptides and nasal delivery of peptides, e.g., to the brain. Other embodiments, such as oral absorption and ocular delivery of hydrophobic drugs are also contemplated. A molecular envelope technology, which involves an engineered polymer envelope which is protected and delivered to the site of the disease, can be used. Doses of about 5 mg/kg can be used, with single or multiple doses, depending on various factors, e.g., the target tissue.

[00241] Lipidoid compounds (e.g., as described in US patent application 20110293703) are also useful in the administration of polynucleotides, and can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure, or a CasZ system of the present disclosure. In one aspect, the aminoalcohol lipidoid compounds are combined with an agent to be delivered to a cell or a subject to form microparticles, nanoparticles, liposomes, or micelles. The aminoalcohol lipidoid compounds may be combined with other aminoalcohol lipidoid compounds, polymers (synthetic or natural), surfactants, cholesterol, carbohydrates, proteins, lipids, etc. to form the particles. These particles may then optionally be combined with a pharmaceutical excipient to form a pharmaceutical composition.

[00242] A poly(beta-amino alcohol) (PBAA) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. US Patent Publication No. 20130302401 relates to a class of poly(beta-amino alcohols) (PBAAs) that has been prepared using combinatorial polymerization.

[00243] Sugar-based particles may be used, for example GalNAc, as described with reference to WO2014118272 (incorporated herein by reference) and Nair, J K et al., 2014, Journal of the American Chemical Society 136 (49), 16958-16961) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure, or a CasZ system of the present disclosure, to a target cell.

[00244] In some cases, lipid nanoparticles (LNPs) are used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure,

a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. Negatively charged polymers such as RNA may be loaded into LNPs at low pH values (e.g., pH 4) where the ionizable lipids display a positive charge. However, at physiological pH values, the LNPs exhibit a low surface charge compatible with longer circulation times. Four species of ionizable cationic lipids have been focused upon, namely 1,2-dilineoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxy-keto-N,N-dimethyl-3-aminopropane (DLinKDMA), and 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA). Preparation of LNPs and is described in, e.g., Rosin et al. (2011) Molecular Therapy 19:1286-2200). The cationic lipids 1,2-dilineoyl-3-dimethylammonium-propane (DLinDAP), 1,2-dilinoleyloxy-3-N,N-dimethylaminopropane (DLinDMA), 1,2-dilinoleyloxyketo-N,N-dimethyl-3-aminopropane (DLinK-DMA), 1,2-dilinoleyl-4-(2-dimethylaminoethyl)-[1,3]-dioxolane (DLinKC2-DMA), (3-o-[2"-(methoxypolyethyleneglycol 2000) succinoyl]-1,2-dimyristoyl-sn-glycol (PEG-S-DMG), and R-3-[(.omega.-methoxy-poly(ethylene glycol)2000) carbamoyl]-1,2-dimyristyloxlpropyl-3-amine (PEG-C-DOMG) may be used. A nucleic acid (e.g., a CasZ guide RNA; a nucleic acid of the present disclosure; etc.) may be encapsulated in LNPs containing DLinDAP, DLinDMA, DLinK-DMA, and DLinKC2-DMA (cationic lipid:DSPC:CHOL: PEGS-DMG or PEG-C-DOMG at 40:10:40:10 molar ratios). In some cases, 0.2% SP-DiOC18 is incorporated.

[00245] Spherical Nucleic Acid (SNA™) constructs and other nanoparticles (particularly gold nanoparticles) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell.. See, e.g., Cutler et al., J. Am. Chem. Soc. 2011 133:9254-9257, Hao et al., Small. 2011 7:3158-3162, Zhang et al., ACS Nano. 2011 5:6962-6970, Cutler et al., J. Am. Chem. Soc. 2012 134:1376-1391, Young et al., Nano Lett. 2012 12:3867-71, Zheng et al., Proc. Natl. Acad. Sci. USA. 2012 109:11975-80, Mirkin, Nanomedicine 2012 7:635-638 Zhang et al., J. Am. Chem. Soc. 2012 134:16488-1691, Weintraub, Nature 2013 495:S14-S16, Choi et al., Proc. Natl. Acad. Sci. USA. 2013 110(19): 7625-7630, Jensen et al., Sci. Transl. Med. 5, 209ra152 (2013) and Mirkin, et al., Small, 10:186-192.

[00246] Self-assembling nanoparticles with RNA may be constructed with polyethyleneimine (PEI) that is PEGylated with an Arg-Gly-Asp (RGD) peptide ligand attached at the distal end of the polyethylene glycol (PEG).

[00247] In general, a "nanoparticle" refers to any particle having a diameter of less than 1000 nm. In some cases, nanoparticles suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a

nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell have a diameter of 500 nm or less, e.g., from 25 nm to 35 nm, from 35 nm to 50 nm, from 50 nm to 75 nm, from 75 nm to 100 nm, from 100 nm to 150 nm, from 150 nm to 200 nm, from 200 nm to 300 nm, from 300 nm to 400 nm, or from 400 nm to 500 nm. In some cases, nanoparticles suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure, or a CasZ system of the present disclosure, to a target cell have a diameter of from 25 nm to 200 nm. In some cases, nanoparticles suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure, or a CasZ system of the present disclosure, to a target cell have a diameter of 100 nm or less In some cases, nanoparticles suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure, or a CasZ system of the present disclosure, to a target cell have a diameter of from 35 nm to 60 nm.

[00248] Nanoparticles suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell may be provided in different forms, e.g., as solid nanoparticles (e.g., metal such as silver, gold, iron, titanium), non-metal, lipid-based solids, polymers), suspensions of nanoparticles, or combinations thereof. Metal, dielectric, and semiconductor nanoparticles may be prepared, as well as hybrid structures (e.g., core-shell nanoparticles). Nanoparticles made of semiconducting material may also be labeled quantum dots if they are small enough (typically below 10 nm) that quantization of electronic energy levels occurs. Such nanoscale particles are used in biomedical applications as drug carriers or imaging agents and may be adapted for similar purposes in the present disclosure.

[00249] Semi-solid and soft nanoparticles are also suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. A prototype nanoparticle of semi-solid nature is the liposome.

[00250] In some cases, an exosome is used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. Exosomes are endogenous nano-vesicles that transport RNAs and proteins, and which can deliver RNA to the brain and other target organs.

[00251] In some cases, a liposome is used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. Liposomes are spherical vesicle structures composed of a uni- or multilamellar lipid bilayer surrounding internal aqueous compartments and a relatively impermeable outer lipophilic phospholipid bilayer. Liposomes can be made from several different types of lipids; however, phospholipids are most commonly used to generate liposomes. Although liposome formation is spontaneous when a lipid film is mixed with an aqueous solution, it can also be expedited by applying force in the form of shaking by using a homogenizer, sonicator, or an extrusion apparatus. Several other additives may be added to liposomes in order to modify their structure and properties. For instance, either cholesterol or sphingomyelin may be added to the liposomal mixture in order to help stabilize the liposomal structure and to prevent the leakage of the liposomal inner cargo. A liposome formulation may be mainly comprised of natural phospholipids and lipids such as 1,2-distearoryl-sn-glycero-3-phosphatidyl choline (DSPC), sphingomyelin, egg phosphatidylcholines and monosialoganglioside.

[00252] A stable nucleic-acid-lipid particle (SNALP) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. The SNALP formulation may contain the lipids 3-N-[(methoxypoly(ethylene glycol) 2000) carbamoyl]-1,2-dimyristyloxy-propylamine (PEG-C-DMA), 1,2-dilinoleyloxy-N,N-dimethyl-3-aminopropane (DLinDMA), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and cholesterol, in a 2:40:10:48 molar percent ratio. The SNALP liposomes may be prepared by formulating D-Lin-DMA and PEG-C-DMA with distearoylphosphatidylcholine (DSPC), Cholesterol and siRNA using a 25:1 lipid/siRNA ratio and a 48/40/10/2 molar ratio of Cholesterol/D-Lin-DMA/DSPC/PEG-C-DMA. The resulting SNALP liposomes can be about 80-100 nm in size. A SNALP may comprise synthetic cholesterol (Sigma-Aldrich, St Louis, Mo., USA), dipalmitoylphosphatidylcholine (Avanti Polar Lipids, Alabaster, Ala., USA), 3-N-[(w-methoxy poly(ethylene glycol)2000)carbamoyl]-1,2-dimyrestyloxypropylamine, and cationic 1,2-dilinoleyloxy-3-N,Ndimethylaminopropane. A SNALP may comprise synthetic cholesterol (Sigma-Aldrich), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC; Avanti Polar Lipids Inc.), PEG-cDMA, and 1,2-dilinoleyloxy-3-(N;N-dimethyl)aminopropane (DLinDMA).

[00253] Other cationic lipids, such as amino lipid 2,2-dilinoleyl-4-dimethylaminoethyl-[1,3]-dioxolane (DLin-KC2-DMA) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present

disclosure, to a target cell. A preformed vesicle with the following lipid composition may be contemplated: amino lipid, distearoylphosphatidylcholine (DSPC), cholesterol and (R)-2,3-bis(octadecyloxy) propyl-1-(methoxy poly(ethylene glycol)2000)propylcarbamate (PEG-lipid) in the molar ratio 40/10/40/10, respectively, and a FVII siRNA/total lipid ratio of approximately 0.05 (w/w). To ensure a narrow particle size distribution in the range of 70-90 nm and a low polydispersity index of 0.11.+-.0.04 (n=56), the particles may be extruded up to three times through 80 nm membranes prior to adding the guide RNA. Particles containing the highly potent amino lipid 16 may be used, in which the molar ratio of the four lipid components 16, DSPC, cholesterol and PEG-lipid (50/10/38.5/1.5) which may be further optimized to enhance in vivo activity.

[00254] Lipids may be formulated with a CasZ system of the present disclosure or component(s) thereof or nucleic acids encoding the same to form lipid nanoparticles (LNPs). Suitable lipids include, but are not limited to, DLin-KC2-DMA4, C12-200 and colipids disteroylphosphatidyl choline, cholesterol, and PEG-DMG may be formulated with a CasZ system, or component thereof, of the present disclosure, using a spontaneous vesicle formation procedure. The component molar ratio may be about 50/10/38.5/1.5 (DLin-KC2-DMA or C12-200/disteroylphosphatidyl choline/cholesterol/PEG-DMG).

[00255] A CasZ system of the present disclosure, or a component thereof, may be delivered encapsulated in PLGA microspheres such as that further described in US published applications 20130252281 and 20130245107 and 20130244279.

[00256] Supercharged proteins can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. Supercharged proteins are a class of engineered or naturally occurring proteins with unusually high positive or negative net theoretical charge. Both supernegatively and superpositively charged proteins exhibit the ability to withstand thermally or chemically induced aggregation. Superpositively charged proteins are also able to penetrate mammalian cells. Associating cargo with these proteins, such as plasmid DNA, RNA, or other proteins, can enable the functional delivery of these macromolecules into mammalian cells both in vitro and in vivo.

[00257] Cell Penetrating Peptides (CPPs) can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell. CPPs typically have an amino acid composition that either contains a high relative abundance of positively charged amino acids such as lysine or arginine or has sequences that contain an alternating pattern of polar/charged amino acids and non-polar, hydrophobic amino acids.

[00258] An implantable device can be used to deliver a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA) (e.g., a CasZ guide RNA, a nucleic acid encoding a CasZ guide RNA, a nucleic acid encoding CasZ polypeptide, a donor template, and the like), or a CasZ system of the present disclosure, to a target cell (e.g., a target cell *in vivo*, where the target cell is a target cell in circulation, a target cell in a tissue, a target cell in an organ, etc.). An implantable device suitable for use in delivering a CasZ polypeptide of the present disclosure, a CasZ fusion polypeptide of the present disclosure, an RNP of the present disclosure, a nucleic acid of the present disclosure (e.g., a CasZ guide RNA and/or a CasZ trancRNA), or a CasZ system of the present disclosure, to a target cell (e.g., a target cell *in vivo*, where the target cell is a target cell in circulation, a target cell in a tissue, a target cell in an organ, etc.) can include a container (e.g., a reservoir, a matrix, etc.) that comprises the CasZ polypeptide, the CasZ fusion polypeptide, the RNP, or the CasZ system (or component thereof, e.g., a nucleic acid of the present disclosure).

[00259] A suitable implantable device can comprise a polymeric substrate, such as a matrix for example, that is used as the device body, and in some cases additional scaffolding materials, such as metals or additional polymers, and materials to enhance visibility and imaging. An implantable delivery device can be advantageous in providing release locally and over a prolonged period, where the polypeptide and/or nucleic acid to be delivered is released directly to a target site, e.g., the extracellular matrix (ECM), the vasculature surrounding a tumor, a diseased tissue, etc. Suitable implantable delivery devices include devices suitable for use in delivering to a cavity such as the abdominal cavity and/or any other type of administration in which the drug delivery system is not anchored or attached, comprising a biostable and/or degradable and/or bioabsorbable polymeric substrate, which may for example optionally be a matrix. In some cases, a suitable implantable drug delivery device comprises degradable polymers, wherein the main release mechanism is bulk erosion. In some cases, a suitable implantable drug delivery device comprises non degradable, or slowly degraded polymers, wherein the main release mechanism is diffusion rather than bulk erosion, so that the outer part functions as membrane, and its internal part functions as a drug reservoir, which practically is not affected by the surroundings for an extended period (for example from about a week to about a few months). Combinations of different polymers with different release mechanisms may also optionally be used. The concentration gradient at the can be maintained effectively constant during a significant period of the total releasing period, and therefore the diffusion rate is effectively constant (termed "zero mode" diffusion). By the term "constant" it is meant a diffusion rate that is maintained above the lower threshold of therapeutic effectiveness, but which may still optionally feature an initial burst and/or may fluctuate, for example increasing and decreasing to a certain degree. The diffusion rate can be so maintained for a prolonged period, and it can be considered

constant to a certain level to optimize the therapeutically effective period, for example the effective silencing period.

[00260] In some cases, the implantable delivery system is designed to shield the nucleotide based therapeutic agent from degradation, whether chemical in nature or due to attack from enzymes and other factors in the body of the subject.

[00261] The site for implantation of the device, or target site, can be selected for maximum therapeutic efficacy. For example, a delivery device can be implanted within or in the proximity of a tumor environment, or the blood supply associated with a tumor. The target location can be, e.g.: 1) the brain at degenerative sites like in Parkinson or Alzheimer disease at the basal ganglia, white and gray matter; 2) the spine, as in the case of amyotrophic lateral sclerosis (ALS); 3) uterine cervix; 4) active and chronic inflammatory joints; 5) dermis as in the case of psoriasis; 7) sympathetic and sensoric nervous sites for analgesic effect; 7) a bone; 8) a site of acute or chronic infection; 9) Intra vaginal; 10) Inner ear--auditory system, labyrinth of the inner ear, vestibular system; 11) Intra tracheal; 12) Intra-cardiac; coronary, epicardiac; 13) urinary tract or bladder; 14) biliary system; 15) parenchymal tissue including and not limited to the kidney, liver, spleen; 16) lymph nodes; 17) salivary glands; 18) dental gums; 19) Intra-articular (into joints); 20) Intra-ocular; 21) Brain tissue; 22) Brain ventricles; 23) Cavities, including abdominal cavity (for example but without limitation, for ovary cancer); 24) Intra esophageal; and 25) Intra rectal; and 26) into the vasculature.

[00262] The method of insertion, such as implantation, may optionally already be used for other types of tissue implantation and/or for insertions and/or for sampling tissues, optionally without modifications, or alternatively optionally only with non-major modifications in such methods. Such methods optionally include but are not limited to brachytherapy methods, biopsy, endoscopy with and/or without ultrasound, such as stereotactic methods into the brain tissue, laparoscopy, including implantation with a laparoscope into joints, abdominal organs, the bladder wall and body cavities.

MODIFIED HOST CELLS

[00263] The present disclosure provides a modified cell comprising a CasZ polypeptide of the present disclosure and/or a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure. The present disclosure provides a modified cell comprising a CasZ polypeptide of the present disclosure, where the modified cell is a cell that does not normally comprise a CasZ polypeptide of the present disclosure. The present disclosure provides a modified cell (e.g., a genetically modified cell) comprising nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure. The present disclosure provides a genetically modified cell that is genetically modified with an mRNA comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure. The present disclosure provides a genetically modified cell that is genetically modified with a recombinant expression vector comprising a nucleotide sequence encoding a CasZ polypeptide of the

present disclosure. The present disclosure provides a genetically modified cell that is genetically modified with a recombinant expression vector comprising: a) a nucleotide sequence encoding a CasZ polypeptide of the present disclosure; and b) a nucleotide sequence encoding a CasZ guide RNA of the present disclosure. The present disclosure provides a genetically modified cell that is genetically modified with a recombinant expression vector comprising: a) a nucleotide sequence encoding a CasZ polypeptide of the present disclosure; b) a nucleotide sequence encoding a CasZ guide RNA of the present disclosure; and c) a nucleotide sequence encoding a donor template.

[00264] A cell that serves as a recipient for a CasZ polypeptide of the present disclosure and/or a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure and/or a CasZ guide RNA of the present disclosure (or a nucleic acid encoding it) and/or a CasZ trancRNA (or a nucleic acid encoding it), can be any of a variety of cells, including, e.g., *in vitro* cells; *in vivo* cells; *ex vivo* cells; primary cells; cancer cells; animal cells; plant cells; algal cells; fungal cells; etc. A cell that serves as a recipient for a CasZ polypeptide of the present disclosure and/or a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure and/or a CasZ guide RNA of the present disclosure is referred to as a "host cell" or a "target cell." A host cell or a target cell can be a recipient of a CasZ system of the present disclosure. A host cell or a target cell can be a recipient of a CasZ RNP of the present disclosure. A host cell or a target cell can be a recipient of a single component of a CasZ system of the present disclosure.

[00265] Non-limiting examples of cells (target cells) include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g., cells from plant crops, fruits, vegetables, grains, soy bean, corn, maize, wheat, seeds, tomatos, rice, cassava, sugarcane, pumpkin, hay, potatos, cotton, cannabis, tobacco, flowering plants, conifers, gymnosperms, angiosperms, ferns, clubmosses, hornworts, liverworts, mosses, dicotyledons, monocotyledons, etc.), an algal cell, (e.g., *Botryococcus braunii*, *Chlamydomonas reinhardtii*, *Nannochloropsis gaditana*, *Chlorella pyrenoidosa*, *Sargassum patens*, *C. agardh*, and the like), seaweeds (e.g. kelp) a fungal cell (e.g., a yeast cell, a cell from a mushroom), an animal cell, a cell from an invertebrate animal (e.g., fruit fly, cnidarian, echinoderm, nematode, etc.), a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal), a cell from a mammal (e.g., an ungulate (e.g., a pig, a cow, a goat, a sheep); a rodent (e.g., a rat, a mouse); a non-human primate; a human; a feline (e.g., a cat); a canine (e.g., a dog); etc.), and the like. In some cases, the cell is a cell that does not originate from a natural organism (e.g., the cell can be a synthetically made cell; also referred to as an artificial cell).

[00266] A cell can be an *in vitro* cell (e.g., a cell in culture, e.g., an established cultured cell line). A cell can be an *ex vivo* cell (cultured cell from an individual). A cell can be and *in vivo* cell (e.g., a cell in an individual). A cell can be an isolated cell. A cell can be a cell inside of an organism. A cell can be an organism. A cell can be a cell in a cell culture (e.g., *in vitro* cell culture). A cell can be one of a

collection of cells. A cell can be a prokaryotic cell or derived from a prokaryotic cell. A cell can be a bacterial cell or can be derived from a bacterial cell. A cell can be an archaeal cell or derived from an archaeal cell. A cell can be a eukaryotic cell or derived from a eukaryotic cell. A cell can be a plant cell or derived from a plant cell. A cell can be an animal cell or derived from an animal cell. A cell can be an invertebrate cell or derived from an invertebrate cell. A cell can be a vertebrate cell or derived from a vertebrate cell. A cell can be a mammalian cell or derived from a mammalian cell. A cell can be a rodent cell or derived from a rodent cell. A cell can be a human cell or derived from a human cell. A cell can be a microbe cell or derived from a microbe cell. A cell can be a fungi cell or derived from a fungi cell. A cell can be an insect cell. A cell can be an arthropod cell. A cell can be a protozoan cell. A cell can be a helminth cell.

[00267] Suitable cells include a stem cell (e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell; a germ cell (e.g., an oocyte, a sperm, an oogonia, a spermatogonia, etc.); a somatic cell, e.g. a fibroblast, an oligodendrocyte, a glial cell, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell, etc.

[00268] Suitable cells include human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplated expanded cardiomyocytes, adipocytes, totipotent cells, pluripotent cells, blood stem cells, myoblasts, adult stem cells, bone marrow cells, mesenchymal cells, embryonic stem cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, exogenous cells, endogenous cells, stem cells, hematopoietic stem cells, bone-marrow derived progenitor cells, myocardial cells, skeletal cells, fetal cells, undifferentiated cells, multi-potent progenitor cells, unipotent progenitor cells, monocytes, cardiac myoblasts, skeletal myoblasts, macrophages, capillary endothelial cells, xenogenic cells, allogenic cells, and post-natal stem cells.

[00269] In some cases, the cell is an immune cell, a neuron, an epithelial cell, and endothelial cell, or a stem cell. In some cases, the immune cell is a T cell, a B cell, a monocyte, a natural killer cell, a dendritic cell, or a macrophage. In some cases, the immune cell is a cytotoxic T cell. In some cases, the immune cell is a helper T cell. In some cases, the immune cell is a regulatory T cell (Treg).

[00270] In some cases, the cell is a stem cell. Stem cells include adult stem cells. Adult stem cells are also referred to as somatic stem cells.

[00271] Adult stem cells are resident in differentiated tissue, but retain the properties of self-renewal and ability to give rise to multiple cell types, usually cell types typical of the tissue in which the stem cells are found. Numerous examples of somatic stem cells are known to those of skill in the art, including muscle stem cells; hematopoietic stem cells; epithelial stem cells; neural stem cells;

mesenchymal stem cells; mammary stem cells; intestinal stem cells; mesodermal stem cells; endothelial stem cells; olfactory stem cells; neural crest stem cells; and the like.

[00272] Stem cells of interest include mammalian stem cells, where the term "mammalian" refers to any animal classified as a mammal, including humans; non-human primates; domestic and farm animals; and zoo, laboratory, sports, or pet animals, such as dogs, horses, cats, cows, mice, rats, rabbits, etc. In some cases, the stem cell is a human stem cell. In some cases, the stem cell is a rodent (e.g., a mouse; a rat) stem cell. In some cases, the stem cell is a non-human primate stem cell.

[00273] Stem cells can express one or more stem cell markers, e.g., SOX9, KRT19, KRT7, LGR5, CA9, FXYD2, CDH6, CLDN18, TSPAN8, BPIFB1, OLFM4, CDH17, and PPARGC1A.

[00274] In some cases, the stem cell is a hematopoietic stem cell (HSC). HSCs are mesoderm-derived cells that can be isolated from bone marrow, blood, cord blood, fetal liver and yolk sac. HSCs are characterized as $CD34^+$ and $CD3^-$. HSCs can repopulate the erythroid, neutrophil-macrophage, megakaryocyte and lymphoid hematopoietic cell lineages *in vivo*. *In vitro*, HSCs can be induced to undergo at least some self-renewing cell divisions and can be induced to differentiate to the same lineages as is seen *in vivo*. As such, HSCs can be induced to differentiate into one or more of erythroid cells, megakaryocytes, neutrophils, macrophages, and lymphoid cells.

[00275] In other cases, the stem cell is a neural stem cell (NSC). Neural stem cells (NSCs) are capable of differentiating into neurons, and glia (including oligodendrocytes, and astrocytes). A neural stem cell is a multipotent stem cell which is capable of multiple divisions, and under specific conditions can produce daughter cells which are neural stem cells, or neural progenitor cells that can be neuroblasts or glioblasts, e.g., cells committed to become one or more types of neurons and glial cells respectively. Methods of obtaining NSCs are known in the art.

[00276] In other cases, the stem cell is a mesenchymal stem cell (MSC). MSCs originally derived from the embryonal mesoderm and isolated from adult bone marrow, can differentiate to form muscle, bone, cartilage, fat, marrow stroma, and tendon. Methods of isolating MSC are known in the art; and any known method can be used to obtain MSC. See, e.g., U.S. Pat. No. 5,736,396, which describes isolation of human MSC.

[00277] A cell is in some cases a plant cell. A plant cell can be a cell of a monocotyledon. A cell can be a cell of a dicotyledon.

[00278] In some cases, the cell is a plant cell. For example, the cell can be a cell of a major agricultural plant, e.g., Barley, Beans (Dry Edible), Canola, Corn, Cotton (Pima), Cotton (Upland), Flaxseed, Hay (Alfalfa), Hay (Non-Alfalfa), Oats, Peanuts, Rice, Sorghum, Soybeans, Sugarbeets, Sugarcane, Sunflowers (Oil), Sunflowers (Non-Oil), Sweet Potatoes , Tobacco (Burley), Tobacco (Flue-cured), Tomatoes, Wheat (Durum), Wheat (Spring), Wheat (Winter), and the like. As another example,

the cell is a cell of a vegetable crops which include but are not limited to, e.g., alfalfa sprouts, aloe leaves, arrow root, arrowhead, artichokes, asparagus, bamboo shoots, banana flowers, bean sprouts, beans, beet tops, beets, bittermelon, bok choy, broccoli, broccoli rabe (rappini), brussels sprouts, cabbage, cabbage sprouts, cactus leaf (nopales), calabaza, cardoon, carrots, cauliflower, celery, chayote, chinese artichoke (crosnes), chinese cabbage, chinese celery, chinese chives, choy sum, chrysanthemum leaves (tung ho), collard greens, corn stalks, corn-sweet, cucumbers, daikon, dandelion greens, dasheen, dau mue (pea tips), donqua (winter melon), eggplant, endive, escarole, fiddle head ferns, field cress, frisee, gai choy (chinese mustard), gailon, galanga (siam, thai ginger), garlic, ginger root, gobo, greens, hanover salad greens, huauzontle, jerusalem artichokes, jicama, kale greens, kohlrabi, lamb's quarters (quilete), lettuce (bibb), lettuce (boston), lettuce (boston red), lettuce (green leaf), lettuce (iceberg), lettuce (lolla rossa), lettuce (oak leaf - green), lettuce (oak leaf - red), lettuce (processed), lettuce (red leaf), lettuce (romaine), lettuce (ruby romaine), lettuce (russian red mustard), linkok, lo bok, long beans, lotus root, mache, maguey (agave) leaves, malanga, mesculin mix, mizuna, moap (smooth luffa), moo, moqua (fuzzy squash), mushrooms, mustard, nagaimo, okra, ong choy, onions green, opo (long squash), ornamental corn, ornamental gourds, parsley, parsnips, peas, peppers (bell type), peppers, pumpkins, radicchio, radish sprouts, radishes, rape greens, rape greens, rhubarb, romaine (baby red), rutabagas, salicornia (sea bean), sinqua (angled/ridged luffa), spinach, squash, straw bales, sugarcane, sweet potatoes, swiss chard, tamarindo, taro, taro leaf, taro shoots, tatsoi, tepeguaje (guaje), tindora, tomatillos, tomatoes, tomatoes (cherry), tomatoes (grape type), tomatoes (plum type), tumeric, turnip tops greens, turnips, water chestnuts, yampi, yams (names), yu choy, yuca (cassava), and the like.

[00279] A cell is in some cases an arthropod cell. For example, the cell can be a cell of a sub-order, a family, a sub-family, a group, a sub-group, or a species of, e.g., *Chelicerata*, *Myriapodia*, *Hexipodia*, *Arachnida*, *Insecta*, *Archaeognatha*, *Thysanura*, *Palaeoptera*, *Ephemeroptera*, *Odonata*, *Anisoptera*, *Zygoptera*, *Neoptera*, *Exopterygota*, *Plecoptera* , *Embioptera* , *Orthoptera*, *Zoraptera* , *Dermaptera*, *Dictyoptera*, *Notoptera*, *Grylloblattidae*, *Mantophasmatidae*, *Phasmatodea* , *Blattaria*, *Isoptera*, *Mantodea*, *Parapneuroptera*, *Psocoptera*, *Thysanoptera*, *Phthiraptera*, *Hemiptera*, *Endopterygota or Holometabola* , *Hymenoptera* , *Coleoptera*, *Strepsiptera*, *Raphidioptera*, *Megaloptera*, *Neuroptera* , *Mecoptera* , *Siphonaptera*, *Diptera*, *Trichoptera*, or *Lepidoptera.*

[00280] A cell is in some cases an insect cell. For example, in some cases, the cell is a cell of a mosquito, a grasshopper, a true bug, a fly, a flea, a bee, a wasp, an ant, a louse, a moth, or a beetle.

KITS

[00281] The present disclosure provides a kit comprising a CasZ system of the present disclosure, or a component of a CasZ system of the present disclosure.

[00282] A kit of the present disclosure can comprise any combination as listed for a CasZ system (e.g., see above). A kit of the present disclosure can comprise: a) a component, as described above, of a

CasZ system of the present disclosure, or can comprise a CasZ system of the present disclosure; and b) one or more additional reagents, e.g., i) a buffer; ii) a protease inhibitor; iii) a nuclease inhibitor; iv) a reagent required to develop or visualize a detectable label; v) a positive and/or negative control target DNA; vi) a positive and/or negative control CasZ guide RNA; vii) a CasZ trancRNA; and the like. A kit of the present disclosure can comprise: a) a component, as described above, of a CasZ system of the present disclosure, or can comprise a CasZ system of the present disclosure; and b) a therapeutic agent.

[00283] A kit of the present disclosure can comprise a recombinant expression vector comprising: a) an insertion site for inserting a nucleic acid comprising a nucleotide sequence encoding a portion of a CasZ guide RNA that hybridizes to a target nucleotide sequence in a target nucleic acid; and b) a nucleotide sequence encoding the CasZ-binding portion of a CasZ guide RNA. A kit of the present disclosure can comprise a recombinant expression vector comprising: a) an insertion site for inserting a nucleic acid comprising a nucleotide sequence encoding a portion of a CasZ guide RNA that hybridizes to a target nucleotide sequence in a target nucleic acid; b) a nucleotide sequence encoding the CasZ-binding portion of a CasZ guide RNA; and c) a nucleotide sequence encoding a CasZ polypeptide of the present disclosure. A kit of the present disclosure can comprise a recombinant expression vector comprising a nucleotide sequence encoding a CasZ trancRNA.

DETECTION OF SSDNA

[00284] A CasZ (Cas14) polypeptide of the present disclosure, once activated by detection of a target DNA (double or single stranded), can promiscuously cleave non-targeted single stranded DNA (ssDNA). Once a CasZ (Cas14) is activated by a guide RNA, which occurs when the guide RNA hybridizes to a target sequence of a target DNA (i.e., the sample includes the target DNA, e.g., target ssDNA), the protein becomes a nuclease that promiscuously cleaves ssDNAs (i.e., the nuclease cleaves non-target ssDNAs, i.e., ssDNAs to which the guide sequence of the guide RNA does not hybridize). Thus, when the target DNA is present in the sample (e.g., in some cases above a threshold amount), the result is cleavage of ssDNAs in the sample, which can be detected using any convenient detection method (e.g., using a labeled single stranded detector DNA). In some cases, a CasZ polypeptide requires, in addition to a CasZ guide RNA, a tranc RNA for activation.

[00285] Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some cases, a detector DNA is used that is single stranded (ssDNA) and does not hybridize with the guide sequence of the guide RNA (i.e., the detector ssDNA is a non-target ssDNA). Such methods can include (a) contacting the sample with: (i) a CasZ polypeptide; (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA; and (iii) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage of the single stranded detector DNA by the CasZ polypeptide, thereby detecting the target DNA. . In some cases, the

methods include can include (a) contacting the sample with: (i) a CasZ polypeptide; (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA; (iii) a CasZ tranc RNA; and (iv) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage of the single stranded detector DNA by the CasZ polypeptide, thereby detecting the target DNA. As noted above, once a subject CasZ polypeptide protein is activated by a guide RNA, which occurs when the sample includes a target DNA to which the guide RNA hybridizes (i.e., the sample includes the targeted target DNA), the CasZ polypeptide is activated and functions as an endoribonuclease that non-specifically cleaves ssDNAs (including non-target ssDNAs) present in the sample. Thus, when the targeted target DNA is present in the sample (e.g., in some cases above a threshold amount), the result is cleavage of ssDNA (including non-target ssDNA) in the sample, which can be detected using any convenient detection method (e.g., using a labeled detector ssDNA).

[00286] Also provided are compositions and methods for cleaving single stranded DNAs (ssDNAs) (e.g., non-target ssDNAs). Such methods can include contacting a population of nucleic acids, wherein said population comprises a target DNA and a plurality of non-target ssDNAs, with: (i) a CasZ polypeptide; and (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA, wherein the CasZ polypeptide cleaves non-target ssDNAs of said plurality. Such methods can include contacting a population of nucleic acids, wherein said population comprises a target DNA and a plurality of non-target ssDNAs, with: (i) a CasZ polypeptide; (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA, and (iii) a CasZ tranc RNA, wherein the CasZ polypeptide cleaves non-target ssDNAs of said plurality. Such methods can be used, e.g., to cleave foreign ssDNAs (e.g., viral DNAs) in a cell.

[00287] The contacting step of a subject method can be carried out in a composition comprising divalent metal ions. The contacting step can be carried out in an acellular environment, e.g., outside of a cell. The contacting step can be carried out inside a cell. The contacting step can be carried out in a cell *in vitro*. The contacting step can be carried out in a cell *ex vivo*. The contacting step can be carried out in a cell *in vivo*.

[00288] The guide RNA can be provided as RNA or as a nucleic acid encoding the guide RNA (e.g., a DNA such as a recombinant expression vector). The tranc RNA can be provided as RNA or as a nucleic acid encoding the guide RNA (e.g., a DNA such as a recombinant expression vector). The CasZ polypeptide can be provided as a protein *per se* or as a nucleic acid encoding the protein (e.g., an mRNA, a DNA such as a recombinant expression vector). In some cases, two or more (e.g., 3 or more, 4 or more, 5 or more, or 6 or more) guide RNAs can be provided. In some cases, a single-molecule RNA

comprising: i) a CasZ guide RNA; and ii) a tranc RNA (or a nucleic acid comprising a nucleotide sequence encoding the single-molecule RNA) is used.

[00289] In some cases (e.g., when contacting a sample with a guide RNA and a CasZ polypeptide; or when contacting a sample with a guide RNA, a CasZ polypeptide, and a tranc RNA), the sample is contacted for 2 hours or less (e.g., 1.5 hours or less, 1 hour or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, or 5 minutes or less, or 1 minute or less) prior to the measuring step. For example, in some cases the sample is contacted for 40 minutes or less prior to the measuring step. In some cases, the sample is contacted for 20 minutes or less prior to the measuring step. In some cases, the sample is contacted for 10 minutes or less prior to the measuring step. In some cases, the sample is contacted for 5 minutes or less prior to the measuring step. In some cases, the sample is contacted for 1 minute or less prior to the measuring step. In some cases, the sample is contacted for from 50 seconds to 60 seconds prior to the measuring step. In some cases, the sample is contacted for from 40 seconds to 50 seconds prior to the measuring step. In some cases, the sample is contacted for from 30 seconds to 40 seconds prior to the measuring step. In some cases, the sample is contacted for from 20 seconds to 30 seconds prior to the measuring step. In some cases, the sample is contacted for from 10 seconds to 20 seconds prior to the measuring step.

[00290] In some cases, a method of the present disclosure for detecting a target DNA comprises: a) contacting a sample with a guide RNA, a CasZ polypeptide, and a detector DNA), where the sample is contacted for 2 hours or less (e.g., 1.5 hours or less, 1 hour or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, or 5 minutes or less, or 1 minute or less), under conditions that provide for *trans* cleavage of the detector DNA; b) maintaining the sample from step (a) for a period of time under conditions that do not provide for *trans* cleavage of the detector RNA; and c) after the time period of step (b), measuring a detectable signal produced by cleavage of the single stranded detector DNA by the CasZ polypeptide, thereby detecting the target DNA. Conditions that provide for *trans* cleavage of the detector DNA include temperature conditions such as from 17°C to about 39°C (e.g., about 37°C). Conditions that do not provide for *trans* cleavage of the detector DNA include temperatures of 10°C or less, 5°C or less, 4°C or less, or 0°C.

[00291] In some cases, a method of the present disclosure for detecting a target DNA comprises: a) contacting a sample with a guide RNA, a tranc RNA, a CasZ polypeptide, and a detector DNA (or contacting a sample with: i) a single-molecule RNA comprising a guide RNA and a tranc RNA; i) a CasZ polypeptide; and iii) a detector DNA), where the sample is contacted for 2 hours or less (e.g., 1.5 hours or less, 1 hour or less, 40 minutes or less, 30 minutes or less, 20 minutes or less, 10 minutes or less, or 5 minutes or less, or 1 minute or less), under conditions that provide for *trans* cleavage of the detector DNA; b) maintaining the sample from step (a) for a period of time under conditions that do not provide for *trans* cleavage of the detector RNA; and c) after the time period of step (b), measuring a

detectable signal produced by cleavage of the single stranded detector DNA by the CasZ polypeptide, thereby detecting the target DNA. Conditions that provide for *trans* cleavage of the detector DNA include temperature conditions such as from 17°C to about 39°C (e.g., about 37°C). Conditions that do not provide for *trans* cleavage of the detector DNA include temperatures of 10°C or less, 5°C or less, 4°C or less, or 0°C.

[00292] In some cases, a detectable signal produced by cleavage of a single-stranded detector DNA is produced for no more than 60 minutes. For example, in some cases, a detectable signal produced by cleavage of a single-stranded detector DNA is produced for no more than 60 minutes, no more than 45 minutes, no more than 30 minutes, no more than 15 minutes, no more than 10 minutes, or no more than 5 minutes. For example, in some cases, a detectable signal produced by cleavage of a single-stranded detector DNA is produced for a period of time of from 1 minute to 60 minutes, e.g., from 1 minute to 5 minutes, from 5 minutes to 10 minutes, from 10 minutes to 15 minutes, from 15 minutes to 30 minutes, from 30 minutes to 45 minutes, or from 45 minutes to 60 minutes. In some cases, after the detectable signal is produced (e.g., produced for no more than 60 minutes), production of the detectable signal can be stopped, e.g., by lowering the temperature of the sample (e.g., lowering the temperature to 10°C or less, 5°C or less, 4°C or less, or 0°C), by adding an inhibitor to the sample, by lyophilizing the sample, by heating the sample to over 40°C, and the like. The measuring step can occur at any time after production of the detectable signal has been stopped. For example, the measuring step can occur from 5 minutes to 48 hours after production of the detectable signal has been stopped. For example, the measuring step can occur from 5 minutes to 15 minutes, from 15 minutes to 30 minutes, from 30 minutes to 60 minutes, from 1 hour to 4 hours, from 4 hours to 8 hours, from 8 hours to 12 hours, from 12 hours to 24 hours, from 24 hours to 36 hours, or from 36 hours to 48 hours, after production of the detectable signal has been stopped. The measuring step can occur more than 48 hours after production of the detectable signal has been stopped.

[00293] A method of the present disclosure for detecting a target DNA (single-stranded or double-stranded) in a sample can detect a target DNA with a high degree of sensitivity. In some cases, a method of the present disclosure can be used to detect a target DNA present in a sample comprising a plurality of DNAs (including the target DNA and a plurality of non-target DNAs), where the target DNA is present at one or more copies per 10^7 non-target DNAs (e.g., one or more copies per 10^6 non-target DNAs, one or more copies per 10^5 non-target DNAs, one or more copies per 10^4 non-target DNAs, one or more copies per 10^3 non-target DNAs, one or more copies per 10^2 non-target DNAs, one or more copies per 50 non-target DNAs, one or more copies per 20 non-target DNAs, one or more copies per 10 non-target DNAs, or one or more copies per 5 non-target DNAs). In some cases, a method of the present disclosure can be used to detect a target DNA present in a sample comprising a plurality of DNAs (including the target DNA and a plurality of non-target DNAs), where the target DNA is present at one

or more copies per 10^{18} non-target DNAs (e.g., one or more copies per 10^{15} non-target DNAs, one or more copies per 10^{12} non-target DNAs, one or more copies per 10^{9} non-target DNAs, one or more copies per 10^{6} non-target DNAs, one or more copies per 10^{5} non-target DNAs, one or more copies per 10^{4} non-target DNAs, one or more copies per 10^{3} non-target DNAs, one or more copies per 10^{2} non-target DNAs, one or more copies per 50 non-target DNAs, one or more copies per 20 non-target DNAs, one or more copies per 10 non-target DNAs, or one or more copies per 5 non-target DNAs).

[00294] In some cases, a method of the present disclosure can detect a target DNA present in a sample, where the target DNA is present at from one copy per 10^{7} non-target DNAs to one copy per 10 non-target DNAs (e.g., from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{3} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{4} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{5} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{6} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10 non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{3} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{4} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{5} non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10 non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{3} non-target DNAs, or from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{4} non-target DNAs).

[00295] In some cases, a method of the present disclosure can detect a target DNA present in a sample, where the target DNA is present at from one copy per 10^{18} non-target DNAs to one copy per 10 non-target DNAs (e.g., from 1 copy per 10^{18} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{15} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{12} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{9} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{3} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{4} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{5} non-target DNAs, from 1 copy per 10^{7} non-target DNAs to 1 copy per 10^{6} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10 non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{3} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{4} non-target DNAs, from 1 copy per 10^{6} non-target DNAs to 1 copy per 10^{5} non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10 non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{2} non-target DNAs, from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{3} non-target DNAs, or from 1 copy per 10^{5} non-target DNAs to 1 copy per 10^{4} non-target DNAs).

[00296] In some cases, a method of the present disclosure can detect a target DNA present in a sample, where the target DNA is present at from one copy per 10^7 non-target DNAs to one copy per 100 non-target DNAs (e.g., from 1 copy per 10^7 non-target DNAs to 1 copy per 10^2 non-target DNAs, from 1 copy per 10^7 non-target DNAs to 1 copy per 10^3 non-target DNAs, from 1 copy per 10^7 non-target DNAs to 1 copy per 10^4 non-target DNAs, from 1 copy per 10^7 non-target DNAs to 1 copy per 10^5 non-target DNAs, from 1 copy per 10^7 non-target DNAs to 1 copy per 10^6 non-target DNAs, from 1 copy per 10^6 non-target DNAs to 1 copy per 100 non-target DNAs, from 1 copy per 10^6 non-target DNAs to 1 copy per 10^2 non-target DNAs, from 1 copy per 10^6 non-target DNAs to 1 copy per 10^3 non-target DNAs, from 1 copy per 10^6 non-target DNAs to 1 copy per 10^4 non-target DNAs, from 1 copy per 10^6 non-target DNAs to 1 copy per 10^5 non-target DNAs, from 1 copy per 10^5 non-target DNAs to 1 copy per 100 non-target DNAs, from 1 copy per 10^5 non-target DNAs to 1 copy per 10^2 non-target DNAs, from 1 copy per 10^5 non-target DNAs to 1 copy per 10^3 non-target DNAs, or from 1 copy per 10^5 non-target DNAs to 1 copy per 10^4 non-target DNAs).

[00297] In some cases, the threshold of detection, for a subject method of detecting a target DNA in a sample, is 10 nM or less. Thus, e.g., the target DNA can be present in the sample in a concentration of 10 nM or less. The term "threshold of detection" is used herein to describe the minimal amount of target DNA that must be present in a sample in order for detection to occur. Thus, as an illustrative example, when a threshold of detection is 10 nM, then a signal can be detected when a target DNA is present in the sample at a concentration of 10 nM or more. In some cases, a method of the present disclosure has a threshold of detection of 5 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 1 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.5 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.1 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.05 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.01 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.005 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.001 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.0005 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.0001 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.00005 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 0.00001 nM or less. In some cases, a method of the present disclosure has a threshold of detection of 10 pM or less. In some cases, a method of the present disclosure has a threshold of detection of 1 pM or less. In some cases, a method of the present disclosure has a threshold of detection of 500 fM or less. In some cases, a method of the present disclosure has a threshold of detection of 250 fM or less. In some cases, a method of the present disclosure has a threshold of

detection of 100 fM or less. In some cases, a method of the present disclosure has a threshold of detection of 50 fM or less. In some cases, a method of the present disclosure has a threshold of detection of 500 aM (attomolar) or less. In some cases, a method of the present disclosure has a threshold of detection of 250 aM or less. In some cases, a method of the present disclosure has a threshold of detection of 100 aM or less. In some cases, a method of the present disclosure has a threshold of detection of 50 aM or less. In some cases, a method of the present disclosure has a threshold of detection of 10 aM or less. In some cases, a method of the present disclosure has a threshold of detection of 1 aM or less.

[00298] In some cases, the threshold of detection (for detecting the target DNA in a subject method), is in a range of from 500 fM to 1 nM (e.g., from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM) (where the concentration refers to the threshold concentration of target DNA at which the target DNA can be detected). In some cases, a method of the present disclosure has a threshold of detection in a range of from 800 fM to 100 pM. In some cases, a method of the present disclosure has a threshold of detection in a range of from 1 pM to 10 pM. In some cases, a method of the present disclosure has a threshold of detection in a range of from 10 fM to 500 fM, e.g., from 10 fM to 50 fM, from 50 fM to 100 fM, from 100 fM to 250 fM, or from 250 fM to 500 fM.

[00299] In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 500 fM to 1 nM (e.g., from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM). In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 800 fM to 100 pM. In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 1 pM to 10 pM.

[00300] In some cases, the threshold of detection (for detecting the target DNA in a subject method), is in a range of from 1 aM to 1 nM (e.g., from 1 aM to 500 pM, from 1 aM to 200 pM, from 1 aM to 100 pM, from 1 aM to 10 pM, from 1 aM to 1 pM, from 100 aM to 1 nM, from 100 aM to 500 pM, from 100 aM to 200 pM, from 100 aM to 100 pM, from 100 aM to 10 pM, from 100 aM to 1 pM, from 250 aM to 1 nM, from 250 aM to 500 pM, from 250 aM to 200 pM, from 250 aM to 100 pM, from 250 aM to 10 pM, from 250 aM to 1 pM, from 500 aM to 1 nM, from 500 aM to 500 pM, from 500 aM to 200 pM, from 500 aM to 100 pM, from 500 aM to 10 pM, from 500 aM to 1 pM, from 750 aM to 1 nM, from 750 aM to 500 pM, from 750 aM to 200 pM, from 750 aM to 100 pM, from 750 aM to 10 pM,

from 750 aM to 1 pM, from 1 fM to 1 nM, from 1 fM to 500 pM, from 1 fM to 200 pM, from 1 fM to 100 pM, from 1 fM to 10 pM, from 1 fM to 1 pM, from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM) (where the concentration refers to the threshold concentration of target DNA at which the target DNA can be detected). In some cases, a method of the present disclosure has a threshold of detection in a range of from 1 aM to 800 aM. In some cases, a method of the present disclosure has a threshold of detection in a range of from 50 aM to 1 pM. In some cases, a method of the present disclosure has a threshold of detection in a range of from 50 aM to 500 fM.

[00301] In some cases, a target DNA is present in a sample in a range of from 1 aM to 1 nM (e.g., from 1 aM to 500 pM, from 1 aM to 200 pM, from 1 aM to 100 pM, from 1 aM to 10 pM, from 1 aM to 1 pM, from 100 aM to 1 nM, from 100 aM to 500 pM, from 100 aM to 200 pM, from 100 aM to 100 pM, from 100 aM to 10 pM, from 100 aM to 1 pM, from 250 aM to 1 nM, from 250 aM to 500 pM, from 250 aM to 200 pM, from 250 aM to 100 pM, from 250 aM to 10 pM, from 250 aM to 1 pM, from 500 aM to 1 nM, from 500 aM to 500 pM, from 500 aM to 200 pM, from 500 aM to 100 pM, from 500 aM to 10 pM, from 500 aM to 1 pM, from 750 aM to 1 nM, from 750 aM to 500 pM, from 750 aM to 200 pM, from 750 aM to 100 pM, from 750 aM to 10 pM, from 750 aM to 1 pM, from 1 fM to 1 nM, from 1 fM to 500 pM, from 1 fM to 200 pM, from 1 fM to 100 pM, from 1 fM to 10 pM, from 1 fM to 1 pM, from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM). In some cases, a target DNA is present in a sample in a range of from 1 aM to 800 aM. In some cases, a target DNA is present in a sample in a range of from 50 aM to 1 pM. In some cases, a target DNA is present in a sample in a range of from 50 aM to 500 fM.

[00302] In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 1 aM to 1 nM (e.g., from 1 aM to 500 pM, from 1 aM to 200 pM, from 1 aM to 100 pM, from 1 aM to 10 pM, from 1 aM to 1 pM, from 100 aM to 1 nM, from 100 aM to 500 pM, from 100 aM to 200 pM, from 100 aM to 100 pM, from 100 aM to 10 pM, from 100 aM to 1 pM, from 250 aM to 1 nM, from 250 aM to 500 pM, from 250 aM to 200 pM, from 250 aM to 100 pM, from 250 aM to 10 pM, from 250 aM to 1 pM, from 500 aM to 1 nM, from 500 aM to 500 pM, from 500 aM to 200 pM, from 500 aM to 100 pM, from 500 aM to 10 pM, from 500 aM to 1 pM, from 750 aM to 1 nM, from 750 aM to 500 pM, from 750 aM to 200 pM, from 750 aM to 100 pM, from 750 aM to 10 pM, from 750 aM to 1 pM, from 1 fM to 1 nM, from 1 fM to 500 pM, from 1 fM to 200 pM, from 1 fM to

100 pM, from 1 fM to 10 pM, from 1 fM to 1 pM, from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM). In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 1 aM to 500 pM. In some cases, the minimum concentration at which a target DNA can be detected in a sample is in a range of from 100 aM to 500 pM.

[00303] In some cases, a target DNA is present in a sample in a range of from 1 aM to 1 nM (e.g., from 1 aM to 500 pM, from 1 aM to 200 pM, from 1 aM to 100 pM, from 1 aM to 10 pM, from 1 aM to 1 pM, from 100 aM to 1 nM, from 100 aM to 500 pM, from 100 aM to 200 pM, from 100 aM to 100 pM, from 100 aM to 10 pM, from 100 aM to 1 pM, from 250 aM to 1 nM, from 250 aM to 500 pM, from 250 aM to 200 pM, from 250 aM to 100 pM, from 250 aM to 10 pM, from 250 aM to 1 pM, from 500 aM to 1 nM, from 500 aM to 500 pM, from 500 aM to 200 pM, from 500 aM to 100 pM, from 500 aM to 10 pM, from 500 aM to 1 pM, from 750 aM to 1 nM, from 750 aM to 500 pM, from 750 aM to 200 pM, from 750 aM to 100 pM, from 750 aM to 10 pM, from 750 aM to 1 pM, from 1 fM to 1 nM, from 1 fM to 500 pM, from 1 fM to 200 pM, from 1 fM to 100 pM, from 1 fM to 10 pM, from 1 fM to 1 pM, from 500 fM to 500 pM, from 500 fM to 200 pM, from 500 fM to 100 pM, from 500 fM to 10 pM, from 500 fM to 1 pM, from 800 fM to 1 nM, from 800 fM to 500 pM, from 800 fM to 200 pM, from 800 fM to 100 pM, from 800 fM to 10 pM, from 800 fM to 1 pM, from 1 pM to 1 nM, from 1 pM to 500 pM, from 1 pM to 200 pM, from 1 pM to 100 pM, or from 1 pM to 10 pM). In some cases, a target DNA is present in a sample in a range of from 1 aM to 500 pM. In some cases, a target DNA is present in a sample in a range of from 100 aM to 500 pM.

[00304] In some cases, a subject composition or method exhibits an attomolar (aM) sensitivity of detection. In some cases, a subject composition or method exhibits a femtomolar (fM) sensitivity of detection. In some cases, a subject composition or method exhibits a picomolar (pM) sensitivity of detection. In some cases, a subject composition or method exhibits a nanomolar (nM) sensitivity of detection.

Target DNA

[00305] A target DNA can be single stranded (ssDNA) or double stranded (dsDNA). When the target DNA is single stranded, there is no preference or requirement for a PAM sequence in the target DNA. However, when the target DNA is dsDNA, a PAM is usually present adjacent to the target sequence of the target DNA (e.g., see discussion of the PAM elsewhere herein). The source of the target DNA can be the same as the source of the sample, e.g., as described below.

[00306] The source of the target DNA can be any source. In some cases, the target DNA is a viral DNA (e.g., a genomic DNA of a DNA virus). As such, subject method can be for detecting the

presence of a viral DNA amongst a population of nucleic acids (e.g., in a sample). A subject method can also be used for the cleavage of non-target ssDNAs in the present of a target DNA. For example, if a method takes place in a cell, a subject method can be used to promiscuously cleave non-target ssDNAs in the cell (ssDNAs that do not hybridize with the guide sequence of the guide RNA) when a particular target DNA is present in the cell (e.g., when the cell is infected with a virus and viral target DNA is detected).

[00307] Examples of possible target DNAs include, but are not limited to, viral DNAs such as: a papovavirus (e.g., human papillomavirus (HPV), polyomavirus); a hepadnavirus (e.g., Hepatitis B Virus (HBV)); a herpesvirus (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), Epstein-Barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, Pityriasis Rosea, kaposi's sarcoma-associated herpesvirus); an adenovirus (e.g., atadenovirus, aviadenovirus, ichtadenovirus, mastadenovirus, siadenovirus); a poxvirus (e.g., smallpox, vaccinia virus, cowpox virus, monkeypox virus, orf virus, pseudocowpox, bovine papular stomatitis virus; tanapox virus, yaba monkey tumor virus; molluscum contagiosum virus (MCV)); a parvovirus (e.g., adeno-associated virus (AAV), Parvovirus B19, human bocavirus, bufavirus, human parv4 G1); Geminiviridae; Nanoviridae; Phycodnaviridae; and the like. In some cases, the target DNA is parasite DNA. In some cases, the target DNA is bacterial DNA, e.g., DNA of a pathogenic bacterium.

Samples

[00308] A subject sample includes nucleic acid (e.g., a plurality of nucleic acids). The term "plurality" is used herein to mean two or more. Thus, in some cases a sample includes two or more (e.g., 3 or more, 5 or more, 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 1,000 or more, or 5,000 or more) nucleic acids (e.g., DNAs). A subject method can be used as a very sensitive way to detect a target DNA present in a sample (e.g., in a complex mixture of nucleic acids such as DNAs). In some cases, the sample includes 5 or more DNAs (e.g., 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 1,000 or more, or 5,000 or more DNAs) that differ from one another in sequence. In some cases, the sample includes 10 or more, 20 or more, 50 or more, 100 or more, 500 or more, 10^3 or more, 5 x 10^3 or more, 10^4 or more, 5 x 10^4 or more, 10^5 or more, 5 x 10^5 or more, 10^6 or more 5 x 10^6 or more, or 10^7 or more, DNAs. In some cases, the sample comprises from 10 to 20, from 20 to 50, from 50 to 100, from 100 to 500, from 500 to 10^3, from 10^3 to 5 x 10^3, from 5 x 10^3 to 10^4, from 10^4 to 5 x 10^4, from 5 x 10^4 to 10^5, from 10^5 to 5 x 10^5, from 5 x 10^5 to 10^6, from 10^6 to 5 x 10^6, or from 5 x 10^6 to 10^7, or more than 10^7, DNAs. In some cases, the sample comprises from 5 to 10^7 DNAs (e.g., that differ from one another in sequence)(e.g., from 5 to 10^6, from 5 to 10^5, from 5 to 50,000, from 5 to 30,000, from 10 to 10^6, from 10 to 10^5, from 10 to 50,000, from 10 to 30,000, from 20 to 10^6, from 20 to 10^5, from 20 to 50,000, or from 20 to 30,000 DNAs). In some cases, the sample includes 20 or more DNAs that differ from one another in sequence. In some cases, the sample includes DNAs from a cell lysate (e.g., a

eukaryotic cell lysate, a mammalian cell lysate, a human cell lysate, a prokaryotic cell lysate, a plant cell lysate, and the like). For example, in some cases the sample includes DNA from a cell such as a eukaryotic cell, e.g., a mammalian cell such as a human cell.

[00309] The term "sample" is used herein to mean any sample that includes DNA (e.g., in order to determine whether a target DNA is present among a population of DNAs). The sample can be derived from any source, e.g., the sample can be a synthetic combination of purified DNAs; the sample can be a cell lysate, an DNA-enriched cell lysate, or DNAs isolated and/or purified from a cell lysate. The sample can be from a patient (e.g., for the purpose of diagnosis). The sample can be from permeabilized cells. The sample can be from crosslinked cells. The sample can be in tissue sections. The sample can be from tissues prepared by crosslinking followed by delipidation and adjustment to make a uniform refractive index. Examples of tissue preparation by crosslinking followed by delipidation and adjustment to make a uniform refractive index have been described in, for example, Shah et al., Development (2016) 143, 2862-2867 doi:10.1242/dev.138560.

[00310] A "sample" can include a target DNA and a plurality of non-target DNAs. In some cases, the target DNA is present in the sample at one copy per 10 non-target DNAs, one copy per 20 non-target DNAs, one copy per 25 non-target DNAs, one copy per 50 non-target DNAs, one copy per 100 non-target DNAs, one copy per 500 non-target DNAs, one copy per 10^3 non-target DNAs, one copy per 5×10^3 non-target DNAs, one copy per 10^4 non-target DNAs, one copy per 5×10^4 non-target DNAs, one copy per 10^5 non-target DNAs, one copy per 5×10^5 non-target DNAs, one copy per 10^6 non-target DNAs, or less than one copy per 10^6 non-target DNAs. In some cases, the target DNA is present in the sample at from one copy per 10 non-target DNAs to 1 copy per 20 non-target DNAs, from 1 copy per 20 non-target DNAs to 1 copy per 50 non-target DNAs, from 1 copy per 50 non-target DNAs to 1 copy per 100 non-target DNAs, from 1 copy per 100 non-target DNAs to 1 copy per 500 non-target DNAs, from 1 copy per 500 non-target DNAs to 1 copy per 10^3 non-target DNAs, from 1 copy per 10^3 non-target DNAs to 1 copy per 5×10^3 non-target DNAs, from 1 copy per 5×10^3 non-target DNAs to 1 copy per 10^4 non-target DNAs, from 1 copy per 10^4 non-target DNAs to 1 copy per 10^5 non-target DNAs, from 1 copy per 10^5 non-target DNAs to 1 copy per 10^6 non-target DNAs, or from 1 copy per 10^6 non-target DNAs to 1 copy per 10^7 non-target DNAs.

[00311] Suitable samples include but are not limited to saliva, blood, serum, plasma, urine, aspirate, and biopsy samples. Thus, the term "sample" with respect to a patient encompasses blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures or cells derived therefrom and the progeny thereof. The definition also includes samples that have been manipulated in any way after their procurement, such as by treatment with reagents; washed; or enrichment for certain cell populations, such as cancer cells. The definition also includes sample that have been enriched for particular types of molecules, *e.g.*, DNAs. The term "sample" encompasses

biological samples such as a clinical sample such as blood, plasma, serum, aspirate, cerebral spinal fluid (CSF), and also includes tissue obtained by surgical resection, tissue obtained by biopsy, cells in culture, cell supernatants, cell lysates, tissue samples, organs, bone marrow, and the like. A "biological sample" includes biological fluids derived therefrom (e.g., cancerous cell, infected cell, etc.), *e.g.*, a sample comprising DNAs that is obtained from such cells (*e.g.*, a cell lysate or other cell extract comprising DNAs).

[00312] A sample can comprise, or can be obtained from, any of a variety of cells, tissues, organs, or acellular fluids. Suitable sample sources include eukaryotic cells, bacterial cells, and archaeal cells. Suitable sample sources include single-celled organisms and multi-cellular organisms. Suitable sample sources include single-cell eukaryotic organisms; a plant or a plant cell; an algal cell, e.g., *Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Sargassum patens, C. agardh*, and the like; a fungal cell (e.g., a yeast cell); an animal cell, tissue, or organ; a cell, tissue, or organ from an invertebrate animal (e.g. fruit fly, cnidarian, echinoderm, nematode, an insect, an arachnid, etc.); a cell, tissue, fluid, or organ from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal); a cell, tissue, fluid, or organ from a mammal (e.g., a human; a non-human primate; an ungulate; a feline; a bovine; an ovine; a caprine; etc.). Suitable sample sources include nematodes, protozoans, and the like. Suitable sample sources include parasites such as helminths, malarial parasites, etc.

[00313] Suitable sample sources include a cell, tissue, or organism of any of the six kingdoms, e.g., Bacteria (e.g., Eubacteria); Archaebacteria; Protista; Fungi; Plantae; and Animalia. Suitable sample sources include plant-like members of the kingdom Protista, including, but not limited to, algae (e.g., green algae, red algae, glaucophytes, cyanobacteria); fungus-like members of Protista, e.g., slime molds, water molds, etc.; animal-like members of Protista, e.g., flagellates (e.g., Euglena), amoeboids (e.g., amoeba), sporozoans (e.g., Apicomplexa, Myxozoa, Microsporidia), and ciliates (e.g., Paramecium). Suitable sample sources include include members of the kingdom Fungi, including, but not limited to, members of any of the phyla: Basidiomycota (club fungi; e.g., members of Agaricus, Amanita, Boletus, Cantherellus, etc.); Ascomycota (sac fungi, including, e.g., Saccharomyces); Mycophycophyta (lichens); Zygomycota (conjugation fungi); and Deuteromycota. Suitable sample sources include include members of the kingdom Plantae, including, but not limited to, members of any of the following divisions: Bryophyta (e.g., mosses), Anthocerotophyta (e.g., hornworts), Hepaticophyta (e.g., liverworts), Lycophyta (e.g., club mosses), Sphenophyta (e.g., horsetails), Psilophyta (e.g., whisk ferns), Ophioglossophyta, Pterophyta (e.g., ferns), Cycadophyta, Gingkophyta, Pinophyta, Gnetophyta, and Magnoliophyta (e.g., flowering plants). Suitable sample sources include include members of the kingdom Animalia, including, but not limited to, members of any of the following phyla: Porifera (sponges); Placozoa; Orthonectida (parasites of marine invertebrates); Rhombozoa; Cnidaria (corals,

anemones, jellyfish, sea pens, sea pansies, sea wasps); Ctenophora (comb jellies); Platyhelminthes (flatworms); Nemertina (ribbon worms); Ngathostomulida (jawed worms)p Gastrotricha; Rotifera; Priapulida; Kinorhyncha; Loricifera; Acanthocephala; Entoprocta; Nemotoda; Nematomorpha; Cycliophora; Mollusca (mollusks); Sipuncula (peanut worms); Annelida (segmented worms); Tardigrada (water bears); Onychophora (velvet worms); Arthropoda (including the subphyla: Chelicerata, Myriapoda, Hexapoda, and Crustacea, where the Chelicerata include, e.g., arachnids, Merostomata, and Pycnogonida, where the Myriapoda include, e.g., Chilopoda (centipedes), Diplopoda (millipedes), Paropoda, and Symphyla, where the Hexapoda include insects, and where the Crustacea include shrimp, krill, barnacles, etc.; Phoronida; Ectoprocta (moss animals); Brachiopoda; Echinodermata (e.g. starfish, sea daisies, feather stars, sea urchins, sea cucumbers, brittle stars, brittle baskets, etc.); Chaetognatha (arrow worms); Hemichordata (acorn worms); and Chordata. Suitable members of Chordata include any member of the following subphyla: Urochordata (sea squirts; including Ascidiacea, Thaliacea, and Larvacea); Cephalochordata (lancelets); Myxini (hagfish); and Vertebrata, where members of Vertebrata include, e.g., members of Petromyzontida (lampreys), Chondrichthyces (cartilaginous fish), Actinopterygii (ray-finned fish), Actinista (coelocanths), Dipnoi (lungfish), Reptilia (reptiles, e.g., snakes, alligators, crocodiles, lizards, etc.), Aves (birds); and Mammalian (mammals). Suitable plants include any monocotyledon and any dicotyledon.

[00314] Suitable sources of a sample include cells, fluid, tissue, or organ taken from an organism; from a particular cell or group of cells isolated from an organism; etc. For example, where the organism is a plant, suitable sources include xylem, the phloem, the cambium layer, leaves, roots, etc. Where the organism is an animal, suitable sources include particular tissues (e.g., lung, liver, heart, kidney, brain, spleen, skin, fetal tissue, etc.), or a particular cell type (e.g., neuronal cells, epithelial cells, endothelial cells, astrocytes, macrophages, glial cells, islet cells, T lymphocytes, B lymphocytes, etc.).

[00315] In some cases, the source of the sample is a (or is suspected of being a diseased cell, fluid, tissue, or organ. In some cases, the source of the sample is a normal (non-diseased) cell, fluid, tissue, or organ. In some cases, the source of the sample is a (or is suspected of being a pathogen-infected cell, tissue, or organ. For example, the source of a sample can be an individual who may or may not be infected – and the sample could be any biological sample (e.g., blood, saliva, biopsy, plasma, serum, bronchoalveolar lavage, sputum, a fecal sample, cerebrospinal fluid, a fine needle aspirate, a swab sample (e.g., a buccal swab, a cervical swab, a nasal swab), interstitial fluid, synovial fluid, nasal discharge, tears, buffy coat, a mucous membrane sample, an epithelial cell sample (e.g., epithelial cell scraping), etc.) collected from the individual. In some cases, the sample is a cell-free liquid sample. In some cases, the sample is a liquid sample that can comprise cells. Pathogens include viruses, fungi, helminths, protozoa, malarial parasites, Plasmodium parasites, Toxoplasma parasites, Schistosoma parasites, and the like. “Helminths” include roundworms, heartworms, and phytophagous nematodes

(Nematoda), flukes (Tematoda), Acanthocephala, and tapeworms (Cestoda). Protozoan infections include infections from Giardia spp., Trichomonas spp., African trypanosomiasis, amoebic dysentery, babesiosis, balantidial dysentery, Chaga's disease, coccidiosis, malaria and toxoplasmosis. Examples of pathogens such as parasitic/protozoan pathogens include, but are not limited to: *Plasmodium falciparum*, *Plasmodium vivax*, *Trypanosoma cruzi* and *Toxoplasma gondii*. Fungal pathogens include, but are not limited to: *Cryptococcus neoformans, Histoplasma capsulatum, Coccidioides immitis, Blastomyces dermatitidis, Chlamydia trachomatis,* and *Candida albicans*. Pathogenic viruses include, e.g., immunodeficiency virus (e.g., HIV); influenza virus; dengue; West Nile virus; herpes virus; yellow fever virus; Hepatitis Virus C; Hepatitis Virus A; Hepatitis Virus B; papillomavirus; and the like. Pathogenic viruses can include DNA viruses such as: a papovavirus (e.g., human papillomavirus (HPV), polyomavirus); a hepadnavirus (e.g., Hepatitis B Virus (HBV)); a herpesvirus (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), epstein-barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, Pityriasis Rosea, kaposi's sarcoma-associated herpesvirus); an adenovirus (e.g., atadenovirus, aviadenovirus, ichtadenovirus, mastadenovirus, siadenovirus); a poxvirus (e.g., smallpox, vaccinia virus, cowpox virus, monkeypox virus, orf virus, pseudocowpox, bovine papular stomatitis virus; tanapox virus, yaba monkey tumor virus; molluscum contagiosum virus (MCV)); a parvovirus (e.g., adeno-associated virus (AAV), Parvovirus B19, human bocavirus, bufavirus, human parv4 G1); Geminiviridae; Nanoviridae; Phycodnaviridae; and the like. Pathogens can include, e.g., DNAviruses [e.g.: a papovavirus (e.g., human papillomavirus (HPV), polyomavirus); a hepadnavirus (e.g., Hepatitis B Virus (HBV)); a herpesvirus (e.g., herpes simplex virus (HSV), varicella zoster virus (VZV), Epstein-barr virus (EBV), cytomegalovirus (CMV), herpes lymphotropic virus, Pityriasis Rosea, kaposi's sarcoma-associated herpesvirus); an adenovirus (e.g., atadenovirus, aviadenovirus, ichtadenovirus, mastadenovirus, siadenovirus); a poxvirus (e.g., smallpox, vaccinia virus, cowpox virus, monkeypox virus, orf virus, pseudocowpox, bovine papular stomatitis virus; tanapox virus, yaba monkey tumor virus; molluscum contagiosum virus (MCV)); a parvovirus (e.g., adeno-associated virus (AAV), Parvovirus B19, human bocavirus, bufavirus, human parv4 G1); Geminiviridae; Nanoviridae; Phycodnaviridae; and the like], *Mycobacterium tuberculosis*, *Streptococcus agalactiae*, methicillin-resistant *Staphylococcus aureus*, *Legionella pneumophila*, *Streptococcus pyogenes*, *Escherichia coli*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, Pneumococcus, *Cryptococcus neoformans*, *Histoplasma capsulatum*, Hemophilus influenzae B, *Treponema pallidum*, Lyme disease spirochetes, *Pseudomonas aeruginosa*, *Mycobacterium leprae*, *Brucella abortus*, rabies virus, influenza virus, cytomegalovirus, herpes simplex virus I, herpes simplex virus II, human serum parvo-like virus, respiratory syncytial virus, varicella-zoster virus, hepatitis B virus, hepatitis C virus, measles virus, adenovirus, human T-cell leukemia viruses, Epstein-Barr virus, murine leukemia virus, mumps virus, vesicular stomatitis virus, Sindbis virus, lymphocytic choriomeningitis virus, wart virus, blue tongue virus, Sendai virus, feline

leukemia virus, Reovirus, polio virus, simian virus 40, mouse mammary tumor virus, dengue virus, rubella virus, West Nile virus, *Plasmodium falciparum, Plasmodium vivax, Toxoplasma gondii, Trypanosoma rangeli, Trypanosoma cruzi, Trypanosoma rhodesiense, Trypanosoma brucei, Schistosoma mansoni, Schistosoma japonicum, Babesia bovis, Eimeria tenella, Onchocerca volvulus, Leishmania tropica, Mycobacterium tuberculosis, Trichinella spiralis, Theileria parva, Taenia hydatigena, Taenia ovis, Taenia saginata, Echinococcus granulosus, Mesocestoides corti, Mycoplasma arthritidis, M. hyorhinis, M. orale, M. arginini, Acholeplasma laidlawii, M. salivarium* and *M. pneumoniae*.

Measuring a detectable signal

[00316] In some cases, a subject method includes a step of measuring (e.g., measuring a detectable signal produced by CasZ-mediated ssDNA cleavage). Because a CasZ polypeptide cleaves non-targeted ssDNA once activated, which occurs when a guide RNA hybridizes with a target DNA in the presence of a CasZ polypeptide (and, in some cases, also including a tranc RNA), a detectable signal can be any signal that is produced when ssDNA is cleaved. For example, in some cases the step of measuring can include one or more of: gold nanoparticle based detection (e.g., see Xu et al., Angew Chem Int Ed Engl. 2007;46(19):3468-70; and Xia et al., Proc Natl Acad Sci U S A. 2010 Jun 15;107(24):10837-41), fluorescence polarization, colloid phase transition/dispersion (e.g., Baksh et al., Nature. 2004 Jan 8;427(6970):139-41), electrochemical detection, semiconductor-based sensing (e.g., Rothberg et al., Nature. 2011 Jul 20;475(7356):348-52; e.g., one could use a phosphatase to generate a pH change after ssDNA cleavage reactions, by opening 2'-3' cyclic phosphates, and by releasing inorganic phosphate into solution), and detection of a labeled detector ssDNA (see elsewhere herein for more details). The readout of such detection methods can be any convenient readout. Examples of possible readouts include but are not limited to: a measured amount of detectable fluorescent signal; a visual analysis of bands on a gel (e.g., bands that represent cleaved product versus uncleaved substrate), a visual or sensor based detection of the presence or absence of a color (i.e., color detection method), and the presence or absence of (or a particular amount of) an electrical signal.

[00317] The measuring can in some cases be quantitative, e.g., in the sense that the amount of signal detected can be used to determine the amount of target DNA present in the sample. The measuring can in some cases be qualitative, e.g., in the sense that the presence or absence of detectable signal can indicate the presence or absence of targeted DNA (e.g., virus, SNP, etc.). In some cases, a detectable signal will not be present (e.g., above a given threshold level) unless the targeted DNA(s) (e.g., virus, SNP, etc.) is present above a particular threshold concentration. In some cases, the threshold of detection can be titrated by modifying the amount of CasZ polypeptide, guide RNA, sample volume, and/or detector ssDNA (if one is used). As such, for example, as would be understood by one of ordinary skill in the art, a number of controls can be used if desired in order to set up one or more reactions, each set up

to detect a different threshold level of target DNA, and thus such a series of reactions could be used to determine the amount of target DNA present in a sample (e.g., one could use such a series of reactions to determine that a target DNA is present in the sample 'at a concentration of at least X'). Non-limiting examples of applications of/uses for the compositions and methods of the disclosure include single-nucleotide polymorphism (SNP) detection, cancer screening, detection of bacterial infection, detection of antibiotic resistance, detection of viral infection, and the like. The compositions and methods of this disclosure can be used to detect any DNA target. For example, any virus that integrates nucleic acid material into the genome can be detected because a subject sample can include cellular genomic DNA – and the guide RNA can be designed to detect integrated nucleotide sequence. A method of the present disclosure in some cases does not include an amplification step. A method of the present disclosure in some cases includes an amplification step.

[00318] In some cases, a method of the present disclosure can be used to determine the amount of a target DNA in a sample (e.g., a sample comprising the target DNA and a plurality of non-target DNAs). Determining the amount of a target DNA in a sample can comprise comparing the amount of detectable signal generated from a test sample to the amount of detectable signal generated from a reference sample. Determining the amount of a target DNA in a sample can comprise: measuring the detectable signal to generate a test measurement; measuring a detectable signal produced by a reference sample to generate a reference measurement; and comparing the test measurement to the reference measurement to determine an amount of target DNA present in the sample.

[00319] For example, in some cases, a method of the present disclosure for determining the amount of a target DNA in a sample comprises: a) contacting the sample (e.g., a sample comprising the target DNA and a plurality of non-target DNAs) with: (i) a guide RNA that hybridizes with the target DNA, (ii) a CasZ polypeptide that cleaves DNAs present in the sample, and (iii) a detector ssDNA; b) measuring a detectable signal produced by CasZ polypeptide-mediated ssDNA cleavage (e.g., cleavage of the detector ssDNA), generating a test measurement; c) measuring a detectable signal produced by a reference sample to generate a reference measurement; and d) comparing the test measurement to the reference measurement to determine an amount of target DNA present in the sample.

[00320] As another example, in some cases, a method of the present disclosure for determining the amount of a target DNA in a sample comprises: a) contacting the sample (e.g., a sample comprising the target DNA and a plurality of non-target DNAs) with: (i) a guide RNA that hybridizes with the target DNA, (ii) a CasZ polypeptide that cleaves DNAs present in the sample, (iii) a tranc RNA; (iv) a detector ssDNA; b) measuring a detectable signal produced by CasZ polypeptide-mediated ssDNA cleavage (e.g., cleavage of the detector ssDNA), generating a test measurement; c) measuring a detectable signal produced by a reference sample to generate a reference measurement; and d) comparing the test measurement to the reference measurement to determine an amount of target DNA present in the sample.

Amplification of nucleic acids in the sample

[00321] In some embodiments, sensitivity of a subject composition and/or method (e.g., for detecting the presence of a target DNA, such as viral DNA or a SNP, in cellular genomic DNA) can be increased by coupling detection with nucleic acid amplification. In some cases, the nucleic acids in a sample are amplified prior to contact with a CasZ polypeptide that cleaves ssDNA (e.g., amplification of nucleic acids in the sample can begin prior to contact with a CasZ polypeptide). In some cases, the nucleic acids in a sample are amplified simultaneous with contact with a CasZ polypeptide. For example, in some cases a subject method includes amplifying nucleic acids of a sample (e.g., by contacting the sample with amplification components) prior to contacting the amplified sample with a CasZ polypeptide. In some cases, a subject method includes contacting a sample with amplification components at the same time (simultaneous with) that the sample is contacted with a CasZ polypeptide. If all components are added simultaneously (amplification components and detection components such as a CasZ polypeptide, a guide RNA, and a detector DNA), it is possible that the trans-cleavage activity of the CasZ polypeptide, will begin to degrade the nucleic acids of the sample at the same time the nucleic acids are undergoing amplification. However, even if this is the case, amplifying and detecting simultaneously can still increase sensitivity compared to performing the method without amplification.

[00322] In some cases, specific sequences (e.g., sequences of a virus, sequences that include a SNP of interest) are amplified from the sample, e.g., using primers. As such, a sequence to which the guide RNA will hybridize can be amplified in order to increase sensitivity of a subject detection method – this could achieve biased amplification of a desired sequence in order to increase the number of copies of the sequence of interest present in the sample relative to other sequences present in the sample. As one illustrative example, if a subject method is being used to determine whether a given sample includes a particular virus (or a particular SNP), a desired region of viral sequence (or non-viral genomic sequence) can be amplified, and the region amplified will include the sequence that would hybridize to the guide RNA if the viral sequence (or SNP) were in fact present in the sample.

[00323] As noted, in some cases the nucleic acids are amplified (e.g., by contact with amplification components) prior to contacting the amplified nucleic acids with a CasZ polypeptide. In some cases, amplification occurs for 10 seconds or more, (e.g., 30 seconds or more, 45 seconds or more, 1 minute or more, 2 minutes or more, 3 minutes or more, 4 minutes or more, 5 minutes or more, 7.5 minutes or more, 10 minutes or more, etc.) prior to contact with an enzymatically active CasZ polypeptide. In some cases, amplification occurs for 2 minutes or more (e.g., 3 minutes or more, 4 minutes or more, 5 minutes or more, 7.5 minutes or more, 10 minutes or more, etc.) prior to contact with an active CasZ polypeptide. In some cases, amplification occurs for a period of time in a range of from 10 seconds to 60 minutes (e.g., 10 seconds to 40 minutes, 10 seconds to 30 minutes, 10 seconds to 20 minutes, 10 seconds to 15 minutes, 10 seconds to 10 minutes, 10 seconds to 5 minutes, 30 seconds to 40

minutes, 30 seconds to 30 minutes, 30 seconds to 20 minutes, 30 seconds to 15 minutes, 30 seconds to 10 minutes, 30 seconds to 5 minutes, 1 minute to 40 minutes, 1 minute to 30 minutes, 1 minute to 20 minutes, 1 minute to 15 minutes, 1 minute to 10 minutes, 1 minute to 5 minutes, 2 minutes to 40 minutes, 2 minutes to 30 minutes, 2 minutes to 20 minutes, 2 minutes to 15 minutes, 2 minutes to 10 minutes, 2 minutes to 5 minutes, 5 minutes to 40 minutes, 5 minutes to 30 minutes, 5 minutes to 20 minutes, 5 minutes to 15 minutes, or 5 minutes to 10 minutes). In some cases, amplification occurs for a period of time in a range of from 5 minutes to 15 minutes. In some cases, amplification occurs for a period of time in a range of from 7 minutes to 12 minutes.

[00324] In some cases, a sample is contacted with amplification components at the same time as contact with a CasZ polypeptide. In some such cases, the CasZ polypeptide is inactive at the time of contact and is activated once nucleic acids in the sample have been amplified.

[00325] Various amplification methods and components will be known to one of ordinary skill in the art and any convenient method can be used (see, e.g., Zanoli and Spoto, Biosensors (Basel). 2013 Mar; 3(1): 18–43; Gill and Ghaemi, Nucleosides, Nucleotides, and Nucleic Acids, 2008, 27: 224-243; Craw and Balachandrana, Lab Chip, 2012, 12, 2469-2486; which are herein incorporated by reference in their entirety). Nucleic acid amplification can comprise polymerase chain reaction (PCR), reverse transcription PCR (RT-PCR), quantitative PCR (qPCR), reverse transcription qPCR (RT-qPCR), nested PCR, multiplex PCR, asymmetric PCR, touchdown PCR, random primer PCR, hemi-nested PCR, polymerase cycling assembly (PCA), colony PCR, ligase chain reaction (LCR), digital PCR, methylation specific-PCR (MSP),co-amplification at lower denaturation temperature-PCR (COLD-PCR), allele-specific PCR, intersequence-specific PCR (ISS-PCR), whole genome amplification (WGA), inverse PCR, and thermal asymmetric interlaced PCR (TAIL-PCR).

[00326] In some cases, the amplification is isothermal amplification. The term "isothermal amplification" indicates a method of nucleic acid (e.g., DNA) amplification (e.g., using enzymatic chain reaction) that can use a single temperature incubation thereby obviating the need for a thermal cycler. Isothermal amplification is a form of nucleic acid amplification which does not rely on the thermal denaturation of the target nucleic acid during the amplification reaction and hence may not require multiple rapid changes in temperature. Isothermal nucleic acid amplification methods can therefore be carried out inside or outside of a laboratory environment. By combining with a reverse transcription step, these amplification methods can be used to isothermally amplify RNA.

[00327] Examples of isothermal amplification methods include but are not limited to: loop-mediated isothermal Amplification (LAMP), helicase-dependent Amplification (HDA), recombinase polymerase amplification (RPA), strand displacement amplification (SDA), nucleic acid sequence-based amplification (NASBA), transcription mediated amplification (TMA), nicking enzyme amplification reaction (NEAR), rolling circle amplification (RCA), multiple

displacement amplification (MDA), Ramification (RAM), circular helicase-dependent amplification (cHDA), single primer isothermal amplification (SPIA), signal mediated amplification of RNA technology (SMART), self-sustained sequence replication (3SR), genome exponential amplification reaction (GEAR) and isothermal multiple displacement amplification (IMDA).

[00328] In some cases, the amplification is recombinase polymerase amplification (RPA) (see, e.g., U.S. patent Nos. 8,030,000; 8,426,134; 8,945,845; 9,309,502; and 9,663,820, which are hereby incorporated by reference in their entirety). Recombinase polymerase amplification (RPA) uses two opposing primers (much like PCR) and employs three enzymes – a recombinase, a single-stranded DNA-binding protein (SSB) and a strand-displacing polymerase. The recombinase pairs oligonucleotide primers with homologous sequence in duplex DNA, SSB binds to displaced strands of DNA to prevent the primers from being displaced, and the strand displacing polymerase begins DNA synthesis where the primer has bound to the target DNA. Adding a reverse transcriptase enzyme to an RPA reaction can facilitate detection RNA as well as DNA, without the need for a separate step to produce cDNA. One example of components for an RPA reaction is as follows (see, e.g., U.S. patent Nos. 8,030,000; 8,426,134; 8,945,845; 9,309,502; 9,663,820): 50mM Tris pH 8.4, 80mM Potassium actetate, 10mM Magnesium acetate, 2 mM DTT, 5% PEG compound (Carbowax-20M), 3mM ATP, 30 mM Phosphocreatine, 100 ng/μl creatine kinase, 420 ng/μl gp32, 140 ng/μl UvsX, 35 ng/μl UvsY, 2000M dNTPs, 300 nM each oligonucleotide, 35 ng/μl Bsu polymerase, and a nucleic acid-containing sample).

[00329] In a transcription mediated amplification (TMA), an RNA polymerase is used to make RNA from a promoter engineered in the primer region, and then a reverse transcriptase synthesizes cDNA from the primer. A third enzyme, e.g., Rnase H can then be used to degrade the RNA target from cDNA without the heat-denatured step. This amplification technique is similar to Self-Sustained Sequence Replication (3SR) and Nucleic Acid Sequence Based Amplification (NASBA), but varies in the enzymes employed. For another example, helicase-dependent amplification (HDA) utilizes a thermostable helicase (Tte-UvrD) rather than heat to unwind dsDNA to create single-strands that are then available for hybridization and extension of primers by polymerase. For yet another example, a loop mediated amplification (LAMP) employs a thermostable polymerase with strand displacement capabilities and a set of four or more specific designed primers. Each primer is designed to have hairpin ends that, once displaced, snap into a hairpin to facilitate self-priming and further polymerase extension. In a LAMP reaction, though the reaction proceeds under isothermal conditions, an initial heat denaturation step is required for double-stranded targets. In addition, amplification yields a ladder pattern of various length products. For yet another example, a strand displacement amplification (SDA) combines the ability of a restriction endonuclease to nick the unmodified strand of its target DNA and an exonuclease-deficient DNA polymerase to extend the 3' end at the nick and displace the downstream DNA strand.

Detector DNA

[00330] In some cases, a subject method includes contacting a sample (e.g., a sample comprising a target DNA and a plurality of non-target ssDNAs) with: i) a CasZ polypeptide; ii) a guide RNA; and iii) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA.

[00331] A suitable single-stranded detector DNA has a length of from 7 nucleotides to 25 nucleotides. For example, a suitable single-stranded detector DNA has a length of from 7 nucleotides to 10 nucleotides, from 11 nucleotides to 15 nucleotides, from 15 nucleotides to 20 nucleotides, or from 20 nucleotides to 25 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of from 10 nucleotides to 15 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 10 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 11 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 12 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 13 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 14 nucleotides. In some cases, a suitable single-stranded detector DNA has a length of 15 nucleotides.

[00332] In some cases, a subject method includes: a) contacting a sample with a labeled single stranded detector DNA (detector ssDNA) that includes a fluorescence-emitting dye pair; a CasZ polypeptide that cleaves the labeled detector ssDNA after it is activated (by binding to the guide RNA in the context of the guide RNA hybridizing to a target DNA); and b) measuring the detectable signal that is produced by the fluorescence-emitting dye pair. For example, in some cases, a subject method includes contacting a sample with a labeled detector ssDNA comprising a fluorescence resonance energy transfer (FRET) pair or a quencher/fluor pair, or both. In some cases, a subject method includes contacting a sample with a labeled detector ssDNA comprising a FRET pair. In some cases, a subject method includes contacting a sample with a labeled detector ssDNA comprising a fluor/quencher pair.

[00333] Fluorescence-emitting dye pairs comprise a FRET pair or a quencher/fluor pair. In both cases of a FRET pair and a quencher/fluor pair, the emission spectrum of one of the dyes overlaps a region of the absorption spectrum of the other dye in the pair. As used herein, the term "fluorescence-emitting dye pair" is a generic term used to encompass both a "fluorescence resonance energy transfer (FRET) pair" and a "quencher/fluor pair," both of which terms are discussed in more detail below. The term "fluorescence-emitting dye pair" is used interchangeably with the phrase "a FRET pair and/or a quencher/fluor pair."

[00334] In some cases (e.g., when the detector ssDNA includes a FRET pair) the labeled detector ssDNA produces an amount of detectable signal prior to being cleaved, and the amount of detectable signal that is measured is reduced when the labeled detector ssDNA is cleaved. In some cases, the

labeled detector ssDNA produces a first detectable signal prior to being cleaved (e.g., from a FRET pair) and a second detectable signal when the labeled detector ssDNA is cleaved (e.g., from a quencher/fluor pair). As such, in some cases, the labeled detector ssDNA comprises a FRET pair and a quencher/fluor pair.

[00335] In some cases, the labeled detector ssDNA comprises a FRET pair. FRET is a process by which radiationless transfer of energy occurs from an excited state fluorophore to a second chromophore in close proximity. The range over which the energy transfer can take place is limited to approximately 10 nanometers (100 angstroms), and the efficiency of transfer is extremely sensitive to the separation distance between fluorophores. Thus, as used herein, the term "FRET" ("fluorescence resonance energy transfer"; also known as "Förster resonance energy transfer") refers to a physical phenomenon involving a donor fluorophore and a matching acceptor fluorophore selected so that the emission spectrum of the donor overlaps the excitation spectrum of the acceptor, and further selected so that when donor and acceptor are in close proximity (usually 10 nm or less) to one another, excitation of the donor will cause excitation of and emission from the acceptor, as some of the energy passes from donor to acceptor via a quantum coupling effect. Thus, a FRET signal serves as a proximity gauge of the donor and acceptor; only when they are in close proximity to one another is a signal generated. The FRET donor moiety (e.g., donor fluorophore) and FRET acceptor moiety (e.g., acceptor fluorophore) are collectively referred to herein as a "FRET pair".

[00336] The donor-acceptor pair (a FRET donor moiety and a FRET acceptor moiety) is referred to herein as a “FRET pair” or a “signal FRET pair.” Thus, in some cases, a subject labeled detector ssDNA includes two signal partners (a signal pair), when one signal partner is a FRET donor moiety and the other signal partner is a FRET acceptor moiety. A subject labeled detector ssDNA that includes such a FRET pair (a FRET donor moiety and a FRET acceptor moiety) will thus exhibit a detectable signal (a FRET signal) when the signal partners are in close proximity (e.g., while on the same RNA molecule), but the signal will be reduced (or absent) when the partners are separated (e.g., after cleavage of the RNA molecule by a CasZ polypeptide).

[00337] FRET donor and acceptor moieties (FRET pairs) will be known to one of ordinary skill in the art and any convenient FRET pair (e.g., any convenient donor and acceptor moiety pair) can be used. Examples of suitable FRET pairs include but are not limited to those presented in Table 1. See also: Bajar et al. Sensors (Basel). 2016 Sep 14;16(9); and Abraham et al. PLoS One. 2015 Aug 3;10(8):e0134436.

[00338] **Table 6.** Examples of FRET pairs (donor and acceptor FRET moieties)

Donor	**Acceptor**
Tryptophan	Dansyl
IAEDANS (1)	DDPM (2)

Donor	Acceptor
BFP	DsRFP
Dansyl	Fluorescein isothiocyanate (FITC)
Dansyl	Octadecylrhodamine
Cyan fluorescent protein (CFP)	Green fluorescent protein (GFP)
CF (3)	Texas Red
Fluorescein	Tetramethylrhodamine
Cy3	Cy5
GFP	Yellow fluorescent protein (YFP)
BODIPY FL (4)	BODIPY FL (4)
Rhodamine 110	Cy3
Rhodamine 6G	Malachite Green
FITC	Eosin Thiosemicarbazide
B-Phycoerythrin	Cy5
Cy5	Cy5.5

(1) 5-(2-iodoacetylaminoethyl)aminonaphthalene-1-sulfonic acid
(2) N-(4-dimethylamino-3,5-dinitrophenyl)maleimide
(3) carboxyfluorescein succinimidyl ester
(4) 4,4-difluoro-4-bora-3a,4a-diaza-s-indacene

[00339] In some cases, a detectable signal is produced when the labeled detector ssDNA is cleaved (e.g., in some cases, the labeled detector ssDNA comprises a quencher/fluor pair). One signal partner of a signal quenching pair produces a detectable signal and the other signal partner is a quencher moiety that quenches the detectable signal of the first signal partner (i.e., the quencher moiety quenches the signal of the signal moiety such that the signal from the signal moiety is reduced (quenched) when the signal partners are in proximity to one another, e.g., when the signal partners of the signal pair are in close proximity).

[00340] For example, in some cases, an amount of detectable signal increases when the labeled detector ssDNA is cleaved. For example, in some cases, the signal exhibited by one signal partner (a signal moiety) is quenched by the other signal partner (a quencher signal moiety), e.g., when both are present on the same ssDNA molecule prior to cleavage by a CasZ polypeptide. Such a signal pair is referred to herein as a "quencher/fluor pair", "quenching pair", or "signal quenching pair." For example, in some cases, one signal partner (e.g., the first signal partner) is a signal moiety that produces a detectable signal that is quenched by the second signal partner (e.g., a quencher moiety). The signal partners of such a quencher/fluor pair will thus produce a detectable signal when the partners are separated (e.g., after cleavage of the detector ssDNA by a CasZ polypeptide), but the signal will be quenched when the partners are in close proximity (e.g., prior to cleavage of the detector ssDNA by a CasZ polypeptide).

[00341] A quencher moiety can quench a signal from the signal moiety (e.g., prior to cleavage of the detector ssDNA by a CasZ polypeptide) to various degrees. In some cases, a quencher moiety quenches the signal from the signal moiety where the signal detected in the presence of the quencher moiety (when the signal partners are in proximity to one another) is 95% or less of the signal detected in the absence of the quencher moiety (when the signal partners are separated). For example, in some cases, the signal detected in the presence of the quencher moiety can be 90% or less, 80% or less, 70% or less, 60% or less, 50% or less, 40% or less, 30% or less, 20% or less, 15% or less, 10% or less, or 5% or less of the signal detected in the absence of the quencher moiety. In some cases, no signal (e.g., above background) is detected in the presence of the quencher moiety.

[00342] In some cases, the signal detected in the absence of the quencher moiety (when the signal partners are separated) is at least 1.2 fold greater (e.g., at least 1.3fold, at least 1.5 fold, at least 1.7 fold, at least 2 fold, at least 2.5 fold, at least 3 fold, at least 3.5 fold, at least 4 fold, at least 5 fold, at least 7 fold, at least 10 fold, at least 20 fold, or at least 50 fold greater) than the signal detected in the presence of the quencher moiety (when the signal partners are in proximity to one another).

[00343] In some cases, the signal moiety is a fluorescent label. In some such cases, the quencher moiety quenches the signal (the light signal) from the fluorescent label (e.g., by absorbing energy in the emission spectra of the label). Thus, when the quencher moiety is not in proximity with the signal moiety, the emission (the signal) from the fluorescent label is detectable because the signal is not absorbed by the quencher moiety. Any convenient donor acceptor pair (signal moiety /quencher moiety pair) can be used and many suitable pairs are known in the art.

[00344] In some cases, the quencher moiety absorbs energy from the signal moiety (also referred to herein as a "detectable label") and then emits a signal (e.g., light at a different wavelength). Thus, in some cases, the quencher moiety is itself a signal moiety (e.g., a signal moiety can be 6-carboxyfluorescein while the quencher moiety can be 6-carboxy-tetramethylrhodamine), and in some such cases, the pair could also be a FRET pair. In some cases, a quencher moiety is a dark quencher. A dark quencher can absorb excitation energy and dissipate the energy in a different way (e.g., as heat). Thus, a dark quencher has minimal to no fluorescence of its own (does not emit fluorescence). Examples of dark quenchers are further described in U.S. patent numbers 8,822,673 and 8,586,718; U.S. patent publications 20140378330, 20140349295, and 20140194611; and international patent applications: WO200142505 and WO200186001, all if which are hereby incorporated by reference in their entirety.

[00345] Examples of fluorescent labels include, but are not limited to: an Alexa Fluor® dye, an ATTO dye (e.g., ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620,

ATTO Rho14, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740), a DyLight dye, a cyanine dye (e.g., Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, Cy7.5), a FluoProbes dye, a Sulfo Cy dye, a Seta dye, an IRIS Dye, a SeTau dye, an SRfluor dye, a Square dye, fluorescein isothiocyanate (FITC), tetramethylrhodamine (TRITC), Texas Red, Oregon Green, Pacific Blue, Pacific Green, Pacific Orange, quantum dots, and a tethered fluorescent protein.

[00346] In some cases, a detectable label is a fluorescent label selected from: an Alexa Fluor® dye, an ATTO dye (e.g., ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740), a DyLight dye, a cyanine dye (e.g., Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, Cy7.5), a FluoProbes dye, a Sulfo Cy dye, a Seta dye, an IRIS Dye, a SeTau dye, an SRfluor dye, a Square dye, fluorescein (FITC), tetramethylrhodamine (TRITC), Texas Red, Oregon Green, Pacific Blue, Pacific Green, and Pacific Orange.

[00347] In some cases, a detectable label is a fluorescent label selected from: an Alexa Fluor® dye, an ATTO dye (e.g., ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, ATTO 740), a DyLight dye, a cyanine dye (e.g., Cy2, Cy3, Cy3.5, Cy3b, Cy5, Cy5.5, Cy7, Cy7.5), a FluoProbes dye, a Sulfo Cy dye, a Seta dye, an IRIS Dye, a SeTau dye, an SRfluor dye, a Square dye, fluorescein (FITC), tetramethylrhodamine (TRITC), Texas Red, Oregon Green, Pacific Blue, Pacific Green, Pacific Orange, a quantum dot, and a tethered fluorescent protein.

[00348] Examples of ATTO dyes include, but are not limited to: ATTO 390, ATTO 425, ATTO 465, ATTO 488, ATTO 495, ATTO 514, ATTO 520, ATTO 532, ATTO Rho6G, ATTO 542, ATTO 550, ATTO 565, ATTO Rho3B, ATTO Rho11, ATTO Rho12, ATTO Thio12, ATTO Rho101, ATTO 590, ATTO 594, ATTO Rho13, ATTO 610, ATTO 620, ATTO Rho14, ATTO 633, ATTO 647, ATTO 647N, ATTO 655, ATTO Oxa12, ATTO 665, ATTO 680, ATTO 700, ATTO 725, and ATTO 740.

[00349] Examples of AlexaFluor dyes include, but are not limited to: Alexa Fluor® 350, Alexa Fluor® 405, Alexa Fluor® 430, Alexa Fluor® 488, Alexa Fluor® 500, Alexa Fluor® 514, Alexa Fluor® 532, Alexa Fluor® 546, Alexa Fluor® 555, Alexa Fluor® 568, Alexa Fluor® 594, Alexa Fluor® 610, Alexa Fluor® 633, Alexa Fluor® 635, Alexa Fluor® 647, Alexa Fluor® 660, Alexa Fluor® 680, Alexa Fluor® 700, Alexa Fluor® 750, Alexa Fluor® 790, and the like.

[00350] Examples of quencher moieties include, but are not limited to: a dark quencher, a Black Hole Quencher® (BHQ®) (e.g., BHQ-0, BHQ-1, BHQ-2, BHQ-3), a Qxl quencher, an ATTO quencher (e.g., ATTO 540Q, ATTO 580Q, and ATTO 612Q), dimethylaminoazobenzenesulfonic acid (Dabsyl), Iowa Black RQ, Iowa Black FQ, IRDye QC-1, a QSY dye (e.g., QSY 7, QSY 9, QSY 21), AbsoluteQuencher, Eclipse, and metal clusters such as gold nanoparticles, and the like.

[00351] In some cases, a quencher moiety is selected from: a dark quencher, a Black Hole Quencher® (BHQ®) (e.g., BHQ-0, BHQ-1, BHQ-2, BHQ-3), a Qxl quencher, an ATTO quencher (e.g., ATTO 540Q, ATTO 580Q, and ATTO 612Q), dimethylaminoazobenzenesulfonic acid (Dabsyl), Iowa Black RQ, Iowa Black FQ, IRDye QC-1, a QSY dye (e.g., QSY 7, QSY 9, QSY 21), AbsoluteQuencher, Eclipse, and a metal cluster.

[00352] Examples of an ATTO quencher include, but are not limited to: ATTO 540Q, ATTO 580Q, and ATTO 612Q. Examples of a Black Hole Quencher® (BHQ®) include, but are not limited to: BHQ-0 (493 nm), BHQ-1 (534 nm), BHQ-2 (579 nm) and BHQ-3 (672 nm).

[00353] For examples of some detectable labels (e.g., fluorescent dyes) and/or quencher moieties, see, e.g., Bao et al., Annu Rev Biomed Eng. 2009;11:25-47; as well as U.S. patent numbers 8,822,673 and 8,586,718; U.S. patent publications 20140378330, 20140349295, 20140194611, 20130323851, 20130224871, 20110223677, 20110190486, 20110172420, 20060179585 and 20030003486; and international patent applications: WO200142505 and WO200186001, all of which are hereby incorporated by reference in their entirety.

[00354] In some cases, cleavage of a labeled detector ssDNA can be detected by measuring a colorimetric read-out. For example, the liberation of a fluorophore (e.g., liberation from a FRET pair, liberation from a quencher/fluor pair, and the like) can result in a wavelength shift (and thus color shift) of a detectable signal. Thus, in some cases, cleavage of a subject labeled detector ssDNA can be detected by a color-shift. Such a shift can be expressed as a loss of an amount of signal of one color (wavelength), a gain in the amount of another color, a change in the ration of one color to another, and the like.

KITS FOR DETECTING TARGET DNA

[00355] The present disclosure provides a kit for detecting a target DNA, e.g., in a sample comprising a plurality of DNAs. In some cases, the kit comprises: (a) a labeled detector ssDNA (e.g., a labeled detector ssDNA comprising a fluorescence-emitting dye pair, e.g., a FRET pair and/or a quencher/fluor pair); and (b) one or more of: (i) a guide RNA, and/or a nucleic acid encoding said guide RNA; and ii) a CasZ polypeptide, and/or a nucleic acid encoding said CasZ polypeptide. In some cases, a nucleic acid encoding a guide RNA includes sequence insertion sites for the insertion of guide sequences by a user.

[00356] In some cases, the kit comprises: (a) a labeled detector ssDNA (e.g., a labeled detector ssDNA comprising a fluorescence-emitting dye pair, e.g., a FRET pair and/or a quencher/fluor pair); and (b) one or more of: (i) a guide RNA, and/or a nucleic acid encoding said guide RNA; ii) a tranc RNA and/or a nucleic acid encoding said guide RNA; and iii) a CasZ polypeptide, and/or a nucleic acid encoding said CasZ polypeptide. In some cases, a nucleic acid encoding a guide RNA includes sequence insertion sites for the insertion of guide sequences by a user.

[00357] In some cases, the kit comprises: (a) a labeled detector ssDNA (e.g., a labeled detector ssDNA comprising a fluorescence-emitting dye pair, e.g., a FRET pair and/or a quencher/fluor pair); and (b) one or more of: (i) a single-molecule RNA comprising a guide RNA and a tranc RNA, and/or a nucleic acid encoding single-molecule RNA; and iii) a CasZ polypeptide, and/or a nucleic acid encoding said CasZ polypeptide. In some cases, a nucleic acid encoding a single-molecule RNA includes sequence insertion sites for the insertion of guide sequences by a user.

[00358] In some cases, a subject kit comprises: (a) a labeled detector ssDNA comprising a fluorescence-emitting dye pair, e.g., a FRET pair and/or a quencher/fluor pair; and (b) one or more of: (i) a guide RNA, and/or a nucleic acid encoding said guide RNA; and/or i) a CasZ polypeptide.

Positive controls

[00359] A kit of the present disclosure (e.g., one that comprises a labeled detector ssDNA and a CasZ polypeptide) can also include a positive control target DNA. In some cases, the kit also includes a positive control guide RNA that comprises a nucleotide sequence that hybridizes to the control target DNA. In some cases, the positive control target DNA is provided in various amounts, in separate containers. In some cases, the positive control target DNA is provided in various known concentrations, in separate containers, along with control non-target DNAs.

Nucleic acids

[00360] While the RNAs of the disclosure (e.g., guide RNAs, tranc RNAs, single-molecule RNAs comprising a guide RNA and a tranc RNA) can be synthesized using any convenient method (e.g., chemical synthesis, *in vitro* using an RNA polymerase enzyme, e.g., T7 polymerase, T3 polymerase, SP6 polymerase, etc.), nucleic acids encoding such RNAs are also envisioned. Additionally, while a CasZ polypeptide of the disclosure can be provided (e.g., as part of a kit) in protein form, nucleic acids (such as mRNA and/or DNA) encoding the CasZ polypeptide can also be provided.

[00361] In some cases, a kit of the present disclosure comprises a nucleic acid (e.g., a DNA, e.g., a recombinant expression vector) that comprises a nucleotide sequence encoding a single-molecule RNA comprising: i) a guide RNA; and ii) a tranc RNA. In some cases, the nucleotide sequence encodes the guide RNA portion of the single-molecule RNA without a guide sequence. For example, in some cases, the nucleic acid comprises a nucleotide sequence encoding: i) a constant region of a guide RNA (a guide

RNA without a guide sequence), and comprises an insertion site for a nucleic acid encoding a guide sequence; and ii) a tranc RNA.

[00362] For example, in some cases, a kit of the present disclosure comprises a nucleic acid (e.g., a DNA, e.g., a recombinant expression vector) that comprises a nucleotide sequence encoding a guide RNA. In some cases, the nucleotide sequence encodes a guide RNA without a guide sequence. For example, in some cases, the nucleic acid comprises a nucleotide sequence encoding a constant region of a guide RNA (a guide RNA without a guide sequence), and comprises an insertion site for a nucleic acid encoding a guide sequence. In some cases, a kit of the present disclosure comprises a nucleic acid (e.g., an mRNA, a DNA, e.g., a recombinant expression vector) that comprises a nucleotide sequence encoding a CasZ polypeptide.

[00363] In some cases, the guide RNA-encoding nucleotide sequence is operably linked to a promoter, e.g., a promoter that is functional in a prokaryotic cell, a promoter that is functional in a eukaryotic cell, a promoter that is functional in a mammalian cell, a promoter that is functional in a human cell, and the like. In some cases, a nucleotide sequence encoding a CasZ polypeptide is operably linked to a promoter, e.g., a promoter that is functional in a prokaryotic cell, a promoter that is functional in a eukaryotic cell, a promoter that is functional in a mammalian cell, a promoter that is functional in a human cell, a cell type-specific promoter, a regulatable promoter, a tissue-specific promoter, and the like.

UTILITY

[00364] CasZ compositions (e.g., expression vectors, kits, compositions, nucleic acids, and the like) find use in a variety of methods. For example, a CasZ compositions of the present disclosure can be used to (i) modify (e.g., cleave, e.g., nick; methylate; etc.) target nucleic acid (DNA or RNA; single stranded or double stranded); (ii) modulate transcription of a target nucleic acid; (iii) label a target nucleic acid; (iv) bind a target nucleic acid (e.g., for purposes of isolation, labeling, imaging, tracking, etc.); (v) modify a polypeptide (e.g., a histone) associated with a target nucleic acid; and the like. Thus, the present disclosure provides a method of modifying a target nucleic acid. In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting the target nucleic acid with: a) a CasZ polypeptide of the present disclosure; and b) one or more (e.g., two) CasZ guide RNAs. In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting the target nucleic acid with: a) a CasZ polypeptide, and b) one or more (e.g., two) CasZ guide RNAs, and c) a CasZ trancRNA. In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting the target nucleic acid with: a) a CasZ polypeptide of the present disclosure; b) a CasZ guide RNA; and c) a donor nucleic acid (e.g, a donor template). In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting the target nucleic acid with: a) a CasZ polypeptide; b) a CasZ guide RNA; c) a CasZ trancRNA, and d) a donor nucleic acid (e.g, a donor template).In some cases, the contacting step is carried out in a cell *in vitro*. In

some cases, the contacting step is carried out in a cell *in vivo*. In some cases, the contacting step is carried out in a cell *ex vivo*.

[00365] Because a method that uses a CasZ polypeptide includes binding of the CasZ polypeptide to a particular region in a target nucleic acid (by virtue of being targeted there by an associated CasZ guide RNA), the methods are generally referred to herein as methods of binding (e.g., a method of binding a target nucleic acid). However, it is to be understood that in some cases, while a method of binding may result in nothing more than binding of the target nucleic acid, in other cases, the method can have different final results (e.g., the method can result in modification of the target nucleic acid, e.g., cleavage/methylation/etc., modulation of transcription from the target nucleic acid; modulation of translation of the target nucleic acid; genome editing; modulation of a protein associated with the target nucleic acid; isolation of the target nucleic acid; etc.).

[00366] For examples of suitable methods (e.g., that are used with CRISPR/Cas9 systems), see, for example, Jinek et al., Science. 2012 Aug 17;337(6096):816-21; Chylinski et al., RNA Biol. 2013 May;10(5):726-37; Ma et al., Biomed Res Int. 2013;2013:270805; Hou et al., Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15644-9; Jinek et al., Elife. 2013;2:e00471; Pattanayak et al., Nat Biotechnol. 2013 Sep;31(9):839-43; Qi et al, Cell. 2013 Feb 28;152(5):1173-83; Wang et al., Cell. 2013 May 9;153(4):910-8; Auer et al., Genome Res. 2013 Oct 31; Chen et al., Nucleic Acids Res. 2013 Nov 1;41(20):e19; Cheng et al., Cell Res. 2013 Oct;23(10):1163-71; Cho et al., Genetics. 2013 Nov;195(3):1177-80; DiCarlo et al., Nucleic Acids Res. 2013 Apr;41(7):4336-43; Dickinson et al., Nat Methods. 2013 Oct;10(10):1028-34; Ebina et al., Sci Rep. 2013;3:2510; Fujii et al, Nucleic Acids Res. 2013 Nov 1;41(20):e187; Hu et al., Cell Res. 2013 Nov;23(11):1322-5; Jiang et al., Nucleic Acids Res. 2013 Nov 1;41(20):e188; Larson et al., Nat Protoc. 2013 Nov;8(11):2180-96; Mali et. at., Nat Methods. 2013 Oct;10(10):957-63; Nakayama et al., Genesis. 2013 Dec;51(12):835-43; Ran et al., Nat Protoc. 2013 Nov;8(11):2281-308; Ran et al., Cell. 2013 Sep 12;154(6):1380-9; Upadhyay et al., G3 (Bethesda). 2013 Dec 9;3(12):2233-8; Walsh et al., Proc Natl Acad Sci U S A. 2013 Sep 24;110(39):15514-5; Xie et al., Mol Plant. 2013 Oct 9; Yang et al., Cell. 2013 Sep 12;154(6):1370-9; and U.S. patents and patent applications: 8,906,616; 8,895,308; 8,889,418; 8,889,356; 8,871,445; 8,865,406; 8,795,965; 8,771,945; 8,697,359; 20140068797; 20140170753; 20140179006; 20140179770; 20140186843; 20140186919; 20140186958; 20140189896; 20140227787; 20140234972; 20140242664; 20140242699; 20140242700; 20140242702; 20140248702; 20140256046; 20140273037; 20140273226; 20140273230; 20140273231; 20140273232; 20140273233; 20140273234; 20140273235; 20140287938; 20140295556; 20140295557; 20140298547; 20140304853; 20140309487; 20140310828; 20140310830; 20140315985; 20140335063; 20140335620; 20140342456; 20140342457; 20140342458; 20140349400; 20140349405; 20140356867; 20140356956; 20140356958; 20140356959; 20140357523; 20140357530; 20140364333; and 20140377868; each of which is hereby incorporated by reference in its entirety.

[00367] For example, the present disclosure provides (but is not limited to) methods of cleaving a target nucleic acid; methods of editing a target nucleic acid; methods of modulating transcription from a target nucleic acid; methods of isolating a target nucleic acid, methods of binding a target nucleic acid, methods of imaging a target nucleic acid, methods of modifying a target nucleic acid, and the like.

[00368] As used herein, the terms/phrases "contact a target nucleic acid" and "contacting a target nucleic acid", for example, with a CasZ polypeptide or with a CasZ fusion polypeptide, etc., encompass all methods for contacting the target nucleic acid. For example, a CasZ polypeptide can be provided to a cell as protein, RNA (encoding the CasZ polypeptide), or DNA (encoding the CasZ polypeptide); while a CasZ guide RNA can be provided as a guide RNA or as a nucleic acid encoding the guide RNA and a CasZ trancRNA can be provided as a trancRNA or as a nucleic acid encoding the trancRNA. As such, when, for example, performing a method in a cell (e.g., inside of a cell *in vitro*, inside of a cell *in vivo*, inside of a cell *ex vivo*), a method that includes contacting the target nucleic acid encompasses the introduction into the cell of any or all of the components in their active/final state (e.g., in the form of a protein(s) for CasZ polypeptide; in the form of a protein for a CasZ fusion polypeptide; in the form of an RNA in some cases for the guide RNA), and also encompasses the introduction into the cell of one or more nucleic acids encoding one or more of the components (e.g., nucleic acid(s) comprising nucleotide sequence(s) encoding a CasZ polypeptide or a CasZ fusion polypeptide, nucleic acid(s) comprising nucleotide sequence(s) encoding guide RNA(s), nucleic acid comprising a nucleotide sequence encoding a donor template, and the like). Because the methods can also be performed *in vitro* outside of a cell, a method that includes contacting a target nucleic acid, (unless otherwise specified) encompasses contacting outside of a cell *in vitro*, inside of a cell *in vitro*, inside of a cell *in vivo*, inside of a cell *ex vivo*, etc.

[00369] In some cases, a method of the present disclosure for modifying a target nucleic acid comprises introducing into a target cell a CasZ locus, e.g., a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide as well as nucleotide sequences of about 1 kilobase (kb) to 5 kb in length surrounding the CasZ-encoding nucleotide sequence from a cell (e.g., in some cases a cell that in its natural state (the state in which it occurs in nature) comprises a CasZ locus) comprising a CasZ locus, where the target cell does not normally (in its natural state) comprise a CasZ locus (e.g., in some cases the locus includes a CasZ trancRNA. However, one or more spacer sequences, encoding guide sequences for the encoded crRNA(s), can be modified such that one or more target sequences of interest are targeted. Thus, for example, in some cases, a method of the present disclosure for modifying a target nucleic acid comprises introducing into a target cell a CasZ locus, e.g., a nucleic acid obtained from a source cell (e.g., in some cases a cell that in its natural state (the state in which it occurs in nature) comprises a CasZ locus), where the nucleic acid has a length of from 100 nucleotides (nt) to 5 kb in length (e.g., from 100 nt to 500 nt, from 500 nt to 1 kb, from 1 kb to 1.5 kb, from 1.5 kb to 2 kb, from 2

kb to 2.5 kb, from 2.5 kb to 3 kb, from 3 kb to 3.5 kb, from 3.5 kb to 4 kb, or from 4 kb to 5 kb in length) and comprises a nucleotide sequence encoding a CasZ polypeptide. As noted above, in some such cases, one or more spacer sequences, encoding guide sequences for the encoded crRNA(s), can be modified such that one or more target sequences of interest are targeted. In some cases, the method comprises introducing into a target cell: i) a CasZ locus; and ii) a donor DNA template. In some cases, the target nucleic acid is in a cell-free composition *in vitro*. In some cases, the target nucleic acid is present in a target cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a prokaryotic cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a eukaryotic cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a mammalian cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a plant cell.

[00370] In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide of the present disclosure, or with a CasZ fusion polypeptide of the present disclosure. In some cases, abmethod of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide and a CasZ guide RNA. In some cases, abmethod of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide, a CasZ guide RNA, and a CasZ trancRNA. In some cases, abmethod of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide, a first CasZ guide RNA, and a second CasZ guide RNA (and in some cases a CasZ trancRNA). In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide of the present disclosure and a CasZ guide RNA and a donor DNA template. In some cases, a method of the present disclosure for modifying a target nucleic acid comprises contacting a target nucleic acid with a CasZ polypeptide of the present disclosure and a CasZ guide RNA and a CasZ trancRNA and a donor DNA template.

[00371] In some cases, the target nucleic acid is in a cell-free composition *in vitro*. In some cases, the target nucleic acid is present in a target cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a prokaryotic cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a eukaryotic cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a mammalian cell. In some cases, the target nucleic acid is present in a target cell, where the target cell is a plant cell.

Target nucleic acids and target cells of interest

[00372] A target nucleic acid can be any nucleic acid (e.g., DNA, RNA), can be double stranded or single stranded, can be any type of nucleic acid (e.g., a chromosome (genomic DNA), derived from a chromosome, chromosomal DNA, plasmid, viral, extracellular, intracellular, mitochondrial, chloroplast,

linear, circular, etc.) and can be from any organism (e.g., as long as the CasZ guide RNA comprises a nucleotide sequence that hybridizes to a target sequence in a target nucleic acid, such that the target nucleic acid can be targeted).

[00373] A target nucleic acid can be DNA or RNA. A target nucleic acid can be double stranded (e.g., dsDNA, dsRNA) or single stranded (e.g., ssRNA, ssDNA). In some cases, a target nucleic acid is single stranded. In some cases, a target nucleic acid is a single stranded RNA (ssRNA). In some cases, a target ssRNA (e.g., a target cell ssRNA, a viral ssRNA, etc.) is selected from: mRNA, rRNA, tRNA, non-coding RNA (ncRNA), long non-coding RNA (lncRNA), and microRNA (miRNA). In some cases, a target nucleic acid is a single stranded DNA (ssDNA) (e.g., a viral DNA). As noted above, in some cases, a target nucleic acid is single stranded.

[00374] A target nucleic acid can be located anywhere, for example, outside of a cell *in vitro*, inside of a cell *in vitro*, inside of a cell *in vivo*, inside of a cell *ex vivo*. Suitable target cells (which can comprise target nucleic acids such as genomic DNA) include, but are not limited to: a bacterial cell; an archaeal cell; a cell of a single-cell eukaryotic organism; a plant cell; an algal cell, e.g., *Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa*, *Sargassum patens, C. agardh*, and the like; a fungal cell (e.g., a yeast cell); an animal cell; a cell from an invertebrate animal (e.g. fruit fly, a cnidarian, an echinoderm, a nematode, etc.); a cell of an insect (e.g., a mosquito; a bee; an agricultural pest; etc.); a cell of an arachnid (e.g., a spider; a tick; etc.); a cell from a vertebrate animal (e.g., a fish, an amphibian, a reptile, a bird, a mammal); a cell from a mammal (e.g., a cell from a rodent; a cell from a human; a cell of a non-human mammal; a cell of a rodent (e.g., a mouse, a rat); a cell of a lagomorph (e.g., a rabbit); a cell of an ungulate (e.g., a cow, a horse, a camel, a llama, a vicuña, a sheep, a goat, etc.); a cell of a marine mammal (e.g., a whale, a seal, an elephant seal, a dolphin, a sea lion; etc.) and the like. Any type of cell may be of interest (e.g. a stem cell, e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell, a germ cell (e.g., an oocyte, a sperm, an oogonia, a spermatogonia, etc.), an adult stem cell, a somatic cell, e.g. a fibroblast, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell; an in vitro or in vivo embryonic cell of an embryo at any stage, e.g., a 1-cell, 2-cell, 4-cell, 8-cell, etc. stage zebrafish embryo; etc.).

[00375] Cells may be from established cell lines or they may be primary cells, where "primary cells", "primary cell lines", and "primary cultures" are used interchangeably herein to refer to cells and cells cultures that have been derived from a subject and allowed to grow in vitro for a limited number of passages, i.e. splittings, of the culture. For example, primary cultures are cultures that may have been passaged 0 times, 1 time, 2 times, 4 times, 5 times, 10 times, or 15 times, but not enough times go through the crisis stage. Typically, the primary cell lines are maintained for fewer than 10 passages *in vitro*. Target cells can be unicellular organisms and/or can be grown in culture. If the cells are primary cells, they may be harvest from an individual by any convenient method. For example, leukocytes may

be conveniently harvested by apheresis, leukocytapheresis, density gradient separation, etc., while cells from tissues such as skin, muscle, bone marrow, spleen, liver, pancreas, lung, intestine, stomach, etc. can be conveniently harvested by biopsy.

[00376] In some of the above applications, the subject methods may be employed to induce target nucleic acid cleavage, target nucleic acid modification, and/or to bind target nucleic acids (e.g., for visualization, for collecting and/or analyzing, etc.) in mitotic or post-mitotic cells *in vivo* and/or *ex vivo* and/or *in vitro* (e.g., to disrupt production of a protein encoded by a targeted mRNA, to cleave or otherwise modify target DNA, to geneically modify a target cell, and the like). Because the guide RNA provides specificity by hybridizing to target nucleic acid, a mitotic and/or post-mitotic cell of interest in the disclosed methods may include a cell from any organism (e.g. a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a plant cell, an algal cell, e.g., *Botryococcus braunii, Chlamydomonas reinhardtii, Nannochloropsis gaditana, Chlorella pyrenoidosa*, *Sargassum patens, C. agardh*, and the like, a fungal cell (e.g., a yeast cell), an animal cell, a cell from an invertebrate animal (e.g. fruit fly, cnidarian, echinoderm, nematode, etc.), a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal), a cell from a mammal, a cell from a rodent, a cell from a human, etc.). In some cases, a subject CasZ protein (and/or nucleic acid encoding the protein such as DNA and/or RNA), and/or CasZ guide RNA (and/or a DNA encoding the guide RNA), and/or donor template, and/or RNP can be intrduced into an individual (i.e., the target cell can be in vivo) (e.g., a mammal, a rat, a mouse, a pig, a primate, a non-human primate, a human, etc.). In some cases, such an administration can be for the purpose of treating and/or preventing a disease, e.g., by editing the genome of targeted cells.

[00377] Plant cells include cells of a monocotyledon, and cells of a dicotyledon. The cells can be root cells, leaf cells, cells of the xylem, cells of the phloem, cells of the cambium, apical meristem cells, parenchyma cells, collenchyma cells, sclerenchyma cells, and the like. Plant cells include cells of agricultural crops such as wheat, corn, rice, sorghum, millet, soybean, etc. Plant cells include cells of agricultural fruit and nut plants, e.g., plant that produce apricots, oranges, lemons, apples, plums, pears, almonds, etc.

[00378] Additional examples of target cells are listed above in the section titled "Modified cells." Non-limiting examples of cells (target cells) include: a prokaryotic cell, eukaryotic cell, a bacterial cell, an archaeal cell, a cell of a single-cell eukaryotic organism, a protozoa cell, a cell from a plant (e.g., cells from plant crops, fruits, vegetables, grains, soy bean, corn, maize, wheat, seeds, tomatos, rice, cassava, sugarcane, pumpkin, hay, potatos, cotton, cannabis, tobacco, flowering plants, conifers, gymnosperms, angiosperms, ferns, clubmosses, hornworts, liverworts, mosses, dicotyledons, monocotyledons, etc.), an algal cell, (e.g., *Botryococcus braunii*, *Chlamydomonas reinhardtii*, *Nannochloropsis gaditana*, *Chlorella pyrenoidosa*, *Sargassum patens*, *C. agardh*, and the like), seaweeds (e.g. kelp) a fungal cell

(e.g., a yeast cell, a cell from a mushroom), an animal cell, a cell from an invertebrate animal (e.g., fruit fly, cnidarian, echinoderm, nematode, etc.), a cell from a vertebrate animal (e.g., fish, amphibian, reptile, bird, mammal), a cell from a mammal (e.g., an ungulate (e.g., a pig, a cow, a goat, a sheep); a rodent (e.g., a rat, a mouse); a non-human primate; a human; a feline (e.g., a cat); a canine (e.g., a dog); etc.), and the like. In some cases, the cell is a cell that does not originate from a natural organism (e.g., the cell can be a synthetically made cell; also referred to as an artificial cell).

[00379] A cell can be an *in vitro* cell (e.g., established cultured cell line). A cell can be an *ex vivo* cell (cultured cell from an individual). A cell can be and *in vivo* cell (e.g., a cell in an individual). A cell can be an isolated cell. A cell can be a cell inside of an organism. A cell can be an organism. A cell can be a cell in a cell culture (e.g., *in vitro* cell culture). A cell can be one of a collection of cells. A cell can be a prokaryotic cell or derived from a prokaryotic cell. A cell can be a bacterial cell or can be derived from a bacterial cell. A cell can be an archaeal cell or derived from an archaeal cell. A cell can be a eukaryotic cell or derived from a eukaryotic cell. A cell can be a plant cell or derived from a plant cell. A cell can be an animal cell or derived from an animal cell. A cell can be an invertebrate cell or derived from an invertebrate cell. A cell can be a vertebrate cell or derived from a vertebrate cell. A cell can be a mammalian cell or derived from a mammalian cell. A cell can be a rodent cell or derived from a rodent cell. A cell can be a human cell or derived from a human cell. A cell can be a microbe cell or derived from a microbe cell. A cell can be a fungi cell or derived from a fungi cell. A cell can be an insect cell. A cell can be an arthropod cell. A cell can be a protozoan cell. A cell can be a helminth cell.

[00380] Suitable cells include a stem cell (e.g. an embryonic stem (ES) cell, an induced pluripotent stem (iPS) cell; a germ cell (e.g., an oocyte, a sperm, an oogonia, a spermatogonia, etc.); a somatic cell, e.g. a fibroblast, an oligodendrocyte, a glial cell, a hematopoietic cell, a neuron, a muscle cell, a bone cell, a hepatocyte, a pancreatic cell, etc.

[00381] Suitable cells include human embryonic stem cells, fetal cardiomyocytes, myofibroblasts, mesenchymal stem cells, autotransplated expanded cardiomyocytes, adipocytes, totipotent cells, pluripotent cells, blood stem cells, myoblasts, adult stem cells, bone marrow cells, mesenchymal cells, embryonic stem cells, parenchymal cells, epithelial cells, endothelial cells, mesothelial cells, fibroblasts, osteoblasts, chondrocytes, exogenous cells, endogenous cells, stem cells, hematopoietic stem cells, bone-marrow derived progenitor cells, myocardial cells, skeletal cells, fetal cells, undifferentiated cells, multi-potent progenitor cells, unipotent progenitor cells, monocytes, cardiac myoblasts, skeletal myoblasts, macrophages, capillary endothelial cells, xenogenic cells, allogenic cells, and post-natal stem cells.

[00382] In some cases, the cell is an immune cell, a neuron, an epithelial cell, and endothelial cell, or a stem cell. In some cases, the immune cell is a T cell, a B cell, a monocyte, a natural killer cell, a

dendritic cell, or a macrophage. In some cases, the immune cell is a cytotoxic T cell. In some cases, the immune cell is a helper T cell. In some cases, the immune cell is a regulatory T cell (Treg).

[00383] In some cases, the cell is a stem cell. Stem cells include adult stem cells. Adult stem cells are also referred to as somatic stem cells.

[00384] Adult stem cells are resident in differentiated tissue, but retain the properties of self-renewal and ability to give rise to multiple cell types, usually cell types typical of the tissue in which the stem cells are found. Numerous examples of somatic stem cells are known to those of skill in the art, including muscle stem cells; hematopoietic stem cells; epithelial stem cells; neural stem cells; mesenchymal stem cells; mammary stem cells; intestinal stem cells; mesodermal stem cells; endothelial stem cells; olfactory stem cells; neural crest stem cells; and the like.

[00385] Stem cells of interest include mammalian stem cells, where the term "mammalian" refers to any animal classified as a mammal, including humans; non-human primates; domestic and farm animals; and zoo, laboratory, sports, or pet animals, such as dogs, horses, cats, cows, mice, rats, rabbits, etc. In some cases, the stem cell is a human stem cell. In some cases, the stem cell is a rodent (e.g., a mouse; a rat) stem cell. In some cases, the stem cell is a non-human primate stem cell.

[00386] Stem cells can express one or more stem cell markers, e.g., SOX9, KRT19, KRT7, LGR5, CA9, FXYD2, CDH6, CLDN18, TSPAN8, BPIFB1, OLFM4, CDH17, and PPARGC1A.

[00387] In some cases, the stem cell is a hematopoietic stem cell (HSC). HSCs are mesoderm-derived cells that can be isolated from bone marrow, blood, cord blood, fetal liver and yolk sac. HSCs are characterized as $CD34^+$ and $CD3^-$. HSCs can repopulate the erythroid, neutrophil-macrophage, megakaryocyte and lymphoid hematopoietic cell lineages *in vivo*. *In vitro*, HSCs can be induced to undergo at least some self-renewing cell divisions and can be induced to differentiate to the same lineages as is seen *in vivo*. As such, HSCs can be induced to differentiate into one or more of erythroid cells, megakaryocytes, neutrophils, macrophages, and lymphoid cells.

[00388] In other cases, the stem cell is a neural stem cell (NSC). Neural stem cells (NSCs) are capable of differentiating into neurons, and glia (including oligodendrocytes, and astrocytes). A neural stem cell is a multipotent stem cell which is capable of multiple divisions, and under specific conditions can produce daughter cells which are neural stem cells, or neural progenitor cells that can be neuroblasts or glioblasts, e.g., cells committed to become one or more types of neurons and glial cells respectively. Methods of obtaining NSCs are known in the art.

[00389] In other cases, the stem cell is a mesenchymal stem cell (MSC). MSCs originally derived from the embryonal mesoderm and isolated from adult bone marrow, can differentiate to form muscle, bone, cartilage, fat, marrow stroma, and tendon. Methods of isolating MSC are known in the art;

and any known method can be used to obtain MSC. See, e.g., U.S. Pat. No. 5,736,396, which describes isolation of human MSC.

[00390] A cell is in some cases a plant cell. A plant cell can be a cell of a monocotyledon. A cell can be a cell of a dicotyledon.

[00391] In some cases, the cell is a plant cell. For example, the cell can be a cell of a major agricultural plant, e.g., Barley, Beans (Dry Edible), Canola, Corn, Cotton (Pima), Cotton (Upland), Flaxseed, Hay (Alfalfa), Hay (Non-Alfalfa), Oats, Peanuts, Rice, Sorghum, Soybeans, Sugarbeets, Sugarcane, Sunflowers (Oil), Sunflowers (Non-Oil), Sweet Potatoes , Tobacco (Burley), Tobacco (Flue-cured), Tomatoes, Wheat (Durum), Wheat (Spring), Wheat (Winter), and the like. As another example, the cell is a cell of a vegetable crops which include but are not limited to, e.g., alfalfa sprouts, aloe leaves, arrow root, arrowhead, artichokes, asparagus, bamboo shoots, banana flowers, bean sprouts, beans, beet tops, beets, bittermelon, bok choy, broccoli, broccoli rabe (rappini), brussels sprouts, cabbage, cabbage sprouts, cactus leaf (nopales), calabaza, cardoon, carrots, cauliflower, celery, chayote, chinese artichoke (crosnes), chinese cabbage, chinese celery, chinese chives, choy sum, chrysanthemum leaves (tung ho), collard greens, corn stalks, corn-sweet, cucumbers, daikon, dandelion greens, dasheen, dau mue (pea tips), donqua (winter melon), eggplant, endive, escarole, fiddle head ferns, field cress, frisee, gai choy (chinese mustard), gailon, galanga (siam, thai ginger), garlic, ginger root, gobo, greens, hanover salad greens, huauzontle, jerusalem artichokes, jicama, kale greens, kohlrabi, lamb's quarters (quilete), lettuce (bibb), lettuce (boston), lettuce (boston red), lettuce (green leaf), lettuce (iceberg), lettuce (lolla rossa), lettuce (oak leaf - green), lettuce (oak leaf - red), lettuce (processed), lettuce (red leaf), lettuce (romaine), lettuce (ruby romaine), lettuce (russian red mustard), linkok, lo bok, long beans, lotus root, mache, maguey (agave) leaves, malanga, mesculin mix, mizuna, moap (smooth luffa), moo, moqua (fuzzy squash), mushrooms, mustard, nagaimo, okra, ong choy, onions green, opo (long squash), ornamental corn, ornamental gourds, parsley, parsnips, peas, peppers (bell type), peppers, pumpkins, radicchio, radish sprouts, radishes, rape greens, rape greens, rhubarb, romaine (baby red), rutabagas, salicornia (sea bean), sinqua (angled/ridged luffa), spinach, squash, straw bales, sugarcane, sweet potatoes, swiss chard, tamarindo, taro, taro leaf, taro shoots, tatsoi, tepeguaje (guaje), tindora, tomatillos, tomatoes, tomatoes (cherry), tomatoes (grape type), tomatoes (plum type), tumeric, turnip tops greens, turnips, water chestnuts, yampi, yams (names), yu choy, yuca (cassava), and the like.

[00392] A cell is in some cases an arthropod cell. For example, the cell can be a cell of a sub-order, a family, a sub-family, a group, a sub-group, or a species of, e.g., *Chelicerata*, *Myriapodia*, *Hexipodia*, *Arachnida*, *Insecta*, *Archaeognatha*, *Thysanura*, *Palaeoptera*, *Ephemeroptera*, *Odonata*, *Anisoptera*, *Zygoptera*, *Neoptera*, *Exopterygota*, *Plecoptera* , *Embioptera* , *Orthoptera*, *Zoraptera* , *Dermaptera*, *Dictyoptera*, *Notoptera*, *Grylloblattidae*, *Mantophasmatidae*, *Phasmatodea* , *Blattaria*, *Isoptera*, *Mantodea*, *Parapneuroptera*, *Psocoptera*, *Thysanoptera*, *Phthiraptera*, *Hemiptera*,

Endopterygota or Holometabola , *Hymenoptera* , *Coleoptera*, *Strepsiptera*, *Raphidioptera*, *Megaloptera*, *Neuroptera* , *Mecoptera* , *Siphonaptera*, *Diptera*, *Trichoptera*, or *Lepidoptera.*

[00393] A cell is in some cases an insect cell. For example, in some cases, the cell is a cell of a mosquito, a grasshopper, a true bug, a fly, a flea, a bee, a wasp, an ant, a louse, a moth, or a beetle.

Donor Polynucleotide (donor template)

[00394] Guided by a CasZ guide RNA, a CasZ protein in some cases generates site-specific double strand breaks (DSBs) or single strand breaks (SSBs) (e.g., when the CasZ protein is a nickase variant) within double-stranded DNA (dsDNA) target nucleic acids, which are repaired either by non-homologous end joining (NHEJ) or homology-directed recombination (HDR).

[00395] In some cases, contacting a target DNA (with a CasZ protein and a CasZ guide RNA) occurs under conditions that are permissive for nonhomologous end joining or homology-directed repair. Thus, in some cases, a subject method includes contacting the target DNA with a donor polynucleotide (e.g., by introducing the donor polynucleotide into a cell), wherein the donor polynucleotide, a portion of the donor polynucleotide, a copy of the donor polynucleotide, or a portion of a copy of the donor polynucleotide integrates into the target DNA. In some cases, the method does not comprise contacting a cell with a donor polynucleotide, and the target DNA is modified such that nucleotides within the target DNA are deleted.

[00396] In some cases, a CasZ trancRNA (or nucleic acid encoding same), a CasZ guide RNA (or nucleic acid encoding same), and/or a CasZ protein (or a nucleic acid encoding same, such as an RNA or a DNA, e.g, one or more expression vectors) are coadministered (e.g., contacted with a target nucleic acid, administered to cells, etc.) with a donor polynucleotide sequence that includes at least a segment with homology to the target DNA sequence, the subject methods may be used to add, i.e. insert or replace, nucleic acid material to a target DNA sequence (e.g. to "knock in" a nucleic acid, e.g., one that encodes for a protein, an siRNA, an miRNA, etc.), to add a tag (e.g., 6xHis, a fluorescent protein (e.g., a green fluorescent protein; a yellow fluorescent protein, etc.), hemagglutinin (HA), FLAG, etc.), to add a regulatory sequence to a gene (e.g. promoter, polyadenylation signal, internal ribosome entry sequence (IRES), 2A peptide, start codon, stop codon, splice signal, localization signal, etc.), to modify a nucleic acid sequence (e.g., introduce a mutation, remove a disease causnig mutation by introducing a correct sequence), and the like. As such, a complex comprising a CasZ guide RNA and CasZ protein (or CasZ guide RNA and CasZ trancRNA and CasZ protein) is useful in any *in vitro* or *in vivo* application in which it is desirable to modify DNA in a site-specific, i.e. "targeted", way, for example gene knock-out, gene knock-in, gene editing, gene tagging, etc., as used in, for example, gene therapy, e.g. to treat a disease or as an antiviral, antipathogenic, or anticancer therapeutic, the production of genetically modified organisms in agriculture, the large scale production of proteins by cells for therapeutic,

diagnostic, or research purposes, the induction of iPS cells, biological research, the targeting of genes of pathogens for deletion or replacement, etc.

[00397] In applications in which it is desirable to insert a polynucleotide sequence into he genome where a target sequence is cleaved, a donor polynucleotide (a nucleic acid comprising a donor sequence) can also be provided to the cell. By a "donor sequence" or "donor polynucleotide" or "donor template" it is meant a nucleic acid sequence to be inserted at the site cleaved by the CasZ protein (e.g., after dsDNA cleavage, after nicking a target DNA, after dual nicking a target DNA, and the like). The donor polynucleotide can contain sufficient homology to a genomic sequence at the target site, e.g. 70%, 80%, 85%, 90%, 95%, or 100% homology with the nucleotide sequences flanking the target site, e.g. within about 50 bases or less of the target site, e.g. within about 30 bases, within about 15 bases, within about 10 bases, within about 5 bases, or immediately flanking the target site, to support homology-directed repair between it and the genomic sequence to which it bears homology. Approximately 25, 50, 100, or 200 nucleotides, or more than 200 nucleotides, of sequence homology between a donor and a genomic sequence (or any integral value between 10 and 200 nucleotides, or more) can support homology-directed repair. Donor polynucleotides can be of any length, e.g. 10 nucleotides or more, 50 nucleotides or more, 100 nucleotides or more, 250 nucleotides or more, 500 nucleotides or more, 1000 nucleotides or more, 5000 nucleotides or more, etc.

[00398] The donor sequence is typically not identical to the genomic sequence that it replaces. Rather, the donor sequence may contain at least one or more single base changes, insertions, deletions, inversions or rearrangements with respect to the genomic sequence, so long as sufficient homology is present to support homology-directed repair (e.g., for gene correction, e.g., to convert a disease-causing base pair ot a non disease-causing base pair). In some embodiments, the donor sequence comprises a non-homologous sequence flanked by two regions of homology, such that homology-directed repair between the target DNA region and the two flanking sequences results in insertion of the non-homologous sequence at the target region. Donor sequences may also comprise a vector backbone containing sequences that are not homologous to the DNA region of interest and that are not intended for insertion into the DNA region of interest. Generally, the homologous region(s) of a donor sequence will have at least 50% sequence identity to a genomic sequence with which recombination is desired. In certain embodiments, 60%, 70%, 80%, 90%, 95%, 98%, 99%, or 99.9% sequence identity is present. Any value between 1% and 100% sequence identity can be present, depending upon the length of the donor polynucleotide.

[00399] The donor sequence may comprise certain sequence differences as compared to the genomic sequence, e.g. restriction sites, nucleotide polymorphisms, selectable markers (e.g., drug resistance genes, fluorescent proteins, enzymes etc.), etc., which may be used to assess for successful insertion of the donor sequence at the cleavage site or in some cases may be used for other purposes

(e.g., to signify expression at the targeted genomic locus). In some cases, if located in a coding region, such nucleotide sequence differences will not change the amino acid sequence, or will make silent amino acid changes (i.e., changes which do not affect the structure or function of the protein). Alternatively, these sequences differences may include flanking recombination sequences such as FLPs, loxP sequences, or the like, that can be activated at a later time for removal of the marker sequence.

[00400] In some cases, the donor sequence is provided to the cell as single-stranded DNA. In some cases, the donor sequence is provided to the cell as double-stranded DNA. It may be introduced into a cell in linear or circular form. If introduced in linear form, the ends of the donor sequence may be protected (e.g., from exonucleolytic degradation) by any convenient method and such methods are known to those of skill in the art. For example, one or more dideoxynucleotide residues can be added to the 3' terminus of a linear molecule and/or self-complementary oligonucleotides can be ligated to one or both ends. See, for example, Chang et al. (1987) Proc. Natl. Acad Sci USA 84:4959-4963; Nehls et al. (1996) Science 272:886-889. Additional methods for protecting exogenous polynucleotides from degradation include, but are not limited to, addition of terminal amino group(s) and the use of modified internucleotide linkages such as, for example, phosphorothioates, phosphoramidates, and O-methyl ribose or deoxyribose residues. As an alternative to protecting the termini of a linear donor sequence, additional lengths of sequence may be included outside of the regions of homology that can be degraded without impacting recombination. A donor sequence can be introduced into a cell as part of a vector molecule having additional sequences such as, for example, replication origins, promoters and genes encoding antibiotic resistance. Moreover, donor sequences can be introduced as naked nucleic acid, as nucleic acid complexed with an agent such as a liposome or poloxamer, or can be delivered by viruses (e.g., adenovirus, AAV), as described elsewhere herein for nucleic acids encoding a CasZ guide RNA and/or a CasZ fusion polypeptide and/or donor polynucleotide.

TRANSGENIC, NON-HUMAN ORGANISMS

[00401] As described above, in some cases, a nucleic acid (e.g., a recombinant expression vector) of the present disclosure (e.g., a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide; a nucleic acid comprising a nucleotide sequence encoding a CasZ fusion polypeptide; etc.), is used as a transgene to generate a transgenic non-human organism that produces a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure. The present disclosure provides a transgenic-non-human organism comprising a nucleotide sequence encoding a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure.

Transgenic, non-human animals

[00402] The present disclosure provides a transgenic non-human animal, which animal comprises a transgene comprising a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide or a CasZ fusion polypeptide. In some embodiments, the genome of the transgenic non-

human animal comprises a nucleotide sequence encoding a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure. In some cases, the transgenic non-human animal is homozygous for the genetic modification. In some cases, the transgenic non-human animal is heterozygous for the genetic modification. In some embodiments, the transgenic non-human animal is a vertebrate, for example, a fish (e.g., salmon, trout, zebra fish, gold fish, puffer fish, cave fish, etc.), an amphibian (frog, newt, salamander, etc.), a bird (e.g., chicken, turkey, etc.), a reptile (e.g., snake, lizard, etc.), a non-human mammal (e.g., an ungulate, e.g., a pig, a cow, a goat, a sheep, etc.; a lagomorph (e.g., a rabbit); a rodent (e.g., a rat, a mouse); a non-human primate; etc.), etc. In some cases, the transgenic non-human animal is an invertebrate. In some cases, the transgenic non-human animal is an insect (e.g., a mosquito; an agricultural pest; etc.). In some cases, the transgenic non-human animal is an arachnid.

[00403] Nucleotide sequences encoding a a CasZ polypeptide,e or a CasZ fusion polypeptide, of the present disclosure can be under the control of (i.e., operably linked to) an unknown promoter (e.g., when the nucleic acid randomly integrates into a host cell genome) or can be under the control of (i.e., operably linked to) a known promoter. Suitable known promoters can be any known promoter and include constitutively active promoters (e.g., CMV promoter), inducible promoters (e.g., heat shock promoter, tetracycline-regulated promoter, steroid-regulated promoter, metal-regulated promoter, estrogen receptor-regulated promoter, etc.), spatially restricted and/or temporally restricted promoters (e.g., a tissue specific promoter, a cell type specific promoter, etc.), etc.

Transgenic plants

[00404] As described above, in some cases, a nucleic acid (e.g., a recombinant expression vector) of the present disclosure (e.g., a nucleic acid comprising a nucleotide sequence encoding a CasZ polypeptide of the present disclosure; a nucleic acid comprising a nucleotide sequence encoding a CasZ fusion polypeptide of the present disclosure; etc.), is used as a transgene to generate a transgenic plant that produces a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure. The present disclosure provides a transgenic plant comprising a nucleotide sequence encoding a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure.In some embodiments, the genome of the transgenic plant comprises a subject nucleic acid. In some embodiments, the transgenic plant is homozygous for the genetic modification. In some embodiments, the transgenic plant is heterozygous for the genetic modification.

[00405] Methods of introducing exogenous nucleic acids into plant cells are well known in the art. Such plant cells are considered "transformed," as defined above. Suitable methods include viral infection (such as double stranded DNA viruses), transfection, conjugation, protoplast fusion, electroporation, particle gun technology, calcium phosphate precipitation, direct microinjection, silicon carbide whiskers technology, Agrobacterium-mediated transformation and the like. The choice of

method is generally dependent on the type of cell being transformed and the circumstances under which the transformation is taking place (i.e. in vitro, ex vivo, or in vivo).

[00406] Transformation methods based upon the soil bacterium *Agrobacterium tumefaciens* are particularly useful for introducing an exogenous nucleic acid molecule into a vascular plant. The wild type form of *Agrobacterium* contains a Ti (tumor-inducing) plasmid that directs production of tumorigenic crown gall growth on host plants. Transfer of the tumor-inducing T-DNA region of the Ti plasmid to a plant genome requires the Ti plasmid-encoded virulence genes as well as T-DNA borders, which are a set of direct DNA repeats that delineate the region to be transferred. An *Agrobacterium*-based vector is a modified form of a Ti plasmid, in which the tumor inducing functions are replaced by the nucleic acid sequence of interest to be introduced into the plant host.

[00407] *Agrobacterium*-mediated transformation generally employs cointegrate vectors or binary vector systems, in which the components of the Ti plasmid are divided between a helper vector, which resides permanently in the *Agrobacterium* host and carries the virulence genes, and a shuttle vector, which contains the gene of interest bounded by T-DNA sequences. A variety of binary vectors is well known in the art and are commercially available, for example, from Clontech (Palo Alto, Calif.). Methods of coculturing *Agrobacterium* with cultured plant cells or wounded tissue such as leaf tissue, root explants, hypocotyledons, stem pieces or tubers, for example, also are well known in the art. See, e.g., Glick and Thompson, (eds.), Methods in Plant Molecular Biology and Biotechnology, Boca Raton, Fla.: CRC Press (1993).

[00408] Microprojectile-mediated transformation also can be used to produce a subject transgenic plant. This method, first described by Klein et al. (Nature 327:70-73 (1987)), relies on microprojectiles such as gold or tungsten that are coated with the desired nucleic acid molecule by precipitation with calcium chloride, spermidine or polyethylene glycol. The microprojectile particles are accelerated at high speed into an angiosperm tissue using a device such as the BIOLISTIC PD-1000 (Biorad; Hercules Calif.).

[00409] A nucleic acid of the present disclosure (e.g., a nucleic acid (e.g., a recombinant expression vector) comprising a nucleotide sequence encoding a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure) may be introduced into a plant in a manner such that the nucleic acid is able to enter a plant cell(s), e.g., via an in vivo or ex vivo protocol. By "in vivo," it is meant in the nucleic acid is administered to a living body of a plant e.g. infiltration. By “ex vivo” it is meant that cells or explants are modified outside of the plant, and then such cells or organs are regenerated to a plant. A number of vectors suitable for stable transformation of plant cells or for the establishment of transgenic plants have been described, including those described in Weissbach and Weissbach, (1989) Methods for Plant Molecular Biology Academic Press, and Gelvin et al., (1990) Plant Molecular Biology Manual, Kluwer Academic Publishers. Specific examples include those derived from a Ti plasmid of

Agrobacterium tumefaciens, as well as those disclosed by Herrera-Estrella et al. (1983) Nature 303: 209, Bevan (1984) Nucl Acid Res. 12: 8711-8721, Klee (1985) Bio/Technolo 3: 637-642. Alternatively, non-Ti vectors can be used to transfer the DNA into plants and cells by using free DNA delivery techniques. By using these methods transgenic plants such as wheat, rice (Christou (1991) Bio/Technology 9:957-9 and 4462) and corn (Gordon-Kamm (1990) Plant Cell 2: 603-618) can be produced. An immature embryo can also be a good target tissue for monocots for direct DNA delivery techniques by using the particle gun (Weeks et al. (1993) Plant Physiol 102: 1077-1084; Vasil (1993) Bio/Technolo 10: 667-674; Wan and Lemeaux (1994) Plant Physiol 104: 37-48 and for Agrobacterium-mediated DNA transfer (Ishida et al. (1996) Nature Biotech 14: 745-750). Exemplary methods for introduction of DNA into chloroplasts are biolistic bombardment, polyethylene glycol transformation of protoplasts, and microinjection (Danieli et al Nat. Biotechnol 16:345-348, 1998; Staub et al Nat. Biotechnol 18: 333-338, 2000; O'Neill et al Plant J. 3:729-738, 1993; Knoblauch et al Nat. Biotechnol 17: 906-909; U.S. Pat. Nos. 5,451,513, 5,545,817, 5,545,818, and 5,576,198; in Intl. Application No. WO 95/16783; and in Boynton et al., Methods in Enzymology 217: 510-536 (1993), Svab et al., Proc. Natl. Acad. Sci. USA 90: 913-917 (1993), and McBride et al., Proc. Natl. Acad. Sci. USA 91: 7301-7305 (1994)). Any vector suitable for the methods of biolistic bombardment, polyethylene glycol transformation of protoplasts and microinjection will be suitable as a targeting vector for chloroplast transformation. Any double stranded DNA vector may be used as a transformation vector, especially when the method of introduction does not utilize Agrobacterium.

[00410] Plants which can be genetically modified include grains, forage crops, fruits, vegetables, oil seed crops, palms, forestry, and vines. Specific examples of plants which can be modified follow: maize, banana, peanut, field peas, sunflower, tomato, canola, tobacco, wheat, barley, oats, potato, soybeans, cotton, carnations, sorghum, lupin and rice.

[00411] The present disclosure provides transformed plant cells, tissues, plants and products that contain the transformed plant cells. A feature of the subject transformed cells, and tissues and products that include the same is the presence of a subject nucleic acid integrated into the genome, and production by plant cells of a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure. Recombinant plant cells of the present invention are useful as populations of recombinant cells, or as a tissue, seed, whole plant, stem, fruit, leaf, root, flower, stem, tuber, grain, animal feed, a field of plants, and the like.

[00412] Nucleotide sequences encoding a CasZ polypeptide, or a CasZ fusion polypeptide, of the present disclosure can be under the control of (i.e., operably linked to) an unknown promoter (e.g., when the nucleic acid randomly integrates into a host cell genome) or can be under the control of (i.e., operably linked to) a known promoter. Suitable known promoters can be any known promoter and

include constitutively active promoters, inducible promoters, spatially restricted and/or temporally restricted promoters, etc.

Examples of Non-Limiting Aspects of the Disclosure

[00413] Aspects, including embodiments, of the present subject matter described above may be beneficial alone or in combination, with one or more other aspects or embodiments. Without limiting the foregoing description, certain non-limiting aspects of the disclosure, numbered 1-36 are provided below. As will be apparent to those of skill in the art upon reading this disclosure, each of the individually numbered aspects may be used or combined with any of the preceding or following individually numbered aspects. This is intended to provide support for all such combinations of aspects and is not limited to combinations of aspects explicitly provided below:

Aspects

[00414] Aspect 1. A method of guiding a CasZ polypeptide to a target sequence of a target nucleic acid, the method comprising contacting the target nucleic acid with an engineered and/or non-naturally occurring complex comprising:(a) a CasZ polypeptide; and (b) a CasZ guide RNA that comprises a guide sequence that hybridizes to a target sequence of the target nucleic acid, and comprises a region that binds to the CasZ polypeptide.

[00415] Aspect 2. The method of aspect 1, wherein the method results in modification of the target nucleic acid, modulation of transcription from the target nucleic acid, or modification of a polypeptide associated with a target nucleic acid.

[00416] Aspect 3. The method of aspect 2, wherein the target nucleic acid is modified by being cleaved.

[00417] Aspect 4. The method of any one of aspects 1-3, wherein the target nucleic acid is selected from: double stranded DNA, single stranded DNA, RNA, genomic DNA, and extrachromosomal DNA.

[00418] Aspect 5. The method of any one of aspects 1-4, wherein the guide sequence and the region that binds to the CasZ polypeptide are heterologous to one another.

[00419] Aspect 6. The method of any one of aspects 1-5, wherein said contacting results in genome editing.

[00420] Aspect 7. The method of any one of aspects 1-5, wherein said contacting takes place outside of a bacterial cell and outside of an archaeal cell.

[00421] Aspect 8. The method of any one of aspects 1-5, wherein said contacting takes place *in vitro* outside of a cell.

[00422] Aspect 9. The method of any one of aspects 1-7, wherein said contacting takes place inside of a target cell.

[00423] Aspect 10. The method of aspect 9, wherein said contacting comprises: introducing into the target cell at least one of: (a) the CasZ polypeptide, or a nucleic acid encoding the CasZ polypeptide; and (b) the CasZ guide RNA, or a nucleic acid encoding the CasZ guide RNA.

[00424] Aspect 11. The method of aspect 10, wherein the nucleic acid encoding the CasZ polypeptide is a non-naturally sequence that is codon optimized for expression in the target cell.

[00425] Aspect 12. The method of any one of aspects 9-11, wherein the target cell is a eukaryotic cell.

[00426] Aspect 13. The method of any one of aspects 9-12, wherein the target cell is in culture *in vitro*.

[00427] Aspect 14. The method of any one of aspects 9-12, wherein the target cell is *in vivo*.

[00428] Aspect 15. The method of any one of aspects 9-12, wherein the target cell is *ex vivo*.

[00429] Aspect 16. The method of aspect 12, wherein the eukaryotic cell is selected from the group consisting of: a plant cell, a fungal cell, a single cell eukaryotic organism, a mammalian cell, a reptile cell, an insect cell, an avian cell, a fish cell, a parasite cell, an arthropod cell, an arachnid cell, a cell of an invertebrate, a cell of a vertebrate, a rodent cell, a mouse cell, a rat cell, a primate cell, a non-human primate cell, and a human cell.

[00430] Aspect 17. The method of any one of aspects 9-16, wherein said contacting further comprises: introducing a DNA donor template into the target cell.

[00431] Aspect 18. The method of any one of aspects 1-17, wherein the method comprises contacting the target nucleic acid with a CasZ transactivating noncoding RNA (trancRNA).

[00432] Aspect 19. The method of any one of aspects 9-17, wherein said contacting comprises: introducing a CasZ transactivating noncoding RNA (trancRNA) and/or a nucleic acid encoding the CasZ trancRNA into the target cell.

[00433] Aspect 20. The method of aspect 18 or aspect 19, wherein the trancRNA comprises a nucleotide sequence having 70% or more (at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%) nucleotide sequence identity with a trancRNA sequence of Table 2.

[00434] Aspect 21. A composition comprising an engineered and/or non-naturally occurring complex comprising: (a) a CasZ polypeptide, or a nucleic acid encoding said CasZ polypeptide; and (b) a CasZ guide RNA, or a nucleic acid encoding said CasZ guide RNA, wherein said CasZ guide RNA comprises a guide sequence that is complementary to a target sequence of a target nucleic acid, and comprises a region that can bind to the CasZ polypeptide.

[00435] Aspect 22. The composition of aspect 21, further comprising a CasZ transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said CasZ trancRNA.

[00436] Aspect 23. A kit comprising an engineered and/or non-naturally occurring complex comprising: (a) a CasZ polypeptide, or a nucleic acid encoding said CasZ polypeptide; (b) a CasZ guide RNA, or a nucleic acid encoding said CasZ guide RNA, wherein said CasZ guide RNA comprises a guide sequence that is complementary to a target sequence of a target nucleic acid, and comprises a region that can bind to the CasZ polypeptide.

[00437] Aspect 24. The kit of aspect 23, further comprising a CasZ transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said CasZ trancRNA.

[00438] Aspect 25. A genetically modified eukaryotic cell, comprising at least one of: (a) a CasZ polypeptide, or a nucleic acid encoding said CasZ polypeptide; (b) a CasZ guide RNA, or a nucleic acid encoding said CasZ guide RNA, wherein said CasZ guide RNA comprises a guide sequence that is complementary to a target sequence of a target nucleic acid, and comprises a region that can bind to the CasZ polypeptide; and (c) a CasZ transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said CasZ trancRNA.

[00439] Aspect 26. The composition, kit, or eukaryotic cell of any one of the preceding aspects, characterized by at least one of: (a) the nucleic acid encoding said CasZ polypeptide comprises a nucleotide sequence that: (i) encodes the CasZ polypeptide and, (ii) is operably linked to a heterologous promoter; (b) the nucleic acid encoding said CasZ guide RNA comprises a nucleotide sequence that: (i) encodes the CasZ guide RNA and, (ii) is operably linked to a heterologous promoter; and (c) the nucleic acid encoding said CasZ trancRNA comprises a nucleotide sequence that: (i) encodes the CasZ trancRNA and, (ii) is operably linked to a heterologous promoter.

[00440] Aspect 27. The composition, kit, or eukaryotic cell of any one of the preceding aspects, for use in a method of therapeutic treatment of a patient.

[00441] Aspect 28. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein at least one of: the nucleic acid encoding said CasZ polypeptide, the nucleic acid encoding said CasZ guide RNA, and the nucleic acid encoding said CasZ trancRNA, is a recombinant expression vector.

[00442] Aspect 29. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein the CasZ guide RNA and/or the CasZ trancRNA comprises one or more of: a modified nucleobase, a modified backbone or non-natural internucleoside linkage, a modified sugar moiety, a Locked Nucleic Acid, a Peptide Nucleic Acid, and a deoxyribonucleotide.

[00443] Aspect 30. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein the CasZ polypeptide is a variant CasZ polypeptide with reduced nuclease activity compared to a corresponding wild type CasZ protein.

[00444] Aspect 31. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein at least one of: the CasZ polypeptide, the nucleic acid encoding the CasZ polypeptide, the CasZ guide RNA, the nucleic acid encoding the CasZ guide RNA, the CasZ trancRNA, and the nucleic acid encoding the CasZ trancRNA; is conjugated to a heterologous moiety.

[00445] Aspect 32. The method, composition, kit, or eukaryotic cell of aspect 31, wherein the heterologous moiety is a heterologous polypeptide.

[00446] Aspect 33. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein the CasZ polypeptide has reduced nuclease activity compared to a corresponding wild type CasZ protein, and is fused to a heterologous polypeptide.

[00447] Aspect 34. The method, composition, kit, or eukaryotic cell of aspect 33, wherein the heterologous polypeptide: (i) has DNA modifying activity, (ii) exhibits the ability to increase or decrease transcription, and/or (iii) has enzymatic activity that modifies a polypeptide associated with DNA.

[00448] Aspect 35. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein the CasZ polypeptide comprises an amino acid sequence having 70% or more (at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 98%, at least 99%, or 100%) amino acid sequence identity with a CasZ protein of Figure 1 or Figure 7.

[00449] Aspect 36. The method, composition, kit, or eukaryotic cell of any one of the preceding aspects, wherein the guide sequence and the region that binds to the CasZ polypeptide are heterologous to one another.

[00450] Aspect 37. A method of detecting a target DNA in a sample, the method comprising: (a) contacting the sample with: (i) a CasZ polypeptide; (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA; and (iii) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage of the single stranded detector DNA by the CasZ, thereby detecting the target DNA.

[00451] Aspect 38. The method of aspect 37, wherein the target DNA is single stranded.

[00452] Aspect 39. The method of aspect 37 or 38, wherein the target DNA is double stranded.

[00453] Aspect 40. The method of any one of aspects 37-39, wherein the target DNA is viral DNA.

[00454] Aspect 41. The method of any one of aspects 37-40, wherein the target DNA is papovavirus, hepdnavirus, herpesvirus, adenovirus, poxvirus, or parvovirus DNA.

[00455] Aspect 42. The method of any one of aspects 37-41, wherein the CasZ polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to the CasZ amino acid sequence set forth in any one of FIGs. 1 and 7.

[00456] Aspect 43. The method of any one of aspects 37-41, wherein the CasZ polypeptide is a Cas14a polypeptide.

[00457] Aspect 44. The method according to any one of aspects 37-43, wherein the sample comprises DNA molecules from a cell lysate.

[00458] Aspect 45. The method according to any one of aspects 37-44, wherein the sample comprises cells.

[00459] Aspect 46. The method according to any one of aspects 37-45, wherein said contacting is carried out inside of a cell *in vitro*, *ex vivo*, or *in vivo*.

[00460] Aspect 47. The method according to aspect 46, wherein the cell is a eukaryotic cell.

[00461] Aspect 48. The method according to any one of aspects 37-47, wherein the target DNA can be detected at a concentration as low as 10 aM.

[00462] Aspect 49. The method according to any one of aspects 37-48, comprising determining an amount of the target DNA present in the sample.

[00463] Aspect 50. The method according to aspect 49, wherein said determining comprises: measuring the detectable signal to generate a test measurement; measuring a detectable signal produced by a reference sample or cell to generate a reference measurement; and comparing the test measurement to the reference measurement to determine an amount of target DNA present in the sample.

[00464] Aspect 51. The method according to any one of aspects 37-50, wherein measuring a detectable signal comprises one or more of: gold nanoparticle based detection, fluorescence polarization, colloid phase transition/dispersion, electrochemical detection, and semiconductor-based sensing.

[00465] Aspect 52. The method according to any one of aspects 37-51, wherein the single stranded detector DNA comprises a fluorescence-emitting dye pair.

[00466] Aspect 53. The method according to aspect 52, wherein the fluorescence-emitting dye pair produces an amount of detectable signal prior to cleavage of the single stranded detector DNA, and the amount of detectable signal is reduced after cleavage of the single stranded detector DNA.

[00467] Aspect 54. The method according to aspect 52, wherein the single stranded detector DNA produces a first detectable signal prior to being cleaved and a second detectable signal after cleavage of the single stranded detector DNA.

[00468] Aspect 55. The method according to any one of aspects 52-54, wherein the fluorescence-emitting dye pair is a fluorescence resonance energy transfer (FRET) pair.

[00469] Aspect 56. The method according to aspect 18, wherein an amount of detectable signal increases after cleavage of the single stranded detector DNA.

[00470] Aspect 57. The method according to aspect 52 or aspect 56, wherein the fluorescence-emitting dye pair is a quencher/fluor pair.

[00471] Aspect 58. The method according to any one of aspects 52-57, wherein the single stranded detector DNA comprises two or more fluorescence-emitting dye pairs.

[00472] Aspect 59. The method according to aspect 58, wherein said two or more fluorescence-emitting dye pairs include a fluorescence resonance energy transfer (FRET) pair and a quencher/fluor pair.

[00473] Aspect 60. The method according to any one of aspects 37-59, wherein the single stranded detector DNA comprises a modified nucleobase, a modified sugar moiety, and/or a modified nucleic acid linkage.

[00474] Aspect 61. The method according to any one of aspects 37-60, wherein the method comprises amplifying nucleic acids in the sample.

[00475] Aspect 62. The method according to aspect 61, wherein said amplifying comprises isothermal amplification.

[00476] Aspect 63. The method according to aspect 62, wherein the isothermal amplification comprises recombinase polymerase amplification (RPA).

[00477] Aspect 64. The method according to any one of aspects 61-63, wherein said amplifying begins prior to the contacting of step (a).

[00478] Aspect 65. The method according to any one of aspects 61-63, wherein said amplifying begins together with the contacting of step (a).

[00479] Aspect 66. A kit for detecting a target DNA in a sample, the kit comprising: (a) a guide RNA, or a nucleic acid encoding the guide RNA; wherein the guide RNA comprises: a region that binds to a CasZ polypeptide, and a guide sequence that is complementary to a target DNA; and (b) a labeled detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA.

[00480] Aspect 67. The kit of aspect 66, further comprising a CasZ polypeptide.

[00481] Aspect 68. The kit of aspect 67, wherein the CasZ polypeptide comprises an amino acid sequence having at least 85% amino acid sequence identity to the CasZ amino acid sequence set forth in any one of FIGs. 1 and 7.

[00482] Aspect 69. The kit of aspect 67, wherein the CasZ polypeptide is a Cas14a polypeptide.

[00483] Aspect 70. The kit of any one of aspects 66-69, wherein the single stranded detector DNA comprises a fluorescence-emitting dye pair.

[00484] Aspect 71. The kit of aspect 70, wherein the fluorescence-emitting dye pair is a FRET pair.

[00485] Aspect 72. The kit of aspect 70, wherein the fluorescence-emitting dye pair is a quencher/fluor pair.

[00486] Aspect 73. The kit of any one of aspects 70-72, wherein the single stranded detector DNA comprises two or more fluorescence-emitting dye pairs.

[00487] Aspect 74. The kit of aspect 73, wherein said two or more fluorescence-emitting dye pairs include a first fluorescence-emitting dye pair that produces a first detectable signal and a second fluorescence-emitting dye pair that produces a second detectable signal.

[00488] Aspect 75. The kit of any one of aspects 66-74, further comprising nucleic acid amplification components.

[00489] Aspect 76. The kit of aspect 75, wherein the nucleic acid amplification components are components for recombinase polymerase amplification (RPA).

[00490] Aspect 77. A method of cleaving single stranded DNAs (ssDNAs), the method comprising: contacting a population of nucleic acids, wherein said population comprises a target DNA and a plurality of non-target ssDNAs, with: (i) a CasZ polypeptide; and (ii) a guide RNA comprising: a region that binds to the CasZ polypeptide, and a guide sequence that hybridizes with the target DNA, wherein the CasZ polypeptide cleaves non-target ssDNAs of said plurality.

[00491] Aspect 78. The method of aspect 77, wherein said contacting is inside of a cell *in vitro*, *ex vivo*, or *in vivo*.

[00492] Aspect 79. The method of aspect 78, wherein the cell is a eukaryotic cell.

[00493] Aspect 80. The method of aspect 79, wherein the eukaryotic cell is a plant cell.

[00494] Aspect 81. The method of any one of aspects 78-80, wherein the non-target ssDNAs are foreign to the cell.

[00495] Aspect 82. The method of aspect 81, wherein the non-target ssDNAs are viral DNAs.

[00496] Aspect 83. The method of any one of aspects 77-82, wherein the target DNA is single stranded.

[00497] Aspect 84. The method of any one of aspects 77-82, wherein the target DNA is double stranded.

[00498] Aspect 85. The method of any one of aspects 77-84, wherein the target DNA is viral DNA.

[00499] Aspect 86. The method of any one of aspects 77-84, wherein the target DNA is papovavirus, hepdnavirus, herpesvirus, adenovirus, poxvirus, or parvovirus DNA.

EXAMPLES

[00500] The following examples are put forth so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the present invention, and are not

intended to limit the scope of what the inventors regard as their invention nor are they intended to represent that the experiments below are all or the only experiments performed. Efforts have been made to ensure accuracy with respect to numbers used (e.g. amounts, temperature, etc.) but some experimental errors and deviations should be accounted for. Unless indicated otherwise, parts are parts by weight, molecular weight is weight average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric. Standard abbreviations may be used, e.g., bp, base pair(s); kb, kilobase(s); pl, picoliter(s); s or sec, second(s); min, minute(s); h or hr, hour(s); aa, amino acid(s); kb, kilobase(s); bp, base pair(s); nt, nucleotide(s); i.m., intramuscular(ly); i.p., intraperitoneal(ly); s.c., subcutaneous(ly); and the like.

Materials and Methods

[00501] The following materials and methods generally apply to the results presented in the Examples described herein except where noted otherwise.

Metagenomics and metatranscriptomics

[00502] The initial analysis was performed on previously assembled and binned metagenomes from two sites: the Rifle Integrated Field Research (IFRC) site, adjacent to the Colorado River near Rifle, Colorado and Crystal Geyser, a cold, CO_2-driven geyser on the Colorado Plateau in Utah. Metatranscriptomic data from IFRC site was used to detect transcription of non-coding elements in nature. Further mining of CRISPR-Cas14 systems was then performed on public metagenomes from IMG/M.

CRISPR-Cas computation analysis

[00503] The assembled contigs from the various samples were scanned with the HMMer suite for known Cas proteins using Hidden Markov Model (HMMs) profiles. Additional HMMs were constructed for Cas14 proteins based on the MAFFT alignments of putative type V effectors that contained less than 800 aa, and were adjacent to acquisition cas genes and CRISPR arrays. These HMMs were iteratively refined by augmenting them with manually selected novel putative Cas14 sequences that were found using the existing Cas14 HMM models. The sequence of Cas14 repeat sequences are provided in Table 3. CRISPR arrays were identified using a local version of the CrisprFinder software and CRISPRDetect. Phylogenetic trees of Cas1 and type V effector proteins were constructed using RAxML with PROTGAMMALG as the substitution model and 100 bootstrap samplings. Trees were visualized using FigTree 1.4.1 (http://tree.bio.ed.ac.uk/software/figtree/). Metatranscriptomic reads were mapped to assembled contigs using Bowtie2. RNase presence analysis was based on HMMs that were built from alignment of KEGG orthologous groups (KOs) downloaded from KEGG database.

[00504] Table 3. Repeat sequences (non-guide sequence portion of a Cas14 guide RNA) of all Cas14 proteins used herein (e.g., see Figure 7) are shown in Table 3.

Cas14 Protein	Repeat sequence	SEQ ID NO:	Scaffold Accession No:
Cas14a.1 (CasZa.3)	GTTGCAGAACCCGAATAGACGAATGAAGGAATGCAAC	53	**NCBI:** MK005734
Cas14a.2 (Za.8)	CTTGCAGAACCCGGATAGACGAATGAAGGAATGCAAC	295	**NCBI:** MK005733
Cas14a.3 (CasZa.3)	GTTGCAGAACCCGAATAGACGAATGAAGGAATGCAAC	53	**NCBI:** MK005732
Cas14a.4 (CasZa.4)	CTATCATATTCAGAACAAAGGGATTAAGGAATGCAAC	54	**NCBI:** MK005735
Cas14a.5 (CasZa.5, CasZb.3)	CTTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	55	**NCBI:** MK005736
Cas14a.6 (CasZa.6)	GTCTACAACTCATTGATAGAAATCAATGAGTTAGACA	56	**IMG/M:** Ga0137385 _10000156
Cas14b.1 (Cas Zb.2)	GTTGCAGAAATAGAATAAAGGAATTAAGGAATGCAAC	59	**NCBI:** MK005737
Cas14b.2 (CasZa.5, CasZb.3)	CTTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	55	**NCBI:** MK005738
Cas14b.3 (CasZb.4)	ATTTCATACTCAGAACAAAGGGATTAAGGAATGCAAC	61	**NCBI:** MK005739
Cas14b.4 (CasZb.16)	GTTTCAGCGCACGAATTAACGAGATGAGAGATGCAAC	303	**NCBI:** MK005740
Cas14b.5 (CasZb.6)	CTTGCAGAAGCTGAATAGACGAATCAAGGAATGCAAC	63	**NCBI:** MK005741
Cas14b.6 (Za.12)	CTTGCAGGCCTTGAATAGAGGAGTTAAGGAATGCAAC	296	**NCBI:** MK005742
Cas14b.7 (CasZb.9)	GTTGCAGCGCCCGAACTGACGAGACGAGAGATGCAAC	66	**IMG/M:** Ga0172369 _10000737
Cas14b.8 (Cas Zb.10)	GTTGCGCGAATAGAATAAAGGAATTAAGGAATGCAAC	67	**IMG/M:** Ga0172369 _10010464
Cas14b.9 (CasZb.11)	AGTTGCATTCCTTAATCCCTCTGTTCAGTTTGTGCAAT	68	**IMG/M:** Ga0172365 _10004421
Cas14b.10 (Zb.13)	GTTGCACAGTGCTAATTAGAGAAACTAGGAATGCAAC	297	**NCBI:** MK005743
Cas14b.11 (CasZc.2)	GTTGCGGCGCGCGAATAAACGAGACTAGGAATGCAAC	70	**NCBI:** MK005744
Cas14b.12 (Zb.14)	CTAGCATATTCAGAACAAAGGGATTAAGGAATGCAAC	298	**NCBI:** MK005745
Cas14b.13	CTTTCATATTCAGAACAAAGGGATTAAGGAATGCAAC	72	**NCBI:**

Cas14 Protein	Repeat sequence	SEQ ID NO:	Scaffold Accession No:
(CasZc.4)			MK005746
Cas14b.14 (Zb.15)	CTTTCATATTCAGAAACTAGGGGTTAAGGACTGCAAC	299	**NCBI:** MK005747
Cas14b.15 (CasZc.6)	GTTGCAGCCCCCGAACTAACGAGATGAGAGATGCAAC	74	**IMG/M:** Ga0116204 _1008574
Cas14b.16 (casZc.7)	CTTGCAGAACAATCATATATGACTAATCAGACTGCAAC	75	**IMG/M:** Ga0078972 _1001015a
Cas14c.1 (Zb.8)	GTTGCATCCCTACGTCGTGAGCACCGGTGAGTGCAAC	300	**NCBI:** MK005748
Cas14c.2 (CasZd.2)	GTCCCTACTCGCTAGGGAAACTAATTGAATGGAAAC	77	**IMG/M:** JGI12048 J13642_ 10201286
Cas14d.1 (CasZe.2)	CTTCCAAACTCGAGCCAGTGGGGAGAGAAGTGGCA	79	**NCBI:** MK005750
Cas14d.2 (CasZe.3)	CCTGTAGACCGGTCTCATTCTGAGAGGGGTATGCAACT	80	**NCBI:** MK005751
Cas14d.3 (CasZe.4)	GTCTCGAGACCCTACAGATTTTGGAGAGGGGTGGGAC	81	**NCBI:** MK005752
Cas14e.1 (CasZf.1)	GTAGCAGGACTCTCCTCGAGAGAAACAGGGGTATGCT	83	**NCBI:** MK005753
Cas14e.2 (CasZf.2)	GTACAATACCTCTCCTTTAAGAGAGGGAGGGGTACGCTAC	84	**NCBI:** MK005754
Cas14e.3 (Zc.5)	GGAAAGGAATCCCCTGAAGGAAACGAGGGGG	301	**NCBI:** MK005755
Cas14f.1 (CasZg.1)	GGTTCCCCCGGGCGCGGGTGGGGTGGCG	86	**NCBI:** MK005756
Cas14f.2 (CasZg.2)	GGCTGCTCCGGGTGCGCGTGGAGCGAGG	87	**IMG/M:** Ga0105042 _100140
Cas14g.1 (Ze.3)	GTGTCCATCAATCAGATTTGCGTTGGCCGGTGCAAT	302	**NCBI:** MK005758
Cas14g.2 (CasZi.2)	GCCGCAGCGGCCGACGCGGCCCTGATCGATGGACAC	90	**IMG/M:** Ga0123330 _1010394
Cas14h.1 (CasZk.1)	GGCTAGCCCGTGCGCGCAGGGACGAGTGG	92	**IMG/M:** Ga0070762 _10001740
Cas14h.2 (CasZk.2)	GCCCGTGCGCGCAGGGACGAGTGG	93	**IMG/M:** Ga0070766 _10011912
Cas14h.3 (CasZk.4)	CCATCGCCCCGCGCGCACGTGGATGAGCC	95	**IMG/M:** Ga0116216 _10000905
Cas14u.1 (CasZa.7)	GTTATAAAGGCGGGGATCGCGACCGAGCGATTGAAAG	57	**IMG/M:** Ga0066793

Cas14 Protein	Repeat sequence	SEQ ID NO:	Scaffold Accession No:
			_10010091
Cas14u.2 (CasZb.8)	GTCTCCATGACTGAAAAGTCGTGGCCGAATTGAAAC	65	**IMG/M:** JGI24730 J26740 _1002785
Cas14u.3 (CasZe.1)	GTTGCATTCGGGTGCAAAACAGGGAGTAGAGTGTAAC	78	**NCBI:** MK005749
Cas14u.4 (CasZj.2)	CTTTTAGACAGTTTAAATTCTAAAGGGTATAAAAC	307	**NCBI:** MK005757
Cas14u.5 (CasZj.1)	GTCGAAATGCCCGCGCGGGGGCGTCGTACCCGCGAC	308	**IMG/M:** Ga0137373 _10000316
Cas14u.6 (CasZk.3)	GTTGCAGCGGCCGACGGAGCGCGAGCGTGGATGCCAC	309	**IMG/M:** Ga0070717 _10000077
Cas14u.7 (CasZl.1)	CTTTAGACTTCTCCGGAAGTCGAATTAATGGAAAC	310	**IMG/M:** JGI12210 **IMG/M:** J13797 _10004690
Cas14u.8 (CasZl.2)	GGGCGCCCCGCGCGAGCGGGGGTTGAAG	311	**IMG/M:** Ga0073904 _10021651

Generation of expression plasmids, RNA and DNA substrates

[00505] Minimal CRISPR loci for putative systems were designed by removing acquisition proteins and generating minimal arrays with a single spacer. These minimal loci were ordered as gBlocks (IDT) and assembled into a plasmid with a tetracycline inducible promoter driving expression of the locus. Plasmid maps were available on Addgene and in the figures. All RNA was in vitro transcribed using T7 polymerase and PCR products as dsDNA template. Resulting IVTs were gel extracted and ethanol precipitated. DNA substrates were obtained from IDT and their sequences are available in Table 4. For radiolabeled cleavage assays DNA oligos were gel extracted from a PAGE gel before radiolabeling. For FQ assays, DNA substrates were used without further purification.

E. coli RNAseq

[00506] Small RNA sequencing was conducted as described previously with modification in Harrington et al. (2017). *E. coli* NEB Stable3 was transformed with a plasmid expressing Cas14a1 system with a tetracycline inducible promoter upstream of the Cas14a1 ORF or the same plasmid with an N-terminal 10x-histidine tag fused to Cas14. Starters were grown up overnight in SOB, diluted 1:100 in

5mL fresh SOB containing 214nM anhydrotetracycline and grown up overnight at 25°C. For sequencing of RNA pulled down with Cas14a, the plasmid containing an N-terminal His-tag fused to Cas14a1 was grown up at 18°C before lysis and purification as described in "Protein purification", stopping after the Ni-NTA elution. Cells were pelleted and RNA was extracted using hot phenol as previously described. Total nucleic acids were treated with TURBO DNase and phenol extracted. The resulting RNA was treated with rSAP which was heat inactivated before addition of T4 PNK. Adapters were ligated onto the small RNA using the NEBnext small RNA kit and gel-extracted on an 8% native PAGE gel. RNA was sequenced on a MiSeq with single end 300bp reads. For analysis, the resulting reads were trimmed using Cutadapt, discarding sequences <8nt and mapped to the plasmid reference using Bowtie2.

PAM depletion assays

[00507] PAM depletion assays were conducted as previously described in Burstein et al. (2017). Randomized plasmid libraries were generated using a primer containing a randomized PAM region adjacent to the target sequence. The randomized primers were hybridized with a primer that was complementary to the 3' end of the primer and the duplex was extended using Klenow Fragment (NEB). The dsDNA containing the target and were digested with EcoRI and NcoI, ligated into pUC19 backbone and transformed into *E. coli* DH5α and >107 cells were harvested. Next *E. coli* NEBstable was transformed with either a CRISPR plasmid or an empty vector control and these transformed *E. coli* were made electrocompetent by repeated washing with 10% glycerol. These electrocompetent cells were transformed with 200ng of the target library and plated on bioassay dishes containing selection for the target (carbenicillin, 100mg l-1) and CRISPR plasmid (chloramphenicol, 30mg l-1). Cells were harvested and prepared for amplicon sequencing on an Illumina MiSeq. The PAM region was extracted using Cutadapt and depletion values were calculated in python. PAMs were visualized using WebLogo.

Transcriptomic RNA mapping

[00508] RNA was extracted from 0.2 mm filters using the Invitrogen TRIzol reagent, followed by genomic DNA removal and cleaning using the Qiagen RNase-Free DNase Set kit and the Qiagen Mini RNeasy kit. An Agilent 2100 Bioanalyzer (Agilent Technologies) was used to assess the integrity of the RNA samples. The Applied Biosystems SOLiD Total RNA-Seq kit was used to generate the cDNA template library. The SOLiD EZ Bead system (Life Technologies) was used to perform emulsion clonal bead amplification to generate bead templates for SOLiD platform sequencing. Samples were sequenced at Pacific Northwest National Laboratory on the 5500XL SOLiD platform. The 50 bp single reads were trimmed using Sickle as in Brown et al. (2015).

Protein purification

[00509] Cas14a1 was purified as described previously with modification. *E. coli* BL21(DE3) RIL were transformed with 10xHis-MBP-Cas14a1 expression plasmid and grown up to OD600 =0.5 in Terrific Broth (TB) and induced with 0.5mM IPTG. Cells were grown overnight at 18°C, collected by centrifugation, resuspended in Lysis Buffer (50 mM Tris-HCl, pH 7.5, 20 mM imidazole, 0.5 mM TCEP, 500 mM NaCl) and broken by sonication. Lysate was batch loaded on to Ni-NTA resin, washed with the above buffer before elution with Elution Buffer (50 mM Tris-HCl, pH 7.5, 300 mM imidazole, 0.5 mM TCEP, 500 mM NaCl). The MBP and His-tag were removed by overnight incubation with TEV at 4°C. The resulting protein exchanged into Buffer A (20 mM HEPES, pH 7.5, 0.5 mM TCEP, 150 mM NaCl) and loaded over tandem MBP, heparin columns (GE, Hi-Trap) and eluted with a linear gradient from Buffer A to Buffer B (20 mM HEPES, pH 7.5, 0.5 mM TCEP, 1250 mM NaCl). The resulting fractions containing Cas14a1 were loaded onto an S200 gel filtration column, flash frozen and stored at -80°C until use.

***In vitro* cleavage assays**

Radiolabeled

[00510] Radiolabeled cleavage assays were conducted in 1× Cleavage Buffer (25 mM NaCl, 20 mM HEPES, pH 7.5, 1 mM DTT, 5% glycerol). 100nM Cas14a1 was complexed with 125nM crRNA and 125nM tracrRNA for 10min at RT. ~1nM radiolabeled DNA or RNA substrate was added and allowed to react for 30min at 37°C. The reaction was stopped by adding 2x Quench Buffer (90% formamide, 25mM EDTA and trace bromophenol blue), heated to 95°C for 2min and run on a 10% polyacrylamide gel containing 7M Urea and 0.5×TBE. Products were visualized by phosphorimaging.

M13 DNA cleavage

[00511] M13 DNA cleavage assays were conducted in 100 mM NaCl, 20 mM HEPES, pH 7.5, 1 mM DTT, 5% glycerol. 250nM Cas14a1 was complexed with 250nM crRNA and 250nM tracrRNA and 250nM ssDNA activator. The reaction was initiated by addition of 5 nM M13 ssDNA plasmid and was quenched by addition of loading buffer supplemented with 10mM EDTA. Products were separated on a 1.5% agarose TAE gel prestained with SYBR gold (Thermofisher).

FQ detection of trans-cleavage

[00512] FQ detection was conducted as previously described in Chen et al. (2018) with modification. 100nM Cas14a1 was complexed with 125nM crRNA, 125nM tracrRNA, 50nM FQ probe and 2nM ssDNA activator in 1× Cleavage Buffer at 37°C for 10 min. The reaction was then initiated by addition of activator DNA when for all reactions except for the RNA optimization experiments where the

variable RNA component was used to initiate. The reaction was monitored in a fluorescence plate reader for up to 120 minutes at 37°C with fluorescence measurements taken every 1 min (λex: 485 nm; λem: 535 nm). The resulting data were background subtracted using the readings taken in the absence of activator and fit using a single exponential decay curve.

Data Availability

[00513] Plasmids used herein are available on Addgene (plasmid numbers 112500, 112501, 112502 , 112503, 112504, 112505, 112506). Oligonucleotides used herein are provided in Table 4 and Table 5. The plasmids used herein are provided in Figure 24. The Cas14 protein sequences used herein are provided in Figure 7.

[00514] Table 4. Oligonucleotides and plasmids used herein.

DNA Name	Sequence	SEQ ID NO:
Radiolabeld DNA activator 1 T strand	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	220
Radiolabeld DNA activator 1 NT strand	GTGCCCGcaTTTTTtaccttacaccgcttgcgaaagttgtcagaagataatCGGCGTAg	221
Radiolabeld DNA activator 2 T strand	tttatatgtttctcctggagataacgcaatcgtgacaactttcgcaagcggtgtaaggtaGCAGGCTTCcgaattccgcgtttttacggc	222
Radiolabeld DNA activator 2 NT strand	gccgtaaaaacgcggaattcgGAAGCCTGCtaccttacaccgcttgcgaaagttgtcacgattgcgttatctccaggagaaacatataaa	223
Radiolabeld Activator 3	gatcttcagcTATACATTATTGCACCAACACTAAGGCAGAGTATGttacctggac	224
Radiolabeld Activator 4	gatcttcagcTTTGTATTACTGGAAGGATGCTTGCTTGAGGTGTAaaaacctggac	225
F-Q 5nt	/56-FAM/TTTTT/3IABkFQ/	226
F-Q 6nt	/56-FAM/TTTTTT/3IABkFQ/	227
F-Q 7nt	/56-FAM/TTTTTTT/3IABkFQ/	228
F-Q 8nt	/56-FAM/TTTTTTTT/3IABkFQ/	229
F-Q 9nt	/56-FAM/TTTTTTTTT/3IABkFQ/	230
F-Q 10nt	/56-FAM/TTTTTTTTTT/3IABkFQ/	231
F-Q 11nt	/56-FAM/TTTTTTTTTTT/3IABkFQ/	232
F-Q 12nt	/56-FAM/TTTTTTTTTTTT/3IABkFQ/	233
F-Q 10nt A/T	/56-FAM/TATATATATA/3IABkFQ/	371

F-Q 6nt A/T	/56-FAM/TATATA/3IABkFQ/	372
F-Q 5nt A/T	/56-FAM/TATAT/3IABkFQ/	373
Target 2, Perfect AAAT 3'	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGT AAACGGCCACAAGC	234
Target 2, Perfect TCGT 3'	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGT GCTCGGCCACAAGC	235
Target 2, 1-2MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGAGCT AAACGGCCACAAGC	236
Target 2, 3-4MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCCTCGT AAACGGCCACAAGC	237
Target 2, 5-6MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGCGGACGT AAACGGCCACAAGC	238
Target 2, 7-8MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGGAGCGCGACGT AAACGGCCACAAGC	239
Target 2, 9-10MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCTGCTCGGCGACGT AAACGGCCACAAGC	240
Target 2, 11-12MM	GCCGGGGTGGTGCCCATCCTGGTCGAGCACGACGGCGACGT AAACGGCCACAAGC	241
Target 2, 13-14MM	GCCGGGGTGGTGCCCATCCTGGTCGACGTGGACGGCGACGT AAACGGCCACAAGC	242
Target 2, 15-16MM	GCCGGGGTGGTGCCCATCCTGGTCCTGCTGGACGGCGACGT AAACGGCCACAAGC	243
Target 2, 17-18MM	GCCGGGGTGGTGCCCATCCTGGAGGAGCTGGACGGCGACGT AAACGGCCACAAGC	244
Target 2, 19-20MM	GCCGGGGTGGTGCCCATCCTCCTCGAGCTGGACGGCGACGT AAACGGCCACAAGC	245
HERC2 Amp Fwd	G*T*G*T*TAATACAAAGGTACAGGAACAAAGAATTTG	246
HERC2 Amp Rev	CAAAGAGAAGCCTCGGCC	247
Target 1, Perfect AAAT 3'	TTTATTCAAGGCAATCACTATCAGCTGTGGAACACCCAGGT AAACTAACACAACT	248
Target 1, Perfect TCGT 3'	TTTATTCAAGGCAATCACTATCAGCTGTGGAACACCCAGGT GCTCTAACACAACT	249
Target 1, 1-2MM	TTTATTCAAGGCAATCACTATCAGCTGTGGAACACCCACCTA AACTAACACAACT	250
Target 1, 3-4MM	TTTATTCAAGGCAATCACTATCAGCTGTGGAACACCGTGGT AAACTAACACAACT	251
Target 1, 5-6MM	TTTATTCAAGGCAATCACTATCAGCTGTGGAACAGGCAGGT AAACTAACACAACT	252
Target 1, 7-8MM	TTTATTCAAGGCAATCACTATCAGCTGTGGAAGTCCCAGGT AAACTAACACAACT	253
Target 1, 9-10MM	TTTATTCAAGGCAATCACTATCAGCTGTGGTTCACCCAGGTA AACTAACACAACT	254
Target 1, 11-12MM	TTTATTCAAGGCAATCACTATCAGCTGTCCAACACCCAGGTA AACTAACACAACT	255

Target 1, 13-14MM	TTTATTCAAGGCAATCACTATCAGCTCAGGAACACCCAGGTAAACTAACACAACT	256
Target 1, 15-16MM	TTTATTCAAGGCAATCACTATCAGGAGTGGAACACCCAGGTAAACTAACACAACT	257
Target 1, 17-18MM	TTTATTCAAGGCAATCACTATCTCCTGTGGAACACCCAGGTAAACTAACACAACT	258
Target 1, 19-20MM	TTTATTCAAGGCAATCACTAAGAGCTGTGGAACACCCAGGTAAACTAACACAACT	259
Target 3, Perfect	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	220
Target 3, 1-2MM	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggCGAAAAAtgCGGGCAC	260
Target 3, 3-4MM	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaAAtaAAAAAtgCGGGCAC	261
Target 3, 5-6MM	cTACGCCGattatcttctgacaactttcgcaagcggtgtGGggtaAAAAAtgCGGGCAC	262
Target 3, 7-8MM	cTACGCCGattatcttctgacaactttcgcaagcggtACaaggtaAAAAAtgCGGGCAC	263
Target 3, 9-10MM	cTACGCCGattatcttctgacaactttcgcaagcgACgtaaggtaAAAAAtgCGGGCAC	264
Target 3, 11-12MM	cTACGCCGattatcttctgacaactttcgcaagTAgtgtaaggtaAAAAAtgCGGGCAC	265
Target 3, 13-14MM	cTACGCCGattatcttctgacaactttcgcaGAcggtgtaaggtaAAAAAtgCGGGCAC	266
Target 3, 15-16MM	cTACGCCGattatcttctgacaactttcgTGagcggtgtaaggtaAAAAAtgCGGGCAC	267
Target 3, 17-18MM	cTACGCCGattatcttctgacaactttTAcaagcggtgtaaggtaAAAAAtgCGGGCAC	268
Target 3, 19-20MM	cTACGCCGattatcttctgacaactCCcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	269
Target 3, 21-22MM	cTACGCCGattatcttctgacaaTCttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	270
Target 3, 23-24MM	cTACGCCGattatcttctgacGGctttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	271
Target 3, 25-26MM	cTACGCCGattatcttctgGTaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	272
Full Length Activator	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	220
-20 5′ activator target	tatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	273
-25 5′ activator target	tctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	274
-30 5′ activator target	caactttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	275
-35 5′ activator target	ttcgcaagcggtgtaaggtaAAAAAtgCGGGCAC	276

-5 3′ activator target	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCG	277
-9 3′ activator target	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAA	278
-14 3′ activator target	cTACGCCGattatcttctgacaactttcgcaagcggtgta	279
-19 3′ activator target	cTACGCCGattatcttctgacaactttcgcaagcg	280
-24 3′ activator target	cTACGCCGattatcttctgacaactttcgc	281
-29 3′ activator target	cTACGCCGattatcttctgacaact	282
-34 3′ activator target	cTACGCCGattatcttctga	283
No loop	caactttcgcaagcggtgtaaggtaAAAAAtgCG	284
0nt SL	atggaatgtggcgaacgctttcaacGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	285
5nt SL	atggaatgtggcgaacgcttagttgGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	286
10nt SL	atggaatgtggcgaagcgaaagttgGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	287
15nt SL	atggaatgtgcgcttgcgaaagttgGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	288
20nt SL	atggatacaccgcttgcgaaagttgGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	289
25nt SL	taccttacaccgcttgcgaaagttgGAAAcaactttcgcaagcggtgtaaggtaAAAAAtgCG	290
M13_1 Oligo	GTTTTATCTTCTGCTGGTGGTTCGTTCGGTATTTTTAATG	291
M13_2 Oligo	CATTAAAAATACCGAACGAACCACCAGCAGAAGATAAAAC	292
M13_3 Oligo	GACCATTTGCGAAATGTATCTAATGGTCAAACTAAATCTACTC	293
M13_4 Oligo	GAGTAGATTTAGTTTGACCATTAGATACATTTCGCAAATGGTC	294

[00515] Table 5. RNA Oligonucleotides.

RNA Name	**Sequence**	**SEQ ID NO:**
ssRNA target	cTACGCCGattatcttctgacaactttcgcaagcggtgtaaggtaAAAAAtgCGGGCACcc	332
crRNA	GGAATGCAACtaccttacaccgcttgcgaa	333
tracrRNA	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTCCCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCATCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCTCGAAACAAATTCATTT	334

crRNA 1	GACGAATGAAGGAATGCAACtaccttacaccgcttgcgaa	335
crRNA 2	GACGAATGAAGGAATGCAACccttacaccgcttgcgaaag	336
crRNA 3	GACGAATGAAGGAATGCAACttacaccgcttgcgaaagtt	337
crRNA 4	GACGAATGAAGGAATGCAACacaccgcttgcgaaagttgt	338
crRNA MM target 2	GACGAATGAAGGAATGCAACCGTCGCCGTCCAGCTCGACCA	339
crRNA MM target 3	GACGAATGAAGGAATGCAACGATCGTTACGCTAACTATGA	340
HERC2 A sgRNA	TTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTCC CTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCAT CAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCATTTgaaaGAATGAAGGAATGCAACacttgacac ttaatgctcaa	341
LbCas12a HERC2 crRNA	GGGTAATTTCTACTAAGTGTAGATacttgacacttaatgctcaa	342
25nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgcttgcgaaagttg	343
20nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgcttgcgaa	335
18nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgcttgcg	344
16nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgcttg	345
14nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgct	346
12nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccg	347
10nt spacer crRNA target 4	GACGAATGAAGGAATGCAACtaccttacac	348
Full repeat crRNA target 4	GTTGCAGAACCCGAATAGACGAATGAAGGAATGCAACtaccttaa caccgcttgcgaa	349
20nt repeat crRNA target 4	GACGAATGAAGGAATGCAACtaccttacaccgcttgcgaa	335
17nt repeat crRNA target 4	GAATGAAGGAATGCAACtaccttacaccgcttgcgaa	350
15nt repeat crRNA target 4	ATGAAGGAATGCAACtaccttacaccgcttgcgaa	351

10nt repeat crRNA target 4	GGAATGCAACtaccttacaccgcttgcgaa	333
tracrRNA +41nt	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCA TCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCATTTTTCCTCTCCAATTCTGCACAAAAAAA GGTGAGTCCTTAT	352
tracrRNA +3nt	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCA TCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCATTT	334
tracrRNA -26	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCA TCAGCCTAATGTCGAGAAGTGCTTTCTT	353
tracrRNA -65	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGG	354
tracrRNA +0	TTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTCC CTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCAT CAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCA	355
tracrRNA +90nt	ttcacacTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCT GTCCCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTT GCATCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAA CCCTCGAAACAAATTCAttttcctctccaattctgcacaaaaaaaggtgagtccttat aaaccggcgtgcagaacgccggctcacctttttttcttcattcgatttta	356
sgRNA 1	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCA TCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCATTTgaaaGAATGAAGGAATGCAACtaccttaca ccgcttgcgaa	357
sgRNA 2	CTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTC CCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCA TCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCT CGAAACAAATTCATTTTTCCTCTCCAATTCTGCACAAgaaaGT TGCAGAACCCGAATAGACGAATGAAGGAATGCAACtaccttacac cgcttgcgaa	358
M13 target 1 crRNA	GACGAATGAAGGAATGCAACTACCGAACGAACCACCAGCA GAAGA	359
M13 target 2 crRNA	GACGAATGAAGGAATGCAACTCTTCTGCTGGTGGTTCGTTC GGTA	360
M13 target 3 crRNA	GACGAATGAAGGAATGCAACGTTTGACCATTAGATACATTT CG	361
M13 target 4 crRNA	GACGAATGAAGGAATGCAACCGAAATGTATCTAATGGTCAA AC	362

Example 1

[00516] **Figure 1** depicts examples of naturally occurring CasZ protein sequences.

[00517] **Figure 2** depicts schematic representations of CasZ loci, which include a Cas1 protein in addition to the CasZ protein.

[00518] **Figure 3** depicts a phylogenetic tree of CasZ sequences in relation to other Class 2 CRISPR/Cas effector protein sequences.

[00519] **Figure 4** depicts a phylogenetic tree of Cas1 sequences from CasZ loci in relation to Cas1 sequences from other Class 2 CRISPR/Cas loci.

[00520] **Figure 5** depicts transcriptomic RNA mapping data demonstrating expression of trancRNA from CasZ loci. The trancRNAs are adjacent to the CasZ repeat array, but do not include the repeat sequence and are not complementary to the repeat sequence. Shown are RNA mapping data for the following loci: CasZa3, CasZb4, CasZc5, CasZd1, and CasZe3. Small repeating aligned arrows represent the repeats of the CRISPR array (indicating the presence of guide RNA-encoding sequence); the peaks outside and adjacent to the repeat arrays represent highly transcribed trancRNAs.

[00521] This metatranscriptomic data was not 16S depleted, and hence large portions of the data were mapped to 16S, and mRNA, for example, was almost not represented at all in these reads. Nonetheless, RNA mapping to the predicted trancRNA regions was observed.

Example 2

[00522] A set of CRISPR-Cas systems from uncultivated archaea that contained Cas14, a family of exceptionally compact RNA-guided nucleases of just 400-700 amino acids were disclosed herein, including Cas1 and Cas2 proteins that are responsible for integrating DNA into CRISPR genomic loci and showed evidence of actively adapting their CRISPR arrays to new infections. Despite their small size, Cas14 proteins were capable of RNA-guided single-stranded DNA (ssDNA) cleavage without restrictive sequence requirements. Moreover, target recognition by Cas14 triggered non-specific cutting of ssDNA molecules. Metagenomic data showed that multiple CRISPR-Cas14 systems evolved independently and suggested a potential evolutionary origin of single-effector CRISPR-based adaptive immunity.

[00523] Competition between microbes and viruses stimulated the evolution of CRISPR-based adaptive immunity to provide protection against infectious agents. In class 2 CRISPR-Cas systems, a single 100-200 kilodalton (kD) CRISPR-associated (Cas) protein with multiple functional domains carried out RNA-guided binding and cutting of DNA or RNA substrates. To determine whether simpler, smaller RNA-guided proteins occurred in nature, terabase-scale metagenomic datasets were queried for uncharacterized genes proximal to both a CRISPR array and cas1, the gene that encoded the universal CRISPR integrase. This analysis identified a diverse family of CRISPR-Cas systems that contain cas1, cas2, cas4, and cas14, described herein, encoding a 40-70 kD polypeptide (Figure 8, Panel A). Twenty-

four (24) different cas14 gene variants have been identified that cluster into three subgroups (Cas14a–c) based on comparative sequence analysis (Figure 8, Panels A–B, Figure 9, Figure 10). Cas14 proteins were ~400–700 amino acids (aa), about half the size of previously known class 2 CRISPR RNA-guided enzymes (Figure 8, Panels C–D). While the identified Cas14 proteins exhibited considerable sequence diversity, all were united by the presence of a predicted RuvC nuclease domain, whose organization was characteristic of Type V CRISPR-Cas DNA-targeting enzymes (Figure 8, Panel D).

[00524] The identified Cas14 proteins occurred almost exclusively within DPANN, a super-phylum of symbiotic archaea characterized by small cell and genome sizes. Phylogenetic comparisons showed that Cas14 proteins were widely diverse with similarities to C2c10 and C2c9, families of bacterial RuvC-domain-containing proteins that were sometimes found near a CRISPR array but never together with other *cas* genes (Figure 8, Panel B and Figure 9). This observation and the small size of *c2c10* and *cas14* genes made it improbable that these systems could function as standalone CRISPR effectors.

[00525] Figure 8, Panels A-D depict architecture and phylogeny of CRISPR-Cas14 genomic loci. Figure 8, Panel A depicts a phylogenetic tree of Type V CRISPR systems. Newly identified miniature CRISPR systems are highlighted in orange. Figure 8, Panel B depicts representative loci architectures for C2c10 and CRISPR-Cas14 systems. Figure 8, Panel C depicts the length distribution of Cas14a-c systems compared to Cas12a-e and Cas9. Figure 8, Panel D depicts the domain organization of Cas14a compared to Cas9 and Cas12a. Protein lengths are drawn to scale.

[00526] Figure 9 depicts the maximum likelihood tree for known Type V CRISPR effectors and class 2 candidates containing a RuvC domain. Inset shows individual orthologs for each newly identified subtype. Figure 10 depicts a maximum likelihood tree for Cas1 from known CRISPR systems.

Example 3

[00527] Based on their proximity to conserved genes responsible for creating genetic memory of infection (*cas1*, *cas2*, *cas4*) (Figure 11, Panel A), it was explored whether CRISPR-Cas14 systems actively acquired DNA sequences into their CRISPR arrays. Assembled metagenomic contiguous DNA sequences (contigs) for multiple CRISPR-Cas14 loci revealed that otherwise identical CRISPR systems showed diversity in their CRISPR arrays, suggesting active adaptation to new infections (Figure 11, Panel B and Figure 12, Panel A). Without intending to be bound by any particular theory, it is proposed that the active acquisition of new DNA sequences indicated that these CRISPR-Cas14 loci encoded functional enzymes with nucleic acid targeting activity despite their small size. To test this possibility, it was investigated whether RNA components were produced from CRISPR-Cas14 loci. Environmental metatranscriptomic sequencing data were analyzed for the presence of RNA from the native archaeal host that contains CRISPR-Cas14a (Figure 12, Panel B and Figure 13, Panel A). In addition to CRISPR

RNAs (crRNAs), a highly abundant non-coding RNA was mapped to about a 130-base pair sequence located between *cas14a* and the adjacent CRISPR array. The 20 nucleotides (nts) at the 3′ end of this transcript were mostly complementary to the repeat segment of the crRNA (Figure 12, Panel C and Figure 13, Panel B), as observed for trans-activating CRISPR RNAs (tracrRNAs) found in association with Cas9, Cas12b and Cas12e CRISPR systems. In these previously studied systems, the double-stranded-RNA-cutting enzyme Ribonuclease III (RNase III) generated mature tracrRNAs and crRNAs, but no genes encoding RNase III were present in *cas14*-containing reconstructed genomes (Figure 14, Panel A). This observation implied that an alternative mechanism for CRISPR-associated RNA processing existed in these hosts.

[00528] To test whether the Cas14a proteins and associated RNA components could assemble in a heterologous organism, a plasmid was introduced into *E. coli* containing a minimal CRISPR-Cas14a locus that included the Cas14 gene, the CRISPR array and intergenic regions containing the putative tracrRNA. Affinity purification of the Cas14a protein from cell lysate and sequencing of co-purifying RNA revealed a highly abundant mature crRNA as well as the putative tracrRNA, suggesting that Cas14 associated with both crRNA and tracrRNA (Figure 14, Panel B). The calculated mass of the assembled Cas14a protein-tracrRNA-crRNA particle was 48% RNA by weight compared to just 17% for *S. pyogenes* Cas9 (SpCas9) (Figure 12, Panel D) and 8% for *F. novicida* Cas12a (FnCas12a), hinting at a central role of the RNA in the architecture of the Cas14a complex. Known class 2 CRISPR systems required a short sequence called a protospacer adjacent motif (PAM) to target double-stranded DNA (dsDNA). To test whether Cas14a required a PAM and could conduct dsDNA interference, *E. coli* was transformed expressing a minimal Cas14a locus with a dsDNA plasmid containing a randomized PAM region next to a sequence matching the target-encoding sequence (spacer) in the Cas14 array. No depletion of a PAM sequence was detected among *E. coli* transformants, suggesting that the CRISPR-Cas14a system was either unable to target dsDNA, could do so without requiring a PAM, or was inactive in this heterologous host (Figure 15, Panels A-D).

[00529] Figure 11, Panels A-B depict acquisition of new spacers by CRISPR-Cas14 systems. Figure 11, Panel A depicts alignment of Cas14 Cas1 orthologs. Expansion shows conservation of previously implicated active site residues highlighted in red boxes. Figure 11, Panel B depicts multiple CRISPR arrays assembled for various CRISPR-Cas14 systems revealing spacer diversity for these CRISPR systems. Orange arrows indicate repeats while variously colored boxes indicate unique spacers.

[00530] Figure 12, Panels A-D depict that CRISPR-Cas14a actively adapts and encodes a tracrRNA. Figure 12, Panel A depicts pacer diversity for Cas14a and Cas14b with CRISPR repeats diagramed in orange and unique spacers shown in different colors. Figure 12, Panel B depicts metatranscriptomics reads mapped to Cas14a1 and Cas14a3. Inset shows expansion of most abundant repeat and spacer sequence. Figure 12, Panel C depicts *in silico* predicted structure of Cas14a1 crRNA

and tracrRNA. RNase III orthologs were not identified in host genomes (Figure 14, Panel A). Figure 12, Panel D depicts fraction of various CRISPR complexes mass made up of by RNA and protein.

[00531] Figure 13, Panels A-B depict metatranscriptomics for CRISPR-Cas14 loci. Figure 13, Panel A depicts environmental RNA sequencing reads for Cas14a orthologs. Location of Cas14 and the CRISPR array indicated below. RNA structures to the right show the *in silico* predicted structure of the tracrRNA identified from metatranscriptomics. Figure 13, Panel B depicts predicted hybridization for Cas14a1 crRNA:tracrRNA duplex.

[00532] Figure 14, Panels A-B depict RNA processing and heterologous expression by CRISPR-Cas14. Figure 14, Panel A depicts the presence of common RNase orthologs in Cas14 containing genomes. Light purple represents hits that were significantly shorter than the expected length for the given RNase. Note that RNase III is absent in all investigated genomes. Figure 14, Panel B depicts small RNAseq reads from heterologous expression of Cas14a1 locus in *E. coli* (Figure 14, Panel B, bottom two graphs) compared to metatranscriptomic reads (Figure 14, Panel B, top graph). Pull down refers to RNA that copurified with Ni-NTA affinity purified Cas14a1.

[00533] Figure 15, Panels A-D depict plasmid depletion by Cas14a1 and SpCas9. Figure 15, Panel A depicts a diagram outlining a PAM discovery experiment. *E. coli* expressing the CRISPR system of interest was challenged with a plasmid containing a randomized PAM sequence flanking the target. The surviving (transformed) cells were harvested and sequenced along with a control harboring an empty vector. The depleted sequences were then sequenced and PAMs depleted more than the PAM Depletion Value Threshold (PDVT) were used to generate a Weblogo. Figure 15, Panels B-D depict PAM sequences depleted by heterologously expressed Cas14a1 transformed with a target plasmid containing a randomized PAM sequence 5' (Figure 15, Panel B) or 3' (Figure 15, Panel C) of the target. "No sequences" indicated that no sequences were found to be depleted at or above the given PDVT.

Example 4

[00534] It was tested whether purified Cas14a-tracrRNA-crRNA complexes were capable of RNA-guided nucleic acid cleavage *in vitro*. All currently reconstituted DNA-targeting class 2 interference complexes were able to recognize both dsDNA and ssDNA substrates. Purified Cas14a-tracrRNA-crRNA complexes were incubated with radiolabeled target oligonucleotides (ssDNA, dsDNA, and ssRNA) bearing 20-nucleotide sequence complementary to the crRNA guide sequence, or a non-complementary ssDNA, and these substrates were analyzed for Cas14a-mediated cleavage. Only in the presence of a complementary ssDNA substrate was any cleavage product detected (Figure 16, Panel A and Figure 17, Panels A-C), and cleavage was dependent on the presence of both tracrRNA and crRNA, which could also be combined into a single-guide RNA (sgRNA) (Figure 16, Panel B and Figure 18). The lack of detectable dsDNA cleavage suggested that Cas14a targeted ssDNA selectively, although it

was possible that some other factor or sequence requirement could enable dsDNA recognition in the native host. Mutation of the conserved active site residues in the Cas14a RuvC domain eliminated cleavage activity (Figure 17, Panel A), implicating RuvC as the domain responsible for DNA cutting. Moreover, Cas14a DNA cleavage was sensitive to truncation of the RNA components to lengths shorter than the naturally produced sequences (Figure 16, Panel B and Figure 19, Panels A-D). These results established Cas14a as the smallest class 2 CRISPR effector demonstrated to conduct programmable RNA-guided DNA cleavage.

[00535] It was tested whether Cas14a required a PAM for ssDNA cleavage *in vitro* by tiling Cas14a guides across a ssDNA substrate (Figure 16, Panel C). Despite sequence variation adjacent to the targets of these different guides, cleavage was observed for all four sequences. The cleavage sites occurred beyond the guide-complementary region of the ssDNA and shifted in response to guide binding position (Figure 16, Panel C). These data demonstrated Cas14a was an ssDNA-targeting CRISPR endonuclease that did not require a PAM for activation.

[00536] Based on the observation that Cas14a cut outside of the crRNA/DNA targeting heteroduplex, it was proposed that Cas14a may possess target-activated non-specific ssDNA cleavage activity, similar to the RuvC-containing enzyme Cas12a. To test this possibility, Cas14a-tracrRNA-crRNA was incubated with a complementary activator DNA and an aliquot of M13 bacteriophage ssDNA bearing no sequence complementarity to the Cas14a crRNA or activator (Figure 16, Panel D). The M13 ssDNA was rapidly degraded to small fragments, an activity that was eliminated by mutation of the conserved Cas14a RuvC active site, suggesting that activation of Cas14a resulted in non-specific ssDNA degradation.

[00537] To investigate the specificity of target-dependent non-specific DNA cutting activity by Cas14a, a fluorophore-quencher (FQ) assay was adapted in which cleavage of dye-labeled ssDNA generates a fluorescent signal (Figure 20, Panel A). When Cas14a was incubated with various guide RNA-target ssDNA pairs, a fluorescent signal was observed only in the presence of the cognate target and showed strong preference for longer FQ-containing substrates (Figure 19, Panel F and Figure 20, Panel A). Cas14a mismatch tolerance was tested by tiling 2-nt mismatches across the targeted region in various ssDNA substrates. Mismatches near the middle of the ssDNA target strongly inhibited Cas14a activity, revealing an internal seed sequence that was distinct from the PAM-proximal seed region observed for dsDNA-targeting CRISPR-Cas systems (Figure 20, Panel B and Figure 21, Panels A-D). Moreover, DNA substrates containing strong secondary structure resulted in reduced activation of Cas14a (Figure 21, Panel E). Truncation of ssDNA substrates also resulted in reduced or undetectable *trans* cleavage (Figure 21, Panel F). These results suggested a mechanism of fidelity distinct from dsDNA-targeting class 2 CRISPR systems, possibly utilizing a preordered region of the crRNA to gate cleavage activity similarly to the RNA-targeting Cas13a enzymes.

[00538] Further investigation of compact Type V systems in metagenomic data revealed a large diversity of systems that, like Cas14a–c, include a gene encoding a short RuvC-containing protein adjacent to acquisition-associated *cas* genes and a CRISPR array. Twenty (20) additional such systems were found that cluster into five main families (Cas14d–h). These families seemed to have evolved from independent domestication events of TnpB, the transposase-associated protein implicated as the evolutionary parent of type V CRISPR effectors. Excluding *cas*14g, which was related to *cas*12b, the *cas14*-like genes formed separate clades on the type V effector phylogeny (Figure 22, Panels A-B), and their *cas1* genes had different origins (Figure 10, Panel A). Altogether 38 CRISPR-Cas14 systems belonging to eight families (Cas14a–h) were identified and eight additional systems that could not be clustered with the analysis (termed Cas14u, Table 3).

[00539] The small size of the Cas14 proteins described herein and their resemblance to type V effector proteins suggested that RNA-guided ssDNA cleavage may have existed as an ancestral class 2 CRISPR system. In this scenario, a small, domesticated TnpB-like ssDNA interference complex may have gained additional domains over time, gradually improving dsDNA recognition and cleavage. Smaller Cas9 orthologs exhibited weaker dsDNA-targeting activity than their larger counterparts but retained the ability to robustly cleave ssDNA. Aside from the evolutionary implications, the ability of Cas14 to specifically target ssDNA suggested a role in defense against ssDNA viruses or mobile genetic elements (MGEs) that propagated through ssDNA intermediates. Without intending to be bound by any particular theory, an ssDNA-targeting CRISPR system may be particularly advantageous in certain marine environments where ssDNA viruses comprised the vast majority of viral abundance.

[00540] **Figure 16**, Panels A-D depict CRISPR-Cas14a as an RNA-guided DNA-endonuclease. Figure 16, Panel A depicts cleavage kinetics of Cas14a1 targeting ssDNA, dsDNA, ssRNA and off-target ssDNA. Figure 16, Panel B depicts a diagram of Cas14a RNP bound to target ssDNA and Cas14a1 cleavage kinetics of radiolabeled ssDNA in the presence of various RNA components. Figure 16, Panel C depicts tiling of a ssDNA substrate by Cas14a1 guide sequences. Figure 16, Panel D depicts cleavage of the ssDNA viral M13 genome with activated Cas14a1.

[00541] **Figure 17**, Panels A-E depict degradation of ssDNA by Cas14a1. Figure 17, Panel A depicts SDS-PAGE of purified Cas14a1 and Cas14a1 point mutants. Figure 17, Panel B depicts optimization of salt, cation and temperature for Cas14a1 cleavage of ssDNA targets. Figure 17, Panel C depicts radiolabled cleavage of ssDNA by Cas14a1 with spacer sequences of various lengths. Figure 17, Panel D depicts alignment of Cas14 with previously studied Cas12 proteins to identify RuvC active site residues and Figure 17, Panel E depicts cleavage of ssDNA by purified Cas14a1 RuvC point mutants.

[00542] **Figure 18** depicts the kinetics of Cas14a1 cleavage of ssDNA with various guide RNA components.

[00543] **Figure 19**, Panels A-F depict optimization of Cas14a1 guide RNA components. Figure 19, Panel A depicts a diagram of Cas14a1 targeting ssDNA. Impact on Cas14a1 cleavage of an FQ ssDNA substrate by varying the spacer length (Figure 19, Panel B), repeat length (Figure 19, Panel C), tracrRNA (Figure 19, Panel D), and fusing the crRNA and tracrRNA together (Figure 19, Panel E). Figure 19, Panel F depicts a heat map showing the background subtracted fluorescence resulting from cleavage of an ssDNA FQ reporter in the presence of various guide and target combinations.

[00544] **Figure 20**, Panels A-E depict high fidelity ssDNA SNP detection by CRISPR-Cas14a. Figure 20, Panel A depicts a fluorescent-quencher (FQ) assay for detection of ssDNA by Cas14a1 and the cleavage kinetics for various length FQ substrates. Figure 20, Panel B depicts cleavage kinetics for Cas14a1 with mismatches tiled across the substrate (individual points represent replicate measurements). Figure 20, panel C depicts a diagram of Cas14-DETECTR strategy and HERC2 eye color SNP. Figure 20, panel D depicts titration of T7 exonuclease and impact on Cas14a-DETECTR. Figure 20, panel E, depicts SNP detection using Cas14a-DETECTR with a blue-eye targeting guide for a blue-eyed and brown-eyed saliva sample compared to ssDNA detection using Cas12a.

[00545] **Figure 21**, Panels A-F depict the impact of various activators on Cas14a1 cleavage rate Figure 21, Panel A depicts a diagram of Cas14a1 targeting of ssDNA with position of mismatches used in panels A-D and raw rates for representative replicates of mismatch (MM) position for Target 1. Cleavage rates for Cas14a targeting substrates with mutations tiled across three different substrates (Figure 21, Panels B-D). Figure 21, Panel E depicts trans cleavage rates for substrates with increasing amounts of secondary structure. Figure 21, Panel F depicts trans leavage rates with truncated substrates. Points represent individual measurements.

[00546] **Figure 22**, Panels A-B depict diversity of CRISPR-Cas14 systems. Figure 22, Panel A depicts representative locus architecture for indicated Cas14 systems. Protein lengths are drawn to scale. Figure 22, Panel B depicts a maximum likelihood tree for Type V effectors including all eight identified subtypes of Cas14.

[00547] **Figure 23,** Panels A-C depict a test of Cas14a1 mediated interference in a heterologous host. Diagram of Cas14a1 and LbCas12a constructs to test interference in *E. coli*. (B) Plaques of ΦX174 spotted on *E. coli* revealing Cas12a- but not Cas14a1-mediated interference. Each spot represents a 10-fold dilution of the ΦX174 stock. (C) Growth curves of *E. coli* expressing Cas14a1 or LbCas12a infected with ΦX174 (T, targeting; NT, non-targeting). Figure 19, Panel F shows a heat map showing the background-subtracted fluorescence resulting from cleavage of a ssDNA FQ reporter in the presence of various guide and target combinations after a 30-minute incubation.

[00548] While the present invention has been described with reference to the specific embodiments thereof, it should be understood by those skilled in the art that various changes may be made and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process step or steps, to the objective, spirit and scope of the present invention. All such modifications are intended to be within the scope of the claims appended hereto.

REFERENCES

1. R. Barrangou *et al.*, CRISPR provides acquired resistance against viruses in prokaryotes. *Science*. **315**, 1709–12 (2007).
2. S. A. Jackson *et al.*, CRISPR-Cas: Adapting to change. *Science*. **356** (6333), pp. 1–9 (2017).
3. S. Shmakov *et al.*, Diversity and evolution of class 2 CRISPR–Cas systems. *Nat. Rev. Microbiol.* **15**, 169–182 (2017).
4. J. S. Chen, J. A. Doudna, The chemistry of Cas9 and its CRISPR colleagues. *Nat. Rev. Chem.* **1**, 0078 (2017).
5. C. T. Brown *et al.*, Unusual biology across a group comprising more than 15% of domain Bacteria. *Nature*. **523**, 208–211 (2015).
6. K. Anantharaman *et al.*, Thousands of microbial genomes shed light on interconnected biogeochemical processes in an aquifer system. *Nat. Commun.* **7**, 13219 (2016).
7. V. M. Markowitz *et al.*, IMG/M 4 version of the integrated metagenome comparative analysis system. *Nucleic Acids Res.* **42**, 568–573 (2014).
8. V. M. Markowitz *et al.*, IMG: The integrated microbial genomes database and comparative analysis system. *Nucleic Acids Res.* **40**, 115–122 (2012).
9. A. J. Probst *et al.*, Genomic resolution of a cold subsurface aquifer community provides metabolic insights for novel microbes adapted to high CO2concentrations. *Environ. Microbiol.* **19**, 459–474 (2017).
10. I. Yosef, M. G. Goren, U. Qimron, Proteins and DNA elements essential for the CRISPR adaptation process in Escherichia coli. *Nucleic Acids Res.* **40**, 5569–5576 (2012).
11. J. K. Nuñez, A. S. Y. Lee, A. Engelman, J. a. Doudna, Integrase-mediated spacer acquisition during CRISPR–Cas adaptive immunity. *Nature*. **519**, 193–198 (2015).
12. S. Shmakov *et al.*, Discovery and Functional Characterization of Diverse Class 2 CRISPR-Cas Systems. *Mol. Cell*. **60**, 385–397 (2015).
13. D. Burstein *et al.*, New CRISPR-Cas systems from uncultivated microbes. *Nature*. **542**, 237–241 (2017).
14. C. Rinke *et al.*, Insights into the phylogeny and coding potential of microbial dark matter. *Nature*. **499**, 431–437 (2013).
15. C. J. Castelle *et al.*, Genomic expansion of domain archaea highlights roles for organisms from new phyla in anaerobic carbon cycling. *Curr. Biol.* **25**, 690–701 (2015).
16. E. Deltcheva *et al.*, CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III. *Nature*. **471**, 602–607 (2011).
17. K. E. Savell, J. J. Day, Applications of CRISPR/CAS9 in the mammalian central nervous system. *Yale J. Biol. Med.* **90** (2017), pp. 567–581.
18. F. J. M. Mojica, C. Díez-Villaseñor, J. García-Martínez, C. Almendros, Short motif sequences determine the targets of the prokaryotic CRISPR defence system. *Microbiology*. **155**, 733–740 (2009).
19. Y. Zhang, R. Rajan, H. S. Seifert, A. Mondragón, E. J. Sontheimer, DNase H Activity of Neisseria meningitidis Cas9. *Mol. Cell*. **60**, 242–255 (2015).
20. E. Ma, L. B. Harrington, M. R. O'Connell, K. Zhou, J. A. Doudna, Single-Stranded DNA

Cleavage by Divergent CRISPR-Cas9 Enzymes. *Mol. Cell.* **60**, 398–407 (2015).
21. J. S. Chen *et al.*, CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science*. **360**, 436–439 (2018).
22. B. Zetsche *et al.*, Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System. *Cell*. **163**, 759–771 (2015).
23. A. East-Seletsky *et al.*, Two distinct RNase activities of CRISPR-C2c2 enable guide-RNA processing and RNA detection. *Nature*. **538**, 270–273 (2016).
24. L. Liu *et al.*, The Molecular Architecture for RNA-Guided RNA Cleavage by Cas13a. *Cell*. **170**, 714–726.e10 (2017).
25. O. O. Abudayyeh *et al.*, C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector. *Science (80-.).* **353**, 1–9 (2016).
26. G. J. Knott *et al.*, Guide-bound structures of an RNA-targeting A-cleaving CRISPR-Cas13a enzyme. *Nat. Struct. Mol. Biol.* **24**, 825–833 (2017).
27. S. Y. Li *et al.*, CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA. *Cell Res.* **28**, 491–493 (2018).
28. H. Eiberg *et al.*, Blue eye color in humans may be caused by a perfectly associated founder mutation in a regulatory element located within the HERC2 gene inhibiting OCA2 expression. *Hum. Genet.* **123**, 177–187 (2008).
29. S. Shmakov *et al.*, Diversity and evolution of class 2 CRISPR–Cas systems. *Nat. Rev. Microbiol.* **15**, 169–182 (2017).
30. E. V Koonin, K. S. Makarova, F. Zhang, Diversity, classification and evolution of CRISPR-Cas systems. *Curr. Opin. Microbiol.* **37**, 67–78 (2017).
31. K. S. Makarova *et al.*, An updated evolutionary classification of CRISPR-Cas systems. *Nat Rev Microbiol*, 1–15 (2015).
32. O. Barabas *et al.*, Mechanism of IS 200 / IS 605 Family DNA Transposases : Activation and Transposon- Directed Target Site Selection, 208–220 (2008).
33. M. Yoshida *et al.*, Quantitative viral community DNA analysis reveals the dominance of single-stranded DNA viruses in offshore upper bathyal sediment from Tohoku, Japan. *Front. Microbiol.* **9**, 1–10 (2018).
34. C. T. Brown *et al.*, Unusual biology across a group comprising more than 15% of domain Bacteria. *Nature*. **523**, 208–211 (2015).
35. K. Anantharaman *et al.*, Thousands of microbial genomes shed light on interconnected biogeochemical processes in an aquifer system. *Nat. Commun.* **7**, 13219 (2016).
36. A. J. Probst *et al.*, Genomic resolution of a cold subsurface aquifer community provides metabolic insights for novel microbes adapted to high CO2concentrations. *Environ. Microbiol.* **19**, 459–474 (2017).
37. V. M. Markowitz *et al.*, IMG/M 4 version of the integrated metagenome comparative analysis system. *Nucleic Acids Res.* **42**, 568–573 (2014).
38. V. M. Markowitz *et al.*, IMG: The integrated microbial genomes database and comparative analysis system. *Nucleic Acids Res.* **40**, 115–122 (2012).
39. R. D. Finn, J. Clements, S. R. Eddy, HMMER web server: interactive sequence similarity searching. *Nucleic Acids Res.* **39**, W29–W37 (2011).
40. D. Burstein *et al.*, New CRISPR-Cas systems from uncultivated microbes. *Nature*. **542**, 237–241 (2017).
41. I. Grissa, G. Vergnaud, C. Pourcel, CRISPRFinder: a web tool to identify clustered regularly interspaced short palindromic repeats. *Nucleic Acids Res.* **35**, W52–W57 (2007).
42. A. Biswas, R. H. J. Staals, S. E. Morales, P. C. Fineran, C. M. Brown, CRISPRDetect: A flexible algorithm to define CRISPR arrays. *BMC Genomics*. **17**, 1–14 (2016).
43. A. Stamatakis, RAxML version 8: A tool for phylogenetic analysis and post-analysis of large phylogenies. *Bioinformatics*. **30**, 1312–1313 (2014).
44. B. Langmead, S. L. Salzberg, Fast gapped-read alignment with Bowtie 2. *Nat Methods*. **9**, 357–359 (2012).

45. H. Ogata *et al.*, KEGG: Kyoto encyclopedia of genes and genomes. *Nucleic Acids Res.* **27**, 29–34 (1999).
46. L. B. Harrington *et al.*, A thermostable Cas9 with increased lifetime in human plasma. *Nat. Commun.* **8**, 1–7 (2017).
47. G. Crooks, G. Hon, J. Chandonia, S. Brenner, NCBI GenBank FTP Site\nWebLogo: a sequence logo generator. *Genome Res.* **14**, 1188–1190 (2004).
48. L. B. Harrington *et al.*, A Broad-Spectrum Inhibitor of CRISPR-Cas9. *Cell.* **170**, 1224–1233.e15 (2017).
49. J. S. Chen *et al.*, CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity. *Science.* **360**, 436–439 (2018).
50. Brown *et al.*, Unusual biology across a group comprising more than 15% of domain Bacteria. *Nature.* **523**, 208–211 (2015), doi:10.1038/nature14486.

2018358051 13 Dec 2024

CLAIMS

1. A method of modifying a target nucleic acid, the method comprising contacting the target nucleic acid with:

(a) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, wherein the guide RNA comprises (i) a guide sequence that hybridizes to a target sequence of the target nucleic acid, and (ii) a region that is bound by the polypeptide.

2. The method of claim 1, wherein the method results in modification of the target nucleic acid, modulation of transcription from the target nucleic acid, or modification of a polypeptide associated with a target nucleic acid.

3. The method of claim 2, wherein the target nucleic acid is modified by being cleaved.

4. The method of any one of claims 1-3, wherein the target nucleic acid is selected from: double stranded DNA, single stranded DNA, RNA, genomic DNA, and extrachromosomal DNA.

5. The method of any one of claims 1-4, wherein the guide sequence and the region bound by the polypeptide are heterologous to one another.

6. The method of any one of claims 1-5, wherein said polypeptide has no nuclease activity.

7. The method of any one of claims 1-6, wherein said contacting takes place in a eukaryotic cell and said contacting comprises introducing into the cell the polypeptide or a nucleic acid encoding the polypeptide and the guide RNA or a nucleic acid encoding the guide RNA.

8. The method of claim 7, wherein said contacting takes place in vitro.

9. The method of claim 7, wherein said contacting takes place in vivo.

10. The method of claim 7, wherein said contacting takes place ex vivo.

11. The method of any one of claims 7-10, wherein the eukaryotic cell is a human cell.

12. The method of any one of claims 7-11, wherein said contacting further comprises: introducing a DNA donor template into the eukaryotic cell.

13. A composition comprising an engineered and/or non-naturally occurring complex comprising:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, or a nucleic acid encoding said guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide.

14. The composition of claim 13, further comprising a transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said trancRNA.

15. A kit comprising an engineered and/or non-naturally occurring complex comprising:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27;

(b) a guide RNA, or a nucleic acid encoding said CasZ guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide.

16. The kit of claim 15, further comprising a transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said trancRNA.

17. A genetically modified eukaryotic cell, comprising at least one of:

(a) a polypeptide, or a nucleic acid encoding said polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(b) a guide RNA, or a nucleic acid encoding said guide RNA, wherein said guide RNA comprises (i) a guide sequence that is complementary to a target sequence of a target nucleic acid, and (ii) a region that is bound by the polypeptide; and optionally

(c) a transactivating noncoding RNA (trancRNA), or a nucleic acid encoding said trancRNA.

18. The composition, kit, or eukaryotic cell of any claims 13-17, characterized by at least one of:

(a) the nucleic acid encoding said polypeptide comprises a nucleotide sequence that:

(i) encodes the polypeptide and, (ii) is operably linked to a heterologous promoter;

(b) the nucleic acid encoding said guide RNA comprises a nucleotide sequence that:

(i) encodes the guide RNA and, (ii) is operably linked to a heterologous promoter; and

(c) the nucleic acid encoding said trancRNA comprises a nucleotide sequence that:

(i) encodes the trancRNA and, (ii) is operably linked to a heterologous promoter.

19. The composition, kit, or eukaryotic cell of any one of claims 13-17, for use in a method of therapeutic treatment of a patient.

20. The method, composition, kit, or eukaryotic cell of any one of the preceding claims, wherein at least one of: the nucleic acid encoding said polypeptide, the nucleic acid encoding said guide RNA, and the nucleic acid encoding said trancRNA, is a recombinant expression vector.

21. The method, composition, kit, or eukaryotic cell of any one of the preceding claims, wherein the guide RNA comprises one or more of: a modified nucleobase, a modified backbone or non-natural internucleoside linkage, a modified sugar moiety, a Locked Nucleic Acid, a Peptide Nucleic Acid, and a deoxyribonucleotide.

22. The method, composition, kit, or eukaryotic cell of any one of the preceding claims, wherein the polypeptide is a variant polypeptide with reduced nuclease activity compared to a corresponding wild type protein.

23. The method, composition, kit, or eukaryotic cell of any one of the preceding claims, wherein at least one the polypeptide is conjugated to a heterologous polypeptide.

2018358051 13 Dec 2024

24. The method, composition, kit, or eukaryotic cell of claim 23, wherein the heterologous polypeptide: (i) has DNA modifying activity, (ii) exhibits the ability to increase or decrease transcription, and/or (iii) has enzymatic activity that modifies a polypeptide associated with DNA.

25. The method, composition, kit, or eukaryotic cell of claim 24, wherein the heterologous polypeptide comprises a methyltransferase.

26. The method, composition, kit, or eukaryotic cell of any one of the preceding claims, wherein the guide sequence and the region that binds to the polypeptide are heterologous to one another.

27. A method of detecting a target DNA in a sample, the method comprising:

(a) contacting the sample with:

(i) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27;

(ii) a guide RNA comprising: a region that is bound by polypeptide, and a guide sequence that hybridizes with the target DNA; and

(iii) a detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA; and

(b) measuring a detectable signal produced by cleavage of the single stranded detector DNA by the , thereby detecting the target DNA.

28. The method according to claim 27, wherein the method comprises amplifying the nucleic acid in the sample and said amplifying begins prior to the contacting of step (a).

29. The method according to claim 27, wherein the method comprises amplifying the nucleic acid in the sample and said amplifying begins together with the contacting of step (a).

30. A kit for detecting a target DNA in a sample, the kit comprising:

(a) a guide RNA, or a nucleic acid encoding the guide RNA; wherein the guide RNA comprises: a region that is bound by a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 85% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27, and a guide sequence that is complementary to a target DNA; and

2018358051 13 Dec 2024

(b) a labeled detector DNA that is single stranded and does not hybridize with the guide sequence of the guide RNA.

31. A method of cleaving single stranded DNAs (ssDNAs), the method comprising:

contacting a population of nucleic acids, wherein said population comprises a target DNA and a plurality of non-target ssDNAs, with:

(i) a polypeptide, wherein the polypeptide comprises an amino acid sequence that is at least 90% identical to a sequence selected from SEQ ID NOS: 1, 2, 3, 9, 10, 11, 14, 17, 18, 25, and 27; and

(ii) a guide RNA comprising: a region that is bound by the polypeptide, and a guide sequence that hybridizes with the target DNA,

wherein the polypeptide cleaves non-target ssDNAs of said plurality.

FIG. 1

>CasZa.1|rifcsphigho2_02_scaffold_2167_39 \N id=61050970
partial=0 scaf=rifcsphigho2_02_scaffold_2167
bin=RIFCSPHIGHO2_02_FULL_Archaea_Woesearchaeota_57_22
sample=Archaea-RifleO2 proj=Rifle Groundwater Metagenome
mEVQKTVMKTLSLRILRPLYSQEIEKEIKEEKERRKQAGGTGELDGGFYKKLEKKHSEMFSFDR
LNLLLNQLQREIAKVYNHAISELYIATIAQGNKSNKHYISSIVYNRAYGYFYNAYIALGICSKV
EANFRSNELLTQQSALPTAKSDNFPIVLHKQKGAEGEDGGFRISTEGSDLIFEIPIPFYEYNGE
NRKEPYKWVKKGGQKPVLKLILSTFRRQRNKGWAKDEGTDAEIRKVTEGKYQVSQIEINRGKKL
GEHQKWFANFSIEQPIYERKPNRSIVGGLDVGIRSPLVCAINNSFSRYSVDSNDVFKFSKQVFA
FRRRLLSKNSLKRKGHGAAHKLEPITEMTEKNDKFRKKIIERWAKEVTNFFVKNQVGIVQIEDL
STMKDREDHFFNQYLRGFWPYYQMQTLIENKLKEYGIEVKRVQAKYTSQLCSNPNCRYWNNYFN
FEYRKVNKFPKFKCEKCNLEISADYNAARNLSTPDIEKFVAKATKGINLPEK
(SEQ ID NO: 1)

>CasZa.2|gwa2_scaffold_18027_12 Putative transposase DNA-binding
domain family id=2625699 partial=0 scaf=gwa2_scaffold_18027
bin=GWA2 Unbinned sample=GWA2 proj=Rifle Groundwater Metagenome
mEEAKTVSKTLSLRILRPLYSAEIEKEIKEEKERRKQGGKSGELDSGFYKKLEKKHTQMFGWDK
LNLMLSQLQRQIARVFNQSISELYIETVIQGKKSNKHYTSKIVYNRAYSVFYNAYLALGITSKV
EANFRSTELLMQKSSLPTAKSDNFPILLHKQKGVEGEEGGFKISADGNDLIFEIPIPFYEYDSA
NKKEPFKWIKKGGQKPTIKLILSTFRRQRNKGWAKDEGTDAEIRKVIEGKYQVSHIEINRGKKL
GDHQKWFVNFTIEQPIYERKLDKNIIGGIDVGIKSPLVCAVNNSFARYSVDSNDVLKFSKQAFA
FRRRLLSKNSLKRSGHGSKNKLDPITRMTEKNDRFRKKIIERWAKEVTNFFIKNQVGTVQIEDL
STMKDRQDNFFNQYLRGFWPYYQMQNLIENKLKEYGIETKRIKARYTSQLCSNPSCRHWNSYFS
FDHRKTNNFPKFKCEKCALEISADYNAARNISTPDIEKFVAKATKGINLPDKNENVILE
(SEQ ID NO: 2)

>CasZa.3|gwa1_scaffold_1795_31 Transposase, IS605 OrfB family
id=2784443 partial=0 scaf=gwa1_scaffold_1795
bin=GWA1_Archaeon_57_19 sample=GWA1 proj=Rifle Groundwater
Metagenome
mAKNTITKTLKLRIVRPYNSAEVEKIVADEKNNREKIALEKNKDKVKEACSKHLKVAAYCTTQV
ERNACLFCKARKLDDKFYQKLRGQFPDAVFWQEISEIFRQLQKQAAEIYNQSLIELYYEIFIKG
KGIANASSVEHYLSDVCYTRAAELFKNAAIASGLRSKIKSNFRLKELKNMKSGLPTTKSDNFPI
PLVKQKGGQYTGFEISNHNSDFIIKIPFGRWQVKKEIDKYRPWEKFDFEQVQKSPKPISLLLST
QRRKRNKGWSKDEGTEAEIKKVMNGDYQTSYIEVKRGSKIGEKSAWMLNLSIDVPKIDKGVDPS
IIGGIDVGVKSPLVCAINNAFSRYSISDNDLFHFNKKMFARRRILLKKNRHKRAGHGAKNKLKP
ITILTEKSERFRKKLIERWACEIADFFIKNKVGTVQmENLESMKRKEDSYFNIRLRGFWPYAEM
QNKIEFKLKQYGIEIRKVAPNNTSKTCSKCGHLNNYFNFEYRKKNKFPHFKCEKCNFKENADYN
AALNISNPKLKSTKEEP (SEQ ID NO: 3)

FIG. 1 (Cont.)

>CasZa.4|CG10_big_fil_rev_8_21_14_0.10_scaffold_20906_2 \N
id=132542232 partial=0
scaf=CG10_big_fil_rev_8_21_14_0.10_scaffold_20906
bin=CG10_big_fil_rev_8_21_14_0_10_UNK
sample=CG10_big_fil_rev_8_21_14_0_10 proj=Crystal Geyser
mERQKVPQIRKIVRVVPLRILRPKYSDVIENALKKFKEKGDDTNTNDFWRAIRDRDTEFFRKEL
NFSEDEINQLERDTLFRVGLDNRVLFSYFDFLQEKLMKDYNKIISKLFINRQSKSSFENDLTDE
EVEELIEKDVTPFYGAYIGKGIKSVIKSNLGGKFIKSVKIDRETKKVTKLTAINIGLMGLPVAK
SDTFPIKIIKTNPDYITFQKSTKENLQKIEDYETGIEYGDLLVQITIPWFKNENKDFSLIKTKE
AIEYYKLNGVGKKDLLNINLVLTTYHIRKKKSWQIDGSSQSLVREMANGELEEKWKSFFDTFIK
KYGDEGKSALVKRRVNKKSRAKGEKGRELNLDERIKRLYDSIKAKSFPSEINLIPENYKWKLHF
SIEIPPMVNDIDSNLYGGIDFGEQNIATLCVKNIEKDDYDFLTIYGNDLLKHAQASYARRRIMR
VQDEYKARGHGKSRKTKAQEDYSERMQKLRQKITERLVKQISDFFLWRNKFHMAVCSLRYEDLN
TLYKGESVKAKRMRQFINKQQLFNGIERKLKDYNSEIYVNSRYPHYTSRLCSKCGKLNLYFDFL
KFRTKNIIIRKNPDGSEIKYMPFFICEFCGWKQAGDKNASANIADKDYQDKLNKEKEFCNIRKP
KSKKEDIGEENEEERDYSRRFNRNSFIYNSLKKDNKLNQEKLFDEWKNQLKRKIDGRNKFEPKE
YKDRFSYLFAYYQEIIKNESES (SEQ ID NO: 4)

>CasZa.5|rifcsplowo2_01_scaffold_34461_9 \N id=58382281
partial=0 scaf=rifcsplowo2_01_scaffold_34461
bin=RifCSPlowO2_01_full_UNK sample=RIFCSPLOWO2_01_FULL
proj=RifleCSP2_LowO2
mVPTELITKTLQLRVIRPLYFEEIEKELAELKEQKEKEFEETNSLLLESKKIDAKSLKKLKRKA
RSSAAVEFWKIAKEKYPDILTKPEMEFIFSEMQKMMARFYNKSMTNIFIEMNNDEKVNPLSLIS
KASTEANQVIKCSSISSGLNRKIAGSINKTKFKQVRDGLISLPTARTETFPISFYKSTANKDEI
PISKINLPSEEEADLTITLPFPFFEIKKEKKGQKAYSYFNIIEKSGRSNNKIDLLLSTHRRQRR
KGWKEEGGTSAEIRRLMEGEFDKEWEIYLGEAEKSEKAKNDLIKNMTRGKLSKDIKEQLEDIQV
KYFSDNNVESWNDLSKEQKQELSKLRKKKVEELKDWKHVKEILKTRAKIGWVELKRGKRQRDRN
KWFVNITITRPPFINKELDDTKFGGIDLGVKVPFVCAVHGSPARLIIKENEILQFNKMVSARNR
QITKDSEQRKGRGKKNKFIKKEIFNERNELFRKKIIERWANQIVKFFEDQKCATVQIENLESFD
RTSYK (SEQ ID NO: 5)

>CasZa.6|037|3300012359.a:Ga0137385_10000156_01776
Zr6.cluA_1a.mostc10like protein
MKSDTKDKKIIIHQTKTLSLRIVKPQSIPMEEFTDLVRYHQMIIFPVYNNGAIDLYKKLFKAKI
QKGNEARAIKYFMNKIVYAPIANTVKNSYIALGYSTKMQSSFSGKRLWDLRFGEATPPTIKADF
PLPFYNQSGFKVSSENGEFIIGIPFGQYTKKTVSDIEKKTSFAWDKFTLEDTTKKTLIELLLST
KTRKMNEGWKNNEGTEAEIKRVMDGTYQVTSLEILQRDDSWFVNFNIAYDSLKKQPDRDKIAGI
HMGITRPLTAVIYNNKYRALSIYPNTVMHLTQKQLARIKEQRTNSKYATGGHGRNAKVTGTDTL
SEAYRQRRKKIIEDWIASIVKFAINNEIGTIYLEDISNTNSFFAAREQKLIYLEDISNTNSFLS
TYKYPISAISDTLQHKLEEKAIQVIRKKAYYVNQICSLCGHYNKGFTYQFRRKNKFPKMKCQGC
LEATSTEFNAAANVANPDYEKLLIKHGLLQLKK (SEQ ID NO: 6)

FIG. 1 (Cont.)

>CasZa.7|127|3300009029.a:Ga0066793_10010091_01298
Zr6.cluA_1.c10.inclusive
MSTITRQVRLSPTPEQSRLLMAHCQQYISTVNVLVAAFDSEVLTGKVSTKDFRAALPSAVKNQA
LRDAQSVFKRSVELGCLPVLKKPHCQWNNQNWRVEGDQLILPICKDGKTQQERFRCAAVALEGK
AGILRIKKKRGKWIADLTVTQEDAPESSGSAIMGVDLGIKVPAVAHIGGKGTRFFGNGRSQRSM
RRRFYARRKTLQKAKKLRAVRKSKGKEARWMKTINHQLSRQIVNHAHALGVGTIKIEALQGIRK
GTTRKSRGAAARKNNRMTNTWSFSQLTLFITYKAQRQGITVEQVDPAYTSQDCPACRARNGAQD
RTYVCSECGWRGHRDTVGAINISRRAGLSGHRRGATGA (SEQ ID NO: 7)

>CasZb.1|bjp_ig2599_sub10_scaffold_488_2 transposase id=60827220
partial=0 scaf=bjp_ig2599_sub10_scaffold_488
bin=BJP_IG2599_SUB10_Micrarchaeota_NOVEL_41_24
sample=BJP_IG2599_SUB10 proj=Borehole JP
mIAQKTIKIKLNPTKEQIIKLNSIIEEYIKVSNFTAKKIAEIQESFTDSGLTQGTCSECGKEKT
YRKYHLLKKDNKLFCITCYKRKYSQFTLQKVEFQNKTGLRNVAKLPKTYYTNAIRFASDTFSGF
DEIIKKKQNRLNSIQNRLNFWKELLYNPSNRNEIKIKVVKYAPKTDTREHPHYYSEAEIKGRIK
RLEKQLKKFKMPKYPEFTSETISLQRELYSWKNPDELKISSITDKNESmNYYGKEYLKRYIDLI
NSQTPQILLEKENNSFYLCFPITKNIEMPKIDDTFEPVGIDWGITRNIAVVSILDSKTKKPKFV
KFYSAGYILGKRKHYKSLRKHFGQKKRQDKINKLGTKEDRFIDSNIHKLAFLIVKEIRNHSNKP
IILMENITDNREEAEKSMRQNILLHSVKSRLQNYIAYKALWNNIPTNLVKPEHTSQICNRCGHQ
DRENRPKGSKLFKCVKCNYMSNADFNASINIARKFYIGEYEPFYKDNEKMKSGVNSISM (SEQ
ID NO: 8)

>CasZb.2|rifcsplowo2_01_scaffold_239_52 IS605 OrfB family
transposase id=57672634 partial=0
scaf=rifcsplowo2_01_scaffold_239 bin=RifCSPlowO2_01_full_UNK
sample=RIFCSPLOWO2_01_FULL proj=RifleCSP2_LowO2
LKLSEQENITTGVKFKLKLDKETSEGLNDYFDEYGKAINFAIKVIQKELAEDRFAGKVRLDENK
KPLLNEDGKKIWDFPNEFCSCGKQVNRYVNGKSLCQECYKNKFTEYGIRKRMYSAKGRKAEQDI
NIKNSTNKISKTHFNYAIREAFILDKSIKKQRKERFRRLREMKKKLQEFIEIRDGNKILCPKIE
KQRVERYIHPSWINKEKKLEDFRGYSMSNVLGKIKILDRNIKREEKSLKEKGQINFKARRLMLD
KSVKFLNDNKISFTISKNLPKEYELDLPEKEKRLNWLKEKIKIIKNQKPKYAYLLRKDDNFYLQ
YTLETEFNLKEDYSGIVGIDRGVSHIAVYTFVHNNGKNERPLFLNSSEILRLKNLQKERDRFLR
RKHNKKRKKSNMRNIEKKIQLILHNYSKQIVDFAKNKNAFIVFEKLEKPKKNRSKMSKKSQYKL
SQFTFKKLSDLVDYKAKREGIKVLYISPEYTSKECSHCGEKVNTQRPFNGNSSLFKCNKCGVEL
NADYNASINIAKKGLNILNSTN
(SEQ ID NO: 9)

FIG. 1 (Cont.)

>CasZb.3|rifcsplowo2_01_scaffold_282_93 IS605 OrfB family transposase id=57678680 partial=0
scaf=rifcsplowo2_01_scaffold_282 bin=RifCSPlowO2_01_full_UNK
sample=RIFCSPLOWO2_01_FULL proj=RifleCSP2_LowO2
mEESIITGVKFKLRIDKETTKKLNEYFDEYGKAINFAVKIIQKELADDRFAGKAKLDQNKNPIL
DENGKKIYEFPDEFCSCGKQVNKYVNNKPFCQECYKIRFTENGIRKRMYSAKGRKAEHKINILN
STNKISKTHFNYAIREAFILDKSIKKQRKKRNERLRESKKRLQQFIDMRDGKREICPTIKGQKV
DRFIHPSWITKDKKLEDFRGYTLSIINSKIKILDRNIKREEKSLKEKGQIIFKAKRLMLDKSIR
FVGDRKVLFTISKTLPKEYELDLPSKEKRLNWLKEKIEIIKNQKPKYAYLLRKNIESEKKPNYE
YYLQYTLEIKPELKDFYDGAIGIDRGINHIAVCTFISNDGKVTPPKFFSSGEILRLKNLQKERD
RFLLRKHNKNRKKGNMRVIENKINLILHRYSKQIVDmAKKLNASIVFEELGRIGKSRTKMKKSQ
RYKLSLFIFKKLSDLVDYKSRREGIRVTYVPPEYTSKECSHCGEKVNTQRPFNGNYSLFKCNKC
GIQLNSDYNASINIAKKGLKIPNST
(SEQ ID NO: 10)

>CasZb.4|rifcsphigho2_01_scaffold_36781_5 transposase, IS605 OrfB family id=55842010 partial=0
scaf=rifcsphigho2_01_scaffold_36781 bin=RifCSPhighO2_01_full_UNK
sample=RIFCSPHIGHO2_01_FULL proj=RifleCSP2_HighO2
LWTIVIGDFIEMPKQDLVTTGIKFKLDVDKETRKKLDDYFDEYGKAINFAVKIIQKNLKEDRFA
GKIALGEDKKPLLDKDGKKIYNYPNESCSCGNQVRRYVNAKPFCVDCYKLKFTENGIRKRMYSA
RGRKADSDINIKNSTNKISKTHFNYAIREGFILDKSLKKQRSKRIKKLLELKRKLQEFIDIRQG
QMVLCPKIKNQRVDKFIHPSWLKRDKKLEEFRGYSLSVVEGKIKIFNRNILREEDSLRQRGHVN
FKANRIMLDKSVRFLDGGKVNFNLNKGLPKEYLLDLPKKENKLSWLNEKISLIKLQKPKYAYLL
RREGSFFIQYTIENVPKTFSDYLGAIGIDRGISHIAVCTFVSKNGVNKAPVFFSSGEILKLKSL
QKQRDLFLRGKHNKIRKKSNMRNIDNKINLILHKYSRNIVNLAKSEKAFIVFEKLEKIKKSRFK
MSKSLQYKLSQFTFKKLSDLVEYKAKIEGIKVDYVPPEYTSKECSHCGEKVDTQRPFNGNSSLF
KCNKCRVQLNADYNASINIAKKSLNISNN (SEQ ID NO: 11)

>CasZb.5|cg1_0.2_scaffold_785_c_37 transposase, IS605 OrfB family id=91826491 partial=0 scaf=cg1_0.2_scaffold_785_c
bin=CG1_02_FULL_Micrarchaeota_47_40_curated sample=CG1_02_FULL
proj=Crystal Geyser
mSKTTISVKLKIIDLSSEKKEFLDNYFNEYAKATTFCQLRIRRLLRNTHWLGKKEKSSKKWIFE
SGICDLCGENKELVNEDRNSGEPAKICKRCYNGRYGNQMIRKLFVSTKKREVQENMDIRRVAKL
NNTHYHRIPEEAFDMIKAADTAEKRRKKNVEYDKKRQMEFIEMFNDEKKRAARPKKPNERETRY
VHISKLESPSKGYTLNGIKRKIDGMGKKIERAEKGLSRKKIFGYQGNRIKLDSNWVRFDLAESE
ITIPSLFKEMKLRITGPTNVHSKSGQIYFAEWFERINKQPNNYCYLIRKTSSNGKYEYYLQYTY
EAEVEANKEYAGCLGVDIGCSKLAAAVYYDSKNKKAQKPIEIFTNPIKKIKMRRREKLIKLLSRV
KVRHRRRKLMQLSKTEPIIDYTCHKTARKIVEMANTAKAFISMENLETGIKQKQQARETKKQKF
YRNMFLFRKLSKLIEYKALLKGIKIVYVKPDYTSQTCSSCGADKEKTERPSQAIFRCLNPTCRY
YQRDINADFNAAVNIAKKALNNTEVVTTLL (SEQ ID NO: 12)

FIG. 1 (Cont.)

>CasZb.6|rifcsphigho2_02_scaffold_55589_5 transposase, IS605 OrfB family id=61682131 partial=0
scaf=rifcsphigho2_02_scaffold_55589 bin=RifCSPhighO2_02_full_UNK
sample=RIFCSPHIGHO2_02_FULL proj=RifleCSP2_HighO2
mARAKNQPYQKLTTTTGIKFKLDLSEEEGKRFDEYFSEYAKAVNFCAKVIYQLRKNLKFAGKKE
LAAKEWKFEISNCDFCNKQKEIYYKNIANGQKVCKGCHRTNFSDNAIRKKMIPVKGRKVESKFN
IHNTTKKISGTHRHWAFEDAADIIESMDKQRKEKQKRLRREKRKLSYFFELFGDPAKRYELPKV
GKQRVPRYLHKIIDKDSLTKKRGYSLSYIKNKIKISERNIERDEKSLRKASPIAFGARKIKMSK
LDPKRAFDLENNVFKIPGKVIKGQYKFFGTNVANEHGKKFYKDRISKILAGKPKYFYLLRKKVA
ESDGNPIFEYYVQWSIDTETPAITSYDNILGIDAGITNLATTVLIPKNLSAEHCSHCGNNHVKP
IFTKFFSGKELKAIKIKSRKQKYFLRGKHNKLVKIKRIRPIEQKVDGYCHVVSKQIVEMAKERN
SCIALEKLEKPKKSKFRQRRREKYAVSMFVFKKLATFIKYKAAREGIEIIPVEPEGTSYTCSHC
KNAQNNQRPYFKPNSKKSWTSMFKCGKCGIELNSDYNAAFNIAQKALNMTSA
(SEQ ID NO: 13)

>CasZb.7|CG03_land_8_20_14_0.80_scaffold_2214_9 transposase, IS605 OrfB family id=135165146 partial=0
scaf=CG03_land_8_20_14_0.80_scaffold_2214
bin=CG03_land_8_20_14_0_80_cor_UNK
sample=CG03_land_8_20_14_0_80_cor proj=Crystal Geyser
mDEKHFFCSYCNKELKISKNLINKISKGSIREDEAVSKAISIHNKKEHSLILGIKFKLFIENKL
DKKKLNEYFDNYSKAVTFAARIFDKIRSPYKFIGLKDKNTKKWTFPKAKCVFCLEEKEVAYANE
KDNSKICTECYLKEFGENGIRKKIYSTRGRKVEPKYNIFNSTKELSSTHYNYAIRDAFQLLDAL
KKQRQKKLKSIFNQKLRLKEFEDIFSDPQKRIELSLKPHQREKRYIHLSKSGQESINRGYTLRF
VRGKIKSLTRNIEREEKSLRKKTPIHFKGNRLMIFPAGIKFDFASNKVKISISKNLPNEFNFSG
TNVKNEHGKSFFKSRIELIKTQKPKYAYVLRKIKREYSKLRNYEIEKIRLENPNADLCDFYLQY
TIETESRNNEEINGIIGIDRGITNLACLVLLKKGDKKPSGVKFYKGNKILGMKIAYRKHLYLLK
GKRNKLRKQRQIRAIEPKINLILHQISKDIVKIAKEKNFAIALEQLEKPKKARFAQRKKEKYKL
ALFTFKNLSTLIEYKSKREGIPVIYVPPEKTSQMCSHCAINGDEHVDTQRPYKKPNAQKPSYSL
FKCNKCGIELNADYNAAFNIAQKGLKTLMLNHSH (SEQ ID NO: 14)

>CasZb.8|058|3300002172.a:JGI24730J26740_1002785_01697 Zr6.newTrpA
MLQTLLVKLDPSKEQYKMLYETMERFNEACNQIAETVFAIHSANKIEVQKTVYYPIREKFGLSA
QLTILAIRKVCEAYKRDKSIKPEFRLDGALVYDQRVLSWKGLDKVSLVTLQGRQIIPIKFGDYQ
KARMDRIRGQADLILVKGVFYLCVVVEVSEESPYDPKGVLGVDLGIKNLAVDSDGEVHSGEQTT
NTRERLDSLKARLQSKGTKSAKRHLKKLSGRMAKFSKDVNHCISKKLVAKAKGTLMSIALEDLQ
GIRDRVTVRKAQRRNLHTWNFGLLRMFVDYKAKIAGVPLVFVDPRNTSRTCPSCGHVAKANRPT
RDEFRCVSCGFAGAADHIAAMNIAFRAEVSQPIVTRFFVQSQAPSFRVG
(SEQ ID NO: 15)

FIG. 1 (Cont.)

>CasZb.9|114|3300013125.a:Ga0172369_10000737_00842
Zr6.cluA_2b.c10_like protein
MDEEPDSAEPNLAPISVKLKLVKLDGEKLAALNDYFNEYAKAVNFCELKMQKIRKNLVNIRGTY
LKEKKAWINQTGECCICKKIDELRCEDKNPDINGKICKKCYNGRYGNQMIRKLFVSTNKRAVPK
SLDIRKVARLHNTHYHRIPPEAADIIKAIETAERKRRNRILFDERRYNELKDALENEEKRVARP
KKPKEREVRYVPISKKDTPSKGYTMNALVRKVSGMAKKIERAKRNLNKRKKIEYLGRRILLDKN
WVRFDFDKSEISIPTMKEFFGEMRFEITGPSNVMSPNGREYFTKWFDRIKAQPDNYCYLLRKES
EDETDFYLQYTWRPDAHPKKDYTGCLGIDIGGSKLASAVYFDADKNRAKQPIQIFSNPIGKWKT
KRQKVIKVLSKAAVRHKTKKLESLRNIEPRIDVHCHRIARKIVGMALAANAFISMENLEGGIRE
KQKAKETKKQKFSRNMFVFRKLSKLIEYKALMEGVKVVYIVPDYTSQLCSSCGTNNTKRPKQAI

FMCQNTECRYFGKNINADFNAAINIAKKALNRKDIVRELS (SEQ ID NO: 16)

>CasZb.10|115|3300013125.a:Ga0172369_10010464_01540
Zr6.cluA_2b.c10_like protein
MEKNNSEQTSITTGIKFKLKLDKETKEKLNNYFDEYGKAINFAVRIIQMQLNDDRLAGKYKRDE
KGKPILGEDGKKILEIPNDFCSCGNQVNHYVNGVSFCQECYKKRFSENGIRKRMYSAKGRKAEQ
DINIKNSTNKISKTHFNYAIREAFNLDKSIKKQREKRFKKLKDMKRKLQEFLEIRDGKRVICPK
IEKQKVERYIHPSWINKEKKLEEFRGYSLSIVNSKIKSFDRNIQREEKSLKEKGQINFKAQRLM
LDKSVKFLKDNKVSFTISKELPKTFELDLPKKEKKLNWLNEKLEIIKNQKPKYAYLLRKENNIF
LQYTLDSIPEIHSEYSGAVGIDRGVSHIAVYTFLDKDGKNERPFFLSSSGILRLKNLQKERDKF
LRKKHNKIRKKGNMRNIEQKINLILHEYSKQIVNFAKDKNAFIVFELLEKPKKSRERMSKKIQY
KLSQFTFKKLSDLVDYKAKREGIKVIYVEPAYTSKDCSHCGERVNTQRPFNGNFSLFKCNKCGI

VLNSDYNASLNIARKGLNISAN (SEQ ID NO: 17)

>CasZb.11|134|3300013127.a:Ga0172365_10004421_00828
Zr6.cluA_2b.c10_like protein
MAEEKFFFCEKCNKDIKIPKNYINKQGAEEKARAKHEHRVHALILGIKFKIYPKKEDISKLNDY
FDEYAKAVTFTAKIVDKLKAPFLFAGKRDKDTSKKKWVFPVDKCSFCKEKTEINYRTKQGKNIC
NSCYLTEFGEQGLLEKIYATKGRKVSSSFNLFNSTKKLTGTHNNYVVKESLQLLDALKKQRSKR
LKKLSNTRRKLKQFEEMFEKEDKRFQLPLKEKQRELRFIHVSQKDRATEFKGYTMNKIKSKIKV
LRRNIEREQRSLNRKSPVFFRGTRIRLSPSVQFDDKDNKIKLTLSKELPKEYSFSGLNVANEHG
RKFFAEKLKLIKENKSKYAYLLRRQVNKNNKKPIYDYYLQYTVEFLPNIITNYNGILGIDRGIN
TLACIVLLENKKEKPSFVKFFSGKGILNLKNKRRKQLYFLKGVHNKYRKQQKIRPIEPRIDQIL
HDISKQIIDLAKEKRVAISLEQLEKPQKPKFRQSRKAKYKLSQFNFKTLSNYIDYKAKKEGIRV
IYIAPEMTSQNCSRCAMKNDLHVNTQRPYKNTSSLFKCNKCGVELNADYNAAFNIAQKGLKILN

S (SEQ ID NO: 18)

FIG. 1 (Cont.)

>CasZc.1|CG08_land_8_20_14_0.20_scaffold_1609_10 Tax=CG_Micra_03 id=133381002 partial=0 scaf=CG08_land_8_20_14_0.20_scaffold_1609 bin=CG08_land_8_20_14_0_20_UNK sample=CG08_land_8_20_14_0_20 proj=Crystal Geyser

mISLKLKLLPDEEQKKLLDEMFWKWASICTRVGFGRADKEDLKPPKDAEGVWFSLTQLNQANTD
INDLREAMKHQKHRLEYEKNRLEAQRDDTQDALKNPDRREISTKRKDLFRPKASVEKGFLKLKY
HQERYWVRRLKEINKLIERKTKTLIKIEKGRIKFKATRITLHQGSFKIRFGDKPAFLIKALSGK
NQIDAPFVVVPEQPICGSVVNSKKYLDEITTNFLAYSVNAMLFGLSRSEEMLLKAKRPEKIKKK
EEKLAKKQSAFENKKKELQKLLGRELTQQEEAIIEETRNQFFQDFEVKITKQYSELLSKIANEL
KQKNDFLKVNKYPILLRKPLKKAKSKKINNLSPSEWKYYLQFGVKPLLKQKSRRKSRNVLGIDR
GLKHLLAVTVLEPDKKTFVWNKLYPNPITGWKWRRRKLLRSLKRLKRRIKSQKHETIHENQTRK
KLKSLQGRIDDLLHNISRKIVETAKEYDAVIVVEDLQSMRQHGRSKGNRLKTLNYALSLFDYAN
VMQLIKYKAGIEGIQIYDVKPAGTSQNCAYCLLAQRDSHEYKRSQENSKIGVCLNPNCQNHKKQ

IDADLNAARVIASCYALKINDSQPFGTRKRFKKRTTN (SEQ ID NO: 19)

>CasZc.2|CG_4_10_14_0.8_um_filter_scaffold_20762_4 Tax=CG_Micra_03 id=144037526 partial=0 scaf=CG_4_10_14_0.8_um_filter_scaffold_20762 bin=CG_4_10_14_0_8_um_filter_cor_UNK sample=CG_4_10_14_0_8_um_filter_cor proj=Crystal Geyser

mETLSLKLKLNPSKEQLLVLDKMFWKWASICTRLGLKKAEMSDLEPPKDAEGVWFSKTQLNQAN
TDVNDLRKAMQHQGKRIEYELDKVENRRNEIQEMLEKPDRRDISPNRKDLFRPKAAVEKGYLKL
KYHKLGYWSKELKTANKLIERKRKTLAKIDAGKMKFKPTRISLHTNSFRIKFGEEPKIALSTTS
KHEKIELPLITSLQRPLKTSCAKKSKTYLDAAILNFLAYSTNAALFGLSRSEEMLLKAKKPEKI
EKRDRKLATKRESFDKKLKTLEKLLERKLSEKEKSVFKRKQTEFFDKFCITLDETYVEALHRIA
EELVSKNKYLEIKKYPVLLRKPESRLRSKKLKNLKPEDWTYYIQFGFQPLLDTPKPIKTKTVLG
IDRGVRHLLAVSIFDPRTKTFTFNRLYSNPIVDWKWRRRKLLRSIKRLKRRLKSEKHVHLHENQ
FKAKLRSLEGRIEDHFHNLSKEIVDLAKENNSVIVVENLGGMRQHGRGRGKWLKALNYALSHFD
YAKVMQLIKYKAELAGVFVYDVAPAGTSINCAYCLLNDKDASNYTRGKVINGKKNTKIGECKTC

KKEFDADLNAARVIALCYEKRLNDPQPFGTRKQFKPKKP (SEQ ID NO: 20)

FIG. 1 (Cont.)

>CasZc.3|CG22_combo_CG10-13_8_21_14_all_scaffold_2003_2 IS605 OrfB family transposase id=130740989 partial=0 scaf=CG22_combo_CG10-13_8_21_14_all_scaffold_2003 bin=CG22_combo_CG10-13_8_21_14_all_UNK sample=CG22_combo_CG10-13_8_21_14_all proj=Crystal Geyser
mKALKLQLIPTRKQYKILDEMFWKWASLANRVSQKGESKETLAPKKDIQKIQFNATQLNQIEKD
IKDLRGAMKEQQKQKERLLLQIQERRSTISEMLNDDNNKERDPHRPLNFRPKGWRKFHTSKHWV
GELSKILRQEDRVKKTIERIVAGKISFKPKRIGIWSSNYKINFFKRKISINPLNSKGFELTLMT
EPTQDLIGKNGGKSVLNNKRYLDDSIKSLLMFALHSRFFGLNNTDTYLLGGKINPSLVKYYKKN
QDMGEFGREIVEKFERKLKQEINEQQKKIIMSQIKEQYSNRDSAFNKDYLGLINEFSEVFNQRK
SERAEYLLDSFEDKIKQIKQEIGESLNISDWDFLIDEAKKAYGYEEGFTEYVYSKRYLEILNKI
VKAVLITDIYFDLRKYPILLRKPLDKIKKISNLKPDEWSYYIQFGYDSINPVQLMSTDKFLGID
RGLTHLLAYSVFDKEKKEFIINQLEPNPIMGWKWKLRKVKRSLQHLERRIRAQKMVKLPENQMK
KKLKSIEPKIEVHYHNISRKIVNLAKDYNASIVVESLEGGGLKQHGRKKNARNRSLNYALSLFD
YGKIASLIKYKADLEGVPMYEVLPAYTSQQCAKCVLEKGSFVDPEIIGYVEDIGIKGSLLDSLF
EGTELSSIQVLKKIKNKIELSARDNHNKEINLILKYNFKGLVIVRGQDKEEIAEHPIKEINGKF
AILDFVYKRGKEKVGKKGNQKVRYTGNKKVGYCSKHGQVDADLNASRVIALCKYLDINDPILFG
EQRKSFK (SEQ ID NO: 21)

>CasZc.4|rifcsphigho2_01_scaffold_82367_2 Tax=CG_Micra_03 id=56177664 partial=0 scaf=rifcsphigho2_01_scaffold_82367 bin=RifCSPhighO2_01_full_UNK sample=RIFCSPHIGHO2_01_FULL proj=RifleCSP2_HighO2
mVTRAIKLKLDPTKNQYKLLNEMFWKWASLANRFSQKGASKETLAPKDGTQKIQFNATQLNQIK
KDVDDLRGAMEKQGKQKERLLIQIQERLLTISEILRDDSKKEKDPHRPQNFRPFGWRRFHTSAY
WSSEASKLTRQVDRVRRTIERIKAGKINFKPKRIGLWSSTYKINFLKKKINISPLKSKSFELDL
ITEPQQKIIGKEGGKSVANSKKYLDDSIKSLLIFAIKSRLFGLNNKDKPLFENIITPNLVRYHK
KGQEQENFKKEVIKKFENKLKKEISQKQKEIIFSQIERQYENRDATFSEDYLRAISEFSEIFNQ
RKKERAKELLNSFNEKIRQLKKEVNGNISEEDLKILEVEAEKAYNYENGFIEWEYSEQFLGVLE
KIARAVLISDNYFDLKKYPILIRKPTNKSKKITNLKPEEWDYYIQFGYGLINSPMKIETKNFMG
IDRGLTHLLAYSIFDRDSEKFTINQLELNPIKGWKWKLRKVKRSLQHLERRMRAQKGVKLPENQ
MKKRLKSIEPKIESYYHNLSRKIVNLAKANNASIVVESLEGGGLKQHGRKKNSRHRALNYALSL
FDYGKIASLIKYKSDLEGVPMYEVLPAYTSQQCAKCVLKKGSFVEPEIIGYIEEIGFKENLLTL
LFEDTGLSSVQVLKKSKNKMTLSARDKEGKMVDLVLKYNFKGLVISQEKKKEEIVEFPIKEIDG
KFAVLDSAYKRGKERISKKGNQKLVYTGNKKVGYCSVHGQVDADLNASRVIALCKYLGINEPIV
FGEQRKSFK (SEQ ID NO: 22)

FIG. 1 (Cont.)

>CasZc.5|gwc1_scaffold_8732_6 Transposase, IS605 OrfB family id=3520800 partial=0 scaf=gwc1_scaffold_8732 bin=GWC1 Unbinned sample=GWC1 proj=Rifle Groundwater Metagenome
LDLITEPIQPHKSSSLRSKEFLEYQISDFLNFSLHSLFFGLASNEGPLVDFKIYDKIVIPKPEE
RFPKKESEEGKKLDSFDKRVEEYYSDKLEKKIERKLNTEEKNVIDREKTRIWGEVNKLEEIRSI
IDEINEIKKQKHISEKSKLLGEKWKKVNNIQETLLSQEYVSLISNLSDELTNKKKELLAKKYSK
FDDKIKKIKEDYGLEFDENTIKKEGEKAFLNPDKFSKYQFSSSYLKLIGEIARSLITYKGFLDL
NKYPIIFRKPINKVKKIHNLEPDEWKYYIQFGYEQINNPKLETENILGIDRGLTHILAYSVFEP
RSSKFILNKLEPNPIEGWKWKLRKLRRSIQNLERRWRAQDNVKLPENQMKKNLRSIEDKVENLY
HNLSRKIVDLAKEKNACIVFEKLEGQGMKQHGRKKSDRLRGLNYKLSLFDYGKIAKLIKYKAEI
EGIPIYRIDSAYTSQNCAKCVLESRRFAQPEEISCLDDFKEGDNLDKRILEGTGLVEAKIYKKL
LKEKKEDFEIEEDIAMFDTKKVIKENKEKTVILDYVYTRRKEIIGTNHKKNIKGIAKYTGNTKI
GYCMKHGQVDADLNASRTIALCKNFDINNPEIWK (SEQ ID NO: 23)

>CasZc.6|109|3300010293.a:Ga0116204_1008574_00822 Zr6.cluA_2a.c10_like protein
MSDESLVSSEDKLAIKIKIVPNAEQAKMLDEMFKKWSSICNRISRGKEDIETLRPDEGKELQFN
STQLNSATMDVSDLKKAMARQGERLEAEVSKLRGRYETIDASLRDPSRRHTNPQKPSSFYPSDW
DISGRLTPRFHTARHYSTELRKLKAKEDKMLKTINKIKNGKIVFKPKRITLWPSSVNMAFKGSR
LLLKPFANGFEMELPIVISPQKTADGKSQKASAEYMRNALLGLAGYSINQLLFGMNRSQKMLAN
AKKPEKVEKFLEQMKNKDANFDKKIKALEGKWLLDRKLKESEKSSIAVVRTKFFKSGKVELNED
YLKLLKHMANEILERDGFVNLNKYPILSRKPMKRYKQKNIDNLKPNMWKYYIQFGYEPIFERKA
SGKPKNIMGIDRGLTHLLAVAVFSPDQQKFLFNHLESNPIMHWKWKLRKIRRSIQHMERRIRAE
KNKHIHEAQLKKRLGSIEEKTEQHYHIVSSKIINWAIEYEAAIVLESLSHMKQRGGKKSVRTRA
LNYALSLFDYEKVARLITYKARIRGIPVYDVLPGMTSKTCATCLLNGSQGAYVRGLETTKAAGK
ATKRKNMKIGKCMVCNSSENSMIDADLNAARVIAICKYKNLNDPQPAGSRKVFKRF
(SEQ ID NO: 24)

>CasZc.7|126|3300005573.a:Ga0078972_1001015_00056 Zr6.cluA_2a.c10_like protein
MLALKLKIMPTEKQAEILDAMFWKWASICSRIAKMKKKVSVKENKKELSKKIPSNSDIWFSKTQ
LCQAEVDVGDHKKALKNFEKRQESLLDELKYKVKAINEVINDESKREIDPNNPSKFRIKDSTKK
GNLNSPKFFTLKKWQKILQENEKRIKKKESTIEKLKRGNIFFNPTKISLHEEEYSINFGSSKLL
LNCFYKYNKKSGINSDQLENKFNEFQNGLNIICSPLQPIRGSSKRSFEFIRNSIINFLMYSLYA
KLFGIPRSVKALMKSNKDENKLKLEEKLKKKKSSFNKTVKEFEKMIGRKLSDNESKILNDESKK
FFEIIKSNNKYIPSEEYLKLLKDISEEIYNSNIDFKPYKYSILIRKPLSKFKSKKLYNLKPTDY
KYYLQLSYEPFSKQLIATKTILGIDRGLKHLLAVSVFDPSQNKFVYNKLIKNPVFKWKKRYHDL
KRSIRNRERRIRALTGVHIHENQLIKKLKSMKNKINVLYHNVSKNIVDLAKKYESTIVLERLEN
LKQHGRSKGKRYKKLNYVLSNFDYKKIESLISYKAKKEGVPVSNINPKYTSKTCAKCLLEVNQL
SELKNEYNRDSKNSKIGICNIHGQIDADLNAARVIALCYSKNLNEPHFK
(SEQ ID NO: 25)

FIG. 1 (Cont.)

>CasZd.1|CG10_big_fil_rev_8_21_14_0.10_scaffold_4477_25 IS605 OrfB family transposase id=132383911 partial=0 scaf=CG10_big_fil_rev_8_21_14_0.10_scaffold_4477 bin=CG10_big_fil_rev_8_21_14_0_10_test2 sample=CG10_big_fil_rev_8_21_14_0_10 proj=Crystal Geyser
VINLFGYKFALYPNKTQEELLNKHLGECGWLYNKAIEQNEYYKADSNIEEAQKKFELLPDKNSD
EAKVLRGNISKDNYVYRTLVKKKKSEINVQIRKAVVLRPAETIRNLAKVKKKGLSVGRLKFIPI
REWDVLPFKQSDQIRLEENYLILEPYGRLKFKMHRPLLGKPKTFCIKRTATDRWTISFSTEYDD
SNMRKNDGGQVGIDVGLKTHLRLSNENPDEDPRYPNPKIWKRYDRRLTILQRRISKSKKLGKNR
TRLRLRLSRLWEKIRNSRADLIQNETYEILSENKLIAIEDLNVKGMQEKKDKKGRKGRTRAQEK
GLHRSISDAAFSEFRRVLEYKAKRFGSEVKPVSAIDSSKECHNCGNKKGMPLESRIYECPKCGL
KIDRDLNSAKVILARATGVRPGSNARADTKISATAGASVQTEGTVSEDFRQQMETSDQKPMQGE
GSKEPPMNPEHKSSGRGSKHVNIGCKNKVGLYNEDENSRSTEKQIMDENRSTTEDMVEIGALHS

PVLTT (SEQ ID NO: 26)

>CasZd.2|053|3300001245.a:JGI12048J13642_10201286_01511 Zr6.c9.inclusive
MIASIDYEAVSQALIVFEFKAKGKDSQYQAIDEAIRSYRFIRNSCLRYWMDNKKVGKYDLNKYC
KVLAKQYPFANKLNSQARQSAAECSWSAISRFYDNCKRKVSGKKGFPKFKKHARSVEYKTSGWK
LSENRKAITFTDKNGIGKLKLKGTYDLHFSQLEDMKRVRLVRRADGYYVQFCISVDVKVETEPT
GKAIGLDVGIKYFLADSSGNTIENPQFYRKAEKKLNRANRRKSKKYIRGVKPQSKNYHKARCRY
ARKHLRVSRQRKEYCKRVAYCVIHSNDVVAYEDLNVKGMVKNRHLAKSISDVAWSTFRHWLEYF
AIKYGKLTIPVAPHNTSQNCSNCDKKVPKSLSTRTHICHHCGYSEDRDVNAAKNILKKALSTVG

QTGSLKLGEIEPLLVLEQSCTRKFDL (SEQ ID NO: 27)

>CasZe.1|19ft_2_nophage_noknown_scaffold_0_545 \N id=8269792 partial=0 scaf=19ft_2_nophage_noknown_scaffold_0 bin=19ft_2_UNK sample=19FT_2_THINNED proj=Rifle Sediment CSP1
LAEENTLHLTLAMSLPLNDLPENRTRSELWRRQWLPQKKLSLLLGVNQSVRKAAADCLRWFEPY
QELLWWEPTDPDGKKLLDKEGRPIKRTAGHMRVLRKLEEIAPFRGYQLGSAVKNGLRHKVADLL
LSYAKRKLDPQFTDKTSYPSIGDQFPIVWTGAFVCYEQSITGQLYLYLPLFPRGSHQEDITNNY
DPDRGPALQVFGEKEIARLSRSTSGLLLPLQFDKWGEATFIRGENNPPTWKATHRRSDKKWLSE
VLLREKDFQPKRVELLVRNGRIFVNVACEIPTKPLLEVENFMGVSFGLEHLVTVVVINRDGNVV
HQRQEPARRYEKTYFARLERLRRRGGPFSQELETFHYRQVAQIVEEALRFKSVPAVEQVGNIPK
GRYNPRLNLRLSYWPFGKLADLTSYKAVKEGLPKPYSVYSATAKMLCSTCGAANKEGDQPISLK

GPTVYCGNCGTRHNTGFNTALNLARRAQELFVKGVVAR (SEQ ID NO: 28)

FIG. 1 (Cont.)

>CasZe.2|RIFCSPHIGHO2_01_FULL_CPR_46_36_rifcsphigho2_01_scaffold_646_49 Tax=RIFCSPHIGHO2_01_FULL_RIF_OD1_04_46_36_curated id=87353177 partial=0 scaf=RIFCSPHIGHO2_01_FULL_CPR_46_36_rifcsphigho2_01_scaffold_646 bin=RIFCSPHIGHO2_01_FULL_OD1_Andersenbacteria_46_36_curated sample=2500-curated-genomes-non-redundant proj=2500 Genomes
mSQSLLKWHDMAGRDKDASRSLQKSAVEGVLLHLTASHRVALEMLEKSVSQTVAVTMEAAQQRL
VIVLEDDPTKATSRKRVISADLQFTREEFGSLPNWAQKLASTCPEIATKYADKHINSIRIAWGV
AKESTNGDAVEQKLQWQIRLLDVTMFLQQLVLQLADKALLEQIPSSIRGGIGQEVAQQVTSHIQ
LLDSGTVLKAELPTISDRNSELARKQWEDAIQTVCTYALPFSRERARILDPGKYAAEDPRGDRL
INIDPMWARVLKGPTVKSLPLLFVSGSSIRIVKLTLPRKHAAGHKHTFTATYLVLPVSREWINS
LPGTVQEKVQWWKKPDVLATQELLVGKGALKKSANTLVIPISAGKKRFFNHILPALQRGFPLQW
QRIVGRSYRRPATHRKWFAQLTIGYTNPSSLPEMALGIHFGMKDILWWALADKQGNILKDGSIP
GNSILDFSLQEKGKIERQQKAGKNVAGKKYGKSLLNATYRVVNGVLEFSKGISAEHASQPIGLG
LETIRFVDKASGSSPVNARHSNWNYGQLSGIFANKAGPAGFSVTEITLKKAQRDLSDAEQARVL
AIEATKRFASRIKRLATKRKDDTLFV (SEQ ID NO: 29)

>CasZe.3|rifcsphigho2_01_scaffold_10981_6 Tax=RIFCSPHIGHO2_01_FULL_OD1_47_10b_curated id=55513311 partial=0 scaf=rifcsphigho2_01_scaffold_10981 bin=RIFCSPHIGHO2_01_FULL_OD1_47_10b sample=2500-genomes proj=2500 Genomes
VEPVEKERFYYRTYTFRLDGQPRTQNLTTQSGWGLLTKAVLDNTKHYWEIVHHARIANQPIVFE
NPVIDEQGNPKLNKLGQPRFWKRPISDIVNQLRALFENQNPYQLGSSLIQGTYWDVAENLASWY
ALNKEYLAGTATWGEPSFPEPHPLTEINQWMPLTFSSGKVVRLLKNASGRYFIGLPILGENNPC
YRMRTIEKLIPCDGKGRVTSGSLILFPLVGIYAQQHRRMTDICESIRTEKGKLAWAQVSIDYVR
EVDKRRRMRRTRKSQGWIQGPWQEVFILRLVLAHKAPKLYKPRCFAGISLGPKTLASCVILDQD
ERVVEKQQWSGSELLSLIHQGEERLRSLREQSKPTWNAAYRKQLKSLINTQVFTIVTFLRERGA
AVRLESIARVRKSTPAPPVNFLLSHWAYRQITERLKDLAIRNGMPLTHSNGSYGVRFTCSQCGA
TNQGIKDPTKYKVDIESETFLCSICSHREIAAVNTATNLAKQLLDE (SEQ ID NO: 30)

>CasZe.4b|rifcsplowo2_02_scaffold_57876_2 hypothetical protein Tax=GWA2_OD1_56_11 id=66016044 partial=0 scaf=rifcsplowo2_02_scaffold_57876 bin=RifCSPlowO2_02_full_UNK sample=RIFCSPLOWO2_02_FULL proj=RifleCSP2_LowO2
mNDTETSETLTSHRTVCAHLHVVGETGSLPRLVEAALAELITLNGRATQALLSLAKNGLVLRRD
KEENLIAAELTLPCRKNKYADVAAKAGEPILATRINNKGKLVTKKWYGEGNSYHIVRFTPETGM
FTVRVFDRYAFDEELLHLHSEVVFGSDLPKGIKAKTDSLPANFLQAVFTSFLELPFQGFPDIVV
KPAMKQAAEQLLSYVQLEAGENQQAEYPDTNERDPELRLVEWQKSLHELSVRTEPFEFVRARDI
DYYAETDRRGNRFVNITPEWTKFAESPFARRLPLKIPPEFCILLRRKTEGHAKIPNRIYLGLQI
FDGVTPDSTLGVLATAEDGKLFWWHDHLDEFSNLEGKPEPKLKNKPQLLMVSLEYDREQRFEES
VGGDRKICLVTLKETRNFRRGWNGRILGIHFQHNPVITWALMDHDAEVLEKGFIEGNAFLGKAL
DKQALNEYLQKGGKWVGDRSFGNKLKGITHTLASLIVRLAREKDAWIALEEISWVQKQSADSVA
NHEIVEQPHHSLTR (SEQ ID NO: 31)

FIG. 1 (Cont.)

>CasZe.4|RIFCSPLOWO2_01_FULL_OD1_45_34b_rifcsplowo2_01_scaffold_3495_33 hypothetical protein Tax=GWA2_OD1_56_11 id=88324948 partial=0
scaf=RIFCSPLOWO2_01_FULL_OD1_45_34b_rifcsplowo2_01_scaffold_3495
bin=RIFCSPLOWO2_01_FULL_OD1_Taylorbacteria_45_34b_curated
sample=2500-curated-genomes proj=2500 Genomes
mNDTETSETLTSHRTVCAHLHVVGETGSLPRLVEAALAELITLNGRATQALLSLAKNGLVLRRD
KEENLIAAELTLPCRKNKYADVAAKAGEPILATRINNKGKLVTKKWYGEGNSYHIVRFTPETGM
FTVRVFDRYAFDEELLHLHSEVVFGSDLPKGIKAKTDSLPANFLQAVFTSFLELPFQGFPDIVV
KPAMKQAAEQLLSYVQLEAGENQQAEYPDTNERDPELRLVEWQKSLHELSVRTEPFEFVRARDI
DYYAETDRRGNRFVNITPEWTKFAESPFARRLPLKIPPEFCILLRRKTEGHAKIPNRIYLGLQI
FDGVTPDSTLGVLATAEDGKLFWWHDHLDEFSNLEGKPEPKLKNKPQLLMVSLEYDREQRFEES
VGGDRKICLVTLKETRNFRRGRHGHTRTDRLPAGNTLWRADFATSAEVAAPKWNGRILGIHFQH
NPVITWALMDHDAEVLEKGFIEGNAFLGKALDKQALNEYLQKGGKWVGDRSFGNKLKGITHTLA
SLIVRLAREKDAWIALEEISWVQKQSADSVANRRFSMWNYSRLATLIEWLGTDIATRDCGTAAP
LAHKVSDYLTHFTCPECGACRKAGQKKEIADTVRAGDILTCRKCGFSGPIPDNFIAEFVAKKAL
ERMLKKKPV (SEQ ID NO: 32)

>CasZf.1|rifcsphigho2_01_scaffold_566_121
Tax=RIFCSPHIGHO2_01_FULL_RIF_OD1_10_44_22b_curated id=55167017
partial=0 scaf=rifcsphigho2_01_scaffold_566
bin=RifCSPhighO2_01_full_UNK sample=RIFCSPHIGHO2_01_FULL
proj=RifleCSP2_HighO2
mAKRNFGEKSEALYRAVRFEVRPSKEELSILLAVSEVLRMLFNSALAERQQVFTEFIASLYAEL
KSASVPEEISEIRKKLREAYKEHSISLFDQINALTARRVEDEAFASVTRNWQEETLDALDGAYK
SFLSLRRKGDYDAHSPRSRDSGFFQKIPGRSGFKIGEGRIALSCGAGRKLSFPIPDYQQGRLAE
TTKLKKFELYRDQPNLAKSGRFWISVVYELPKPEATTCQSEQVAFVALGASSIGVVSQRGEEVI
ALWRSDKHWVPKIEAVEERMKRRVKGSRGWLRLLNSGKRRMHMISSRQHVQDEREIVDYLVRNH
GSHFVVTELVVRSKEGKLADSSKPERGGSLGLNWAAQNTGSLSRLVRQLEEKVKEHGGSVRKHK
LTLTEAPPARGAENKLWMARKLRESFLKEV (SEQ ID NO: 33)

>CasZf.2|rifcsplowo2_01_scaffold_81231_1 transposase, IS605 OrfB family, central region id=58737995 partial=0
scaf=rifcsplowo2_01_scaffold_81231 bin=RifCSPlowO2_01_full_UNK
sample=RIFCSPLOWO2_01_FULL proj=RifleCSP2_LowO2
LAKNDEKELLYQSVKFEIYPDESKIRVLTRVSNILVLVWNSALGERRARFELYIAPLYEELKKF
PRKSAESNALRQKIREGYKEHIPTFFDQLKKLLTPMRKEDPALLGSVPRAYQEETLNTLNGSFV
SFMTLRRNNDMDAKPPKGRAEDRFHEISGRSGFKIDGSEFVLSTKEQKLRFPIPNYQLEKLKEA
KQIKKFTLYQSRDRRFWISIAYEIELPDQRPFNPEEVIYIAFGASSIGVISPEGEKVIDFWRPD
KHWKPKIKEVENRMRSCKKGSRAWKKRAAARRKMYAMTQRQQKLNHREIVASLLRLGFHFVVTE
YTVRSKPGKLADGSNPKRGGAPQGFNWSAQNTGSFGEFILWLKQKVKEQGGTVQTFRLVLGQSE
RPEKRGRDNKIEMVRLLREKYLESQTIVV (SEQ ID NO: 34)

FIG. 1 (Cont.)

>CasZf.3|rifcsphigho2_01_scaffold_4702_81 IS605 OrfB family transposase id=55366684 partial=0
scaf=rifcsphigho2_01_scaffold_4702 bin=RifCSPhighO2_01_full_UNK
sample=RIFCSPHIGHO2_01_FULL proj=RifleCSP2_HighO2
mAKGKKKEGKPLYRAVRFEIFPTSDQITLFLRVSKNLQQVWNEAWQERQSCYEQFFGSIYERIG
QAKKRAQEAGFSEVWENEAKKGLNKKLRQQEISMQLVSEKESLLQELSIAFQEHGVTLYDQING
LTARRIIGEFALIPRNWQEETLDSLDGSFKSFLALRKNGDPDAKPPRQRVSENSFYKIPGRSGF
KVSNGQIYLSFGKIGQTLTSVIPEFQLKRLETAIKLKKFELCRDERDMAKPGRFWISVAYEIPK
PEKVPVVSKQITYLAIGASRLGVVSPKGEFCLNLPRSDYHWKPQINALQERLEGVVKGSRKWKK
RMAACTRMFAKLGHQQKQHGQYEVVKKLLRHGVHFVVTELKVRSKPGALADASKSDRKGSPTGP
NWSAQNTGNIARLIQKLTDKASEHGGTVIKRNPPLLSLEERQLPDAQRKIFIAKKLREEFLADQ
K (SEQ ID NO: 35)

>CasZg.1|rifcsp13_1_sub10_scaffold_3_54 \N id=12787801 partial=0
scaf=rifcsp13_1_sub10_scaffold_3 bin=RifCSP13_1_UNK
sample=RIFCSP13_1 proj=Rifle Sediment CSP2
mAKREKKDDVVLRGTKMRIYPTDRQVTLMDMWRRRCISLWNLLLNLETAAYGAKNTRSKLGWRS
IWARVVEENHAKALIVYQHGKCKKDGSFVLKRDGTVKHPPRERFPGDRKILLGLFDALRHTLDK
GAKCKCNVNQPYALTRAWLDETGHGARTADIIAWLKDFKGECDCTAISTAAKYCPAPPTAELLT
KIKRAAPADDLPVDQAILLDLFGALRGGLKQKECDHTHARTVAYFEKHELAGRAEDILAWLIAH
GGTCDCKIVEEAANHCPGPRLFIWEHELAMIMARLKAEPRTEWIGDLPSHAAQTVVKDLVKALQ
TMLKERAKAAAGDESARKTGFPKFKKQAYAAGSVYFPNTTmFFDVAAGRVQLPNGCGSMRCEIP
RQLVAELLERNLKPGLVIGAQLGLLGGRIWRQGDRWYLSCQWERPQPTLLPKTGRTAGVKIAAS
IVFTTYDNRGQTKEYPMPPADKKLTAVHLVAGKQNSRALEAQKEKEKKLKARKERLRLGKLEKG
HDPNALKPLKRPRVRRSKLFYKSAARLAACEAIERDRRDGFLHRVTNEIVHKFDAVSVQKMSVA
PMMRRQKQKEKQIESKKNEAKKEDNGAAKKPRNLKPVRKLLRHVAMARGRQFLEYKYNDLRGPG
SVLIADRLEPEVQECSRCGTKNPQMKDGRRLLRCIGVLPDGTDCDAVLPRNRNAARNAEKRLRK
HREAHNA (SEQ ID NO: 36)

>CasZg.2|033|3300009991.a:Ga0105042_100140_01533
Zr6.c9.inclusive
MNEVLPIPAVGEDAADTIMRGSKMRIYPSVRQAATMDLWRRRCIQLWNLLLELEQAAYSGENRR
TQIGWRSIWATVVEDSHAEAVRVAREGKKRKDGTFRKAPSGKEIPPLDPAMLAKIQRQMNGAVD
VDPKTGEVTPAQPRLFMWEHELQKIMARLKQAPRTHWIDDLPSHAAQSVVKDLIKALQAMLRER
KKRASGIGGRDTGFPKFKKNRYAAGSVYFANTQLRFEAKRGKAGDPDAVRGEFARVKLPNGVGW
MECRMPRHINAAHAYAQATLMGGRIWRQGENWYLSCQWKMPKPAPLPRAGRTAAIKIAAAIPIT
TVDNRGQTREYAMPPIDRERIAAHAAAGRAQSRALEARKRRAKKREAYAKKRHAKKLERGIAAK
PPGRARIKLSPGFYAAAAKLAKLEAEDANAREAWLHEITTQIVRNFDVIAVPRMEVAKLMKKPE
PPEEKEEQVKAPWQGKRRSLKAARVMMRRTAMALIQTTLKYKAVDLRGPQAYEEIAPLDVTAAA
CSGCGVLKPEWKMARAKGREIMRCQEPLPGGKTCNTVLTYTRNSARVIGRELAVRLAERQKA
(SEQ ID NO: 37)

FIG. 1 (Cont.)

>CasZh.1|rifcsp2_19_4_full_scaffold_168_120 transposase id=102318404 partial=0 scaf=rifcsp2_19_4_full_scaffold_168 bin=RifCSP19_4_full_UNK sample=RIFCSP19_4_FULL proj=Rifle Sediment CSP1

mTTQKTYNFCFYDQRFFELSKEAGEVYSRSLEEFWKIYDETGVWLSKFDLQKHMRNKLERKLLH
SDSFLGAMQQVHANLASWKQAKKVVPDACPPRKPKFLQAILFKKSQIKYKNGFLRLTLGTEKEF
LYLKWDINIPLPIYGSVTYSKTRGWKINLCLETEVEQKNLSENKYLSIDLGVKRVATIFDGENT
ITLSGKKFMGLMHYRNKLNGKTQSRLSHKKKGSNNYKKIQRAKRKTTDRLLNIQKEMLHKYSSF
IVNYAIRNDIGNIIIGDNSSTHDSPNMRGKTNQKISQNPEQKLKNYIKYKFESISGRVDIVPEP
YTSRKCPHCKNIKKSSPKGRTYKCKKCGFIFDRDGVGAINIYNENVSFGQIISPGRIRSLTEPI

GMKFHNEIYFKSYVAA (SEQ ID NO: 38)

>CasZi.1|RBG_13_scaffold_1401_19 Tax=RBG_13_Planctomycetes_46_10_curated id=16386779 partial=0 scaf=RBG_13_scaffold_1401 bin=RBG_13_Planctomycetes_46_10 sample=2500-genomes proj=2500 Genomes

mSVRSFQARVECDKQTMEHLWRTHKVFNERLPEIIKILFKMKRGECGQNDKQKSLYKSISQSIL
EANAQNADYLLNSVSIKGWKPGTAKKYRNASFTWADDAAKLSSQGIHVYDKKQVLGDLPGMMSQ
MVCRQSVEAISGHIELTKKWEKEHNEWLKEKEKWESEDEHKKYLDLREKFEQFEQSIGGKITKR
RGRWHLYLKWLSDNPDFAAWRGNKAVINPLSEKAQIRINKAKPNKKNSVERDEFFKANPEMKAL
DNLHGYYERNFVRRRKTKKNPDGFDHKPTFTLPHPTIHPRWFVFNKPKTNPEGYRKLILPKKAG
DLGSLEMRLLTGEKNKGNYPDDWISVKFKADPRLSLIRPVKGRRVVRKGKEQGQTKETDSYEFF
DKHLKKWRPAKLSGVKLIFPDKTPKAAYLYFTCDIPDEPLTETAKKIQWLETGDVTKKGKKRKK
KVLPHGLVSCAVDLSMRRGTTGFATLCRYENGKIHILRSRNLWVGYKEGKGCHPYRWTEGPDLG
HIAKHKREIRILRSKRGKPVKGEESHIDLQKHIDYMGEDRFKKAARTIVNFALNTENAASKNGF
YPRADVLLLENLEGLIPDAEKERGINRALAGWNRRHLVERVIEMAKDAGFKRRVFEIPPYGTSQ
VCSKCGALGRRYSIIRENNRREIRFGYVEKLFACPNCGYCANADHNASVNLNRRFLIEDSFKSY

YDWKRLSEKKQKEEIETIESKLMDKLCAMHKISRGSISK (SEQ ID NO: 39)

FIG. 1 (Cont.)

>CasZi.2|026|3300009652.a:Ga0123330_1010394_01528
Zr6.c2c1.inclusive
MHLWRTHCVFNQRLPALLKRLFAMRRGEVGGNEAQRQVYQRVAQFVLARDAKDSVDLLNAVSLR
KRSANSAFKKKATISCNGQAREVTGEEVFAEAVALASKGVFAYDKDDMRAGLPDSLFQPLTRDA
VACMRSHEELVATWKKEYREWRDRKSEWEAEPEHALYLNLRPKFEEGEAARGGRFRKRAERDHA
YLDWLEANPQLAAWRRKAPPAVVPIDEAGKRRIARAKAWKQASVRAEEFWKRNPELHALHKIHV
QYLREFVRPRRTRRNKRREGFKQRPTFTMPDPVRHPRWCLFNAPQTSPQGYRLLRLPQSRRTVG
SVELRLLTGPSDGAGFPDAWVNVRFKADPRLAQLRPVKVPRTVTRGKNKGAKVEADGFRYYDDQ
LLIERDAQVSGVKLLFRDIRMAPFADKPIEDRLLSATPYLVFAVEIKDEARTERAKAIRFDETS
ELTKSGKKRKTLPAGLVSVAVDLDTRGVGFLTRAVIGVPEIQQTHHGVRLLQSRYVAVGQVEAR
ASGEAEWSPGPDLAHIARHKREIRRLRQLRGKPVKGERSHVRLQAHIDRMGEDRFKKAARKIVN
EALRGSNPAAGDPYTRADVLLYESLETLLPDAERERGINRALLRWNRAKLIEHLKRMCDDAGIR
HFPVSPFGTSQVCSKCGALGRRYSLARENGRAVIRFGWVERLFACPNPECPGRRPDRPDRPFTC
NSDHNASVNLHRVFALGDQAVAAFRALAPRDSPARTLAVKRVEDTLRPQLMRVHKLADAGVDSP
F (SEQ ID NO: 40)

>CasZj.1|130|3300012532.a:Ga0137373_10000316_00700 c2c4
MATLVYRYGVRAHGSARQQDAVVSDPAMLEQLRLGHELRNALVGVQHRYEDGKRAVWSGFASVA
AADHRVTTGETAVAELEKQARAEHSADRTAATRQGTAESLKAARAAVKQARADRKAAMAAVAEQ
AKPKIQALGDDRDAEIKDLYRRFCQDGVLLPRCGRCAGDLRSDGDCTDCGAAHEPRKLYWATYN
AIREDHQTAVKLVEAKRKAGQPARLRFRRWTGDGTLTVQLQRMHGPACRCVTCAEKLTRRARKT
DPQAPAVAADPAYPPTDPPRDPALLASGQGKWRNVLQLGTWIPPGEWSAMSRAERRRVGRSHIG
WQLGGGRQLTLPVQLHRQMPADADVAMAQLTRVRVGGRHRMSVALTAKLPDPPQVQGLPPVALH
LGWRQRPDGSLRVATWACPQPLDLPPAVADVVVSHGGRWGEVIMPARWLADAEVPPRLLGRRDK
AMEPVLEALADWLEAHTEACTARMTPALVRRWRSQGRLAGLTNRWRGQPPTGSAEILTYLEAWR
IQDKLLWERESHLRRRLAARRDDAWRRVASWLARHAGVLVVDDADIAELRRRDDPADTDPTMPA
SAAQAARARAALAAPGRLRHLATITATRDGLGVHTVASAGLTRLHRKCGHQAQPDPRYAASAVV
TCPGCGNGYDQDYNAAMLMLDRQQQP (SEQ ID NO: 41)

>CasZk.1|012|3300005602.a:Ga0070762_10001740_01506
Zr6.c9.inclusive
MSRVELHRAYKFRLYPTPAQVAELAEWERQLRRLYNLAHSQRLAAMQRHVRPKSPGVLKSECLS
CGAVAVAEIGTDGKAKKTVKHAVGCSVLECRSCGGSPDAEGRTAHTAACSFVDYYRQGREMTQL
LEEDDQLARVVCSARQETLRDLEKAWQRWHKMPGFGKPHFKKRIDSCRIYFSTPKSWAVDLGYL
SFTGVASSVGRIKIRQDRVWPGDAKFSSCHVVRDVDEWYAVFPLTFTKEIEKPKGGAVGINRGA
VHAIADSTGRVVDSPKFYARSLGVIRHRARLLDRKVPFGRAVKPSPTKYHGLPKADIDAAAARV
NASPGRLVYEARARGSIAAAEAHLAALVLPAPRQTSQLPSEGRNRERARRFLALAHQRVRRQRE
WFLHNESAHYAQSYTKIAIEDWSTKEMTSSEPRDAEEMKRVTRARNRSILDVGWYELGRQIAYK
SEATGAEFAKVDPGLRETETHVPEAIVRERDVDVSGMLRGEAGISGTCSRCGGLLRASASGHAD
AECEVCLHVEVGDVNAAVNVLKRAMFPGAAPPSKEKAKVTIGIKGRKKKRAA
(SEQ ID NO: 42)

FIG. 1 (Cont.)

>CasZk.2|016|3300005921.a:Ga0070766_10011912_01491
Zr6.c9.inclusive
MSRVELHRAYKFRLYPTPVQVAELSEWERQLRRLYNLGHEQRLLTLTRHLRPKSPGVLKGECLS
CDSTQVQEVGADGRPKTTVRHAEQCPTLACRSCGALRDAEGRTAHTVACAFVDYYRQGREMTEL
LAADDQLARVVCSARQEVLRDLDKAWQRWRKMPGFGKPRFKRRTDSCRIYFSTPKAWKLEGGHL
SFTGAATTVGAIKMRQDRNWPASVQFSSCHVVRDVDEWYAVFPLTFVAEVARPKGGAVGINRGA
VHAIADSTGRVVDSPRYYARALGVIRHRARLFDRKVPSGHAVKPSPTKYRGLSAIEVDRVARAT
GFTPGRVVTEALNRGGVAYAECALAAIAVLGHGPERPLTSDGRNREKARKFLALAHQRVRRQRE
WFLHNESAHYARTYSKIAIEDWSTKEMTASEPQGEETRRVTRSRNRSILDVGWYELGRQLAYKT
EATGAEFAQVDPGLKETETNVPKAIADARDVDVSGMLRGEAGISGTCSKCGGLLRAPASGHADA
ECEICLNVEVGDVNAAVNVLKRAMFPGDAPPASGEKPKVSIGIKGRQKKKKAA
(SEQ ID NO: 43)

>CasZk.3|106|3300009698.a:Ga0116216_10000905_01565 c2c9
MEAIATGMSPERRVELGILPGSVELKRAYKFRLYPMKVQQAELSEWERQLRRLYNLAHEQRLAA
LLRYRDWDFQKGACPSCRVAVPGVHTAACDHVDYFRQAREMTQLLEVDAQLSRVICCARQEVLR
DLDKAWQRWRKKLGGRPRFKRRTDSCRIYLSTPKHWEIAGRYLRLSGLASSVGEIRIEQDRAFP
EGALLSSCSIVRDVDEWYACLPLTFTQPIERAPHRSVGLNRGVVHALADSDGRVVDSPKFFERA
LATVQKRSRDLARKVSGSRNAHKARIKLAKAHQRVRRQRAAFLHQESAYYSKGFDLVALEDMSV
RKMTATAGEAPEMGRGAQRDLNRGILDVGWYELARQIDYKRLAHGGELLRVDPGQTTPLACVTE
EQPARGISSACAVCGIPLARPASGNARMRCTACGSSQVGDVNAAENVLTRALSSAPSGPKSPKA
SIKIKGRQKRLGTPANRAGEASGGDPPVRGPVEGGTLAYVVEPVSESQSDT
(SEQ ID NO: 44)

>CasZk.4|072|3300006028.a:Ga0070717_10000077_00263
Zr6.c9.inclusive
MTVRTYKYRAYPTPEQAEALTSWLRFASQLYNAALEHRKNAWGRHDAHGRGFRFWDGDAAPRKK
SDPPGRWVYRGGGGAHISKNDQGKLLTEFRREHAELLPPGMPALVQHEVLARLERSMAAFFQRA
TKGQKAGYPRWRSEHRYDSLTFGLTSPSKERFDPETGESLGRGKTVGAGTYHNGDLRLTGLGEL
RILEHRRIPMGAIPKSVIVRRSGKRWFVSIAMEMPSVEPAASGRPAVGLDMGVVTWGTAFTADT
SAAAALVADLRRMATDPSDCRRLEELEREAAQLSEVLAHCRARGLDPARPRRCPKELTKLYRRS
LHRLGELDRACARIRRRLQAAHDIAEPVPDEAGSAVLIEGSNAGMRHARRVARTQRRVARRTRA
GHAHSNRRKKAVQAYARAKERERSARGDHRHKVSRALVRQFEEISVEALDIKQLTVAPEHNPDP
QPDLPAHVQRRRNRGELDAAWGAFFAALDYKAADAGGRVARKPAPHTTQECARCGTLVPKPISL
RVHRCPACGYTAPRTVNSARNVLQRPLEEPGRAGPSGANGRGVPHAVA (SEQ ID NO: 45)

FIG. 1 (Cont.)

>CasZ1.1|004|3300001256.a:JGI12210J13797_10004690_01983 c2c9
MNCRYRYRIYPTPGQRQSLARLFGCVRVVWNDALFLCRQSEKLPKNSELQKLCITQAKKTEARG
WLGQVSAIPLQQSVADLGVAFKNFFQSRSGKRKGKKVNPPRVKRRNNRQGARFTRGGFKVKTSK
VYLARIGDIKIKWSRPLPSEPSSVTVIKDCAGQYFLSFVVEVKPEIKPPKNPSIGIDLGLKTFA
SCSNGEKIDSPDYSRLYRKLKRCQRRLAKRQRGSKRRERMRVKVAKLNAQIRDKRKDFLHKLST
KVVNENQVIALEDLNVGGMLKNRKLSRAISQAGWYEFRSLCEGKAEKHNRDFRVISRWEPTSQV
CSECGYRWGKIDLSVRSIVCINCGVEHDRDDNASVNIEQAGLKVGVGHTHDSKRTGSACKTSNG
AVCVEPSTHREYVQLTLFDW (SEQ ID NO: 46)

>CasZ1.2|014|3300005660.a:Ga0073904_10021651_01988 c2c9
MKSRWTFRCYPTPEQEQHLARTFGCVRFVWNWALRARTDAFRAGERIGYPATDKALTLLKQQPE
TVWLNEVSSVCLQQALRDLQVAFSNFFDKRAAHPSFKRKEARQSANYTERGFSFDHERRILKLA
KIGAIKVKWSRKAIPHPSSIRLIRTASGKYFVSLVVETQPAPMPETGESVGVDFGVARLATLSN
GERISNPKHGAKWQRRLAFYQKRLARATKGSKRRMRIKRHVARIHEKIGNSRSDTLHKLSTDLV
TRFDLICVEDLNLRGMVKNHSLARSLHDASIGSAIRMIEEKAERYGKNVVKIDRWFPSSKTCSD
CGHIVEQLPLNVREWTCPECGTTHDRDANAAANILAVGQTVSAHGGTVRRSRAKASERKSQRSA
NRQGVNRA (SEQ ID NO: 47)

FIG. 2









	#	Cas1	Organism	Locus example
Za	5	I-B	DPANN	
Zb	7	I-B	DPANN	
Zc	5	I-B	DPANN	
Zd	1	I-B	DPANN	
Ze	4	III-D*	CPR	
Zf	3	III-D	CPR	
Zg	1	I-E	Phage?	
Zh	1	II-C	MGE	
Zi	1	I-U	Plancto	

FIG. 3



Type V Tree
CasZe
CasZi
CasZh
CasZg
CasZd
CasZf
CasZa
CasZb
CasZc
V subtype
V-A
V-B
V-C
V-D (Y)
V-E (X)
C2c4
C2c5
C2c8
C2c9
C2c10
Za
Zb
Zc
Zd
Ze
Zf
Zg
Zh
Zi

FIG. 4



Cas1 tree
CasZi
CasZh
CasZa-d
CasZe
CasZf
CasZe
CasZg
Cas subtype
I–A
I–B
I–C
I–D
I–E
I–F
I–U
III–A
III–B
III–C
III–D
IV
V–A
V–B
V–C
V–D (Y)
V–E (X)
VI
II–A
II–B
II–C
II-novel
Za
Zb
Zc
Zd
Ze
Zf
Zg
Zh
Zi
Casposon

Figure 5




Figure 5 (Cont. 1)

Figure 5 (Cont. 2)





Figure 5 (Cont. 3)






Figure 5 (Cont. 4)




Figure 5 (Cont. 5)

Figure 5 (Cont. 6)




Figure 6



bits
2
1
0
5'
1
2
3
4
5
6
7
8
9
10
3'
weblogo berkeley.edu
bits
2
1
0
5'
1
2
3
4
5
6
7
8
9
10
3'
weblogo berkeley.edu

FIG. 7

>Cas14a.1|gwa1_scaffold_1795_curated|25635..27224|revcom
PEEKTSKLKPNSINLAANYDANEKFNCKECKFHPFKNKKRYEFNFYNNLHGCKSCTKST
NNPAVKRIEIGYQKLKFEIKNQMEAYPWFGRLRINFYSDEKRKMSELNEMQVTGVKNKI
FFDAIECAWREILKKRFRESKETLITIPKLKNKAGHGARKHRNKKLLIRRRAFMKKNFH
FLDNDSISYRSFANNIACVLPSKVGVDIGGIISPDVGKDIKPVDISLNLMWASKEGIKS
GRKVEIYSTQYDGNMVKKIEAETGEDKSWGKNRKRRQTSLLLSIPKPSKQVQEFDFKEW
PRYKDIEKKVQWRGFPIKIIFDSNHNSIEFGTYQGGKQKVLPIPFNDSKTTPLGSKMNK
LEKLRFNSKIKSRLGSAIAANKFLEAARTYCVDSLYHEVSSANAIGKGKIFIEYYLEIL
SQNYIEAAQKQLQRFIESIEQWFVADPFQGRLKQYFKDDLKRAKCFLCANREVQTTCYA
AVKLHKSCAEKVKDKNKELAIKERNNKEDAVIKEVEASNYPRVIRLKLTKTITNKAM
(SEQ ID NO:306)

>Cas14a.2|gwa2_scaffold_18027_curated|7105..8628
ELIVNENKDPLNIGKTAKAVFKEIDPTSINRAANYDASIELACKECKFKPFNNTKRHDF
SFYSNWHRCSPNSCLQSTYRAKIRKTEIGYEKLKNEILNQMQYYPWFGRLYQNFFNDQR
DKMTSLDEIQVTGVQNKIFFNTVEKAWREIIKKRFRDNKETMRTIPDLKNKSGHGSRKL
SNKSLLRRRFAFAQKSFKLVDNSDVSYRAFSNNVACVLPSKIGVDIGGIINKDLKREYI
PQEITFNVFWKQHDGLKKGRNIEIHSVQYKGEIVKRIEADTGEDKAWGKNRQRRFTSLI
LKITPKQGGKKIWKFPEKKNASDYEYFPIPIEFILDNGDASIKFGGEEGEVGKQKHLLI
PFNDSKATPLSSKQMLLETSRFNAEVKSTIGLALYANYFVSYARNYVIKSTYHKNSKKG
QIVTEIYLESISQNFVRAIQRQLQSLMLNLKDWGFMQTHKKELKKYFGSDLEGSKGGQK
RREKEEKIEKEIEASYLPRLIRLSLTKSVTKAEEM (SEQ ID NO:305)

>Cas14a.3|rifcsphigho2_02_scaffold_2167_curated|30296..31798|revcom
KEPLNIGKTAKAVFKEIDPTSLNRAANYDASIELNCKECKFKPFKNVKRYEFNFYNNWY
RCNPNSCLQSTYKAQVRKVEIGYEKLKNEILTQMQYYPWFGRLYQNFFHDERDKMTSLD
EIQVIGVQNKVFFNTVEKAWREIIKKRFKDNKETMETIPELKHAAGHGKRKLSNKSLLR
RRFAFVQKSFKFVDNSDVSYRSFSNNIACVLPSRIGVDLGGVISRNPKREYIPQEISFN
AFWKQHEGLKKGRNIEIQSVQYKGETVKRIEADTGEDKAWGKNRQRRFTSLILKLVPKQ
GGKKVWKYPEKRNEGNYEYFPIPIEFILDSGETSIRFGGDEGEAGKQKHLVIPFNDSKA
TPLASQQTLLENSRFNAEVKSCIGLAIYANYFYGYARNYVISSIYHKNSKNGQAITAIY
LESIAHNYVKAIERQLQNLLLNLRDFSFMESHKKELKKYFGGDLEGTGGAQKRREKEEK
IEKEIEQSYLPRLIRLSLTKMVTKQVEM (SEQ ID NO:304)

FIG. 7 (Cont.)

>Cas14a.4|CG10_big_fil_rev_8_21_14_0.10_scaffold_20906_curated|649..2829
SESENKIIEQYYAFLYSFRDKYEKPEFKNRGDIKRKLQNKWEDFLKEQNLKNDKKLSNYIFSNRNFRRSYDREEENEEGIDEKKSKPKRINCFEKEKNLKDQYDKDAINASANKDGAQKWGCFECIFFPMYKIESGDPNKRIIINKTRFKLFDFYLNLKGCKSCLRSTYHPYRSNVYIESNYDKLKREIGNFLQQKNIFQRMRKAKVSEGKYLTNLDEYRLSCVAMHFKNRWLFFDSIQKVLRETIKQRLKQMRESYDEQAKTKRSKGHGRAKYEDQVRMIRRRAYSAQAHKLLDNGYITLFDYDDKEINKVCLTAINQEGFDIGGYLNSDIDNVMPPIEISFHLKWKYNEPILNIESPFSKAKISDYLRKIREDLNLERGKEGKARSKKNVRRKVLASKGEDGYKKIFTDFFSKWKEELEGNAMERVLSQSSGDIQWSKKKRIHYTTLVLNINLLDKKGVGNLKYYEIAEKTKILSFDKNENKFWPITIQVLLDGYEIGTEYDEIKQLNEKTSKQFTIYDPNTKIIKIPFTDSKAVPLGMLGINIATLKTVKKTERDIKVSKIFKGGLNSKIVSKIGKGIYAGYFPTVDKEILEEVEEDTLDNEFSSKSQRNIFLKSIIKNYDKMLKEQLFDFYSFLVRNDLGVRFLTDRELQNIEDESFNLEKRFFETDRDRIARWFDNTNTDDGKEKFKKLANEIVDSYKPRLIRLPVVRVIKRIQPVKQREM (SEQ ID NO:178)

>Cas14a.5|rifcsplowo2_01_scaffold_34461_curated|4968..6521
KYSTRDFSELNEIQVTACKQDEFFKVIQNAWREIIKKRFLENRENFIEKKIFKNKKGRGKRQESDKTIQRNRASVMKNFQLIENEKIILRAPSGHVACVFPVKVGLDIGGFKTDDLEKNIFPPRTITINVFWKNRDRQRKGRKLEVWGIKARTKLIEKVHKWDKLEEVKKKRLKSLEQKQEKSLDNWSEVNNDSFYKVQIDELQEKIDKSLKGRTMNKILDNKAKESKEAEGLYIEWEKDFEGEMLRRIEASTGGEEKWGKRRQRRHTSLLLDIKNNSRGSKEIINFYSYAKQGKKEKKIEFFPFPLTITLDAEEESPLNIKSIPIEDKNATSKYFSIPFTETRATPLSILGDRVQKFKTKNISGAIKRNLGSSISSCKIVQNAETSAKSILSLPNVKEDNNMEIFINTMSKNYFRAMMKQMESFIFEMEPKTLIDPYKEKAIKWFEVAASSRAKRKLKKLSKADIKKSELLLSNTEEFEKEKQEKLEALEKEIEEFYLPRIVRLQLTKTILETPVM (SEQ ID NO:179)

>Cas14a.6|3300012359.a|Ga0137385_10000156|41289..42734
KKLQLLGHKILLKEYDPNAVNAAANFETSTAELCGQCKMKPFKNKRRFQYTFGKNYHGCLSCIQNVYYAKKRIVQIAKEELKHQLTDSIASIPYKYTSLFSNTNSIDELYILKQERAAFFSNTNSIDELYITGIENNIAFKVISAIWDEIIKKRRQRYAESLTDTGTVKANRGHGGTAYKSNTRQEKIRALQKQTLHMVTNPYISLARYKNNYIVATLPRTIGMHIGAIKDRDPQKKLSDYAINFNVFWSDDRQLIELSTVQYTGDMVRKIEAETGENNKWGENMKRTKTSLLLEILTKKTTDELTFKDWAFSTKKEIDSVTKKTYQGFPIGIIFEGNESSVKFGSQNYFPLPFDAKITPPTAEGFRLDWLRKGSFSSQMKTSYGLAIYSNKVTNAIPAYVIKNMFYKIARAENGKQIKAKFLKKYLDIAGNNYVPFIIMQHYRVLDTFEEMPISQPKVIRLSLTKTQHIIIKKDKTDSKM (SEQ ID NO:180)

FIG. 7 (Cont.)

>Cas14b.1|rifcsplowo2_01_scaffold_239_curated|54653..56257
NTSNLINLGKKAINISANYDANLEVGCKNCKFLSSNGNFPRQTNVKEGCHSCEKSTYEP
SIYLVKIGERKAKYDVLDSLKKFTFQSLKYQSKKSMKSRNKKPKELKEFVIFANKNKAF
DVIQKSYNHLILQIKKEINRMNSKKRKKNHKRRLFRDREKQLNKLRLIESSNLFLPREN
KGNNHVFTYVAIHSVGRDIGVIGSYDEKLNFETELTYQLYFNDDKRLLYAYKPKQNKII
KIKEKLWNLRKEKEPLDLEYEKPLNKSITFSIKNDNLFKVSKDLMLRRAKFNIQGKEKL
SKEERKINRDLIKIKGLVNSMSYGRFDELKKEKNIWSPHIYREVRQKEIKPCLIKNGDR
IEIFEQLKKKMERLRRFREKRQKKISKDLIFAERIAYNFHTKSIKNTSNKINIDQEAKR
GKASYMRKRIGYETFKNKYCEQCLSKGNVYRNVQKGCSCFENPFDWIKKGDENLLPKKN
EDLRVKGAFRDEALEKQIVKIAFNIAKGYEDFYDNLGESTEKDLKLKFKVGTTINEQES
LKL (SEQ ID NO:181)

>Cas14b.2|rifcsplowo2_01_scaffold_282_curated|77370..78983
TSNPIKLGKKAINISANYDSNLQIGCKNCKFLSYNGNFPRQTNVKEGCHSCEKSTYEPP
VYTVRIGERRSKYDVLDSLKKFIFLSLKYRQSKKMKTRSKGIRGLEEFVISANLKKAMD
VIQKSYRHLILNIKNEIVRMNGKKRNKNHKRLLFRDREKQLNKLRLIEGSSFFKPPTVK
GDNSIFTCVAIHNIGRDIGIAGDYFDKLEPKIELTYQLYYEYNPKKESEINKRLLYAYK
PKQNKIIEIKEKLWNLRKEKSPLDLEYEKPLTKSITFLVKRDGVFRISKDLMLRKAKFI
IQGKEKLSKEERKINRDLIKIKSNIISLTYGRFDELKKDKTIWSPHIFRDVKQGKITPC
IERKGDRMDIFQQLRKKSERLRENRKKRQKKISKDLIFAERIAYNFHTKSIKNTSNLIN
IKHEAKRGKASYMRKRIGNETFRIKYCEQCFPKNNVYKNVQKGCSCFEDPFEYIKKGNE
DLIPNKNQDLKAKGAFRDDALEKQIIKVAFNIAKGYEDFYENLKKTTEKDIRLKFKVGT
IISEEM (SEQ ID NO:182)

>Cas14b.3|rifcsphigho2_01_scaffold_36781_curated|2592..4217
NNSINLSKKAINISANYDANLQVRCKNCKFLSSNGNFPRQTDVKEGCHSCEKSTYEPPV
YDVKIGEIKAKYEVLDSLKKFTFQSLKYQLSKSMKFRSKKIKELKEFVIFAKESKALNV
INRSYKHLILNIKNDINRMNSKKRIKNHKGRLFLDRQKQLSKLKLIEGSSFFVPAKNVG
NKSVFTCVAIHSIGRDIGIAGLYDSFTKPVNEITYQIFFSGERRLLYAYKPKQLKILSI
KENLWSLKNEKKPLDLLYEKPLGKNLNFNVKGGDLFRVSKDLMIRNAKFNVHGRQRLSD
EERLINRNFIKIKGEVVSLSYGRFEELKKDRKLWSPHIFKDVRQNKIKPCLVMQGQRID
IFEQLKRKLELLKKIRKSRQKKLSKDLIFGERIAYNFHTKSIKNTSNKINIDSDAKRGR
ASYMRKRIGNETFKLKYCDVCFPKANVYRRVQNGCSCSENPYNYIKKGDKDLLPKKDEG
LAIKGAFRDEKLNKQIIKVAFNIAKGYEDFYDDLKKRTEKDVDLKFKIGTTVLDQKPME
IFDGIVITWL (SEQ ID NO:183)

FIG. 7 (Cont.)

>Cas14b.4|cg1_0.2_scaffold_785_c_curated|32521..34155
LLTTVVETNNLAKKAINVAANFDANIDRQYYRCTPNLCRFIAQSPRETKEKDAGCSSCT
QSTYDPKVYVIKIGKLLAKYEILKSLKRFLFMNRYFKQKKTERAQQKQKIGTELNEMSI
FAKATNAMEVIKRATKHCTYDIIPETKSLQMLKRRRHRVKVRSLLKILKERRMKIKKIP
NTFIEIPKQAKKNKSDYYVAAALKSCGIDVGLCGAYEKNAEVEAEYTYQLYYEYKGNSS
TKRILYCYNNPQKNIREFWEAFYIQGSKSHVNTPGTIRLKMEKFLSPITIESEALDFRV
WNSDLKIRNGQYGFIKKRSLGKEAREIKKGMGDIKRKIGNLTYGKSPSELKSIHVYRTE
RENPKKPRAARKKEDNFMEIFEMQRKKDYEVNKKRRKEATDAAKIMDFAEEPIRHYHTN
NLKAVRRIDMNEQVERKKTSVFLKRIMQNGYRGNYCRKCIKAPEGSNRDENVLEKNEGC
LDCIGSEFIWKKSSKEKKGLWHTNRLLRRIRLQCFTTAKAYENFYNDLFEKKESSLDII
KLKVSITTKSM (SEQ ID NO:184)

>Cas14b.5|rifcsphigho2_02_scaffold_55589_curated|1904..3598
ASTMNLAKQAINFAANYDSNLEIGCKGCKFMSTWSKKSNPKFYPRQNNQANKCHSCTYS
TGEPEVPIIEIGERAAKYKIFTALKKFVFMSVAYKERRRQRFKSKKPKELKELAICSNR
EKAMEVIQKSVVHCYGDVKQEIPRIRKIKVLKNHKGRLFYKQKRSKIKIAKLEKGSFFK
TFIPKVHNNGCHSCHEASLNKPILVTTALNTIGADIGLINDYSTIAPTETDISWQVYYE
FIPNGDSEAVKKRLLYFYKPKGALIKSIRDKYFKKGHENAVNTGFFKYQGKIVKGPIKF
VNNELDFARKPDLKSMKIKRAGFAIPSAKRLSKEDREINRESIKIKNKIYSLSYGRKKT
LSDKDIIKHLYRPVRQKGVKPLEYRKAPDGFLEFFYSLKRKERRLRKQKEKRQKDMSEI
IDAADEFAWHRHTGSIKKTTNHINFKSEVKRGKVPIMKKRIANDSFNTRHCGKCVKQGN
AINKYYIEKQKNCFDCNSIEFKWEKAALEKKGAFKLNKRLQYIVKACFNVAKAYESFYE
DFRKGEEESLDLKFKIGTTTTLKQYPQNKARAM (SEQ ID NO:185)

>Cas14b.6|CG03_land_8_20_14_0.80_scaffold_2214_curated|6634
..8466|revcom
HSHNLMLTKLGKQAINFAANYDANLEIGCKNCKFLSYSPKQANPKKYPRQTDVHEDGNI
ACHSCMQSTKEPPVYIVPIGERKSKYEILTSLNKFTFLALKYKEKKRQAFRAKKPKELQ
ELAIAFNKEKAIKVIDKSIQHLILNIKPEIARIQRQKRLKNRKGKLLYLHKRYAIKMGL
IKNGKYFKVGSPKKDGKKLLVLCALNTIGRDIGIIGNIEENNRSETEITYQLYFDCLDA
NPNELRIKEIEYNRLKSYERKIKRLVYAYKPKQTKILEIRSKFFSKGHENKVNTGSFNF
ENPLNKSISIKVKNSAFDFKIGAPFIMLRNGKFHIPTKKRLSKEEREINRTLSKIKGRV
FRLTYGRNISEQGSKSLHIYRKERQHPKLSLEIRKQPDSFIDEFEKLRLKQNFISKLKK
QRQKKLADLLQFADRIAYNYHTSSLEKTSNFINYKPEVKRGRTSYIKKRIGNEGFEKLY
CETCIKSNDKENAYAVEKEELCFVCKAKPFTWKKTNKDKLGIFKYPSRIKDFIRAAFTV
AKSYNDFYENLKKKDLKNEIFLKFKIGLILSHEKKNHISIAKSVAEDERISGKSIKNIL
NKSIKLEKNCYSCFFHKEDM (SEQ ID NO:186)

FIG. 7 (Cont.)

>Cas14b.7|3300013125.a|Ga0172369_10000737|994..2652|revcom
SLERVIDKRNLAKKAINIAANFDANINKGFYRCETNQCMFIAQKPRKTNNTGCSSCLQS
TYDPVIYVVKVGEMLAKYEILKSLKRFVFMNRSFKQKKTEKAKQKERIGGELNEMSIFA
NAALAMGVIKRAIRHCHVDIRPEINRLSELKKTKHRVAAKSLVKIVKQRKTKWKGIPNS
FIQIPQKARNKDADFYVASALKSGGIDIGLCGTYDKKPHADPRWTYQLYFDTEDESEKR
LLYCYNDPQAKIRDFWKTFYERGNPSMVNSPGTIEFRMEGFFEKMTPISIESKDFDFRV
WNKDLLIRRGLYEIKKRKNLNRKAREIKKAMGSVKRVLANMTYGKSPTDKKSIPVYRVE
REKPKKPRAVRKEENELADKLENYRREDFLIRNRRKREATEIAKIIDAAEPPIRHYHTN
HLRAVKRIDLSKPVARKNTSVFLKRIMQNGYRGNYCKKCIKGNIDPNKDECRLEDIKKC
ICCEGTQNIWAKKEKLYTGRINVLNKRIKQMKLECFNVAKAYENFYDNLAALKEGDLKV
LKLKVSIPALNPEASDPEEDM (SEQ ID NO:187)

>Cas14b.8|3300013125.a|Ga0172369_10010464|885..2489|revcom
NASINLGKRAINLSANYDSNLVIGCKNCKFLSFNGNFPRQTNVREGCHSCDKSTYAPEV
YIVKIGERKAKYDVLDSLKKFTFQSLKYQIKKSMRERSKKPKELLEFVIFANKDKAFNV
IQKSYEHLILNIKQEINRMNGKKRIKNHKKRLFKDREKQLNKLRLIGSSSLFFPRENKG
DKDLFTYVAIHSVGRDIGVAGSYESHIEPISDLTYQLFINNEKRLLYAYKPKQNKIIEL
KENLWNLKKEKKPLDLEFTKPLEKSITFSVKNDKLFKVSKDLMLRQAKFNIQGKEKLSK
EERQINRDFSKIKSNVISLSYGRFEELKKEKNIWSPHIYREVKQKEIKPCIVRKGDRIE
LFEQLKRKMDKLKKFRKERQKKISKDLNFAERIAYNFHTKSIKNTSNKINIDQEAKRGK
ASYMRKRIGNESFRKKYCEQCFSVGNVYHNVQNGCSCFDNPIELIKKGDEGLIPKGKED
RKYKGALRDDNLQMQIIRVAFNIAKGYEDFYNNLKEKTEKDLKLKFKIGTTISTQESNN
KEM (SEQ ID NO:188)

>Cas14b.9|3300013127.a|Ga0172365_10004421|633..2366|revcom
SNLIKLGKQAINFAANYDANLEVGCKNCKFLSSTNKYPRQTNVHLDNKMACRSCNQSTM
EPAIYIVRIGEKKAKYDIYNSLTKFNFQSLKYKAKRSQRFKPKQPKELQELSIAVRKEK
ALDIIQKSIDHLIQDIRPEIPRIKQQKRYKNHVGKLFYLQKRRKNKLNLIGKGSFFKVF
SPKEKKNELLVICALTNIGRDIGLIGNYNTIINPLFEVTYQLYYDYIPKKNNKNVQRRL
LYAYKSKNEKILKLKEAFFKRGHENAVNLGSFSYEKPLEKSLTLKIKNDKDDFQVSPSL
RIRTGRFFVPSKRNLSRQEREINRRLVKIKSKIKNMTYGKFETARDKQSVHIFRLERQK
EKLPLQFRKDEKEFMEEFQKLKRRTNSLKKLRKSRQKKLADLLQLSEKVVYNNHTGTLK
KTSNFLNFSSSVKRGKTAYIKELLGQEGFETLYCSNCINKGQKTRYNIETKEKCFSCKD
VPFVWKKKSTDKDRKGAFLFPAKLKDVIKATFTVAKAYEDFYDNLKSIDEKKPYIKFKI
GLILAHVRHEHKARAKEEAGQKNIYNKPIKIDKNCKECFFFKEEAM (SEQ ID NO:189
)

FIG. 7 (Cont.)

>Cas14b.10|CG08_land_8_20_14_0.20_scaffold_1609_curated|6134..7975
NTTRKKFRKRTGFPQSDNIKLAYCSAIVRAANLDADIQKKHNQCNPNLCVGIKSNEQSR
KYEHSDRQALLCYACNQSTGAPKVDYIQIGEIGAKYKILQMVNAYDFLSLAYNLTKLRN
GKSRGHQRMSQLDEVVIVADYEKATEVIKRSINHLLDDIRGQLSKLKKRTQNEHITEHK
QSKIRRKLRKLSRLLKRRRWKWGTIPNPYLKNWVFTKKDPELVTVALLHKLGRDIGLVN
RSKRRSKQKLLPKVGFQLYYKWESPSLNNIKKSKAKKLPKRLLIPYKNVKLFDNKQKLE
NAIKSLLESYQKTIKVEFDQFFQNRTEEIIAEEQQTLERGLLKQLEKKKNEFASQKKAL
KEEKKKIKEPRKAKLLMEESRSLGFLMANVSYALFNTTTIEDLYKKSNVVSGCIPQEPVV
VFPADIQNKGSLAKILFAPKDGFRIKFSGQHLTIRTAKFKIRGKEIKILTKTKREILKN
IEKLRRVWYREQHYKLKLFGKEVSAKPRFLDKRKTSIERRDPNKLADQTDDRQAELRNK
EYELRHKQHKMAERLDNIDTNAQNLQTLSFWVGEADKPPKLDEKDARGFGVRTCISAWK
WFMEDLLKKQEEDPLLKLKLSIM (SEQ ID NO:190)

>Cas14b.11|CG_4_10_14_0.8_um_filter_scaffold_20762_curated|1372..3219
PKKPKFQKRTGFPQPDNLRKEYCLAIVRAANLDADFEKKCTKCEGIKTNKKGNIVKGRT
YNSADKDNLLCYACNISTGAPAVDYVFVGALEAKYKILQMVKAYDFHSLAYNLAKLWKG
RGRGHQRMGGLNEVVIVSNNEKALDVIEKSLNHFHDEIRGELSRLKAKFQNEHLHVHKE
SKLRRKLRKISRLLKRRRWKWDVIPNSYLRNFTFTKTRPDFISVALLHRVGRDIGLVTK
TKIPKPTDLLPQFGFQIYYTWDEPKLNKLKKSRLRSEPKRLLVPYKKIELYKNKSVLEE
AIRHLAEVYTEDLTICFKDFFETQKRKFVSKEKESLKRELLKELTKLKKDFSERKTALK
RDRKEIKEPKKAKLLMEESRSLGFLAANTSYALFNLIAADLYTKSKKACSTKLPRQLST
ILPLEIKEHKSTTSLAIKPEEGFKIRFSNTHLSIRTPKFKMKGADIKALTKRKREILKN
ATKLEKSWYGLKHYKLKLYGKEVAAKPRFLDKRNPSIDRRDPKELMEQIENRRNEVKDL
EYEIRKGQHQMAKRLDNVDTNAQNLQTKSFWVGEADKPPELDSMEAKKLGLRTCISAWK
WFMKDLVLLQEKSPNLKLKLSLTEM (SEQ ID NO:191)

>Cas14b.12|CG22_combo_CG10-13_8_21_14_all_scaffold_2003_curated|553..2880|revcom
KFSKRQEGFLIPDNIDLYKCLAIVRSANLDADVQGHKSCYGVKKNGTYRVKQNGKKGVK
EKGRKYVFDLIAFKGNIEKIPHEAIEEKDQGRVIVLGKFNYKLILNIEKNHNDRASLEI
KNKIKKLVQISSLETGEFLSDLLSGKIGIDEVYGIIEPDVFSGKELVCKACQQSTYAPL
VEYMPVGELDAKYKILSAIKGYDFLSLAYNLSRNRANKKRGHQKLGGGELSEVVISANY
DKALNVIKRSINHYHVEIKPEISKLKKKMQNEPLKVMKQARIRRELHQLSRKVKRLKWK
WGMIPNPELQNIIFEKKEKDFVSYALLHTLGRDIGLFKDTSMLQVPNISDYGFQIYYSW
EDPKLNSIKKIKDLPKRLLIPYKRLDFYIDTILVAKVIKNLIELYRKSYVYETFGEEYG
YAKKAEDILFDWDSINLSEGIEQKIQKIKDEFSDLLYEARESKRQNFVESFENILGLYD
KNFASDRNSYQEKIQSMIIKKQQENIEQKLKREFKEVIERGFEGMDQNKKYYKVLSPNI
KGGLLYTDTNNLGFFRSHLAFMLLSKISDDLYRKNNLVSKGGNKGILDQTPETMLTLEF
GKSNLPNISIKRKFFNIKYNSSWIGIRKPKFSIKGAVIREITKKVRDEQRLIKSLEGVW
HKSTHFKRWGKPRFNLPRHPDREKNNDDNLMESITSRREQIQLLLREKQKQQEKMAGRL
DKIDKEIQNLQTANFQIKQIDKKPALTEKSEGKQSVRNALSAWKWFMEDLIKYQKRTPI
LQLKLAKM (SEQ ID NO: 192)

FIG. 7 (Cont.)

>Cas14b.13|rifcsphigho2_01_scaffold_82367_curated|1523..3856|revcom
KFSKRQEGFVIPENIGLYKCLAIVRSANLDADVQGHVSCYGVKKNGTYVLKQNGKKSIR
EKGRKYASDLVAFKGDIEKIPFEVIEEKKKEQSIVLGKFNYKLVLDVMKGEKDRASLTM
KNKSKKLVQVSSLGTDEFLLTLLNEKFGIEEIYGIIEPEVFSGKKLVCKACQQSTYAPL
VEYMPVGELDSKYKILSAIKGYDFLSLAYNLARHRSNKKRGHQKLGGGELSEVVISANN
AKALNVIKRSLNHYYSEIKPEISKLRKKMQNEPLKVGKQARMRRELHQLSRKVKRLKWK
WGKIPNLELQNITFKESDRDFISYALLHTLGRDIGMFNKTEIKMPSNILGYGFQIYYDW
EEPKLNTIKKSKNTPKRILIPYKKLDFYNDSILVARAIKELVGLFQESYEWEIFGNEYN
YAKEAEVELIKLDEESINGNVEKKLQRIKENFSNLLEKAREKKRQNFIESFESIARLYD
ESFTADRNEYQREIQSFIIEKQKQSIEKKLKNEFKKIVEKKFNEQEQGKKHYRVLNPTI
INEFLPKDKNNLGFLRSKIAFILLSKISDDLYKKSNAVSKGGEKGIIKQQPETILDLEF
SKSKLPSINIKKKLFNIKYTSSWLGIRKPKFNIKGAKIREITRRVRDVQRTLKSAESSW
YASTHFRRWGFPRFNQPRHPDKEKKSDDRLIESITLLREQIQILLREKQKGQKEMAGRL
DDVDKKIQNLQTANFQIKQTGDKPALTEKSAGKQSFRNALSAWKWFMENLLKYQNKTPD
LKLKIARTVM (SEQ ID NO: 193)

>Cas14b.14|gwc1_scaffold_8732_curated|2705..4537
KWIEPNNIDFNKCLAITRSANLDADVQGHKMCYGIKTNGTYKAIGKINKKHNTGIIEKR
RTYVYDLIVTKEKNEKIVKKTDFMAIDEEIEFDEKKEKLLKKYIKAEVLGTGELIRKDL
NDGEKFDDLCSIEEPQAFRRSELVCKACNQSTYASDIRYIPIGEIEAKYKILKAIKGYD
FLSLKYNLGRLRDSKKRGHQKMGQGELKEFVICANKEKALDVIKRSLNHYLNEVKDEIS
RLNKKMQNEPLKVNDQARWRRELNQISRRLKRLKWKWGEIPNPELKNLIFKSSRPEFVS
YALIHTLGRDIGLINETELKPNNIQEYGFQIYYKWEDPELNHIKKVKNIPKRFIIPYKN
LDLFGKYTILSRAIEGILKLYSSSFQYKSFKDPNLFAKEGEKKITNEDFELGYDEKIKK
IKDDFKSYKKALLEKKKNTLEDSLNSILSVYEQSLLTEQINNVKKWKEGLLKSKESIHK
QKKIENIEDIISRIEELKNVEGWIRTKERDIVNKEETNLKREIKKELKDSYYEEVRKDF
SDLKKGEESEKKPFREEPKPIVIKDYIKFDVLPGENSALGFFLSHLSFNLFDSIQYELF
EKSRLSSSKHPQIPETILDL (SEQ ID NO: 194)

>Cas14b.15|3300010293.a|Ga0116204_1008574|2134..4032
FRKFVKRSGAPQPDNLNKYKCIAIVRAANLDADIMSNESSNCVMCKGIKMNKRKTAKGA
AKTTELGRVYAGQSGNLLCTACTKSTMGPLVDYVPIGRIRAKYTILRAVKEYDFLSLAY
NLARTRVSKKGGRQKMHSLSELVIAAEYEIAWNIIKSSVIHYHQETKEEISGLRKKLQA
EHIHKNKEARIRREMHQISRRIKRLKWKWHMIPNSELHNFLFKQQDPSFVAVALLHTLG
RDIGMINKPKGSAKREFIPEYGFQIYYKWMNPKLNDINKQKYRKMPKRSLIPYKNLNVF
GDRELIENAMHKLLKLYDENLEVKGSKFFKTRVVAISSKESEKLKRDLLWKGELAKIKK
DFNADKNKMQELFKEVKEPKKANALMKQSRNMGFLLQNISYGALGLLANRMYEASAKQS
KGDATKQPSIVIPLEMEFGNAFPKLLLRSGKFAMNVSSPWLTIRKPKFVIKGNKIKNIT
KLMKDEKAKLKRLETSYHRATHFRPTLRGSIDWDSPYFSSPKQPNTHRRSPDRLSADIT
EYRGRLKSVEAELREGQRAMAKKLDSVDMTASNLQTSNFQLEKGEDPRLTEIDEKGRSI
RNCISSWKKFMEDLMKAQEANPVIKIKIALKDESSVLSEDSM (SEQ ID NO: 195)

FIG. 7 (Cont.)

>Cas14b.16|3300005573.a|Ga0078972_1001015a|33750..35627
KFHPENLNKSYCLAIVRAANLDADIQGHINCIGIKSNKSDRNYENKLESLQNVELLCKA
CTKSTYKPNINSVPVGEKKAKYSILSEIKKYDFNSLVYNLKKYRKGKSRGHQKLNELRE
LVITSEYKKALDVINKSVNHYLVNIKNKMSKLKKILQNEHIHVGTLARIRRERNRISRK
LDHYRKKWKFVPNKILKNYVFKNQSPDFVSVALLHKLGRDIGLITKTAILQKSFPEYSL
QLYYKYDTPKLNYLKKSKFKSLPKRILISYKYPKFDINSNYIEESIDKLLKLYEESPIY
KNNSKIIEFFKKSEDNLIKSENDSLKRGIMKEFEKVTKNFSSKKKKLKEELKLKNEDKN
SKMLAKVSRPIGFLKAYLSYMLFNIISNRIFEFSRKSSGRIPQLPSCIINLGNQFENFK
NELQDSNIGSKKNYKYFCNLLLKSSGFNISYEEEHLSIKTPNFFINGRKLKEITSEKKK
IRKENEQLIKQWKKLTFFKPSNLNGKKTSDKIRFKSPNNPDIERKSEDNIVENIAKVKY
KLEDLLSEQRKEFNKLAKKHDGVDVEAQCLQTKSFWIDSNSPIKKSLEKKNEKVSVKKK
MKAIRSCISAWKWFMADLIEAQKETPMIKLKLALM (SEQ ID NO: 196)

>Cas14c.1|CG10_big_fil_rev_8_21_14_0.10_scaffold_4477_curat
ed|19327..20880|revcom
TTLVPSHLAGIEVMDETTSRNEDMIQKETSRSNEDENYLGVKNKCGINVHKSGRGSSKH
EPNMPPEKSGEGQMPKQDSTEMQQRFDESVTGETQVSAGATASIKTDARANSGPRVGTA
RALIVKASNLDRDIKLGCKPCEYIRSELPMGKKNGCNHCEKSSDIASVPKVESGFRKAK
YELVRRFESFAADSISRHLGKEQARTRGKRGKKDKKEQMGKVNLDEIAILKNESLIEYT
ENQILDARSNRIKEWLRSLRLRLRTRNKGLKKSKSIRRQLITLRRDYRKWIKPNPYRPD
EDPNENSLRLHTKLGVDIGVQGGDNKRMNSDDYETSFSITWRDTATRKICFTKPKGLLP
RHMKFKLRGYPELILYNEELRIQDSQKFPLVDWERIPIFKLRGVSLGKKKVKALNRITE
APRLVVAKRIQVNIESKKKKVLTRYVYNDKSINGRLVKAEDSNKDPLLEFKKQAEEINS
DAKYYENQEIAKNYLWGCEGLHKNLLEEQTKNPYLAFKYGFLNIV (SEQ ID
NO:197)

>Cas14c.2|3300001245.a|JGI12048J13642_10201286|4257..5489|r
evcom
LDFKRTCSQELVLLPEIEGLKLSGTQGVTSLAKKLINKAANVDRDESYGCHHCIHTRTS
LSKPVKKDCNSCNQSTNHPAVPITLKGYKIAFYELWHRFTSWAVDSISKALHRNKVMGK
VNLDEYAVVDNSHIVCYAVRKCYEKRQRSVRLHKRAYRCRAKHYNKSQPKVGRIYKKSK
RRNARNLKKEAKRYFQPNEITNGSSDALFYKIGVDLGIAKGTPETEVKVDVSICFQVYY
GDARRVLRVRKMDELQSFHLDYTGKLKLKGIGNKDTFTIAKRNESLKWGSTKYEVSRAH
KKFKPFGKKGSVKRKCNDYFRSIASWSCEAASQRAQSNLKNAFPYQKALVKCYKNLDYK
GVKKNDMWYRLCSNRIFRYSRIAEDIAQYQSDKGKAKFEFVILAQSVAEYDISAIM
(SEQ ID NO: 198)

FIG. 7 (Cont.)

>Cas14d.1|RIFCSPHIGHO2_01_FULL_CPR_46_36_rifcsphigho2_01_scaffold_646_curated|49808..51616|revcom
VFLTDDKRKTALRKIRSAFRKTAEIALVRAQEADSLDRQAKKLTIETVSFGAPGAKNAF
IGSLQGYNWNSHRANVPSSGSAKDVFRITELGLGIPQSAHEASIGKSFELVGNVVRYTA
NLLSKGYKKGAVNKGAKQQREIKGKEQLSFDLISNGPISGDKLINGQKDALAWWLIDKM
GFHIGLAMEPLSSPNTYGITLQAFWKRHTAPRRYSRGVIRQWQLPFGRQLAPLIHNFFR
KKGASIPIVLTNASKKLAGKGVLLEQTALVDPKKWWQVKEQVTGPLSNIWERSVPLVLY
TATFTHKHGAAHKRPLTLKVIRISSGSVFLLPLSKVTPGKLVRAWMPDINILRDGRPDE
AAYKGPDLIRARERSFPLAYTCVTQIADEWQKRALESNRDSITPLEAKLVTGSDLLQIH
STVQQAVEQGIGGRISSPIQELLAKDALQLVLQQLFMTVDLLRIQWQLKQEVADGNTSE
KAVGWAIRISNIHKDAYKTAIEPCTSALKQAWNPLSGFEERTFQLDASIVRKRSTAKTP
DDELVIVLRQQAAEMTVAVTQSVSKELMELAVRHSATLHLLVGEVASKQLSRSADKDRG
AMDHWKLLSQSM (SEQ ID NO: 199)

>Cas14d.2|rifcsphigho2_01_scaffold_10981_curated|5762..7246|revcom
EDLLQKALNTATNVAAIERHSCISCLFTESEIDVKYKTPDKIGQNTAGCQSCTFRVGYS
GNSHTLPMGNRIALDKLRETIQRYAWHSLLFNVPPAPTSKRVRAISELRVAAGRERLFT
VITFVQTNILSKLQKRYAANWTPKSQERLSRLREEGQHILSLLESGSWQQKEVVREDQD
LIVCSALTKPGLSIGAFCRPKYLKPAKHALVLRLIFVEQWPGQIWGQSKRTRRMRRRKD
VERVYDISVQAWALKGKETRISECIDTMRRHQQAYIGVLPFLILSGSTVRGKGDCPILK
EITRMRYCPNNEGLIPLGIFYRGSANKLLRVVKGSSFTLPMWQNIETLPHPEPFSPEGW
TATGALYEKNLAYWSALNEAVDWYTGQILSSGLQYPNQNEFLARLQNVIDSIPRKWFRP
QGLKNLKPNGQEDIVPNEFVIPQNAIRAHHVIEWYHKTNDLVAKTLLGWGSQTTLNQTR
PQGDLRFTYTRYYFREKEVPEV (SEQ ID NO: 200)

>Cas14d.3|RIFCSPLOWO2_01_FULL_OD1_45_34b_rifcsplowo2_01_scaffold_3495_curated|25656..27605|revcom
VPKKKLMRELAKKAVFEAIFNDPIPGSFGCKRCTLIDGARVTDAIEKKQGAKRCAGCEP
CTFHTLYDSVKHALPAATGCDRTAIDTGLWEILTALRSYNWMSFRRNAVSDASQKQVWS
IEELAIWADKERALRVILSALTHTIGKLKNGFSRDGVWKGGKQLYENLAQKDLAKGLFA
NGEIFGKELVEADHDMLAWTIVPNHQFHIGLIRGNWKPAAVEASTAFDARWLTNGAPLR
DTRTHGHRGRRFNRTEKLTVLCIKRDGGVSEEFRQERDYELSVMLLQPKNKLKPEPKGE
LNSFEDLHDHWWFLKGDEATALVGLTSDPTVGDFIQLGLYIRNPIKAHGETKRRLLICF
EPPIKLPLRRAFPSEAFKTWEPTINVFRNGRRDTEAYYDIDRARVFEFPETRVSLEHLS
KQWEVLRLEPDRENTDPYEAQQNEGAELQVYSLLQEAAQKMAPKVVIDPFGQFPLELFS
TFVAQLFNAPLSDTKAKIGKPLDSGFVVESHLHLLEEDFAYRDFVRVTFMGTEPTFRVI
HYSNGEGYWKKTVLKGKNNIRTALIPEGAKAAVDAYKNKRCPLTLEAAILNEEKDRRLV
LGNKALSLLAQTARGNLTILEALAAEVLRPLSGTEGVVHLHACVTRHSTLTESTETDNM
(SEQ ID NO: 201)

FIG. 7 (Cont.)

>Cas14e.1|rifcsphigho2_01_scaffold_566_curated|113069..114313
VEKLFSERLKRAMWLKNEAGRAPPAETLTLKHKRVSGGHEKVKEELQRVLRSLSGTNQAAWNLGLSGGREPKSSDALKGEKSRVVLETVVFHSGHNRVLYDVIEREDQVHQRSSIMHMRRKGSNLLRLWGRSGKVRRKMREEVAEIKPVWHKDSRWLAIVEEGRQSVVGISSAGLAVFAVQESQCTTAEPKPLEYVVSIWFRGSKALNPQDRYLEFKKLKTTEALRGQQYDPIPFSLKRGAGCSLAIRGEGIKFGSRGPIKQFFGSDRSRPSHADYDGKRRLSLFSKYAGDLADLTEEQWNRTVSAFAEDEVRRATLANIQDFLSISHEKYAERLKKRIESIEEPVSASKLEAYLSAIFETFVQQREALASNFLMRLVESVALLISLEEKSPRVEFRVARYLAESKEGFNRKAM (SEQ ID NO: 202)

>Cas14e.2|rifcsplowo2_01_scaffold_81231_curated|976..2217
VVITQSELYKERLLRVMEIKNDRGRKEPRESQGLVLRFTQVTGGQEKVKQKLWLIFEGFSGTNQASWNFGQPAGGRKPNSGDALKGPKSRVTYETVVFHFGLRLLSAVIERHNLKQQRQTMAYMKRRAAARKKWARSGKKCSRMRNEVEKIKPKWHKDPRWFDIVKEGEPSIVGISSAGFAIYIVEEPNFPRQDPLEIEYAISIWFRRDRSQYLTFKKIQKAEKLKELQYNPIPFRLKQEKTSLVFESGDIKFGSRGSIEHFRDEARGKPPKADMDNNRRLTMFSVFSGNLTNLTEEQYARPVSGLLAPDEKRMPTLLKKLQDFFTPIHEKYGERIKQRLANSEASKRPFKKLEEYLPAIYLEFRARREGLASNWVLVLINSVRTLVRIKSEDPYIEFKVSQYLLEKEDNKAL (SEQ ID NO: 203)

>Cas14e.3|rifcsphigho2_01_scaffold_4702_curated|82881..84230|revcom
KQDALFEERLKKAIFIKRQADPLQREELSLLPPNRKIVTGGHESAKDTLKQILRAINGTNQASWNPGTPSGKRDSKSADALAGPKSRVKLETVVFHVGHRLLKKVVEYQGHQKQQHGLKAFMRTCAAMRKKWKRSGKVVGELREQLANIQPKWHYDSRPLNLCFEGKPSVVGLRSAGIALYTIQKSVVPVKEPKPIEYAVSIWFRGPKAMDREDRCLEFKKLKIATELRKLQFEPIVSTLTQGIKGFSLYIQGNSVKFGSRGPIKYFSNESVRQRPPKADPDGNKRLALFSKFSGDLSDLTEEQWNRPILAFEGIIRRATLGNIQDYLTVGHEQFAISLEQLLSEKESVLQMSIEQQRLKKNLGKKAENEWVESFGAEQARKKAQGIREYISGFFQEYCSQREQWAENWVQQLNKSVRLFLTIQDSTPFIEFRVARYLPKGEKKKGKAM (SEQ ID NO: 204)

>Cas14f.1|rifcsp13_1_sub10_scaffold_3_curated|38906..41041
ANHAERHKRLRKEANRAANRNRPLVADCDTGDPLVGICRLLRRGDKMQPNKTGCRSCEQVEPELRDAILVSGPGRLDNYKYELFQRGRAMAVHRLLKRVPKLNRPKKAAGNDEKKAENKKSEIQKEKQKQRRMMPAVSMKQVSVADFKHVIENTVRHLFGDRRDREIAECAALRAASKYFLKSRRVRPRKLPKLANPDHGKELKGLRLREKRAKLKKEKEKQAELARSNQKGAVLHVATLKKDAPPMPYEKTQGRNDYTTFVISAAIKVGATRGTKPLLTPQPREWQCSLYWRDGQRWIRGGLLGLQAGIVLGPKLNRELLEAVLQRPIECRMSGCGNPLQVRGAAVDFFMTTNPFYVSGAAYAQKKFKPFGTKRASEDGAAAKAREKLMTQLAKVLDKVVTQAAHSPLDGIWETRPEAKLRAMIMALEHEWIFLRPGPCHNAAEEVIKCDCTGGHAILWALIDEARGALEHKEFYAVTRAHTHDCEKQKLGGRLAGFLDLLIAQDVPLDDAPAARKIKTLLEATPPAPCYKAATSIATCDCEGKFDKLWAIIDATRAGHGTEDLWARTLAYPQNVNCKCKAGKDLTHRLADFLGLLIKRDGPFRERPPHKVTGDRKLVFSGDKKCKGHQYVILAKAHNEEVVRAWISRWGLKSRTNKAGYAATELNLLLNWLSICRRRWMDMLTVQRDTPYIRMKTGRLVVDDKKERKAM (SEQ ID NO: 205)

FIG. 7 (Cont.)

>Cas14f.2|3300009991.a|Ga0105042_100140|1624..3348
AKQREALRVALERGIVRASNRTYTLVTNCTKGGPLPEQCRMIERGKARAMKWEPKLVGC
GSCAAATVDLPAIEEYAQPGRLDVAKYKLTTQILAMATRRMMVRAAKLSRRKGQWPAKV
QEEKEEPPEPKKMLKAVEMRPVAIVDFNRVIQTTIEHLWAERANADEAELKALKAAAAY
FGPSLKIRARGPPKAAIGRELKKAHRKKAYAERKKARRKRAELARSQARGAAAHAAIRE
RDIPPMAYERTQGRNDVTTIPIAAAIKIAATRGARPLPAPKPMKWQCSLYWNEGQRWIR
GGMLTAQAYAHAANIHRPMRCEMWGVGNPLKVRAFEGRVADPDGAKGRKAEFRLQTNAF
YVSGAAYRNKKFKPFGTDRGGIGSARKKRERLMAQLAKILDKVVSQAAHSPLDDIWHTR
PAQKLRAMIKQLEHEWMFLRPQAPTVEGTKPDVDVAGNMQRQIKALMAPDLPPIEKGSP
AKRFTGDKRKKGERAVRVAEAHSDEVVTAWISRWGIQTRRNEGSYAAQELELLLNWLQI
CRRRWLDMTAAQRVSPYIRMKSGRMITDAADEGVAPIPLVENM (SEQ ID NO: 206
)

>Cas14g.1|RBG_13_scaffold_1401_curated|15949..18180
KSISGRSIKHMACLKDMLKSEITEIEEKQKKESLRKWDYYSKFSDEILFRRNLNVSANH
DANACYGCNPCAFLKEVYGFRIERRNNERIISYRRGLAGCKSCVQSTGYPPIEFVRRKF
GADKAMEIVREVLHRRNWGALARNIGREKEADPILGELNELLLVDARPYFGNKSAANET
NLAFNVITRAAKKFRDEGMYDIHKQLDIHSEEGKVPKGRKSRLIRIERKHKAIHGLDPG
ETWRYPHCGKGEKYGVWLNRSRLIHIKGNEYRCLTAFGTTGRRMSLDVACSVLGHPLVK
KKRKKGKKTVDGTELWQIKKATETLPEDPIDCTFYLYAAKPTKDPFILKVGSLKAPRWK
KLHKDFFEYSDTEKTQGQEKGKRVVRRGKVPRILSLRPDAKFKVSIWDDPYNGKNKEGT
LLRMELSGLDGAKKPLILKRYGEPNTKPKNFVFWRPHITPHPLTFTPKHDFGDPNKKTK
RRRVFNREYYGHLNDLAKMEPNAKFFEDREVSNKKNPKAKNIRIQAKESLPNIVAKNGR
WAAFDPNDSLWKLYLHWRGRRKTIKGGISQEFQEFKERLDLYKKHEDESEWKEKEKLWE
NHEKEWKKTLEIHGSIAEVSQRCVMQSMMGPLDGLVQKKDYVHIGQSSLKAADDAWTFS
ANRYKKATGPKWGKISVSNLLYDANQANAELISQSISKYLSKQKDNQGCEGRKMKFLIK
IIEPLRENFVKHTRWLHEMTQKDCEVRAQFSRVSM (SEQ ID NO:207)

>Cas14g.2|3300009652.a|Ga0123330_1010394|2814..5123
FPSDVGADALKHVRMLQPRLTDEVRKVALTRAPSDRPALARFAAVAQDGLAFVRHLNVS
ANHDSNCTFPRDPRDPRRGPCEPNPCAFLREVWGFRIVARGNERALSYRRGLAGCKSCV
QSTGFPSVPFHRIGADDCMRKLHEILKARNWRLLARNIGREREADPLLTELSEYLLVDA
RTYPDGAAPNSGRLAENVIKRAAKKFRDEGMRDIHAQLRVHSREGKVPKGRLQRLRRIE
RKHRAIHALDPGPSWEAEGSARAEVQGVAVYRSQLLRVGHHTQQIEPVGIVARTLFGVG
RTDLDVAVSVLGAPLTKRKKGSKTLESTEDFRIAKARETRAEDKIEVAFVLYPTASLLR
DEIPKDAFPAMRIDRFLLKVGSVQADREILLQDDYYRFGDAEVKAGKNKGRTVTRPVKV
PRLQALRPDAKFRVNVWADPFGAGDSPGTLLRLEVSGVTRRSQPLRLLRYGQPSTQPAN
FLCWRPHRVPDPMTFTPRQKFGERRKNRRTRRPRVFERLYQVHIKHLAHLEPNRKWFEE
ARVSAQKWAKARAIRRKGAEDIPVVAPPAKRRWAALQPNAELWDLYAHDREARKRFRGG
RAAEGEEFKPRLNLYLAHEPEAEWESKRDRWERYEKKWTAVLEEHSRMCAVADRTLPQF
LSDPLGARMDDKDYAFVGKSALAVAEAFVEEGTVERAQGNCSITAKKKFASNASRKRLS
VANLLDVSDKADRALVFQAVRQYVQRQAENGGVEGRRMAFLRKLLAPLRQNFVCHTRWL
HM (SEQ ID NO: 208)

FIG. 7 (Cont.)

>Cas14h.1|3300005602.a|Ga0070762_10001740|7377..9071|revcom
AARKKKRGKIGITVKAKEKSPPAAGPFMARKLVNVAANVDGVEVHLCVECEADAHGSAS
ARLLGGCRSCTGSIGAEGRLMGSVDVDRERVIAEPVHTETERLGPDVKAFEAGTAESKY
AIQRGLEYWGVDLISRNRARTVRKMEEADRPESSTMEKTSWDEIAIKTYSQAYHASENH
LFWERQRRVRQHALALFRRARERNRGESPLQSTQRPAPLVLAALHAEAAAISGRARAEY
VLRGPSANVRAAAADIDAKPLGHYKTPSPKVARGFPVKRDLLRARHRIVGLSRAYFKPS
DVVRGTSDAIAHVAGRNIGVAGGKPKEIEKTFTLPFVAYWEDVDRVVHCSSFKADGPWV
RDQRIKIRGVSSAVGTFSLYGLDVAWSKPTSFYIRCSDIRKKFHPKGFGPMKHWRQWAK
ELDRLTEQRASCVVRALQDDEELLQTMERGQRYYDVFSCAATHATRGEADPSGGCSRCE
LVSCGVAHKVTKKAKGDTGIEAVAVAGCSLCESKLVGPSKPRVHRQMAALRQSHALNYL
RRLQREWEALEAVQAPTPYLRFKYARHLEVRSM (SEQ ID NO: 209)

>Cas14h.2|3300005921.a|Ga0070766_10011912|384..2081
AAKKKKQRGKIGISVKPKEGSAPPADGPFMARKLVNVAANVDGVEVNLCIECEADAHGS
APARLLGGCKSCTGSIGAEGRLMGSVDVDRADAIAKPVNTETEKLGPDVQAFEAGTAET
KYALQRGLEYWGVDLISRNRSRTVRRTEEGQPESATMEKTSWDEIAIKSYTRAYHASEN
HLFWERQRRVRQHALALFKRAKERNRGDSTLPREPGHGLVAIAALACEAYAVGGRNLAE
TVVRGPTFGTARAVRDVEIASLGRYKTPSPKVAHGSPVKRDFLRARHRIVGLARAYYRP
SDVVRGTSDAIAHVAGRNIGVAGGKPRAVEAVFTLPFVAYWEDVDRVVHCSSFQVSAPW
NRDQRMKIAGVTTAAGTFSLHGGELKWAKPTSFYIRCSDTRRKFRPKGFGPMKRWRQWA
KDLDRLVEQRASCVVRALQDDAALLETMERGQRYYDVFACAVTHATRGEADRLAGCSRC
ALTPCQEAHRVTTKPRGDAGVEQVQTSDCSLCEGKLVGPSKPRLHRTLTLLRQEHGLNY
LRRLQREWESLEAVQVPTPYLRFKYARHLEVRSM (SEQ ID NO: 210)

>Cas14h.3|3300009698.a|Ga0116216_10000905|8005..9504
TDSQSESVPEVVYALTGGEVPGRVPPDGGSAEGARNAPTGLRKQRGKIKISAKPSKPGS
PASSLARTLVNEAANVDGVQSSGCATCRMRANGSAPRALPIGCVACASSIGRAPQEETV
CALPTTQGPDVRLLEGGHALRKYDIQRALEYWGVDLIGRNLDRQAGRGMEPAEGATATM
KRVSMDELAVLDFGKSYYASEQHLFAARQRRVRQHAKALKIRAKHANRSGSVKRALDRS
RKQVTALAREFFKPSDVVRGDSDALAHVVGRNLGVSRHPAREIPQTFTLPLCAYWEDVD
RVISCSSLLAGEPFARDQEIRIEGVSSALGSLRLYRGAIEWHKPTSLYIRCSDTRRKFR
PRGGLKKRWRQWAKDLDRLVEQRACCIVRSLQADVELLQTMERAQRFYDVHDCAATHVG
PVAVRCSPCAGKQFDWDRYRLLAALRQEHALNYLRRLQREWESLEAQQVKMPYLRFKYA
RKLEVSGPLIGLEVRREPSMGTAIAEM (SEQ ID NO: 211)

>Cas14u.1|3300009029.a|Ga0066793_10010091|37..1113|revcom
AGTAGRRHGSLGARRSINIAGVTDRHGRWGCESCVYTRDQAGNRARCAPCDQSTYAPDV
QEVTIGQRQAKYTIFLTLQSFSWTNTMRNNKRAAAGRSKRTTGKRIGQLAEIKITGVGL
AHAHNVIQRSLQHNITKMWRAEKGKSKRVARLKKAKQLTKRRAYFRRRMSRQSRGNGFF
RTGKGGIHAVAPVKIGLDVGMIASGSSEPADEQTVTLDAIWKGRKKKIRLIGAKGELAV
AACRFREQQTKGDKCIPLILQDGEVRWNQNNWQCHPKKLVPLCGLEVSRKFVSQADRLA
QNKVASPLAARFDKTSVKGTLVESDFAAVLVNVTSIYQQCHAMLLRSQEPTPSLRVQRT
ITSM (SEQ ID NO: 212)

FIG. 7 (Cont.)

>Cas14u.2|3300002172.a|JGI24730J26740_1002785|496..1605|rev
com
GVRFSPAQSQVFFRTVIPQSVEARFAINMAAIHDAAGAFGCSVCRFEDRTPRNAKAVHG
CSPCTRSTNRPDVFVLPVGAIKAKYDVFMRLLGFNWTHLNRRQAKRVTVRDRIGQLDEL
AISMLTGKAKAVLKKSICHNVDKSFKAMRGSLKKLHRKASKTGKSQLRAKLSDLRERTN
TTQEGSHVEGDSDVALNKIGLDVGLVGKPDYPSEESVEVVVCLYFVGKVLILDAQGRIR
DMRAKQYDGFKIPIIQRGQLTVLSVKDLGKWSLVRQDYVLAGDLRFEPKISKDRKYAEC
VKRIALITLQASLGFKERIPYYVTKQVEIKNASHIAFVTEAIQNCAENFREMTEYLMKY
QEKSPDLKVLLTQLM (SEQ ID NO: 213)

>Cas14u.3|19ft_2_nophage_noknown_scaffold_0_curated|508188.
.509648
RAVVGKVFLEQARRALNLATNFGTNHRTGCNGCYVTPGKLSIPQDGEKNAAGCTSCLMK
ATASYVSYPKPLGEKVAKYSTLDALKGFPWYSLRLNLRPNYRGKPINGVQEVAPVSKFR
LAEEVIQAVQRYHFTELEQSFPGGRRRLRELRAFYTKEYRRAPEQRQHVVNGDRNIVVV
TVLHELGFSVGMFNEVELLPKTPIECAVNVFIRGNRVLLEVRKPQFDKERLLVESLWKK
DSRRHTAKWTPPNNEGRIFTAEGWKDFQLPLLLGSTSRSLRAIEKEGFVQLAPGRDPDY
NNTIDEQHSGRPFLPLYLYLQGTISQEYCVFAGTWVIPFQDGISPYSTKDTFQPDLKRK
AYSLLLDAVKHRLGNKVASGLQYGRFPAIEELKRLVRMHGATRKIPRGEKDLLKKGDPD
TPEWWLLEQYPEFWRLCDAAAKRVSQNVGLLLSLKKQPLWQRRWLESRTRNEPLDNLPL
SMALTLHLTNEEAL (SEQ ID NO: 214)

>Cas14u.4|rifcsp2_19_4_full_scaffold_168_curated|84455..856
57
AAVYSKFYIENHFKMGIPETLSRIRGPSIIQGFSVNENYINIAGVGDRDFIFGCKKCKY
TRGKPSSKKINKCHPCKRSTYPEPVIDVRGSISEFKYKIYNKLKQEPNQSIKQNTKGRM
NPSDHTSSNDGIIINGIDNRIAYNVIFSSYKHLMEKQINLLRDTTKRKARQIKKYNNSG
KKKHSLRSQTKGNLKNRYHMLGMFKKGSLTITNEGDFITAVRKVGLDISLYKNESLNKQ
EVETELCLNIKWGRTKSYTVSGYIPLPINIDWKLYLFEKETGLTLRLFGNKYKIQSKKF
LIAQLFKPKRPPCADPVVKKAQKWSALNAHVQQMAGLFSDSHLLKRELKNRMHKQLDFK
SLWVGTEDYIKWFEELSRSYVEGAEKSLEFFRQDYFCFNYTKQTTM (SEQ ID NO: 215
)

>Cas14u.5|3300012532.a|Ga0137373_10000316|3286..5286
PQQQRDLMLMAANYDQDYGNGCGPCTVVASAAYRPDPQAQHGCKRHLRTLGASAVTHVG
LGDRTATITALHRLRGPAALAARARAAQAASAPMTPDTDAPDDRRRLEAIDADDVVLVG
AHRALWSAVRRWADDRRAALRRRLHSEREWLLKDQIRWAELYTLIEASGTPPQGRWRNT
LGALRGQSRWRRVLAPTMRATCAETHAELWDALAELVPEMAKDRRGLLRPPVEADALWR
APMIVEGWRGGHSVVVDAVAPPLDLPQPCAWTAVRLSGDPRQRWGLHLAVPPLGQVQPP
DPLKATLAVSMRHRGGVRVRTLQAMAVDADAPMQRHLQVPLTLQRGGGLQWGIHSRGVR
RREARSMASWEGPPIWTGLQLVNRWKGQGSALLAPDRPPDTPPYAPDAAVAPAQPDTKR
ARRTLKEACTVCRCAPGHMRQLQVTLTGDGTWRRFRLRAPQGAKRKAEVLKVATQHDER
IANYTAWYLKRPEHAAGCDTCDGDSRLDGACRGCRPLLVGDQCFRRYLDKIEADRDDGL
AQIKPKAQEAVAAMAAKRDARAQKVAARAAKLSEATGQRTAATRDASHEARAQKELEAV
ATEGTTVRHDAAAVSAFGSWVARKGDEYRHQVGVLANRLEHGLRLQELMAPDSVVADQQ
RASGHARVGYRYVLTAM (SEQ ID NO:216)


FIG. 7 (Cont.)

>Cas14u.6|3300006028.a|Ga0070717_10000077|54519..56201|revcom
AVAHPVGRGNAGSPGARGPEELPRQLVNRASNVTRPATYGCAPCRHVRLSIPKPVLTGC
RACEQTTHPAPKRAVRGGADAAKYDLAAFFAGWAADLEGRNRRRQVHAPLDPQPDPNHE
PAVTLQKIDLAEVSIEEFQRVLARSVKHRHDGRASREREKARAYAQVAKKRRNSHAHGA
RTRRAVRRQTRAVRRAHRMGANSGEILVASGAEDPVPEAIDHAAQLRRRIRACARDLEG
LRHLSRRYLKTLEKPCRRPRAPDLGRARCHALVESLQAAERELEELRRCDSPDTAMRRL
DAVLAAAAASTDATFATGWTVVGMDLGVAPRGSAAPEVSPMEMAISVFWRKGSRRVIVSK
PIAGMPIRRHELIRLEGLGTLRLDGNHYTGAGVTKGRGLSEGTEPDFREKSPSTLGFTL
SDYRHESRWRPYGAKQGKTARQFFAAMSRELRALVEHQVLAPMGPPLLEAHERRFETLL
KGQDNKSIHAGGGGRYVWRGPPDSKKRPAADGDWFRFGRGHADHRGWANKRHELAANYL
QSAFRLWSTLAEAQEPTPYARYKYTRVTM (SEQ ID NO:217)

>Cas14u.7|3300001256.a|JGI12210J13797_10004690|5792..7006
WDFLTLQVYERHTSPEVCVAGNSTKCASGTRKSDHTHGVGVKLGAQEINVSANDDRDHE
VGCNICVISRVSLDIKGWRYGCESCVQSTPEWRSIVRFDRNHKEAKGECLSRFEYWGAQ
SIARSLKRNKLMGGVNLDELAIVQNENVVKTSLKHLFDKRKDRIQANLKAVKVRMRERR
KSGRQRKALRRQCRKLKRYLRSYDPSDIKEGNSCSAFTKLGLDIGISPNKPPKIEPKVE
VVFSLFYQGACDKIVTVSSPESPLPRSWKIKIDGIRALYVKSTKVKFGGRTFRAGQRNN
RRKVRPPNVKKGKRKGSRSQFFNKFAVGLDAVSQQLPIASVQGLWGRAETKKAQTICLK
QLESNKPLKESQRCLFLADNWVVRVCGFLRALSQRQGPTPYIRYRYRCNM (SEQ ID
NO:218)

>Cas14u.8|3300005660.a|Ga0073904_10021651|765..1943
ARNVGQRNASRQSKRESAKARSRRVTGGHASVTQGVALINAAANADRDHTTGCEPCTWE
RVNLPLQEVIHGCDSCTKSSPFWRDIKVVNKGYREAKEEIMRIASGISADHLSRALSHN
KVMGRLNLDEVCILDFRTVLDTSLKHLTDSRSNGIKEHIRAVHRKIRMRRKSGKTARAL
RKQYFALRRQWKAGHKPNSIREGNSLTALRAVGFDVGVSEGTEPMPAPQTEVVLSVFYK
GSATRILRISSPHPIAKRSWKVKIAGIKALKLIRREHDFSFGRETYNASQRAEKRKFSP
HAARKDFFNSFAVQLDRLAQQLCVSSVENLWVTEPQQKLLTLAKDTAPYGIREGARFAD
TRARLAWNWVFRVCGFTRALHQEQEPTPYCRFTWRSKM (SEQ ID NO:219)

FIG. 8


A
Type V CRISPR
Cas12a
(Cpf1)
Cas12d
(CasY)
Cas12c
(C2c3)
Cas14a
(6 variants)
Cas12e
(CasX)
Cas14b
(16 variants)
Cas12b
(C2c1)
Cas14c (2 variants)
= New, miniature CRISPR systems




B
CRISPR array
C2c10 Locus
C2c10
Type V-F Loci
Cas1
2
Cas4
Cas14a
Cas14b
Cas1
2
Cas4
Cas1
2
Cas4
Cas14c

FIG. 8 (Cont.)

C


1500
1200
900
600
Length (amino acids)
Cas9
Cas12
Cas14
Cas Effector

D



SpCas9 (II-A)
1368aa
FnCas12a (V-A)
1300aa
Cas14a (V-F)
530aa
= RuvC Nuclease
= HNH Nuclease

FIG. 9



Cas14a1|rifcsphigho2 01 scaffold 2167 curated|30296..31798|revcom
Cas14a2|gwa2 scaffold 18027 curated|7105..8628
Cas14a3|gwa1 scaffold 1795 curated|25635..27224|revcom
Cas14a5|rifcsplowo2 01 scaffold 34461 curated|4968..6521
Cas14a6|3300012359.a|Ga0137385 |000156|41289..42734
Cas14a4|CG10 big fil rev 8 21 14 0.10 scaffold 20906 curated|649..2829
Cas14b8|3300013125.a|Ga0172369 100104641885..2489|revcom
Cas14b1|rifcsplowo2 01 scaffold 239 curated|54653..56257
Cas14b2|rifcsplowo2 01 scaffold 282 curated|77370..78983
Cas14b3|rifcsphigho2 01 scaffold 36781 curated|2592..4217
Cas14b5|rifcsphigho2 02 scaffold 55589 curated|1904..3598
Cas14b6|CG03 land 8 20 14 0.80 scaffold 2214 curated|6634..8466|revcom
Cas14b9|3300013127.a|Ga0172365 10004421|633..2366|revcom
Cas14b4|cg1 0.2 scaffold 785 c curated|32521..34155
Cas14b7|3300013125.a|Ga0172369 10000737|994..2652|revcom
Cas14b10|CG08 land 8 20 14 0.20 scaffold 1609 curated|6134..7975
Cas14b11|CG 4 10 14 0.8 um filter scaffold 20762 curated|1372..3219
Cas14b12|CG22 combo CG10-13 8 21 14 all scaffold 2003 curated|553..2880|revcom
Cas14b13|rifcsphigho2 01 scaffold 82367 curated|1523..3856|revcom
Cas14b14|gwc1 scaffold 8732 curated|2705..4537
Cas14b15|3300010293.a|Ga0116204 1008574|2134..4032
Cas14b16|3300005573.a|Ga0078972 1001015a|33750..35627
Cas14c1|CG10 big fil rev 8 21 14 0.10 scaffold 4477 curated|19327..20880|revcom
Cas14c2|3300001245.a|JGI12048J13642 10201286|4257..5489|revcom
C2c10
C2c10
Cas14a
C2c4JDUV01000002.1|28488..27076
C2c5
Cas14b
C2c8|KB901025.1|19229..19011
Cas12b
Cas12a|JRNR01000108.11..2492
Cas12c
Cas12d
Cas12e
Cas12a
Cas14c
C2c9
C2c9|LSIU01000262.1|9240..10514
C2c8|JMEB01000112.1|762..1
C2c9|CCIN01000047.1|3246..2737
C2c8
C2c4
C2c4|LFPO01000007.1|134156..132627

FIG. 10



h
f
d, e
c
a
a-c
d
g
Cas subtype
III-A
III-B
III-C
III-D
IV
V-A
V-B
V-C
V-D
V-E
VI
I-A
I-B
I-C
I-D
I-E
I-F
I-U
II-A
II-B
II-C
Cas14a-associated
Cas14b-associated
Cas14c-associated
Cas14d-associated
Cas14e-associated
Cas14f-associated
Cas14g-associated
Cas14h-associated
Cas14u-associated
Casposon

Figure 11, Panels A-B




Figure 12, Panels A-D




FIG. 13



A
Cas14a1
1,854
RNAseq Coverage
Cas14a
Cas14a2
2,822
RNAseq Coverage
Cas14a
Cas14a3
495
RNAseq Coverage
Cas14a

FIG. 13 (Cont.)

A (Cont.)




FIG. 13 (Cont.)

A (Cont.)




FIG. 13 (Cont.)

A (Cont.)




FIG. 13 (Cont.)




Figure 14, Panels A-B




FIG. 15

A





E. coli containing
Cas14 CRISPR locus, SpCas9 or
empty vector
+ Randomized PAM
plasmid target
Antibiotic selection
for target plasmid
PAM Sequencing
NNNNNNN
NNNNNNN
NNNNNNN
Determine depeleted sequences containing
targeted PAM
bits
2
1
0
5'
1
2
3
4
5
6
7
8
3'

FIG. 15 (Cont.)

B




PDVT




20 No Sequences

FIG. 15 (Cont.)

C



PDVT



20 No Sequences

FIG. 15 (Cont.)




FIG. 16





FIG. 16 (Cont.)

B


tracrRNA
3'
5'
crRNA
ssDNA
target
3'
Cleavage
sites



ssRNA
dsDNA
ssDNA
1.0
0.5
0
Fraction Cleaved
0
2
4
6
8
10
Time (min)
+crRNA
+tracrRNA
+crRNA,
+tracrRNA
+sgRNA

FIG. 16 (Cont.)



C
crRNA
1
2
3
4
5'
ssDNA target 3'
crRNA: - 1 2 3 4
S
P
40
30
20
10
D
Activated Cas14a1
M13 bacteriophage ssDNA
Cas14a1
dCas14a (1.5hr)
Time: 0
1.5hr
M13 Substrate
M13 Products
RNA + Activator
3kb
1kb
0.5kb
100bp

FIG. 17



A
kDa
100
70
55
40
wt
D326A
E422A
E510A
R490A
B
Cas14a1
ssDNA
Variable:
NaCl
Metal
Temp
-
25mM
50mM
75mM
100mM
150mM
200mM
250mM
EDTA
Ca
Co
Cu
Mg
Mn
Ni
Zn
RT
37
45
55
S
P
C
Cas14a1
ssDNA
Spacer Length:
-
10nt
12nt
14nt
16nt
18nt
20nt
25nt
S
P

FIG. 17 (Cont.)



D
Identity
FnCas12a
AsCas12a
Cas12e
Transposase,
Cas14a4
Cas14a3
Cas14a2
Cas14a1
Cas14b11
Cas14b12
Cas14b13
Cas14b14
Cas14b4
Cas14b5
Cas14b6
Cas14b3
Cas14b1
Cas14b2

FIG. 17 (Cont.)

D (Cont.)




FIG. 17 (Cont.)




FIG. 18




FIG. 19



A
Cas14a
tracrRNA 3'
crRNA 5'
3'
ssDNA target
B
kObs (min-1)
0.025
0.020
0.015
0.010
0.005
0.000
25nt
20nt
16nt
14nt
14nt
12nt
10nt
spacer
spacer
spacer
spacer
spacer
spacer
spacer
C
kObs (min-1)
0.025
0.020
0.015
0.010
0.005
0.000
Full
20nt
17nt
15nt
10nt

FIG. 19 (Cont.)




D
E
Tetraloop
kObs (min-1)
0.00
0.01
0.02
1
2
3
4
tracrRNA
tracrRNA
tracrRNA
tracrRNA
short
tracrRNA
long
sgRNA
1
sgRNA
2

FIG. 19 (Cont.)

F


Guide RNA
1
2
3
4
Target DNA
1
2
3
4
15000
10000
5000
0



Fluorescence (AU)
20000
15000
10000
5000
0
Target 1
Target 2
Target 3
Target 4
Guide 1
Guide 2
Guide 3
Guide 4

FIG. 20



A
Cas14a
+ ssDNA activator
F
Q
T5:
T12:
T12
T11
T10
T9
T8
T7
T6
T5
Fluorescence (AU)
60000
40000
20000
0
0
50
100
Time (min)

FIG. 20 (Cont.)



B
5'
Perfect
5'
1-2MM
5'
19-20MM
5'
k_{Obs} (min-1)
0.1
0.01
0.001
0.0001
Perfect, AAAT 3'
Perfect, TCGT 3'
1-2MM
3-4MM
5-6MM
7-8MM
9-10MM
11-12MM
13-14MM
15-16MM
17-18MM
19-20MM
Internal seed

FIG. 20 (Cont.)

C



Saliva sample
Amplification
dsDNA targets
PT
Cas14a + T7 exonuclease
HERC2 gene
Brown-eye SNP: TTCATTTGAGCATTAAATGTCAAGTTCTGC
Blue-eye SNP: TTCATTTGAGCATTAAGTGTCAAGTTCTGC
crRNA: AACTCGTAATTCACAGTTCA

FIG. 20 (Cont.)



D
Bkgd-subtracted fluorescence (AU)
5000
4000
3000
2000
1000
0
0
1.25
2.50
5.00
10.00
u T7 exonuclease added
E
Bkgd-subtracted fluorescence (AU)
10000
5000
0
Cas14a G SNP
Cas14a A SNP
Cas12a G SNP
Cas12a A SNP

FIG. 21



A
5'
Perfect Target
5'
1-2MM
5'
...
...
19-20MM
5'
Fluorescence (AU)
30000
20000
10000
0
0
50
100
Time (min)
AGCA PAM
1-2MM
3-4MM
5-6MM
7-8MM
9-10MM
11-12MM
13-14MM
15-16MM
17-18MM
19-20MM
TTTA PAM

FIG. 21 (Cont.)



B
Target 2
k_{Obs} (min-1)
0.1
0.01
0.001
0.0001
AGCA PAM
1-2MM
3-4MM
5-6MM
7-8MM
9-10MM
11-12MM
13-14MM
15-16MM
17-18MM
19-20MM
TTTA PAM
C
Target 3
k_{Obs} (min-1)
0.1
0.01
0.001
0.0001
Perfect
1-2MM
3-4MM
5-6MM
7-8MM
9-10MM
11-12MM
13-14MM
15-16MM
17-18MM
19-20MM
21-22MM
23-24MM
25-26MM
D
Target 1
k_{Obs} (min-1)
0.1
0.01
0.001
0.0001
AGCA PAM
1-2MM
3-4MM
5-6MM
7-8MM
9-10MM
11-12MM
13-14MM
15-16MM
17-18MM
19-20MM
TTTA PAM

FIG. 21 (Cont.)



E
No loop
5'
34 30 25 20 15 9
5nt SL
5'
34 30 25 20 15 9
25nt SL
5'
34 30 25 20 15 9
Hairpin substrates
kCleave (min-1)
0.15
0.10
0.05
0.00
No loop
0nt SL
5nt SL
10nt SL
15nt SL
20nt SL
25nt SL
F
Full
54 35 30 25 20 14
5' -20nt
5' -35nt
3' -5nt
3' -34nt
Activator length
kCleave (min-1)
0.08
0.06
0.04
0.02
0.00
5' -20nt
5' -25nt
5' -30nt
5' -35nt
Full
3' -5nt
3' -9nt
3' -14nt
3' -19nt
3' -24nt
3' -29nt
3' -34nt

FIG. 22



A
Cas1
2
Cas4
Cas14a
508aa
Cas14b
614aa
Cas1
2
Cas4
Cas14c
518aa
Cas1
2
Cas4
Cas14d
650aa
Cas1
Cas14e
415aa
Cas1
2
Cas14f
712aa
Cas1
2
Cas1+4
2
Cas14g
744aa
Cas1
2
Cas14h
565aa

FIG. 22 (Cont.)



B
Cas12a (Cpf1)
Cas12b (C2c1)
Cas12c (C2c3)
Cas12d (CasY)
Cas12e (CasX)
C2c4
C2c5
C2c8
C2c10
Cas14a-associated
Cas14b-associated
Cas14c-associated
Cas14d-associated
Cas14e-associated
Cas14f-associated
Cas14g-associated
Cas14h-associated
Cas14u-associated
Cas14a
Cas14g
Cas14f
Cas14c
Cas14h
Cas14e
Cas14b
Cas14d

FIG. 23




A
Tet Promoter
Cas14a
tracrRNA
Tet Promoter
PBAD promoter
Cas12a (Cpf1)
B
LbCas12a
Non-targeting spacer
Targeting spacer
ΦX174 phage
Cas14a1
Non-targeting spacer
Targeting spacer
ΦX174 phage

FIG. 23 (Cont.)


Cas12a, no Phage
Cas12a T guide
Cas12a NT guide
Cas14, No phage
Cas14 T guide
Cas14 NT guide
OD 600
1.0
0.8
0.6
0.4
0.2
0
500
1000
Time (min)

C

FIG. 24

Plasmid pLBH533_MBP-Cas14b2 expression (Addgene Plasmid Number 112506)

GCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCGAGATCTCGATCC
CGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGTGCCGGCTCCGGAGAGCTC
TTTAATTAAGCGGCCGCCCTGCAGGACTCGAGTTCTAGAAATAATTTTGTTTAACTTTAAGAAGGAGATA
TACATATGAAATCTTCTCACCATCACCATCACCATGGTTCTTCTATGAAAATCGAAGA
AGGTAAACTGGTAATCTGGATTAACGGCGATAAAGGCTATAACGGTCTCGCTGAAGTCGGTAAGAAATTC
GAGAAAGATACCGGAATTAAAGTCACCGTTGAGCATCCGGATAAACTGGAAGAGAAATTCCCACAGGTTG
CGGCAACTGGCGATGGCCCTGACATTATCTTCTGGGCACACGACCGCTTTGGTGGCTACGCTCAATCTGG
CCTGTTGGCTGAAATCACCCCGGACAAAGCGTTCCAGGACAAGCTGTATCCGTTTACCTGGGATGCCGTA
CGTTACAACGGCAAGCTGATTGCTTACCCGATCGCTGTTATCGCTGATTTATAACAAAGATC
TGCTGCCGAACCCCGCCAAAAACCTGGGAAGATCCCGGCGCTGGATAAAGAACTGAAAGCGAAAGGTAA
GAGCGCGCTGATGTTCAACCTGCAAGAACCGTACTTCACCTGGCCGCTGATTGCTGCTGACGGGGGTTAT
GCGTTCAAGTATGAAAACGGCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTGGCGCGAAAGCGG
GTCTGACCTTCCTGGTTGACCTGATTAAAAACAAACACATGAATGCAGACCGATTACTCCATCGCAGA
AGCTGCCTTTAATAAAGGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCCAACATCGACACC
AGCAAAGTGAATTATGGTGTACTGCCGACCTTCAAGGGTCAACCATCCAAACCGTTCGTTCGGCG
TGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTCCTCGAAAACTATCT
GCTGACTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTGGGTGCCGTAGGCGCTGAAGTCTTAC
GAGGAAGAGTTGGCGAAAGATCCACGTATTGCCGCCACTATGGAAAACGCCCAGAAAGGTGAAATCATGC
CGAACATCCCGCAGATGTCCGCTTTCTGGTATGCCGTGCTACTGCGGTGATCAACGCCGCCAGCGGTCG
TCAGACTGTCGATGAAGCCCTGAAAGACGCGCAGACTAATTCGAGCTCGAACAACAACAATAACAATT
AACAACAACCTCGGGATCGAGGAAAACCTGTACTTCCAATCCAATGCAATGGAAGAAAGCATTATTACCG
GTGTGAAATTCAAACTGCGCATCGATAAAGAAACCACCAAAAAAACTGAACGAGTACTTCGATGAATATGG
CAAAGCAATTAACTTCGCCGTGAAGATCATTCAGAAAAGAACTGGCAGATGATCGTTTTTGCAGGTAAAGCA
AAACTGGACCAGAATAAAAACCCGATCCTGGATGAAAACGGCAAAAAAATCTATGAATTCCCGGATGAAT
TTTGCAGCTGTGGTAAACAGGTTAACGTTACGAACAAACCGTTTTGCCAAGAGTGCTATAAAAAT
CCGCTTTACCGAAAATGGTATTCGCAAACGTATGTATAGCGCCAAAGGTCGTAAAGCCGAACATAAAATC
AATATCCTGAACAGCACCAACAAGATCAGCAAAACCCATTTTAACTATGCCATTCGCGAAGCCTTCATTC
TGGATAAAGCATCAAAAAGCAGCGCAAAAACGTAATGAACGTCTGCGTGAAAGTAAAAACGTCTGCA
GCAGTTTATCGATATGCGTGATGGTAAACGTGAAATTTGCCCGACCATTAAAGGTCAGAAAGTGGATCGT
TTTATTCATCCGAGCTGGATCACCAAAGATAAAAAGCTGGAAGATTTTCGCGGTTATACCCTGAGCATTA

FIG. 24 (Cont.)

TCAACAGCAAAATTAAGATTCTGGATCGCAACATCAAACGCGAAGAAAAAAGCCTGAAAGAAAAAGGCCA
GATCATCTTTAAAGCCAAACGTCTGATGCTGGATAAATCCATTCGTTTTGTTGGTGATCGCAAAGTGCTG
TTTACAATTAGTAAAACCCTGCCGAAAGAGTATGAACTGGATCTGCCGAGCAAAGAAAAACGGCTGAATT
GGCTGAAAGAGAAGATCGAGATTATCAAGAACCAGAAAATATGCCTATCTGCTGCGCAAAAACAT
TGAGAGCGAAAAAAAAACCGAACTATGAGTACTACACCCTGGAAATTAAACCGGAACTGAAA
GATTTTTATGATGGTGCCATTGACCGTGGCATTAATCATATTGCCGTTTGCACCTTTATTAGCA
ACGATGGTAAAGTTACCCCTCCGAAATTTTTCAGCAGCGGTGAAATTCTGCGTCTGAAAAATCTGCAGAA
AGAGCGTGATCGCTTTCTGCTGCGTAAACACAACAAAAAAATCGCAAAAAAAGGCAACATGCGCGTGATCGAA
ACTGAGCCTGTTCATCTTCAAGAAACTGAGCGATCTGGTTGATTACAAAAAGCCGTCGTGAAGGTATTCGT
AACAAAATCAATCTGATCCTGCACCGTTATAGCAAGCAGATTGTTGATATGGCCAAAAAGCTGAATGCCA
GTTACCTATGTTCCGCCTGAATATACCAGCAAAGAATGTAGCCATTGCGGTGAAAAAGTTAATACCCAGC
GCATTGTTTTTTGAAGAACTGGGTCGTATTTGGTAAAAGCCGCACCAAAATGAAAAAAGCCAGCGTTATAA
GTCCGTTTAATGGCAACTATAGCCTGTTTAAATGCAACAAATGTGGCATCCAGCTGATTCAGGATTATAA
TGCAAGCATCAACATTGCGAAAAAGGCCTGAAAATTCCGAATAGCACCTAATAACATTGGAAGTGGATA
ACGGATCCGCGATCGCGGCGCCACCTGGTGGCCCGGTACCACGCGTGCGCGCTGATCCGGCTGCT
AACAAAGCCCGAAAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGG
CCTCTAAACGGGTCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTG
TGGTCGCCATGATCGCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCGAGCAGGACTGGGCGGCGGCCAAA
GCGGTCGGACAGTGCTCCGAGAACGGGTGCGCATAGAAATTGCATCAACGCATATAGCGCTAGCAGCACG
CCATAGTGACTGGCGATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCA
AGCCTATGCCTACAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACA
CGGTGCCTGACTGCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGT
CAAACATGAGAATTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATA
ATAATGGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTT
TCTAAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAA
AAGGAAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCT
GTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTT
ACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGAT
GAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGT
CGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATG
GCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCT
GACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTT

FIG. 24 (Cont.)

GATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACGACGAGGCGTGACACCACGATGCCTGCAGCAA
TGGCAACAACGTTGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGA
CTGGATGGAGGCGGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCT
GATAAATCTGGAGCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCT
CCCGTATCGTAGTTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGA
GATAGGTGCCTCACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGAT
TTAAAACTTCATTTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCC
CTTAACGTGAGTTTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCC
TTTTTTTCTGCGCGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCG
GATCAAGAGCTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCC
TTCTAGTGTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCT
AATCCTGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAG
TTACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGA
CCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGC
GGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCC
TGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAG
GGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTT
TGCTCACATGTTCTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCT
GATACCGCTCGCCGCAGCCGAACCGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGA
TGCGGTATTTTCTCCTTACGCATCTGTGCGGTATTTCACACCGCAATGGTGCACTCTCAGTACAATCTGC
TCTGATGCCGCATAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCCG
ACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCT
GTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGAGGCAGCTGC
GGTAAAGCTCATCAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTT
GAGTTTCTCCAGAAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTTCCTGT
TTGGTCACTGATGCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGA
GGATGCTCACGATACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACT
GGCGGTATGGATGCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGAT
GTAGGTGTTCCACAGGGTAGCCAGCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTG
ACTTCCGCGTTTCCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGA
CGTTTTGCAGCAGCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAA
CCCCGCCAGCCTAGCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGC

FIG. 24 (Cont.)

TGCCCGAGATGCGCCGCGTGCGGCTGCTGGAGATGGCGCGACGCGATGGATATGTTCTGCCAAGGGTTGGT
TTGCGCATTCACAGTTCTCCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATCCGTTAGCGAGG
TGCCGCCGGCTTCCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGCGGGGAGGCAGAC
AAGGTATAGGCGCGGCCTACAATCCATGCCAACCCGTTCCATGTGCTCGCCGAGGCGGCATAAATCGCC
GTGACGATCAGCGGTCCAATGATCGAAGTTAGGCTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCT
GATGGTCGTCATCTACCTGCCTGGACAGCATGGCCTGCAACGCGGGCATCCCGATGCCGCGGAAGGCGAG
AAGAATCATAATGGGGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTCG
GCCGCCATGCCCGGCGATAATGGCCTGCTTCTCGCCCGAAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTT
GAGCGAGGGCGTGCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCG
GTCCTCGCCGAAAATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTC
ATAAGTGCGGCGACGATAGTCATGCCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGG
GCATCGGTCGACGCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTT
GAGCACCGCCGCCGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCT
GCCACCATACCCACGCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGA
TGTCGGCGATATAGGCGCCA (SEQ ID NO: 493)

FIG. 24 (Cont.)

Plasmid pLBH547_Tet-Cas14b2Locus (AddGene Plasmid Number: 112504)

ATCGTTGATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGAAAAGAATTCAAAAGATCTAAAGAGGA
GAAAGGATCTATGGAAGAAAGCATTATTACCGGTGTGAAATTCAAACTGCGCATCGATAAAGAAACCACC
AAAAAACTGAACGAGTACTTCGATGAATATGGCAAAGCAATTAACTTCGCCGTGAAGATCATTCAGAAAG
AACTGGCAGATGATCGTTTTTGCAGGTAAAGCAAAACTGGACCAGAATAAAAACCCGATCCTGGATGAAAA
CGGCAAAAAAAATCTATGAATTCCCGGATGAATTTTTGCAGCTGTGGTAAACAGGTTAACAAGTACGTTAAC
AACAAACCGTTTTTGCCAAGAGTGCTATAAAATCCGCTTTACCGAAAAATGGTATTCGCAAACGTATGTATA
GCGCCAAAGGTCGTAAAGCCGAACATAAAATCAATATCCTGAACAGCACCAACAAGATCAGCAAAAACCCA
TTTTAACTATGCCATTCGCGAAGCCTTCATTCTGGATAAAAGCATCAAAAAGCAGCGCAAAAAACGTAAT
GAACGTCTGCGTGAAAGTAAAAAAACGTCTGCAGCAGTTTATCGATATGCGTGATGGTAAACGTGAAATTT
GCCCGACCATTAAAGGTCAGAAAGTGGATCGTTTTATTCATCCGAGCTGGATCACCAAAGATAAAAAGCT
GGAAGATTTTCGCGGTTATACCCTGAGCATTATCAACAGCAAAAATTAAGATTCTGGATCGCAACATCAAA
CGCGAAGAAAAAAGCCTGAAAGAAAAAGGCCAGATCATCTTTATAAAGCCAAACGTCTGATGCTGGATAAAT
CCATTCGTTTTGTTGGTGATCGCAAAGTGCTGTTTACAATTAGTAAAACCCTGCCGAAAGAGTATGAACT
GGATCTGCCGAGCAAAGAAAAACGGCTGAATTGGCTGAAAGAGAAGATCGAGATTTATCAAGAACCAGAAA
CCGAAATATGCCTATCTGCTGCGCAAAAACATTGAGAGCGAAAAAAACCGAACTATGAGTACTATCTGC
AGTACACCCTGGAAATTAAACCGGAACTGAAAGATTTTATGATGGTGCCATTGGTATTGACCGTGGCAT
TAATCATATTGCCGTTTGCACCTTTATTAGCAACGATGGTAAAGTTACCCCTCCGAAATTTTTTCAGCAGC
GGTGAAATTCTGCGTCTGAAAAAATCTGCAGAAAGAGCGTGATCGCTTTCTGCTGCGTAAACACAACAAAA
ATCGCAAAAAAGGCAACATGCGCGTGATCGAAAAACAAAATCAATCTGATCCTGCACCGTTATAGCAAGCA
GATTGTTGATATGGCCAAAAAGCTGAATGCCAGCATTGTTTTTGAAGAACTGGGTCGTATTGGTAAAAGC
CGCACCAAAATGAAAAAAAGCCAGCGTTATAAACTGAGCCTGTTCATCTTCAAGAAACTGAGGCGATCTGG
TTGATTACAAAAGCCGTCGTGAAGGTATTCGTTACCTATGTTCCGCCTGAATATACCAGCAAAGAATG
TAGCCATTGCGGTGAAAAAGTTAATACCCAGCGTCCGTTTAATGGCAACTATAGCCTGTTTAAATGCAAC
AAATGTGGCATCCAGCTGAACAGCGATTATAATGCAAGCATCAACATTGCGAAAAAGGGCCTGAAAATTC
CGAATAGCACCTAATAATGTTGGTTAAGCCACAATATGGAATATTGTTCTTATGGACAGTATTGACTTAA
ATTAATAATCTTCGAAGGCTATATGCGGAAGATTTGGCGTTGTTGTAACGCAATAAGGGGTAACCCTGAA
AAGGTTTGAAATCATATAAACCTAGTTTTATTGAGTTTAGGCTCAGATAAAATGAACAGACCAATCTTT
AATTCCGTTCTGATTTTAAAAAATCAGAATCTCTTTATAAATAGTATTTACAAAAAGTGTACATTCCAAAAT

FIG. 24 (Cont.)

CCGAAAGCAGAATTGACCTTTTTAAGCCTAAAAAAGCCAAATTTCAAGGCTCTTTCATACTCAGAACAAA
GGGATTAAGGAATGCAACTACCTTACACCGCTTGCGAAAGTTGTCAGAAGATAATCTTTCATACTCAGAA
CAAAGGGATTAAGGAATGCAACTATCTTATCCATTTCTTGACATCAAATTTTCTTGCAGCATCTGAATTG
CTTAATTGCTTTCCTTGCTTCAGCAGGAAATAGCCAAGATTTTCCAGTTCTGCTGGCGTTATTGCAAGCA
CGGGGATTTTTGTGCTTGCTGTAGATTTTTGTTCTTCAGGACCTTCTTTTTCCATGCTAGAGTCACACTGGC
TCACCTTCGGGTGGGCCTTTTCTGCGTTTATACCTAGGGATATATTCCGCTTCCTCGCTCACTGACTCGCT
ACGCTCGGTCGTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCC
AGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGGCTCCGCCCCCCTGA
CAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCG
TTTCCCCCTGGCGGCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGT
TATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACT
GTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCC
GGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTC
ATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTCGG
TTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTTCGTTTTCAGAGC
AAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAGAT
TTCAGTGCAATTTATCTCTTCAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTTACTAGTG
CTTGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATCCAGATGGAGTTCTG
AGGTCATTACTGGATCTATCAACAGGAGTCCAAGCGAGCTCGATATCAAATTACGCCCCGCCCTGCCACT
CATCGCAGTACTGTTGTAATTCATTAAGCATTCTGCCGACATGGAAGCCATCACAAACGGCATGATGAAC
CTGAATCGCCAGCGGCATCAGCACCTTGTCGCCTTGCGTATAATATTTGCCCATGGTGAAAACGGGGGCG
AAGAAGTTGTCCATATTGGCCACGTTTAAATCAAAACTGGTGAAACTCACCCAGGGATTGGCTGAGACGA
AAAACATATTCTCAATAAACCCTTTAGGGAAATAGGCCAGGTTTTCACCGTAACACGCCACATCTTGCGA
ATATATGTGTAGAAACTGCCGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGC
TCATGGAAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATAC
GAAATTCCGGATGAGCATTCATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATT
TTTCTTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACT
GACTGAAATGCCTCAAAATGTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTT
TTTTCTCCATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCT
TATTTCATTATGGTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAGATATCGACG
TCTTAAGACCCACTTTCACATTTAAGTTGTTTTTCTAATCCGCATATGATCAATTCAAGGCCGAATAAGA
AGGCTGGCTCTGCACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAATGGCGGCATACTATCAGT

FIG. 24 (Cont.)

AGTAGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTGATCTTCCAATACCGCAACCTAAAGTAAAA
TGCCCCACAGCGCTGAGTGCATTATAATGCATTCTCTAGTGAAAAAACCTTGTTGGCATAAAAAGGCTAATT
GATTTTCGAGAGTTTCATACTGTTTTTCTGTAGGCCGTGTACCTAAATGTACTTTTGCTCCATCGCGATG
ACTTAGTAAAGCACATCTAAAACTTTTAGCGTTATTACGTAAAAAAATCTTGCCAGCTTTCCCCTTCTAAA
GGGCAAAAGTGAGTATGGTGCCTATCTAACATCTCAATGGCTAAGGCGTCGAGCAAAGCCCGCTTATTTTT
TTACATGCCAATACAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTTACGGGTTGTTAAACCTTC
GATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACTTTACTTTTATCTAATCTAGACATCATT
AATTCCTAATTTTTTGTTGACACTCT (SEQ ID NO: 494)

FIG. 24 (Cont.)

Plasmid pLBH559_Tet-HisCas14a1Locus (AddGene Plasmid Number: 112502)

TAATTCCTAATTTTTGTTGACACTCTATCGTTGATAGAGTTATTTTACCACTCCCTATCAGTGATAGAGA
AAAGAATTCAAAAAGATCTAAAGAGGAGAAAGGATCTATGAAATCTCTCACCATCACCATCACCATGAAAACC
TGTACTTCCAATCCAATATTTGGAAGTGGAATGGCCAAAAACACCATTACCAAAACACTGAAACTGCGTAT
TGTGCGTCCGTATAATAGCGCAGAAGTGGAAAAAATTGTTGCCGACGAAAAAAACAACCGCGAAAAAATC
GCACTGGAAAAGAACAAAGACAAAGTGAAAGAAGCCTGCAGCAAACATCTGAAAGTTGCAGCATATTGTA
CCACACAGGTTGAACGTAATGCATGCCTGTTTTGTAAAGCACGTAAACTGGATGACAAATTCTACCAAAA
ACTGCGTGGTCAGTTTCCGGATGCAGTTTTTTGGCAAGAAATCAGCGAAATTTTTCGCCAGCTGCAGAAA
CAGGCAGCAGAAATCTATAATCAGAGCCTGATCGAACTGTACTACGAGATTTTTATCAAAGGCAAAGGTA
TTGCAAATGCCAGCAGCGTTGAACATTATCTGAGTGATGTTTGTTATACCCGTGCAGCAGAACTGTTTAA
AAACGCAGCAATTGCAAGCGGTCTGCGTAGCAAAATCAAAAGCAATTTTCGTCTGAAAGAACTGAAAAAC
ATGAAAAGTGGTCTGCCGACCACCAAAAGCGATAATTTTCCGATTCCGCTGGTTAAACAGAAAGGTGGTC
AGTATACCGGTTTTGAAATTAGCAATCATAATAGCGACTTCATCAAGATTCCGTTTGGTCGTTGGCA
GGTCAAAAAAGAGATTGATAAATATCGTCCGTGGGAGAAATTTGACTTTGAACAGGTTCAGAAAAGCCCG
AAACCGATTAGCCTGCTGAGCACCCAGCGTCGTAAACGTAATAAAGGTTGGAGCAAAGATGAAGGCA
CCGAAGCCGAAATCAAAAAAGTTATGAATGGCGATTATCAGACCAGCTACATTGAAGTTAAACGTGGCAG
CAAAATCGGTGAAAAAAAGCGCATGGATGCTGAATCTGAGCATTGATGTTCCGAAAATTGATAAAGGTGTG
GATCCGAGCATTATTGGTGGTATTTGATTGAACGTGGTTTGCGCAATTAACAATGCAT
TTAGCCGTTATAGCATCAGCGATAACGACCTGTTTCACTTCAACAAGAAAATGTTTGCACGTCGTCGTAT
CCTGCTGAAAAAAAAACCGTCATAAACGTGCAGGTCATGGTGCAAAAAACAACTGAAACCGATCACCATT
CTGACCGAAAAAAGTGAACGTTTTCGCAAAAAGCTGATTGAACGTTGGGCATGTGAAATCGCGGATTTCT
TCATTAAAAACAAAGTTGGCACCGTGCAGATGGAAAATCTGGAAAGCATGAAACGTAAAGAGGACAGCTA
TTTTAACATTCGCCTGCGTGGCTTTTGGCCGTATGCAGAAATGCAGAACAAAATCGAATTCAAACTGAAG
CAGTATGGCATCGAAATTCGTAAAGTTGCACCGAATATAATACCAGCAAAACCTGTAGCAAATGTGGCCATC
TGAACAACTATTTCAACTTCGAGTACCGCAAGAAAAACACAAATTCCCGCACTTTAAATGCGAAAAAATGCAA
CTTCAAAGAAAACGCCGATTATAATGCAGCCCTGAATATTTCAAACCCGAAACTGAAAAAGCACCAAAAGAG
GAACCGTAAATATTTATACTTTATCCTTCATTGACAAAAAATGAGAATGTTATCCCAGATAACATTTG
ATGTACACAGATTCACACTTCACTGATAAAGTGGAGAACCGCTTCACCAAAAGCTGTCCCTTAGGGGATT
AGAACTTGAGTGAAGGTGGGCTGCTTGCATCAGCCTAATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCC
TCGAAACAAATTCATTTTTCCTCTCCAATTCTGCACAAAAAAAGGTGAGTCCTTATAAACCGGCGTGCAG

FIG. 24 (Cont.)

AACGCCGGCTCACCTTTTTCTTCATTCGATTTTATGCTTAAAAGCCGTAAAAACGCGGAATTCGGCGCC
GTTGCAGAACCCGAATAGACGAATGAAGGAATGCAACTACCTTACACCGCTTGCGAAAGTTGTCAGAAGA
TAATCTTGCAGAACCCGAATAGACGAATGAAGGAATGCAATCTTGACAGAGCCCGATTGCGTTATCTCCA
GGAGAAACATATAAAAGCATCAACCGCTGATCGGACTAGAGTCACACTGGCTCACCTTCGGGTGGGCCTT
TCTGCGTTTATACCTAGGGATATATTCCGCTTCCTCGCTCACTGACTCGCTACGCTCGGTCGTTCGACTG
CGGCGAGCGGGAAATGGCTTACGAACGGGGCGGAGATTTCCTGGAAGATGCCAGGAAGATACTTAACAGGG
AAGTGAGAGGGCCGAGGGCAAAGCCGTTTTTCCATAGGCTCCGCCCCCCTGACAAGCATCACGAAATCTGA
CGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTATAAAGATACCAGGCGTTTCCCCCTGGCGGCTCCC
TCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGGTGTCATTCCGCTGTTATGGCCGCGTTTGTCTCA
TTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCGCTCCAAGCTGGACTGTATGCACGAACCCCCCGT
TCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGTCTTGAGTCCAACCCGGAAAGACATGCAAAAGCA
CCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAGTTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAA
ACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAAGCCAGTTACCTTCGGGTTCAAAGAGTTGGTAGCTC
AGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTTTCGTTTTCAGAGCAAGAGATTACGCGCAGACC
AAAACGATCTCAAGAAGATCATCTTATTAATCAGATAAAATATTTCTAGATTTCAGTGCAATTTATCTCT
TCAAATGTAGCACCTGAAGTCAGCCCCATACGATATAAGTTGTTACTAGTGCTTGGATTCTCACCAATAA
AAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATCCAGATGGAGTTCTGAGGTCATTACTGGATCTAT
CAACAGGAGTCCAAGCGAGCTCGATATCAAATTACGCCCCGCCCTGCCACTCATCGCAGTACTGTTGTAA
TTCATTAAGCATTCTGCCGACATGGAAGCCATCACAAACGGCATGATGAACCTGAATCGCCAGCGGCATC
AGCACCTTGTCGCCTTGCGTATAATATTTGCCCATGGTGAAAACGGGGGCGAAGAAGTTGTCCATATTGG
CCACGTTTAAATCAAAACTGGTGAAACTCACCCAGGGATTGGCTGAGACGAAAAACATATTCTCAATAAA
CCCTTTAGGGAAATAGGCCAGGTTTTCACCGTAACACGCCACATCTTGCGAATATATGTGTAGAAACTGC
CGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAAACGTTTCAGTTTGCTCATGGAAAACGGTGTAAC
AAGGGTGAACACTATCCCATATCACCAGCTCACCGTCTTTCATTGCCATACGAAATTCCGGATGAGCATT
CATCAGGCGGGCAAGAATGTGAATAAAGGCCGGATAAAACTTGTGCTTATTTTTCTTTACGGTCTTTAAA
AAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGGTACATTGAGCAACTGACTGAAATGCCTCAAAAT
GTTCTTTACGATGCCATTGGGATATATCAACGGTGGTATATCCAGTGATTTTTTTCTCCATTTTAGCTTC
CTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACGCCCGGTAGTGATCTTATTTCATTATGGTGAAAG
TTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTCGCCAGATATCGACGTCTTAAGACCCACTTTCAC
ATTTAAGTTGTTTTTCTAATCCGCATATGATCAATTCAAGGCCGAATAAGAAGGCTGGCTCTGCACCTTG
GTGATCAAATAATTCGATAGCTTGTCGTAATAATGGCGGCATACTATCAGTAGTAGGTGTTTCCCTTTCT
TCTTTAGCGACTTGATGCTCTTGATCTTCCAATACGCAACCTAAAGTAAAATGCCCCACAGCGCTGAGTG

FIG. 24 (Cont.)

CATATAATGCATTCTCTAGTGAAAAACCTTGTTGGCATAAAAAGGCTAATTGATTTTCGAGAGTTTCATA
CTGTTTTTCTGTAGGCCGTGTACCTAAATGTACTTTTGATCCATCGCGATGACTTAGTAAAGCACATCTA
AAACTTTTAGCGTTATTACGTAAAAAATCTTGCCAGCTTTCCCCTTCTAAAGGGCAAAAGTGAGTATGGT
GCCTATCTAACATCTCAATGGCTAAGGCGTCGAGCAAAGCCCGCTTATTTTTTACATGCCAATACAATGT
AGGCTGCTCTACACCTAGCTTCTGGGCGAGTTTACGGGTTGTTAAACCTTCGATTCCGACCTCATTAAGC
AGCTCTAATGCGCTGTTAATCACTTTACTTTATCTAATCTAGACATCAT (SEQ ID NO: 495)

FIG. 24 (Cont.)

Plasmid pLBH545_Tet-Cas14a1_Locus (Addgene Plasmid Number: 112501)

TTACTTTTATCTAATCTAGACATCATTAATTCCTAATTTTTGTTGACACTCTATCGTTGATAGAGTTATT
TTACCACTCCCTATCAGTGATAGAGAAAAGAATTCAAAAGATCTAAAGAGGAAAGGATCTATGGCCAA
AAACACCATTACCAAAACACTGCGTATTGTGCGTCCGTATAATAGCGCAGAAGTGGAAAAAATT
GTTGCCGACGAAAAAAACAACCGCGAAAAAATCGCACTGGAAAAAGAACAAAGACAAAGTGAAAGAAGCCT
GCAGCAAACATCTGAAAGTTGCAGCATATTGTACCACACAGGTTGAACGTAATGCATGCCTGTTTTGTAA
AGCACGTAAACTGGATGACAAATTCTACCAAAAACTGCGTGGTCAGTTCCGGATGCAGTTTTTTGGCAA
GAAATCAGCGAAATTTTTTCGCCAGCTGCAGAAACAGGCAGCAGAAATCTATAATCAGAGCCTGATCGAAC
TGTACTACGAGATTTTTTATCAAAGGCAAAGGTATTGCCAGCAGCGTTGAACATTATCTGAGTGA
TGTTTGTTATACCCGTGCAGCAGAACTGTTTAAAAACGCAGCAATTGCAAGCGGTCTGCGTAGCAAAATC
AAAAGCAATTTTCGTCTGAAAGAACTGAAAAACATGAAAAGTGGTCTGCCGACCACCAAAAGCGATAATT
TTCCGATTCCGCTGGTTAACAGAAAGGTGGTCAGTATACCGGTTTTGAAATTAGCAATCATAATAGCGA
CTTCATCATCAAGATTCCGTTTGGTCGTTGGCAGGTCAAAAAAGAGATTGATAAATATCGTCCGTGGGAG
AAATTTGACTTTGAACAGGTTCAGAAAAGCCCGAACCGATTAGCCTGCTGAGCACCCAGCGTCGTA
AACGTAATAAAGGTTGGAGCAAAGATGAAGGCACCGAAGCCGAAATCAAAAAAGTTATGAATGGCGATTA
TCAGACCAGCTACATTGAAGTTAAACGTGGCAGCAAAATCGGTGAAAAAAAGCGCATGGATGCTGAATCTG
AGCATTGATGTTCCGAAAATTGATAAAGGTGTGGATCCGAGCATTATTGGTGGTATTGATGTTGGTGTTA
AATCACCGCTGGTTTGCGCAATTTAACAATGCATTTAGCCGTTATAGCGATAACGACCTGTTTTCA
CTTCAACAAGAAAAATGTTTTGCACGTCGTCGTATCCTGCTGAAAAAAAAACCGTCATAAACGTGCAGGTCAT
GGTGCAAAAAACAAACTGAAACCGATCACCATTCTGACCGAAAAAAGTGAACGTTTTCGCAAAAAGCTGA
TTGAACGTTGGGCATGTGAAATCGCGGATTTTCTTCATTAAAAACAAAGTTGGCACCGTGCAGATGGAAAA
TCTGGAAAGCATGAAACGTAAAGAGGACAGCTATTTTTAACATTCGCCTGCGTGGCTTTTTGGCCGTATGCA
GAAATGCAGAACAAAATCGAATTCAAACTGAAGCAGTATGGCATCGAAATTCGTAAAGTTGCACCGAATA
ATACCAGCAAAACCTGTAGCAAATGTGGCCATCTGAACAACTATTTCAACTTCGAGTACCGCAAGAAAAA
CAAATTCCCGCACTTTAAATGCGAAAAATGCAACTTCAAAGAAAACGCCGATTATAATGCAGCCCTGAAT
ATTTCAAACCCGAAACTGAAAAGCACCAAAGAGGAACCGTAAATATTTATACTTTATTATCCTTCATTGA
CAAAAATGAGAATGTTATCCCAGATAACATTTGATGTACACAGATTCACACTTCACTGATAAAGTGGAGA
ACCGCTTCACCAAAAGCTGTCCCTTAGGGGATTAGAACTTGAGTGAAGGTGGGCTGCTTGCATCAGCCTA
ATGTCGAGAAGTGCTTTCTTCGGAAAGTAACCCTCGAAACAAATTCATTTTTCCTCTCCAATTCTGCACA

FIG. 24 (Cont.)

AAAAAAGGTGAGTCCTTATAACCGGCGTGCAGAACGCCGGCTCACCTTTTTCTTCATTCGATTTTATG
CTTAAAAGCCGTAAAAACGCGGAATTCGGCGCCGTTGCAGAACCCGAATAGACGAATGAAGGAATGCAAC
TACCTTACACCGCTTGCGAAAGTTGTCAGAAGATAATCTTGCAGAACCCGAATAGACGAATGAAGGAATG
CAATCTTGACAGAGCCCGATTGCGTTATCTCCAGGAGAAACATATAAAAGCATCAACCGCTGATCGGACT
AGAGTCACACTGGCTCACCTTCGGGTGGGCCTTTCTGCGTTTATACCTAGGGATATATTCCGCTTCCTCG
CTCACTGACTCGCTACGCTCGGTCGTTCGACTGCGGCGAGCGGAAATGGCTTACGAACGGGGCGGAGATT
TCCTGGAAGATGCCAGGAAGATACTTAACAGGGAAGTGAGAGGGCCGCGGCAAAGCCGTTTTTCCATAGG
CTCCGCCCCCCTGACAAGCATCACGAAATCTGACGCTCAAATCAGTGGTGGCGAAACCCGACAGGACTAT
AAAGATACCAGGCGTTTCCCCCTGGCGGCTCTCCCTCGTGCGCTCTCCTGTTCCTGCCTTTCGGTTTACCGG
TGTCATTCCGCTGTTATGGCCGCGTTTGTCTCATTCCACGCCTGACACTCAGTTCCGGGTAGGCAGTTCG
CTCCAAGCTGGACTGTATGCACGAACCCCCCGTTCAGTCCGACCGCTGCGCCTTATCCGGTAACTATCGT
CTTGAGTCCAACCCGGAAAGACATGCAAAAGCACCACTGGCAGCAGCCACTGGTAATTGATTTAGAGGAG
TTAGTCTTGAAGTCATGCGCCGGTTAAGGCTAAACTGAAAGGACAAGTTTTGGTGACTGCGCTCCTCCAA
GCCAGTTACCTTCGGTTCAAAGAGTTGGTAGCTCAGAGAACCTTCGAAAAACCGCCCTGCAAGGCGGTTTT
TTCGTTTTCAGAGCAAGAGATTACGCGCAGACCAAAACGATCTCAAGAAGATCATCTTATTAATCAGATA
AAATATTTCTAGATTTCAGTGCAATTTATCTCTTCAAATAGTAGCACCTGAAGTCAGCCCCATACGATATA
AGTTGTTACTAGTGCTTGGATTCTCACCAATAAAAAACGCCCGGCGGCAACCGAGCGTTCTGAACAAATC
CAGATGGAGTTCTGAGGTCATTACTGGATCTATCAACAGGAGTCCAAGCGAGCTCGATATCAAATTACGC
CCCGCCCTGCCACTCATCGCAGTACTGTTGTAATTCATTAAGCATTCTGCCGACATGGAAGCCATCACAA
ACGGCATGATGAACCTGAATCGCCAGCGGCATCAGCACCTTGTCGCCTTGCGTATAATATTTGCCCATGG
TGAAAACGGGGGCGAAGAAGTTGTCCATATTGGCCACGTTTAAATCAAAACTGGTGAAACTCACCCAGGG
ATTGGCTGAGACGAAAAACATATTCTCAATAAACCCTTTAGGGAAATAGGCCAGTTTTCACCGTAACAC
GCCACATCTTGCGAATATATGTGTAGAAACTGCCGGAAATCGTCGTGGTATTCACTCCAGAGCGATGAAA
ACGTTTCAGTTTGCTCATGGAAAACGGTGTAACAAGGGTGAACACTATCCCATATCACCAGCTCACCGTC
TTTCATTGCCATACGAAATTCCGGATGAGCATTCATCAGGCGGGCAAGAATGTGAATAAAGGCCGGAATAA
AACTTGTGCTTATTTTTCTTTACGGTCTTTAAAAAGGCCGTAATATCCAGCTGAACGGTCTGGTTATAGG
TACATTGAGCAACTGACTGAAATGCCTCAAAATGTTCTTTACGATGCCATTGGGATATATCAACGGTGGT
ATATCCAGTGATTTTTTTCTCCATTTTAGCTTCCTTAGCTCCTGAAAATCTCGATAACTCAAAAAATACG
CCCGGTAGTGATCTTATTTCATTATGGTGAAAGTTGGAACCTCTTACGTGCCGATCAACGTCTCATTTTC
GCCAGATATCGACGTCTTAAGACCCACTTTCACATTTAAGTTGTTTTTCTAATCCGCATATGATCAATTC
AAGGCCGAATAAGAAGGCTGGCTCTGCACCTTGGTGATCAAATAATTCGATAGCTTGTCGTAATAATGGC
GGCATACTATCAGTAGTAGGTGTTTCCCTTTCTTCTTTAGCGACTTGATGCTCTTGATCTTCCAATACGC

FIG. 24 (Cont.)

AACCTAAAGTAAAATGCCCCACAGCGCTGAGTGCATATAATGCATTCTCTAGTGAAAAACCTTGTTGGCA
TAAAAAGGCTAATTGATTTTTCGAGAGTTTTCATACTGTTTTTCTGTAGGCCGTGTACCTAAATGTACTTTT
GCTCCATCGCGATGACTTAGTAAAGCACATCTAAAACTTTTAGCGTTATTACGTAAAAAATCTTGCCAGC
TTTCCCCTTCTAAAGGGCAAAAGTGAGTATGGTGCCTATCTAACATCTCAATGGCTAAGGCGTCGAGCAA
AGCCCGCTTATTTTTTACATGCCAATACAATGTAGGCTGCTCTACACCTAGCTTCTGGGCGAGTTTACGG
GTTGTTAAACCTTCGATTCCGACCTCATTAAGCAGCTCTAATGCGCTGTTAATCACT (SEQ ID NO: 496)

FIG. 24 (Cont.)

Plasmid pLBH531_MBP-Cas14a1 expression (Addgene Plasmid Number: 112500)

ACCCACGCCCGAAACAAGCGCTCATGAGCCCGAAGTGGCGAGCCCGATCTTCCCCATCGGTGATGTCGGCG
ATATAGGCGCCAGCAACCGCACCTGTGGCGCCGGTGATGCCGGCCACGATGCGTCCGGCGTAGAGGATCG
AGATCTCGATCCCGCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGTGCCGGC
TCCGGAGAGCTCTTTAATTAAGCGGCCGCCTGCAGGACTCGAGTTCTAGAAATAATTTTGTTTAACTTT
AAGAAGGAGATATACATATGAAATCTTCTCACCATCACCATCACCATGGTTCTTCTAT
GAAAATCGAAGAAGGTAAACTGGTAATCTGGATTAACGGCGATAAAGGCTATAACGGTCTCGCTGAAGTC
GGTAAGAAATTCGAGAAAGATACCGGAATTAAAGTCACCGTTGAGCATCCGGATAAACTGGAAGAGAAAT
TCCCACAGGTTGCGGCAACTGGCGATGGCCCTGACATTATCTTCTGGGCACACGACCGCTTTGGTGGCTA
CGCTCAATCTGGCCTGTTGGCTGAAATCACCCCGGACAAAGCGTTCCAGGACAAGCTGTATCCGTTTACC
TGGGATGCCGTACGTTACAACGGCAAGCTGATTGCTTACCCGATCGCTGTTGAAGCGTTATCGCTGATTT
ATAACAAAGATCTGCTGCCGAACCCGCCAAAAACCTGGGAAGAGATCCCGGCGCTGGATAAAGAACTGAA
AGCGAAAGGTAAGAGCGCGCTGATGTTCAACCTGCAAGAACCGTACTTCACCTGGCCGCTGATTGCTGCT
GACGGGGGTTATGCGTTCAAGTATGAAAACGGCAAGTACGACATTAAAGACGTGGGCGTGGATAACGCTG
GCGCGAAAGCGGGTCTGACCTTCCTGGTTGACCTGATTAAAAACAAACACATGAATGCAGACACCGATTA
CTCCATCGCAGAAGCTGCCTTTAATAAAGGCGAAACAGCGATGACCATCAACGGCCCGTGGGCATGGTCC
AACATCGACACCAGCAAAGTGAATTATGGTGTAACGGTACTGCCGACCTTCAAGGGTCAACCATCCAAAC
CGTTCGTTGGCGTGCTGAGCGCAGGTATTAACGCCGCCAGTCCGAACAAAGAGCTGGCAAAAGAGTTCCT
CGAAAACTATCTGCTGATGAAGGTCTGGAAGCGGTTAATAAAGACAAACCGCTGGGTGCCGTAGCG
CTGAAGTCTTACGAGGAAGAGTTGGCGAAAGATCCACGTATTGCCGCCACTATGGAAAACGCCCAGAAAG
GTGAAATCATGCCGAACATCCCGCAGATGTCCGCTTTCTGGTATGCCGTGCGTACTGCGGTGATCAACGC
CGCCAGCGGTCGTCAGACTGTCGATGAAGCCCTGAAAGACGCGCAGACTAATTCGAGCTCGAACAACAAC
AACAATAACAATAACAACAACCTCGGGATCGAGGAAAACCTGTACTTCCAATCCAATGCAATGGCCAAAA
ACACCATTACCAAAACACTGCGTATTGTGCGTCCGTATAATAGCGCAGAAGTGGAAAAAATTGT
TGCCGACGAAAAAAACACCGCGAAAAAATCGCACTGGAAAAGAACAAAGACAAAGTGAAAGAAGCCTGC
AGCAAACATCTGAAAGTTGCAGCATATTGTACCACACAGGTTGAACGTAATGCATGCCTGTTTTGTAAAG
CACGTAAACTGGATGACAAATTCTACCAAAAAACTGCGTGGTCAGTTTCCGGATGCAGTTTTTTGGCAAGA
AATCAGCGAAATTTTTCGCCAGCTGCAGCAGAAACAGGCAGCAGAAATCTATAATCAGAGCCTGATCGAACTG

FIG. 24 (Cont.)

TACTACGAGATTTTTATCAAAGGCAAAGGTATTGCAAATGCCAGCGTTGAACATTATCTGAGTGATG
TTTGTTATACCCGTGCAGCAGAACTGTTTAAAAACGCAGCAATTGCAAGCGGTCTGCGTAGCAAAATCAA
AAGCAATTTTCGTCTGAAAGAACTGAAAAACATGAAAAGTGGTCTGCCGACCACCAAAAGCGATAATTTT
CCGATTCCGCTGGTTAAACAGAAAGGTGGTCAGTATACCGGTTTTGAAATTAGCAATCATAATAGCGACT
TCATCATCAAGATTCCGTTTGGTCGTTGGCAGGTCAAAAAAAGAGATTGATAAATATCGTCCGTGGGAGAAA
ATTTGACTTTGAACAGGTTCAGAAAAGCCCCGAAACCGATTAGCCTGCTGCTGAGCACCCAGCGTCGTAAA
CGTAATAAAGGTTGGAGCAAAGATGAAGGCACCGAAAGCCGAAATCAAAAAAGTTATGAATGGCGATTATC
AGACCAGCTACATTGAAGTTAACCGTGGCAGCAAAATCTGTGTGAAAAAAAGCGCATGGATGCTGAATCTGAG
CATTGATGTTCCGAAAATTGATAAAGGTGTGGATCCGAGCATTATTGGTGGTATTGATGTTGGTGTTAAA
TCACCGCTGGTTTGCGCAATTAACAATGCATTTAGCCGTTATAGCATCAGCGATAACGGACCTGTTTCACT
TCAACAAGAAAATGTTTTGCACGTCGTATCCTGCTGAAAAAAAACCGTCATAAACGTGCAGGTCATGG
TGCAAAAAAACAAACTGAAAACCGATCACCATTCTGACCGAAAAAAGTGAACGTTTTCGCAAAAAGCTGATT
GAACGTTGGGCATGTGAAATCGCGGATTTCTTCATTAAAAACAAAGTTGGCACCGTGCAGATGGAAAAATC
TGGAAAGCATGAAACGTAAAGAGGACAGCTATTTTAACATTCGCCTGCGTGGCTTTTGGCCGTATGCAGA
AATGCAGAACAAAATCGAATTCAAACTGAAGCAGTATGGCATCGAAATTCGTAAAGTTGCACCGAAATAAT
ACCAGCAAAACCTGTAGCAAATGTGGCCATCTGAACAACTATTTCAACTTCGAGTACCGCAAGAAAAACA
AATTCCCGCACTTTAAATGCGAAAAATGCAACTTCAAAGAAAACGCCCGATTATAATGCAGCCCTGAATAT
TTCAAACCCGAAACTGAAAAGCACCAAAGAGGAACCGTAATAACATTGGAAGTGGATAACGGATCCGCGA
TCGCGGCGCCGCCACCTGGTGGCCGGTACCACGCGTGCGCGCTGCTAACAAAGCCCGA
AAGGAAGCTGAGTTGGCTGCTGCCACCGCTGAGCAATAACTAGCATAACCCCTTGGGGCCTCTAAACGGG
TCTTGAGGGGTTTTTTGCTGAAAGGAGGAACTATATCCGGATATCCACAGGACGGGTGTGGTCGCCATGA
TCGCCGTAGTCGATAGTGGCTCCAAGTAGCGAAGCAGGACTGGGCGGCGGCCAAAGCGGTCGGACAG
TGCTCCGAGAACGGGTGCGCATAGAAATTGCATCAACGCATATAGCGCTAGCAGCACGCCATAGTGACTG
GCGATGCTGTCGGAATGGACGATATCCCGCAAGAGGCCCGGCAGTACCGGCATAACCAAGCCTATGCCTA
CAGCATCCAGGGTGACGGTGCCGAGGATGACGATGAGCGCATTGTTAGATTTCATACACGGTGCCTGACT
GCGTTAGCAATTTAACTGTGATAAACTACCGCATTAAAGCTTATCGATGATAAGCTGTCAAACATGAGAA
TTCTTGAAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAATGGTTTCT
TAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCTAAATACATT
CAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAAAGGAAGAGTAT
GAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTGCCTTCCTGTTTTTGCTCAC
CCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCACGAGTGGGTTACATCGAACTGG

FIG. 24 (Cont.)

ATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAACGTTTTCCAATGATGAGCACTTTTAA
AGTTCTGCTATGTGGCGCGGTATTATCCCGTGTTGACGCCGGGCAAGAGCAACTCGGTCGCCGCATACAC
TATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACAGAAAAGCATCTTACGGATGGCATGACAGTAA
GAGAATTATGCAGTGCTGCCATAACCATGAGTGATAACACTGCGGCCAACTTACTTCTGACAACGATCGG
AGGACCGAAGGAGCTAACCGCTTTTTTGCACAACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAA
CCGGAGCTGAATGAAGCCATACCAAACGACGAGCGTGACACCACGATGCCTGCAGCAATGGCAACAACGT
TGCGCAAACTATTAACTGGCGAACTACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGC
GGATAAAGTTGCAGGACCACTTCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGA
GCCGGTGAGCGTGGGTCTCGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAG
TTATCTACACGACGGGGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTC
ACTGATTAAGCATTGGTAACTGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCAT
TTTTAATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGT
TTTCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTGCCGGATCAAGAGCTA
CCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTTCCTTCTAGTGTAGC
CGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCCTGTTACC
AGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTTACCGGATAAG
GCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAACGACCTACACCGAAC
TGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGAGAAAGGCGGACAGGTATCC
GGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCCAGGGGGAAACGCCTGGTATCTTTAT
AGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTTTGTGATGCTCGTCAGGGGGGCGGAGCC
TATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCCTGGCCTTTTGCTGGCCTTTTGCTCACATGTT
CTTTCCTGCGTTATCCCCTGATTCTGTGGATAACCGTATTACCGCCTTTGAGTGAGCTGATACCGCTCGC
CGCAGCCGAACGACCGAGCGCAGCGAGTCAGTGAGCGAGGAAGCGGAAGAGCGCCTGATGCGGTATTTTC
TCCTTACGCATCTGTGCGGTATTTCACACCGCAATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCA
TAGTTAAGCCAGTATACACTCCGCTATCGCTACGTGACTGGGTCATGGCTGCGCCCCGACACCCGCCAAC
ACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCATCCGCTTACAGACAAGCTGTGACCGTCTCC
GGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCACCGAAACGCGCGCGAGGCAGCTGCGGTAAAGCTCAT
CAGCGTGGTCGTGAAGCGATTCACAGATGTCTGCCTGTTCATCCGCGTCCAGCTCGTTGAGTTTCTCCAG
AAGCGTTAATGTCTGGCTTCTGATAAAGCGGGCCATGTTAAGGGCGGTTTTTCCTGTTTGGTCACTGAT
GCCTCCGTGTAAGGGGGATTTCTGTTCATGGGGGTAATGATACCGATGAAACGAGAGAGGATGCTCACGA
TACGGGTTACTGATGATGAACATGCCCGGTTACTGGAACGTTGTGAGGGTAAACAACTGGCGGTATGGAT

FIG. 24 (Cont.)

GCGGCGGGACCAGAGAAAAATCACTCAGGGTCAATGCCAGCGCTTCGTTAATACAGATGTAGGTGTTCCA
CAGGGTAGCCAGCATCCTGCGATGCAGATCCGGAACATAATGGTGCAGGGCGCTGACTTCCGCGTTT
CCAGACTTTACGAAACACGGAAACCGAAGACCATTCATGTTGTTGCTCAGGTCGCAGACGTTTTGCAGCA
GCAGTCGCTTCACGTTCGCTCGCGTATCGGTGATTCATTCTGCTAACCAGTAAGGCAACCCCGCCAGCCT
AGCCCGGGTCCTCAACGACAGGAGCACGATCATGCGCACCCGTGGCCAGGACCCAACGCTGCCCGAGATGC
GCCGCGTGCGGCTGCTGGAGATGGCGCGACGCGATGGATATGTTCTGCCAAGGGTTGGTTTGCGCATTCAC
AGTTCTCCGCAAGAATTGATTGGCTCCAATTCTTGGAGTGGTGAATCCGTTAGCGAGGTGCCGCCGGCTT
CCATTCAGGTCGAGGTGGCCCGGCTCCATGCACCGCGACGCAACGCGGGGAGGCAGACAAGGTATAGGGC
GGCGCCTACAATCCATGCCAACCCGTTCCATGTGCTCGCCGAGGCGGCATAAATCGCCGTGACGATCAGC
GGTCCAATGATCGAAGTTAGGCTGGTAAGAGCCGCGAGCGATCCTTGAAGCTGTCCCTGATGGTCGTCAT
CTACCTGCCTGGACAGCATGGCCTGCAACGCGCGGGCATCCCGATGCCGCCGGAAGGAGAAGAATCATAAT
GGGGAAGGCCATCCAGCCTCGCGTCGCGAACGCCAGCAAGACGTAGCCCAGCGCGTCGGCCGCCATGCCG
GCGATAATGGCCTGCTTCTCGCCCGAAACGTTTGGTGGCGGGACCAGTGACGAAGGCTTGAGCGAGGGCGT
GCAAGATTCCGAATACCGCAAGCGACAGGCCGATCATCGTCGCGCTCCAGCGAAAGCGGTCCTCGCCGAAA
AATGACCCAGAGCGCTGCCGGCACCTGTCCTACGAGTTGCATGATAAAGAAGACAGTCATAAGTGCGGCG
ACGATAGTCATGCCCCGCGCCCACCGGAAGGAGCTGACTGGGTTGAAGGCTCTCAAGGGCATCGGTCGAC
GCTCTCCCTTATGCGACTCCTGCATTAGGAAGCAGCCCAGTAGTAGGTTGAGGCCGTTGAGCACCGCCGC
CGCAAGGAATGGTGCATGCAAGGAGATGGCGCCCAACAGTCCCCCGGCCACGGGGCCTGCCACCAT
(SEQ ID NO: 497)

FIG. 25

A



pLBH533_MBP-Cas14b2 expression
7580 bp
1000
2000
3000
4000
5000
6000
7000
T7 promoter
10xHis
MBP
TEV site
T7 terminator
AmpR promoter
AmpR
ori
bom
rop
pBRrevBam (7556..7575)
SphI (7450)
EcoNI (7385)
SalI (7357)
PshAI (7296)
SgrAI (18)
T7 (79..98)
PacI (146)
NotI (151)
SbfI (163)
PaeR7I- PspXI- XhoI (167)
XbaI (174)
NdeI (214)
NcoI (254)
BsiWI (557)
BmgBI (809)
BclI* (1309)
MBP-F (1341..1364)
AgeI (1467)
BamHI (3083)
AsiSI (3093)
AscI (3098)
SexAI* (3105)
DraIII (3109)
FseI (3117)
Acc65I (3120)
KpnI (3124)
MluI (3126)
T7 Term (3188..3206)
NheI (3419)
BmtI (3423)
HindIII (3619)
pBRfoEco (3670..3688)
ZraI (3727)
AatII (3729)
AhdI (4648)
Amp-R (4079..4098)
BsmBI (5892)
pGEX 3' (5891..5913)
PflFI- Tth111I (5791)
BstZ17I (5766)
pRS-marker (5731..5750)
BspQI- SapI (5653)
L4440 (5634..5651)
PciI (5536)
pBR322ori-F (5381..5400)

FIG. 25 (Cont.)

B



pLBH547_Tet-Cas14b2Locus
4715 bp
Tet-R (4594..4613)
EcoNI (4476)
SnaBI (4448)
BglII (57)
BfuAI- BspMI (222)
NmeAIII (942)
BmrI (1389)
BseYI (1567)
PspFI (1571)
BstEII (1809)
BsrGI (1946)
PpuMI (2277)
AvrII (2342)
L4440 (2363..2380)
BsrBI (2406)
SacII (2484)
pBR322ori-F (2577..2596)
BssSaI (2609)
EarI (3102)
SpeI (3144)
Eco53kI (3258)
BamII- BsiHKAI- Bsp1286I (3260)
NcoI (3411)
PasI (3481)
BpmI (3596)
AclI (3627)
BspEI (3716)
CAT-R (3845..3864)
ZraI (4059)
AatII (4061)
AflII (4062)
NdeI (4104)
AleI (4147)
AfeI (4281)
BstAPI (4295)
NsiI (4300)
RBS
tetR/tetA promoters
tet operator
TetR
cat promoter
CmR
lambda t0 terminator
T7Te terminator
500
1000
1500
2000
2500
3000
3500
4000
4500

FIG. 25 (Cont.)

C



pLBH559_Tet-HisCas14a1Locus
4670 bp
Tet-R (4575..4594)
HincII (18)
BglII (83)
SphI (375)
MfeI (639)
AccI (773)
BstZ17I (774)
BlpI (929)
BseYI (936)
PsPFI (940)
BamHI (1120)
FspI (1174)
BmgBI (1250)
BciVI (1268)
BglI (1488)
BsrGI (1822)
Bsu36I (1880)
NgoMIV (2034)
NaeI (2036)
KasI (2095)
NarI (2096)
SfoI (2097)
PluTI (2099)
PshAI (2278)
AvrII (2323)
L4440 (2344..2361)
SacII (2465)
BsrBI (2387)
pBR322ori-F (2558..2577)
BssSaI (2590)
BstBI (2950)
EarI (3083)
SpeI (3125)
Eco53kI (3239)
SacI (3241)
ScaI (3280)
NcoI (3392)
PasI (3462)
PflMI* (3468)
BsrDI (3680)
CAT-R (3826..3845)
ZraI (4040)
AatII (4042)
AflII (4043)
NdeI (4085)
AleI (4128)
AfeI (4262)
NruI (4386)
SnaBI (4429)
EcoNI (4457)
500
1000
1500
2000
2500
3000
3500
4000
4500
tetR/tetA promoters
RBS
REV site
tet operator
TetR
cat promoter
CmR
lambda t0 terminator
T7Te terminator

FIG. 25 (Cont.)

D




pLBH545_Tet-Cas14a1_Locus
4607 bp
RBS
tetR/tetA promoters
tet operator
TetR
cat promoter
CmR
lambda t0 terminator
T7Te terminator
500
1000
1500
2000
2500
3000
3500
4000
4500
EcoNI (4420)
SnaBI (4392)
NruI (4349)
AfeI (4225)
AleI (4091)
NdeI (4048)
AflII (4006)
AatII (4005)
ZraI (4003)
CAT-R (3789..3808)
BsrDI (3643)
PflMI* (3431)
PasI (3425)
NcoI (3355)
ScaI (3243)
SacI (3204)
Eco53kI (3202)
SpeI (3088)
EarI (3046)
BstBI (2913)
Acc65I (2553)
KpnI (3521..2540)
MluI (2428)
T7 Term (2350)
NheI (2307..2324)
AvrII (2286)
PshAI (2241)
PluTI (2062)
SfoI (2060)
NarI (2059)
KasI (2058)
NaeI (1999)
NgoMIV (1997)
Bsu36I (1843)
BsrGI (1785)
BglII (1451)
BciVI (1231)
BmgBI (1213)
FspI (1137)
BamHI (1083)
PspFI (903)
BseYI (899)
BlpI (892)
BstZ17I (737)
AccI (736)
MfeI (602)
XcmI (385)
SphI (338)
BglII (109)
HinCII (44)
Tet-R (4538..4557)

FIG. 25 (Cont.)

E


pLBH531_MBP-Cas14a1 expression
7556 bp
T7 promoter
10xHis
MBP
TEV site
T7 terminator
AmpR promoter
AmpR
ori
bom
rop
1000
2000
3000
4000
5000
6000
7000
pBRrevBam (58..77)
T7 (161..180)
MBP-F (1423..1446)
T7 Term (3246..3264)
pBRforEco (3728..3746)
Amp-R (4137..4156)
pGEX 3' (5949..5971)
pRS-marker (5789..5808)
L4440 (5692..5709)
pBR322ori-F (5439..5458)
EcoNI (7443)
SalI (7415)
PshAI (7354)
NruI (7096)
Bpu10I (6486)
BsmBI (5950)
PflFI- Tth111I (5849)
BspQI- SapI (5711)
PciI (5594)
SgrAI (100)
PacI (228)
NotI (233)
SbfI (245)
PaeR7I- PspXI- XhoI (249)
XbaI (256)
NdeI (296)
NcoI (336)
BsrWI (639)
BclI (1391)
XcmI (1783)
MfeI(2000)
AgeI (2137)
SspI (3078)
AsiSI (3151)
AscI (3156)
SexAI* (3163)
DraIII (3167)
FseI (3175)
Acc65I (3178)
KpnI (3182)
MluI (3184)
NheI (3477)
BmtI (3481)
HindIII (3677)
BspDI- ClaI (3684)
AatII (3787)
ZraI (3785)
AhdI (4706)
ScaI (4225)

SEQUENCE LISTING

<110> The Regents of the University of California
Doudna, Jennifer A
Burstein, David
Chen, Janice S
Harrington, Lucas B
Paez-Espino, David
Banfield, Jillian F

<120> CASZ COMPOSITIONS AND METHODS OF USE

<130> BERK-374WO

<150> US 62/580,395
<151> 2017-11-01

<160> 373

<170> PatentIn version 3.5

<210> 1
<211> 500
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 1

Met Glu Val Gln Lys Thr Val Met Lys Thr Leu Ser Leu Arg Ile Leu
1 5 10 15

Arg Pro Leu Tyr Ser Gln Glu Ile Glu Lys Glu Ile Lys Glu Glu Lys
20 25 30

Glu Arg Arg Lys Gln Ala Gly Gly Thr Gly Glu Leu Asp Gly Gly Phe
35 40 45

Tyr Lys Lys Leu Glu Lys Lys His Ser Glu Met Phe Ser Phe Asp Arg
50 55 60

Leu Asn Leu Leu Leu Asn Gln Leu Gln Arg Glu Ile Ala Lys Val Tyr

```
65                  70                  75                  80

Asn His Ala Ile Ser Glu Leu Tyr Ile Ala Thr Ile Ala Gln Gly Asn
                85                  90                  95

Lys Ser Asn Lys His Tyr Ile Ser Ser Ile Val Tyr Asn Arg Ala Tyr
            100                 105                 110

Gly Tyr Phe Tyr Asn Ala Tyr Ile Ala Leu Gly Ile Cys Ser Lys Val
        115                 120                 125

Glu Ala Asn Phe Arg Ser Asn Glu Leu Leu Thr Gln Gln Ser Ala Leu
    130                 135                 140

Pro Thr Ala Lys Ser Asp Asn Phe Pro Ile Val Leu His Lys Gln Lys
145                 150                 155                 160

Gly Ala Glu Gly Glu Asp Gly Gly Phe Arg Ile Ser Thr Glu Gly Ser
                165                 170                 175

Asp Leu Ile Phe Glu Ile Pro Ile Pro Phe Tyr Glu Tyr Asn Gly Glu
            180                 185                 190

Asn Arg Lys Glu Pro Tyr Lys Trp Val Lys Lys Gly Gly Gln Lys Pro
        195                 200                 205

Val Leu Lys Leu Ile Leu Ser Thr Phe Arg Arg Gln Arg Asn Lys Gly
    210                 215                 220

Trp Ala Lys Asp Glu Gly Thr Asp Ala Glu Ile Arg Lys Val Thr Glu
225                 230                 235                 240

Gly Lys Tyr Gln Val Ser Gln Ile Glu Ile Asn Arg Gly Lys Lys Leu
                245                 250                 255

Gly Glu His Gln Lys Trp Phe Ala Asn Phe Ser Ile Glu Gln Pro Ile
```

```
            260                 265                 270

Tyr Glu Arg Lys Pro Asn Arg Ser Ile Val Gly Gly Leu Asp Val Gly
        275                 280                 285

Ile Arg Ser Pro Leu Val Cys Ala Ile Asn Asn Ser Phe Ser Arg Tyr
    290                 295                 300

Ser Val Asp Ser Asn Asp Val Phe Lys Phe Ser Lys Gln Val Phe Ala
305                 310                 315                 320

Phe Arg Arg Arg Leu Leu Ser Lys Asn Ser Leu Lys Arg Lys Gly His
                325                 330                 335

Gly Ala Ala His Lys Leu Glu Pro Ile Thr Glu Met Thr Glu Lys Asn
            340                 345                 350

Asp Lys Phe Arg Lys Lys Ile Ile Glu Arg Trp Ala Lys Glu Val Thr
        355                 360                 365

Asn Phe Phe Val Lys Asn Gln Val Gly Ile Val Gln Ile Glu Asp Leu
    370                 375                 380

Ser Thr Met Lys Asp Arg Glu Asp His Phe Phe Asn Gln Tyr Leu Arg
385                 390                 395                 400

Gly Phe Trp Pro Tyr Tyr Gln Met Gln Thr Leu Ile Glu Asn Lys Leu
                405                 410                 415

Lys Glu Tyr Gly Ile Glu Val Lys Arg Val Gln Ala Lys Tyr Thr Ser
            420                 425                 430

Gln Leu Cys Ser Asn Pro Asn Cys Arg Tyr Trp Asn Asn Tyr Phe Asn
        435                 440                 445

Phe Glu Tyr Arg Lys Val Asn Lys Phe Pro Lys Phe Lys Cys Glu Lys
```

```
    450                 455                 460

Cys Asn Leu Glu Ile Ser Ala Asp Tyr Asn Ala Ala Arg Asn Leu Ser
465                 470                 475                 480

Thr Pro Asp Ile Glu Lys Phe Val Ala Lys Ala Thr Lys Gly Ile Asn
                485                 490                 495

Leu Pro Glu Lys
            500
```

<210> 2
<211> 507
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 2

```
Met Glu Glu Ala Lys Thr Val Ser Lys Thr Leu Ser Leu Arg Ile Leu
1               5                   10                  15

Arg Pro Leu Tyr Ser Ala Glu Ile Glu Lys Glu Ile Lys Glu Glu Lys
            20                  25                  30

Glu Arg Arg Lys Gln Gly Gly Lys Ser Gly Glu Leu Asp Ser Gly Phe
        35                  40                  45

Tyr Lys Lys Leu Glu Lys Lys His Thr Gln Met Phe Gly Trp Asp Lys
    50                  55                  60

Leu Asn Leu Met Leu Ser Gln Leu Gln Arg Gln Ile Ala Arg Val Phe
65                  70                  75                  80

Asn Gln Ser Ile Ser Glu Leu Tyr Ile Glu Thr Val Ile Gln Gly Lys
                85                  90                  95
```

```
Lys Ser Asn Lys His Tyr Thr Ser Lys Ile Val Tyr Asn Arg Ala Tyr
            100                 105                 110

Ser Val Phe Tyr Asn Ala Tyr Leu Ala Leu Gly Ile Thr Ser Lys Val
        115                 120                 125

Glu Ala Asn Phe Arg Ser Thr Glu Leu Leu Met Gln Lys Ser Ser Leu
    130                 135                 140

Pro Thr Ala Lys Ser Asp Asn Phe Pro Ile Leu Leu His Lys Gln Lys
145                 150                 155                 160

Gly Val Glu Gly Glu Glu Gly Gly Phe Lys Ile Ser Ala Asp Gly Asn
                165                 170                 175

Asp Leu Ile Phe Glu Ile Pro Ile Pro Phe Tyr Glu Tyr Asp Ser Ala
            180                 185                 190

Asn Lys Lys Glu Pro Phe Lys Trp Ile Lys Lys Gly Gly Gln Lys Pro
        195                 200                 205

Thr Ile Lys Leu Ile Leu Ser Thr Phe Arg Arg Gln Arg Asn Lys Gly
    210                 215                 220

Trp Ala Lys Asp Glu Gly Thr Asp Ala Glu Ile Arg Lys Val Ile Glu
225                 230                 235                 240

Gly Lys Tyr Gln Val Ser His Ile Glu Ile Asn Arg Gly Lys Lys Leu
                245                 250                 255

Gly Asp His Gln Lys Trp Phe Val Asn Phe Thr Ile Glu Gln Pro Ile
            260                 265                 270

Tyr Glu Arg Lys Leu Asp Lys Asn Ile Ile Gly Gly Ile Asp Val Gly
        275                 280                 285
```

```
Ile Lys Ser Pro Leu Val Cys Ala Val Asn Asn Ser Phe Ala Arg Tyr
    290                 295                 300

Ser Val Asp Ser Asn Asp Val Leu Lys Phe Ser Lys Gln Ala Phe Ala
305                 310                 315                 320

Phe Arg Arg Arg Leu Leu Ser Lys Asn Ser Leu Lys Arg Ser Gly His
                325                 330                 335

Gly Ser Lys Asn Lys Leu Asp Pro Ile Thr Arg Met Thr Glu Lys Asn
            340                 345                 350

Asp Arg Phe Arg Lys Lys Ile Ile Glu Arg Trp Ala Lys Glu Val Thr
        355                 360                 365

Asn Phe Phe Ile Lys Asn Gln Val Gly Thr Val Gln Ile Glu Asp Leu
    370                 375                 380

Ser Thr Met Lys Asp Arg Gln Asp Asn Phe Phe Asn Gln Tyr Leu Arg
385                 390                 395                 400

Gly Phe Trp Pro Tyr Tyr Gln Met Gln Asn Leu Ile Glu Asn Lys Leu
                405                 410                 415

Lys Glu Tyr Gly Ile Glu Thr Lys Arg Ile Lys Ala Arg Tyr Thr Ser
            420                 425                 430

Gln Leu Cys Ser Asn Pro Ser Cys Arg His Trp Asn Ser Tyr Phe Ser
        435                 440                 445

Phe Asp His Arg Lys Thr Asn Asn Phe Pro Lys Phe Lys Cys Glu Lys
    450                 455                 460

Cys Ala Leu Glu Ile Ser Ala Asp Tyr Asn Ala Ala Arg Asn Ile Ser
465                 470                 475                 480
```

Thr Pro Asp Ile Glu Lys Phe Val Ala Lys Ala Thr Lys Gly Ile Asn
485 490 495

Leu Pro Asp Lys Asn Glu Asn Val Ile Leu Glu
500 505

<210> 3
<211> 529
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 3

Met Ala Lys Asn Thr Ile Thr Lys Thr Leu Lys Leu Arg Ile Val Arg
1 5 10 15

Pro Tyr Asn Ser Ala Glu Val Glu Lys Ile Val Ala Asp Glu Lys Asn
20 25 30

Asn Arg Glu Lys Ile Ala Leu Glu Lys Asn Lys Asp Lys Val Lys Glu
35 40 45

Ala Cys Ser Lys His Leu Lys Val Ala Ala Tyr Cys Thr Thr Gln Val
50 55 60

Glu Arg Asn Ala Cys Leu Phe Cys Lys Ala Arg Lys Leu Asp Asp Lys
65 70 75 80

Phe Tyr Gln Lys Leu Arg Gly Gln Phe Pro Asp Ala Val Phe Trp Gln
85 90 95

Glu Ile Ser Glu Ile Phe Arg Gln Leu Gln Lys Gln Ala Ala Glu Ile
100 105 110

Tyr Asn Gln Ser Leu Ile Glu Leu Tyr Tyr Glu Ile Phe Ile Lys Gly

```
        115                 120                 125

Lys Gly Ile Ala Asn Ala Ser Ser Val Glu His Tyr Leu Ser Asp Val
    130                 135                 140

Cys Tyr Thr Arg Ala Ala Glu Leu Phe Lys Asn Ala Ala Ile Ala Ser
145                 150                 155                 160

Gly Leu Arg Ser Lys Ile Lys Ser Asn Phe Arg Leu Lys Glu Leu Lys
                165                 170                 175

Asn Met Lys Ser Gly Leu Pro Thr Thr Lys Ser Asp Asn Phe Pro Ile
            180                 185                 190

Pro Leu Val Lys Gln Lys Gly Gly Gln Tyr Thr Gly Phe Glu Ile Ser
        195                 200                 205

Asn His Asn Ser Asp Phe Ile Ile Lys Ile Pro Phe Gly Arg Trp Gln
    210                 215                 220

Val Lys Lys Glu Ile Asp Lys Tyr Arg Pro Trp Glu Lys Phe Asp Phe
225                 230                 235                 240

Glu Gln Val Gln Lys Ser Pro Lys Pro Ile Ser Leu Leu Leu Ser Thr
                245                 250                 255

Gln Arg Arg Lys Arg Asn Lys Gly Trp Ser Lys Asp Glu Gly Thr Glu
            260                 265                 270

Ala Glu Ile Lys Lys Val Met Asn Gly Asp Tyr Gln Thr Ser Tyr Ile
        275                 280                 285

Glu Val Lys Arg Gly Ser Lys Ile Gly Glu Lys Ser Ala Trp Met Leu
    290                 295                 300

Asn Leu Ser Ile Asp Val Pro Lys Ile Asp Lys Gly Val Asp Pro Ser
```

```
305                 310                 315                 320

Ile Ile Gly Gly Ile Asp Val Gly Val Lys Ser Pro Leu Val Cys Ala
                325                 330                 335

Ile Asn Asn Ala Phe Ser Arg Tyr Ser Ile Ser Asp Asn Asp Leu Phe
            340                 345                 350

His Phe Asn Lys Lys Met Phe Ala Arg Arg Arg Ile Leu Leu Lys Lys
        355                 360                 365

Asn Arg His Lys Arg Ala Gly His Gly Ala Lys Asn Lys Leu Lys Pro
    370                 375                 380

Ile Thr Ile Leu Thr Glu Lys Ser Glu Arg Phe Arg Lys Lys Leu Ile
385                 390                 395                 400

Glu Arg Trp Ala Cys Glu Ile Ala Asp Phe Phe Ile Lys Asn Lys Val
                405                 410                 415

Gly Thr Val Gln Met Glu Asn Leu Glu Ser Met Lys Arg Lys Glu Asp
            420                 425                 430

Ser Tyr Phe Asn Ile Arg Leu Arg Gly Phe Trp Pro Tyr Ala Glu Met
        435                 440                 445

Gln Asn Lys Ile Glu Phe Lys Leu Lys Gln Tyr Gly Ile Glu Ile Arg
    450                 455                 460

Lys Val Ala Pro Asn Asn Thr Ser Lys Thr Cys Ser Lys Cys Gly His
465                 470                 475                 480

Leu Asn Asn Tyr Phe Asn Phe Glu Tyr Arg Lys Lys Asn Lys Phe Pro
                485                 490                 495

His Phe Lys Cys Glu Lys Cys Asn Phe Lys Glu Asn Ala Asp Tyr Asn
```

500 505 510

Ala Ala Leu Asn Ile Ser Asn Pro Lys Leu Lys Ser Thr Lys Glu Glu
515 520 525

Pro

<210> 4
<211> 726
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 4

Met Glu Arg Gln Lys Val Pro Gln Ile Arg Lys Ile Val Arg Val Val
1 5 10 15

Pro Leu Arg Ile Leu Arg Pro Lys Tyr Ser Asp Val Ile Glu Asn Ala
20 25 30

Leu Lys Lys Phe Lys Glu Lys Gly Asp Asp Thr Asn Thr Asn Asp Phe
35 40 45

Trp Arg Ala Ile Arg Asp Arg Asp Thr Glu Phe Phe Arg Lys Glu Leu
50 55 60

Asn Phe Ser Glu Asp Glu Ile Asn Gln Leu Glu Arg Asp Thr Leu Phe
65 70 75 80

Arg Val Gly Leu Asp Asn Arg Val Leu Phe Ser Tyr Phe Asp Phe Leu
85 90 95

Gln Glu Lys Leu Met Lys Asp Tyr Asn Lys Ile Ile Ser Lys Leu Phe
100 105 110

```
Ile Asn Arg Gln Ser Lys Ser Ser Phe Glu Asn Asp Leu Thr Asp Glu
        115                 120                 125

Glu Val Glu Glu Leu Ile Glu Lys Asp Val Thr Pro Phe Tyr Gly Ala
    130                 135                 140

Tyr Ile Gly Lys Gly Ile Lys Ser Val Ile Lys Ser Asn Leu Gly Gly
145                 150                 155                 160

Lys Phe Ile Lys Ser Val Lys Ile Asp Arg Glu Thr Lys Lys Val Thr
                165                 170                 175

Lys Leu Thr Ala Ile Asn Ile Gly Leu Met Gly Leu Pro Val Ala Lys
            180                 185                 190

Ser Asp Thr Phe Pro Ile Lys Ile Ile Lys Thr Asn Pro Asp Tyr Ile
        195                 200                 205

Thr Phe Gln Lys Ser Thr Lys Glu Asn Leu Gln Lys Ile Glu Asp Tyr
    210                 215                 220

Glu Thr Gly Ile Glu Tyr Gly Asp Leu Leu Val Gln Ile Thr Ile Pro
225                 230                 235                 240

Trp Phe Lys Asn Glu Asn Lys Asp Phe Ser Leu Ile Lys Thr Lys Glu
                245                 250                 255

Ala Ile Glu Tyr Tyr Lys Leu Asn Gly Val Gly Lys Lys Asp Leu Leu
            260                 265                 270

Asn Ile Asn Leu Val Leu Thr Thr Tyr His Ile Arg Lys Lys Lys Ser
        275                 280                 285

Trp Gln Ile Asp Gly Ser Ser Gln Ser Leu Val Arg Glu Met Ala Asn
    290                 295                 300
```

```
Gly Glu Leu Glu Glu Lys Trp Lys Ser Phe Phe Asp Thr Phe Ile Lys
305                 310                 315                 320


Lys Tyr Gly Asp Glu Gly Lys Ser Ala Leu Val Lys Arg Arg Val Asn
                325                 330                 335


Lys Lys Ser Arg Ala Lys Gly Glu Lys Gly Arg Glu Leu Asn Leu Asp
            340                 345                 350


Glu Arg Ile Lys Arg Leu Tyr Asp Ser Ile Lys Ala Lys Ser Phe Pro
        355                 360                 365


Ser Glu Ile Asn Leu Ile Pro Glu Asn Tyr Lys Trp Lys Leu His Phe
    370                 375                 380


Ser Ile Glu Ile Pro Pro Met Val Asn Asp Ile Asp Ser Asn Leu Tyr
385                 390                 395                 400


Gly Gly Ile Asp Phe Gly Glu Gln Asn Ile Ala Thr Leu Cys Val Lys
                405                 410                 415


Asn Ile Glu Lys Asp Asp Tyr Asp Phe Leu Thr Ile Tyr Gly Asn Asp
            420                 425                 430


Leu Leu Lys His Ala Gln Ala Ser Tyr Ala Arg Arg Arg Ile Met Arg
        435                 440                 445


Val Gln Asp Glu Tyr Lys Ala Arg Gly His Gly Lys Ser Arg Lys Thr
    450                 455                 460


Lys Ala Gln Glu Asp Tyr Ser Glu Arg Met Gln Lys Leu Arg Gln Lys
465                 470                 475                 480


Ile Thr Glu Arg Leu Val Lys Gln Ile Ser Asp Phe Phe Leu Trp Arg
                485                 490                 495
```

```
Asn Lys Phe His Met Ala Val Cys Ser Leu Arg Tyr Glu Asp Leu Asn
            500                 505                 510

Thr Leu Tyr Lys Gly Glu Ser Val Lys Ala Lys Arg Met Arg Gln Phe
        515                 520                 525

Ile Asn Lys Gln Gln Leu Phe Asn Gly Ile Glu Arg Lys Leu Lys Asp
    530                 535                 540

Tyr Asn Ser Glu Ile Tyr Val Asn Ser Arg Tyr Pro His Tyr Thr Ser
545                 550                 555                 560

Arg Leu Cys Ser Lys Cys Gly Lys Leu Asn Leu Tyr Phe Asp Phe Leu
                565                 570                 575

Lys Phe Arg Thr Lys Asn Ile Ile Ile Arg Lys Asn Pro Asp Gly Ser
            580                 585                 590

Glu Ile Lys Tyr Met Pro Phe Phe Ile Cys Glu Phe Cys Gly Trp Lys
        595                 600                 605

Gln Ala Gly Asp Lys Asn Ala Ser Ala Asn Ile Ala Asp Lys Asp Tyr
    610                 615                 620

Gln Asp Lys Leu Asn Lys Glu Lys Glu Phe Cys Asn Ile Arg Lys Pro
625                 630                 635                 640

Lys Ser Lys Lys Glu Asp Ile Gly Glu Glu Asn Glu Glu Glu Arg Asp
                645                 650                 655

Tyr Ser Arg Arg Phe Asn Arg Asn Ser Phe Ile Tyr Asn Ser Leu Lys
            660                 665                 670

Lys Asp Asn Lys Leu Asn Gln Glu Lys Leu Phe Asp Glu Trp Lys Asn
        675                 680                 685
```

```
Gln Leu Lys Arg Lys Ile Asp Gly Arg Asn Lys Phe Glu Pro Lys Glu
    690                 695                 700

Tyr Lys Asp Arg Phe Ser Tyr Leu Phe Ala Tyr Tyr Gln Glu Ile Ile
705                 710                 715                 720

Lys Asn Glu Ser Glu Ser
                725
```

<210> 5
<211> 517
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 5

```
Met Val Pro Thr Glu Leu Ile Thr Lys Thr Leu Gln Leu Arg Val Ile
1               5                   10                  15

Arg Pro Leu Tyr Phe Glu Glu Ile Glu Lys Glu Leu Ala Glu Leu Lys
            20                  25                  30

Glu Gln Lys Glu Lys Glu Phe Glu Glu Thr Asn Ser Leu Leu Leu Glu
        35                  40                  45

Ser Lys Lys Ile Asp Ala Lys Ser Leu Lys Lys Leu Lys Arg Lys Ala
    50                  55                  60

Arg Ser Ser Ala Ala Val Glu Phe Trp Lys Ile Ala Lys Glu Lys Tyr
65                  70                  75                  80

Pro Asp Ile Leu Thr Lys Pro Glu Met Glu Phe Ile Phe Ser Glu Met
                85                  90                  95

Gln Lys Met Met Ala Arg Phe Tyr Asn Lys Ser Met Thr Asn Ile Phe
```

```
            100                 105                 110

Ile Glu Met Asn Asn Asp Glu Lys Val Asn Pro Leu Ser Leu Ile Ser
        115                 120                 125

Lys Ala Ser Thr Glu Ala Asn Gln Val Ile Lys Cys Ser Ser Ile Ser
    130                 135                 140

Ser Gly Leu Asn Arg Lys Ile Ala Gly Ser Ile Asn Lys Thr Lys Phe
145                 150                 155                 160

Lys Gln Val Arg Asp Gly Leu Ile Ser Leu Pro Thr Ala Arg Thr Glu
                165                 170                 175

Thr Phe Pro Ile Ser Phe Tyr Lys Ser Thr Ala Asn Lys Asp Glu Ile
            180                 185                 190

Pro Ile Ser Lys Ile Asn Leu Pro Ser Glu Glu Glu Ala Asp Leu Thr
        195                 200                 205

Ile Thr Leu Pro Phe Pro Phe Phe Glu Ile Lys Lys Glu Lys Lys Gly
    210                 215                 220

Gln Lys Ala Tyr Ser Tyr Phe Asn Ile Ile Glu Lys Ser Gly Arg Ser
225                 230                 235                 240

Asn Asn Lys Ile Asp Leu Leu Leu Ser Thr His Arg Arg Gln Arg Arg
                245                 250                 255

Lys Gly Trp Lys Glu Glu Gly Gly Thr Ser Ala Glu Ile Arg Arg Leu
            260                 265                 270

Met Glu Gly Glu Phe Asp Lys Glu Trp Glu Ile Tyr Leu Gly Glu Ala
        275                 280                 285

Glu Lys Ser Glu Lys Ala Lys Asn Asp Leu Ile Lys Asn Met Thr Arg
```

```
    290                 295                 300

Gly Lys Leu Ser Lys Asp Ile Lys Glu Gln Leu Glu Asp Ile Gln Val
305                 310                 315                 320

Lys Tyr Phe Ser Asp Asn Asn Val Glu Ser Trp Asn Asp Leu Ser Lys
                325                 330                 335

Glu Gln Lys Gln Glu Leu Ser Lys Leu Arg Lys Lys Lys Val Glu Glu
            340                 345                 350

Leu Lys Asp Trp Lys His Val Lys Glu Ile Leu Lys Thr Arg Ala Lys
        355                 360                 365

Ile Gly Trp Val Glu Leu Lys Arg Gly Lys Arg Gln Arg Asp Arg Asn
    370                 375                 380

Lys Trp Phe Val Asn Ile Thr Ile Thr Arg Pro Pro Phe Ile Asn Lys
385                 390                 395                 400

Glu Leu Asp Asp Thr Lys Phe Gly Gly Ile Asp Leu Gly Val Lys Val
                405                 410                 415

Pro Phe Val Cys Ala Val His Gly Ser Pro Ala Arg Leu Ile Ile Lys
            420                 425                 430

Glu Asn Glu Ile Leu Gln Phe Asn Lys Met Val Ser Ala Arg Asn Arg
        435                 440                 445

Gln Ile Thr Lys Asp Ser Glu Gln Arg Lys Gly Arg Gly Lys Lys Asn
    450                 455                 460

Lys Phe Ile Lys Lys Glu Ile Phe Asn Glu Arg Asn Glu Leu Phe Arg
465                 470                 475                 480

Lys Lys Ile Ile Glu Arg Trp Ala Asn Gln Ile Val Lys Phe Phe Glu
```

485 490 495

Asp Gln Lys Cys Ala Thr Val Gln Ile Glu Asn Leu Glu Ser Phe Asp
500 505 510

Arg Thr Ser Tyr Lys
515

<210> 6
<211> 481
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 6

Met Lys Ser Asp Thr Lys Asp Lys Lys Ile Ile Ile His Gln Thr Lys
1 5 10 15

Thr Leu Ser Leu Arg Ile Val Lys Pro Gln Ser Ile Pro Met Glu Glu
20 25 30

Phe Thr Asp Leu Val Arg Tyr His Gln Met Ile Ile Phe Pro Val Tyr
35 40 45

Asn Asn Gly Ala Ile Asp Leu Tyr Lys Lys Leu Phe Lys Ala Lys Ile
50 55 60

Gln Lys Gly Asn Glu Ala Arg Ala Ile Lys Tyr Phe Met Asn Lys Ile
65 70 75 80

Val Tyr Ala Pro Ile Ala Asn Thr Val Lys Asn Ser Tyr Ile Ala Leu
85 90 95

Gly Tyr Ser Thr Lys Met Gln Ser Ser Phe Ser Gly Lys Arg Leu Trp
100 105 110

```
Asp Leu Arg Phe Gly Glu Ala Thr Pro Pro Thr Ile Lys Ala Asp Phe
        115                 120                 125


Pro Leu Pro Phe Tyr Asn Gln Ser Gly Phe Lys Val Ser Ser Glu Asn
    130                 135                 140


Gly Glu Phe Ile Ile Gly Ile Pro Phe Gly Gln Tyr Thr Lys Lys Thr
145                 150                 155                 160


Val Ser Asp Ile Glu Lys Lys Thr Ser Phe Ala Trp Asp Lys Phe Thr
                165                 170                 175


Leu Glu Asp Thr Thr Lys Lys Thr Leu Ile Glu Leu Leu Leu Ser Thr
            180                 185                 190


Lys Thr Arg Lys Met Asn Glu Gly Trp Lys Asn Asn Glu Gly Thr Glu
        195                 200                 205


Ala Glu Ile Lys Arg Val Met Asp Gly Thr Tyr Gln Val Thr Ser Leu
    210                 215                 220


Glu Ile Leu Gln Arg Asp Asp Ser Trp Phe Val Asn Phe Asn Ile Ala
225                 230                 235                 240


Tyr Asp Ser Leu Lys Lys Gln Pro Asp Arg Asp Lys Ile Ala Gly Ile
                245                 250                 255


His Met Gly Ile Thr Arg Pro Leu Thr Ala Val Ile Tyr Asn Asn Lys
            260                 265                 270


Tyr Arg Ala Leu Ser Ile Tyr Pro Asn Thr Val Met His Leu Thr Gln
        275                 280                 285


Lys Gln Leu Ala Arg Ile Lys Glu Gln Arg Thr Asn Ser Lys Tyr Ala
    290                 295                 300
```

```
Thr Gly Gly His Gly Arg Asn Ala Lys Val Thr Gly Thr Asp Thr Leu
305                 310                 315                 320


Ser Glu Ala Tyr Arg Gln Arg Arg Lys Lys Ile Ile Glu Asp Trp Ile
                325                 330                 335


Ala Ser Ile Val Lys Phe Ala Ile Asn Asn Glu Ile Gly Thr Ile Tyr
            340                 345                 350


Leu Glu Asp Ile Ser Asn Thr Asn Ser Phe Phe Ala Ala Arg Glu Gln
        355                 360                 365


Lys Leu Ile Tyr Leu Glu Asp Ile Ser Asn Thr Asn Ser Phe Leu Ser
    370                 375                 380


Thr Tyr Lys Tyr Pro Ile Ser Ala Ile Ser Asp Thr Leu Gln His Lys
385                 390                 395                 400


Leu Glu Glu Lys Ala Ile Gln Val Ile Arg Lys Lys Ala Tyr Tyr Val
                405                 410                 415


Asn Gln Ile Cys Ser Leu Cys Gly His Tyr Asn Lys Gly Phe Thr Tyr
            420                 425                 430


Gln Phe Arg Arg Lys Asn Lys Phe Pro Lys Met Lys Cys Gln Gly Cys
        435                 440                 445


Leu Glu Ala Thr Ser Thr Glu Phe Asn Ala Ala Ala Asn Val Ala Asn
    450                 455                 460


Pro Asp Tyr Glu Lys Leu Leu Ile Lys His Gly Leu Leu Gln Leu Lys
465                 470                 475                 480


Lys
```

<210> 7
<211> 358
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 7

```
Met Ser Thr Ile Thr Arg Gln Val Arg Leu Ser Pro Thr Pro Glu Gln
1               5                   10                  15


Ser Arg Leu Leu Met Ala His Cys Gln Gln Tyr Ile Ser Thr Val Asn
            20                  25                  30


Val Leu Val Ala Ala Phe Asp Ser Glu Val Leu Thr Gly Lys Val Ser
        35                  40                  45


Thr Lys Asp Phe Arg Ala Ala Leu Pro Ser Ala Val Lys Asn Gln Ala
    50                  55                  60


Leu Arg Asp Ala Gln Ser Val Phe Lys Arg Ser Val Glu Leu Gly Cys
65                  70                  75                  80


Leu Pro Val Leu Lys Lys Pro His Cys Gln Trp Asn Asn Gln Asn Trp
                85                  90                  95


Arg Val Glu Gly Asp Gln Leu Ile Leu Pro Ile Cys Lys Asp Gly Lys
            100                 105                 110


Thr Gln Gln Glu Arg Phe Arg Cys Ala Ala Val Ala Leu Glu Gly Lys
        115                 120                 125


Ala Gly Ile Leu Arg Ile Lys Lys Lys Arg Gly Lys Trp Ile Ala Asp
    130                 135                 140


Leu Thr Val Thr Gln Glu Asp Ala Pro Glu Ser Ser Gly Ser Ala Ile
```

```
145                 150                 155                 160

Met Gly Val Asp Leu Gly Ile Lys Val Pro Ala Val Ala His Ile Gly
                165                 170                 175

Gly Lys Gly Thr Arg Phe Phe Gly Asn Gly Arg Ser Gln Arg Ser Met
            180                 185                 190

Arg Arg Arg Phe Tyr Ala Arg Arg Lys Thr Leu Gln Lys Ala Lys Lys
        195                 200                 205

Leu Arg Ala Val Arg Lys Ser Lys Gly Lys Glu Ala Arg Trp Met Lys
    210                 215                 220

Thr Ile Asn His Gln Leu Ser Arg Gln Ile Val Asn His Ala His Ala
225                 230                 235                 240

Leu Gly Val Gly Thr Ile Lys Ile Glu Ala Leu Gln Gly Ile Arg Lys
                245                 250                 255

Gly Thr Thr Arg Lys Ser Arg Gly Ala Ala Ala Arg Lys Asn Asn Arg
            260                 265                 270

Met Thr Asn Thr Trp Ser Phe Ser Gln Leu Thr Leu Phe Ile Thr Tyr
        275                 280                 285

Lys Ala Gln Arg Gln Gly Ile Thr Val Glu Gln Val Asp Pro Ala Tyr
    290                 295                 300

Thr Ser Gln Asp Cys Pro Ala Cys Arg Ala Arg Asn Gly Ala Gln Asp
305                 310                 315                 320

Arg Thr Tyr Val Cys Ser Glu Cys Gly Trp Arg Gly His Arg Asp Thr
                325                 330                 335

Val Gly Ala Ile Asn Ile Ser Arg Arg Ala Gly Leu Ser Gly His Arg
```

340 345 350

Arg Gly Ala Thr Gly Ala
355

<210> 8
<211> 507
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 8

Met Ile Ala Gln Lys Thr Ile Lys Ile Lys Leu Asn Pro Thr Lys Glu
1 5 10 15

Gln Ile Ile Lys Leu Asn Ser Ile Ile Glu Glu Tyr Ile Lys Val Ser
20 25 30

Asn Phe Thr Ala Lys Lys Ile Ala Glu Ile Gln Glu Ser Phe Thr Asp
35 40 45

Ser Gly Leu Thr Gln Gly Thr Cys Ser Glu Cys Gly Lys Glu Lys Thr
50 55 60

Tyr Arg Lys Tyr His Leu Leu Lys Lys Asp Asn Lys Leu Phe Cys Ile
65 70 75 80

Thr Cys Tyr Lys Arg Lys Tyr Ser Gln Phe Thr Leu Gln Lys Val Glu
85 90 95

Phe Gln Asn Lys Thr Gly Leu Arg Asn Val Ala Lys Leu Pro Lys Thr
100 105 110

Tyr Tyr Thr Asn Ala Ile Arg Phe Ala Ser Asp Thr Phe Ser Gly Phe
115 120 125

```
Asp Glu Ile Ile Lys Lys Lys Gln Asn Arg Leu Asn Ser Ile Gln Asn
    130                 135                 140

Arg Leu Asn Phe Trp Lys Glu Leu Leu Tyr Asn Pro Ser Asn Arg Asn
145                 150                 155                 160

Glu Ile Lys Ile Lys Val Val Lys Tyr Ala Pro Lys Thr Asp Thr Arg
                165                 170                 175

Glu His Pro His Tyr Tyr Ser Glu Ala Glu Ile Lys Gly Arg Ile Lys
            180                 185                 190

Arg Leu Glu Lys Gln Leu Lys Lys Phe Lys Met Pro Lys Tyr Pro Glu
        195                 200                 205

Phe Thr Ser Glu Thr Ile Ser Leu Gln Arg Glu Leu Tyr Ser Trp Lys
    210                 215                 220

Asn Pro Asp Glu Leu Lys Ile Ser Ser Ile Thr Asp Lys Asn Glu Ser
225                 230                 235                 240

Met Asn Tyr Tyr Gly Lys Glu Tyr Leu Lys Arg Tyr Ile Asp Leu Ile
                245                 250                 255

Asn Ser Gln Thr Pro Gln Ile Leu Leu Glu Lys Glu Asn Asn Ser Phe
            260                 265                 270

Tyr Leu Cys Phe Pro Ile Thr Lys Asn Ile Glu Met Pro Lys Ile Asp
        275                 280                 285

Asp Thr Phe Glu Pro Val Gly Ile Asp Trp Gly Ile Thr Arg Asn Ile
    290                 295                 300

Ala Val Val Ser Ile Leu Asp Ser Lys Thr Lys Lys Pro Lys Phe Val
305                 310                 315                 320
```

```
Lys Phe Tyr Ser Ala Gly Tyr Ile Leu Gly Lys Arg Lys His Tyr Lys
                325                 330                 335

Ser Leu Arg Lys His Phe Gly Gln Lys Lys Arg Gln Asp Lys Ile Asn
            340                 345                 350

Lys Leu Gly Thr Lys Glu Asp Arg Phe Ile Asp Ser Asn Ile His Lys
        355                 360                 365

Leu Ala Phe Leu Ile Val Lys Glu Ile Arg Asn His Ser Asn Lys Pro
    370                 375                 380

Ile Ile Leu Met Glu Asn Ile Thr Asp Asn Arg Glu Glu Ala Glu Lys
385                 390                 395                 400

Ser Met Arg Gln Asn Ile Leu Leu His Ser Val Lys Ser Arg Leu Gln
                405                 410                 415

Asn Tyr Ile Ala Tyr Lys Ala Leu Trp Asn Asn Ile Pro Thr Asn Leu
            420                 425                 430

Val Lys Pro Glu His Thr Ser Gln Ile Cys Asn Arg Cys Gly His Gln
        435                 440                 445

Asp Arg Glu Asn Arg Pro Lys Gly Ser Lys Leu Phe Lys Cys Val Lys
    450                 455                 460

Cys Asn Tyr Met Ser Asn Ala Asp Phe Asn Ala Ser Ile Asn Ile Ala
465                 470                 475                 480

Arg Lys Phe Tyr Ile Gly Glu Tyr Glu Pro Phe Tyr Lys Asp Asn Glu
                485                 490                 495

Lys Met Lys Ser Gly Val Asn Ser Ile Ser Met
            500                 505
```

<210> 9
<211> 534
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 9

```
Leu Lys Leu Ser Glu Gln Glu Asn Ile Thr Thr Gly Val Lys Phe Lys
1               5                   10                  15


Leu Lys Leu Asp Lys Glu Thr Ser Glu Gly Leu Asn Asp Tyr Phe Asp
            20                  25                  30


Glu Tyr Gly Lys Ala Ile Asn Phe Ala Ile Lys Val Ile Gln Lys Glu
        35                  40                  45


Leu Ala Glu Asp Arg Phe Ala Gly Lys Val Arg Leu Asp Glu Asn Lys
    50                  55                  60


Lys Pro Leu Leu Asn Glu Asp Gly Lys Lys Ile Trp Asp Phe Pro Asn
65                  70                  75                  80


Glu Phe Cys Ser Cys Gly Lys Gln Val Asn Arg Tyr Val Asn Gly Lys
                85                  90                  95


Ser Leu Cys Gln Glu Cys Tyr Lys Asn Lys Phe Thr Glu Tyr Gly Ile
            100                 105                 110


Arg Lys Arg Met Tyr Ser Ala Lys Gly Arg Lys Ala Glu Gln Asp Ile
        115                 120                 125


Asn Ile Lys Asn Ser Thr Asn Lys Ile Ser Lys Thr His Phe Asn Tyr
    130                 135                 140


Ala Ile Arg Glu Ala Phe Ile Leu Asp Lys Ser Ile Lys Lys Gln Arg
```

```
145                 150                 155                 160

Lys Glu Arg Phe Arg Arg Leu Arg Glu Met Lys Lys Lys Leu Gln Glu
                165                 170                 175

Phe Ile Glu Ile Arg Asp Gly Asn Lys Ile Leu Cys Pro Lys Ile Glu
            180                 185                 190

Lys Gln Arg Val Glu Arg Tyr Ile His Pro Ser Trp Ile Asn Lys Glu
        195                 200                 205

Lys Lys Leu Glu Asp Phe Arg Gly Tyr Ser Met Ser Asn Val Leu Gly
    210                 215                 220

Lys Ile Lys Ile Leu Asp Arg Asn Ile Lys Arg Glu Glu Lys Ser Leu
225                 230                 235                 240

Lys Glu Lys Gly Gln Ile Asn Phe Lys Ala Arg Arg Leu Met Leu Asp
                245                 250                 255

Lys Ser Val Lys Phe Leu Asn Asp Asn Lys Ile Ser Phe Thr Ile Ser
            260                 265                 270

Lys Asn Leu Pro Lys Glu Tyr Glu Leu Asp Leu Pro Glu Lys Glu Lys
        275                 280                 285

Arg Leu Asn Trp Leu Lys Glu Lys Ile Lys Ile Ile Lys Asn Gln Lys
    290                 295                 300

Pro Lys Tyr Ala Tyr Leu Leu Arg Lys Asp Asp Asn Phe Tyr Leu Gln
305                 310                 315                 320

Tyr Thr Leu Glu Thr Glu Phe Asn Leu Lys Glu Asp Tyr Ser Gly Ile
                325                 330                 335

Val Gly Ile Asp Arg Gly Val Ser His Ile Ala Val Tyr Thr Phe Val
```

```
            340                 345                 350

His Asn Asn Gly Lys Asn Glu Arg Pro Leu Phe Leu Asn Ser Ser Glu
        355                 360                 365

Ile Leu Arg Leu Lys Asn Leu Gln Lys Glu Arg Asp Arg Phe Leu Arg
    370                 375                 380

Arg Lys His Asn Lys Lys Arg Lys Lys Ser Asn Met Arg Asn Ile Glu
385                 390                 395                 400

Lys Lys Ile Gln Leu Ile Leu His Asn Tyr Ser Lys Gln Ile Val Asp
                405                 410                 415

Phe Ala Lys Asn Lys Asn Ala Phe Ile Val Phe Glu Lys Leu Glu Lys
            420                 425                 430

Pro Lys Lys Asn Arg Ser Lys Met Ser Lys Lys Ser Gln Tyr Lys Leu
        435                 440                 445

Ser Gln Phe Thr Phe Lys Lys Leu Ser Asp Leu Val Asp Tyr Lys Ala
    450                 455                 460

Lys Arg Glu Gly Ile Lys Val Leu Tyr Ile Ser Pro Glu Tyr Thr Ser
465                 470                 475                 480

Lys Glu Cys Ser His Cys Gly Glu Lys Val Asn Thr Gln Arg Pro Phe
                485                 490                 495

Asn Gly Asn Ser Ser Leu Phe Lys Cys Asn Lys Cys Gly Val Glu Leu
            500                 505                 510

Asn Ala Asp Tyr Asn Ala Ser Ile Asn Ile Ala Lys Lys Gly Leu Asn
        515                 520                 525

Ile Leu Asn Ser Thr Asn
```

530

<210> 10
<211> 537
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 10

Met Glu Glu Ser Ile Ile Thr Gly Val Lys Phe Lys Leu Arg Ile Asp
1 5 10 15

Lys Glu Thr Thr Lys Lys Leu Asn Glu Tyr Phe Asp Glu Tyr Gly Lys
20 25 30

Ala Ile Asn Phe Ala Val Lys Ile Ile Gln Lys Glu Leu Ala Asp Asp
35 40 45

Arg Phe Ala Gly Lys Ala Lys Leu Asp Gln Asn Lys Asn Pro Ile Leu
50 55 60

Asp Glu Asn Gly Lys Lys Ile Tyr Glu Phe Pro Asp Glu Phe Cys Ser
65 70 75 80

Cys Gly Lys Gln Val Asn Lys Tyr Val Asn Asn Lys Pro Phe Cys Gln
85 90 95

Glu Cys Tyr Lys Ile Arg Phe Thr Glu Asn Gly Ile Arg Lys Arg Met
100 105 110

Tyr Ser Ala Lys Gly Arg Lys Ala Glu His Lys Ile Asn Ile Leu Asn
115 120 125

Ser Thr Asn Lys Ile Ser Lys Thr His Phe Asn Tyr Ala Ile Arg Glu
130 135 140

```
Ala Phe Ile Leu Asp Lys Ser Ile Lys Lys Gln Arg Lys Lys Arg Asn
145                 150                 155                 160

Glu Arg Leu Arg Glu Ser Lys Lys Arg Leu Gln Gln Phe Ile Asp Met
                165                 170                 175

Arg Asp Gly Lys Arg Glu Ile Cys Pro Thr Ile Lys Gly Gln Lys Val
            180                 185                 190

Asp Arg Phe Ile His Pro Ser Trp Ile Thr Lys Asp Lys Lys Leu Glu
        195                 200                 205

Asp Phe Arg Gly Tyr Thr Leu Ser Ile Ile Asn Ser Lys Ile Lys Ile
    210                 215                 220

Leu Asp Arg Asn Ile Lys Arg Glu Glu Lys Ser Leu Lys Glu Lys Gly
225                 230                 235                 240

Gln Ile Ile Phe Lys Ala Lys Arg Leu Met Leu Asp Lys Ser Ile Arg
                245                 250                 255

Phe Val Gly Asp Arg Lys Val Leu Phe Thr Ile Ser Lys Thr Leu Pro
            260                 265                 270

Lys Glu Tyr Glu Leu Asp Leu Pro Ser Lys Glu Lys Arg Leu Asn Trp
        275                 280                 285

Leu Lys Glu Lys Ile Glu Ile Ile Lys Asn Gln Lys Pro Lys Tyr Ala
    290                 295                 300

Tyr Leu Leu Arg Lys Asn Ile Glu Ser Glu Lys Lys Pro Asn Tyr Glu
305                 310                 315                 320

Tyr Tyr Leu Gln Tyr Thr Leu Glu Ile Lys Pro Glu Leu Lys Asp Phe
                325                 330                 335
```

```
Tyr Asp Gly Ala Ile Gly Ile Asp Arg Gly Ile Asn His Ile Ala Val
            340                 345                 350

Cys Thr Phe Ile Ser Asn Asp Gly Lys Val Thr Pro Pro Lys Phe Phe
        355                 360                 365

Ser Ser Gly Glu Ile Leu Arg Leu Lys Asn Leu Gln Lys Glu Arg Asp
    370                 375                 380

Arg Phe Leu Leu Arg Lys His Asn Lys Asn Arg Lys Lys Gly Asn Met
385                 390                 395                 400

Arg Val Ile Glu Asn Lys Ile Asn Leu Ile Leu His Arg Tyr Ser Lys
                405                 410                 415

Gln Ile Val Asp Met Ala Lys Lys Leu Asn Ala Ser Ile Val Phe Glu
            420                 425                 430

Glu Leu Gly Arg Ile Gly Lys Ser Arg Thr Lys Met Lys Lys Ser Gln
        435                 440                 445

Arg Tyr Lys Leu Ser Leu Phe Ile Phe Lys Lys Leu Ser Asp Leu Val
    450                 455                 460

Asp Tyr Lys Ser Arg Arg Glu Gly Ile Arg Val Thr Tyr Val Pro Pro
465                 470                 475                 480

Glu Tyr Thr Ser Lys Glu Cys Ser His Cys Gly Glu Lys Val Asn Thr
                485                 490                 495

Gln Arg Pro Phe Asn Gly Asn Tyr Ser Leu Phe Lys Cys Asn Lys Cys
            500                 505                 510

Gly Ile Gln Leu Asn Ser Asp Tyr Asn Ala Ser Ile Asn Ile Ala Lys
        515                 520                 525
```

Lys Gly Leu Lys Ile Pro Asn Ser Thr
530 535

<210> 11
<211> 540
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 11

Leu Trp Thr Ile Val Ile Gly Asp Phe Ile Glu Met Pro Lys Gln Asp
1 5 10 15

Leu Val Thr Thr Gly Ile Lys Phe Lys Leu Asp Val Asp Lys Glu Thr
20 25 30

Arg Lys Lys Leu Asp Asp Tyr Phe Asp Glu Tyr Gly Lys Ala Ile Asn
35 40 45

Phe Ala Val Lys Ile Ile Gln Lys Asn Leu Lys Glu Asp Arg Phe Ala
50 55 60

Gly Lys Ile Ala Leu Gly Glu Asp Lys Lys Pro Leu Leu Asp Lys Asp
65 70 75 80

Gly Lys Lys Ile Tyr Asn Tyr Pro Asn Glu Ser Cys Ser Cys Gly Asn
85 90 95

Gln Val Arg Arg Tyr Val Asn Ala Lys Pro Phe Cys Val Asp Cys Tyr
100 105 110

Lys Leu Lys Phe Thr Glu Asn Gly Ile Arg Lys Arg Met Tyr Ser Ala
115 120 125

Arg Gly Arg Lys Ala Asp Ser Asp Ile Asn Ile Lys Asn Ser Thr Asn

```
    130                 135                 140

Lys Ile Ser Lys Thr His Phe Asn Tyr Ala Ile Arg Glu Gly Phe Ile
145                 150                 155                 160

Leu Asp Lys Ser Leu Lys Lys Gln Arg Ser Lys Arg Ile Lys Lys Leu
                165                 170                 175

Leu Glu Leu Lys Arg Lys Leu Gln Glu Phe Ile Asp Ile Arg Gln Gly
            180                 185                 190

Gln Met Val Leu Cys Pro Lys Ile Lys Asn Gln Arg Val Asp Lys Phe
        195                 200                 205

Ile His Pro Ser Trp Leu Lys Arg Asp Lys Lys Leu Glu Glu Phe Arg
    210                 215                 220

Gly Tyr Ser Leu Ser Val Val Glu Gly Lys Ile Lys Ile Phe Asn Arg
225                 230                 235                 240

Asn Ile Leu Arg Glu Glu Asp Ser Leu Arg Gln Arg Gly His Val Asn
                245                 250                 255

Phe Lys Ala Asn Arg Ile Met Leu Asp Lys Ser Val Arg Phe Leu Asp
            260                 265                 270

Gly Gly Lys Val Asn Phe Asn Leu Asn Lys Gly Leu Pro Lys Glu Tyr
        275                 280                 285

Leu Leu Asp Leu Pro Lys Lys Glu Asn Lys Leu Ser Trp Leu Asn Glu
    290                 295                 300

Lys Ile Ser Leu Ile Lys Leu Gln Lys Pro Lys Tyr Ala Tyr Leu Leu
305                 310                 315                 320

Arg Arg Glu Gly Ser Phe Phe Ile Gln Tyr Thr Ile Glu Asn Val Pro
```

```
                325                 330                 335

Lys Thr Phe Ser Asp Tyr Leu Gly Ala Ile Gly Ile Asp Arg Gly Ile
            340                 345                 350

Ser His Ile Ala Val Cys Thr Phe Val Ser Lys Asn Gly Val Asn Lys
        355                 360                 365

Ala Pro Val Phe Phe Ser Ser Gly Glu Ile Leu Lys Leu Lys Ser Leu
    370                 375                 380

Gln Lys Gln Arg Asp Leu Phe Leu Arg Gly Lys His Asn Lys Ile Arg
385                 390                 395                 400

Lys Lys Ser Asn Met Arg Asn Ile Asp Asn Lys Ile Asn Leu Ile Leu
                405                 410                 415

His Lys Tyr Ser Arg Asn Ile Val Asn Leu Ala Lys Ser Glu Lys Ala
            420                 425                 430

Phe Ile Val Phe Glu Lys Leu Glu Lys Ile Lys Lys Ser Arg Phe Lys
        435                 440                 445

Met Ser Lys Ser Leu Gln Tyr Lys Leu Ser Gln Phe Thr Phe Lys Lys
    450                 455                 460

Leu Ser Asp Leu Val Glu Tyr Lys Ala Lys Ile Glu Gly Ile Lys Val
465                 470                 475                 480

Asp Tyr Val Pro Pro Glu Tyr Thr Ser Lys Glu Cys Ser His Cys Gly
                485                 490                 495

Glu Lys Val Asp Thr Gln Arg Pro Phe Asn Gly Asn Ser Ser Leu Phe
            500                 505                 510

Lys Cys Asn Lys Cys Arg Val Gln Leu Asn Ala Asp Tyr Asn Ala Ser
```

515 520 525

Ile Asn Ile Ala Lys Lys Ser Leu Asn Ile Ser Asn
530 535 540

<210> 12
<211> 542
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 12

Met Ser Lys Thr Thr Ile Ser Val Lys Leu Lys Ile Ile Asp Leu Ser
1 5 10 15

Ser Glu Lys Lys Glu Phe Leu Asp Asn Tyr Phe Asn Glu Tyr Ala Lys
20 25 30

Ala Thr Thr Phe Cys Gln Leu Arg Ile Arg Arg Leu Leu Arg Asn Thr
35 40 45

His Trp Leu Gly Lys Lys Glu Lys Ser Ser Lys Lys Trp Ile Phe Glu
50 55 60

Ser Gly Ile Cys Asp Leu Cys Gly Glu Asn Lys Glu Leu Val Asn Glu
65 70 75 80

Asp Arg Asn Ser Gly Glu Pro Ala Lys Ile Cys Lys Arg Cys Tyr Asn
85 90 95

Gly Arg Tyr Gly Asn Gln Met Ile Arg Lys Leu Phe Val Ser Thr Lys
100 105 110

Lys Arg Glu Val Gln Glu Asn Met Asp Ile Arg Arg Val Ala Lys Leu
115 120 125

```
Asn Asn Thr His Tyr His Arg Ile Pro Glu Glu Ala Phe Asp Met Ile
    130                 135                 140

Lys Ala Ala Asp Thr Ala Glu Lys Arg Arg Lys Lys Asn Val Glu Tyr
145                 150                 155                 160

Asp Lys Lys Arg Gln Met Glu Phe Ile Glu Met Phe Asn Asp Glu Lys
                165                 170                 175

Lys Arg Ala Ala Arg Pro Lys Lys Pro Asn Glu Arg Glu Thr Arg Tyr
            180                 185                 190

Val His Ile Ser Lys Leu Glu Ser Pro Ser Lys Gly Tyr Thr Leu Asn
        195                 200                 205

Gly Ile Lys Arg Lys Ile Asp Gly Met Gly Lys Lys Ile Glu Arg Ala
    210                 215                 220

Glu Lys Gly Leu Ser Arg Lys Lys Ile Phe Gly Tyr Gln Gly Asn Arg
225                 230                 235                 240

Ile Lys Leu Asp Ser Asn Trp Val Arg Phe Asp Leu Ala Glu Ser Glu
                245                 250                 255

Ile Thr Ile Pro Ser Leu Phe Lys Glu Met Lys Leu Arg Ile Thr Gly
            260                 265                 270

Pro Thr Asn Val His Ser Lys Ser Gly Gln Ile Tyr Phe Ala Glu Trp
        275                 280                 285

Phe Glu Arg Ile Asn Lys Gln Pro Asn Asn Tyr Cys Tyr Leu Ile Arg
    290                 295                 300

Lys Thr Ser Ser Asn Gly Lys Tyr Glu Tyr Tyr Leu Gln Tyr Thr Tyr
305                 310                 315                 320
```

```
Glu Ala Glu Val Glu Ala Asn Lys Glu Tyr Ala Gly Cys Leu Gly Val
                325                 330                 335

Asp Ile Gly Cys Ser Lys Leu Ala Ala Ala Val Tyr Tyr Asp Ser Lys
            340                 345                 350

Asn Lys Lys Ala Gln Lys Pro Ile Glu Ile Phe Thr Asn Pro Ile Lys
        355                 360                 365

Lys Ile Lys Met Arg Arg Glu Lys Leu Ile Lys Leu Leu Ser Arg Val
    370                 375                 380

Lys Val Arg His Arg Arg Arg Lys Leu Met Gln Leu Ser Lys Thr Glu
385                 390                 395                 400

Pro Ile Ile Asp Tyr Thr Cys His Lys Thr Ala Arg Lys Ile Val Glu
                405                 410                 415

Met Ala Asn Thr Ala Lys Ala Phe Ile Ser Met Glu Asn Leu Glu Thr
            420                 425                 430

Gly Ile Lys Gln Lys Gln Gln Ala Arg Glu Thr Lys Lys Gln Lys Phe
        435                 440                 445

Tyr Arg Asn Met Phe Leu Phe Arg Lys Leu Ser Lys Leu Ile Glu Tyr
    450                 455                 460

Lys Ala Leu Leu Lys Gly Ile Lys Ile Val Tyr Val Lys Pro Asp Tyr
465                 470                 475                 480

Thr Ser Gln Thr Cys Ser Ser Cys Gly Ala Asp Lys Glu Lys Thr Glu
                485                 490                 495

Arg Pro Ser Gln Ala Ile Phe Arg Cys Leu Asn Pro Thr Cys Arg Tyr
            500                 505                 510
```

Tyr Gln Arg Asp Ile Asn Ala Asp Phe Asn Ala Ala Val Asn Ile Ala
515 520 525

Lys Lys Ala Leu Asn Asn Thr Glu Val Val Thr Thr Leu Leu
530 535 540

<210> 13
<211> 564
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 13

Met Ala Arg Ala Lys Asn Gln Pro Tyr Gln Lys Leu Thr Thr Thr Thr
1 5 10 15

Gly Ile Lys Phe Lys Leu Asp Leu Ser Glu Glu Glu Gly Lys Arg Phe
20 25 30

Asp Glu Tyr Phe Ser Glu Tyr Ala Lys Ala Val Asn Phe Cys Ala Lys
35 40 45

Val Ile Tyr Gln Leu Arg Lys Asn Leu Lys Phe Ala Gly Lys Lys Glu
50 55 60

Leu Ala Ala Lys Glu Trp Lys Phe Glu Ile Ser Asn Cys Asp Phe Cys
65 70 75 80

Asn Lys Gln Lys Glu Ile Tyr Tyr Lys Asn Ile Ala Asn Gly Gln Lys
85 90 95

Val Cys Lys Gly Cys His Arg Thr Asn Phe Ser Asp Asn Ala Ile Arg
100 105 110

Lys Lys Met Ile Pro Val Lys Gly Arg Lys Val Glu Ser Lys Phe Asn

```
        115                 120                 125

Ile His Asn Thr Thr Lys Lys Ile Ser Gly Thr His Arg His Trp Ala
    130                 135                 140

Phe Glu Asp Ala Ala Asp Ile Ile Glu Ser Met Asp Lys Gln Arg Lys
145                 150                 155                 160

Glu Lys Gln Lys Arg Leu Arg Arg Glu Lys Arg Lys Leu Ser Tyr Phe
                165                 170                 175

Phe Glu Leu Phe Gly Asp Pro Ala Lys Arg Tyr Glu Leu Pro Lys Val
            180                 185                 190

Gly Lys Gln Arg Val Pro Arg Tyr Leu His Lys Ile Ile Asp Lys Asp
        195                 200                 205

Ser Leu Thr Lys Lys Arg Gly Tyr Ser Leu Ser Tyr Ile Lys Asn Lys
    210                 215                 220

Ile Lys Ile Ser Glu Arg Asn Ile Glu Arg Asp Glu Lys Ser Leu Arg
225                 230                 235                 240

Lys Ala Ser Pro Ile Ala Phe Gly Ala Arg Lys Ile Lys Met Ser Lys
                245                 250                 255

Leu Asp Pro Lys Arg Ala Phe Asp Leu Glu Asn Asn Val Phe Lys Ile
            260                 265                 270

Pro Gly Lys Val Ile Lys Gly Gln Tyr Lys Phe Phe Gly Thr Asn Val
        275                 280                 285

Ala Asn Glu His Gly Lys Lys Phe Tyr Lys Asp Arg Ile Ser Lys Ile
    290                 295                 300

Leu Ala Gly Lys Pro Lys Tyr Phe Tyr Leu Leu Arg Lys Lys Val Ala
```

```
305                 310                 315                 320

Glu Ser Asp Gly Asn Pro Ile Phe Glu Tyr Tyr Val Gln Trp Ser Ile
                325                 330                 335

Asp Thr Glu Thr Pro Ala Ile Thr Ser Tyr Asp Asn Ile Leu Gly Ile
            340                 345                 350

Asp Ala Gly Ile Thr Asn Leu Ala Thr Thr Val Leu Ile Pro Lys Asn
        355                 360                 365

Leu Ser Ala Glu His Cys Ser His Cys Gly Asn Asn His Val Lys Pro
    370                 375                 380

Ile Phe Thr Lys Phe Phe Ser Gly Lys Glu Leu Lys Ala Ile Lys Ile
385                 390                 395                 400

Lys Ser Arg Lys Gln Lys Tyr Phe Leu Arg Gly Lys His Asn Lys Leu
                405                 410                 415

Val Lys Ile Lys Arg Ile Arg Pro Ile Glu Gln Lys Val Asp Gly Tyr
            420                 425                 430

Cys His Val Val Ser Lys Gln Ile Val Glu Met Ala Lys Glu Arg Asn
        435                 440                 445

Ser Cys Ile Ala Leu Glu Lys Leu Glu Lys Pro Lys Lys Ser Lys Phe
    450                 455                 460

Arg Gln Arg Arg Arg Glu Lys Tyr Ala Val Ser Met Phe Val Phe Lys
465                 470                 475                 480

Lys Leu Ala Thr Phe Ile Lys Tyr Lys Ala Ala Arg Glu Gly Ile Glu
                485                 490                 495

Ile Ile Pro Val Glu Pro Glu Gly Thr Ser Tyr Thr Cys Ser His Cys
```

500 505 510

Lys Asn Ala Gln Asn Asn Gln Arg Pro Tyr Phe Lys Pro Asn Ser Lys
515 520 525

Lys Ser Trp Thr Ser Met Phe Lys Cys Gly Lys Cys Gly Ile Glu Leu
530 535 540

Asn Ser Asp Tyr Asn Ala Ala Phe Asn Ile Ala Gln Lys Ala Leu Asn
545 550 555 560

Met Thr Ser Ala

<210> 14
<211> 610
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 14

Met Asp Glu Lys His Phe Phe Cys Ser Tyr Cys Asn Lys Glu Leu Lys
1 5 10 15

Ile Ser Lys Asn Leu Ile Asn Lys Ile Ser Lys Gly Ser Ile Arg Glu
20 25 30

Asp Glu Ala Val Ser Lys Ala Ile Ser Ile His Asn Lys Lys Glu His
35 40 45

Ser Leu Ile Leu Gly Ile Lys Phe Lys Leu Phe Ile Glu Asn Lys Leu
50 55 60

Asp Lys Lys Lys Leu Asn Glu Tyr Phe Asp Asn Tyr Ser Lys Ala Val
65 70 75 80

```
Thr Phe Ala Ala Arg Ile Phe Asp Lys Ile Arg Ser Pro Tyr Lys Phe
                85                  90                  95

Ile Gly Leu Lys Asp Lys Asn Thr Lys Lys Trp Thr Phe Pro Lys Ala
            100                 105                 110

Lys Cys Val Phe Cys Leu Glu Glu Lys Glu Val Ala Tyr Ala Asn Glu
        115                 120                 125

Lys Asp Asn Ser Lys Ile Cys Thr Glu Cys Tyr Leu Lys Glu Phe Gly
    130                 135                 140

Glu Asn Gly Ile Arg Lys Lys Ile Tyr Ser Thr Arg Gly Arg Lys Val
145                 150                 155                 160

Glu Pro Lys Tyr Asn Ile Phe Asn Ser Thr Lys Glu Leu Ser Ser Thr
                165                 170                 175

His Tyr Asn Tyr Ala Ile Arg Asp Ala Phe Gln Leu Leu Asp Ala Leu
            180                 185                 190

Lys Lys Gln Arg Gln Lys Lys Leu Lys Ser Ile Phe Asn Gln Lys Leu
        195                 200                 205

Arg Leu Lys Glu Phe Glu Asp Ile Phe Ser Asp Pro Gln Lys Arg Ile
    210                 215                 220

Glu Leu Ser Leu Lys Pro His Gln Arg Glu Lys Arg Tyr Ile His Leu
225                 230                 235                 240

Ser Lys Ser Gly Gln Glu Ser Ile Asn Arg Gly Tyr Thr Leu Arg Phe
                245                 250                 255

Val Arg Gly Lys Ile Lys Ser Leu Thr Arg Asn Ile Glu Arg Glu Glu
            260                 265                 270
```

```
Lys Ser Leu Arg Lys Lys Thr Pro Ile His Phe Lys Gly Asn Arg Leu
        275                 280                 285

Met Ile Phe Pro Ala Gly Ile Lys Phe Asp Phe Ala Ser Asn Lys Val
    290                 295                 300

Lys Ile Ser Ile Ser Lys Asn Leu Pro Asn Glu Phe Asn Phe Ser Gly
305                 310                 315                 320

Thr Asn Val Lys Asn Glu His Gly Lys Ser Phe Phe Lys Ser Arg Ile
                325                 330                 335

Glu Leu Ile Lys Thr Gln Lys Pro Lys Tyr Ala Tyr Val Leu Arg Lys
            340                 345                 350

Ile Lys Arg Glu Tyr Ser Lys Leu Arg Asn Tyr Glu Ile Glu Lys Ile
        355                 360                 365

Arg Leu Glu Asn Pro Asn Ala Asp Leu Cys Asp Phe Tyr Leu Gln Tyr
    370                 375                 380

Thr Ile Glu Thr Glu Ser Arg Asn Asn Glu Glu Ile Asn Gly Ile Ile
385                 390                 395                 400

Gly Ile Asp Arg Gly Ile Thr Asn Leu Ala Cys Leu Val Leu Leu Lys
                405                 410                 415

Lys Gly Asp Lys Lys Pro Ser Gly Val Lys Phe Tyr Lys Gly Asn Lys
            420                 425                 430

Ile Leu Gly Met Lys Ile Ala Tyr Arg Lys His Leu Tyr Leu Leu Lys
        435                 440                 445

Gly Lys Arg Asn Lys Leu Arg Lys Gln Arg Gln Ile Arg Ala Ile Glu
    450                 455                 460
```

```
Pro Lys Ile Asn Leu Ile Leu His Gln Ile Ser Lys Asp Ile Val Lys
465                 470                 475                 480


Ile Ala Lys Glu Lys Asn Phe Ala Ile Ala Leu Glu Gln Leu Glu Lys
                485                 490                 495


Pro Lys Lys Ala Arg Phe Ala Gln Arg Lys Lys Glu Lys Tyr Lys Leu
            500                 505                 510


Ala Leu Phe Thr Phe Lys Asn Leu Ser Thr Leu Ile Glu Tyr Lys Ser
        515                 520                 525


Lys Arg Glu Gly Ile Pro Val Ile Tyr Val Pro Pro Glu Lys Thr Ser
    530                 535                 540


Gln Met Cys Ser His Cys Ala Ile Asn Gly Asp Glu His Val Asp Thr
545                 550                 555                 560


Gln Arg Pro Tyr Lys Lys Pro Asn Ala Gln Lys Pro Ser Tyr Ser Leu
                565                 570                 575


Phe Lys Cys Asn Lys Cys Gly Ile Glu Leu Asn Ala Asp Tyr Asn Ala
            580                 585                 590


Ala Phe Asn Ile Ala Gln Lys Gly Leu Lys Thr Leu Met Leu Asn His
        595                 600                 605


Ser His
    610


<210>  15
<211>  369
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence
```

<400> 15

```
Met Leu Gln Thr Leu Leu Val Lys Leu Asp Pro Ser Lys Glu Gln Tyr
1               5                  10                  15

Lys Met Leu Tyr Glu Thr Met Glu Arg Phe Asn Glu Ala Cys Asn Gln
            20                  25                  30

Ile Ala Glu Thr Val Phe Ala Ile His Ser Ala Asn Lys Ile Glu Val
        35                  40                  45

Gln Lys Thr Val Tyr Tyr Pro Ile Arg Glu Lys Phe Gly Leu Ser Ala
    50                  55                  60

Gln Leu Thr Ile Leu Ala Ile Arg Lys Val Cys Glu Ala Tyr Lys Arg
65                  70                  75                  80

Asp Lys Ser Ile Lys Pro Glu Phe Arg Leu Asp Gly Ala Leu Val Tyr
                85                  90                  95

Asp Gln Arg Val Leu Ser Trp Lys Gly Leu Asp Lys Val Ser Leu Val
            100                 105                 110

Thr Leu Gln Gly Arg Gln Ile Ile Pro Ile Lys Phe Gly Asp Tyr Gln
        115                 120                 125

Lys Ala Arg Met Asp Arg Ile Arg Gly Gln Ala Asp Leu Ile Leu Val
    130                 135                 140

Lys Gly Val Phe Tyr Leu Cys Val Val Val Glu Val Ser Glu Glu Ser
145                 150                 155                 160

Pro Tyr Asp Pro Lys Gly Val Leu Gly Val Asp Leu Gly Ile Lys Asn
                165                 170                 175

Leu Ala Val Asp Ser Asp Gly Glu Val His Ser Gly Glu Gln Thr Thr
```

```
            180                 185                 190

Asn Thr Arg Glu Arg Leu Asp Ser Leu Lys Ala Arg Leu Gln Ser Lys
        195                 200                 205

Gly Thr Lys Ser Ala Lys Arg His Leu Lys Lys Leu Ser Gly Arg Met
    210                 215                 220

Ala Lys Phe Ser Lys Asp Val Asn His Cys Ile Ser Lys Lys Leu Val
225                 230                 235                 240

Ala Lys Ala Lys Gly Thr Leu Met Ser Ile Ala Leu Glu Asp Leu Gln
                245                 250                 255

Gly Ile Arg Asp Arg Val Thr Val Arg Lys Ala Gln Arg Arg Asn Leu
            260                 265                 270

His Thr Trp Asn Phe Gly Leu Leu Arg Met Phe Val Asp Tyr Lys Ala
        275                 280                 285

Lys Ile Ala Gly Val Pro Leu Val Phe Val Asp Pro Arg Asn Thr Ser
    290                 295                 300

Arg Thr Cys Pro Ser Cys Gly His Val Ala Lys Ala Asn Arg Pro Thr
305                 310                 315                 320

Arg Asp Glu Phe Arg Cys Val Ser Cys Gly Phe Ala Gly Ala Ala Asp
                325                 330                 335

His Ile Ala Ala Met Asn Ile Ala Phe Arg Ala Glu Val Ser Gln Pro
            340                 345                 350

Ile Val Thr Arg Phe Phe Val Gln Ser Gln Ala Pro Ser Phe Arg Val
        355                 360                 365

Gly
```

<210> 16
<211> 552
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 16

```
Met Asp Glu Glu Pro Asp Ser Ala Glu Pro Asn Leu Ala Pro Ile Ser
1               5                  10                  15


Val Lys Leu Lys Leu Val Lys Leu Asp Gly Glu Lys Leu Ala Ala Leu
            20                  25                  30


Asn Asp Tyr Phe Asn Glu Tyr Ala Lys Ala Val Asn Phe Cys Glu Leu
        35                  40                  45


Lys Met Gln Lys Ile Arg Lys Asn Leu Val Asn Ile Arg Gly Thr Tyr
    50                  55                  60


Leu Lys Glu Lys Lys Ala Trp Ile Asn Gln Thr Gly Glu Cys Cys Ile
65                  70                  75                  80


Cys Lys Lys Ile Asp Glu Leu Arg Cys Glu Asp Lys Asn Pro Asp Ile
                85                  90                  95


Asn Gly Lys Ile Cys Lys Lys Cys Tyr Asn Gly Arg Tyr Gly Asn Gln
            100                 105                 110


Met Ile Arg Lys Leu Phe Val Ser Thr Asn Lys Arg Ala Val Pro Lys
        115                 120                 125


Ser Leu Asp Ile Arg Lys Val Ala Arg Leu His Asn Thr His Tyr His
    130                 135                 140
```

```
Arg Ile Pro Pro Glu Ala Ala Asp Ile Ile Lys Ala Ile Glu Thr Ala
145                 150                 155                 160


Glu Arg Lys Arg Arg Asn Arg Ile Leu Phe Asp Glu Arg Arg Tyr Asn
                165                 170                 175


Glu Leu Lys Asp Ala Leu Glu Asn Glu Glu Lys Arg Val Ala Arg Pro
            180                 185                 190


Lys Lys Pro Lys Glu Arg Glu Val Arg Tyr Val Pro Ile Ser Lys Lys
        195                 200                 205


Asp Thr Pro Ser Lys Gly Tyr Thr Met Asn Ala Leu Val Arg Lys Val
    210                 215                 220


Ser Gly Met Ala Lys Lys Ile Glu Arg Ala Lys Arg Asn Leu Asn Lys
225                 230                 235                 240


Arg Lys Lys Ile Glu Tyr Leu Gly Arg Arg Ile Leu Leu Asp Lys Asn
                245                 250                 255


Trp Val Arg Phe Asp Phe Asp Lys Ser Glu Ile Ser Ile Pro Thr Met
            260                 265                 270


Lys Glu Phe Phe Gly Glu Met Arg Phe Glu Ile Thr Gly Pro Ser Asn
        275                 280                 285


Val Met Ser Pro Asn Gly Arg Glu Tyr Phe Thr Lys Trp Phe Asp Arg
    290                 295                 300


Ile Lys Ala Gln Pro Asp Asn Tyr Cys Tyr Leu Leu Arg Lys Glu Ser
305                 310                 315                 320


Glu Asp Glu Thr Asp Phe Tyr Leu Gln Tyr Thr Trp Arg Pro Asp Ala
                325                 330                 335
```

```
His Pro Lys Lys Asp Tyr Thr Gly Cys Leu Gly Ile Asp Ile Gly Gly
            340                 345                 350

Ser Lys Leu Ala Ser Ala Val Tyr Phe Asp Ala Asp Lys Asn Arg Ala
        355                 360                 365

Lys Gln Pro Ile Gln Ile Phe Ser Asn Pro Ile Gly Lys Trp Lys Thr
    370                 375                 380

Lys Arg Gln Lys Val Ile Lys Val Leu Ser Lys Ala Ala Val Arg His
385                 390                 395                 400

Lys Thr Lys Lys Leu Glu Ser Leu Arg Asn Ile Glu Pro Arg Ile Asp
                405                 410                 415

Val His Cys His Arg Ile Ala Arg Lys Ile Val Gly Met Ala Leu Ala
            420                 425                 430

Ala Asn Ala Phe Ile Ser Met Glu Asn Leu Glu Gly Gly Ile Arg Glu
        435                 440                 445

Lys Gln Lys Ala Lys Glu Thr Lys Lys Gln Lys Phe Ser Arg Asn Met
    450                 455                 460

Phe Val Phe Arg Lys Leu Ser Lys Leu Ile Glu Tyr Lys Ala Leu Met
465                 470                 475                 480

Glu Gly Val Lys Val Val Tyr Ile Val Pro Asp Tyr Thr Ser Gln Leu
                485                 490                 495

Cys Ser Ser Cys Gly Thr Asn Asn Thr Lys Arg Pro Lys Gln Ala Ile
            500                 505                 510

Phe Met Cys Gln Asn Thr Glu Cys Arg Tyr Phe Gly Lys Asn Ile Asn
        515                 520                 525
```

Ala Asp Phe Asn Ala Ala Ile Asn Ile Ala Lys Lys Ala Leu Asn Arg
    530   535   540

Lys Asp Ile Val Arg Glu Leu Ser
545   550

<210> 17
<211> 534
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 17

Met Glu Lys Asn Asn Ser Glu Gln Thr Ser Ile Thr Thr Gly Ile Lys
1   5   10   15

Phe Lys Leu Lys Leu Asp Lys Glu Thr Lys Glu Lys Leu Asn Asn Tyr
            20   25   30

Phe Asp Glu Tyr Gly Lys Ala Ile Asn Phe Ala Val Arg Ile Ile Gln
        35   40   45

Met Gln Leu Asn Asp Asp Arg Leu Ala Gly Lys Tyr Lys Arg Asp Glu
    50   55   60

Lys Gly Lys Pro Ile Leu Gly Glu Asp Gly Lys Lys Ile Leu Glu Ile
65   70   75   80

Pro Asn Asp Phe Cys Ser Cys Gly Asn Gln Val Asn His Tyr Val Asn
                85   90   95

Gly Val Ser Phe Cys Gln Glu Cys Tyr Lys Lys Arg Phe Ser Glu Asn
            100   105   110

Gly Ile Arg Lys Arg Met Tyr Ser Ala Lys Gly Arg Lys Ala Glu Gln

```
        115                 120                 125

Asp Ile Asn Ile Lys Asn Ser Thr Asn Lys Ile Ser Lys Thr His Phe
    130                 135                 140

Asn Tyr Ala Ile Arg Glu Ala Phe Asn Leu Asp Lys Ser Ile Lys Lys
145                 150                 155                 160

Gln Arg Glu Lys Arg Phe Lys Lys Leu Lys Asp Met Lys Arg Lys Leu
                165                 170                 175

Gln Glu Phe Leu Glu Ile Arg Asp Gly Lys Arg Val Ile Cys Pro Lys
            180                 185                 190

Ile Glu Lys Gln Lys Val Glu Arg Tyr Ile His Pro Ser Trp Ile Asn
        195                 200                 205

Lys Glu Lys Lys Leu Glu Glu Phe Arg Gly Tyr Ser Leu Ser Ile Val
    210                 215                 220

Asn Ser Lys Ile Lys Ser Phe Asp Arg Asn Ile Gln Arg Glu Glu Lys
225                 230                 235                 240

Ser Leu Lys Glu Lys Gly Gln Ile Asn Phe Lys Ala Gln Arg Leu Met
                245                 250                 255

Leu Asp Lys Ser Val Lys Phe Leu Lys Asp Asn Lys Val Ser Phe Thr
            260                 265                 270

Ile Ser Lys Glu Leu Pro Lys Thr Phe Glu Leu Asp Leu Pro Lys Lys
        275                 280                 285

Glu Lys Lys Leu Asn Trp Leu Asn Glu Lys Leu Glu Ile Ile Lys Asn
    290                 295                 300

Gln Lys Pro Lys Tyr Ala Tyr Leu Leu Arg Lys Glu Asn Asn Ile Phe
```

```
305                 310                 315                 320

Leu Gln Tyr Thr Leu Asp Ser Ile Pro Glu Ile His Ser Glu Tyr Ser
                325                 330                 335

Gly Ala Val Gly Ile Asp Arg Gly Val Ser His Ile Ala Val Tyr Thr
            340                 345                 350

Phe Leu Asp Lys Asp Gly Lys Asn Glu Arg Pro Phe Phe Leu Ser Ser
        355                 360                 365

Ser Gly Ile Leu Arg Leu Lys Asn Leu Gln Lys Glu Arg Asp Lys Phe
    370                 375                 380

Leu Arg Lys Lys His Asn Lys Ile Arg Lys Lys Gly Asn Met Arg Asn
385                 390                 395                 400

Ile Glu Gln Lys Ile Asn Leu Ile Leu His Glu Tyr Ser Lys Gln Ile
                405                 410                 415

Val Asn Phe Ala Lys Asp Lys Asn Ala Phe Ile Val Phe Glu Leu Leu
            420                 425                 430

Glu Lys Pro Lys Lys Ser Arg Glu Arg Met Ser Lys Lys Ile Gln Tyr
        435                 440                 445

Lys Leu Ser Gln Phe Thr Phe Lys Lys Leu Ser Asp Leu Val Asp Tyr
    450                 455                 460

Lys Ala Lys Arg Glu Gly Ile Lys Val Ile Tyr Val Glu Pro Ala Tyr
465                 470                 475                 480

Thr Ser Lys Asp Cys Ser His Cys Gly Glu Arg Val Asn Thr Gln Arg
                485                 490                 495

Pro Phe Asn Gly Asn Phe Ser Leu Phe Lys Cys Asn Lys Cys Gly Ile
```

500 505 510

Val Leu Asn Ser Asp Tyr Asn Ala Ser Leu Asn Ile Ala Arg Lys Gly
515 520 525

Leu Asn Ile Ser Ala Asn
530

<210> 18
<211> 577
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 18

Met Ala Glu Glu Lys Phe Phe Phe Cys Glu Lys Cys Asn Lys Asp Ile
1 5 10 15

Lys Ile Pro Lys Asn Tyr Ile Asn Lys Gln Gly Ala Glu Glu Lys Ala
20 25 30

Arg Ala Lys His Glu His Arg Val His Ala Leu Ile Leu Gly Ile Lys
35 40 45

Phe Lys Ile Tyr Pro Lys Lys Glu Asp Ile Ser Lys Leu Asn Asp Tyr
50 55 60

Phe Asp Glu Tyr Ala Lys Ala Val Thr Phe Thr Ala Lys Ile Val Asp
65 70 75 80

Lys Leu Lys Ala Pro Phe Leu Phe Ala Gly Lys Arg Asp Lys Asp Thr
85 90 95

Ser Lys Lys Lys Trp Val Phe Pro Val Asp Lys Cys Ser Phe Cys Lys
100 105 110

```
Glu Lys Thr Glu Ile Asn Tyr Arg Thr Lys Gln Gly Lys Asn Ile Cys
        115                 120                 125

Asn Ser Cys Tyr Leu Thr Glu Phe Gly Glu Gln Gly Leu Leu Glu Lys
    130                 135                 140

Ile Tyr Ala Thr Lys Gly Arg Lys Val Ser Ser Ser Phe Asn Leu Phe
145                 150                 155                 160

Asn Ser Thr Lys Lys Leu Thr Gly Thr His Asn Asn Tyr Val Val Lys
                165                 170                 175

Glu Ser Leu Gln Leu Leu Asp Ala Leu Lys Lys Gln Arg Ser Lys Arg
            180                 185                 190

Leu Lys Lys Leu Ser Asn Thr Arg Arg Lys Leu Lys Gln Phe Glu Glu
        195                 200                 205

Met Phe Glu Lys Glu Asp Lys Arg Phe Gln Leu Pro Leu Lys Glu Lys
    210                 215                 220

Gln Arg Glu Leu Arg Phe Ile His Val Ser Gln Lys Asp Arg Ala Thr
225                 230                 235                 240

Glu Phe Lys Gly Tyr Thr Met Asn Lys Ile Lys Ser Lys Ile Lys Val
                245                 250                 255

Leu Arg Arg Asn Ile Glu Arg Glu Gln Arg Ser Leu Asn Arg Lys Ser
            260                 265                 270

Pro Val Phe Phe Arg Gly Thr Arg Ile Arg Leu Ser Pro Ser Val Gln
        275                 280                 285

Phe Asp Asp Lys Asp Asn Lys Ile Lys Leu Thr Leu Ser Lys Glu Leu
    290                 295                 300
```

```
Pro Lys Glu Tyr Ser Phe Ser Gly Leu Asn Val Ala Asn Glu His Gly
305                 310                 315                 320


Arg Lys Phe Phe Ala Glu Lys Leu Lys Leu Ile Lys Glu Asn Lys Ser
                325                 330                 335


Lys Tyr Ala Tyr Leu Leu Arg Arg Gln Val Asn Lys Asn Asn Lys Lys
            340                 345                 350


Pro Ile Tyr Asp Tyr Tyr Leu Gln Tyr Thr Val Glu Phe Leu Pro Asn
        355                 360                 365


Ile Ile Thr Asn Tyr Asn Gly Ile Leu Gly Ile Asp Arg Gly Ile Asn
    370                 375                 380


Thr Leu Ala Cys Ile Val Leu Leu Glu Asn Lys Lys Glu Lys Pro Ser
385                 390                 395                 400


Phe Val Lys Phe Phe Ser Gly Lys Gly Ile Leu Asn Leu Lys Asn Lys
                405                 410                 415


Arg Arg Lys Gln Leu Tyr Phe Leu Lys Gly Val His Asn Lys Tyr Arg
            420                 425                 430


Lys Gln Gln Lys Ile Arg Pro Ile Glu Pro Arg Ile Asp Gln Ile Leu
        435                 440                 445


His Asp Ile Ser Lys Gln Ile Ile Asp Leu Ala Lys Glu Lys Arg Val
    450                 455                 460


Ala Ile Ser Leu Glu Gln Leu Glu Lys Pro Gln Lys Pro Lys Phe Arg
465                 470                 475                 480


Gln Ser Arg Lys Ala Lys Tyr Lys Leu Ser Gln Phe Asn Phe Lys Thr
                485                 490                 495
```

Leu Ser Asn Tyr Ile Asp Tyr Lys Ala Lys Lys Glu Gly Ile Arg Val
500 505 510

Ile Tyr Ile Ala Pro Glu Met Thr Ser Gln Asn Cys Ser Arg Cys Ala
515 520 525

Met Lys Asn Asp Leu His Val Asn Thr Gln Arg Pro Tyr Lys Asn Thr
530 535 540

Ser Ser Leu Phe Lys Cys Asn Lys Cys Gly Val Glu Leu Asn Ala Asp
545 550 555 560

Tyr Asn Ala Ala Phe Asn Ile Ala Gln Lys Gly Leu Lys Ile Leu Asn
565 570 575

Ser

<210> 19
<211> 613
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 19

Met Ile Ser Leu Lys Leu Lys Leu Leu Pro Asp Glu Glu Gln Lys Lys
1 5 10 15

Leu Leu Asp Glu Met Phe Trp Lys Trp Ala Ser Ile Cys Thr Arg Val
20 25 30

Gly Phe Gly Arg Ala Asp Lys Glu Asp Leu Lys Pro Pro Lys Asp Ala
35 40 45

Glu Gly Val Trp Phe Ser Leu Thr Gln Leu Asn Gln Ala Asn Thr Asp

```
    50                  55                  60

Ile Asn Asp Leu Arg Glu Ala Met Lys His Gln Lys His Arg Leu Glu
65                  70                  75                  80

Tyr Glu Lys Asn Arg Leu Glu Ala Gln Arg Asp Asp Thr Gln Asp Ala
                85                  90                  95

Leu Lys Asn Pro Asp Arg Arg Glu Ile Ser Thr Lys Arg Lys Asp Leu
            100                 105                 110

Phe Arg Pro Lys Ala Ser Val Glu Lys Gly Phe Leu Lys Leu Lys Tyr
        115                 120                 125

His Gln Glu Arg Tyr Trp Val Arg Arg Leu Lys Glu Ile Asn Lys Leu
    130                 135                 140

Ile Glu Arg Lys Thr Lys Thr Leu Ile Lys Ile Glu Lys Gly Arg Ile
145                 150                 155                 160

Lys Phe Lys Ala Thr Arg Ile Thr Leu His Gln Gly Ser Phe Lys Ile
                165                 170                 175

Arg Phe Gly Asp Lys Pro Ala Phe Leu Ile Lys Ala Leu Ser Gly Lys
            180                 185                 190

Asn Gln Ile Asp Ala Pro Phe Val Val Val Pro Glu Gln Pro Ile Cys
        195                 200                 205

Gly Ser Val Val Asn Ser Lys Lys Tyr Leu Asp Glu Ile Thr Thr Asn
    210                 215                 220

Phe Leu Ala Tyr Ser Val Asn Ala Met Leu Phe Gly Leu Ser Arg Ser
225                 230                 235                 240

Glu Glu Met Leu Leu Lys Ala Lys Arg Pro Glu Lys Ile Lys Lys Lys
```

```
                245                 250                 255

Glu Glu Lys Leu Ala Lys Lys Gln Ser Ala Phe Glu Asn Lys Lys Lys
            260                 265                 270

Glu Leu Gln Lys Leu Leu Gly Arg Glu Leu Thr Gln Gln Glu Glu Ala
        275                 280                 285

Ile Ile Glu Glu Thr Arg Asn Gln Phe Phe Gln Asp Phe Glu Val Lys
    290                 295                 300

Ile Thr Lys Gln Tyr Ser Glu Leu Leu Ser Lys Ile Ala Asn Glu Leu
305                 310                 315                 320

Lys Gln Lys Asn Asp Phe Leu Lys Val Asn Lys Tyr Pro Ile Leu Leu
                325                 330                 335

Arg Lys Pro Leu Lys Lys Ala Lys Ser Lys Lys Ile Asn Asn Leu Ser
            340                 345                 350

Pro Ser Glu Trp Lys Tyr Tyr Leu Gln Phe Gly Val Lys Pro Leu Leu
        355                 360                 365

Lys Gln Lys Ser Arg Arg Lys Ser Arg Asn Val Leu Gly Ile Asp Arg
    370                 375                 380

Gly Leu Lys His Leu Leu Ala Val Thr Val Leu Glu Pro Asp Lys Lys
385                 390                 395                 400

Thr Phe Val Trp Asn Lys Leu Tyr Pro Asn Pro Ile Thr Gly Trp Lys
                405                 410                 415

Trp Arg Arg Arg Lys Leu Leu Arg Ser Leu Lys Arg Leu Lys Arg Arg
            420                 425                 430

Ile Lys Ser Gln Lys His Glu Thr Ile His Glu Asn Gln Thr Arg Lys
```

435 440 445

Lys Leu Lys Ser Leu Gln Gly Arg Ile Asp Asp Leu Leu His Asn Ile
450 455 460

Ser Arg Lys Ile Val Glu Thr Ala Lys Glu Tyr Asp Ala Val Ile Val
465 470 475 480

Val Glu Asp Leu Gln Ser Met Arg Gln His Gly Arg Ser Lys Gly Asn
485 490 495

Arg Leu Lys Thr Leu Asn Tyr Ala Leu Ser Leu Phe Asp Tyr Ala Asn
500 505 510

Val Met Gln Leu Ile Lys Tyr Lys Ala Gly Ile Glu Gly Ile Gln Ile
515 520 525

Tyr Asp Val Lys Pro Ala Gly Thr Ser Gln Asn Cys Ala Tyr Cys Leu
530 535 540

Leu Ala Gln Arg Asp Ser His Glu Tyr Lys Arg Ser Gln Glu Asn Ser
545 550 555 560

Lys Ile Gly Val Cys Leu Asn Pro Asn Cys Gln Asn His Lys Lys Gln
565 570 575

Ile Asp Ala Asp Leu Asn Ala Ala Arg Val Ile Ala Ser Cys Tyr Ala
580 585 590

Leu Lys Ile Asn Asp Ser Gln Pro Phe Gly Thr Arg Lys Arg Phe Lys
595 600 605

Lys Arg Thr Thr Asn
610

<210> 20

<211> 615
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 20

```
Met Glu Thr Leu Ser Leu Lys Leu Lys Leu Asn Pro Ser Lys Glu Gln
1               5                  10                  15


Leu Leu Val Leu Asp Lys Met Phe Trp Lys Trp Ala Ser Ile Cys Thr
            20                  25                  30


Arg Leu Gly Leu Lys Lys Ala Glu Met Ser Asp Leu Glu Pro Pro Lys
        35                  40                  45


Asp Ala Glu Gly Val Trp Phe Ser Lys Thr Gln Leu Asn Gln Ala Asn
    50                  55                  60


Thr Asp Val Asn Asp Leu Arg Lys Ala Met Gln His Gln Gly Lys Arg
65                  70                  75                  80


Ile Glu Tyr Glu Leu Asp Lys Val Glu Asn Arg Arg Asn Glu Ile Gln
                85                  90                  95


Glu Met Leu Glu Lys Pro Asp Arg Arg Asp Ile Ser Pro Asn Arg Lys
            100                 105                 110


Asp Leu Phe Arg Pro Lys Ala Ala Val Glu Lys Gly Tyr Leu Lys Leu
        115                 120                 125


Lys Tyr His Lys Leu Gly Tyr Trp Ser Lys Glu Leu Lys Thr Ala Asn
    130                 135                 140


Lys Leu Ile Glu Arg Lys Arg Lys Thr Leu Ala Lys Ile Asp Ala Gly
145                 150                 155                 160
```

```
Lys Met Lys Phe Lys Pro Thr Arg Ile Ser Leu His Thr Asn Ser Phe
                165                 170                 175


Arg Ile Lys Phe Gly Glu Glu Pro Lys Ile Ala Leu Ser Thr Thr Ser
            180                 185                 190


Lys His Glu Lys Ile Glu Leu Pro Leu Ile Thr Ser Leu Gln Arg Pro
        195                 200                 205


Leu Lys Thr Ser Cys Ala Lys Lys Ser Lys Thr Tyr Leu Asp Ala Ala
    210                 215                 220


Ile Leu Asn Phe Leu Ala Tyr Ser Thr Asn Ala Ala Leu Phe Gly Leu
225                 230                 235                 240


Ser Arg Ser Glu Glu Met Leu Leu Lys Ala Lys Lys Pro Glu Lys Ile
                245                 250                 255


Glu Lys Arg Asp Arg Lys Leu Ala Thr Lys Arg Glu Ser Phe Asp Lys
            260                 265                 270


Lys Leu Lys Thr Leu Glu Lys Leu Leu Glu Arg Lys Leu Ser Glu Lys
        275                 280                 285


Glu Lys Ser Val Phe Lys Arg Lys Gln Thr Glu Phe Phe Asp Lys Phe
    290                 295                 300


Cys Ile Thr Leu Asp Glu Thr Tyr Val Glu Ala Leu His Arg Ile Ala
305                 310                 315                 320


Glu Glu Leu Val Ser Lys Asn Lys Tyr Leu Glu Ile Lys Lys Tyr Pro
                325                 330                 335


Val Leu Leu Arg Lys Pro Glu Ser Arg Leu Arg Ser Lys Lys Leu Lys
            340                 345                 350
```

```
Asn Leu Lys Pro Glu Asp Trp Thr Tyr Tyr Ile Gln Phe Gly Phe Gln
        355                 360                 365

Pro Leu Leu Asp Thr Pro Lys Pro Ile Lys Thr Lys Thr Val Leu Gly
    370                 375                 380

Ile Asp Arg Gly Val Arg His Leu Leu Ala Val Ser Ile Phe Asp Pro
385                 390                 395                 400

Arg Thr Lys Thr Phe Thr Phe Asn Arg Leu Tyr Ser Asn Pro Ile Val
                405                 410                 415

Asp Trp Lys Trp Arg Arg Arg Lys Leu Leu Arg Ser Ile Lys Arg Leu
            420                 425                 430

Lys Arg Arg Leu Lys Ser Glu Lys His Val His Leu His Glu Asn Gln
        435                 440                 445

Phe Lys Ala Lys Leu Arg Ser Leu Glu Gly Arg Ile Glu Asp His Phe
    450                 455                 460

His Asn Leu Ser Lys Glu Ile Val Asp Leu Ala Lys Glu Asn Asn Ser
465                 470                 475                 480

Val Ile Val Val Glu Asn Leu Gly Gly Met Arg Gln His Gly Arg Gly
                485                 490                 495

Arg Gly Lys Trp Leu Lys Ala Leu Asn Tyr Ala Leu Ser His Phe Asp
            500                 505                 510

Tyr Ala Lys Val Met Gln Leu Ile Lys Tyr Lys Ala Glu Leu Ala Gly
        515                 520                 525

Val Phe Val Tyr Asp Val Ala Pro Ala Gly Thr Ser Ile Asn Cys Ala
    530                 535                 540
```

```
Tyr Cys Leu Leu Asn Asp Lys Asp Ala Ser Asn Tyr Thr Arg Gly Lys
545                 550                 555                 560


Val Ile Asn Gly Lys Lys Asn Thr Lys Ile Gly Glu Cys Lys Thr Cys
                565                 570                 575


Lys Lys Glu Phe Asp Ala Asp Leu Asn Ala Ala Arg Val Ile Ala Leu
            580                 585                 590


Cys Tyr Glu Lys Arg Leu Asn Asp Pro Gln Pro Phe Gly Thr Arg Lys
        595                 600                 605


Gln Phe Lys Pro Lys Lys Pro
    610                 615


<210>  21
<211>  775
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  21

Met Lys Ala Leu Lys Leu Gln Leu Ile Pro Thr Arg Lys Gln Tyr Lys
1               5                   10                  15


Ile Leu Asp Glu Met Phe Trp Lys Trp Ala Ser Leu Ala Asn Arg Val
            20                  25                  30


Ser Gln Lys Gly Glu Ser Lys Glu Thr Leu Ala Pro Lys Lys Asp Ile
        35                  40                  45


Gln Lys Ile Gln Phe Asn Ala Thr Gln Leu Asn Gln Ile Glu Lys Asp
    50                  55                  60


Ile Lys Asp Leu Arg Gly Ala Met Lys Glu Gln Gln Lys Gln Lys Glu
```

```
65                  70                  75                  80

Arg Leu Leu Leu Gln Ile Gln Glu Arg Arg Ser Thr Ile Ser Glu Met
                85                  90                  95

Leu Asn Asp Asp Asn Asn Lys Glu Arg Asp Pro His Arg Pro Leu Asn
            100                 105                 110

Phe Arg Pro Lys Gly Trp Arg Lys Phe His Thr Ser Lys His Trp Val
        115                 120                 125

Gly Glu Leu Ser Lys Ile Leu Arg Gln Glu Asp Arg Val Lys Lys Thr
    130                 135                 140

Ile Glu Arg Ile Val Ala Gly Lys Ile Ser Phe Lys Pro Lys Arg Ile
145                 150                 155                 160

Gly Ile Trp Ser Ser Asn Tyr Lys Ile Asn Phe Phe Lys Arg Lys Ile
                165                 170                 175

Ser Ile Asn Pro Leu Asn Ser Lys Gly Phe Glu Leu Thr Leu Met Thr
            180                 185                 190

Glu Pro Thr Gln Asp Leu Ile Gly Lys Asn Gly Gly Lys Ser Val Leu
        195                 200                 205

Asn Asn Lys Arg Tyr Leu Asp Asp Ser Ile Lys Ser Leu Leu Met Phe
    210                 215                 220

Ala Leu His Ser Arg Phe Phe Gly Leu Asn Asn Thr Asp Thr Tyr Leu
225                 230                 235                 240

Leu Gly Gly Lys Ile Asn Pro Ser Leu Val Lys Tyr Tyr Lys Lys Asn
                245                 250                 255

Gln Asp Met Gly Glu Phe Gly Arg Glu Ile Val Glu Lys Phe Glu Arg
```

```
            260                 265                 270

Lys Leu Lys Gln Glu Ile Asn Glu Gln Gln Lys Lys Ile Ile Met Ser
        275                 280                 285

Gln Ile Lys Glu Gln Tyr Ser Asn Arg Asp Ser Ala Phe Asn Lys Asp
    290                 295                 300

Tyr Leu Gly Leu Ile Asn Glu Phe Ser Glu Val Phe Asn Gln Arg Lys
305                 310                 315                 320

Ser Glu Arg Ala Glu Tyr Leu Leu Asp Ser Phe Glu Asp Lys Ile Lys
                325                 330                 335

Gln Ile Lys Gln Glu Ile Gly Glu Ser Leu Asn Ile Ser Asp Trp Asp
            340                 345                 350

Phe Leu Ile Asp Glu Ala Lys Lys Ala Tyr Gly Tyr Glu Glu Gly Phe
        355                 360                 365

Thr Glu Tyr Val Tyr Ser Lys Arg Tyr Leu Glu Ile Leu Asn Lys Ile
    370                 375                 380

Val Lys Ala Val Leu Ile Thr Asp Ile Tyr Phe Asp Leu Arg Lys Tyr
385                 390                 395                 400

Pro Ile Leu Leu Arg Lys Pro Leu Asp Lys Ile Lys Lys Ile Ser Asn
                405                 410                 415

Leu Lys Pro Asp Glu Trp Ser Tyr Tyr Ile Gln Phe Gly Tyr Asp Ser
            420                 425                 430

Ile Asn Pro Val Gln Leu Met Ser Thr Asp Lys Phe Leu Gly Ile Asp
        435                 440                 445

Arg Gly Leu Thr His Leu Leu Ala Tyr Ser Val Phe Asp Lys Glu Lys
```

```
    450                 455                 460

Lys Glu Phe Ile Ile Asn Gln Leu Glu Pro Asn Pro Ile Met Gly Trp
465                 470                 475                 480

Lys Trp Lys Leu Arg Lys Val Lys Arg Ser Leu Gln His Leu Glu Arg
                485                 490                 495

Arg Ile Arg Ala Gln Lys Met Val Lys Leu Pro Glu Asn Gln Met Lys
            500                 505                 510

Lys Lys Leu Lys Ser Ile Glu Pro Lys Ile Glu Val His Tyr His Asn
        515                 520                 525

Ile Ser Arg Lys Ile Val Asn Leu Ala Lys Asp Tyr Asn Ala Ser Ile
    530                 535                 540

Val Val Glu Ser Leu Glu Gly Gly Gly Leu Lys Gln His Gly Arg Lys
545                 550                 555                 560

Lys Asn Ala Arg Asn Arg Ser Leu Asn Tyr Ala Leu Ser Leu Phe Asp
                565                 570                 575

Tyr Gly Lys Ile Ala Ser Leu Ile Lys Tyr Lys Ala Asp Leu Glu Gly
            580                 585                 590

Val Pro Met Tyr Glu Val Leu Pro Ala Tyr Thr Ser Gln Gln Cys Ala
        595                 600                 605

Lys Cys Val Leu Glu Lys Gly Ser Phe Val Asp Pro Glu Ile Ile Gly
    610                 615                 620

Tyr Val Glu Asp Ile Gly Ile Lys Gly Ser Leu Leu Asp Ser Leu Phe
625                 630                 635                 640

Glu Gly Thr Glu Leu Ser Ser Ile Gln Val Leu Lys Lys Ile Lys Asn
```

645 650 655

Lys Ile Glu Leu Ser Ala Arg Asp Asn His Asn Lys Glu Ile Asn Leu
660 665 670

Ile Leu Lys Tyr Asn Phe Lys Gly Leu Val Ile Val Arg Gly Gln Asp
675 680 685

Lys Glu Glu Ile Ala Glu His Pro Ile Lys Glu Ile Asn Gly Lys Phe
690 695 700

Ala Ile Leu Asp Phe Val Tyr Lys Arg Gly Lys Glu Lys Val Gly Lys
705 710 715 720

Lys Gly Asn Gln Lys Val Arg Tyr Thr Gly Asn Lys Lys Val Gly Tyr
725 730 735

Cys Ser Lys His Gly Gln Val Asp Ala Asp Leu Asn Ala Ser Arg Val
740 745 750

Ile Ala Leu Cys Lys Tyr Leu Asp Ile Asn Asp Pro Ile Leu Phe Gly
755 760 765

Glu Gln Arg Lys Ser Phe Lys
770 775

<210> 22
<211> 777
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 22

Met Val Thr Arg Ala Ile Lys Leu Lys Leu Asp Pro Thr Lys Asn Gln
1 5 10 15

```
Tyr Lys Leu Leu Asn Glu Met Phe Trp Lys Trp Ala Ser Leu Ala Asn
            20                  25                  30

Arg Phe Ser Gln Lys Gly Ala Ser Lys Glu Thr Leu Ala Pro Lys Asp
        35                  40                  45

Gly Thr Gln Lys Ile Gln Phe Asn Ala Thr Gln Leu Asn Gln Ile Lys
    50                  55                  60

Lys Asp Val Asp Asp Leu Arg Gly Ala Met Glu Lys Gln Gly Lys Gln
65                  70                  75                  80

Lys Glu Arg Leu Leu Ile Gln Ile Gln Glu Arg Leu Leu Thr Ile Ser
                85                  90                  95

Glu Ile Leu Arg Asp Asp Ser Lys Lys Glu Lys Asp Pro His Arg Pro
            100                 105                 110

Gln Asn Phe Arg Pro Phe Gly Trp Arg Arg Phe His Thr Ser Ala Tyr
        115                 120                 125

Trp Ser Ser Glu Ala Ser Lys Leu Thr Arg Gln Val Asp Arg Val Arg
    130                 135                 140

Arg Thr Ile Glu Arg Ile Lys Ala Gly Lys Ile Asn Phe Lys Pro Lys
145                 150                 155                 160

Arg Ile Gly Leu Trp Ser Ser Thr Tyr Lys Ile Asn Phe Leu Lys Lys
                165                 170                 175

Lys Ile Asn Ile Ser Pro Leu Lys Ser Lys Ser Phe Glu Leu Asp Leu
            180                 185                 190

Ile Thr Glu Pro Gln Gln Lys Ile Ile Gly Lys Glu Gly Gly Lys Ser
        195                 200                 205
```

```
Val Ala Asn Ser Lys Lys Tyr Leu Asp Asp Ser Ile Lys Ser Leu Leu
    210                 215                 220

Ile Phe Ala Ile Lys Ser Arg Leu Phe Gly Leu Asn Asn Lys Asp Lys
225                 230                 235                 240

Pro Leu Phe Glu Asn Ile Ile Thr Pro Asn Leu Val Arg Tyr His Lys
                245                 250                 255

Lys Gly Gln Glu Gln Glu Asn Phe Lys Lys Glu Val Ile Lys Lys Phe
            260                 265                 270

Glu Asn Lys Leu Lys Lys Glu Ile Ser Gln Lys Gln Lys Glu Ile Ile
        275                 280                 285

Phe Ser Gln Ile Glu Arg Gln Tyr Glu Asn Arg Asp Ala Thr Phe Ser
    290                 295                 300

Glu Asp Tyr Leu Arg Ala Ile Ser Glu Phe Ser Glu Ile Phe Asn Gln
305                 310                 315                 320

Arg Lys Lys Glu Arg Ala Lys Glu Leu Leu Asn Ser Phe Asn Glu Lys
                325                 330                 335

Ile Arg Gln Leu Lys Lys Glu Val Asn Gly Asn Ile Ser Glu Glu Asp
            340                 345                 350

Leu Lys Ile Leu Glu Val Glu Ala Glu Lys Ala Tyr Asn Tyr Glu Asn
        355                 360                 365

Gly Phe Ile Glu Trp Glu Tyr Ser Glu Gln Phe Leu Gly Val Leu Glu
    370                 375                 380

Lys Ile Ala Arg Ala Val Leu Ile Ser Asp Asn Tyr Phe Asp Leu Lys
385                 390                 395                 400
```

```
Lys Tyr Pro Ile Leu Ile Arg Lys Pro Thr Asn Lys Ser Lys Lys Ile
                405                 410                 415

Thr Asn Leu Lys Pro Glu Glu Trp Asp Tyr Tyr Ile Gln Phe Gly Tyr
            420                 425                 430

Gly Leu Ile Asn Ser Pro Met Lys Ile Glu Thr Lys Asn Phe Met Gly
        435                 440                 445

Ile Asp Arg Gly Leu Thr His Leu Leu Ala Tyr Ser Ile Phe Asp Arg
    450                 455                 460

Asp Ser Glu Lys Phe Thr Ile Asn Gln Leu Glu Leu Asn Pro Ile Lys
465                 470                 475                 480

Gly Trp Lys Trp Lys Leu Arg Lys Val Lys Arg Ser Leu Gln His Leu
                485                 490                 495

Glu Arg Arg Met Arg Ala Gln Lys Gly Val Lys Leu Pro Glu Asn Gln
            500                 505                 510

Met Lys Lys Arg Leu Lys Ser Ile Glu Pro Lys Ile Glu Ser Tyr Tyr
        515                 520                 525

His Asn Leu Ser Arg Lys Ile Val Asn Leu Ala Lys Ala Asn Asn Ala
    530                 535                 540

Ser Ile Val Val Glu Ser Leu Glu Gly Gly Gly Leu Lys Gln His Gly
545                 550                 555                 560

Arg Lys Lys Asn Ser Arg His Arg Ala Leu Asn Tyr Ala Leu Ser Leu
                565                 570                 575

Phe Asp Tyr Gly Lys Ile Ala Ser Leu Ile Lys Tyr Lys Ser Asp Leu
            580                 585                 590
```

```
Glu Gly Val Pro Met Tyr Glu Val Leu Pro Ala Tyr Thr Ser Gln Gln
        595                 600                 605


Cys Ala Lys Cys Val Leu Lys Lys Gly Ser Phe Val Glu Pro Glu Ile
    610                 615                 620


Ile Gly Tyr Ile Glu Glu Ile Gly Phe Lys Glu Asn Leu Leu Thr Leu
625                 630                 635                 640


Leu Phe Glu Asp Thr Gly Leu Ser Ser Val Gln Val Leu Lys Lys Ser
                645                 650                 655


Lys Asn Lys Met Thr Leu Ser Ala Arg Asp Lys Glu Gly Lys Met Val
            660                 665                 670


Asp Leu Val Leu Lys Tyr Asn Phe Lys Gly Leu Val Ile Ser Gln Glu
        675                 680                 685


Lys Lys Lys Glu Glu Ile Val Glu Phe Pro Ile Lys Glu Ile Asp Gly
    690                 695                 700


Lys Phe Ala Val Leu Asp Ser Ala Tyr Lys Arg Gly Lys Glu Arg Ile
705                 710                 715                 720


Ser Lys Lys Gly Asn Gln Lys Leu Val Tyr Thr Gly Asn Lys Lys Val
                725                 730                 735


Gly Tyr Cys Ser Val His Gly Gln Val Asp Ala Asp Leu Asn Ala Ser
            740                 745                 750


Arg Val Ile Ala Leu Cys Lys Tyr Leu Gly Ile Asn Glu Pro Ile Val
        755                 760                 765


Phe Gly Glu Gln Arg Lys Ser Phe Lys
    770                 775
```

<210> 23
<211> 610
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 23

```
Leu Asp Leu Ile Thr Glu Pro Ile Gln Pro His Lys Ser Ser Ser Leu
1               5                  10                  15


Arg Ser Lys Glu Phe Leu Glu Tyr Gln Ile Ser Asp Phe Leu Asn Phe
            20                  25                  30


Ser Leu His Ser Leu Phe Phe Gly Leu Ala Ser Asn Glu Gly Pro Leu
        35                  40                  45


Val Asp Phe Lys Ile Tyr Asp Lys Ile Val Ile Pro Lys Pro Glu Glu
    50                  55                  60


Arg Phe Pro Lys Lys Glu Ser Glu Glu Gly Lys Lys Leu Asp Ser Phe
65                  70                  75                  80


Asp Lys Arg Val Glu Glu Tyr Tyr Ser Asp Lys Leu Glu Lys Lys Ile
                85                  90                  95


Glu Arg Lys Leu Asn Thr Glu Glu Lys Asn Val Ile Asp Arg Glu Lys
            100                 105                 110


Thr Arg Ile Trp Gly Glu Val Asn Lys Leu Glu Glu Ile Arg Ser Ile
        115                 120                 125


Ile Asp Glu Ile Asn Glu Ile Lys Lys Gln Lys His Ile Ser Glu Lys
    130                 135                 140


Ser Lys Leu Leu Gly Glu Lys Trp Lys Lys Val Asn Asn Ile Gln Glu
```

```
145                 150                 155                 160

Thr Leu Leu Ser Gln Glu Tyr Val Ser Leu Ile Ser Asn Leu Ser Asp
                165                 170                 175

Glu Leu Thr Asn Lys Lys Lys Glu Leu Leu Ala Lys Lys Tyr Ser Lys
            180                 185                 190

Phe Asp Asp Lys Ile Lys Lys Ile Lys Glu Asp Tyr Gly Leu Glu Phe
        195                 200                 205

Asp Glu Asn Thr Ile Lys Lys Glu Gly Glu Lys Ala Phe Leu Asn Pro
    210                 215                 220

Asp Lys Phe Ser Lys Tyr Gln Phe Ser Ser Ser Tyr Leu Lys Leu Ile
225                 230                 235                 240

Gly Glu Ile Ala Arg Ser Leu Ile Thr Tyr Lys Gly Phe Leu Asp Leu
                245                 250                 255

Asn Lys Tyr Pro Ile Ile Phe Arg Lys Pro Ile Asn Lys Val Lys Lys
            260                 265                 270

Ile His Asn Leu Glu Pro Asp Glu Trp Lys Tyr Tyr Ile Gln Phe Gly
        275                 280                 285

Tyr Glu Gln Ile Asn Asn Pro Lys Leu Glu Thr Glu Asn Ile Leu Gly
    290                 295                 300

Ile Asp Arg Gly Leu Thr His Ile Leu Ala Tyr Ser Val Phe Glu Pro
305                 310                 315                 320

Arg Ser Ser Lys Phe Ile Leu Asn Lys Leu Glu Pro Asn Pro Ile Glu
                325                 330                 335

Gly Trp Lys Trp Lys Leu Arg Lys Leu Arg Arg Ser Ile Gln Asn Leu
```

```
            340                 345                 350

Glu Arg Arg Trp Arg Ala Gln Asp Asn Val Lys Leu Pro Glu Asn Gln
        355                 360                 365

Met Lys Lys Asn Leu Arg Ser Ile Glu Asp Lys Val Glu Asn Leu Tyr
    370                 375                 380

His Asn Leu Ser Arg Lys Ile Val Asp Leu Ala Lys Glu Lys Asn Ala
385                 390                 395                 400

Cys Ile Val Phe Glu Lys Leu Glu Gly Gln Gly Met Lys Gln His Gly
                405                 410                 415

Arg Lys Lys Ser Asp Arg Leu Arg Gly Leu Asn Tyr Lys Leu Ser Leu
            420                 425                 430

Phe Asp Tyr Gly Lys Ile Ala Lys Leu Ile Lys Tyr Lys Ala Glu Ile
        435                 440                 445

Glu Gly Ile Pro Ile Tyr Arg Ile Asp Ser Ala Tyr Thr Ser Gln Asn
    450                 455                 460

Cys Ala Lys Cys Val Leu Glu Ser Arg Arg Phe Ala Gln Pro Glu Glu
465                 470                 475                 480

Ile Ser Cys Leu Asp Asp Phe Lys Glu Gly Asp Asn Leu Asp Lys Arg
                485                 490                 495

Ile Leu Glu Gly Thr Gly Leu Val Glu Ala Lys Ile Tyr Lys Lys Leu
            500                 505                 510

Leu Lys Glu Lys Lys Glu Asp Phe Glu Ile Glu Glu Asp Ile Ala Met
        515                 520                 525

Phe Asp Thr Lys Lys Val Ile Lys Glu Asn Lys Glu Lys Thr Val Ile
```

530 535 540

Leu Asp Tyr Val Tyr Thr Arg Arg Lys Glu Ile Ile Gly Thr Asn His
545 550 555 560

Lys Lys Asn Ile Lys Gly Ile Ala Lys Tyr Thr Gly Asn Thr Lys Ile
565 570 575

Gly Tyr Cys Met Lys His Gly Gln Val Asp Ala Asp Leu Asn Ala Ser
580 585 590

Arg Thr Ile Ala Leu Cys Lys Asn Phe Asp Ile Asn Asn Pro Glu Ile
595 600 605

Trp Lys
610

<210> 24
<211> 632
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 24

Met Ser Asp Glu Ser Leu Val Ser Ser Glu Asp Lys Leu Ala Ile Lys
1 5 10 15

Ile Lys Ile Val Pro Asn Ala Glu Gln Ala Lys Met Leu Asp Glu Met
20 25 30

Phe Lys Lys Trp Ser Ser Ile Cys Asn Arg Ile Ser Arg Gly Lys Glu
35 40 45

Asp Ile Glu Thr Leu Arg Pro Asp Glu Gly Lys Glu Leu Gln Phe Asn
50 55 60

```
Ser Thr Gln Leu Asn Ser Ala Thr Met Asp Val Ser Asp Leu Lys Lys
65                  70                  75                  80

Ala Met Ala Arg Gln Gly Glu Arg Leu Glu Ala Glu Val Ser Lys Leu
                85                  90                  95

Arg Gly Arg Tyr Glu Thr Ile Asp Ala Ser Leu Arg Asp Pro Ser Arg
            100                 105                 110

Arg His Thr Asn Pro Gln Lys Pro Ser Ser Phe Tyr Pro Ser Asp Trp
        115                 120                 125

Asp Ile Ser Gly Arg Leu Thr Pro Arg Phe His Thr Ala Arg His Tyr
    130                 135                 140

Ser Thr Glu Leu Arg Lys Leu Lys Ala Lys Glu Asp Lys Met Leu Lys
145                 150                 155                 160

Thr Ile Asn Lys Ile Lys Asn Gly Lys Ile Val Phe Lys Pro Lys Arg
                165                 170                 175

Ile Thr Leu Trp Pro Ser Ser Val Asn Met Ala Phe Lys Gly Ser Arg
            180                 185                 190

Leu Leu Leu Lys Pro Phe Ala Asn Gly Phe Glu Met Glu Leu Pro Ile
        195                 200                 205

Val Ile Ser Pro Gln Lys Thr Ala Asp Gly Lys Ser Gln Lys Ala Ser
    210                 215                 220

Ala Glu Tyr Met Arg Asn Ala Leu Leu Gly Leu Ala Gly Tyr Ser Ile
225                 230                 235                 240

Asn Gln Leu Leu Phe Gly Met Asn Arg Ser Gln Lys Met Leu Ala Asn
                245                 250                 255
```

```
Ala Lys Lys Pro Glu Lys Val Glu Lys Phe Leu Glu Gln Met Lys Asn
            260                 265                 270

Lys Asp Ala Asn Phe Asp Lys Lys Ile Lys Ala Leu Glu Gly Lys Trp
        275                 280                 285

Leu Leu Asp Arg Lys Leu Lys Glu Ser Glu Lys Ser Ser Ile Ala Val
    290                 295                 300

Val Arg Thr Lys Phe Phe Lys Ser Gly Lys Val Glu Leu Asn Glu Asp
305                 310                 315                 320

Tyr Leu Lys Leu Leu Lys His Met Ala Asn Glu Ile Leu Glu Arg Asp
                325                 330                 335

Gly Phe Val Asn Leu Asn Lys Tyr Pro Ile Leu Ser Arg Lys Pro Met
            340                 345                 350

Lys Arg Tyr Lys Gln Lys Asn Ile Asp Asn Leu Lys Pro Asn Met Trp
        355                 360                 365

Lys Tyr Tyr Ile Gln Phe Gly Tyr Glu Pro Ile Phe Glu Arg Lys Ala
    370                 375                 380

Ser Gly Lys Pro Lys Asn Ile Met Gly Ile Asp Arg Gly Leu Thr His
385                 390                 395                 400

Leu Leu Ala Val Ala Val Phe Ser Pro Asp Gln Gln Lys Phe Leu Phe
                405                 410                 415

Asn His Leu Glu Ser Asn Pro Ile Met His Trp Lys Trp Lys Leu Arg
            420                 425                 430

Lys Ile Arg Arg Ser Ile Gln His Met Glu Arg Arg Ile Arg Ala Glu
        435                 440                 445
```

```
Lys Asn Lys His Ile His Glu Ala Gln Leu Lys Lys Arg Leu Gly Ser
    450                 455                 460


Ile Glu Glu Lys Thr Glu Gln His Tyr His Ile Val Ser Ser Lys Ile
465                 470                 475                 480


Ile Asn Trp Ala Ile Glu Tyr Glu Ala Ala Ile Val Leu Glu Ser Leu
                485                 490                 495


Ser His Met Lys Gln Arg Gly Gly Lys Lys Ser Val Arg Thr Arg Ala
            500                 505                 510


Leu Asn Tyr Ala Leu Ser Leu Phe Asp Tyr Glu Lys Val Ala Arg Leu
        515                 520                 525


Ile Thr Tyr Lys Ala Arg Ile Arg Gly Ile Pro Val Tyr Asp Val Leu
    530                 535                 540


Pro Gly Met Thr Ser Lys Thr Cys Ala Thr Cys Leu Leu Asn Gly Ser
545                 550                 555                 560


Gln Gly Ala Tyr Val Arg Gly Leu Glu Thr Thr Lys Ala Ala Gly Lys
                565                 570                 575


Ala Thr Lys Arg Lys Asn Met Lys Ile Gly Lys Cys Met Val Cys Asn
            580                 585                 590


Ser Ser Glu Asn Ser Met Ile Asp Ala Asp Leu Asn Ala Ala Arg Val
        595                 600                 605


Ile Ala Ile Cys Lys Tyr Lys Asn Leu Asn Asp Pro Gln Pro Ala Gly
    610                 615                 620


Ser Arg Lys Val Phe Lys Arg Phe
625                 630
```

<210> 25
<211> 625
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 25

```
Met Leu Ala Leu Lys Leu Lys Ile Met Pro Thr Glu Lys Gln Ala Glu
1               5                  10                  15


Ile Leu Asp Ala Met Phe Trp Lys Trp Ala Ser Ile Cys Ser Arg Ile
            20                  25                  30


Ala Lys Met Lys Lys Lys Val Ser Val Lys Glu Asn Lys Lys Glu Leu
        35                  40                  45


Ser Lys Lys Ile Pro Ser Asn Ser Asp Ile Trp Phe Ser Lys Thr Gln
    50                  55                  60


Leu Cys Gln Ala Glu Val Asp Val Gly Asp His Lys Lys Ala Leu Lys
65                  70                  75                  80


Asn Phe Glu Lys Arg Gln Glu Ser Leu Leu Asp Glu Leu Lys Tyr Lys
                85                  90                  95


Val Lys Ala Ile Asn Glu Val Ile Asn Asp Glu Ser Lys Arg Glu Ile
            100                 105                 110


Asp Pro Asn Asn Pro Ser Lys Phe Arg Ile Lys Asp Ser Thr Lys Lys
        115                 120                 125


Gly Asn Leu Asn Ser Pro Lys Phe Phe Thr Leu Lys Lys Trp Gln Lys
    130                 135                 140


Ile Leu Gln Glu Asn Glu Lys Arg Ile Lys Lys Lys Glu Ser Thr Ile
```

```
145                 150                 155                 160

Glu Lys Leu Lys Arg Gly Asn Ile Phe Phe Asn Pro Thr Lys Ile Ser
                165                 170                 175

Leu His Glu Glu Glu Tyr Ser Ile Asn Phe Gly Ser Ser Lys Leu Leu
            180                 185                 190

Leu Asn Cys Phe Tyr Lys Tyr Asn Lys Lys Ser Gly Ile Asn Ser Asp
        195                 200                 205

Gln Leu Glu Asn Lys Phe Asn Glu Phe Gln Asn Gly Leu Asn Ile Ile
    210                 215                 220

Cys Ser Pro Leu Gln Pro Ile Arg Gly Ser Ser Lys Arg Ser Phe Glu
225                 230                 235                 240

Phe Ile Arg Asn Ser Ile Ile Asn Phe Leu Met Tyr Ser Leu Tyr Ala
                245                 250                 255

Lys Leu Phe Gly Ile Pro Arg Ser Val Lys Ala Leu Met Lys Ser Asn
            260                 265                 270

Lys Asp Glu Asn Lys Leu Lys Leu Glu Glu Lys Leu Lys Lys Lys Lys
        275                 280                 285

Ser Ser Phe Asn Lys Thr Val Lys Glu Phe Glu Lys Met Ile Gly Arg
    290                 295                 300

Lys Leu Ser Asp Asn Glu Ser Lys Ile Leu Asn Asp Glu Ser Lys Lys
305                 310                 315                 320

Phe Phe Glu Ile Ile Lys Ser Asn Asn Lys Tyr Ile Pro Ser Glu Glu
                325                 330                 335

Tyr Leu Lys Leu Leu Lys Asp Ile Ser Glu Glu Ile Tyr Asn Ser Asn
```

340 345 350

Ile Asp Phe Lys Pro Tyr Lys Tyr Ser Ile Leu Ile Arg Lys Pro Leu
355 360 365

Ser Lys Phe Lys Ser Lys Lys Leu Tyr Asn Leu Lys Pro Thr Asp Tyr
370 375 380

Lys Tyr Tyr Leu Gln Leu Ser Tyr Glu Pro Phe Ser Lys Gln Leu Ile
385 390 395 400

Ala Thr Lys Thr Ile Leu Gly Ile Asp Arg Gly Leu Lys His Leu Leu
405 410 415

Ala Val Ser Val Phe Asp Pro Ser Gln Asn Lys Phe Val Tyr Asn Lys
420 425 430

Leu Ile Lys Asn Pro Val Phe Lys Trp Lys Lys Arg Tyr His Asp Leu
435 440 445

Lys Arg Ser Ile Arg Asn Arg Glu Arg Arg Ile Arg Ala Leu Thr Gly
450 455 460

Val His Ile His Glu Asn Gln Leu Ile Lys Lys Leu Lys Ser Met Lys
465 470 475 480

Asn Lys Ile Asn Val Leu Tyr His Asn Val Ser Lys Asn Ile Val Asp
485 490 495

Leu Ala Lys Lys Tyr Glu Ser Thr Ile Val Leu Glu Arg Leu Glu Asn
500 505 510

Leu Lys Gln His Gly Arg Ser Lys Gly Lys Arg Tyr Lys Lys Leu Asn
515 520 525

Tyr Val Leu Ser Asn Phe Asp Tyr Lys Lys Ile Glu Ser Leu Ile Ser

530 535 540

Tyr Lys Ala Lys Lys Glu Gly Val Pro Val Ser Asn Ile Asn Pro Lys
545 550 555 560

Tyr Thr Ser Lys Thr Cys Ala Lys Cys Leu Leu Glu Val Asn Gln Leu
565 570 575

Ser Glu Leu Lys Asn Glu Tyr Asn Arg Asp Ser Lys Asn Ser Lys Ile
580 585 590

Gly Ile Cys Asn Ile His Gly Gln Ile Asp Ala Asp Leu Asn Ala Ala
595 600 605

Arg Val Ile Ala Leu Cys Tyr Ser Lys Asn Leu Asn Glu Pro His Phe
610 615 620

Lys
625

<210> 26
<211> 517
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 26

Val Ile Asn Leu Phe Gly Tyr Lys Phe Ala Leu Tyr Pro Asn Lys Thr
1 5 10 15

Gln Glu Glu Leu Leu Asn Lys His Leu Gly Glu Cys Gly Trp Leu Tyr
20 25 30

Asn Lys Ala Ile Glu Gln Asn Glu Tyr Tyr Lys Ala Asp Ser Asn Ile
35 40 45

```
Glu Glu Ala Gln Lys Lys Phe Glu Leu Leu Pro Asp Lys Asn Ser Asp
    50                  55                  60

Glu Ala Lys Val Leu Arg Gly Asn Ile Ser Lys Asp Asn Tyr Val Tyr
65                  70                  75                  80

Arg Thr Leu Val Lys Lys Lys Lys Ser Glu Ile Asn Val Gln Ile Arg
                85                  90                  95

Lys Ala Val Val Leu Arg Pro Ala Glu Thr Ile Arg Asn Leu Ala Lys
            100                 105                 110

Val Lys Lys Lys Gly Leu Ser Val Gly Arg Leu Lys Phe Ile Pro Ile
        115                 120                 125

Arg Glu Trp Asp Val Leu Pro Phe Lys Gln Ser Asp Gln Ile Arg Leu
    130                 135                 140

Glu Glu Asn Tyr Leu Ile Leu Glu Pro Tyr Gly Arg Leu Lys Phe Lys
145                 150                 155                 160

Met His Arg Pro Leu Leu Gly Lys Pro Lys Thr Phe Cys Ile Lys Arg
                165                 170                 175

Thr Ala Thr Asp Arg Trp Thr Ile Ser Phe Ser Thr Glu Tyr Asp Asp
            180                 185                 190

Ser Asn Met Arg Lys Asn Asp Gly Gly Gln Val Gly Ile Asp Val Gly
        195                 200                 205

Leu Lys Thr His Leu Arg Leu Ser Asn Glu Asn Pro Asp Glu Asp Pro
    210                 215                 220

Arg Tyr Pro Asn Pro Lys Ile Trp Lys Arg Tyr Asp Arg Arg Leu Thr
225                 230                 235                 240
```

```
Ile Leu Gln Arg Arg Ile Ser Lys Ser Lys Lys Leu Gly Lys Asn Arg
                245                 250                 255

Thr Arg Leu Arg Leu Arg Leu Ser Arg Leu Trp Glu Lys Ile Arg Asn
            260                 265                 270

Ser Arg Ala Asp Leu Ile Gln Asn Glu Thr Tyr Glu Ile Leu Ser Glu
        275                 280                 285

Asn Lys Leu Ile Ala Ile Glu Asp Leu Asn Val Lys Gly Met Gln Glu
    290                 295                 300

Lys Lys Asp Lys Lys Gly Arg Lys Gly Arg Thr Arg Ala Gln Glu Lys
305                 310                 315                 320

Gly Leu His Arg Ser Ile Ser Asp Ala Ala Phe Ser Glu Phe Arg Arg
                325                 330                 335

Val Leu Glu Tyr Lys Ala Lys Arg Phe Gly Ser Glu Val Lys Pro Val
            340                 345                 350

Ser Ala Ile Asp Ser Ser Lys Glu Cys His Asn Cys Gly Asn Lys Lys
        355                 360                 365

Gly Met Pro Leu Glu Ser Arg Ile Tyr Glu Cys Pro Lys Cys Gly Leu
    370                 375                 380

Lys Ile Asp Arg Asp Leu Asn Ser Ala Lys Val Ile Leu Ala Arg Ala
385                 390                 395                 400

Thr Gly Val Arg Pro Gly Ser Asn Ala Arg Ala Asp Thr Lys Ile Ser
                405                 410                 415

Ala Thr Ala Gly Ala Ser Val Gln Thr Glu Gly Thr Val Ser Glu Asp
            420                 425                 430
```

```
Phe Arg Gln Gln Met Glu Thr Ser Asp Gln Lys Pro Met Gln Gly Glu
        435                 440                 445


Gly Ser Lys Glu Pro Pro Met Asn Pro Glu His Lys Ser Ser Gly Arg
    450                 455                 460


Gly Ser Lys His Val Asn Ile Gly Cys Lys Asn Lys Val Gly Leu Tyr
465                 470                 475                 480


Asn Glu Asp Glu Asn Ser Arg Ser Thr Glu Lys Gln Ile Met Asp Glu
                485                 490                 495


Asn Arg Ser Thr Thr Glu Asp Met Val Glu Ile Gly Ala Leu His Ser
            500                 505                 510


Pro Val Leu Thr Thr
        515


<210>  27
<211>  410
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  27

Met Ile Ala Ser Ile Asp Tyr Glu Ala Val Ser Gln Ala Leu Ile Val
1               5                   10                  15


Phe Glu Phe Lys Ala Lys Gly Lys Asp Ser Gln Tyr Gln Ala Ile Asp
            20                  25                  30


Glu Ala Ile Arg Ser Tyr Arg Phe Ile Arg Asn Ser Cys Leu Arg Tyr
        35                  40                  45


Trp Met Asp Asn Lys Lys Val Gly Lys Tyr Asp Leu Asn Lys Tyr Cys
```

```
    50                  55                  60

Lys Val Leu Ala Lys Gln Tyr Pro Phe Ala Asn Lys Leu Asn Ser Gln
65                  70                  75                  80

Ala Arg Gln Ser Ala Ala Glu Cys Ser Trp Ser Ala Ile Ser Arg Phe
                85                  90                  95

Tyr Asp Asn Cys Lys Arg Lys Val Ser Gly Lys Lys Gly Phe Pro Lys
            100                 105                 110

Phe Lys Lys His Ala Arg Ser Val Glu Tyr Lys Thr Ser Gly Trp Lys
        115                 120                 125

Leu Ser Glu Asn Arg Lys Ala Ile Thr Phe Thr Asp Lys Asn Gly Ile
    130                 135                 140

Gly Lys Leu Lys Leu Lys Gly Thr Tyr Asp Leu His Phe Ser Gln Leu
145                 150                 155                 160

Glu Asp Met Lys Arg Val Arg Leu Val Arg Arg Ala Asp Gly Tyr Tyr
                165                 170                 175

Val Gln Phe Cys Ile Ser Val Asp Val Lys Val Glu Thr Glu Pro Thr
            180                 185                 190

Gly Lys Ala Ile Gly Leu Asp Val Gly Ile Lys Tyr Phe Leu Ala Asp
        195                 200                 205

Ser Ser Gly Asn Thr Ile Glu Asn Pro Gln Phe Tyr Arg Lys Ala Glu
    210                 215                 220

Lys Lys Leu Asn Arg Ala Asn Arg Arg Lys Ser Lys Lys Tyr Ile Arg
225                 230                 235                 240

Gly Val Lys Pro Gln Ser Lys Asn Tyr His Lys Ala Arg Cys Arg Tyr
```

245 250 255

Ala Arg Lys His Leu Arg Val Ser Arg Gln Arg Lys Glu Tyr Cys Lys
260 265 270

Arg Val Ala Tyr Cys Val Ile His Ser Asn Asp Val Val Ala Tyr Glu
275 280 285

Asp Leu Asn Val Lys Gly Met Val Lys Asn Arg His Leu Ala Lys Ser
290 295 300

Ile Ser Asp Val Ala Trp Ser Thr Phe Arg His Trp Leu Glu Tyr Phe
305 310 315 320

Ala Ile Lys Tyr Gly Lys Leu Thr Ile Pro Val Ala Pro His Asn Thr
325 330 335

Ser Gln Asn Cys Ser Asn Cys Asp Lys Lys Val Pro Lys Ser Leu Ser
340 345 350

Thr Arg Thr His Ile Cys His His Cys Gly Tyr Ser Glu Asp Arg Asp
355 360 365

Val Asn Ala Ala Lys Asn Ile Leu Lys Lys Ala Leu Ser Thr Val Gly
370 375 380

Gln Thr Gly Ser Leu Lys Leu Gly Glu Ile Glu Pro Leu Leu Val Leu
385 390 395 400

Glu Gln Ser Cys Thr Arg Lys Phe Asp Leu
405 410

<210> 28
<211> 486
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 28

```
Leu Ala Glu Glu Asn Thr Leu His Leu Thr Leu Ala Met Ser Leu Pro
1               5                  10                  15


Leu Asn Asp Leu Pro Glu Asn Arg Thr Arg Ser Glu Leu Trp Arg Arg
            20                  25                  30


Gln Trp Leu Pro Gln Lys Lys Leu Ser Leu Leu Leu Gly Val Asn Gln
        35                  40                  45


Ser Val Arg Lys Ala Ala Ala Asp Cys Leu Arg Trp Phe Glu Pro Tyr
    50                  55                  60


Gln Glu Leu Leu Trp Trp Glu Pro Thr Asp Pro Asp Gly Lys Lys Leu
65                  70                  75                  80


Leu Asp Lys Glu Gly Arg Pro Ile Lys Arg Thr Ala Gly His Met Arg
                85                  90                  95


Val Leu Arg Lys Leu Glu Glu Ile Ala Pro Phe Arg Gly Tyr Gln Leu
            100                 105                 110


Gly Ser Ala Val Lys Asn Gly Leu Arg His Lys Val Ala Asp Leu Leu
        115                 120                 125


Leu Ser Tyr Ala Lys Arg Lys Leu Asp Pro Gln Phe Thr Asp Lys Thr
    130                 135                 140


Ser Tyr Pro Ser Ile Gly Asp Gln Phe Pro Ile Val Trp Thr Gly Ala
145                 150                 155                 160


Phe Val Cys Tyr Glu Gln Ser Ile Thr Gly Gln Leu Tyr Leu Tyr Leu
                165                 170                 175
```

```
Pro Leu Phe Pro Arg Gly Ser His Gln Glu Asp Ile Thr Asn Asn Tyr
            180                 185                 190

Asp Pro Asp Arg Gly Pro Ala Leu Gln Val Phe Gly Glu Lys Glu Ile
        195                 200                 205

Ala Arg Leu Ser Arg Ser Thr Ser Gly Leu Leu Leu Pro Leu Gln Phe
    210                 215                 220

Asp Lys Trp Gly Glu Ala Thr Phe Ile Arg Gly Glu Asn Asn Pro Pro
225                 230                 235                 240

Thr Trp Lys Ala Thr His Arg Arg Ser Asp Lys Lys Trp Leu Ser Glu
                245                 250                 255

Val Leu Leu Arg Glu Lys Asp Phe Gln Pro Lys Arg Val Glu Leu Leu
            260                 265                 270

Val Arg Asn Gly Arg Ile Phe Val Asn Val Ala Cys Glu Ile Pro Thr
        275                 280                 285

Lys Pro Leu Leu Glu Val Glu Asn Phe Met Gly Val Ser Phe Gly Leu
    290                 295                 300

Glu His Leu Val Thr Val Val Val Ile Asn Arg Asp Gly Asn Val Val
305                 310                 315                 320

His Gln Arg Gln Glu Pro Ala Arg Arg Tyr Glu Lys Thr Tyr Phe Ala
                325                 330                 335

Arg Leu Glu Arg Leu Arg Arg Arg Gly Gly Pro Phe Ser Gln Glu Leu
            340                 345                 350

Glu Thr Phe His Tyr Arg Gln Val Ala Gln Ile Val Glu Glu Ala Leu
        355                 360                 365
```

```
Arg Phe Lys Ser Val Pro Ala Val Glu Gln Val Gly Asn Ile Pro Lys
    370                 375                 380


Gly Arg Tyr Asn Pro Arg Leu Asn Leu Arg Leu Ser Tyr Trp Pro Phe
385                 390                 395                 400


Gly Lys Leu Ala Asp Leu Thr Ser Tyr Lys Ala Val Lys Glu Gly Leu
                405                 410                 415


Pro Lys Pro Tyr Ser Val Tyr Ser Ala Thr Ala Lys Met Leu Cys Ser
            420                 425                 430


Thr Cys Gly Ala Ala Asn Lys Glu Gly Asp Gln Pro Ile Ser Leu Lys
        435                 440                 445


Gly Pro Thr Val Tyr Cys Gly Asn Cys Gly Thr Arg His Asn Thr Gly
    450                 455                 460


Phe Asn Thr Ala Leu Asn Leu Ala Arg Arg Ala Gln Glu Leu Phe Val
465                 470                 475                 480


Lys Gly Val Val Ala Arg
                485


<210>  29
<211>  602
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  29

Met Ser Gln Ser Leu Leu Lys Trp His Asp Met Ala Gly Arg Asp Lys
1               5                   10                  15


Asp Ala Ser Arg Ser Leu Gln Lys Ser Ala Val Glu Gly Val Leu Leu
```

```
            20                  25                  30

His Leu Thr Ala Ser His Arg Val Ala Leu Glu Met Leu Glu Lys Ser
        35                  40                  45

Val Ser Gln Thr Val Ala Val Thr Met Glu Ala Ala Gln Gln Arg Leu
    50                  55                  60

Val Ile Val Leu Glu Asp Asp Pro Thr Lys Ala Thr Ser Arg Lys Arg
65                  70                  75                  80

Val Ile Ser Ala Asp Leu Gln Phe Thr Arg Glu Glu Phe Gly Ser Leu
                85                  90                  95

Pro Asn Trp Ala Gln Lys Leu Ala Ser Thr Cys Pro Glu Ile Ala Thr
            100                 105                 110

Lys Tyr Ala Asp Lys His Ile Asn Ser Ile Arg Ile Ala Trp Gly Val
        115                 120                 125

Ala Lys Glu Ser Thr Asn Gly Asp Ala Val Glu Gln Lys Leu Gln Trp
    130                 135                 140

Gln Ile Arg Leu Leu Asp Val Thr Met Phe Leu Gln Gln Leu Val Leu
145                 150                 155                 160

Gln Leu Ala Asp Lys Ala Leu Leu Glu Gln Ile Pro Ser Ser Ile Arg
                165                 170                 175

Gly Gly Ile Gly Gln Glu Val Ala Gln Gln Val Thr Ser His Ile Gln
            180                 185                 190

Leu Leu Asp Ser Gly Thr Val Leu Lys Ala Glu Leu Pro Thr Ile Ser
        195                 200                 205

Asp Arg Asn Ser Glu Leu Ala Arg Lys Gln Trp Glu Asp Ala Ile Gln
```

```
    210                 215                 220

Thr Val Cys Thr Tyr Ala Leu Pro Phe Ser Arg Glu Arg Ala Arg Ile
225                 230                 235                 240

Leu Asp Pro Gly Lys Tyr Ala Ala Glu Asp Pro Arg Gly Asp Arg Leu
                245                 250                 255

Ile Asn Ile Asp Pro Met Trp Ala Arg Val Leu Lys Gly Pro Thr Val
            260                 265                 270

Lys Ser Leu Pro Leu Leu Phe Val Ser Gly Ser Ser Ile Arg Ile Val
        275                 280                 285

Lys Leu Thr Leu Pro Arg Lys His Ala Ala Gly His Lys His Thr Phe
    290                 295                 300

Thr Ala Thr Tyr Leu Val Leu Pro Val Ser Arg Glu Trp Ile Asn Ser
305                 310                 315                 320

Leu Pro Gly Thr Val Gln Glu Lys Val Gln Trp Trp Lys Lys Pro Asp
                325                 330                 335

Val Leu Ala Thr Gln Glu Leu Leu Val Gly Lys Gly Ala Leu Lys Lys
            340                 345                 350

Ser Ala Asn Thr Leu Val Ile Pro Ile Ser Ala Gly Lys Lys Arg Phe
        355                 360                 365

Phe Asn His Ile Leu Pro Ala Leu Gln Arg Gly Phe Pro Leu Gln Trp
    370                 375                 380

Gln Arg Ile Val Gly Arg Ser Tyr Arg Arg Pro Ala Thr His Arg Lys
385                 390                 395                 400

Trp Phe Ala Gln Leu Thr Ile Gly Tyr Thr Asn Pro Ser Ser Leu Pro
```

```
                405                 410                 415

Glu Met Ala Leu Gly Ile His Phe Gly Met Lys Asp Ile Leu Trp Trp
            420                 425                 430

Ala Leu Ala Asp Lys Gln Gly Asn Ile Leu Lys Asp Gly Ser Ile Pro
        435                 440                 445

Gly Asn Ser Ile Leu Asp Phe Ser Leu Gln Glu Lys Gly Lys Ile Glu
    450                 455                 460

Arg Gln Gln Lys Ala Gly Lys Asn Val Ala Gly Lys Lys Tyr Gly Lys
465                 470                 475                 480

Ser Leu Leu Asn Ala Thr Tyr Arg Val Val Asn Gly Val Leu Glu Phe
                485                 490                 495

Ser Lys Gly Ile Ser Ala Glu His Ala Ser Gln Pro Ile Gly Leu Gly
            500                 505                 510

Leu Glu Thr Ile Arg Phe Val Asp Lys Ala Ser Gly Ser Ser Pro Val
        515                 520                 525

Asn Ala Arg His Ser Asn Trp Asn Tyr Gly Gln Leu Ser Gly Ile Phe
    530                 535                 540

Ala Asn Lys Ala Gly Pro Ala Gly Phe Ser Val Thr Glu Ile Thr Leu
545                 550                 555                 560

Lys Lys Ala Gln Arg Asp Leu Ser Asp Ala Glu Gln Ala Arg Val Leu
                565                 570                 575

Ala Ile Glu Ala Thr Lys Arg Phe Ala Ser Arg Ile Lys Arg Leu Ala
            580                 585                 590

Thr Lys Arg Lys Asp Asp Thr Leu Phe Val
```

595 600

<210> 30
<211> 494
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 30

Val Glu Pro Val Glu Lys Glu Arg Phe Tyr Tyr Arg Thr Tyr Thr Phe
1 5 10 15

Arg Leu Asp Gly Gln Pro Arg Thr Gln Asn Leu Thr Thr Gln Ser Gly
20 25 30

Trp Gly Leu Leu Thr Lys Ala Val Leu Asp Asn Thr Lys His Tyr Trp
35 40 45

Glu Ile Val His His Ala Arg Ile Ala Asn Gln Pro Ile Val Phe Glu
50 55 60

Asn Pro Val Ile Asp Glu Gln Gly Asn Pro Lys Leu Asn Lys Leu Gly
65 70 75 80

Gln Pro Arg Phe Trp Lys Arg Pro Ile Ser Asp Ile Val Asn Gln Leu
85 90 95

Arg Ala Leu Phe Glu Asn Gln Asn Pro Tyr Gln Leu Gly Ser Ser Leu
100 105 110

Ile Gln Gly Thr Tyr Trp Asp Val Ala Glu Asn Leu Ala Ser Trp Tyr
115 120 125

Ala Leu Asn Lys Glu Tyr Leu Ala Gly Thr Ala Thr Trp Gly Glu Pro
130 135 140

```
Ser Phe Pro Glu Pro His Pro Leu Thr Glu Ile Asn Gln Trp Met Pro
145                 150                 155                 160


Leu Thr Phe Ser Ser Gly Lys Val Val Arg Leu Leu Lys Asn Ala Ser
                165                 170                 175


Gly Arg Tyr Phe Ile Gly Leu Pro Ile Leu Gly Glu Asn Asn Pro Cys
            180                 185                 190


Tyr Arg Met Arg Thr Ile Glu Lys Leu Ile Pro Cys Asp Gly Lys Gly
        195                 200                 205


Arg Val Thr Ser Gly Ser Leu Ile Leu Phe Pro Leu Val Gly Ile Tyr
    210                 215                 220


Ala Gln Gln His Arg Arg Met Thr Asp Ile Cys Glu Ser Ile Arg Thr
225                 230                 235                 240


Glu Lys Gly Lys Leu Ala Trp Ala Gln Val Ser Ile Asp Tyr Val Arg
                245                 250                 255


Glu Val Asp Lys Arg Arg Arg Met Arg Arg Thr Arg Lys Ser Gln Gly
            260                 265                 270


Trp Ile Gln Gly Pro Trp Gln Glu Val Phe Ile Leu Arg Leu Val Leu
        275                 280                 285


Ala His Lys Ala Pro Lys Leu Tyr Lys Pro Arg Cys Phe Ala Gly Ile
    290                 295                 300


Ser Leu Gly Pro Lys Thr Leu Ala Ser Cys Val Ile Leu Asp Gln Asp
305                 310                 315                 320


Glu Arg Val Val Glu Lys Gln Gln Trp Ser Gly Ser Glu Leu Leu Ser
                325                 330                 335
```

```
Leu Ile His Gln Gly Glu Glu Arg Leu Arg Ser Leu Arg Glu Gln Ser
            340                 345                 350


Lys Pro Thr Trp Asn Ala Ala Tyr Arg Lys Gln Leu Lys Ser Leu Ile
        355                 360                 365


Asn Thr Gln Val Phe Thr Ile Val Thr Phe Leu Arg Glu Arg Gly Ala
    370                 375                 380


Ala Val Arg Leu Glu Ser Ile Ala Arg Val Arg Lys Ser Thr Pro Ala
385                 390                 395                 400


Pro Pro Val Asn Phe Leu Leu Ser His Trp Ala Tyr Arg Gln Ile Thr
                405                 410                 415


Glu Arg Leu Lys Asp Leu Ala Ile Arg Asn Gly Met Pro Leu Thr His
            420                 425                 430


Ser Asn Gly Ser Tyr Gly Val Arg Phe Thr Cys Ser Gln Cys Gly Ala
        435                 440                 445


Thr Asn Gln Gly Ile Lys Asp Pro Thr Lys Tyr Lys Val Asp Ile Glu
    450                 455                 460


Ser Glu Thr Phe Leu Cys Ser Ile Cys Ser His Arg Glu Ile Ala Ala
465                 470                 475                 480


Val Asn Thr Ala Thr Asn Leu Ala Lys Gln Leu Leu Asp Glu
                485                 490


<210>  31
<211>  526
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence
```

<400> 31

```
Met Asn Asp Thr Glu Thr Ser Glu Thr Leu Thr Ser His Arg Thr Val
1               5                  10                  15


Cys Ala His Leu His Val Val Gly Glu Thr Gly Ser Leu Pro Arg Leu
            20                  25                  30


Val Glu Ala Ala Leu Ala Glu Leu Ile Thr Leu Asn Gly Arg Ala Thr
        35                  40                  45


Gln Ala Leu Leu Ser Leu Ala Lys Asn Gly Leu Val Leu Arg Arg Asp
    50                  55                  60


Lys Glu Glu Asn Leu Ile Ala Ala Glu Leu Thr Leu Pro Cys Arg Lys
65                  70                  75                  80


Asn Lys Tyr Ala Asp Val Ala Ala Lys Ala Gly Glu Pro Ile Leu Ala
                85                  90                  95


Thr Arg Ile Asn Asn Lys Gly Lys Leu Val Thr Lys Lys Trp Tyr Gly
            100                 105                 110


Glu Gly Asn Ser Tyr His Ile Val Arg Phe Thr Pro Glu Thr Gly Met
        115                 120                 125


Phe Thr Val Arg Val Phe Asp Arg Tyr Ala Phe Asp Glu Glu Leu Leu
    130                 135                 140


His Leu His Ser Glu Val Val Phe Gly Ser Asp Leu Pro Lys Gly Ile
145                 150                 155                 160


Lys Ala Lys Thr Asp Ser Leu Pro Ala Asn Phe Leu Gln Ala Val Phe
                165                 170                 175


Thr Ser Phe Leu Glu Leu Pro Phe Gln Gly Phe Pro Asp Ile Val Val
```

```
            180                 185                 190

Lys Pro Ala Met Lys Gln Ala Ala Glu Gln Leu Leu Ser Tyr Val Gln
        195                 200                 205

Leu Glu Ala Gly Glu Asn Gln Gln Ala Glu Tyr Pro Asp Thr Asn Glu
    210                 215                 220

Arg Asp Pro Glu Leu Arg Leu Val Glu Trp Gln Lys Ser Leu His Glu
225                 230                 235                 240

Leu Ser Val Arg Thr Glu Pro Phe Glu Phe Val Arg Ala Arg Asp Ile
                245                 250                 255

Asp Tyr Tyr Ala Glu Thr Asp Arg Arg Gly Asn Arg Phe Val Asn Ile
            260                 265                 270

Thr Pro Glu Trp Thr Lys Phe Ala Glu Ser Pro Phe Ala Arg Arg Leu
        275                 280                 285

Pro Leu Lys Ile Pro Pro Glu Phe Cys Ile Leu Leu Arg Arg Lys Thr
    290                 295                 300

Glu Gly His Ala Lys Ile Pro Asn Arg Ile Tyr Leu Gly Leu Gln Ile
305                 310                 315                 320

Phe Asp Gly Val Thr Pro Asp Ser Thr Leu Gly Val Leu Ala Thr Ala
                325                 330                 335

Glu Asp Gly Lys Leu Phe Trp Trp His Asp His Leu Asp Glu Phe Ser
            340                 345                 350

Asn Leu Glu Gly Lys Pro Glu Pro Lys Leu Lys Asn Lys Pro Gln Leu
        355                 360                 365

Leu Met Val Ser Leu Glu Tyr Asp Arg Glu Gln Arg Phe Glu Glu Ser
```

370 375 380

Val Gly Gly Asp Arg Lys Ile Cys Leu Val Thr Leu Lys Glu Thr Arg
385 390 395 400

Asn Phe Arg Arg Gly Trp Asn Gly Arg Ile Leu Gly Ile His Phe Gln
405 410 415

His Asn Pro Val Ile Thr Trp Ala Leu Met Asp His Asp Ala Glu Val
420 425 430

Leu Glu Lys Gly Phe Ile Glu Gly Asn Ala Phe Leu Gly Lys Ala Leu
435 440 445

Asp Lys Gln Ala Leu Asn Glu Tyr Leu Gln Lys Gly Gly Lys Trp Val
450 455 460

Gly Asp Arg Ser Phe Gly Asn Lys Leu Lys Gly Ile Thr His Thr Leu
465 470 475 480

Ala Ser Leu Ile Val Arg Leu Ala Arg Glu Lys Asp Ala Trp Ile Ala
485 490 495

Leu Glu Glu Ile Ser Trp Val Gln Lys Gln Ser Ala Asp Ser Val Ala
500 505 510

Asn His Glu Ile Val Glu Gln Pro His His Ser Leu Thr Arg
515 520 525

<210> 32
<211> 649
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 32

```
Met Asn Asp Thr Glu Thr Ser Glu Thr Leu Thr Ser His Arg Thr Val
1               5                  10                  15

Cys Ala His Leu His Val Val Gly Glu Thr Gly Ser Leu Pro Arg Leu
            20                  25                  30

Val Glu Ala Ala Leu Ala Glu Leu Ile Thr Leu Asn Gly Arg Ala Thr
        35                  40                  45

Gln Ala Leu Leu Ser Leu Ala Lys Asn Gly Leu Val Leu Arg Arg Asp
    50                  55                  60

Lys Glu Glu Asn Leu Ile Ala Ala Glu Leu Thr Leu Pro Cys Arg Lys
65                  70                  75                  80

Asn Lys Tyr Ala Asp Val Ala Ala Lys Ala Gly Glu Pro Ile Leu Ala
                85                  90                  95

Thr Arg Ile Asn Asn Lys Gly Lys Leu Val Thr Lys Lys Trp Tyr Gly
            100                 105                 110

Glu Gly Asn Ser Tyr His Ile Val Arg Phe Thr Pro Glu Thr Gly Met
        115                 120                 125

Phe Thr Val Arg Val Phe Asp Arg Tyr Ala Phe Asp Glu Glu Leu Leu
    130                 135                 140

His Leu His Ser Glu Val Val Phe Gly Ser Asp Leu Pro Lys Gly Ile
145                 150                 155                 160

Lys Ala Lys Thr Asp Ser Leu Pro Ala Asn Phe Leu Gln Ala Val Phe
                165                 170                 175

Thr Ser Phe Leu Glu Leu Pro Phe Gln Gly Phe Pro Asp Ile Val Val
            180                 185                 190
```

```
Lys Pro Ala Met Lys Gln Ala Ala Glu Gln Leu Leu Ser Tyr Val Gln
        195                 200                 205


Leu Glu Ala Gly Glu Asn Gln Gln Ala Glu Tyr Pro Asp Thr Asn Glu
    210                 215                 220


Arg Asp Pro Glu Leu Arg Leu Val Glu Trp Gln Lys Ser Leu His Glu
225                 230                 235                 240


Leu Ser Val Arg Thr Glu Pro Phe Glu Phe Val Arg Ala Arg Asp Ile
                245                 250                 255


Asp Tyr Tyr Ala Glu Thr Asp Arg Arg Gly Asn Arg Phe Val Asn Ile
            260                 265                 270


Thr Pro Glu Trp Thr Lys Phe Ala Glu Ser Pro Phe Ala Arg Arg Leu
        275                 280                 285


Pro Leu Lys Ile Pro Pro Glu Phe Cys Ile Leu Leu Arg Arg Lys Thr
    290                 295                 300


Glu Gly His Ala Lys Ile Pro Asn Arg Ile Tyr Leu Gly Leu Gln Ile
305                 310                 315                 320


Phe Asp Gly Val Thr Pro Asp Ser Thr Leu Gly Val Leu Ala Thr Ala
                325                 330                 335


Glu Asp Gly Lys Leu Phe Trp Trp His Asp His Leu Asp Glu Phe Ser
            340                 345                 350


Asn Leu Glu Gly Lys Pro Glu Pro Lys Leu Lys Asn Lys Pro Gln Leu
        355                 360                 365


Leu Met Val Ser Leu Glu Tyr Asp Arg Glu Gln Arg Phe Glu Glu Ser
    370                 375                 380
```

```
Val Gly Gly Asp Arg Lys Ile Cys Leu Val Thr Leu Lys Glu Thr Arg
385                 390                 395                 400


Asn Phe Arg Arg Gly Arg His Gly His Thr Arg Thr Asp Arg Leu Pro
                405                 410                 415


Ala Gly Asn Thr Leu Trp Arg Ala Asp Phe Ala Thr Ser Ala Glu Val
            420                 425                 430


Ala Ala Pro Lys Trp Asn Gly Arg Ile Leu Gly Ile His Phe Gln His
        435                 440                 445


Asn Pro Val Ile Thr Trp Ala Leu Met Asp His Asp Ala Glu Val Leu
    450                 455                 460


Glu Lys Gly Phe Ile Glu Gly Asn Ala Phe Leu Gly Lys Ala Leu Asp
465                 470                 475                 480


Lys Gln Ala Leu Asn Glu Tyr Leu Gln Lys Gly Gly Lys Trp Val Gly
                485                 490                 495


Asp Arg Ser Phe Gly Asn Lys Leu Lys Gly Ile Thr His Thr Leu Ala
            500                 505                 510


Ser Leu Ile Val Arg Leu Ala Arg Glu Lys Asp Ala Trp Ile Ala Leu
        515                 520                 525


Glu Glu Ile Ser Trp Val Gln Lys Gln Ser Ala Asp Ser Val Ala Asn
    530                 535                 540


Arg Arg Phe Ser Met Trp Asn Tyr Ser Arg Leu Ala Thr Leu Ile Glu
545                 550                 555                 560


Trp Leu Gly Thr Asp Ile Ala Thr Arg Asp Cys Gly Thr Ala Ala Pro
                565                 570                 575
```

```
Leu Ala His Lys Val Ser Asp Tyr Leu Thr His Phe Thr Cys Pro Glu
            580                 585                 590


Cys Gly Ala Cys Arg Lys Ala Gly Gln Lys Lys Glu Ile Ala Asp Thr
        595                 600                 605


Val Arg Ala Gly Asp Ile Leu Thr Cys Arg Lys Cys Gly Phe Ser Gly
    610                 615                 620


Pro Ile Pro Asp Asn Phe Ile Ala Glu Phe Val Ala Lys Lys Ala Leu
625                 630                 635                 640


Glu Arg Met Leu Lys Lys Lys Pro Val
                645


<210>  33
<211>  414
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  33

Met Ala Lys Arg Asn Phe Gly Glu Lys Ser Glu Ala Leu Tyr Arg Ala
1               5                   10                  15


Val Arg Phe Glu Val Arg Pro Ser Lys Glu Glu Leu Ser Ile Leu Leu
            20                  25                  30


Ala Val Ser Glu Val Leu Arg Met Leu Phe Asn Ser Ala Leu Ala Glu
        35                  40                  45


Arg Gln Gln Val Phe Thr Glu Phe Ile Ala Ser Leu Tyr Ala Glu Leu
    50                  55                  60


Lys Ser Ala Ser Val Pro Glu Glu Ile Ser Glu Ile Arg Lys Lys Leu
```

```
65                  70                  75                  80

Arg Glu Ala Tyr Lys Glu His Ser Ile Ser Leu Phe Asp Gln Ile Asn
                85                  90                  95

Ala Leu Thr Ala Arg Arg Val Glu Asp Glu Ala Phe Ala Ser Val Thr
            100                 105                 110

Arg Asn Trp Gln Glu Glu Thr Leu Asp Ala Leu Asp Gly Ala Tyr Lys
        115                 120                 125

Ser Phe Leu Ser Leu Arg Arg Lys Gly Asp Tyr Asp Ala His Ser Pro
    130                 135                 140

Arg Ser Arg Asp Ser Gly Phe Phe Gln Lys Ile Pro Gly Arg Ser Gly
145                 150                 155                 160

Phe Lys Ile Gly Glu Gly Arg Ile Ala Leu Ser Cys Gly Ala Gly Arg
                165                 170                 175

Lys Leu Ser Phe Pro Ile Pro Asp Tyr Gln Gln Gly Arg Leu Ala Glu
            180                 185                 190

Thr Thr Lys Leu Lys Lys Phe Glu Leu Tyr Arg Asp Gln Pro Asn Leu
        195                 200                 205

Ala Lys Ser Gly Arg Phe Trp Ile Ser Val Val Tyr Glu Leu Pro Lys
    210                 215                 220

Pro Glu Ala Thr Thr Cys Gln Ser Glu Gln Val Ala Phe Val Ala Leu
225                 230                 235                 240

Gly Ala Ser Ser Ile Gly Val Val Ser Gln Arg Gly Glu Glu Val Ile
                245                 250                 255

Ala Leu Trp Arg Ser Asp Lys His Trp Val Pro Lys Ile Glu Ala Val
```

260 265 270

Glu Glu Arg Met Lys Arg Arg Val Lys Gly Ser Arg Gly Trp Leu Arg
275 280 285

Leu Leu Asn Ser Gly Lys Arg Arg Met His Met Ile Ser Ser Arg Gln
290 295 300

His Val Gln Asp Glu Arg Glu Ile Val Asp Tyr Leu Val Arg Asn His
305 310 315 320

Gly Ser His Phe Val Val Thr Glu Leu Val Val Arg Ser Lys Glu Gly
325 330 335

Lys Leu Ala Asp Ser Ser Lys Pro Glu Arg Gly Gly Ser Leu Gly Leu
340 345 350

Asn Trp Ala Ala Gln Asn Thr Gly Ser Leu Ser Arg Leu Val Arg Gln
355 360 365

Leu Glu Glu Lys Val Lys Glu His Gly Gly Ser Val Arg Lys His Lys
370 375 380

Leu Thr Leu Thr Glu Ala Pro Pro Ala Arg Gly Ala Glu Asn Lys Leu
385 390 395 400

Trp Met Ala Arg Lys Leu Arg Glu Ser Phe Leu Lys Glu Val
405 410

<210> 34
<211> 413
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 34

```
Leu Ala Lys Asn Asp Glu Lys Glu Leu Leu Tyr Gln Ser Val Lys Phe
1               5                  10                  15

Glu Ile Tyr Pro Asp Glu Ser Lys Ile Arg Val Leu Thr Arg Val Ser
            20                  25                  30

Asn Ile Leu Val Leu Val Trp Asn Ser Ala Leu Gly Glu Arg Arg Ala
        35                  40                  45

Arg Phe Glu Leu Tyr Ile Ala Pro Leu Tyr Glu Glu Leu Lys Lys Phe
    50                  55                  60

Pro Arg Lys Ser Ala Glu Ser Asn Ala Leu Arg Gln Lys Ile Arg Glu
65                  70                  75                  80

Gly Tyr Lys Glu His Ile Pro Thr Phe Phe Asp Gln Leu Lys Lys Leu
                85                  90                  95

Leu Thr Pro Met Arg Lys Glu Asp Pro Ala Leu Leu Gly Ser Val Pro
            100                 105                 110

Arg Ala Tyr Gln Glu Glu Thr Leu Asn Thr Leu Asn Gly Ser Phe Val
        115                 120                 125

Ser Phe Met Thr Leu Arg Arg Asn Asn Asp Met Asp Ala Lys Pro Pro
    130                 135                 140

Lys Gly Arg Ala Glu Asp Arg Phe His Glu Ile Ser Gly Arg Ser Gly
145                 150                 155                 160

Phe Lys Ile Asp Gly Ser Glu Phe Val Leu Ser Thr Lys Glu Gln Lys
                165                 170                 175

Leu Arg Phe Pro Ile Pro Asn Tyr Gln Leu Glu Lys Leu Lys Glu Ala
            180                 185                 190
```

```
Lys Gln Ile Lys Lys Phe Thr Leu Tyr Gln Ser Arg Asp Arg Arg Phe
        195                 200                 205

Trp Ile Ser Ile Ala Tyr Glu Ile Glu Leu Pro Asp Gln Arg Pro Phe
    210                 215                 220

Asn Pro Glu Glu Val Ile Tyr Ile Ala Phe Gly Ala Ser Ser Ile Gly
225                 230                 235                 240

Val Ile Ser Pro Glu Gly Glu Lys Val Ile Asp Phe Trp Arg Pro Asp
                245                 250                 255

Lys His Trp Lys Pro Lys Ile Lys Glu Val Glu Asn Arg Met Arg Ser
            260                 265                 270

Cys Lys Lys Gly Ser Arg Ala Trp Lys Lys Arg Ala Ala Ala Arg Arg
        275                 280                 285

Lys Met Tyr Ala Met Thr Gln Arg Gln Gln Lys Leu Asn His Arg Glu
    290                 295                 300

Ile Val Ala Ser Leu Leu Arg Leu Gly Phe His Phe Val Val Thr Glu
305                 310                 315                 320

Tyr Thr Val Arg Ser Lys Pro Gly Lys Leu Ala Asp Gly Ser Asn Pro
                325                 330                 335

Lys Arg Gly Gly Ala Pro Gln Gly Phe Asn Trp Ser Ala Gln Asn Thr
            340                 345                 350

Gly Ser Phe Gly Glu Phe Ile Leu Trp Leu Lys Gln Lys Val Lys Glu
        355                 360                 365

Gln Gly Gly Thr Val Gln Thr Phe Arg Leu Val Leu Gly Gln Ser Glu
    370                 375                 380
```

```
Arg Pro Glu Lys Arg Gly Arg Asp Asn Lys Ile Glu Met Val Arg Leu
385                 390                 395                 400


Leu Arg Glu Lys Tyr Leu Glu Ser Gln Thr Ile Val Val
                405                 410


<210>  35
<211>  449
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  35

Met Ala Lys Gly Lys Lys Lys Glu Gly Lys Pro Leu Tyr Arg Ala Val
1               5                   10                  15


Arg Phe Glu Ile Phe Pro Thr Ser Asp Gln Ile Thr Leu Phe Leu Arg
            20                  25                  30


Val Ser Lys Asn Leu Gln Gln Val Trp Asn Glu Ala Trp Gln Glu Arg
        35                  40                  45


Gln Ser Cys Tyr Glu Gln Phe Phe Gly Ser Ile Tyr Glu Arg Ile Gly
    50                  55                  60


Gln Ala Lys Lys Arg Ala Gln Glu Ala Gly Phe Ser Glu Val Trp Glu
65                  70                  75                  80


Asn Glu Ala Lys Lys Gly Leu Asn Lys Lys Leu Arg Gln Gln Glu Ile
                85                  90                  95


Ser Met Gln Leu Val Ser Glu Lys Glu Ser Leu Leu Gln Glu Leu Ser
            100                 105                 110


Ile Ala Phe Gln Glu His Gly Val Thr Leu Tyr Asp Gln Ile Asn Gly
```

```
        115                 120                 125

Leu Thr Ala Arg Arg Ile Ile Gly Glu Phe Ala Leu Ile Pro Arg Asn
    130                 135                 140

Trp Gln Glu Glu Thr Leu Asp Ser Leu Asp Gly Ser Phe Lys Ser Phe
145                 150                 155                 160

Leu Ala Leu Arg Lys Asn Gly Asp Pro Asp Ala Lys Pro Pro Arg Gln
                165                 170                 175

Arg Val Ser Glu Asn Ser Phe Tyr Lys Ile Pro Gly Arg Ser Gly Phe
            180                 185                 190

Lys Val Ser Asn Gly Gln Ile Tyr Leu Ser Phe Gly Lys Ile Gly Gln
        195                 200                 205

Thr Leu Thr Ser Val Ile Pro Glu Phe Gln Leu Lys Arg Leu Glu Thr
    210                 215                 220

Ala Ile Lys Leu Lys Lys Phe Glu Leu Cys Arg Asp Glu Arg Asp Met
225                 230                 235                 240

Ala Lys Pro Gly Arg Phe Trp Ile Ser Val Ala Tyr Glu Ile Pro Lys
                245                 250                 255

Pro Glu Lys Val Pro Val Val Ser Lys Gln Ile Thr Tyr Leu Ala Ile
            260                 265                 270

Gly Ala Ser Arg Leu Gly Val Val Ser Pro Lys Gly Glu Phe Cys Leu
        275                 280                 285

Asn Leu Pro Arg Ser Asp Tyr His Trp Lys Pro Gln Ile Asn Ala Leu
    290                 295                 300

Gln Glu Arg Leu Glu Gly Val Val Lys Gly Ser Arg Lys Trp Lys Lys
```

305 310 315 320

Arg Met Ala Ala Cys Thr Arg Met Phe Ala Lys Leu Gly His Gln Gln
325 330 335

Lys Gln His Gly Gln Tyr Glu Val Val Lys Lys Leu Leu Arg His Gly
340 345 350

Val His Phe Val Val Thr Glu Leu Lys Val Arg Ser Lys Pro Gly Ala
355 360 365

Leu Ala Asp Ala Ser Lys Ser Asp Arg Lys Gly Ser Pro Thr Gly Pro
370 375 380

Asn Trp Ser Ala Gln Asn Thr Gly Asn Ile Ala Arg Leu Ile Gln Lys
385 390 395 400

Leu Thr Asp Lys Ala Ser Glu His Gly Gly Thr Val Ile Lys Arg Asn
405 410 415

Pro Pro Leu Leu Ser Leu Glu Glu Arg Gln Leu Pro Asp Ala Gln Arg
420 425 430

Lys Ile Phe Ile Ala Lys Lys Leu Arg Glu Glu Phe Leu Ala Asp Gln
435 440 445

Lys

<210> 36
<211> 711
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 36

```
Met Ala Lys Arg Glu Lys Lys Asp Asp Val Val Leu Arg Gly Thr Lys
1               5                  10                  15

Met Arg Ile Tyr Pro Thr Asp Arg Gln Val Thr Leu Met Asp Met Trp
            20                  25                  30

Arg Arg Arg Cys Ile Ser Leu Trp Asn Leu Leu Leu Asn Leu Glu Thr
        35                  40                  45

Ala Ala Tyr Gly Ala Lys Asn Thr Arg Ser Lys Leu Gly Trp Arg Ser
    50                  55                  60

Ile Trp Ala Arg Val Val Glu Glu Asn His Ala Lys Ala Leu Ile Val
65                  70                  75                  80

Tyr Gln His Gly Lys Cys Lys Lys Asp Gly Ser Phe Val Leu Lys Arg
                85                  90                  95

Asp Gly Thr Val Lys His Pro Pro Arg Glu Arg Phe Pro Gly Asp Arg
            100                 105                 110

Lys Ile Leu Leu Gly Leu Phe Asp Ala Leu Arg His Thr Leu Asp Lys
        115                 120                 125

Gly Ala Lys Cys Lys Cys Asn Val Asn Gln Pro Tyr Ala Leu Thr Arg
    130                 135                 140

Ala Trp Leu Asp Glu Thr Gly His Gly Ala Arg Thr Ala Asp Ile Ile
145                 150                 155                 160

Ala Trp Leu Lys Asp Phe Lys Gly Glu Cys Asp Cys Thr Ala Ile Ser
                165                 170                 175

Thr Ala Ala Lys Tyr Cys Pro Ala Pro Pro Thr Ala Glu Leu Leu Thr
            180                 185                 190
```

```
Lys Ile Lys Arg Ala Ala Pro Ala Asp Asp Leu Pro Val Asp Gln Ala
        195                 200                 205


Ile Leu Leu Asp Leu Phe Gly Ala Leu Arg Gly Gly Leu Lys Gln Lys
    210                 215                 220


Glu Cys Asp His Thr His Ala Arg Thr Val Ala Tyr Phe Glu Lys His
225                 230                 235                 240


Glu Leu Ala Gly Arg Ala Glu Asp Ile Leu Ala Trp Leu Ile Ala His
                245                 250                 255


Gly Gly Thr Cys Asp Cys Lys Ile Val Glu Glu Ala Ala Asn His Cys
            260                 265                 270


Pro Gly Pro Arg Leu Phe Ile Trp Glu His Glu Leu Ala Met Ile Met
        275                 280                 285


Ala Arg Leu Lys Ala Glu Pro Arg Thr Glu Trp Ile Gly Asp Leu Pro
    290                 295                 300


Ser His Ala Ala Gln Thr Val Val Lys Asp Leu Val Lys Ala Leu Gln
305                 310                 315                 320


Thr Met Leu Lys Glu Arg Ala Lys Ala Ala Ala Gly Asp Glu Ser Ala
                325                 330                 335


Arg Lys Thr Gly Phe Pro Lys Phe Lys Lys Gln Ala Tyr Ala Ala Gly
            340                 345                 350


Ser Val Tyr Phe Pro Asn Thr Thr Met Phe Phe Asp Val Ala Ala Gly
        355                 360                 365


Arg Val Gln Leu Pro Asn Gly Cys Gly Ser Met Arg Cys Glu Ile Pro
    370                 375                 380
```

```
Arg Gln Leu Val Ala Glu Leu Leu Glu Arg Asn Leu Lys Pro Gly Leu
385                 390                 395                 400


Val Ile Gly Ala Gln Leu Gly Leu Leu Gly Gly Arg Ile Trp Arg Gln
                405                 410                 415


Gly Asp Arg Trp Tyr Leu Ser Cys Gln Trp Glu Arg Pro Gln Pro Thr
            420                 425                 430


Leu Leu Pro Lys Thr Gly Arg Thr Ala Gly Val Lys Ile Ala Ala Ser
        435                 440                 445


Ile Val Phe Thr Thr Tyr Asp Asn Arg Gly Gln Thr Lys Glu Tyr Pro
    450                 455                 460


Met Pro Pro Ala Asp Lys Lys Leu Thr Ala Val His Leu Val Ala Gly
465                 470                 475                 480


Lys Gln Asn Ser Arg Ala Leu Glu Ala Gln Lys Glu Lys Glu Lys Lys
                485                 490                 495


Leu Lys Ala Arg Lys Glu Arg Leu Arg Leu Gly Lys Leu Glu Lys Gly
            500                 505                 510


His Asp Pro Asn Ala Leu Lys Pro Leu Lys Arg Pro Arg Val Arg Arg
        515                 520                 525


Ser Lys Leu Phe Tyr Lys Ser Ala Ala Arg Leu Ala Ala Cys Glu Ala
    530                 535                 540


Ile Glu Arg Asp Arg Arg Asp Gly Phe Leu His Arg Val Thr Asn Glu
545                 550                 555                 560


Ile Val His Lys Phe Asp Ala Val Ser Val Gln Lys Met Ser Val Ala
                565                 570                 575
```

```
Pro Met Met Arg Arg Gln Lys Gln Lys Glu Lys Gln Ile Glu Ser Lys
            580                 585                 590


Lys Asn Glu Ala Lys Lys Glu Asp Asn Gly Ala Ala Lys Lys Pro Arg
        595                 600                 605


Asn Leu Lys Pro Val Arg Lys Leu Leu Arg His Val Ala Met Ala Arg
    610                 615                 620


Gly Arg Gln Phe Leu Glu Tyr Lys Tyr Asn Asp Leu Arg Gly Pro Gly
625                 630                 635                 640


Ser Val Leu Ile Ala Asp Arg Leu Glu Pro Glu Val Gln Glu Cys Ser
                645                 650                 655


Arg Cys Gly Thr Lys Asn Pro Gln Met Lys Asp Gly Arg Arg Leu Leu
            660                 665                 670


Arg Cys Ile Gly Val Leu Pro Asp Gly Thr Asp Cys Asp Ala Val Leu
        675                 680                 685


Pro Arg Asn Arg Asn Ala Ala Arg Asn Ala Glu Lys Arg Leu Arg Lys
    690                 695                 700


His Arg Glu Ala His Asn Ala
705                 710
```

<210> 37
<211> 574
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 37

```
Met Asn Glu Val Leu Pro Ile Pro Ala Val Gly Glu Asp Ala Ala Asp
```

```
1               5                   10                  15

Thr Ile Met Arg Gly Ser Lys Met Arg Ile Tyr Pro Ser Val Arg Gln
            20                  25                  30

Ala Ala Thr Met Asp Leu Trp Arg Arg Arg Cys Ile Gln Leu Trp Asn
        35                  40                  45

Leu Leu Leu Glu Leu Glu Gln Ala Ala Tyr Ser Gly Glu Asn Arg Arg
    50                  55                  60

Thr Gln Ile Gly Trp Arg Ser Ile Trp Ala Thr Val Val Glu Asp Ser
65                  70                  75                  80

His Ala Glu Ala Val Arg Val Ala Arg Glu Gly Lys Lys Arg Lys Asp
                85                  90                  95

Gly Thr Phe Arg Lys Ala Pro Ser Gly Lys Glu Ile Pro Pro Leu Asp
            100                 105                 110

Pro Ala Met Leu Ala Lys Ile Gln Arg Gln Met Asn Gly Ala Val Asp
        115                 120                 125

Val Asp Pro Lys Thr Gly Glu Val Thr Pro Ala Gln Pro Arg Leu Phe
    130                 135                 140

Met Trp Glu His Glu Leu Gln Lys Ile Met Ala Arg Leu Lys Gln Ala
145                 150                 155                 160

Pro Arg Thr His Trp Ile Asp Asp Leu Pro Ser His Ala Ala Gln Ser
                165                 170                 175

Val Val Lys Asp Leu Ile Lys Ala Leu Gln Ala Met Leu Arg Glu Arg
            180                 185                 190

Lys Lys Arg Ala Ser Gly Ile Gly Gly Arg Asp Thr Gly Phe Pro Lys
```

```
        195                 200                 205

Phe Lys Lys Asn Arg Tyr Ala Ala Gly Ser Val Tyr Phe Ala Asn Thr
    210                 215                 220

Gln Leu Arg Phe Glu Ala Lys Arg Gly Lys Ala Gly Asp Pro Asp Ala
225                 230                 235                 240

Val Arg Gly Glu Phe Ala Arg Val Lys Leu Pro Asn Gly Val Gly Trp
                245                 250                 255

Met Glu Cys Arg Met Pro Arg His Ile Asn Ala Ala His Ala Tyr Ala
            260                 265                 270

Gln Ala Thr Leu Met Gly Gly Arg Ile Trp Arg Gln Gly Glu Asn Trp
        275                 280                 285

Tyr Leu Ser Cys Gln Trp Lys Met Pro Lys Pro Ala Pro Leu Pro Arg
    290                 295                 300

Ala Gly Arg Thr Ala Ala Ile Lys Ile Ala Ala Ala Ile Pro Ile Thr
305                 310                 315                 320

Thr Val Asp Asn Arg Gly Gln Thr Arg Glu Tyr Ala Met Pro Pro Ile
                325                 330                 335

Asp Arg Glu Arg Ile Ala Ala His Ala Ala Ala Gly Arg Ala Gln Ser
            340                 345                 350

Arg Ala Leu Glu Ala Arg Lys Arg Arg Ala Lys Lys Arg Glu Ala Tyr
        355                 360                 365

Ala Lys Lys Arg His Ala Lys Lys Leu Glu Arg Gly Ile Ala Ala Lys
    370                 375                 380

Pro Pro Gly Arg Ala Arg Ile Lys Leu Ser Pro Gly Phe Tyr Ala Ala
```

385 390 395 400

Ala Ala Lys Leu Ala Lys Leu Glu Ala Glu Asp Ala Asn Ala Arg Glu
405 410 415

Ala Trp Leu His Glu Ile Thr Thr Gln Ile Val Arg Asn Phe Asp Val
420 425 430

Ile Ala Val Pro Arg Met Glu Val Ala Lys Leu Met Lys Lys Pro Glu
435 440 445

Pro Pro Glu Glu Lys Glu Glu Gln Val Lys Ala Pro Trp Gln Gly Lys
450 455 460

Arg Arg Ser Leu Lys Ala Ala Arg Val Met Met Arg Arg Thr Ala Met
465 470 475 480

Ala Leu Ile Gln Thr Thr Leu Lys Tyr Lys Ala Val Asp Leu Arg Gly
485 490 495

Pro Gln Ala Tyr Glu Glu Ile Ala Pro Leu Asp Val Thr Ala Ala Ala
500 505 510

Cys Ser Gly Cys Gly Val Leu Lys Pro Glu Trp Lys Met Ala Arg Ala
515 520 525

Lys Gly Arg Glu Ile Met Arg Cys Gln Glu Pro Leu Pro Gly Gly Lys
530 535 540

Thr Cys Asn Thr Val Leu Thr Tyr Thr Arg Asn Ser Ala Arg Val Ile
545 550 555 560

Gly Arg Glu Leu Ala Val Arg Leu Ala Glu Arg Gln Lys Ala
565 570

<210> 38

<211> 400
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 38

Met Thr Thr Gln Lys Thr Tyr Asn Phe Cys Phe Tyr Asp Gln Arg Phe
1 5 10 15

Phe Glu Leu Ser Lys Glu Ala Gly Glu Val Tyr Ser Arg Ser Leu Glu
20 25 30

Glu Phe Trp Lys Ile Tyr Asp Glu Thr Gly Val Trp Leu Ser Lys Phe
35 40 45

Asp Leu Gln Lys His Met Arg Asn Lys Leu Glu Arg Lys Leu Leu His
50 55 60

Ser Asp Ser Phe Leu Gly Ala Met Gln Gln Val His Ala Asn Leu Ala
65 70 75 80

Ser Trp Lys Gln Ala Lys Lys Val Val Pro Asp Ala Cys Pro Pro Arg
85 90 95

Lys Pro Lys Phe Leu Gln Ala Ile Leu Phe Lys Lys Ser Gln Ile Lys
100 105 110

Tyr Lys Asn Gly Phe Leu Arg Leu Thr Leu Gly Thr Glu Lys Glu Phe
115 120 125

Leu Tyr Leu Lys Trp Asp Ile Asn Ile Pro Leu Pro Ile Tyr Gly Ser
130 135 140

Val Thr Tyr Ser Lys Thr Arg Gly Trp Lys Ile Asn Leu Cys Leu Glu
145 150 155 160

```
Thr Glu Val Glu Gln Lys Asn Leu Ser Glu Asn Lys Tyr Leu Ser Ile
                165                 170                 175

Asp Leu Gly Val Lys Arg Val Ala Thr Ile Phe Asp Gly Glu Asn Thr
            180                 185                 190

Ile Thr Leu Ser Gly Lys Lys Phe Met Gly Leu Met His Tyr Arg Asn
        195                 200                 205

Lys Leu Asn Gly Lys Thr Gln Ser Arg Leu Ser His Lys Lys Lys Gly
    210                 215                 220

Ser Asn Asn Tyr Lys Lys Ile Gln Arg Ala Lys Arg Lys Thr Thr Asp
225                 230                 235                 240

Arg Leu Leu Asn Ile Gln Lys Glu Met Leu His Lys Tyr Ser Ser Phe
                245                 250                 255

Ile Val Asn Tyr Ala Ile Arg Asn Asp Ile Gly Asn Ile Ile Ile Gly
            260                 265                 270

Asp Asn Ser Ser Thr His Asp Ser Pro Asn Met Arg Gly Lys Thr Asn
        275                 280                 285

Gln Lys Ile Ser Gln Asn Pro Glu Gln Lys Leu Lys Asn Tyr Ile Lys
    290                 295                 300

Tyr Lys Phe Glu Ser Ile Ser Gly Arg Val Asp Ile Val Pro Glu Pro
305                 310                 315                 320

Tyr Thr Ser Arg Lys Cys Pro His Cys Lys Asn Ile Lys Lys Ser Ser
                325                 330                 335

Pro Lys Gly Arg Thr Tyr Lys Cys Lys Lys Cys Gly Phe Ile Phe Asp
            340                 345                 350
```

Arg Asp Gly Val Gly Ala Ile Asn Ile Tyr Asn Glu Asn Val Ser Phe
355 360 365

Gly Gln Ile Ile Ser Pro Gly Arg Ile Arg Ser Leu Thr Glu Pro Ile
370 375 380

Gly Met Lys Phe His Asn Glu Ile Tyr Phe Lys Ser Tyr Val Ala Ala
385 390 395 400

<210> 39
<211> 743
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 39

Met Ser Val Arg Ser Phe Gln Ala Arg Val Glu Cys Asp Lys Gln Thr
1 5 10 15

Met Glu His Leu Trp Arg Thr His Lys Val Phe Asn Glu Arg Leu Pro
20 25 30

Glu Ile Ile Lys Ile Leu Phe Lys Met Lys Arg Gly Glu Cys Gly Gln
35 40 45

Asn Asp Lys Gln Lys Ser Leu Tyr Lys Ser Ile Ser Gln Ser Ile Leu
50 55 60

Glu Ala Asn Ala Gln Asn Ala Asp Tyr Leu Leu Asn Ser Val Ser Ile
65 70 75 80

Lys Gly Trp Lys Pro Gly Thr Ala Lys Lys Tyr Arg Asn Ala Ser Phe
85 90 95

Thr Trp Ala Asp Asp Ala Ala Lys Leu Ser Ser Gln Gly Ile His Val

```
            100                 105                 110

Tyr Asp Lys Lys Gln Val Leu Gly Asp Leu Pro Gly Met Met Ser Gln
        115                 120                 125

Met Val Cys Arg Gln Ser Val Glu Ala Ile Ser Gly His Ile Glu Leu
    130                 135                 140

Thr Lys Lys Trp Glu Lys Glu His Asn Glu Trp Leu Lys Glu Lys Glu
145                 150                 155                 160

Lys Trp Glu Ser Glu Asp Glu His Lys Lys Tyr Leu Asp Leu Arg Glu
                165                 170                 175

Lys Phe Glu Gln Phe Glu Gln Ser Ile Gly Gly Lys Ile Thr Lys Arg
            180                 185                 190

Arg Gly Arg Trp His Leu Tyr Leu Lys Trp Leu Ser Asp Asn Pro Asp
        195                 200                 205

Phe Ala Ala Trp Arg Gly Asn Lys Ala Val Ile Asn Pro Leu Ser Glu
    210                 215                 220

Lys Ala Gln Ile Arg Ile Asn Lys Ala Lys Pro Asn Lys Lys Asn Ser
225                 230                 235                 240

Val Glu Arg Asp Glu Phe Phe Lys Ala Asn Pro Glu Met Lys Ala Leu
                245                 250                 255

Asp Asn Leu His Gly Tyr Tyr Glu Arg Asn Phe Val Arg Arg Arg Lys
            260                 265                 270

Thr Lys Lys Asn Pro Asp Gly Phe Asp His Lys Pro Thr Phe Thr Leu
        275                 280                 285

Pro His Pro Thr Ile His Pro Arg Trp Phe Val Phe Asn Lys Pro Lys
```

```
    290                 295                 300

Thr Asn Pro Glu Gly Tyr Arg Lys Leu Ile Leu Pro Lys Lys Ala Gly
305                 310                 315                 320

Asp Leu Gly Ser Leu Glu Met Arg Leu Leu Thr Gly Glu Lys Asn Lys
                325                 330                 335

Gly Asn Tyr Pro Asp Asp Trp Ile Ser Val Lys Phe Lys Ala Asp Pro
            340                 345                 350

Arg Leu Ser Leu Ile Arg Pro Val Lys Gly Arg Arg Val Val Arg Lys
        355                 360                 365

Gly Lys Glu Gln Gly Gln Thr Lys Glu Thr Asp Ser Tyr Glu Phe Phe
    370                 375                 380

Asp Lys His Leu Lys Lys Trp Arg Pro Ala Lys Leu Ser Gly Val Lys
385                 390                 395                 400

Leu Ile Phe Pro Asp Lys Thr Pro Lys Ala Ala Tyr Leu Tyr Phe Thr
                405                 410                 415

Cys Asp Ile Pro Asp Glu Pro Leu Thr Glu Thr Ala Lys Lys Ile Gln
            420                 425                 430

Trp Leu Glu Thr Gly Asp Val Thr Lys Lys Gly Lys Lys Arg Lys Lys
        435                 440                 445

Lys Val Leu Pro His Gly Leu Val Ser Cys Ala Val Asp Leu Ser Met
    450                 455                 460

Arg Arg Gly Thr Thr Gly Phe Ala Thr Leu Cys Arg Tyr Glu Asn Gly
465                 470                 475                 480

Lys Ile His Ile Leu Arg Ser Arg Asn Leu Trp Val Gly Tyr Lys Glu
```

485 490 495

Gly Lys Gly Cys His Pro Tyr Arg Trp Thr Glu Gly Pro Asp Leu Gly
500 505 510

His Ile Ala Lys His Lys Arg Glu Ile Arg Ile Leu Arg Ser Lys Arg
515 520 525

Gly Lys Pro Val Lys Gly Glu Glu Ser His Ile Asp Leu Gln Lys His
530 535 540

Ile Asp Tyr Met Gly Glu Asp Arg Phe Lys Lys Ala Ala Arg Thr Ile
545 550 555 560

Val Asn Phe Ala Leu Asn Thr Glu Asn Ala Ala Ser Lys Asn Gly Phe
565 570 575

Tyr Pro Arg Ala Asp Val Leu Leu Leu Glu Asn Leu Glu Gly Leu Ile
580 585 590

Pro Asp Ala Glu Lys Glu Arg Gly Ile Asn Arg Ala Leu Ala Gly Trp
595 600 605

Asn Arg Arg His Leu Val Glu Arg Val Ile Glu Met Ala Lys Asp Ala
610 615 620

Gly Phe Lys Arg Arg Val Phe Glu Ile Pro Pro Tyr Gly Thr Ser Gln
625 630 635 640

Val Cys Ser Lys Cys Gly Ala Leu Gly Arg Arg Tyr Ser Ile Ile Arg
645 650 655

Glu Asn Asn Arg Arg Glu Ile Arg Phe Gly Tyr Val Glu Lys Leu Phe
660 665 670

Ala Cys Pro Asn Cys Gly Tyr Cys Ala Asn Ala Asp His Asn Ala Ser

675 680 685

Val Asn Leu Asn Arg Arg Phe Leu Ile Glu Asp Ser Phe Lys Ser Tyr
690 695 700

Tyr Asp Trp Lys Arg Leu Ser Glu Lys Lys Gln Lys Glu Glu Ile Glu
705 710 715 720

Thr Ile Glu Ser Lys Leu Met Asp Lys Leu Cys Ala Met His Lys Ile
725 730 735

Ser Arg Gly Ser Ile Ser Lys
740

<210> 40
<211> 769
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 40

Met His Leu Trp Arg Thr His Cys Val Phe Asn Gln Arg Leu Pro Ala
1 5 10 15

Leu Leu Lys Arg Leu Phe Ala Met Arg Arg Gly Glu Val Gly Gly Asn
20 25 30

Glu Ala Gln Arg Gln Val Tyr Gln Arg Val Ala Gln Phe Val Leu Ala
35 40 45

Arg Asp Ala Lys Asp Ser Val Asp Leu Leu Asn Ala Val Ser Leu Arg
50 55 60

Lys Arg Ser Ala Asn Ser Ala Phe Lys Lys Lys Ala Thr Ile Ser Cys
65 70 75 80

```
Asn Gly Gln Ala Arg Glu Val Thr Gly Glu Glu Val Phe Ala Glu Ala
                85                  90                  95

Val Ala Leu Ala Ser Lys Gly Val Phe Ala Tyr Asp Lys Asp Asp Met
            100                 105                 110

Arg Ala Gly Leu Pro Asp Ser Leu Phe Gln Pro Leu Thr Arg Asp Ala
        115                 120                 125

Val Ala Cys Met Arg Ser His Glu Glu Leu Val Ala Thr Trp Lys Lys
    130                 135                 140

Glu Tyr Arg Glu Trp Arg Asp Arg Lys Ser Glu Trp Glu Ala Glu Pro
145                 150                 155                 160

Glu His Ala Leu Tyr Leu Asn Leu Arg Pro Lys Phe Glu Glu Gly Glu
                165                 170                 175

Ala Ala Arg Gly Gly Arg Phe Arg Lys Arg Ala Glu Arg Asp His Ala
            180                 185                 190

Tyr Leu Asp Trp Leu Glu Ala Asn Pro Gln Leu Ala Ala Trp Arg Arg
        195                 200                 205

Lys Ala Pro Pro Ala Val Val Pro Ile Asp Glu Ala Gly Lys Arg Arg
    210                 215                 220

Ile Ala Arg Ala Lys Ala Trp Lys Gln Ala Ser Val Arg Ala Glu Glu
225                 230                 235                 240

Phe Trp Lys Arg Asn Pro Glu Leu His Ala Leu His Lys Ile His Val
                245                 250                 255

Gln Tyr Leu Arg Glu Phe Val Arg Pro Arg Arg Thr Arg Arg Asn Lys
            260                 265                 270
```

```
Arg Arg Glu Gly Phe Lys Gln Arg Pro Thr Phe Thr Met Pro Asp Pro
        275                 280                 285

Val Arg His Pro Arg Trp Cys Leu Phe Asn Ala Pro Gln Thr Ser Pro
    290                 295                 300

Gln Gly Tyr Arg Leu Leu Arg Leu Pro Gln Ser Arg Arg Thr Val Gly
305                 310                 315                 320

Ser Val Glu Leu Arg Leu Leu Thr Gly Pro Ser Asp Gly Ala Gly Phe
                325                 330                 335

Pro Asp Ala Trp Val Asn Val Arg Phe Lys Ala Asp Pro Arg Leu Ala
            340                 345                 350

Gln Leu Arg Pro Val Lys Val Pro Arg Thr Val Thr Arg Gly Lys Asn
        355                 360                 365

Lys Gly Ala Lys Val Glu Ala Asp Gly Phe Arg Tyr Tyr Asp Asp Gln
    370                 375                 380

Leu Leu Ile Glu Arg Asp Ala Gln Val Ser Gly Val Lys Leu Leu Phe
385                 390                 395                 400

Arg Asp Ile Arg Met Ala Pro Phe Ala Asp Lys Pro Ile Glu Asp Arg
                405                 410                 415

Leu Leu Ser Ala Thr Pro Tyr Leu Val Phe Ala Val Glu Ile Lys Asp
            420                 425                 430

Glu Ala Arg Thr Glu Arg Ala Lys Ala Ile Arg Phe Asp Glu Thr Ser
        435                 440                 445

Glu Leu Thr Lys Ser Gly Lys Lys Arg Lys Thr Leu Pro Ala Gly Leu
    450                 455                 460
```

```
Val Ser Val Ala Val Asp Leu Asp Thr Arg Gly Val Gly Phe Leu Thr
465                 470                 475                 480


Arg Ala Val Ile Gly Val Pro Glu Ile Gln Gln Thr His His Gly Val
                485                 490                 495


Arg Leu Leu Gln Ser Arg Tyr Val Ala Val Gly Gln Val Glu Ala Arg
            500                 505                 510


Ala Ser Gly Glu Ala Glu Trp Ser Pro Gly Pro Asp Leu Ala His Ile
        515                 520                 525


Ala Arg His Lys Arg Glu Ile Arg Arg Leu Arg Gln Leu Arg Gly Lys
    530                 535                 540


Pro Val Lys Gly Glu Arg Ser His Val Arg Leu Gln Ala His Ile Asp
545                 550                 555                 560


Arg Met Gly Glu Asp Arg Phe Lys Lys Ala Ala Arg Lys Ile Val Asn
                565                 570                 575


Glu Ala Leu Arg Gly Ser Asn Pro Ala Ala Gly Asp Pro Tyr Thr Arg
            580                 585                 590


Ala Asp Val Leu Leu Tyr Glu Ser Leu Glu Thr Leu Leu Pro Asp Ala
        595                 600                 605


Glu Arg Glu Arg Gly Ile Asn Arg Ala Leu Leu Arg Trp Asn Arg Ala
    610                 615                 620


Lys Leu Ile Glu His Leu Lys Arg Met Cys Asp Asp Ala Gly Ile Arg
625                 630                 635                 640


His Phe Pro Val Ser Pro Phe Gly Thr Ser Gln Val Cys Ser Lys Cys
                645                 650                 655
```

Gly Ala Leu Gly Arg Arg Tyr Ser Leu Ala Arg Glu Asn Gly Arg Ala
660 665 670

Val Ile Arg Phe Gly Trp Val Glu Arg Leu Phe Ala Cys Pro Asn Pro
675 680 685

Glu Cys Pro Gly Arg Arg Pro Asp Arg Pro Asp Arg Pro Phe Thr Cys
690 695 700

Asn Ser Asp His Asn Ala Ser Val Asn Leu His Arg Val Phe Ala Leu
705 710 715 720

Gly Asp Gln Ala Val Ala Ala Phe Arg Ala Leu Ala Pro Arg Asp Ser
725 730 735

Pro Ala Arg Thr Leu Ala Val Lys Arg Val Glu Asp Thr Leu Arg Pro
740 745 750

Gln Leu Met Arg Val His Lys Leu Ala Asp Ala Gly Val Asp Ser Pro
755 760 765

Phe

<210> 41
<211> 666
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 41

Met Ala Thr Leu Val Tyr Arg Tyr Gly Val Arg Ala His Gly Ser Ala
1 5 10 15

Arg Gln Gln Asp Ala Val Val Ser Asp Pro Ala Met Leu Glu Gln Leu

```
            20                  25                  30

Arg Leu Gly His Glu Leu Arg Asn Ala Leu Val Gly Val Gln His Arg
        35                  40                  45

Tyr Glu Asp Gly Lys Arg Ala Val Trp Ser Gly Phe Ala Ser Val Ala
    50                  55                  60

Ala Ala Asp His Arg Val Thr Thr Gly Glu Thr Ala Val Ala Glu Leu
65                  70                  75                  80

Glu Lys Gln Ala Arg Ala Glu His Ser Ala Asp Arg Thr Ala Ala Thr
                85                  90                  95

Arg Gln Gly Thr Ala Glu Ser Leu Lys Ala Ala Arg Ala Ala Val Lys
            100                 105                 110

Gln Ala Arg Ala Asp Arg Lys Ala Ala Met Ala Ala Val Ala Glu Gln
        115                 120                 125

Ala Lys Pro Lys Ile Gln Ala Leu Gly Asp Asp Arg Asp Ala Glu Ile
    130                 135                 140

Lys Asp Leu Tyr Arg Arg Phe Cys Gln Asp Gly Val Leu Leu Pro Arg
145                 150                 155                 160

Cys Gly Arg Cys Ala Gly Asp Leu Arg Ser Asp Gly Asp Cys Thr Asp
                165                 170                 175

Cys Gly Ala Ala His Glu Pro Arg Lys Leu Tyr Trp Ala Thr Tyr Asn
            180                 185                 190

Ala Ile Arg Glu Asp His Gln Thr Ala Val Lys Leu Val Glu Ala Lys
        195                 200                 205

Arg Lys Ala Gly Gln Pro Ala Arg Leu Arg Phe Arg Arg Trp Thr Gly
```

```
    210                 215                 220

Asp Gly Thr Leu Thr Val Gln Leu Gln Arg Met His Gly Pro Ala Cys
225                 230                 235                 240

Arg Cys Val Thr Cys Ala Glu Lys Leu Thr Arg Arg Ala Arg Lys Thr
                245                 250                 255

Asp Pro Gln Ala Pro Ala Val Ala Ala Asp Pro Ala Tyr Pro Pro Thr
            260                 265                 270

Asp Pro Pro Arg Asp Pro Ala Leu Leu Ala Ser Gly Gln Gly Lys Trp
        275                 280                 285

Arg Asn Val Leu Gln Leu Gly Thr Trp Ile Pro Pro Gly Glu Trp Ser
    290                 295                 300

Ala Met Ser Arg Ala Glu Arg Arg Arg Val Gly Arg Ser His Ile Gly
305                 310                 315                 320

Trp Gln Leu Gly Gly Gly Arg Gln Leu Thr Leu Pro Val Gln Leu His
                325                 330                 335

Arg Gln Met Pro Ala Asp Ala Asp Val Ala Met Ala Gln Leu Thr Arg
            340                 345                 350

Val Arg Val Gly Gly Arg His Arg Met Ser Val Ala Leu Thr Ala Lys
        355                 360                 365

Leu Pro Asp Pro Pro Gln Val Gln Gly Leu Pro Pro Val Ala Leu His
    370                 375                 380

Leu Gly Trp Arg Gln Arg Pro Asp Gly Ser Leu Arg Val Ala Thr Trp
385                 390                 395                 400

Ala Cys Pro Gln Pro Leu Asp Leu Pro Pro Ala Val Ala Asp Val Val
```

405 410 415

Val Ser His Gly Gly Arg Trp Gly Glu Val Ile Met Pro Ala Arg Trp
420 425 430

Leu Ala Asp Ala Glu Val Pro Pro Arg Leu Leu Gly Arg Arg Asp Lys
435 440 445

Ala Met Glu Pro Val Leu Glu Ala Leu Ala Asp Trp Leu Glu Ala His
450 455 460

Thr Glu Ala Cys Thr Ala Arg Met Thr Pro Ala Leu Val Arg Arg Trp
465 470 475 480

Arg Ser Gln Gly Arg Leu Ala Gly Leu Thr Asn Arg Trp Arg Gly Gln
485 490 495

Pro Pro Thr Gly Ser Ala Glu Ile Leu Thr Tyr Leu Glu Ala Trp Arg
500 505 510

Ile Gln Asp Lys Leu Leu Trp Glu Arg Glu Ser His Leu Arg Arg Arg
515 520 525

Leu Ala Ala Arg Arg Asp Asp Ala Trp Arg Arg Val Ala Ser Trp Leu
530 535 540

Ala Arg His Ala Gly Val Leu Val Val Asp Asp Ala Asp Ile Ala Glu
545 550 555 560

Leu Arg Arg Arg Asp Asp Pro Ala Asp Thr Asp Pro Thr Met Pro Ala
565 570 575

Ser Ala Ala Gln Ala Ala Arg Ala Arg Ala Ala Leu Ala Ala Pro Gly
580 585 590

Arg Leu Arg His Leu Ala Thr Ile Thr Ala Thr Arg Asp Gly Leu Gly

595 600 605

Val His Thr Val Ala Ser Ala Gly Leu Thr Arg Leu His Arg Lys Cys
610 615 620

Gly His Gln Ala Gln Pro Asp Pro Arg Tyr Ala Ala Ser Ala Val Val
625 630 635 640

Thr Cys Pro Gly Cys Gly Asn Gly Tyr Asp Gln Asp Tyr Asn Ala Ala
645 650 655

Met Leu Met Leu Asp Arg Gln Gln Gln Pro
660 665

<210> 42
<211> 564
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 42

Met Ser Arg Val Glu Leu His Arg Ala Tyr Lys Phe Arg Leu Tyr Pro
1 5 10 15

Thr Pro Ala Gln Val Ala Glu Leu Ala Glu Trp Glu Arg Gln Leu Arg
20 25 30

Arg Leu Tyr Asn Leu Ala His Ser Gln Arg Leu Ala Ala Met Gln Arg
35 40 45

His Val Arg Pro Lys Ser Pro Gly Val Leu Lys Ser Glu Cys Leu Ser
50 55 60

Cys Gly Ala Val Ala Val Ala Glu Ile Gly Thr Asp Gly Lys Ala Lys
65 70 75 80

```
Lys Thr Val Lys His Ala Val Gly Cys Ser Val Leu Glu Cys Arg Ser
                85                  90                  95

Cys Gly Gly Ser Pro Asp Ala Glu Gly Arg Thr Ala His Thr Ala Ala
            100                 105                 110

Cys Ser Phe Val Asp Tyr Tyr Arg Gln Gly Arg Glu Met Thr Gln Leu
        115                 120                 125

Leu Glu Glu Asp Asp Gln Leu Ala Arg Val Val Cys Ser Ala Arg Gln
    130                 135                 140

Glu Thr Leu Arg Asp Leu Glu Lys Ala Trp Gln Arg Trp His Lys Met
145                 150                 155                 160

Pro Gly Phe Gly Lys Pro His Phe Lys Lys Arg Ile Asp Ser Cys Arg
                165                 170                 175

Ile Tyr Phe Ser Thr Pro Lys Ser Trp Ala Val Asp Leu Gly Tyr Leu
            180                 185                 190

Ser Phe Thr Gly Val Ala Ser Ser Val Gly Arg Ile Lys Ile Arg Gln
        195                 200                 205

Asp Arg Val Trp Pro Gly Asp Ala Lys Phe Ser Ser Cys His Val Val
    210                 215                 220

Arg Asp Val Asp Glu Trp Tyr Ala Val Phe Pro Leu Thr Phe Thr Lys
225                 230                 235                 240

Glu Ile Glu Lys Pro Lys Gly Gly Ala Val Gly Ile Asn Arg Gly Ala
                245                 250                 255

Val His Ala Ile Ala Asp Ser Thr Gly Arg Val Val Asp Ser Pro Lys
            260                 265                 270
```

```
Phe Tyr Ala Arg Ser Leu Gly Val Ile Arg His Arg Ala Arg Leu Leu
        275                 280                 285

Asp Arg Lys Val Pro Phe Gly Arg Ala Val Lys Pro Ser Pro Thr Lys
    290                 295                 300

Tyr His Gly Leu Pro Lys Ala Asp Ile Asp Ala Ala Ala Ala Arg Val
305                 310                 315                 320

Asn Ala Ser Pro Gly Arg Leu Val Tyr Glu Ala Arg Ala Arg Gly Ser
                325                 330                 335

Ile Ala Ala Ala Glu Ala His Leu Ala Ala Leu Val Leu Pro Ala Pro
            340                 345                 350

Arg Gln Thr Ser Gln Leu Pro Ser Glu Gly Arg Asn Arg Glu Arg Ala
        355                 360                 365

Arg Arg Phe Leu Ala Leu Ala His Gln Arg Val Arg Arg Gln Arg Glu
    370                 375                 380

Trp Phe Leu His Asn Glu Ser Ala His Tyr Ala Gln Ser Tyr Thr Lys
385                 390                 395                 400

Ile Ala Ile Glu Asp Trp Ser Thr Lys Glu Met Thr Ser Ser Glu Pro
                405                 410                 415

Arg Asp Ala Glu Glu Met Lys Arg Val Thr Arg Ala Arg Asn Arg Ser
            420                 425                 430

Ile Leu Asp Val Gly Trp Tyr Glu Leu Gly Arg Gln Ile Ala Tyr Lys
        435                 440                 445

Ser Glu Ala Thr Gly Ala Glu Phe Ala Lys Val Asp Pro Gly Leu Arg
    450                 455                 460
```

```
Glu Thr Glu Thr His Val Pro Glu Ala Ile Val Arg Glu Arg Asp Val
465                 470                 475                 480


Asp Val Ser Gly Met Leu Arg Gly Glu Ala Gly Ile Ser Gly Thr Cys
                485                 490                 495


Ser Arg Cys Gly Gly Leu Leu Arg Ala Ser Ala Ser Gly His Ala Asp
            500                 505                 510


Ala Glu Cys Glu Val Cys Leu His Val Glu Val Gly Asp Val Asn Ala
        515                 520                 525


Ala Val Asn Val Leu Lys Arg Ala Met Phe Pro Gly Ala Ala Pro Pro
    530                 535                 540


Ser Lys Glu Lys Ala Lys Val Thr Ile Gly Ile Lys Gly Arg Lys Lys
545                 550                 555                 560


Lys Arg Ala Ala



<210>  43
<211>  565
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  43

Met Ser Arg Val Glu Leu His Arg Ala Tyr Lys Phe Arg Leu Tyr Pro
1               5                   10                  15


Thr Pro Val Gln Val Ala Glu Leu Ser Glu Trp Glu Arg Gln Leu Arg
            20                  25                  30


Arg Leu Tyr Asn Leu Gly His Glu Gln Arg Leu Leu Thr Leu Thr Arg
```

```
        35                  40                  45

His Leu Arg Pro Lys Ser Pro Gly Val Leu Lys Gly Glu Cys Leu Ser
    50                  55                  60

Cys Asp Ser Thr Gln Val Gln Glu Val Gly Ala Asp Gly Arg Pro Lys
65                  70                  75                  80

Thr Thr Val Arg His Ala Glu Gln Cys Pro Thr Leu Ala Cys Arg Ser
                85                  90                  95

Cys Gly Ala Leu Arg Asp Ala Glu Gly Arg Thr Ala His Thr Val Ala
            100                 105                 110

Cys Ala Phe Val Asp Tyr Tyr Arg Gln Gly Arg Glu Met Thr Glu Leu
        115                 120                 125

Leu Ala Ala Asp Asp Gln Leu Ala Arg Val Val Cys Ser Ala Arg Gln
    130                 135                 140

Glu Val Leu Arg Asp Leu Asp Lys Ala Trp Gln Arg Trp Arg Lys Met
145                 150                 155                 160

Pro Gly Phe Gly Lys Pro Arg Phe Lys Arg Arg Thr Asp Ser Cys Arg
                165                 170                 175

Ile Tyr Phe Ser Thr Pro Lys Ala Trp Lys Leu Glu Gly Gly His Leu
            180                 185                 190

Ser Phe Thr Gly Ala Ala Thr Thr Val Gly Ala Ile Lys Met Arg Gln
        195                 200                 205

Asp Arg Asn Trp Pro Ala Ser Val Gln Phe Ser Ser Cys His Val Val
    210                 215                 220

Arg Asp Val Asp Glu Trp Tyr Ala Val Phe Pro Leu Thr Phe Val Ala
```

225 230 235 240

Glu Val Ala Arg Pro Lys Gly Gly Ala Val Gly Ile Asn Arg Gly Ala
245 250 255

Val His Ala Ile Ala Asp Ser Thr Gly Arg Val Val Asp Ser Pro Arg
260 265 270

Tyr Tyr Ala Arg Ala Leu Gly Val Ile Arg His Arg Ala Arg Leu Phe
275 280 285

Asp Arg Lys Val Pro Ser Gly His Ala Val Lys Pro Ser Pro Thr Lys
290 295 300

Tyr Arg Gly Leu Ser Ala Ile Glu Val Asp Arg Val Ala Arg Ala Thr
305 310 315 320

Gly Phe Thr Pro Gly Arg Val Val Thr Glu Ala Leu Asn Arg Gly Gly
325 330 335

Val Ala Tyr Ala Glu Cys Ala Leu Ala Ala Ile Ala Val Leu Gly His
340 345 350

Gly Pro Glu Arg Pro Leu Thr Ser Asp Gly Arg Asn Arg Glu Lys Ala
355 360 365

Arg Lys Phe Leu Ala Leu Ala His Gln Arg Val Arg Arg Gln Arg Glu
370 375 380

Trp Phe Leu His Asn Glu Ser Ala His Tyr Ala Arg Thr Tyr Ser Lys
385 390 395 400

Ile Ala Ile Glu Asp Trp Ser Thr Lys Glu Met Thr Ala Ser Glu Pro
405 410 415

Gln Gly Glu Glu Thr Arg Arg Val Thr Arg Ser Arg Asn Arg Ser Ile

```
            420                 425                 430

Leu Asp Val Gly Trp Tyr Glu Leu Gly Arg Gln Leu Ala Tyr Lys Thr
        435                 440                 445

Glu Ala Thr Gly Ala Glu Phe Ala Gln Val Asp Pro Gly Leu Lys Glu
    450                 455                 460

Thr Glu Thr Asn Val Pro Lys Ala Ile Ala Asp Ala Arg Asp Val Asp
465                 470                 475                 480

Val Ser Gly Met Leu Arg Gly Glu Ala Gly Ile Ser Gly Thr Cys Ser
                485                 490                 495

Lys Cys Gly Gly Leu Leu Arg Ala Pro Ala Ser Gly His Ala Asp Ala
            500                 505                 510

Glu Cys Glu Ile Cys Leu Asn Val Glu Val Gly Asp Val Asn Ala Ala
        515                 520                 525

Val Asn Val Leu Lys Arg Ala Met Phe Pro Gly Asp Ala Pro Pro Ala
    530                 535                 540

Ser Gly Glu Lys Pro Lys Val Ser Ile Gly Ile Lys Gly Arg Gln Lys
545                 550                 555                 560

Lys Lys Lys Ala Ala
                565
```

<210> 44
<211> 499
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 44

```
Met Glu Ala Ile Ala Thr Gly Met Ser Pro Glu Arg Arg Val Glu Leu
1               5                  10                  15

Gly Ile Leu Pro Gly Ser Val Glu Leu Lys Arg Ala Tyr Lys Phe Arg
            20                  25                  30

Leu Tyr Pro Met Lys Val Gln Gln Ala Glu Leu Ser Glu Trp Glu Arg
        35                  40                  45

Gln Leu Arg Arg Leu Tyr Asn Leu Ala His Glu Gln Arg Leu Ala Ala
    50                  55                  60

Leu Leu Arg Tyr Arg Asp Trp Asp Phe Gln Lys Gly Ala Cys Pro Ser
65                  70                  75                  80

Cys Arg Val Ala Val Pro Gly Val His Thr Ala Ala Cys Asp His Val
                85                  90                  95

Asp Tyr Phe Arg Gln Ala Arg Glu Met Thr Gln Leu Leu Glu Val Asp
            100                 105                 110

Ala Gln Leu Ser Arg Val Ile Cys Cys Ala Arg Gln Glu Val Leu Arg
        115                 120                 125

Asp Leu Asp Lys Ala Trp Gln Arg Trp Arg Lys Lys Leu Gly Gly Arg
    130                 135                 140

Pro Arg Phe Lys Arg Arg Thr Asp Ser Cys Arg Ile Tyr Leu Ser Thr
145                 150                 155                 160

Pro Lys His Trp Glu Ile Ala Gly Arg Tyr Leu Arg Leu Ser Gly Leu
                165                 170                 175

Ala Ser Ser Val Gly Glu Ile Arg Ile Glu Gln Asp Arg Ala Phe Pro
            180                 185                 190
```

```
Glu Gly Ala Leu Leu Ser Ser Cys Ser Ile Val Arg Asp Val Asp Glu
        195                 200                 205

Trp Tyr Ala Cys Leu Pro Leu Thr Phe Thr Gln Pro Ile Glu Arg Ala
    210                 215                 220

Pro His Arg Ser Val Gly Leu Asn Arg Gly Val Val His Ala Leu Ala
225                 230                 235                 240

Asp Ser Asp Gly Arg Val Val Asp Ser Pro Lys Phe Phe Glu Arg Ala
                245                 250                 255

Leu Ala Thr Val Gln Lys Arg Ser Arg Asp Leu Ala Arg Lys Val Ser
            260                 265                 270

Gly Ser Arg Asn Ala His Lys Ala Arg Ile Lys Leu Ala Lys Ala His
        275                 280                 285

Gln Arg Val Arg Arg Gln Arg Ala Ala Phe Leu His Gln Glu Ser Ala
    290                 295                 300

Tyr Tyr Ser Lys Gly Phe Asp Leu Val Ala Leu Glu Asp Met Ser Val
305                 310                 315                 320

Arg Lys Met Thr Ala Thr Ala Gly Glu Ala Pro Glu Met Gly Arg Gly
                325                 330                 335

Ala Gln Arg Asp Leu Asn Arg Gly Ile Leu Asp Val Gly Trp Tyr Glu
            340                 345                 350

Leu Ala Arg Gln Ile Asp Tyr Lys Arg Leu Ala His Gly Gly Glu Leu
        355                 360                 365

Leu Arg Val Asp Pro Gly Gln Thr Thr Pro Leu Ala Cys Val Thr Glu
    370                 375                 380
```

```
Glu Gln Pro Ala Arg Gly Ile Ser Ser Ala Cys Ala Val Cys Gly Ile
385                 390                 395                 400


Pro Leu Ala Arg Pro Ala Ser Gly Asn Ala Arg Met Arg Cys Thr Ala
                405                 410                 415


Cys Gly Ser Ser Gln Val Gly Asp Val Asn Ala Ala Glu Asn Val Leu
            420                 425                 430


Thr Arg Ala Leu Ser Ser Ala Pro Ser Gly Pro Lys Ser Pro Lys Ala
        435                 440                 445


Ser Ile Lys Ile Lys Gly Arg Gln Lys Arg Leu Gly Thr Pro Ala Asn
    450                 455                 460


Arg Ala Gly Glu Ala Ser Gly Gly Asp Pro Pro Val Arg Gly Pro Val
465                 470                 475                 480


Glu Gly Gly Thr Leu Ala Tyr Val Val Glu Pro Val Ser Glu Ser Gln
                485                 490                 495


Ser Asp Thr
```

<210> 45
<211> 560
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 45

```
Met Thr Val Arg Thr Tyr Lys Tyr Arg Ala Tyr Pro Thr Pro Glu Gln
1               5                   10                  15


Ala Glu Ala Leu Thr Ser Trp Leu Arg Phe Ala Ser Gln Leu Tyr Asn
```

```
            20                  25                  30

Ala Ala Leu Glu His Arg Lys Asn Ala Trp Gly Arg His Asp Ala His
        35                  40                  45

Gly Arg Gly Phe Arg Phe Trp Asp Gly Asp Ala Ala Pro Arg Lys Lys
    50                  55                  60

Ser Asp Pro Pro Gly Arg Trp Val Tyr Arg Gly Gly Gly Gly Ala His
65                  70                  75                  80

Ile Ser Lys Asn Asp Gln Gly Lys Leu Leu Thr Glu Phe Arg Arg Glu
                85                  90                  95

His Ala Glu Leu Leu Pro Pro Gly Met Pro Ala Leu Val Gln His Glu
            100                 105                 110

Val Leu Ala Arg Leu Glu Arg Ser Met Ala Ala Phe Phe Gln Arg Ala
        115                 120                 125

Thr Lys Gly Gln Lys Ala Gly Tyr Pro Arg Trp Arg Ser Glu His Arg
    130                 135                 140

Tyr Asp Ser Leu Thr Phe Gly Leu Thr Ser Pro Ser Lys Glu Arg Phe
145                 150                 155                 160

Asp Pro Glu Thr Gly Glu Ser Leu Gly Arg Gly Lys Thr Val Gly Ala
                165                 170                 175

Gly Thr Tyr His Asn Gly Asp Leu Arg Leu Thr Gly Leu Gly Glu Leu
            180                 185                 190

Arg Ile Leu Glu His Arg Arg Ile Pro Met Gly Ala Ile Pro Lys Ser
        195                 200                 205

Val Ile Val Arg Arg Ser Gly Lys Arg Trp Phe Val Ser Ile Ala Met
```

210 215 220

Glu Met Pro Ser Val Glu Pro Ala Ala Ser Gly Arg Pro Ala Val Gly
225 230 235 240

Leu Asp Met Gly Val Val Thr Trp Gly Thr Ala Phe Thr Ala Asp Thr
245 250 255

Ser Ala Ala Ala Ala Leu Val Ala Asp Leu Arg Arg Met Ala Thr Asp
260 265 270

Pro Ser Asp Cys Arg Arg Leu Glu Glu Leu Glu Arg Glu Ala Ala Gln
275 280 285

Leu Ser Glu Val Leu Ala His Cys Arg Ala Arg Gly Leu Asp Pro Ala
290 295 300

Arg Pro Arg Arg Cys Pro Lys Glu Leu Thr Lys Leu Tyr Arg Arg Ser
305 310 315 320

Leu His Arg Leu Gly Glu Leu Asp Arg Ala Cys Ala Arg Ile Arg Arg
325 330 335

Arg Leu Gln Ala Ala His Asp Ile Ala Glu Pro Val Pro Asp Glu Ala
340 345 350

Gly Ser Ala Val Leu Ile Glu Gly Ser Asn Ala Gly Met Arg His Ala
355 360 365

Arg Arg Val Ala Arg Thr Gln Arg Arg Val Ala Arg Arg Thr Arg Ala
370 375 380

Gly His Ala His Ser Asn Arg Arg Lys Lys Ala Val Gln Ala Tyr Ala
385 390 395 400

Arg Ala Lys Glu Arg Glu Arg Ser Ala Arg Gly Asp His Arg His Lys

405 410 415

Val Ser Arg Ala Leu Val Arg Gln Phe Glu Glu Ile Ser Val Glu Ala
420 425 430

Leu Asp Ile Lys Gln Leu Thr Val Ala Pro Glu His Asn Pro Asp Pro
435 440 445

Gln Pro Asp Leu Pro Ala His Val Gln Arg Arg Arg Asn Arg Gly Glu
450 455 460

Leu Asp Ala Ala Trp Gly Ala Phe Phe Ala Ala Leu Asp Tyr Lys Ala
465 470 475 480

Ala Asp Ala Gly Gly Arg Val Ala Arg Lys Pro Ala Pro His Thr Thr
485 490 495

Gln Glu Cys Ala Arg Cys Gly Thr Leu Val Pro Lys Pro Ile Ser Leu
500 505 510

Arg Val His Arg Cys Pro Ala Cys Gly Tyr Thr Ala Pro Arg Thr Val
515 520 525

Asn Ser Ala Arg Asn Val Leu Gln Arg Pro Leu Glu Glu Pro Gly Arg
530 535 540

Ala Gly Pro Ser Gly Ala Asn Gly Arg Gly Val Pro His Ala Val Ala
545 550 555 560

<210> 46
<211> 404
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 46

```
Met Asn Cys Arg Tyr Arg Tyr Arg Ile Tyr Pro Thr Pro Gly Gln Arg
1               5                   10                  15


Gln Ser Leu Ala Arg Leu Phe Gly Cys Val Arg Val Val Trp Asn Asp
            20                  25                  30


Ala Leu Phe Leu Cys Arg Gln Ser Glu Lys Leu Pro Lys Asn Ser Glu
        35                  40                  45


Leu Gln Lys Leu Cys Ile Thr Gln Ala Lys Lys Thr Glu Ala Arg Gly
    50                  55                  60


Trp Leu Gly Gln Val Ser Ala Ile Pro Leu Gln Gln Ser Val Ala Asp
65                  70                  75                  80


Leu Gly Val Ala Phe Lys Asn Phe Phe Gln Ser Arg Ser Gly Lys Arg
                85                  90                  95


Lys Gly Lys Lys Val Asn Pro Pro Arg Val Lys Arg Arg Asn Asn Arg
            100                 105                 110


Gln Gly Ala Arg Phe Thr Arg Gly Gly Phe Lys Val Lys Thr Ser Lys
        115                 120                 125


Val Tyr Leu Ala Arg Ile Gly Asp Ile Lys Ile Lys Trp Ser Arg Pro
    130                 135                 140


Leu Pro Ser Glu Pro Ser Ser Val Thr Val Ile Lys Asp Cys Ala Gly
145                 150                 155                 160


Gln Tyr Phe Leu Ser Phe Val Val Glu Val Lys Pro Glu Ile Lys Pro
                165                 170                 175


Pro Lys Asn Pro Ser Ile Gly Ile Asp Leu Gly Leu Lys Thr Phe Ala
            180                 185                 190
```

```
Ser Cys Ser Asn Gly Glu Lys Ile Asp Ser Pro Asp Tyr Ser Arg Leu
        195                 200                 205

Tyr Arg Lys Leu Lys Arg Cys Gln Arg Arg Leu Ala Lys Arg Gln Arg
    210                 215                 220

Gly Ser Lys Arg Arg Glu Arg Met Arg Val Lys Val Ala Lys Leu Asn
225                 230                 235                 240

Ala Gln Ile Arg Asp Lys Arg Lys Asp Phe Leu His Lys Leu Ser Thr
                245                 250                 255

Lys Val Val Asn Glu Asn Gln Val Ile Ala Leu Glu Asp Leu Asn Val
            260                 265                 270

Gly Gly Met Leu Lys Asn Arg Lys Leu Ser Arg Ala Ile Ser Gln Ala
        275                 280                 285

Gly Trp Tyr Glu Phe Arg Ser Leu Cys Glu Gly Lys Ala Glu Lys His
    290                 295                 300

Asn Arg Asp Phe Arg Val Ile Ser Arg Trp Glu Pro Thr Ser Gln Val
305                 310                 315                 320

Cys Ser Glu Cys Gly Tyr Arg Trp Gly Lys Ile Asp Leu Ser Val Arg
                325                 330                 335

Ser Ile Val Cys Ile Asn Cys Gly Val Glu His Asp Arg Asp Asp Asn
            340                 345                 350

Ala Ser Val Asn Ile Glu Gln Ala Gly Leu Lys Val Gly Val Gly His
        355                 360                 365

Thr His Asp Ser Lys Arg Thr Gly Ser Ala Cys Lys Thr Ser Asn Gly
    370                 375                 380
```

Ala Val Cys Val Glu Pro Ser Thr His Arg Glu Tyr Val Gln Leu Thr
385 390 395 400

Leu Phe Asp Trp

<210> 47
<211> 392
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 47

Met Lys Ser Arg Trp Thr Phe Arg Cys Tyr Pro Thr Pro Glu Gln Glu
1 5 10 15

Gln His Leu Ala Arg Thr Phe Gly Cys Val Arg Phe Val Trp Asn Trp
20 25 30

Ala Leu Arg Ala Arg Thr Asp Ala Phe Arg Ala Gly Glu Arg Ile Gly
35 40 45

Tyr Pro Ala Thr Asp Lys Ala Leu Thr Leu Leu Lys Gln Gln Pro Glu
50 55 60

Thr Val Trp Leu Asn Glu Val Ser Ser Val Cys Leu Gln Gln Ala Leu
65 70 75 80

Arg Asp Leu Gln Val Ala Phe Ser Asn Phe Phe Asp Lys Arg Ala Ala
85 90 95

His Pro Ser Phe Lys Arg Lys Glu Ala Arg Gln Ser Ala Asn Tyr Thr
100 105 110

Glu Arg Gly Phe Ser Phe Asp His Glu Arg Arg Ile Leu Lys Leu Ala

```
        115                 120                 125

Lys Ile Gly Ala Ile Lys Val Lys Trp Ser Arg Lys Ala Ile Pro His
    130                 135                 140

Pro Ser Ser Ile Arg Leu Ile Arg Thr Ala Ser Gly Lys Tyr Phe Val
145                 150                 155                 160

Ser Leu Val Val Glu Thr Gln Pro Ala Pro Met Pro Glu Thr Gly Glu
                165                 170                 175

Ser Val Gly Val Asp Phe Gly Val Ala Arg Leu Ala Thr Leu Ser Asn
            180                 185                 190

Gly Glu Arg Ile Ser Asn Pro Lys His Gly Ala Lys Trp Gln Arg Arg
        195                 200                 205

Leu Ala Phe Tyr Gln Lys Arg Leu Ala Arg Ala Thr Lys Gly Ser Lys
    210                 215                 220

Arg Arg Met Arg Ile Lys Arg His Val Ala Arg Ile His Glu Lys Ile
225                 230                 235                 240

Gly Asn Ser Arg Ser Asp Thr Leu His Lys Leu Ser Thr Asp Leu Val
                245                 250                 255

Thr Arg Phe Asp Leu Ile Cys Val Glu Asp Leu Asn Leu Arg Gly Met
            260                 265                 270

Val Lys Asn His Ser Leu Ala Arg Ser Leu His Asp Ala Ser Ile Gly
        275                 280                 285

Ser Ala Ile Arg Met Ile Glu Glu Lys Ala Glu Arg Tyr Gly Lys Asn
    290                 295                 300

Val Val Lys Ile Asp Arg Trp Phe Pro Ser Ser Lys Thr Cys Ser Asp
```

305 310 315 320

Cys Gly His Ile Val Glu Gln Leu Pro Leu Asn Val Arg Glu Trp Thr
325 330 335

Cys Pro Glu Cys Gly Thr Thr His Asp Arg Asp Ala Asn Ala Ala Ala
340 345 350

Asn Ile Leu Ala Val Gly Gln Thr Val Ser Ala His Gly Gly Thr Val
355 360 365

Arg Arg Ser Arg Ala Lys Ala Ser Glu Arg Lys Ser Gln Arg Ser Ala
370 375 380

Asn Arg Gln Gly Val Asn Arg Ala
385 390

<210> 48
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 48

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10

<210> 49
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 49

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala

1 5 10

<210> 50
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 50

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10

<210> 51
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 51
gttgcattcc ttcattcgtc tattcgggtt ctgcaac 37

<210> 52
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 52
gttgcattcc ttcattcgtc tatccgggtt ctgcaag 37

<210> 53
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 53
gttgcagaac ccgaatagac gaatgaagga atgcaac 37

<210> 54
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 54
ctatcatatt cagaacaaag ggattaagga atgcaac 37

<210> 55
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 55
ctttcatact cagaacaaag ggattaagga atgcaac 37

<210> 56
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 56
gtctacaact cattgataga aatcaatgag ttagaca 37

<210> 57
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 57
gttataaagg cggggatcgc gaccgagcga ttgaaag 37

<210> 58
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 58
gttgcattcc ttaattcatt ttctcaatat cggaaac 37

<210> 59
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 59
gttgcagaaa tagaataaag gaattaagga atgcaac 37

<210> 60
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 60
ctttcatact cagaacaaag ggattaagga atgcaac 37

<210> 61
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 61
atttcatact cagaacaaag ggattaagga atgcaac 37

<210> 62
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 62
gtttcagcgc acgaattaac gagatgagag atgcaact 38

<210> 63
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 63
cttgcagaag ctgaatagac gaatcaagga atgcaac 37

<210> 64
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 64
cacttgcagg ccttgaatag aggagttaag gaatgcaac 39

<210> 65
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 65
gtctccatga ctgaaaagtc gtggccgaat tgaaac 36

<210> 66
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 66
gttgcagcgc ccgaactgac gagacgagag atgcaac 37

<210> 67
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 67
gttgcgcgaa tagaataaag gaattaagga atgcaac 37

<210> 68
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 68
agttgcattc cttaatccct ctgttcagtt tgtgcaat 38

<210> 69
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 69
gttgcattcc tagtttctct aattagcact gtgcaac 37

<210> 70
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 70
gttgcggcgc gcgaataaac gagactagga atgcaac 37

<210> 71
<211> 41
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 71
actagttgca ttccttaatc cctttgttct gaatatgcta g 41

<210> 72
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 72
ctttcatatt cagaacaaag ggattaagga atgcaac 37

<210> 73
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 73
gttgcagtcc ttaaccccta gtttctgaat atgaaagat 39

<210> 74
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 74
gttgcagccc ccgaactaac gagatgagag atgcaac 37

<210> 75
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 75
cttgcagaac aatcatatat gactaatcag actgcaac 38

<210> 76
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 76
gttgcactca ccggtgctca cgacgtaggg atgcaac 37

<210> 77
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 77
gtccctactc gctagggaaa ctaattgaat ggaaac 36

<210> 78
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 78
gttgcattcg ggtgcaaaac agggagtaga gtgtaac 37

<210> 79
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 79
cttccaaact cgagccagtg gggagagaag tggca 35

<210> 80
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 80
cctgtagacc ggtctcattc tgagaggggt atgcaact 38

<210> 81
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 81
gtctcgagac cctacagatt ttggagaggg gtgggac 37

<210> 82
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 82
gtcccacccc tctccaaaat ctgtagggtc tcgagac 37

<210> 83
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 83
gtagcaggac tctcctcgag agaaacaggg gtatgct 37

<210> 84
<211> 40
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 84
gtacaatacc tctcctttaa gagagggagg ggtacgctac 40

<210> 85
<211> 31
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 85
ccccctcgtt tccttcaggg gattcctttc c 31

<210> 86
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 86
ggttcccccg ggcgcgggtg gggtggcg 28

<210> 87
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 87
ggctgctccg ggtgcgcgtg gagcgagg 28

<210> 88
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 88
gttttatacc ctttagaatt taaactgtct aaaag 35

<210> 89
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 89
attgcaccgg ccaacgcaaa tctgattgat ggacac 36

<210> 90
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 90
gccgcagcgg ccgacgcggc cctgatcgat ggacac 36

<210> 91
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 91
gtcgaaatgc ccgcgcgggg gcgtcgtacc cgcgac 36

<210> 92
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 92
ggctagcccg tgcgcgcagg gacgagtgg 29

<210> 93
<211> 24
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 93
gcccgtgcgc gcagggacga gtgg 24

<210> 94
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 94
gttgcagcgg ccgacggagc gcgagcgtgg atgccac 37

<210> 95
<211> 29
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 95
ccatcgcccc gcgcgcacgt ggatgagcc 29

<210> 96
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 96
ctttagactt ctccggaagt cgaattaatg gaaac 35

<210> 97
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 97
gggcgccccg cgcgagcggg ggttgaag 28

<210> 98
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 98

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10

<210> 99
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 99

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10

<210> 100
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 100

Ala Ala Ala Ala Ala Ala Ala Ala Ala Ala
1 5 10

<210> 101

<211> 84
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 101

Met Ala Ser Met Ile Ser Ser Ser Ala Val Thr Thr Val Ser Arg Ala
1 5 10 15

Ser Arg Gly Gln Ser Ala Ala Met Ala Pro Phe Gly Gly Leu Lys Ser
20 25 30

Met Thr Gly Phe Pro Val Arg Lys Val Asn Thr Asp Ile Thr Ser Ile
35 40 45

Thr Ser Asn Gly Gly Arg Val Lys Cys Met Gln Val Trp Pro Pro Ile
50 55 60

Gly Lys Lys Lys Phe Glu Thr Leu Ser Tyr Leu Pro Pro Leu Thr Arg
65 70 75 80

Asp Ser Arg Ala

<210> 102
<211> 57
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 102

Met Ala Ser Met Ile Ser Ser Ser Ala Val Thr Thr Val Ser Arg Ala
1 5 10 15

Ser Arg Gly Gln Ser Ala Ala Met Ala Pro Phe Gly Gly Leu Lys Ser

20 25 30

Met Thr Gly Phe Pro Val Arg Lys Val Asn Thr Asp Ile Thr Ser Ile
35 40 45

Thr Ser Asn Gly Gly Arg Val Lys Ser
50 55

<210> 103
<211> 85
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 103

Met Ala Ser Ser Met Leu Ser Ser Ala Thr Met Val Ala Ser Pro Ala
1 5 10 15

Gln Ala Thr Met Val Ala Pro Phe Asn Gly Leu Lys Ser Ser Ala Ala
20 25 30

Phe Pro Ala Thr Arg Lys Ala Asn Asn Asp Ile Thr Ser Ile Thr Ser
35 40 45

Asn Gly Gly Arg Val Asn Cys Met Gln Val Trp Pro Pro Ile Glu Lys
50 55 60

Lys Lys Phe Glu Thr Leu Ser Tyr Leu Pro Asp Leu Thr Asp Ser Gly
65 70 75 80

Gly Arg Val Asn Cys
85

<210> 104
<211> 76
<212> PRT

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 104

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu
1 5 10 15

Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val
20 25 30

Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser
35 40 45

Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg
50 55 60

Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Cys
65 70 75

<210> 105
<211> 76
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 105

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Trp Asn Pro Ser Leu
1 5 10 15

Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val
20 25 30

Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser
35 40 45

Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg
    50   55   60

Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Cys
65   70   75

<210> 106
<211> 72
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 106

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro
1   5   10   15

Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu
            20   25   30

Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val
        35   40   45

Leu Lys Lys Asp Ser Ile Phe Met Gln Leu Phe Cys Ser Phe Arg Ile
    50   55   60

Ser Ala Ser Val Ala Thr Ala Cys
65   70

<210> 107
<211> 69
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 107

Met Ala Ala Leu Val Thr Ser Gln Leu Ala Thr Ser Gly Thr Val Leu
1 5 10 15

Ser Val Thr Asp Arg Phe Arg Arg Pro Gly Phe Gln Gly Leu Arg Pro
20 25 30

Arg Asn Pro Ala Asp Ala Ala Leu Gly Met Arg Thr Val Gly Ala Ser
35 40 45

Ala Ala Pro Lys Gln Ser Arg Lys Pro His Arg Phe Asp Arg Arg Cys
50 55 60

Leu Ser Met Val Val
65

<210> 108
<211> 77
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 108

Met Ala Ala Leu Thr Thr Ser Gln Leu Ala Thr Ser Ala Thr Gly Phe
1 5 10 15

Gly Ile Ala Asp Arg Ser Ala Pro Ser Ser Leu Leu Arg His Gly Phe
20 25 30

Gln Gly Leu Lys Pro Arg Ser Pro Ala Gly Gly Asp Ala Thr Ser Leu
35 40 45

Ser Val Thr Thr Ser Ala Arg Ala Thr Pro Lys Gln Gln Arg Ser Val
50 55 60

Gln Arg Gly Ser Arg Arg Phe Pro Ser Val Val Val Cys

65 70 75

<210> 109
<211> 57
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 109

Met Ala Ser Ser Val Leu Ser Ser Ala Ala Val Ala Thr Arg Ser Asn
1 5 10 15

Val Ala Gln Ala Asn Met Val Ala Pro Phe Thr Gly Leu Lys Ser Ala
20 25 30

Ala Ser Phe Pro Val Ser Arg Lys Gln Asn Leu Asp Ile Thr Ser Ile
35 40 45

Ala Ser Asn Gly Gly Arg Val Gln Cys
50 55

<210> 110
<211> 65
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 110

Met Glu Ser Leu Ala Ala Thr Ser Val Phe Ala Pro Ser Arg Val Ala
1 5 10 15

Val Pro Ala Ala Arg Ala Leu Val Arg Ala Gly Thr Val Val Pro Thr
20 25 30

Arg Arg Thr Ser Ser Thr Ser Gly Thr Ser Gly Val Lys Cys Ser Ala

35 40 45

Ala Val Thr Pro Gln Ala Ser Pro Val Ile Ser Arg Ser Ala Ala Ala
50 55 60

Ala
65

<210> 111
<211> 72
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 111

Met Gly Ala Ala Ala Thr Ser Met Gln Ser Leu Lys Phe Ser Asn Arg
1 5 10 15

Leu Val Pro Pro Ser Arg Arg Leu Ser Pro Val Pro Asn Asn Val Thr
20 25 30

Cys Asn Asn Leu Pro Lys Ser Ala Ala Pro Val Arg Thr Val Lys Cys
35 40 45

Cys Ala Ser Ser Trp Asn Ser Thr Ile Asn Gly Ala Ala Ala Thr Thr
50 55 60

Asn Gly Ala Ser Ala Ala Ser Ser
65 70

<210> 112
<211> 20
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<220>
<221> misc_feature
<222> (4)..(4)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (8)..(8)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (11)..(11)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (15)..(15)
<223> Xaa can be any naturally occurring amino acid

<220>
<221> misc_feature
<222> (19)..(19)
<223> Xaa can be any naturally occurring amino acid

<400> 112

Gly Leu Phe Xaa Ala Leu Leu Xaa Leu Leu Xaa Ser Leu Trp Xaa Leu
1 5 10 15

Leu Leu Xaa Ala
20

<210> 113
<211> 20
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 113

Gly Leu Phe His Ala Leu Leu His Leu Leu His Ser Leu Trp His Leu

1 5 10 15

Leu Leu His Ala
20

<210> 114
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 114

Pro Lys Lys Lys Arg Lys Val
1 5

<210> 115
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 115

Lys Arg Pro Ala Ala Thr Lys Lys Ala Gly Gln Ala Lys Lys Lys Lys
1 5 10 15

<210> 116
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 116

Pro Ala Ala Lys Arg Val Lys Leu Asp
1 5

<210> 117
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 117

Arg Gln Arg Arg Asn Glu Leu Lys Arg Ser Pro
1 5 10

<210> 118
<211> 38
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 118

Asn Gln Ser Ser Asn Phe Gly Pro Met Lys Gly Gly Asn Phe Gly Gly
1 5 10 15

Arg Ser Ser Gly Pro Tyr Gly Gly Gly Gly Gln Tyr Phe Ala Lys Pro
20 25 30

Arg Asn Gln Gly Gly Tyr
35

<210> 119
<211> 42
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 119

Arg Met Arg Ile Glx Phe Lys Asn Lys Gly Lys Asp Thr Ala Glu Leu

1 5 10 15

Arg Arg Arg Arg Val Glu Val Ser Val Glu Leu Arg Lys Ala Lys Lys
20 25 30

Asp Glu Gln Ile Leu Lys Arg Arg Asn Val
35 40

<210> 120
<211> 8
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 120

Val Ser Arg Lys Arg Pro Arg Pro
1 5

<210> 121
<211> 8
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 121

Pro Pro Lys Lys Ala Arg Glu Asp
1 5

<210> 122
<211> 8
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 122

Pro Gln Pro Lys Lys Lys Pro Leu
1 5

<210> 123
<211> 12
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 123

Ser Ala Leu Ile Lys Lys Lys Lys Lys Met Ala Pro
1 5 10

<210> 124
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 124

Asp Arg Leu Arg Arg
1 5

<210> 125
<211> 7
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 125

Pro Lys Gln Lys Lys Arg Lys
1 5

<210> 126

<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 126

Arg Lys Leu Lys Lys Lys Ile Lys Lys Leu
1 5 10

<210> 127
<211> 10
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 127

Arg Glu Lys Lys Lys Phe Leu Lys Arg Arg
1 5 10

<210> 128
<211> 20
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 128

Lys Arg Lys Gly Asp Glu Val Asp Gly Val Asp Glu Val Ala Lys Lys
1 5 10 15

Lys Ser Lys Lys
20

<210> 129
<211> 17
<212> PRT

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 129

Arg Lys Cys Leu Gln Ala Gly Met Asn Leu Glu Ala Arg Lys Thr Lys
1 5 10 15

Lys

<210> 130
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 130

Tyr Gly Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5 10

<210> 131
<211> 12
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 131

Arg Arg Gln Arg Arg Thr Ser Lys Leu Met Lys Arg
1 5 10

<210> 132
<211> 27
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 132

Gly Trp Thr Leu Asn Ser Ala Gly Tyr Leu Leu Gly Lys Ile Asn Leu
1 5 10 15

Lys Ala Leu Ala Ala Leu Ala Lys Lys Ile Leu
20 25

<210> 133
<211> 33
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 133

Lys Ala Leu Ala Trp Glu Ala Lys Leu Ala Lys Ala Leu Ala Lys Ala
1 5 10 15

Leu Ala Lys His Leu Ala Lys Ala Leu Ala Lys Ala Leu Lys Cys Glu
20 25 30

Ala

<210> 134
<211> 16
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 134

Arg Gln Ile Lys Ile Trp Phe Gln Asn Arg Arg Met Lys Trp Lys Lys
1 5 10 15

<210> 135
<211> 9
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 135

Arg Lys Lys Arg Arg Gln Arg Arg Arg
1 5

<210> 136
<211> 8
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 136

Arg Lys Lys Arg Arg Gln Arg Arg
1 5

<210> 137
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 137

Tyr Ala Arg Ala Ala Ala Arg Gln Ala Arg Ala
1 5 10

<210> 138
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 138

Thr His Arg Leu Pro Arg Arg Arg Arg Arg Arg
1 5 10

<210> 139
<211> 11
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 139

Gly Gly Arg Arg Ala Arg Arg Arg Arg Arg Arg
1 5 10

<210> 140
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 140

Gly Ser Gly Gly Ser
1 5

<210> 141
<211> 6
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 141

Gly Gly Ser Gly Gly Ser

1 5

<210> 142
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 142

Gly Gly Gly Ser
1

<210> 143
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 143

Gly Gly Ser Gly
1

<210> 144
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 144

Gly Gly Ser Gly Gly
1 5

<210> 145
<211> 5
<212> PRT

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 145

Gly Ser Gly Ser Gly
1   5

<210> 146
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 146

Gly Ser Gly Gly Gly
1   5

<210> 147
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 147

Gly Gly Gly Ser Gly
1   5

<210> 148
<211> 5
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 148

Gly Ser Ser Ser Gly
1 5

<210> 149
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 149

Ala Ala Ala Ala
1

<210> 150
<211> 4
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 150

Ala Ala Ala Ala
1

<210> 151
<211> 80
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 151
cgattcctcc ctacagtagt taggtatagc cgaaaggtag agactaaatc tgtagttgga 60

gtgggccgct tgcatcggcc 80

<210> 152

<211> 122
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 152
tcgtctcgag ggttaccaaa attggcactt ctcgacttta ggccgatgca agcggcccac 60

tccactacag atttagtctc taccttgcgg ctatacctaa cttactgtag ggaggaatcg 120

tg 122

<210> 153
<211> 91
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 153
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta a 91

<210> 154
<211> 114
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 154
cagaataata ctgacttact aagatatctt gagggtatac ccgaaaagat tggcgttgtt 60

gcaacgcaat aagatgtaaa tctgaaaagg tttggaatca tataaataat ttta 114

<210> 155
<211> 104
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 155
aagccaagat atggaatgcc attgtaatat tatggtgttg acttagttta gatttaaaca 60

atcttcgatg gctatatgcg gaaggtttgg cgtcgttgta acgc 104

<210> 156
<211> 213
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 156
cagtgtgcat agctataaca ctacgcaaag actgctaaag agcgatgtgc tctatcgcag 60

tctcaccttt aatggactta cggatctttt ggagcactaa gctccgctgc ggtgcaacac 120

cgccctttc ttgcctctgc ttgccctttc cggttattat agccgggaga gtgcggaaga 180

ttaccgctct agctcgcagc atgttactga gtc 213

<210> 157
<211> 94
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 157
gcaagtcatt cggggacact ttttgttatt taaagtgttt tagataaatc agtgtcatgc 60

tgaataacga cccgacctat aaataacata atcc 94

<210> 158
<211> 252
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 158
gtccttaagg tactacacat tacatgtgaa cgtggagcta ataatagaaa tattattaga 60

ctacacctta ttaataacgg taggagatct atatggtctt gaatggaata gtaattgtga 120

aattataatt tctgttctta gctacttaag atggctcgtt gcaagccact cgggggctct 180

cttgaagtca aagagcttta gacaaatcag tgtcaaactg aataacgacc cgaccatgac 240

ttcataatcc cg 252

<210> 159
<211> 152
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 159
ctcgaggcta tttcatactc agaacaaagg gattaaggaa tgcaacccat ttcaaaatct 60

gtggaattat cacaaccatt aacatttcat actcagaaca aagggattaa ggaatgcaac 120

ggacaccttg ctatgtcctt ttgatgtatg tg 152

<210> 160
<211> 61
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 160
ctcgaggcta tttcatactc agaacaaagc tcagaacaaa gggaataagg aatgcaacgg 60

a 61

<210> 161
<211> 101
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 161
ctcagaaaca aagggattaa ggaatgcaac ccatttcaaa atctgtggaa actcagaaca 60

aagggattaa ggaatgcaac ggacaccttg ctatgtcctt c 101

<210> 162
<211> 86
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 162
ctcagaacaa agggattaag gaatgcaacc catttcctca gaacaaaggg attaaggaat 60

gcaacggaca ccttgctatg tccttc 86

<210> 163
<211> 76
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 163
ctcagaacaa agggattaag gaatgcaacc catttctcag aacaaaggga ttaaggaatg 60

caacggacac cttgct 76

<210> 164
<211> 82
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 164
ctcagaacaa agggattaag gaatgcaacc catttcaaaa ctcagaacaa agggattaag 60

gaatgcaacg gacaccttgc ta 82

<210> 165
<211> 72
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 165
ctcagaacaa agggattaag gaatgcaacc catttcctca gaacaaaggg attaaggaat 60

gcaacggaca cc 72

<210> 166
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 166
ctcagaacaa agggattaag gaatgcaacc cgggattaag gaatgcaacg gacaccttg 59

<210> 167
<211> 50
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 167
ctcagaacaa agggattaag gaatgcaacc aacggacacc ttgctatgtc 50

<210> 168
<211> 45
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 168
ctcagaacaa agggattaag gaatgcaacc catttcaaaa tctgt 45

<210> 169
<211> 41
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 169
ctcagaacaa agggattaag gaatgcaacc catttcaaaa t 41

<210> 170
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 170
ctcagaacaa agggattaag gaatgcaacc catttc 36

<210> 171
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 171
ctcagaacaa agggattaag gaatgcaacc catttc 36

<210> 172
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 172
ctcagaacaa agggattaag gaatgcaacc catttc 36

<210> 173
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 173
ctcagaacaa agggattaag gaatgcaacc catttca 37

<210> 174
<211> 38
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 174
ctcagaacaa agggattaag gaatgcaacc catttcaa 38

<210> 175
<211> 46
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 175
ctcagaacaa agggattaag gaatgcaacc catttcaaaa tctgtg 46

<210> 176
<211> 46
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 176
ctcagaacaa agggattaag gaatgcaacc catttcaaaa tctgtg 46

<210> 177
<211> 44
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 177
ctcagaacaa agggattaag gaatgcaacc catttcaaaa tctg 44

<210> 178
<211> 726
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 178

Ser Glu Ser Glu Asn Lys Ile Ile Glu Gln Tyr Tyr Ala Phe Leu Tyr
1 5 10 15

Ser Phe Arg Asp Lys Tyr Glu Lys Pro Glu Phe Lys Asn Arg Gly Asp
20 25 30

Ile Lys Arg Lys Leu Gln Asn Lys Trp Glu Asp Phe Leu Lys Glu Gln
35 40 45

Asn Leu Lys Asn Asp Lys Lys Leu Ser Asn Tyr Ile Phe Ser Asn Arg
50 55 60

Asn Phe Arg Arg Ser Tyr Asp Arg Glu Glu Glu Asn Glu Glu Gly Ile
65 70 75 80

Asp Glu Lys Lys Ser Lys Pro Lys Arg Ile Asn Cys Phe Glu Lys Glu

```
                85                  90                  95

Lys Asn Leu Lys Asp Gln Tyr Asp Lys Asp Ala Ile Asn Ala Ser Ala
            100                 105                 110

Asn Lys Asp Gly Ala Gln Lys Trp Gly Cys Phe Glu Cys Ile Phe Phe
        115                 120                 125

Pro Met Tyr Lys Ile Glu Ser Gly Asp Pro Asn Lys Arg Ile Ile Ile
    130                 135                 140

Asn Lys Thr Arg Phe Lys Leu Phe Asp Phe Tyr Leu Asn Leu Lys Gly
145                 150                 155                 160

Cys Lys Ser Cys Leu Arg Ser Thr Tyr His Pro Tyr Arg Ser Asn Val
                165                 170                 175

Tyr Ile Glu Ser Asn Tyr Asp Lys Leu Lys Arg Glu Ile Gly Asn Phe
            180                 185                 190

Leu Gln Gln Lys Asn Ile Phe Gln Arg Met Arg Lys Ala Lys Val Ser
        195                 200                 205

Glu Gly Lys Tyr Leu Thr Asn Leu Asp Glu Tyr Arg Leu Ser Cys Val
    210                 215                 220

Ala Met His Phe Lys Asn Arg Trp Leu Phe Phe Asp Ser Ile Gln Lys
225                 230                 235                 240

Val Leu Arg Glu Thr Ile Lys Gln Arg Leu Lys Gln Met Arg Glu Ser
                245                 250                 255

Tyr Asp Glu Gln Ala Lys Thr Lys Arg Ser Lys Gly His Gly Arg Ala
            260                 265                 270

Lys Tyr Glu Asp Gln Val Arg Met Ile Arg Arg Arg Ala Tyr Ser Ala
```

```
        275                 280                 285

Gln Ala His Lys Leu Leu Asp Asn Gly Tyr Ile Thr Leu Phe Asp Tyr
    290                 295                 300

Asp Asp Lys Glu Ile Asn Lys Val Cys Leu Thr Ala Ile Asn Gln Glu
305                 310                 315                 320

Gly Phe Asp Ile Gly Gly Tyr Leu Asn Ser Asp Ile Asp Asn Val Met
                325                 330                 335

Pro Pro Ile Glu Ile Ser Phe His Leu Lys Trp Lys Tyr Asn Glu Pro
            340                 345                 350

Ile Leu Asn Ile Glu Ser Pro Phe Ser Lys Ala Lys Ile Ser Asp Tyr
        355                 360                 365

Leu Arg Lys Ile Arg Glu Asp Leu Asn Leu Glu Arg Gly Lys Glu Gly
    370                 375                 380

Lys Ala Arg Ser Lys Lys Asn Val Arg Arg Lys Val Leu Ala Ser Lys
385                 390                 395                 400

Gly Glu Asp Gly Tyr Lys Lys Ile Phe Thr Asp Phe Phe Ser Lys Trp
                405                 410                 415

Lys Glu Glu Leu Glu Gly Asn Ala Met Glu Arg Val Leu Ser Gln Ser
            420                 425                 430

Ser Gly Asp Ile Gln Trp Ser Lys Lys Lys Arg Ile His Tyr Thr Thr
        435                 440                 445

Leu Val Leu Asn Ile Asn Leu Leu Asp Lys Lys Gly Val Gly Asn Leu
    450                 455                 460

Lys Tyr Tyr Glu Ile Ala Glu Lys Thr Lys Ile Leu Ser Phe Asp Lys
```

```
465                 470                 475                 480

Asn Glu Asn Lys Phe Trp Pro Ile Thr Ile Gln Val Leu Leu Asp Gly
                485                 490                 495

Tyr Glu Ile Gly Thr Glu Tyr Asp Glu Ile Lys Gln Leu Asn Glu Lys
            500                 505                 510

Thr Ser Lys Gln Phe Thr Ile Tyr Asp Pro Asn Thr Lys Ile Ile Lys
        515                 520                 525

Ile Pro Phe Thr Asp Ser Lys Ala Val Pro Leu Gly Met Leu Gly Ile
    530                 535                 540

Asn Ile Ala Thr Leu Lys Thr Val Lys Lys Thr Glu Arg Asp Ile Lys
545                 550                 555                 560

Val Ser Lys Ile Phe Lys Gly Gly Leu Asn Ser Lys Ile Val Ser Lys
                565                 570                 575

Ile Gly Lys Gly Ile Tyr Ala Gly Tyr Phe Pro Thr Val Asp Lys Glu
            580                 585                 590

Ile Leu Glu Glu Val Glu Glu Asp Thr Leu Asp Asn Glu Phe Ser Ser
        595                 600                 605

Lys Ser Gln Arg Asn Ile Phe Leu Lys Ser Ile Ile Lys Asn Tyr Asp
    610                 615                 620

Lys Met Leu Lys Glu Gln Leu Phe Asp Phe Tyr Ser Phe Leu Val Arg
625                 630                 635                 640

Asn Asp Leu Gly Val Arg Phe Leu Thr Asp Arg Glu Leu Gln Asn Ile
                645                 650                 655

Glu Asp Glu Ser Phe Asn Leu Glu Lys Arg Phe Phe Glu Thr Asp Arg
```

660 665 670

Asp Arg Ile Ala Arg Trp Phe Asp Asn Thr Asn Thr Asp Asp Gly Lys
675 680 685

Glu Lys Phe Lys Lys Leu Ala Asn Glu Ile Val Asp Ser Tyr Lys Pro
690 695 700

Arg Leu Ile Arg Leu Pro Val Val Arg Val Ile Lys Arg Ile Gln Pro
705 710 715 720

Val Lys Gln Arg Glu Met
725

<210> 179
<211> 517
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 179

Lys Tyr Ser Thr Arg Asp Phe Ser Glu Leu Asn Glu Ile Gln Val Thr
1 5 10 15

Ala Cys Lys Gln Asp Glu Phe Phe Lys Val Ile Gln Asn Ala Trp Arg
20 25 30

Glu Ile Ile Lys Lys Arg Phe Leu Glu Asn Arg Glu Asn Phe Ile Glu
35 40 45

Lys Lys Ile Phe Lys Asn Lys Lys Gly Arg Gly Lys Arg Gln Glu Ser
50 55 60

Asp Lys Thr Ile Gln Arg Asn Arg Ala Ser Val Met Lys Asn Phe Gln
65 70 75 80

```
Leu Ile Glu Asn Glu Lys Ile Ile Leu Arg Ala Pro Ser Gly His Val
                85                  90                  95

Ala Cys Val Phe Pro Val Lys Val Gly Leu Asp Ile Gly Gly Phe Lys
            100                 105                 110

Thr Asp Asp Leu Glu Lys Asn Ile Phe Pro Pro Arg Thr Ile Thr Ile
        115                 120                 125

Asn Val Phe Trp Lys Asn Arg Asp Arg Gln Arg Lys Gly Arg Lys Leu
    130                 135                 140

Glu Val Trp Gly Ile Lys Ala Arg Thr Lys Leu Ile Glu Lys Val His
145                 150                 155                 160

Lys Trp Asp Lys Leu Glu Glu Val Lys Lys Lys Arg Leu Lys Ser Leu
                165                 170                 175

Glu Gln Lys Gln Glu Lys Ser Leu Asp Asn Trp Ser Glu Val Asn Asn
            180                 185                 190

Asp Ser Phe Tyr Lys Val Gln Ile Asp Glu Leu Gln Glu Lys Ile Asp
        195                 200                 205

Lys Ser Leu Lys Gly Arg Thr Met Asn Lys Ile Leu Asp Asn Lys Ala
    210                 215                 220

Lys Glu Ser Lys Glu Ala Glu Gly Leu Tyr Ile Glu Trp Glu Lys Asp
225                 230                 235                 240

Phe Glu Gly Glu Met Leu Arg Arg Ile Glu Ala Ser Thr Gly Gly Glu
                245                 250                 255

Glu Lys Trp Gly Lys Arg Arg Gln Arg Arg His Thr Ser Leu Leu Leu
            260                 265                 270
```

```
Asp Ile Lys Asn Asn Ser Arg Gly Ser Lys Glu Ile Ile Asn Phe Tyr
        275                 280                 285

Ser Tyr Ala Lys Gln Gly Lys Lys Glu Lys Lys Ile Glu Phe Phe Pro
    290                 295                 300

Phe Pro Leu Thr Ile Thr Leu Asp Ala Glu Glu Glu Ser Pro Leu Asn
305                 310                 315                 320

Ile Lys Ser Ile Pro Ile Glu Asp Lys Asn Ala Thr Ser Lys Tyr Phe
                325                 330                 335

Ser Ile Pro Phe Thr Glu Thr Arg Ala Thr Pro Leu Ser Ile Leu Gly
            340                 345                 350

Asp Arg Val Gln Lys Phe Lys Thr Lys Asn Ile Ser Gly Ala Ile Lys
        355                 360                 365

Arg Asn Leu Gly Ser Ser Ile Ser Ser Cys Lys Ile Val Gln Asn Ala
    370                 375                 380

Glu Thr Ser Ala Lys Ser Ile Leu Ser Leu Pro Asn Val Lys Glu Asp
385                 390                 395                 400

Asn Asn Met Glu Ile Phe Ile Asn Thr Met Ser Lys Asn Tyr Phe Arg
                405                 410                 415

Ala Met Met Lys Gln Met Glu Ser Phe Ile Phe Glu Met Glu Pro Lys
            420                 425                 430

Thr Leu Ile Asp Pro Tyr Lys Glu Lys Ala Ile Lys Trp Phe Glu Val
        435                 440                 445

Ala Ala Ser Ser Arg Ala Lys Arg Lys Leu Lys Lys Leu Ser Lys Ala
    450                 455                 460
```

```
Asp Ile Lys Lys Ser Glu Leu Leu Leu Ser Asn Thr Glu Glu Phe Glu
465                 470                 475                 480


Lys Glu Lys Gln Glu Lys Leu Glu Ala Leu Glu Lys Glu Ile Glu Glu
                485                 490                 495


Phe Tyr Leu Pro Arg Ile Val Arg Leu Gln Leu Thr Lys Thr Ile Leu
            500                 505                 510


Glu Thr Pro Val Met
        515


<210>  180
<211>  481
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  180

Lys Lys Leu Gln Leu Leu Gly His Lys Ile Leu Leu Lys Glu Tyr Asp
1               5                   10                  15


Pro Asn Ala Val Asn Ala Ala Ala Asn Phe Glu Thr Ser Thr Ala Glu
            20                  25                  30


Leu Cys Gly Gln Cys Lys Met Lys Pro Phe Lys Asn Lys Arg Arg Phe
        35                  40                  45


Gln Tyr Thr Phe Gly Lys Asn Tyr His Gly Cys Leu Ser Cys Ile Gln
    50                  55                  60


Asn Val Tyr Tyr Ala Lys Lys Arg Ile Val Gln Ile Ala Lys Glu Glu
65                  70                  75                  80


Leu Lys His Gln Leu Thr Asp Ser Ile Ala Ser Ile Pro Tyr Lys Tyr
```

```
                85                  90                  95

Thr Ser Leu Phe Ser Asn Thr Asn Ser Ile Asp Glu Leu Tyr Ile Leu
            100                 105                 110

Lys Gln Glu Arg Ala Ala Phe Phe Ser Asn Thr Asn Ser Ile Asp Glu
        115                 120                 125

Leu Tyr Ile Thr Gly Ile Glu Asn Asn Ile Ala Phe Lys Val Ile Ser
    130                 135                 140

Ala Ile Trp Asp Glu Ile Ile Lys Lys Arg Arg Gln Arg Tyr Ala Glu
145                 150                 155                 160

Ser Leu Thr Asp Thr Gly Thr Val Lys Ala Asn Arg Gly His Gly Gly
                165                 170                 175

Thr Ala Tyr Lys Ser Asn Thr Arg Gln Glu Lys Ile Arg Ala Leu Gln
            180                 185                 190

Lys Gln Thr Leu His Met Val Thr Asn Pro Tyr Ile Ser Leu Ala Arg
        195                 200                 205

Tyr Lys Asn Asn Tyr Ile Val Ala Thr Leu Pro Arg Thr Ile Gly Met
    210                 215                 220

His Ile Gly Ala Ile Lys Asp Arg Asp Pro Gln Lys Lys Leu Ser Asp
225                 230                 235                 240

Tyr Ala Ile Asn Phe Asn Val Phe Trp Ser Asp Asp Arg Gln Leu Ile
                245                 250                 255

Glu Leu Ser Thr Val Gln Tyr Thr Gly Asp Met Val Arg Lys Ile Glu
            260                 265                 270

Ala Glu Thr Gly Glu Asn Asn Lys Trp Gly Glu Asn Met Lys Arg Thr
```

```
        275                 280                 285

Lys Thr Ser Leu Leu Leu Glu Ile Leu Thr Lys Lys Thr Thr Asp Glu
    290                 295                 300

Leu Thr Phe Lys Asp Trp Ala Phe Ser Thr Lys Lys Glu Ile Asp Ser
305                 310                 315                 320

Val Thr Lys Lys Thr Tyr Gln Gly Phe Pro Ile Gly Ile Ile Phe Glu
                325                 330                 335

Gly Asn Glu Ser Ser Val Lys Phe Gly Ser Gln Asn Tyr Phe Pro Leu
            340                 345                 350

Pro Phe Asp Ala Lys Ile Thr Pro Pro Thr Ala Glu Gly Phe Arg Leu
        355                 360                 365

Asp Trp Leu Arg Lys Gly Ser Phe Ser Ser Gln Met Lys Thr Ser Tyr
    370                 375                 380

Gly Leu Ala Ile Tyr Ser Asn Lys Val Thr Asn Ala Ile Pro Ala Tyr
385                 390                 395                 400

Val Ile Lys Asn Met Phe Tyr Lys Ile Ala Arg Ala Glu Asn Gly Lys
                405                 410                 415

Gln Ile Lys Ala Lys Phe Leu Lys Lys Tyr Leu Asp Ile Ala Gly Asn
            420                 425                 430

Asn Tyr Val Pro Phe Ile Ile Met Gln His Tyr Arg Val Leu Asp Thr
        435                 440                 445

Phe Glu Glu Met Pro Ile Ser Gln Pro Lys Val Ile Arg Leu Ser Leu
    450                 455                 460

Thr Lys Thr Gln His Ile Ile Ile Lys Lys Asp Lys Thr Asp Ser Lys
```

465 470 475 480

Met

<210> 181
<211> 534
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 181

Asn Thr Ser Asn Leu Ile Asn Leu Gly Lys Lys Ala Ile Asn Ile Ser
1 5 10 15

Ala Asn Tyr Asp Ala Asn Leu Glu Val Gly Cys Lys Asn Cys Lys Phe
20 25 30

Leu Ser Ser Asn Gly Asn Phe Pro Arg Gln Thr Asn Val Lys Glu Gly
35 40 45

Cys His Ser Cys Glu Lys Ser Thr Tyr Glu Pro Ser Ile Tyr Leu Val
50 55 60

Lys Ile Gly Glu Arg Lys Ala Lys Tyr Asp Val Leu Asp Ser Leu Lys
65 70 75 80

Lys Phe Thr Phe Gln Ser Leu Lys Tyr Gln Ser Lys Lys Ser Met Lys
85 90 95

Ser Arg Asn Lys Lys Pro Lys Glu Leu Lys Glu Phe Val Ile Phe Ala
100 105 110

Asn Lys Asn Lys Ala Phe Asp Val Ile Gln Lys Ser Tyr Asn His Leu
115 120 125

```
Ile Leu Gln Ile Lys Lys Glu Ile Asn Arg Met Asn Ser Lys Lys Arg
    130                 135                 140

Lys Lys Asn His Lys Arg Arg Leu Phe Arg Asp Arg Glu Lys Gln Leu
145                 150                 155                 160

Asn Lys Leu Arg Leu Ile Glu Ser Ser Asn Leu Phe Leu Pro Arg Glu
                165                 170                 175

Asn Lys Gly Asn Asn His Val Phe Thr Tyr Val Ala Ile His Ser Val
            180                 185                 190

Gly Arg Asp Ile Gly Val Ile Gly Ser Tyr Asp Glu Lys Leu Asn Phe
        195                 200                 205

Glu Thr Glu Leu Thr Tyr Gln Leu Tyr Phe Asn Asp Asp Lys Arg Leu
    210                 215                 220

Leu Tyr Ala Tyr Lys Pro Lys Gln Asn Lys Ile Ile Lys Ile Lys Glu
225                 230                 235                 240

Lys Leu Trp Asn Leu Arg Lys Glu Lys Glu Pro Leu Asp Leu Glu Tyr
                245                 250                 255

Glu Lys Pro Leu Asn Lys Ser Ile Thr Phe Ser Ile Lys Asn Asp Asn
            260                 265                 270

Leu Phe Lys Val Ser Lys Asp Leu Met Leu Arg Arg Ala Lys Phe Asn
        275                 280                 285

Ile Gln Gly Lys Glu Lys Leu Ser Lys Glu Glu Arg Lys Ile Asn Arg
    290                 295                 300

Asp Leu Ile Lys Ile Lys Gly Leu Val Asn Ser Met Ser Tyr Gly Arg
305                 310                 315                 320
```

```
Phe Asp Glu Leu Lys Lys Glu Lys Asn Ile Trp Ser Pro His Ile Tyr
                325                 330                 335

Arg Glu Val Arg Gln Lys Glu Ile Lys Pro Cys Leu Ile Lys Asn Gly
            340                 345                 350

Asp Arg Ile Glu Ile Phe Glu Gln Leu Lys Lys Lys Met Glu Arg Leu
        355                 360                 365

Arg Arg Phe Arg Glu Lys Arg Gln Lys Lys Ile Ser Lys Asp Leu Ile
    370                 375                 380

Phe Ala Glu Arg Ile Ala Tyr Asn Phe His Thr Lys Ser Ile Lys Asn
385                 390                 395                 400

Thr Ser Asn Lys Ile Asn Ile Asp Gln Glu Ala Lys Arg Gly Lys Ala
                405                 410                 415

Ser Tyr Met Arg Lys Arg Ile Gly Tyr Glu Thr Phe Lys Asn Lys Tyr
            420                 425                 430

Cys Glu Gln Cys Leu Ser Lys Gly Asn Val Tyr Arg Asn Val Gln Lys
        435                 440                 445

Gly Cys Ser Cys Phe Glu Asn Pro Phe Asp Trp Ile Lys Lys Gly Asp
    450                 455                 460

Glu Asn Leu Leu Pro Lys Lys Asn Glu Asp Leu Arg Val Lys Gly Ala
465                 470                 475                 480

Phe Arg Asp Glu Ala Leu Glu Lys Gln Ile Val Lys Ile Ala Phe Asn
                485                 490                 495

Ile Ala Lys Gly Tyr Glu Asp Phe Tyr Asp Asn Leu Gly Glu Ser Thr
            500                 505                 510
```

Glu Lys Asp Leu Lys Leu Lys Phe Lys Val Gly Thr Thr Ile Asn Glu
        515   520   525

Gln Glu Ser Leu Lys Leu
    530

<210> 182
<211> 537
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 182

Thr Ser Asn Pro Ile Lys Leu Gly Lys Lys Ala Ile Asn Ile Ser Ala
1   5   10   15

Asn Tyr Asp Ser Asn Leu Gln Ile Gly Cys Lys Asn Cys Lys Phe Leu
            20   25   30

Ser Tyr Asn Gly Asn Phe Pro Arg Gln Thr Asn Val Lys Glu Gly Cys
        35   40   45

His Ser Cys Glu Lys Ser Thr Tyr Glu Pro Pro Val Tyr Thr Val Arg
    50   55   60

Ile Gly Glu Arg Arg Ser Lys Tyr Asp Val Leu Asp Ser Leu Lys Lys
65   70   75   80

Phe Ile Phe Leu Ser Leu Lys Tyr Arg Gln Ser Lys Lys Met Lys Thr
                85   90   95

Arg Ser Lys Gly Ile Arg Gly Leu Glu Glu Phe Val Ile Ser Ala Asn
            100   105   110

Leu Lys Lys Ala Met Asp Val Ile Gln Lys Ser Tyr Arg His Leu Ile

```
        115                 120                 125

Leu Asn Ile Lys Asn Glu Ile Val Arg Met Asn Gly Lys Lys Arg Asn
    130                 135                 140

Lys Asn His Lys Arg Leu Leu Phe Arg Asp Arg Glu Lys Gln Leu Asn
145                 150                 155                 160

Lys Leu Arg Leu Ile Glu Gly Ser Ser Phe Phe Lys Pro Pro Thr Val
                165                 170                 175

Lys Gly Asp Asn Ser Ile Phe Thr Cys Val Ala Ile His Asn Ile Gly
            180                 185                 190

Arg Asp Ile Gly Ile Ala Gly Asp Tyr Phe Asp Lys Leu Glu Pro Lys
        195                 200                 205

Ile Glu Leu Thr Tyr Gln Leu Tyr Tyr Glu Tyr Asn Pro Lys Lys Glu
    210                 215                 220

Ser Glu Ile Asn Lys Arg Leu Leu Tyr Ala Tyr Lys Pro Lys Gln Asn
225                 230                 235                 240

Lys Ile Ile Glu Ile Lys Glu Lys Leu Trp Asn Leu Arg Lys Glu Lys
                245                 250                 255

Ser Pro Leu Asp Leu Glu Tyr Glu Lys Pro Leu Thr Lys Ser Ile Thr
            260                 265                 270

Phe Leu Val Lys Arg Asp Gly Val Phe Arg Ile Ser Lys Asp Leu Met
        275                 280                 285

Leu Arg Lys Ala Lys Phe Ile Ile Gln Gly Lys Glu Lys Leu Ser Lys
    290                 295                 300

Glu Glu Arg Lys Ile Asn Arg Asp Leu Ile Lys Ile Lys Ser Asn Ile
```

305 310 315 320

Ile Ser Leu Thr Tyr Gly Arg Phe Asp Glu Leu Lys Lys Asp Lys Thr
325 330 335

Ile Trp Ser Pro His Ile Phe Arg Asp Val Lys Gln Gly Lys Ile Thr
340 345 350

Pro Cys Ile Glu Arg Lys Gly Asp Arg Met Asp Ile Phe Gln Gln Leu
355 360 365

Arg Lys Lys Ser Glu Arg Leu Arg Glu Asn Arg Lys Lys Arg Gln Lys
370 375 380

Lys Ile Ser Lys Asp Leu Ile Phe Ala Glu Arg Ile Ala Tyr Asn Phe
385 390 395 400

His Thr Lys Ser Ile Lys Asn Thr Ser Asn Leu Ile Asn Ile Lys His
405 410 415

Glu Ala Lys Arg Gly Lys Ala Ser Tyr Met Arg Lys Arg Ile Gly Asn
420 425 430

Glu Thr Phe Arg Ile Lys Tyr Cys Glu Gln Cys Phe Pro Lys Asn Asn
435 440 445

Val Tyr Lys Asn Val Gln Lys Gly Cys Ser Cys Phe Glu Asp Pro Phe
450 455 460

Glu Tyr Ile Lys Lys Gly Asn Glu Asp Leu Ile Pro Asn Lys Asn Gln
465 470 475 480

Asp Leu Lys Ala Lys Gly Ala Phe Arg Asp Asp Ala Leu Glu Lys Gln
485 490 495

Ile Ile Lys Val Ala Phe Asn Ile Ala Lys Gly Tyr Glu Asp Phe Tyr

500 505 510

Glu Asn Leu Lys Lys Thr Thr Glu Lys Asp Ile Arg Leu Lys Phe Lys
515 520 525

Val Gly Thr Ile Ile Ser Glu Glu Met
530 535

<210> 183
<211> 541
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 183

Asn Asn Ser Ile Asn Leu Ser Lys Lys Ala Ile Asn Ile Ser Ala Asn
1 5 10 15

Tyr Asp Ala Asn Leu Gln Val Arg Cys Lys Asn Cys Lys Phe Leu Ser
20 25 30

Ser Asn Gly Asn Phe Pro Arg Gln Thr Asp Val Lys Glu Gly Cys His
35 40 45

Ser Cys Glu Lys Ser Thr Tyr Glu Pro Pro Val Tyr Asp Val Lys Ile
50 55 60

Gly Glu Ile Lys Ala Lys Tyr Glu Val Leu Asp Ser Leu Lys Lys Phe
65 70 75 80

Thr Phe Gln Ser Leu Lys Tyr Gln Leu Ser Lys Ser Met Lys Phe Arg
85 90 95

Ser Lys Lys Ile Lys Glu Leu Lys Glu Phe Val Ile Phe Ala Lys Glu
100 105 110

```
Ser Lys Ala Leu Asn Val Ile Asn Arg Ser Tyr Lys His Leu Ile Leu
        115                 120                 125


Asn Ile Lys Asn Asp Ile Asn Arg Met Asn Ser Lys Lys Arg Ile Lys
    130                 135                 140


Asn His Lys Gly Arg Leu Phe Leu Asp Arg Gln Lys Gln Leu Ser Lys
145                 150                 155                 160


Leu Lys Leu Ile Glu Gly Ser Ser Phe Phe Val Pro Ala Lys Asn Val
                165                 170                 175


Gly Asn Lys Ser Val Phe Thr Cys Val Ala Ile His Ser Ile Gly Arg
            180                 185                 190


Asp Ile Gly Ile Ala Gly Leu Tyr Asp Ser Phe Thr Lys Pro Val Asn
        195                 200                 205


Glu Ile Thr Tyr Gln Ile Phe Phe Ser Gly Glu Arg Arg Leu Leu Tyr
    210                 215                 220


Ala Tyr Lys Pro Lys Gln Leu Lys Ile Leu Ser Ile Lys Glu Asn Leu
225                 230                 235                 240


Trp Ser Leu Lys Asn Glu Lys Lys Pro Leu Asp Leu Leu Tyr Glu Lys
                245                 250                 255


Pro Leu Gly Lys Asn Leu Asn Phe Asn Val Lys Gly Gly Asp Leu Phe
            260                 265                 270


Arg Val Ser Lys Asp Leu Met Ile Arg Asn Ala Lys Phe Asn Val His
        275                 280                 285


Gly Arg Gln Arg Leu Ser Asp Glu Glu Arg Leu Ile Asn Arg Asn Phe
    290                 295                 300
```

```
Ile Lys Ile Lys Gly Glu Val Val Ser Leu Ser Tyr Gly Arg Phe Glu
305                 310                 315                 320


Glu Leu Lys Lys Asp Arg Lys Leu Trp Ser Pro His Ile Phe Lys Asp
                325                 330                 335


Val Arg Gln Asn Lys Ile Lys Pro Cys Leu Val Met Gln Gly Gln Arg
            340                 345                 350


Ile Asp Ile Phe Glu Gln Leu Lys Arg Lys Leu Glu Leu Leu Lys Lys
        355                 360                 365


Ile Arg Lys Ser Arg Gln Lys Lys Leu Ser Lys Asp Leu Ile Phe Gly
    370                 375                 380


Glu Arg Ile Ala Tyr Asn Phe His Thr Lys Ser Ile Lys Asn Thr Ser
385                 390                 395                 400


Asn Lys Ile Asn Ile Asp Ser Asp Ala Lys Arg Gly Arg Ala Ser Tyr
                405                 410                 415


Met Arg Lys Arg Ile Gly Asn Glu Thr Phe Lys Leu Lys Tyr Cys Asp
            420                 425                 430


Val Cys Phe Pro Lys Ala Asn Val Tyr Arg Arg Val Gln Asn Gly Cys
        435                 440                 445


Ser Cys Ser Glu Asn Pro Tyr Asn Tyr Ile Lys Lys Gly Asp Lys Asp
    450                 455                 460


Leu Leu Pro Lys Lys Asp Glu Gly Leu Ala Ile Lys Gly Ala Phe Arg
465                 470                 475                 480


Asp Glu Lys Leu Asn Lys Gln Ile Ile Lys Val Ala Phe Asn Ile Ala
                485                 490                 495
```

Lys Gly Tyr Glu Asp Phe Tyr Asp Asp Leu Lys Lys Arg Thr Glu Lys
500 505 510

Asp Val Asp Leu Lys Phe Lys Ile Gly Thr Thr Val Leu Asp Gln Lys
515 520 525

Pro Met Glu Ile Phe Asp Gly Ile Val Ile Thr Trp Leu
530 535 540

<210> 184
<211> 542
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 184

Leu Leu Thr Thr Val Val Glu Thr Asn Asn Leu Ala Lys Lys Ala Ile
1 5 10 15

Asn Val Ala Ala Asn Phe Asp Ala Asn Ile Asp Arg Gln Tyr Tyr Arg
20 25 30

Cys Thr Pro Asn Leu Cys Arg Phe Ile Ala Gln Ser Pro Arg Glu Thr
35 40 45

Lys Glu Lys Asp Ala Gly Cys Ser Ser Cys Thr Gln Ser Thr Tyr Asp
50 55 60

Pro Lys Val Tyr Val Ile Lys Ile Gly Lys Leu Leu Ala Lys Tyr Glu
65 70 75 80

Ile Leu Lys Ser Leu Lys Arg Phe Leu Phe Met Asn Arg Tyr Phe Lys
85 90 95

Gln Lys Lys Thr Glu Arg Ala Gln Gln Lys Gln Lys Ile Gly Thr Glu

```
            100                 105                 110

Leu Asn Glu Met Ser Ile Phe Ala Lys Ala Thr Asn Ala Met Glu Val
        115                 120                 125

Ile Lys Arg Ala Thr Lys His Cys Thr Tyr Asp Ile Ile Pro Glu Thr
    130                 135                 140

Lys Ser Leu Gln Met Leu Lys Arg Arg Arg His Arg Val Lys Val Arg
145                 150                 155                 160

Ser Leu Leu Lys Ile Leu Lys Glu Arg Arg Met Lys Ile Lys Lys Ile
                165                 170                 175

Pro Asn Thr Phe Ile Glu Ile Pro Lys Gln Ala Lys Lys Asn Lys Ser
            180                 185                 190

Asp Tyr Tyr Val Ala Ala Ala Leu Lys Ser Cys Gly Ile Asp Val Gly
        195                 200                 205

Leu Cys Gly Ala Tyr Glu Lys Asn Ala Glu Val Glu Ala Glu Tyr Thr
    210                 215                 220

Tyr Gln Leu Tyr Tyr Glu Tyr Lys Gly Asn Ser Ser Thr Lys Arg Ile
225                 230                 235                 240

Leu Tyr Cys Tyr Asn Asn Pro Gln Lys Asn Ile Arg Glu Phe Trp Glu
                245                 250                 255

Ala Phe Tyr Ile Gln Gly Ser Lys Ser His Val Asn Thr Pro Gly Thr
            260                 265                 270

Ile Arg Leu Lys Met Glu Lys Phe Leu Ser Pro Ile Thr Ile Glu Ser
        275                 280                 285

Glu Ala Leu Asp Phe Arg Val Trp Asn Ser Asp Leu Lys Ile Arg Asn
```

```
    290                 295                 300

Gly Gln Tyr Gly Phe Ile Lys Lys Arg Ser Leu Gly Lys Glu Ala Arg
305                 310                 315                 320

Glu Ile Lys Lys Gly Met Gly Asp Ile Lys Arg Lys Ile Gly Asn Leu
                325                 330                 335

Thr Tyr Gly Lys Ser Pro Ser Glu Leu Lys Ser Ile His Val Tyr Arg
            340                 345                 350

Thr Glu Arg Glu Asn Pro Lys Lys Pro Arg Ala Ala Arg Lys Lys Glu
        355                 360                 365

Asp Asn Phe Met Glu Ile Phe Glu Met Gln Arg Lys Lys Asp Tyr Glu
    370                 375                 380

Val Asn Lys Lys Arg Arg Lys Glu Ala Thr Asp Ala Ala Lys Ile Met
385                 390                 395                 400

Asp Phe Ala Glu Glu Pro Ile Arg His Tyr His Thr Asn Asn Leu Lys
                405                 410                 415

Ala Val Arg Arg Ile Asp Met Asn Glu Gln Val Glu Arg Lys Lys Thr
            420                 425                 430

Ser Val Phe Leu Lys Arg Ile Met Gln Asn Gly Tyr Arg Gly Asn Tyr
        435                 440                 445

Cys Arg Lys Cys Ile Lys Ala Pro Glu Gly Ser Asn Arg Asp Glu Asn
    450                 455                 460

Val Leu Glu Lys Asn Glu Gly Cys Leu Asp Cys Ile Gly Ser Glu Phe
465                 470                 475                 480

Ile Trp Lys Lys Ser Ser Lys Glu Lys Lys Gly Leu Trp His Thr Asn
```

485 490 495

Arg Leu Leu Arg Arg Ile Arg Leu Gln Cys Phe Thr Thr Ala Lys Ala
500 505 510

Tyr Glu Asn Phe Tyr Asn Asp Leu Phe Glu Lys Lys Glu Ser Ser Leu
515 520 525

Asp Ile Ile Lys Leu Lys Val Ser Ile Thr Thr Lys Ser Met
530 535 540

<210> 185
<211> 564
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 185

Ala Ser Thr Met Asn Leu Ala Lys Gln Ala Ile Asn Phe Ala Ala Asn
1 5 10 15

Tyr Asp Ser Asn Leu Glu Ile Gly Cys Lys Gly Cys Lys Phe Met Ser
20 25 30

Thr Trp Ser Lys Lys Ser Asn Pro Lys Phe Tyr Pro Arg Gln Asn Asn
35 40 45

Gln Ala Asn Lys Cys His Ser Cys Thr Tyr Ser Thr Gly Glu Pro Glu
50 55 60

Val Pro Ile Ile Glu Ile Gly Glu Arg Ala Ala Lys Tyr Lys Ile Phe
65 70 75 80

Thr Ala Leu Lys Lys Phe Val Phe Met Ser Val Ala Tyr Lys Glu Arg
85 90 95

```
Arg Arg Gln Arg Phe Lys Ser Lys Lys Pro Lys Glu Leu Lys Glu Leu
            100                 105                 110


Ala Ile Cys Ser Asn Arg Glu Lys Ala Met Glu Val Ile Gln Lys Ser
        115                 120                 125


Val Val His Cys Tyr Gly Asp Val Lys Gln Glu Ile Pro Arg Ile Arg
    130                 135                 140


Lys Ile Lys Val Leu Lys Asn His Lys Gly Arg Leu Phe Tyr Lys Gln
145                 150                 155                 160


Lys Arg Ser Lys Ile Lys Ile Ala Lys Leu Glu Lys Gly Ser Phe Phe
                165                 170                 175


Lys Thr Phe Ile Pro Lys Val His Asn Asn Gly Cys His Ser Cys His
            180                 185                 190


Glu Ala Ser Leu Asn Lys Pro Ile Leu Val Thr Thr Ala Leu Asn Thr
        195                 200                 205


Ile Gly Ala Asp Ile Gly Leu Ile Asn Asp Tyr Ser Thr Ile Ala Pro
    210                 215                 220


Thr Glu Thr Asp Ile Ser Trp Gln Val Tyr Tyr Glu Phe Ile Pro Asn
225                 230                 235                 240


Gly Asp Ser Glu Ala Val Lys Lys Arg Leu Leu Tyr Phe Tyr Lys Pro
                245                 250                 255


Lys Gly Ala Leu Ile Lys Ser Ile Arg Asp Lys Tyr Phe Lys Lys Gly
            260                 265                 270


His Glu Asn Ala Val Asn Thr Gly Phe Phe Lys Tyr Gln Gly Lys Ile
        275                 280                 285
```

```
Val Lys Gly Pro Ile Lys Phe Val Asn Asn Glu Leu Asp Phe Ala Arg
    290                 295                 300

Lys Pro Asp Leu Lys Ser Met Lys Ile Lys Arg Ala Gly Phe Ala Ile
305                 310                 315                 320

Pro Ser Ala Lys Arg Leu Ser Lys Glu Asp Arg Glu Ile Asn Arg Glu
                325                 330                 335

Ser Ile Lys Ile Lys Asn Lys Ile Tyr Ser Leu Ser Tyr Gly Arg Lys
            340                 345                 350

Lys Thr Leu Ser Asp Lys Asp Ile Ile Lys His Leu Tyr Arg Pro Val
        355                 360                 365

Arg Gln Lys Gly Val Lys Pro Leu Glu Tyr Arg Lys Ala Pro Asp Gly
    370                 375                 380

Phe Leu Glu Phe Phe Tyr Ser Leu Lys Arg Lys Glu Arg Arg Leu Arg
385                 390                 395                 400

Lys Gln Lys Glu Lys Arg Gln Lys Asp Met Ser Glu Ile Ile Asp Ala
                405                 410                 415

Ala Asp Glu Phe Ala Trp His Arg His Thr Gly Ser Ile Lys Lys Thr
            420                 425                 430

Thr Asn His Ile Asn Phe Lys Ser Glu Val Lys Arg Gly Lys Val Pro
        435                 440                 445

Ile Met Lys Lys Arg Ile Ala Asn Asp Ser Phe Asn Thr Arg His Cys
    450                 455                 460

Gly Lys Cys Val Lys Gln Gly Asn Ala Ile Asn Lys Tyr Tyr Ile Glu
465                 470                 475                 480
```

Lys Gln Lys Asn Cys Phe Asp Cys Asn Ser Ile Glu Phe Lys Trp Glu
485 490 495

Lys Ala Ala Leu Glu Lys Lys Gly Ala Phe Lys Leu Asn Lys Arg Leu
500 505 510

Gln Tyr Ile Val Lys Ala Cys Phe Asn Val Ala Lys Ala Tyr Glu Ser
515 520 525

Phe Tyr Glu Asp Phe Arg Lys Gly Glu Glu Glu Ser Leu Asp Leu Lys
530 535 540

Phe Lys Ile Gly Thr Thr Thr Thr Leu Lys Gln Tyr Pro Gln Asn Lys
545 550 555 560

Ala Arg Ala Met

<210> 186
<211> 610
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 186

His Ser His Asn Leu Met Leu Thr Lys Leu Gly Lys Gln Ala Ile Asn
1 5 10 15

Phe Ala Ala Asn Tyr Asp Ala Asn Leu Glu Ile Gly Cys Lys Asn Cys
20 25 30

Lys Phe Leu Ser Tyr Ser Pro Lys Gln Ala Asn Pro Lys Lys Tyr Pro
35 40 45

Arg Gln Thr Asp Val His Glu Asp Gly Asn Ile Ala Cys His Ser Cys

```
    50                  55                  60

Met Gln Ser Thr Lys Glu Pro Pro Val Tyr Ile Val Pro Ile Gly Glu
65                  70                  75                  80

Arg Lys Ser Lys Tyr Glu Ile Leu Thr Ser Leu Asn Lys Phe Thr Phe
                85                  90                  95

Leu Ala Leu Lys Tyr Lys Glu Lys Lys Arg Gln Ala Phe Arg Ala Lys
            100                 105                 110

Lys Pro Lys Glu Leu Gln Glu Leu Ala Ile Ala Phe Asn Lys Glu Lys
        115                 120                 125

Ala Ile Lys Val Ile Asp Lys Ser Ile Gln His Leu Ile Leu Asn Ile
    130                 135                 140

Lys Pro Glu Ile Ala Arg Ile Gln Arg Gln Lys Arg Leu Lys Asn Arg
145                 150                 155                 160

Lys Gly Lys Leu Leu Tyr Leu His Lys Arg Tyr Ala Ile Lys Met Gly
                165                 170                 175

Leu Ile Lys Asn Gly Lys Tyr Phe Lys Val Gly Ser Pro Lys Lys Asp
            180                 185                 190

Gly Lys Lys Leu Leu Val Leu Cys Ala Leu Asn Thr Ile Gly Arg Asp
        195                 200                 205

Ile Gly Ile Ile Gly Asn Ile Glu Glu Asn Asn Arg Ser Glu Thr Glu
    210                 215                 220

Ile Thr Tyr Gln Leu Tyr Phe Asp Cys Leu Asp Ala Asn Pro Asn Glu
225                 230                 235                 240

Leu Arg Ile Lys Glu Ile Glu Tyr Asn Arg Leu Lys Ser Tyr Glu Arg
```

```
                245                 250                 255

Lys Ile Lys Arg Leu Val Tyr Ala Tyr Lys Pro Lys Gln Thr Lys Ile
            260                 265                 270

Leu Glu Ile Arg Ser Lys Phe Phe Ser Lys Gly His Glu Asn Lys Val
        275                 280                 285

Asn Thr Gly Ser Phe Asn Phe Glu Asn Pro Leu Asn Lys Ser Ile Ser
    290                 295                 300

Ile Lys Val Lys Asn Ser Ala Phe Asp Phe Lys Ile Gly Ala Pro Phe
305                 310                 315                 320

Ile Met Leu Arg Asn Gly Lys Phe His Ile Pro Thr Lys Lys Arg Leu
                325                 330                 335

Ser Lys Glu Glu Arg Glu Ile Asn Arg Thr Leu Ser Lys Ile Lys Gly
            340                 345                 350

Arg Val Phe Arg Leu Thr Tyr Gly Arg Asn Ile Ser Glu Gln Gly Ser
        355                 360                 365

Lys Ser Leu His Ile Tyr Arg Lys Glu Arg Gln His Pro Lys Leu Ser
    370                 375                 380

Leu Glu Ile Arg Lys Gln Pro Asp Ser Phe Ile Asp Glu Phe Glu Lys
385                 390                 395                 400

Leu Arg Leu Lys Gln Asn Phe Ile Ser Lys Leu Lys Lys Gln Arg Gln
                405                 410                 415

Lys Lys Leu Ala Asp Leu Leu Gln Phe Ala Asp Arg Ile Ala Tyr Asn
            420                 425                 430

Tyr His Thr Ser Ser Leu Glu Lys Thr Ser Asn Phe Ile Asn Tyr Lys
```

```
        435                 440                 445

Pro Glu Val Lys Arg Gly Arg Thr Ser Tyr Ile Lys Lys Arg Ile Gly
    450                 455                 460

Asn Glu Gly Phe Glu Lys Leu Tyr Cys Glu Thr Cys Ile Lys Ser Asn
465                 470                 475                 480

Asp Lys Glu Asn Ala Tyr Ala Val Glu Lys Glu Glu Leu Cys Phe Val
                485                 490                 495

Cys Lys Ala Lys Pro Phe Thr Trp Lys Lys Thr Asn Lys Asp Lys Leu
            500                 505                 510

Gly Ile Phe Lys Tyr Pro Ser Arg Ile Lys Asp Phe Ile Arg Ala Ala
        515                 520                 525

Phe Thr Val Ala Lys Ser Tyr Asn Asp Phe Tyr Glu Asn Leu Lys Lys
    530                 535                 540

Lys Asp Leu Lys Asn Glu Ile Phe Leu Lys Phe Lys Ile Gly Leu Ile
545                 550                 555                 560

Leu Ser His Glu Lys Lys Asn His Ile Ser Ile Ala Lys Ser Val Ala
                565                 570                 575

Glu Asp Glu Arg Ile Ser Gly Lys Ser Ile Lys Asn Ile Leu Asn Lys
            580                 585                 590

Ser Ile Lys Leu Glu Lys Asn Cys Tyr Ser Cys Phe Phe His Lys Glu
        595                 600                 605

Asp Met
    610
```

<210> 187

<211> 552
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 187

```
Ser Leu Glu Arg Val Ile Asp Lys Arg Asn Leu Ala Lys Lys Ala Ile
1               5                  10                  15


Asn Ile Ala Ala Asn Phe Asp Ala Asn Ile Asn Lys Gly Phe Tyr Arg
            20                  25                  30


Cys Glu Thr Asn Gln Cys Met Phe Ile Ala Gln Lys Pro Arg Lys Thr
        35                  40                  45


Asn Asn Thr Gly Cys Ser Ser Cys Leu Gln Ser Thr Tyr Asp Pro Val
    50                  55                  60


Ile Tyr Val Val Lys Val Gly Glu Met Leu Ala Lys Tyr Glu Ile Leu
65                  70                  75                  80


Lys Ser Leu Lys Arg Phe Val Phe Met Asn Arg Ser Phe Lys Gln Lys
                85                  90                  95


Lys Thr Glu Lys Ala Lys Gln Lys Glu Arg Ile Gly Gly Glu Leu Asn
            100                 105                 110


Glu Met Ser Ile Phe Ala Asn Ala Ala Leu Ala Met Gly Val Ile Lys
        115                 120                 125


Arg Ala Ile Arg His Cys His Val Asp Ile Arg Pro Glu Ile Asn Arg
    130                 135                 140


Leu Ser Glu Leu Lys Lys Thr Lys His Arg Val Ala Ala Lys Ser Leu
145                 150                 155                 160
```

```
Val Lys Ile Val Lys Gln Arg Lys Thr Lys Trp Lys Gly Ile Pro Asn
                165                 170                 175


Ser Phe Ile Gln Ile Pro Gln Lys Ala Arg Asn Lys Asp Ala Asp Phe
            180                 185                 190


Tyr Val Ala Ser Ala Leu Lys Ser Gly Gly Ile Asp Ile Gly Leu Cys
        195                 200                 205


Gly Thr Tyr Asp Lys Lys Pro His Ala Asp Pro Arg Trp Thr Tyr Gln
    210                 215                 220


Leu Tyr Phe Asp Thr Glu Asp Glu Ser Glu Lys Arg Leu Leu Tyr Cys
225                 230                 235                 240


Tyr Asn Asp Pro Gln Ala Lys Ile Arg Asp Phe Trp Lys Thr Phe Tyr
                245                 250                 255


Glu Arg Gly Asn Pro Ser Met Val Asn Ser Pro Gly Thr Ile Glu Phe
            260                 265                 270


Arg Met Glu Gly Phe Phe Glu Lys Met Thr Pro Ile Ser Ile Glu Ser
        275                 280                 285


Lys Asp Phe Asp Phe Arg Val Trp Asn Lys Asp Leu Leu Ile Arg Arg
    290                 295                 300


Gly Leu Tyr Glu Ile Lys Lys Arg Lys Asn Leu Asn Arg Lys Ala Arg
305                 310                 315                 320


Glu Ile Lys Lys Ala Met Gly Ser Val Lys Arg Val Leu Ala Asn Met
                325                 330                 335


Thr Tyr Gly Lys Ser Pro Thr Asp Lys Lys Ser Ile Pro Val Tyr Arg
            340                 345                 350
```

```
Val Glu Arg Glu Lys Pro Lys Lys Pro Arg Ala Val Arg Lys Glu Glu
        355                 360                 365

Asn Glu Leu Ala Asp Lys Leu Glu Asn Tyr Arg Arg Glu Asp Phe Leu
    370                 375                 380

Ile Arg Asn Arg Arg Lys Arg Glu Ala Thr Glu Ile Ala Lys Ile Ile
385                 390                 395                 400

Asp Ala Ala Glu Pro Pro Ile Arg His Tyr His Thr Asn His Leu Arg
                405                 410                 415

Ala Val Lys Arg Ile Asp Leu Ser Lys Pro Val Ala Arg Lys Asn Thr
            420                 425                 430

Ser Val Phe Leu Lys Arg Ile Met Gln Asn Gly Tyr Arg Gly Asn Tyr
        435                 440                 445

Cys Lys Lys Cys Ile Lys Gly Asn Ile Asp Pro Asn Lys Asp Glu Cys
    450                 455                 460

Arg Leu Glu Asp Ile Lys Lys Cys Ile Cys Cys Glu Gly Thr Gln Asn
465                 470                 475                 480

Ile Trp Ala Lys Lys Glu Lys Leu Tyr Thr Gly Arg Ile Asn Val Leu
                485                 490                 495

Asn Lys Arg Ile Lys Gln Met Lys Leu Glu Cys Phe Asn Val Ala Lys
            500                 505                 510

Ala Tyr Glu Asn Phe Tyr Asp Asn Leu Ala Ala Leu Lys Glu Gly Asp
        515                 520                 525

Leu Lys Val Leu Lys Leu Lys Val Ser Ile Pro Ala Leu Asn Pro Glu
    530                 535                 540
```

Ala Ser Asp Pro Glu Glu Asp Met
545 550

<210> 188
<211> 534
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 188

Asn Ala Ser Ile Asn Leu Gly Lys Arg Ala Ile Asn Leu Ser Ala Asn
1 5 10 15

Tyr Asp Ser Asn Leu Val Ile Gly Cys Lys Asn Cys Lys Phe Leu Ser
20 25 30

Phe Asn Gly Asn Phe Pro Arg Gln Thr Asn Val Arg Glu Gly Cys His
35 40 45

Ser Cys Asp Lys Ser Thr Tyr Ala Pro Glu Val Tyr Ile Val Lys Ile
50 55 60

Gly Glu Arg Lys Ala Lys Tyr Asp Val Leu Asp Ser Leu Lys Lys Phe
65 70 75 80

Thr Phe Gln Ser Leu Lys Tyr Gln Ile Lys Lys Ser Met Arg Glu Arg
85 90 95

Ser Lys Lys Pro Lys Glu Leu Leu Glu Phe Val Ile Phe Ala Asn Lys
100 105 110

Asp Lys Ala Phe Asn Val Ile Gln Lys Ser Tyr Glu His Leu Ile Leu
115 120 125

Asn Ile Lys Gln Glu Ile Asn Arg Met Asn Gly Lys Lys Arg Ile Lys

```
    130                 135                 140

Asn His Lys Lys Arg Leu Phe Lys Asp Arg Glu Lys Gln Leu Asn Lys
145                 150                 155                 160

Leu Arg Leu Ile Gly Ser Ser Ser Leu Phe Phe Pro Arg Glu Asn Lys
                165                 170                 175

Gly Asp Lys Asp Leu Phe Thr Tyr Val Ala Ile His Ser Val Gly Arg
            180                 185                 190

Asp Ile Gly Val Ala Gly Ser Tyr Glu Ser His Ile Glu Pro Ile Ser
        195                 200                 205

Asp Leu Thr Tyr Gln Leu Phe Ile Asn Asn Glu Lys Arg Leu Leu Tyr
    210                 215                 220

Ala Tyr Lys Pro Lys Gln Asn Lys Ile Ile Glu Leu Lys Glu Asn Leu
225                 230                 235                 240

Trp Asn Leu Lys Lys Glu Lys Lys Pro Leu Asp Leu Glu Phe Thr Lys
                245                 250                 255

Pro Leu Glu Lys Ser Ile Thr Phe Ser Val Lys Asn Asp Lys Leu Phe
            260                 265                 270

Lys Val Ser Lys Asp Leu Met Leu Arg Gln Ala Lys Phe Asn Ile Gln
        275                 280                 285

Gly Lys Glu Lys Leu Ser Lys Glu Glu Arg Gln Ile Asn Arg Asp Phe
    290                 295                 300

Ser Lys Ile Lys Ser Asn Val Ile Ser Leu Ser Tyr Gly Arg Phe Glu
305                 310                 315                 320

Glu Leu Lys Lys Glu Lys Asn Ile Trp Ser Pro His Ile Tyr Arg Glu
```

```
                325                 330                 335

Val Lys Gln Lys Glu Ile Lys Pro Cys Ile Val Arg Lys Gly Asp Arg
            340                 345                 350

Ile Glu Leu Phe Glu Gln Leu Lys Arg Lys Met Asp Lys Leu Lys Lys
        355                 360                 365

Phe Arg Lys Glu Arg Gln Lys Lys Ile Ser Lys Asp Leu Asn Phe Ala
    370                 375                 380

Glu Arg Ile Ala Tyr Asn Phe His Thr Lys Ser Ile Lys Asn Thr Ser
385                 390                 395                 400

Asn Lys Ile Asn Ile Asp Gln Glu Ala Lys Arg Gly Lys Ala Ser Tyr
                405                 410                 415

Met Arg Lys Arg Ile Gly Asn Glu Ser Phe Arg Lys Lys Tyr Cys Glu
            420                 425                 430

Gln Cys Phe Ser Val Gly Asn Val Tyr His Asn Val Gln Asn Gly Cys
        435                 440                 445

Ser Cys Phe Asp Asn Pro Ile Glu Leu Ile Lys Lys Gly Asp Glu Gly
    450                 455                 460

Leu Ile Pro Lys Gly Lys Glu Asp Arg Lys Tyr Lys Gly Ala Leu Arg
465                 470                 475                 480

Asp Asp Asn Leu Gln Met Gln Ile Ile Arg Val Ala Phe Asn Ile Ala
                485                 490                 495

Lys Gly Tyr Glu Asp Phe Tyr Asn Asn Leu Lys Glu Lys Thr Glu Lys
            500                 505                 510

Asp Leu Lys Leu Lys Phe Lys Ile Gly Thr Thr Ile Ser Thr Gln Glu
```

515 520 525

Ser Asn Asn Lys Glu Met
530

<210> 189
<211> 577
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 189

Ser Asn Leu Ile Lys Leu Gly Lys Gln Ala Ile Asn Phe Ala Ala Asn
1 5 10 15

Tyr Asp Ala Asn Leu Glu Val Gly Cys Lys Asn Cys Lys Phe Leu Ser
20 25 30

Ser Thr Asn Lys Tyr Pro Arg Gln Thr Asn Val His Leu Asp Asn Lys
35 40 45

Met Ala Cys Arg Ser Cys Asn Gln Ser Thr Met Glu Pro Ala Ile Tyr
50 55 60

Ile Val Arg Ile Gly Glu Lys Lys Ala Lys Tyr Asp Ile Tyr Asn Ser
65 70 75 80

Leu Thr Lys Phe Asn Phe Gln Ser Leu Lys Tyr Lys Ala Lys Arg Ser
85 90 95

Gln Arg Phe Lys Pro Lys Gln Pro Lys Glu Leu Gln Glu Leu Ser Ile
100 105 110

Ala Val Arg Lys Glu Lys Ala Leu Asp Ile Ile Gln Lys Ser Ile Asp
115 120 125

```
His Leu Ile Gln Asp Ile Arg Pro Glu Ile Pro Arg Ile Lys Gln Gln
    130                 135                 140

Lys Arg Tyr Lys Asn His Val Gly Lys Leu Phe Tyr Leu Gln Lys Arg
145                 150                 155                 160

Arg Lys Asn Lys Leu Asn Leu Ile Gly Lys Gly Ser Phe Phe Lys Val
                165                 170                 175

Phe Ser Pro Lys Glu Lys Lys Asn Glu Leu Leu Val Ile Cys Ala Leu
            180                 185                 190

Thr Asn Ile Gly Arg Asp Ile Gly Leu Ile Gly Asn Tyr Asn Thr Ile
        195                 200                 205

Ile Asn Pro Leu Phe Glu Val Thr Tyr Gln Leu Tyr Tyr Asp Tyr Ile
    210                 215                 220

Pro Lys Lys Asn Asn Lys Asn Val Gln Arg Arg Leu Leu Tyr Ala Tyr
225                 230                 235                 240

Lys Ser Lys Asn Glu Lys Ile Leu Lys Leu Lys Glu Ala Phe Phe Lys
                245                 250                 255

Arg Gly His Glu Asn Ala Val Asn Leu Gly Ser Phe Ser Tyr Glu Lys
            260                 265                 270

Pro Leu Glu Lys Ser Leu Thr Leu Lys Ile Lys Asn Asp Lys Asp Asp
        275                 280                 285

Phe Gln Val Ser Pro Ser Leu Arg Ile Arg Thr Gly Arg Phe Phe Val
    290                 295                 300

Pro Ser Lys Arg Asn Leu Ser Arg Gln Glu Arg Glu Ile Asn Arg Arg
305                 310                 315                 320
```

```
Leu Val Lys Ile Lys Ser Lys Ile Lys Asn Met Thr Tyr Gly Lys Phe
                325                 330                 335

Glu Thr Ala Arg Asp Lys Gln Ser Val His Ile Phe Arg Leu Glu Arg
            340                 345                 350

Gln Lys Glu Lys Leu Pro Leu Gln Phe Arg Lys Asp Glu Lys Glu Phe
        355                 360                 365

Met Glu Glu Phe Gln Lys Leu Lys Arg Arg Thr Asn Ser Leu Lys Lys
    370                 375                 380

Leu Arg Lys Ser Arg Gln Lys Lys Leu Ala Asp Leu Leu Gln Leu Ser
385                 390                 395                 400

Glu Lys Val Val Tyr Asn Asn His Thr Gly Thr Leu Lys Lys Thr Ser
                405                 410                 415

Asn Phe Leu Asn Phe Ser Ser Ser Val Lys Arg Gly Lys Thr Ala Tyr
            420                 425                 430

Ile Lys Glu Leu Leu Gly Gln Glu Gly Phe Glu Thr Leu Tyr Cys Ser
        435                 440                 445

Asn Cys Ile Asn Lys Gly Gln Lys Thr Arg Tyr Asn Ile Glu Thr Lys
    450                 455                 460

Glu Lys Cys Phe Ser Cys Lys Asp Val Pro Phe Val Trp Lys Lys Lys
465                 470                 475                 480

Ser Thr Asp Lys Asp Arg Lys Gly Ala Phe Leu Phe Pro Ala Lys Leu
                485                 490                 495

Lys Asp Val Ile Lys Ala Thr Phe Thr Val Ala Lys Ala Tyr Glu Asp
            500                 505                 510
```

Phe Tyr Asp Asn Leu Lys Ser Ile Asp Glu Lys Lys Pro Tyr Ile Lys
        515   520   525

Phe Lys Ile Gly Leu Ile Leu Ala His Val Arg His Glu His Lys Ala
    530   535   540

Arg Ala Lys Glu Glu Ala Gly Gln Lys Asn Ile Tyr Asn Lys Pro Ile
545   550   555   560

Lys Ile Asp Lys Asn Cys Lys Glu Cys Phe Phe Phe Lys Glu Glu Ala
                565   570   575

Met

<210> 190
<211> 613
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 190

Asn Thr Thr Arg Lys Lys Phe Arg Lys Arg Thr Gly Phe Pro Gln Ser
1   5   10   15

Asp Asn Ile Lys Leu Ala Tyr Cys Ser Ala Ile Val Arg Ala Ala Asn
            20   25   30

Leu Asp Ala Asp Ile Gln Lys Lys His Asn Gln Cys Asn Pro Asn Leu
        35   40   45

Cys Val Gly Ile Lys Ser Asn Glu Gln Ser Arg Lys Tyr Glu His Ser
    50   55   60

Asp Arg Gln Ala Leu Leu Cys Tyr Ala Cys Asn Gln Ser Thr Gly Ala

```
65                  70                  75                  80

Pro Lys Val Asp Tyr Ile Gln Ile Gly Glu Ile Gly Ala Lys Tyr Lys
                85                  90                  95

Ile Leu Gln Met Val Asn Ala Tyr Asp Phe Leu Ser Leu Ala Tyr Asn
            100                 105                 110

Leu Thr Lys Leu Arg Asn Gly Lys Ser Arg Gly His Gln Arg Met Ser
        115                 120                 125

Gln Leu Asp Glu Val Val Ile Val Ala Asp Tyr Glu Lys Ala Thr Glu
    130                 135                 140

Val Ile Lys Arg Ser Ile Asn His Leu Leu Asp Asp Ile Arg Gly Gln
145                 150                 155                 160

Leu Ser Lys Leu Lys Lys Arg Thr Gln Asn Glu His Ile Thr Glu His
                165                 170                 175

Lys Gln Ser Lys Ile Arg Arg Lys Leu Arg Lys Leu Ser Arg Leu Leu
            180                 185                 190

Lys Arg Arg Arg Trp Lys Trp Gly Thr Ile Pro Asn Pro Tyr Leu Lys
        195                 200                 205

Asn Trp Val Phe Thr Lys Lys Asp Pro Glu Leu Val Thr Val Ala Leu
    210                 215                 220

Leu His Lys Leu Gly Arg Asp Ile Gly Leu Val Asn Arg Ser Lys Arg
225                 230                 235                 240

Arg Ser Lys Gln Lys Leu Leu Pro Lys Val Gly Phe Gln Leu Tyr Tyr
                245                 250                 255

Lys Trp Glu Ser Pro Ser Leu Asn Asn Ile Lys Lys Ser Lys Ala Lys
```

```
            260                 265                 270

Lys Leu Pro Lys Arg Leu Leu Ile Pro Tyr Lys Asn Val Lys Leu Phe
        275                 280                 285

Asp Asn Lys Gln Lys Leu Glu Asn Ala Ile Lys Ser Leu Leu Glu Ser
    290                 295                 300

Tyr Gln Lys Thr Ile Lys Val Glu Phe Asp Gln Phe Phe Gln Asn Arg
305                 310                 315                 320

Thr Glu Glu Ile Ile Ala Glu Glu Gln Gln Thr Leu Glu Arg Gly Leu
                325                 330                 335

Leu Lys Gln Leu Glu Lys Lys Lys Asn Glu Phe Ala Ser Gln Lys Lys
            340                 345                 350

Ala Leu Lys Glu Glu Lys Lys Lys Ile Lys Glu Pro Arg Lys Ala Lys
        355                 360                 365

Leu Leu Met Glu Glu Ser Arg Ser Leu Gly Phe Leu Met Ala Asn Val
    370                 375                 380

Ser Tyr Ala Leu Phe Asn Thr Thr Ile Glu Asp Leu Tyr Lys Lys Ser
385                 390                 395                 400

Asn Val Val Ser Gly Cys Ile Pro Gln Glu Pro Val Val Val Phe Pro
                405                 410                 415

Ala Asp Ile Gln Asn Lys Gly Ser Leu Ala Lys Ile Leu Phe Ala Pro
            420                 425                 430

Lys Asp Gly Phe Arg Ile Lys Phe Ser Gly Gln His Leu Thr Ile Arg
        435                 440                 445

Thr Ala Lys Phe Lys Ile Arg Gly Lys Glu Ile Lys Ile Leu Thr Lys
```

```
    450                 455                 460

Thr Lys Arg Glu Ile Leu Lys Asn Ile Glu Lys Leu Arg Arg Val Trp
465                 470                 475                 480

Tyr Arg Glu Gln His Tyr Lys Leu Lys Leu Phe Gly Lys Glu Val Ser
                485                 490                 495

Ala Lys Pro Arg Phe Leu Asp Lys Arg Lys Thr Ser Ile Glu Arg Arg
            500                 505                 510

Asp Pro Asn Lys Leu Ala Asp Gln Thr Asp Asp Arg Gln Ala Glu Leu
        515                 520                 525

Arg Asn Lys Glu Tyr Glu Leu Arg His Lys Gln His Lys Met Ala Glu
    530                 535                 540

Arg Leu Asp Asn Ile Asp Thr Asn Ala Gln Asn Leu Gln Thr Leu Ser
545                 550                 555                 560

Phe Trp Val Gly Glu Ala Asp Lys Pro Pro Lys Leu Asp Glu Lys Asp
                565                 570                 575

Ala Arg Gly Phe Gly Val Arg Thr Cys Ile Ser Ala Trp Lys Trp Phe
            580                 585                 590

Met Glu Asp Leu Leu Lys Lys Gln Glu Glu Asp Pro Leu Leu Lys Leu
        595                 600                 605

Lys Leu Ser Ile Met
    610


<210>  191
<211>  615
<212>  PRT
<213>  Artificial sequence
```

<220>
<223> Synthetic sequence

<400> 191

```
Pro Lys Lys Pro Lys Phe Gln Lys Arg Thr Gly Phe Pro Gln Pro Asp
1               5                  10                  15

Asn Leu Arg Lys Glu Tyr Cys Leu Ala Ile Val Arg Ala Ala Asn Leu
            20                  25                  30

Asp Ala Asp Phe Glu Lys Lys Cys Thr Lys Cys Glu Gly Ile Lys Thr
        35                  40                  45

Asn Lys Lys Gly Asn Ile Val Lys Gly Arg Thr Tyr Asn Ser Ala Asp
    50                  55                  60

Lys Asp Asn Leu Leu Cys Tyr Ala Cys Asn Ile Ser Thr Gly Ala Pro
65                  70                  75                  80

Ala Val Asp Tyr Val Phe Val Gly Ala Leu Glu Ala Lys Tyr Lys Ile
                85                  90                  95

Leu Gln Met Val Lys Ala Tyr Asp Phe His Ser Leu Ala Tyr Asn Leu
            100                 105                 110

Ala Lys Leu Trp Lys Gly Arg Gly Arg Gly His Gln Arg Met Gly Gly
        115                 120                 125

Leu Asn Glu Val Val Ile Val Ser Asn Asn Glu Lys Ala Leu Asp Val
    130                 135                 140

Ile Glu Lys Ser Leu Asn His Phe His Asp Glu Ile Arg Gly Glu Leu
145                 150                 155                 160

Ser Arg Leu Lys Ala Lys Phe Gln Asn Glu His Leu His Val His Lys
                165                 170                 175
```

```
Glu Ser Lys Leu Arg Arg Lys Leu Arg Lys Ile Ser Arg Leu Leu Lys
            180                 185                 190


Arg Arg Arg Trp Lys Trp Asp Val Ile Pro Asn Ser Tyr Leu Arg Asn
        195                 200                 205


Phe Thr Phe Thr Lys Thr Arg Pro Asp Phe Ile Ser Val Ala Leu Leu
    210                 215                 220


His Arg Val Gly Arg Asp Ile Gly Leu Val Thr Lys Thr Lys Ile Pro
225                 230                 235                 240


Lys Pro Thr Asp Leu Leu Pro Gln Phe Gly Phe Gln Ile Tyr Tyr Thr
                245                 250                 255


Trp Asp Glu Pro Lys Leu Asn Lys Leu Lys Lys Ser Arg Leu Arg Ser
            260                 265                 270


Glu Pro Lys Arg Leu Leu Val Pro Tyr Lys Lys Ile Glu Leu Tyr Lys
        275                 280                 285


Asn Lys Ser Val Leu Glu Glu Ala Ile Arg His Leu Ala Glu Val Tyr
    290                 295                 300


Thr Glu Asp Leu Thr Ile Cys Phe Lys Asp Phe Phe Glu Thr Gln Lys
305                 310                 315                 320


Arg Lys Phe Val Ser Lys Glu Lys Glu Ser Leu Lys Arg Glu Leu Leu
                325                 330                 335


Lys Glu Leu Thr Lys Leu Lys Lys Asp Phe Ser Glu Arg Lys Thr Ala
            340                 345                 350


Leu Lys Arg Asp Arg Lys Glu Ile Lys Glu Pro Lys Lys Ala Lys Leu
        355                 360                 365
```

```
Leu Met Glu Glu Ser Arg Ser Leu Gly Phe Leu Ala Ala Asn Thr Ser
    370                 375                 380

Tyr Ala Leu Phe Asn Leu Ile Ala Ala Asp Leu Tyr Thr Lys Ser Lys
385                 390                 395                 400

Lys Ala Cys Ser Thr Lys Leu Pro Arg Gln Leu Ser Thr Ile Leu Pro
                405                 410                 415

Leu Glu Ile Lys Glu His Lys Ser Thr Thr Ser Leu Ala Ile Lys Pro
            420                 425                 430

Glu Glu Gly Phe Lys Ile Arg Phe Ser Asn Thr His Leu Ser Ile Arg
        435                 440                 445

Thr Pro Lys Phe Lys Met Lys Gly Ala Asp Ile Lys Ala Leu Thr Lys
    450                 455                 460

Arg Lys Arg Glu Ile Leu Lys Asn Ala Thr Lys Leu Glu Lys Ser Trp
465                 470                 475                 480

Tyr Gly Leu Lys His Tyr Lys Leu Lys Leu Tyr Gly Lys Glu Val Ala
                485                 490                 495

Ala Lys Pro Arg Phe Leu Asp Lys Arg Asn Pro Ser Ile Asp Arg Arg
            500                 505                 510

Asp Pro Lys Glu Leu Met Glu Gln Ile Glu Asn Arg Arg Asn Glu Val
        515                 520                 525

Lys Asp Leu Glu Tyr Glu Ile Arg Lys Gly Gln His Gln Met Ala Lys
    530                 535                 540

Arg Leu Asp Asn Val Asp Thr Asn Ala Gln Asn Leu Gln Thr Lys Ser
545                 550                 555                 560
```

Phe Trp Val Gly Glu Ala Asp Lys Pro Pro Glu Leu Asp Ser Met Glu
565 570 575

Ala Lys Lys Leu Gly Leu Arg Thr Cys Ile Ser Ala Trp Lys Trp Phe
580 585 590

Met Lys Asp Leu Val Leu Leu Gln Glu Lys Ser Pro Asn Leu Lys Leu
595 600 605

Lys Leu Ser Leu Thr Glu Met
610 615

<210> 192
<211> 775
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 192

Lys Phe Ser Lys Arg Gln Glu Gly Phe Leu Ile Pro Asp Asn Ile Asp
1 5 10 15

Leu Tyr Lys Cys Leu Ala Ile Val Arg Ser Ala Asn Leu Asp Ala Asp
20 25 30

Val Gln Gly His Lys Ser Cys Tyr Gly Val Lys Lys Asn Gly Thr Tyr
35 40 45

Arg Val Lys Gln Asn Gly Lys Lys Gly Val Lys Glu Lys Gly Arg Lys
50 55 60

Tyr Val Phe Asp Leu Ile Ala Phe Lys Gly Asn Ile Glu Lys Ile Pro
65 70 75 80

His Glu Ala Ile Glu Glu Lys Asp Gln Gly Arg Val Ile Val Leu Gly

```
                85                  90                  95

Lys Phe Asn Tyr Lys Leu Ile Leu Asn Ile Glu Lys Asn His Asn Asp
            100                 105                 110

Arg Ala Ser Leu Glu Ile Lys Asn Lys Ile Lys Lys Leu Val Gln Ile
        115                 120                 125

Ser Ser Leu Glu Thr Gly Glu Phe Leu Ser Asp Leu Leu Ser Gly Lys
    130                 135                 140

Ile Gly Ile Asp Glu Val Tyr Gly Ile Ile Glu Pro Asp Val Phe Ser
145                 150                 155                 160

Gly Lys Glu Leu Val Cys Lys Ala Cys Gln Gln Ser Thr Tyr Ala Pro
                165                 170                 175

Leu Val Glu Tyr Met Pro Val Gly Glu Leu Asp Ala Lys Tyr Lys Ile
            180                 185                 190

Leu Ser Ala Ile Lys Gly Tyr Asp Phe Leu Ser Leu Ala Tyr Asn Leu
        195                 200                 205

Ser Arg Asn Arg Ala Asn Lys Lys Arg Gly His Gln Lys Leu Gly Gly
    210                 215                 220

Gly Glu Leu Ser Glu Val Val Ile Ser Ala Asn Tyr Asp Lys Ala Leu
225                 230                 235                 240

Asn Val Ile Lys Arg Ser Ile Asn His Tyr His Val Glu Ile Lys Pro
                245                 250                 255

Glu Ile Ser Lys Leu Lys Lys Lys Met Gln Asn Glu Pro Leu Lys Val
            260                 265                 270

Met Lys Gln Ala Arg Ile Arg Arg Glu Leu His Gln Leu Ser Arg Lys
```

```
        275                 280                 285

Val Lys Arg Leu Lys Trp Lys Trp Gly Met Ile Pro Asn Pro Glu Leu
    290                 295                 300

Gln Asn Ile Ile Phe Glu Lys Lys Glu Lys Asp Phe Val Ser Tyr Ala
305                 310                 315                 320

Leu Leu His Thr Leu Gly Arg Asp Ile Gly Leu Phe Lys Asp Thr Ser
                325                 330                 335

Met Leu Gln Val Pro Asn Ile Ser Asp Tyr Gly Phe Gln Ile Tyr Tyr
            340                 345                 350

Ser Trp Glu Asp Pro Lys Leu Asn Ser Ile Lys Lys Ile Lys Asp Leu
        355                 360                 365

Pro Lys Arg Leu Leu Ile Pro Tyr Lys Arg Leu Asp Phe Tyr Ile Asp
    370                 375                 380

Thr Ile Leu Val Ala Lys Val Ile Lys Asn Leu Ile Glu Leu Tyr Arg
385                 390                 395                 400

Lys Ser Tyr Val Tyr Glu Thr Phe Gly Glu Glu Tyr Gly Tyr Ala Lys
                405                 410                 415

Lys Ala Glu Asp Ile Leu Phe Asp Trp Asp Ser Ile Asn Leu Ser Glu
            420                 425                 430

Gly Ile Glu Gln Lys Ile Gln Lys Ile Lys Asp Glu Phe Ser Asp Leu
        435                 440                 445

Leu Tyr Glu Ala Arg Glu Ser Lys Arg Gln Asn Phe Val Glu Ser Phe
    450                 455                 460

Glu Asn Ile Leu Gly Leu Tyr Asp Lys Asn Phe Ala Ser Asp Arg Asn
```

```
465                 470                 475                 480

Ser Tyr Gln Glu Lys Ile Gln Ser Met Ile Ile Lys Lys Gln Gln Glu
                485                 490                 495

Asn Ile Glu Gln Lys Leu Lys Arg Glu Phe Lys Glu Val Ile Glu Arg
            500                 505                 510

Gly Phe Glu Gly Met Asp Gln Asn Lys Lys Tyr Tyr Lys Val Leu Ser
        515                 520                 525

Pro Asn Ile Lys Gly Gly Leu Leu Tyr Thr Asp Thr Asn Asn Leu Gly
    530                 535                 540

Phe Phe Arg Ser His Leu Ala Phe Met Leu Leu Ser Lys Ile Ser Asp
545                 550                 555                 560

Asp Leu Tyr Arg Lys Asn Asn Leu Val Ser Lys Gly Gly Asn Lys Gly
                565                 570                 575

Ile Leu Asp Gln Thr Pro Glu Thr Met Leu Thr Leu Glu Phe Gly Lys
            580                 585                 590

Ser Asn Leu Pro Asn Ile Ser Ile Lys Arg Lys Phe Phe Asn Ile Lys
        595                 600                 605

Tyr Asn Ser Ser Trp Ile Gly Ile Arg Lys Pro Lys Phe Ser Ile Lys
    610                 615                 620

Gly Ala Val Ile Arg Glu Ile Thr Lys Lys Val Arg Asp Glu Gln Arg
625                 630                 635                 640

Leu Ile Lys Ser Leu Glu Gly Val Trp His Lys Ser Thr His Phe Lys
                645                 650                 655

Arg Trp Gly Lys Pro Arg Phe Asn Leu Pro Arg His Pro Asp Arg Glu
```

660 665 670

Lys Asn Asn Asp Asp Asn Leu Met Glu Ser Ile Thr Ser Arg Arg Glu
675 680 685

Gln Ile Gln Leu Leu Leu Arg Glu Lys Gln Lys Gln Gln Glu Lys Met
690 695 700

Ala Gly Arg Leu Asp Lys Ile Asp Lys Glu Ile Gln Asn Leu Gln Thr
705 710 715 720

Ala Asn Phe Gln Ile Lys Gln Ile Asp Lys Lys Pro Ala Leu Thr Glu
725 730 735

Lys Ser Glu Gly Lys Gln Ser Val Arg Asn Ala Leu Ser Ala Trp Lys
740 745 750

Trp Phe Met Glu Asp Leu Ile Lys Tyr Gln Lys Arg Thr Pro Ile Leu
755 760 765

Gln Leu Lys Leu Ala Lys Met
770 775

<210> 193
<211> 777
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 193

Lys Phe Ser Lys Arg Gln Glu Gly Phe Val Ile Pro Glu Asn Ile Gly
1 5 10 15

Leu Tyr Lys Cys Leu Ala Ile Val Arg Ser Ala Asn Leu Asp Ala Asp
20 25 30

```
Val Gln Gly His Val Ser Cys Tyr Gly Val Lys Lys Asn Gly Thr Tyr
        35                  40                  45

Val Leu Lys Gln Asn Gly Lys Lys Ser Ile Arg Glu Lys Gly Arg Lys
    50                  55                  60

Tyr Ala Ser Asp Leu Val Ala Phe Lys Gly Asp Ile Glu Lys Ile Pro
65                  70                  75                  80

Phe Glu Val Ile Glu Glu Lys Lys Lys Glu Gln Ser Ile Val Leu Gly
                85                  90                  95

Lys Phe Asn Tyr Lys Leu Val Leu Asp Val Met Lys Gly Glu Lys Asp
            100                 105                 110

Arg Ala Ser Leu Thr Met Lys Asn Lys Ser Lys Lys Leu Val Gln Val
        115                 120                 125

Ser Ser Leu Gly Thr Asp Glu Phe Leu Leu Thr Leu Leu Asn Glu Lys
    130                 135                 140

Phe Gly Ile Glu Glu Ile Tyr Gly Ile Ile Glu Pro Glu Val Phe Ser
145                 150                 155                 160

Gly Lys Lys Leu Val Cys Lys Ala Cys Gln Gln Ser Thr Tyr Ala Pro
                165                 170                 175

Leu Val Glu Tyr Met Pro Val Gly Glu Leu Asp Ser Lys Tyr Lys Ile
            180                 185                 190

Leu Ser Ala Ile Lys Gly Tyr Asp Phe Leu Ser Leu Ala Tyr Asn Leu
        195                 200                 205

Ala Arg His Arg Ser Asn Lys Lys Arg Gly His Gln Lys Leu Gly Gly
    210                 215                 220
```

```
Gly Glu Leu Ser Glu Val Val Ile Ser Ala Asn Asn Ala Lys Ala Leu
225                 230                 235                 240


Asn Val Ile Lys Arg Ser Leu Asn His Tyr Tyr Ser Glu Ile Lys Pro
                245                 250                 255


Glu Ile Ser Lys Leu Arg Lys Lys Met Gln Asn Glu Pro Leu Lys Val
            260                 265                 270


Gly Lys Gln Ala Arg Met Arg Arg Glu Leu His Gln Leu Ser Arg Lys
        275                 280                 285


Val Lys Arg Leu Lys Trp Lys Trp Gly Lys Ile Pro Asn Leu Glu Leu
    290                 295                 300


Gln Asn Ile Thr Phe Lys Glu Ser Asp Arg Asp Phe Ile Ser Tyr Ala
305                 310                 315                 320


Leu Leu His Thr Leu Gly Arg Asp Ile Gly Met Phe Asn Lys Thr Glu
                325                 330                 335


Ile Lys Met Pro Ser Asn Ile Leu Gly Tyr Gly Phe Gln Ile Tyr Tyr
            340                 345                 350


Asp Trp Glu Glu Pro Lys Leu Asn Thr Ile Lys Lys Ser Lys Asn Thr
        355                 360                 365


Pro Lys Arg Ile Leu Ile Pro Tyr Lys Lys Leu Asp Phe Tyr Asn Asp
    370                 375                 380


Ser Ile Leu Val Ala Arg Ala Ile Lys Glu Leu Val Gly Leu Phe Gln
385                 390                 395                 400


Glu Ser Tyr Glu Trp Glu Ile Phe Gly Asn Glu Tyr Asn Tyr Ala Lys
                405                 410                 415
```

```
Glu Ala Glu Val Glu Leu Ile Lys Leu Asp Glu Glu Ser Ile Asn Gly
            420                 425                 430

Asn Val Glu Lys Lys Leu Gln Arg Ile Lys Glu Asn Phe Ser Asn Leu
        435                 440                 445

Leu Glu Lys Ala Arg Glu Lys Lys Arg Gln Asn Phe Ile Glu Ser Phe
    450                 455                 460

Glu Ser Ile Ala Arg Leu Tyr Asp Glu Ser Phe Thr Ala Asp Arg Asn
465                 470                 475                 480

Glu Tyr Gln Arg Glu Ile Gln Ser Phe Ile Ile Glu Lys Gln Lys Gln
                485                 490                 495

Ser Ile Glu Lys Lys Leu Lys Asn Glu Phe Lys Lys Ile Val Glu Lys
            500                 505                 510

Lys Phe Asn Glu Gln Glu Gln Gly Lys Lys His Tyr Arg Val Leu Asn
        515                 520                 525

Pro Thr Ile Ile Asn Glu Phe Leu Pro Lys Asp Lys Asn Asn Leu Gly
    530                 535                 540

Phe Leu Arg Ser Lys Ile Ala Phe Ile Leu Leu Ser Lys Ile Ser Asp
545                 550                 555                 560

Asp Leu Tyr Lys Lys Ser Asn Ala Val Ser Lys Gly Gly Glu Lys Gly
                565                 570                 575

Ile Ile Lys Gln Gln Pro Glu Thr Ile Leu Asp Leu Glu Phe Ser Lys
            580                 585                 590

Ser Lys Leu Pro Ser Ile Asn Ile Lys Lys Lys Leu Phe Asn Ile Lys
        595                 600                 605
```

```
Tyr Thr Ser Ser Trp Leu Gly Ile Arg Lys Pro Lys Phe Asn Ile Lys
    610                 615                 620

Gly Ala Lys Ile Arg Glu Ile Thr Arg Arg Val Arg Asp Val Gln Arg
625                 630                 635                 640

Thr Leu Lys Ser Ala Glu Ser Ser Trp Tyr Ala Ser Thr His Phe Arg
                645                 650                 655

Arg Trp Gly Phe Pro Arg Phe Asn Gln Pro Arg His Pro Asp Lys Glu
            660                 665                 670

Lys Lys Ser Asp Asp Arg Leu Ile Glu Ser Ile Thr Leu Leu Arg Glu
        675                 680                 685

Gln Ile Gln Ile Leu Leu Arg Glu Lys Gln Lys Gly Gln Lys Glu Met
    690                 695                 700

Ala Gly Arg Leu Asp Asp Val Asp Lys Lys Ile Gln Asn Leu Gln Thr
705                 710                 715                 720

Ala Asn Phe Gln Ile Lys Gln Thr Gly Asp Lys Pro Ala Leu Thr Glu
                725                 730                 735

Lys Ser Ala Gly Lys Gln Ser Phe Arg Asn Ala Leu Ser Ala Trp Lys
            740                 745                 750

Trp Phe Met Glu Asn Leu Leu Lys Tyr Gln Asn Lys Thr Pro Asp Leu
        755                 760                 765

Lys Leu Lys Ile Ala Arg Thr Val Met
    770                 775
```

<210> 194
<211> 610
<212> PRT

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 194

Lys Trp Ile Glu Pro Asn Asn Ile Asp Phe Asn Lys Cys Leu Ala Ile
1 5 10 15

Thr Arg Ser Ala Asn Leu Asp Ala Asp Val Gln Gly His Lys Met Cys
20 25 30

Tyr Gly Ile Lys Thr Asn Gly Thr Tyr Lys Ala Ile Gly Lys Ile Asn
35 40 45

Lys Lys His Asn Thr Gly Ile Ile Glu Lys Arg Arg Thr Tyr Val Tyr
50 55 60

Asp Leu Ile Val Thr Lys Glu Lys Asn Glu Lys Ile Val Lys Lys Thr
65 70 75 80

Asp Phe Met Ala Ile Asp Glu Glu Ile Glu Phe Asp Glu Lys Lys Glu
85 90 95

Lys Leu Leu Lys Lys Tyr Ile Lys Ala Glu Val Leu Gly Thr Gly Glu
100 105 110

Leu Ile Arg Lys Asp Leu Asn Asp Gly Glu Lys Phe Asp Asp Leu Cys
115 120 125

Ser Ile Glu Glu Pro Gln Ala Phe Arg Arg Ser Glu Leu Val Cys Lys
130 135 140

Ala Cys Asn Gln Ser Thr Tyr Ala Ser Asp Ile Arg Tyr Ile Pro Ile
145 150 155 160

Gly Glu Ile Glu Ala Lys Tyr Lys Ile Leu Lys Ala Ile Lys Gly Tyr

```
                165                 170                 175

Asp Phe Leu Ser Leu Lys Tyr Asn Leu Gly Arg Leu Arg Asp Ser Lys
            180                 185                 190

Lys Arg Gly His Gln Lys Met Gly Gln Gly Glu Leu Lys Glu Phe Val
        195                 200                 205

Ile Cys Ala Asn Lys Glu Lys Ala Leu Asp Val Ile Lys Arg Ser Leu
    210                 215                 220

Asn His Tyr Leu Asn Glu Val Lys Asp Glu Ile Ser Arg Leu Asn Lys
225                 230                 235                 240

Lys Met Gln Asn Glu Pro Leu Lys Val Asn Asp Gln Ala Arg Trp Arg
                245                 250                 255

Arg Glu Leu Asn Gln Ile Ser Arg Arg Leu Lys Arg Leu Lys Trp Lys
            260                 265                 270

Trp Gly Glu Ile Pro Asn Pro Glu Leu Lys Asn Leu Ile Phe Lys Ser
        275                 280                 285

Ser Arg Pro Glu Phe Val Ser Tyr Ala Leu Ile His Thr Leu Gly Arg
    290                 295                 300

Asp Ile Gly Leu Ile Asn Glu Thr Glu Leu Lys Pro Asn Asn Ile Gln
305                 310                 315                 320

Glu Tyr Gly Phe Gln Ile Tyr Tyr Lys Trp Glu Asp Pro Glu Leu Asn
                325                 330                 335

His Ile Lys Lys Val Lys Asn Ile Pro Lys Arg Phe Ile Ile Pro Tyr
            340                 345                 350

Lys Asn Leu Asp Leu Phe Gly Lys Tyr Thr Ile Leu Ser Arg Ala Ile
```

```
        355                 360                 365

Glu Gly Ile Leu Lys Leu Tyr Ser Ser Ser Phe Gln Tyr Lys Ser Phe
    370                 375                 380

Lys Asp Pro Asn Leu Phe Ala Lys Glu Gly Glu Lys Lys Ile Thr Asn
385                 390                 395                 400

Glu Asp Phe Glu Leu Gly Tyr Asp Glu Lys Ile Lys Lys Ile Lys Asp
                405                 410                 415

Asp Phe Lys Ser Tyr Lys Lys Ala Leu Leu Glu Lys Lys Lys Asn Thr
            420                 425                 430

Leu Glu Asp Ser Leu Asn Ser Ile Leu Ser Val Tyr Glu Gln Ser Leu
        435                 440                 445

Leu Thr Glu Gln Ile Asn Asn Val Lys Lys Trp Lys Glu Gly Leu Leu
    450                 455                 460

Lys Ser Lys Glu Ser Ile His Lys Gln Lys Lys Ile Glu Asn Ile Glu
465                 470                 475                 480

Asp Ile Ile Ser Arg Ile Glu Glu Leu Lys Asn Val Glu Gly Trp Ile
                485                 490                 495

Arg Thr Lys Glu Arg Asp Ile Val Asn Lys Glu Glu Thr Asn Leu Lys
            500                 505                 510

Arg Glu Ile Lys Lys Glu Leu Lys Asp Ser Tyr Tyr Glu Glu Val Arg
        515                 520                 525

Lys Asp Phe Ser Asp Leu Lys Lys Gly Glu Glu Ser Glu Lys Lys Pro
    530                 535                 540

Phe Arg Glu Glu Pro Lys Pro Ile Val Ile Lys Asp Tyr Ile Lys Phe
```

545 550 555 560

Asp Val Leu Pro Gly Glu Asn Ser Ala Leu Gly Phe Phe Leu Ser His
565 570 575

Leu Ser Phe Asn Leu Phe Asp Ser Ile Gln Tyr Glu Leu Phe Glu Lys
580 585 590

Ser Arg Leu Ser Ser Ser Lys His Pro Gln Ile Pro Glu Thr Ile Leu
595 600 605

Asp Leu
610

<210> 195
<211> 632
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 195

Phe Arg Lys Phe Val Lys Arg Ser Gly Ala Pro Gln Pro Asp Asn Leu
1 5 10 15

Asn Lys Tyr Lys Cys Ile Ala Ile Val Arg Ala Ala Asn Leu Asp Ala
20 25 30

Asp Ile Met Ser Asn Glu Ser Ser Asn Cys Val Met Cys Lys Gly Ile
35 40 45

Lys Met Asn Lys Arg Lys Thr Ala Lys Gly Ala Ala Lys Thr Thr Glu
50 55 60

Leu Gly Arg Val Tyr Ala Gly Gln Ser Gly Asn Leu Leu Cys Thr Ala
65 70 75 80

```
Cys Thr Lys Ser Thr Met Gly Pro Leu Val Asp Tyr Val Pro Ile Gly
                85                  90                  95

Arg Ile Arg Ala Lys Tyr Thr Ile Leu Arg Ala Val Lys Glu Tyr Asp
            100                 105                 110

Phe Leu Ser Leu Ala Tyr Asn Leu Ala Arg Thr Arg Val Ser Lys Lys
        115                 120                 125

Gly Gly Arg Gln Lys Met His Ser Leu Ser Glu Leu Val Ile Ala Ala
    130                 135                 140

Glu Tyr Glu Ile Ala Trp Asn Ile Ile Lys Ser Ser Val Ile His Tyr
145                 150                 155                 160

His Gln Glu Thr Lys Glu Glu Ile Ser Gly Leu Arg Lys Lys Leu Gln
                165                 170                 175

Ala Glu His Ile His Lys Asn Lys Glu Ala Arg Ile Arg Arg Glu Met
            180                 185                 190

His Gln Ile Ser Arg Arg Ile Lys Arg Leu Lys Trp Lys Trp His Met
        195                 200                 205

Ile Pro Asn Ser Glu Leu His Asn Phe Leu Phe Lys Gln Gln Asp Pro
    210                 215                 220

Ser Phe Val Ala Val Ala Leu Leu His Thr Leu Gly Arg Asp Ile Gly
225                 230                 235                 240

Met Ile Asn Lys Pro Lys Gly Ser Ala Lys Arg Glu Phe Ile Pro Glu
                245                 250                 255

Tyr Gly Phe Gln Ile Tyr Tyr Lys Trp Met Asn Pro Lys Leu Asn Asp
            260                 265                 270
```

```
Ile Asn Lys Gln Lys Tyr Arg Lys Met Pro Lys Arg Ser Leu Ile Pro
        275                 280                 285

Tyr Lys Asn Leu Asn Val Phe Gly Asp Arg Glu Leu Ile Glu Asn Ala
    290                 295                 300

Met His Lys Leu Leu Lys Leu Tyr Asp Glu Asn Leu Glu Val Lys Gly
305                 310                 315                 320

Ser Lys Phe Phe Lys Thr Arg Val Val Ala Ile Ser Ser Lys Glu Ser
                325                 330                 335

Glu Lys Leu Lys Arg Asp Leu Leu Trp Lys Gly Glu Leu Ala Lys Ile
            340                 345                 350

Lys Lys Asp Phe Asn Ala Asp Lys Asn Lys Met Gln Glu Leu Phe Lys
        355                 360                 365

Glu Val Lys Glu Pro Lys Lys Ala Asn Ala Leu Met Lys Gln Ser Arg
    370                 375                 380

Asn Met Gly Phe Leu Leu Gln Asn Ile Ser Tyr Gly Ala Leu Gly Leu
385                 390                 395                 400

Leu Ala Asn Arg Met Tyr Glu Ala Ser Ala Lys Gln Ser Lys Gly Asp
                405                 410                 415

Ala Thr Lys Gln Pro Ser Ile Val Ile Pro Leu Glu Met Glu Phe Gly
            420                 425                 430

Asn Ala Phe Pro Lys Leu Leu Leu Arg Ser Gly Lys Phe Ala Met Asn
        435                 440                 445

Val Ser Ser Pro Trp Leu Thr Ile Arg Lys Pro Lys Phe Val Ile Lys
    450                 455                 460
```

```
Gly Asn Lys Ile Lys Asn Ile Thr Lys Leu Met Lys Asp Glu Lys Ala
465                 470                 475                 480


Lys Leu Lys Arg Leu Glu Thr Ser Tyr His Arg Ala Thr His Phe Arg
                485                 490                 495


Pro Thr Leu Arg Gly Ser Ile Asp Trp Asp Ser Pro Tyr Phe Ser Ser
            500                 505                 510


Pro Lys Gln Pro Asn Thr His Arg Arg Ser Pro Asp Arg Leu Ser Ala
        515                 520                 525


Asp Ile Thr Glu Tyr Arg Gly Arg Leu Lys Ser Val Glu Ala Glu Leu
    530                 535                 540


Arg Glu Gly Gln Arg Ala Met Ala Lys Lys Leu Asp Ser Val Asp Met
545                 550                 555                 560


Thr Ala Ser Asn Leu Gln Thr Ser Asn Phe Gln Leu Glu Lys Gly Glu
                565                 570                 575


Asp Pro Arg Leu Thr Glu Ile Asp Glu Lys Gly Arg Ser Ile Arg Asn
            580                 585                 590


Cys Ile Ser Ser Trp Lys Lys Phe Met Glu Asp Leu Met Lys Ala Gln
        595                 600                 605


Glu Ala Asn Pro Val Ile Lys Ile Lys Ile Ala Leu Lys Asp Glu Ser
    610                 615                 620


Ser Val Leu Ser Glu Asp Ser Met
625                 630


<210>  196
<211>  625
<212>  PRT
```

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 196

Lys Phe His Pro Glu Asn Leu Asn Lys Ser Tyr Cys Leu Ala Ile Val
1 5 10 15

Arg Ala Ala Asn Leu Asp Ala Asp Ile Gln Gly His Ile Asn Cys Ile
20 25 30

Gly Ile Lys Ser Asn Lys Ser Asp Arg Asn Tyr Glu Asn Lys Leu Glu
35 40 45

Ser Leu Gln Asn Val Glu Leu Leu Cys Lys Ala Cys Thr Lys Ser Thr
50 55 60

Tyr Lys Pro Asn Ile Asn Ser Val Pro Val Gly Glu Lys Lys Ala Lys
65 70 75 80

Tyr Ser Ile Leu Ser Glu Ile Lys Lys Tyr Asp Phe Asn Ser Leu Val
85 90 95

Tyr Asn Leu Lys Lys Tyr Arg Lys Gly Lys Ser Arg Gly His Gln Lys
100 105 110

Leu Asn Glu Leu Arg Glu Leu Val Ile Thr Ser Glu Tyr Lys Lys Ala
115 120 125

Leu Asp Val Ile Asn Lys Ser Val Asn His Tyr Leu Val Asn Ile Lys
130 135 140

Asn Lys Met Ser Lys Leu Lys Lys Ile Leu Gln Asn Glu His Ile His
145 150 155 160

Val Gly Thr Leu Ala Arg Ile Arg Arg Glu Arg Asn Arg Ile Ser Arg

```
                165                 170                 175

Lys Leu Asp His Tyr Arg Lys Lys Trp Lys Phe Val Pro Asn Lys Ile
            180                 185                 190

Leu Lys Asn Tyr Val Phe Lys Asn Gln Ser Pro Asp Phe Val Ser Val
        195                 200                 205

Ala Leu Leu His Lys Leu Gly Arg Asp Ile Gly Leu Ile Thr Lys Thr
    210                 215                 220

Ala Ile Leu Gln Lys Ser Phe Pro Glu Tyr Ser Leu Gln Leu Tyr Tyr
225                 230                 235                 240

Lys Tyr Asp Thr Pro Lys Leu Asn Tyr Leu Lys Lys Ser Lys Phe Lys
                245                 250                 255

Ser Leu Pro Lys Arg Ile Leu Ile Ser Tyr Lys Tyr Pro Lys Phe Asp
            260                 265                 270

Ile Asn Ser Asn Tyr Ile Glu Glu Ser Ile Asp Lys Leu Leu Lys Leu
        275                 280                 285

Tyr Glu Glu Ser Pro Ile Tyr Lys Asn Asn Ser Lys Ile Ile Glu Phe
    290                 295                 300

Phe Lys Lys Ser Glu Asp Asn Leu Ile Lys Ser Glu Asn Asp Ser Leu
305                 310                 315                 320

Lys Arg Gly Ile Met Lys Glu Phe Glu Lys Val Thr Lys Asn Phe Ser
                325                 330                 335

Ser Lys Lys Lys Lys Leu Lys Glu Glu Leu Lys Leu Lys Asn Glu Asp
            340                 345                 350

Lys Asn Ser Lys Met Leu Ala Lys Val Ser Arg Pro Ile Gly Phe Leu
```

```
        355                 360                 365

Lys Ala Tyr Leu Ser Tyr Met Leu Phe Asn Ile Ile Ser Asn Arg Ile
    370                 375                 380

Phe Glu Phe Ser Arg Lys Ser Ser Gly Arg Ile Pro Gln Leu Pro Ser
385                 390                 395                 400

Cys Ile Ile Asn Leu Gly Asn Gln Phe Glu Asn Phe Lys Asn Glu Leu
                405                 410                 415

Gln Asp Ser Asn Ile Gly Ser Lys Lys Asn Tyr Lys Tyr Phe Cys Asn
            420                 425                 430

Leu Leu Leu Lys Ser Ser Gly Phe Asn Ile Ser Tyr Glu Glu Glu His
        435                 440                 445

Leu Ser Ile Lys Thr Pro Asn Phe Phe Ile Asn Gly Arg Lys Leu Lys
    450                 455                 460

Glu Ile Thr Ser Glu Lys Lys Lys Ile Arg Lys Glu Asn Glu Gln Leu
465                 470                 475                 480

Ile Lys Gln Trp Lys Lys Leu Thr Phe Phe Lys Pro Ser Asn Leu Asn
                485                 490                 495

Gly Lys Lys Thr Ser Asp Lys Ile Arg Phe Lys Ser Pro Asn Asn Pro
            500                 505                 510

Asp Ile Glu Arg Lys Ser Glu Asp Asn Ile Val Glu Asn Ile Ala Lys
        515                 520                 525

Val Lys Tyr Lys Leu Glu Asp Leu Leu Ser Glu Gln Arg Lys Glu Phe
    530                 535                 540

Asn Lys Leu Ala Lys Lys His Asp Gly Val Asp Val Glu Ala Gln Cys
```

545 550 555 560

Leu Gln Thr Lys Ser Phe Trp Ile Asp Ser Asn Ser Pro Ile Lys Lys
565 570 575

Ser Leu Glu Lys Lys Asn Glu Lys Val Ser Val Lys Lys Lys Met Lys
580 585 590

Ala Ile Arg Ser Cys Ile Ser Ala Trp Lys Trp Phe Met Ala Asp Leu
595 600 605

Ile Glu Ala Gln Lys Glu Thr Pro Met Ile Lys Leu Lys Leu Ala Leu
610 615 620

Met
625

<210> 197
<211> 517
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 197

Thr Thr Leu Val Pro Ser His Leu Ala Gly Ile Glu Val Met Asp Glu
1 5 10 15

Thr Thr Ser Arg Asn Glu Asp Met Ile Gln Lys Glu Thr Ser Arg Ser
20 25 30

Asn Glu Asp Glu Asn Tyr Leu Gly Val Lys Asn Lys Cys Gly Ile Asn
35 40 45

Val His Lys Ser Gly Arg Gly Ser Ser Lys His Glu Pro Asn Met Pro
50 55 60

```
Pro Glu Lys Ser Gly Glu Gly Gln Met Pro Lys Gln Asp Ser Thr Glu
65                  70                  75                  80

Met Gln Gln Arg Phe Asp Glu Ser Val Thr Gly Glu Thr Gln Val Ser
                85                  90                  95

Ala Gly Ala Thr Ala Ser Ile Lys Thr Asp Ala Arg Ala Asn Ser Gly
            100                 105                 110

Pro Arg Val Gly Thr Ala Arg Ala Leu Ile Val Lys Ala Ser Asn Leu
        115                 120                 125

Asp Arg Asp Ile Lys Leu Gly Cys Lys Pro Cys Glu Tyr Ile Arg Ser
    130                 135                 140

Glu Leu Pro Met Gly Lys Lys Asn Gly Cys Asn His Cys Glu Lys Ser
145                 150                 155                 160

Ser Asp Ile Ala Ser Val Pro Lys Val Glu Ser Gly Phe Arg Lys Ala
                165                 170                 175

Lys Tyr Glu Leu Val Arg Arg Phe Glu Ser Phe Ala Ala Asp Ser Ile
            180                 185                 190

Ser Arg His Leu Gly Lys Glu Gln Ala Arg Thr Arg Gly Lys Arg Gly
        195                 200                 205

Lys Lys Asp Lys Lys Glu Gln Met Gly Lys Val Asn Leu Asp Glu Ile
    210                 215                 220

Ala Ile Leu Lys Asn Glu Ser Leu Ile Glu Tyr Thr Glu Asn Gln Ile
225                 230                 235                 240

Leu Asp Ala Arg Ser Asn Arg Ile Lys Glu Trp Leu Arg Ser Leu Arg
                245                 250                 255
```

```
Leu Arg Leu Arg Thr Arg Asn Lys Gly Leu Lys Lys Ser Lys Ser Ile
            260                 265                 270

Arg Arg Gln Leu Ile Thr Leu Arg Arg Asp Tyr Arg Lys Trp Ile Lys
        275                 280                 285

Pro Asn Pro Tyr Arg Pro Asp Glu Asp Pro Asn Glu Asn Ser Leu Arg
    290                 295                 300

Leu His Thr Lys Leu Gly Val Asp Ile Gly Val Gln Gly Gly Asp Asn
305                 310                 315                 320

Lys Arg Met Asn Ser Asp Asp Tyr Glu Thr Ser Phe Ser Ile Thr Trp
                325                 330                 335

Arg Asp Thr Ala Thr Arg Lys Ile Cys Phe Thr Lys Pro Lys Gly Leu
            340                 345                 350

Leu Pro Arg His Met Lys Phe Lys Leu Arg Gly Tyr Pro Glu Leu Ile
        355                 360                 365

Leu Tyr Asn Glu Glu Leu Arg Ile Gln Asp Ser Gln Lys Phe Pro Leu
    370                 375                 380

Val Asp Trp Glu Arg Ile Pro Ile Phe Lys Leu Arg Gly Val Ser Leu
385                 390                 395                 400

Gly Lys Lys Lys Val Lys Ala Leu Asn Arg Ile Thr Glu Ala Pro Arg
                405                 410                 415

Leu Val Val Ala Lys Arg Ile Gln Val Asn Ile Glu Ser Lys Lys Lys
            420                 425                 430

Lys Val Leu Thr Arg Tyr Val Tyr Asn Asp Lys Ser Ile Asn Gly Arg
        435                 440                 445
```

```
Leu Val Lys Ala Glu Asp Ser Asn Lys Asp Pro Leu Leu Glu Phe Lys
    450                 455                 460


Lys Gln Ala Glu Glu Ile Asn Ser Asp Ala Lys Tyr Tyr Glu Asn Gln
465                 470                 475                 480


Glu Ile Ala Lys Asn Tyr Leu Trp Gly Cys Glu Gly Leu His Lys Asn
                485                 490                 495


Leu Leu Glu Glu Gln Thr Lys Asn Pro Tyr Leu Ala Phe Lys Tyr Gly
            500                 505                 510


Phe Leu Asn Ile Val
        515


<210>  198
<211>  410
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  198

Leu Asp Phe Lys Arg Thr Cys Ser Gln Glu Leu Val Leu Leu Pro Glu
1               5                   10                  15


Ile Glu Gly Leu Lys Leu Ser Gly Thr Gln Gly Val Thr Ser Leu Ala
            20                  25                  30


Lys Lys Leu Ile Asn Lys Ala Ala Asn Val Asp Arg Asp Glu Ser Tyr
        35                  40                  45


Gly Cys His His Cys Ile His Thr Arg Thr Ser Leu Ser Lys Pro Val
    50                  55                  60


Lys Lys Asp Cys Asn Ser Cys Asn Gln Ser Thr Asn His Pro Ala Val
```

```
65                  70                  75                  80

Pro Ile Thr Leu Lys Gly Tyr Lys Ile Ala Phe Tyr Glu Leu Trp His
                85                  90                  95

Arg Phe Thr Ser Trp Ala Val Asp Ser Ile Ser Lys Ala Leu His Arg
            100                 105                 110

Asn Lys Val Met Gly Lys Val Asn Leu Asp Glu Tyr Ala Val Val Asp
        115                 120                 125

Asn Ser His Ile Val Cys Tyr Ala Val Arg Lys Cys Tyr Glu Lys Arg
    130                 135                 140

Gln Arg Ser Val Arg Leu His Lys Arg Ala Tyr Arg Cys Arg Ala Lys
145                 150                 155                 160

His Tyr Asn Lys Ser Gln Pro Lys Val Gly Arg Ile Tyr Lys Lys Ser
                165                 170                 175

Lys Arg Arg Asn Ala Arg Asn Leu Lys Lys Glu Ala Lys Arg Tyr Phe
            180                 185                 190

Gln Pro Asn Glu Ile Thr Asn Gly Ser Ser Asp Ala Leu Phe Tyr Lys
        195                 200                 205

Ile Gly Val Asp Leu Gly Ile Ala Lys Gly Thr Pro Glu Thr Glu Val
    210                 215                 220

Lys Val Asp Val Ser Ile Cys Phe Gln Val Tyr Tyr Gly Asp Ala Arg
225                 230                 235                 240

Arg Val Leu Arg Val Arg Lys Met Asp Glu Leu Gln Ser Phe His Leu
                245                 250                 255

Asp Tyr Thr Gly Lys Leu Lys Leu Lys Gly Ile Gly Asn Lys Asp Thr
```

260 265 270

Phe Thr Ile Ala Lys Arg Asn Glu Ser Leu Lys Trp Gly Ser Thr Lys
275 280 285

Tyr Glu Val Ser Arg Ala His Lys Lys Phe Lys Pro Phe Gly Lys Lys
290 295 300

Gly Ser Val Lys Arg Lys Cys Asn Asp Tyr Phe Arg Ser Ile Ala Ser
305 310 315 320

Trp Ser Cys Glu Ala Ala Ser Gln Arg Ala Gln Ser Asn Leu Lys Asn
325 330 335

Ala Phe Pro Tyr Gln Lys Ala Leu Val Lys Cys Tyr Lys Asn Leu Asp
340 345 350

Tyr Lys Gly Val Lys Lys Asn Asp Met Trp Tyr Arg Leu Cys Ser Asn
355 360 365

Arg Ile Phe Arg Tyr Ser Arg Ile Ala Glu Asp Ile Ala Gln Tyr Gln
370 375 380

Ser Asp Lys Gly Lys Ala Lys Phe Glu Phe Val Ile Leu Ala Gln Ser
385 390 395 400

Val Ala Glu Tyr Asp Ile Ser Ala Ile Met
405 410

<210> 199
<211> 602
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 199

```
Val Phe Leu Thr Asp Asp Lys Arg Lys Thr Ala Leu Arg Lys Ile Arg
1               5                  10                  15

Ser Ala Phe Arg Lys Thr Ala Glu Ile Ala Leu Val Arg Ala Gln Glu
            20                  25                  30

Ala Asp Ser Leu Asp Arg Gln Ala Lys Lys Leu Thr Ile Glu Thr Val
        35                  40                  45

Ser Phe Gly Ala Pro Gly Ala Lys Asn Ala Phe Ile Gly Ser Leu Gln
    50                  55                  60

Gly Tyr Asn Trp Asn Ser His Arg Ala Asn Val Pro Ser Ser Gly Ser
65                  70                  75                  80

Ala Lys Asp Val Phe Arg Ile Thr Glu Leu Gly Leu Gly Ile Pro Gln
                85                  90                  95

Ser Ala His Glu Ala Ser Ile Gly Lys Ser Phe Glu Leu Val Gly Asn
            100                 105                 110

Val Val Arg Tyr Thr Ala Asn Leu Leu Ser Lys Gly Tyr Lys Lys Gly
        115                 120                 125

Ala Val Asn Lys Gly Ala Lys Gln Gln Arg Glu Ile Lys Gly Lys Glu
    130                 135                 140

Gln Leu Ser Phe Asp Leu Ile Ser Asn Gly Pro Ile Ser Gly Asp Lys
145                 150                 155                 160

Leu Ile Asn Gly Gln Lys Asp Ala Leu Ala Trp Trp Leu Ile Asp Lys
                165                 170                 175

Met Gly Phe His Ile Gly Leu Ala Met Glu Pro Leu Ser Ser Pro Asn
            180                 185                 190
```

```
Thr Tyr Gly Ile Thr Leu Gln Ala Phe Trp Lys Arg His Thr Ala Pro
        195                 200                 205

Arg Arg Tyr Ser Arg Gly Val Ile Arg Gln Trp Gln Leu Pro Phe Gly
    210                 215                 220

Arg Gln Leu Ala Pro Leu Ile His Asn Phe Phe Arg Lys Lys Gly Ala
225                 230                 235                 240

Ser Ile Pro Ile Val Leu Thr Asn Ala Ser Lys Lys Leu Ala Gly Lys
                245                 250                 255

Gly Val Leu Leu Glu Gln Thr Ala Leu Val Asp Pro Lys Lys Trp Trp
            260                 265                 270

Gln Val Lys Glu Gln Val Thr Gly Pro Leu Ser Asn Ile Trp Glu Arg
        275                 280                 285

Ser Val Pro Leu Val Leu Tyr Thr Ala Thr Phe Thr His Lys His Gly
    290                 295                 300

Ala Ala His Lys Arg Pro Leu Thr Leu Lys Val Ile Arg Ile Ser Ser
305                 310                 315                 320

Gly Ser Val Phe Leu Leu Pro Leu Ser Lys Val Thr Pro Gly Lys Leu
                325                 330                 335

Val Arg Ala Trp Met Pro Asp Ile Asn Ile Leu Arg Asp Gly Arg Pro
            340                 345                 350

Asp Glu Ala Ala Tyr Lys Gly Pro Asp Leu Ile Arg Ala Arg Glu Arg
        355                 360                 365

Ser Phe Pro Leu Ala Tyr Thr Cys Val Thr Gln Ile Ala Asp Glu Trp
    370                 375                 380
```

```
Gln Lys Arg Ala Leu Glu Ser Asn Arg Asp Ser Ile Thr Pro Leu Glu
385                 390                 395                 400


Ala Lys Leu Val Thr Gly Ser Asp Leu Leu Gln Ile His Ser Thr Val
                405                 410                 415


Gln Gln Ala Val Glu Gln Gly Ile Gly Gly Arg Ile Ser Ser Pro Ile
            420                 425                 430


Gln Glu Leu Leu Ala Lys Asp Ala Leu Gln Leu Val Leu Gln Gln Leu
        435                 440                 445


Phe Met Thr Val Asp Leu Leu Arg Ile Gln Trp Gln Leu Lys Gln Glu
    450                 455                 460


Val Ala Asp Gly Asn Thr Ser Glu Lys Ala Val Gly Trp Ala Ile Arg
465                 470                 475                 480


Ile Ser Asn Ile His Lys Asp Ala Tyr Lys Thr Ala Ile Glu Pro Cys
                485                 490                 495


Thr Ser Ala Leu Lys Gln Ala Trp Asn Pro Leu Ser Gly Phe Glu Glu
            500                 505                 510


Arg Thr Phe Gln Leu Asp Ala Ser Ile Val Arg Lys Arg Ser Thr Ala
        515                 520                 525


Lys Thr Pro Asp Asp Glu Leu Val Ile Val Leu Arg Gln Gln Ala Ala
    530                 535                 540


Glu Met Thr Val Ala Val Thr Gln Ser Val Ser Lys Glu Leu Met Glu
545                 550                 555                 560


Leu Ala Val Arg His Ser Ala Thr Leu His Leu Leu Val Gly Glu Val
                565                 570                 575
```

Ala Ser Lys Gln Leu Ser Arg Ser Ala Asp Lys Asp Arg Gly Ala Met
580 585 590

Asp His Trp Lys Leu Leu Ser Gln Ser Met
595 600

<210> 200
<211> 494
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 200

Glu Asp Leu Leu Gln Lys Ala Leu Asn Thr Ala Thr Asn Val Ala Ala
1 5 10 15

Ile Glu Arg His Ser Cys Ile Ser Cys Leu Phe Thr Glu Ser Glu Ile
20 25 30

Asp Val Lys Tyr Lys Thr Pro Asp Lys Ile Gly Gln Asn Thr Ala Gly
35 40 45

Cys Gln Ser Cys Thr Phe Arg Val Gly Tyr Ser Gly Asn Ser His Thr
50 55 60

Leu Pro Met Gly Asn Arg Ile Ala Leu Asp Lys Leu Arg Glu Thr Ile
65 70 75 80

Gln Arg Tyr Ala Trp His Ser Leu Leu Phe Asn Val Pro Pro Ala Pro
85 90 95

Thr Ser Lys Arg Val Arg Ala Ile Ser Glu Leu Arg Val Ala Ala Gly
100 105 110

Arg Glu Arg Leu Phe Thr Val Ile Thr Phe Val Gln Thr Asn Ile Leu

```
        115                 120                 125

Ser Lys Leu Gln Lys Arg Tyr Ala Ala Asn Trp Thr Pro Lys Ser Gln
    130                 135                 140

Glu Arg Leu Ser Arg Leu Arg Glu Glu Gly Gln His Ile Leu Ser Leu
145                 150                 155                 160

Leu Glu Ser Gly Ser Trp Gln Gln Lys Glu Val Val Arg Glu Asp Gln
                165                 170                 175

Asp Leu Ile Val Cys Ser Ala Leu Thr Lys Pro Gly Leu Ser Ile Gly
            180                 185                 190

Ala Phe Cys Arg Pro Lys Tyr Leu Lys Pro Ala Lys His Ala Leu Val
        195                 200                 205

Leu Arg Leu Ile Phe Val Glu Gln Trp Pro Gly Gln Ile Trp Gly Gln
    210                 215                 220

Ser Lys Arg Thr Arg Arg Met Arg Arg Arg Lys Asp Val Glu Arg Val
225                 230                 235                 240

Tyr Asp Ile Ser Val Gln Ala Trp Ala Leu Lys Gly Lys Glu Thr Arg
                245                 250                 255

Ile Ser Glu Cys Ile Asp Thr Met Arg Arg His Gln Gln Ala Tyr Ile
            260                 265                 270

Gly Val Leu Pro Phe Leu Ile Leu Ser Gly Ser Thr Val Arg Gly Lys
        275                 280                 285

Gly Asp Cys Pro Ile Leu Lys Glu Ile Thr Arg Met Arg Tyr Cys Pro
    290                 295                 300

Asn Asn Glu Gly Leu Ile Pro Leu Gly Ile Phe Tyr Arg Gly Ser Ala
```

305 310 315 320

Asn Lys Leu Leu Arg Val Val Lys Gly Ser Ser Phe Thr Leu Pro Met
325 330 335

Trp Gln Asn Ile Glu Thr Leu Pro His Pro Glu Pro Phe Ser Pro Glu
340 345 350

Gly Trp Thr Ala Thr Gly Ala Leu Tyr Glu Lys Asn Leu Ala Tyr Trp
355 360 365

Ser Ala Leu Asn Glu Ala Val Asp Trp Tyr Thr Gly Gln Ile Leu Ser
370 375 380

Ser Gly Leu Gln Tyr Pro Asn Gln Asn Glu Phe Leu Ala Arg Leu Gln
385 390 395 400

Asn Val Ile Asp Ser Ile Pro Arg Lys Trp Phe Arg Pro Gln Gly Leu
405 410 415

Lys Asn Leu Lys Pro Asn Gly Gln Glu Asp Ile Val Pro Asn Glu Phe
420 425 430

Val Ile Pro Gln Asn Ala Ile Arg Ala His His Val Ile Glu Trp Tyr
435 440 445

His Lys Thr Asn Asp Leu Val Ala Lys Thr Leu Leu Gly Trp Gly Ser
450 455 460

Gln Thr Thr Leu Asn Gln Thr Arg Pro Gln Gly Asp Leu Arg Phe Thr
465 470 475 480

Tyr Thr Arg Tyr Tyr Phe Arg Glu Lys Glu Val Pro Glu Val
485 490

<210> 201

<211> 649
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 201

Val Pro Lys Lys Lys Leu Met Arg Glu Leu Ala Lys Lys Ala Val Phe
1 5 10 15

Glu Ala Ile Phe Asn Asp Pro Ile Pro Gly Ser Phe Gly Cys Lys Arg
20 25 30

Cys Thr Leu Ile Asp Gly Ala Arg Val Thr Asp Ala Ile Glu Lys Lys
35 40 45

Gln Gly Ala Lys Arg Cys Ala Gly Cys Glu Pro Cys Thr Phe His Thr
50 55 60

Leu Tyr Asp Ser Val Lys His Ala Leu Pro Ala Ala Thr Gly Cys Asp
65 70 75 80

Arg Thr Ala Ile Asp Thr Gly Leu Trp Glu Ile Leu Thr Ala Leu Arg
85 90 95

Ser Tyr Asn Trp Met Ser Phe Arg Arg Asn Ala Val Ser Asp Ala Ser
100 105 110

Gln Lys Gln Val Trp Ser Ile Glu Glu Leu Ala Ile Trp Ala Asp Lys
115 120 125

Glu Arg Ala Leu Arg Val Ile Leu Ser Ala Leu Thr His Thr Ile Gly
130 135 140

Lys Leu Lys Asn Gly Phe Ser Arg Asp Gly Val Trp Lys Gly Gly Lys
145 150 155 160

```
Gln Leu Tyr Glu Asn Leu Ala Gln Lys Asp Leu Ala Lys Gly Leu Phe
                165                 170                 175

Ala Asn Gly Glu Ile Phe Gly Lys Glu Leu Val Glu Ala Asp His Asp
            180                 185                 190

Met Leu Ala Trp Thr Ile Val Pro Asn His Gln Phe His Ile Gly Leu
        195                 200                 205

Ile Arg Gly Asn Trp Lys Pro Ala Ala Val Glu Ala Ser Thr Ala Phe
    210                 215                 220

Asp Ala Arg Trp Leu Thr Asn Gly Ala Pro Leu Arg Asp Thr Arg Thr
225                 230                 235                 240

His Gly His Arg Gly Arg Arg Phe Asn Arg Thr Glu Lys Leu Thr Val
                245                 250                 255

Leu Cys Ile Lys Arg Asp Gly Gly Val Ser Glu Glu Phe Arg Gln Glu
            260                 265                 270

Arg Asp Tyr Glu Leu Ser Val Met Leu Leu Gln Pro Lys Asn Lys Leu
        275                 280                 285

Lys Pro Glu Pro Lys Gly Glu Leu Asn Ser Phe Glu Asp Leu His Asp
    290                 295                 300

His Trp Trp Phe Leu Lys Gly Asp Glu Ala Thr Ala Leu Val Gly Leu
305                 310                 315                 320

Thr Ser Asp Pro Thr Val Gly Asp Phe Ile Gln Leu Gly Leu Tyr Ile
                325                 330                 335

Arg Asn Pro Ile Lys Ala His Gly Glu Thr Lys Arg Arg Leu Leu Ile
            340                 345                 350
```

```
Cys Phe Glu Pro Pro Ile Lys Leu Pro Leu Arg Arg Ala Phe Pro Ser
        355                 360                 365


Glu Ala Phe Lys Thr Trp Glu Pro Thr Ile Asn Val Phe Arg Asn Gly
    370                 375                 380


Arg Arg Asp Thr Glu Ala Tyr Tyr Asp Ile Asp Arg Ala Arg Val Phe
385                 390                 395                 400


Glu Phe Pro Glu Thr Arg Val Ser Leu Glu His Leu Ser Lys Gln Trp
                405                 410                 415


Glu Val Leu Arg Leu Glu Pro Asp Arg Glu Asn Thr Asp Pro Tyr Glu
            420                 425                 430


Ala Gln Gln Asn Glu Gly Ala Glu Leu Gln Val Tyr Ser Leu Leu Gln
        435                 440                 445


Glu Ala Ala Gln Lys Met Ala Pro Lys Val Val Ile Asp Pro Phe Gly
    450                 455                 460


Gln Phe Pro Leu Glu Leu Phe Ser Thr Phe Val Ala Gln Leu Phe Asn
465                 470                 475                 480


Ala Pro Leu Ser Asp Thr Lys Ala Lys Ile Gly Lys Pro Leu Asp Ser
                485                 490                 495


Gly Phe Val Val Glu Ser His Leu His Leu Leu Glu Glu Asp Phe Ala
            500                 505                 510


Tyr Arg Asp Phe Val Arg Val Thr Phe Met Gly Thr Glu Pro Thr Phe
        515                 520                 525


Arg Val Ile His Tyr Ser Asn Gly Glu Gly Tyr Trp Lys Lys Thr Val
    530                 535                 540
```

```
Leu Lys Gly Lys Asn Asn Ile Arg Thr Ala Leu Ile Pro Glu Gly Ala
545                 550                 555                 560


Lys Ala Ala Val Asp Ala Tyr Lys Asn Lys Arg Cys Pro Leu Thr Leu
                565                 570                 575


Glu Ala Ala Ile Leu Asn Glu Glu Lys Asp Arg Arg Leu Val Leu Gly
            580                 585                 590


Asn Lys Ala Leu Ser Leu Leu Ala Gln Thr Ala Arg Gly Asn Leu Thr
        595                 600                 605


Ile Leu Glu Ala Leu Ala Ala Glu Val Leu Arg Pro Leu Ser Gly Thr
    610                 615                 620


Glu Gly Val Val His Leu His Ala Cys Val Thr Arg His Ser Thr Leu
625                 630                 635                 640


Thr Glu Ser Thr Glu Thr Asp Asn Met
                645


<210>  202
<211>  414
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  202

Val Glu Lys Leu Phe Ser Glu Arg Leu Lys Arg Ala Met Trp Leu Lys
1               5                   10                  15


Asn Glu Ala Gly Arg Ala Pro Pro Ala Glu Thr Leu Thr Leu Lys His
            20                  25                  30


Lys Arg Val Ser Gly Gly His Glu Lys Val Lys Glu Glu Leu Gln Arg
```

```
        35                  40                  45

Val Leu Arg Ser Leu Ser Gly Thr Asn Gln Ala Ala Trp Asn Leu Gly
    50                  55                  60

Leu Ser Gly Gly Arg Glu Pro Lys Ser Ser Asp Ala Leu Lys Gly Glu
65                  70                  75                  80

Lys Ser Arg Val Val Leu Glu Thr Val Val Phe His Ser Gly His Asn
                85                  90                  95

Arg Val Leu Tyr Asp Val Ile Glu Arg Glu Asp Gln Val His Gln Arg
            100                 105                 110

Ser Ser Ile Met His Met Arg Arg Lys Gly Ser Asn Leu Leu Arg Leu
        115                 120                 125

Trp Gly Arg Ser Gly Lys Val Arg Arg Lys Met Arg Glu Glu Val Ala
    130                 135                 140

Glu Ile Lys Pro Val Trp His Lys Asp Ser Arg Trp Leu Ala Ile Val
145                 150                 155                 160

Glu Glu Gly Arg Gln Ser Val Val Gly Ile Ser Ser Ala Gly Leu Ala
                165                 170                 175

Val Phe Ala Val Gln Glu Ser Gln Cys Thr Thr Ala Glu Pro Lys Pro
            180                 185                 190

Leu Glu Tyr Val Val Ser Ile Trp Phe Arg Gly Ser Lys Ala Leu Asn
        195                 200                 205

Pro Gln Asp Arg Tyr Leu Glu Phe Lys Lys Leu Lys Thr Thr Glu Ala
    210                 215                 220

Leu Arg Gly Gln Gln Tyr Asp Pro Ile Pro Phe Ser Leu Lys Arg Gly
```

225 230 235 240

Ala Gly Cys Ser Leu Ala Ile Arg Gly Glu Gly Ile Lys Phe Gly Ser
245 250 255

Arg Gly Pro Ile Lys Gln Phe Phe Gly Ser Asp Arg Ser Arg Pro Ser
260 265 270

His Ala Asp Tyr Asp Gly Lys Arg Arg Leu Ser Leu Phe Ser Lys Tyr
275 280 285

Ala Gly Asp Leu Ala Asp Leu Thr Glu Glu Gln Trp Asn Arg Thr Val
290 295 300

Ser Ala Phe Ala Glu Asp Glu Val Arg Arg Ala Thr Leu Ala Asn Ile
305 310 315 320

Gln Asp Phe Leu Ser Ile Ser His Glu Lys Tyr Ala Glu Arg Leu Lys
325 330 335

Lys Arg Ile Glu Ser Ile Glu Glu Pro Val Ser Ala Ser Lys Leu Glu
340 345 350

Ala Tyr Leu Ser Ala Ile Phe Glu Thr Phe Val Gln Gln Arg Glu Ala
355 360 365

Leu Ala Ser Asn Phe Leu Met Arg Leu Val Glu Ser Val Ala Leu Leu
370 375 380

Ile Ser Leu Glu Glu Lys Ser Pro Arg Val Glu Phe Arg Val Ala Arg
385 390 395 400

Tyr Leu Ala Glu Ser Lys Glu Gly Phe Asn Arg Lys Ala Met
405 410

<210> 203

<211> 413
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 203

Val Val Ile Thr Gln Ser Glu Leu Tyr Lys Glu Arg Leu Leu Arg Val
1 5 10 15

Met Glu Ile Lys Asn Asp Arg Gly Arg Lys Glu Pro Arg Glu Ser Gln
20 25 30

Gly Leu Val Leu Arg Phe Thr Gln Val Thr Gly Gly Gln Glu Lys Val
35 40 45

Lys Gln Lys Leu Trp Leu Ile Phe Glu Gly Phe Ser Gly Thr Asn Gln
50 55 60

Ala Ser Trp Asn Phe Gly Gln Pro Ala Gly Gly Arg Lys Pro Asn Ser
65 70 75 80

Gly Asp Ala Leu Lys Gly Pro Lys Ser Arg Val Thr Tyr Glu Thr Val
85 90 95

Val Phe His Phe Gly Leu Arg Leu Leu Ser Ala Val Ile Glu Arg His
100 105 110

Asn Leu Lys Gln Gln Arg Gln Thr Met Ala Tyr Met Lys Arg Arg Ala
115 120 125

Ala Ala Arg Lys Lys Trp Ala Arg Ser Gly Lys Lys Cys Ser Arg Met
130 135 140

Arg Asn Glu Val Glu Lys Ile Lys Pro Lys Trp His Lys Asp Pro Arg
145 150 155 160

```
Trp Phe Asp Ile Val Lys Glu Gly Glu Pro Ser Ile Val Gly Ile Ser
                165                 170                 175


Ser Ala Gly Phe Ala Ile Tyr Ile Val Glu Glu Pro Asn Phe Pro Arg
            180                 185                 190


Gln Asp Pro Leu Glu Ile Glu Tyr Ala Ile Ser Ile Trp Phe Arg Arg
        195                 200                 205


Asp Arg Ser Gln Tyr Leu Thr Phe Lys Lys Ile Gln Lys Ala Glu Lys
    210                 215                 220


Leu Lys Glu Leu Gln Tyr Asn Pro Ile Pro Phe Arg Leu Lys Gln Glu
225                 230                 235                 240


Lys Thr Ser Leu Val Phe Glu Ser Gly Asp Ile Lys Phe Gly Ser Arg
                245                 250                 255


Gly Ser Ile Glu His Phe Arg Asp Glu Ala Arg Gly Lys Pro Pro Lys
            260                 265                 270


Ala Asp Met Asp Asn Asn Arg Arg Leu Thr Met Phe Ser Val Phe Ser
        275                 280                 285


Gly Asn Leu Thr Asn Leu Thr Glu Glu Gln Tyr Ala Arg Pro Val Ser
    290                 295                 300


Gly Leu Leu Ala Pro Asp Glu Lys Arg Met Pro Thr Leu Leu Lys Lys
305                 310                 315                 320


Leu Gln Asp Phe Phe Thr Pro Ile His Glu Lys Tyr Gly Glu Arg Ile
                325                 330                 335


Lys Gln Arg Leu Ala Asn Ser Glu Ala Ser Lys Arg Pro Phe Lys Lys
            340                 345                 350
```

```
Leu Glu Glu Tyr Leu Pro Ala Ile Tyr Leu Glu Phe Arg Ala Arg Arg
        355                 360                 365


Glu Gly Leu Ala Ser Asn Trp Val Leu Val Leu Ile Asn Ser Val Arg
    370                 375                 380


Thr Leu Val Arg Ile Lys Ser Glu Asp Pro Tyr Ile Glu Phe Lys Val
385                 390                 395                 400


Ser Gln Tyr Leu Leu Glu Lys Glu Asp Asn Lys Ala Leu
                405                 410


<210>  204
<211>  449
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  204

Lys Gln Asp Ala Leu Phe Glu Glu Arg Leu Lys Lys Ala Ile Phe Ile
1               5                   10                  15


Lys Arg Gln Ala Asp Pro Leu Gln Arg Glu Glu Leu Ser Leu Leu Pro
            20                  25                  30


Pro Asn Arg Lys Ile Val Thr Gly Gly His Glu Ser Ala Lys Asp Thr
        35                  40                  45


Leu Lys Gln Ile Leu Arg Ala Ile Asn Gly Thr Asn Gln Ala Ser Trp
    50                  55                  60


Asn Pro Gly Thr Pro Ser Gly Lys Arg Asp Ser Lys Ser Ala Asp Ala
65                  70                  75                  80


Leu Ala Gly Pro Lys Ser Arg Val Lys Leu Glu Thr Val Val Phe His
```

85 90 95

Val Gly His Arg Leu Leu Lys Lys Val Val Glu Tyr Gln Gly His Gln
100 105 110

Lys Gln Gln His Gly Leu Lys Ala Phe Met Arg Thr Cys Ala Ala Met
115 120 125

Arg Lys Lys Trp Lys Arg Ser Gly Lys Val Val Gly Glu Leu Arg Glu
130 135 140

Gln Leu Ala Asn Ile Gln Pro Lys Trp His Tyr Asp Ser Arg Pro Leu
145 150 155 160

Asn Leu Cys Phe Glu Gly Lys Pro Ser Val Val Gly Leu Arg Ser Ala
165 170 175

Gly Ile Ala Leu Tyr Thr Ile Gln Lys Ser Val Val Pro Val Lys Glu
180 185 190

Pro Lys Pro Ile Glu Tyr Ala Val Ser Ile Trp Phe Arg Gly Pro Lys
195 200 205

Ala Met Asp Arg Glu Asp Arg Cys Leu Glu Phe Lys Lys Leu Lys Ile
210 215 220

Ala Thr Glu Leu Arg Lys Leu Gln Phe Glu Pro Ile Val Ser Thr Leu
225 230 235 240

Thr Gln Gly Ile Lys Gly Phe Ser Leu Tyr Ile Gln Gly Asn Ser Val
245 250 255

Lys Phe Gly Ser Arg Gly Pro Ile Lys Tyr Phe Ser Asn Glu Ser Val
260 265 270

Arg Gln Arg Pro Pro Lys Ala Asp Pro Asp Gly Asn Lys Arg Leu Ala

```
        275                 280                 285

Leu Phe Ser Lys Phe Ser Gly Asp Leu Ser Asp Leu Thr Glu Glu Gln
    290                 295                 300

Trp Asn Arg Pro Ile Leu Ala Phe Glu Gly Ile Ile Arg Arg Ala Thr
305                 310                 315                 320

Leu Gly Asn Ile Gln Asp Tyr Leu Thr Val Gly His Glu Gln Phe Ala
                325                 330                 335

Ile Ser Leu Glu Gln Leu Leu Ser Glu Lys Glu Ser Val Leu Gln Met
            340                 345                 350

Ser Ile Glu Gln Gln Arg Leu Lys Lys Asn Leu Gly Lys Lys Ala Glu
        355                 360                 365

Asn Glu Trp Val Glu Ser Phe Gly Ala Glu Gln Ala Arg Lys Lys Ala
    370                 375                 380

Gln Gly Ile Arg Glu Tyr Ile Ser Gly Phe Phe Gln Glu Tyr Cys Ser
385                 390                 395                 400

Gln Arg Glu Gln Trp Ala Glu Asn Trp Val Gln Gln Leu Asn Lys Ser
                405                 410                 415

Val Arg Leu Phe Leu Thr Ile Gln Asp Ser Thr Pro Phe Ile Glu Phe
            420                 425                 430

Arg Val Ala Arg Tyr Leu Pro Lys Gly Glu Lys Lys Lys Gly Lys Ala
        435                 440                 445

Met
```

<210> 205

<211> 711
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 205

Ala Asn His Ala Glu Arg His Lys Arg Leu Arg Lys Glu Ala Asn Arg
1 5 10 15

Ala Ala Asn Arg Asn Arg Pro Leu Val Ala Asp Cys Asp Thr Gly Asp
20 25 30

Pro Leu Val Gly Ile Cys Arg Leu Leu Arg Arg Gly Asp Lys Met Gln
35 40 45

Pro Asn Lys Thr Gly Cys Arg Ser Cys Glu Gln Val Glu Pro Glu Leu
50 55 60

Arg Asp Ala Ile Leu Val Ser Gly Pro Gly Arg Leu Asp Asn Tyr Lys
65 70 75 80

Tyr Glu Leu Phe Gln Arg Gly Arg Ala Met Ala Val His Arg Leu Leu
85 90 95

Lys Arg Val Pro Lys Leu Asn Arg Pro Lys Lys Ala Ala Gly Asn Asp
100 105 110

Glu Lys Lys Ala Glu Asn Lys Lys Ser Glu Ile Gln Lys Glu Lys Gln
115 120 125

Lys Gln Arg Arg Met Met Pro Ala Val Ser Met Lys Gln Val Ser Val
130 135 140

Ala Asp Phe Lys His Val Ile Glu Asn Thr Val Arg His Leu Phe Gly
145 150 155 160

```
Asp Arg Arg Asp Arg Glu Ile Ala Glu Cys Ala Ala Leu Arg Ala Ala
                165                 170                 175

Ser Lys Tyr Phe Leu Lys Ser Arg Arg Val Arg Pro Arg Lys Leu Pro
            180                 185                 190

Lys Leu Ala Asn Pro Asp His Gly Lys Glu Leu Lys Gly Leu Arg Leu
        195                 200                 205

Arg Glu Lys Arg Ala Lys Leu Lys Lys Glu Lys Glu Lys Gln Ala Glu
    210                 215                 220

Leu Ala Arg Ser Asn Gln Lys Gly Ala Val Leu His Val Ala Thr Leu
225                 230                 235                 240

Lys Lys Asp Ala Pro Pro Met Pro Tyr Glu Lys Thr Gln Gly Arg Asn
                245                 250                 255

Asp Tyr Thr Thr Phe Val Ile Ser Ala Ala Ile Lys Val Gly Ala Thr
            260                 265                 270

Arg Gly Thr Lys Pro Leu Leu Thr Pro Gln Pro Arg Glu Trp Gln Cys
        275                 280                 285

Ser Leu Tyr Trp Arg Asp Gly Gln Arg Trp Ile Arg Gly Gly Leu Leu
    290                 295                 300

Gly Leu Gln Ala Gly Ile Val Leu Gly Pro Lys Leu Asn Arg Glu Leu
305                 310                 315                 320

Leu Glu Ala Val Leu Gln Arg Pro Ile Glu Cys Arg Met Ser Gly Cys
                325                 330                 335

Gly Asn Pro Leu Gln Val Arg Gly Ala Ala Val Asp Phe Phe Met Thr
            340                 345                 350
```

```
Thr Asn Pro Phe Tyr Val Ser Gly Ala Ala Tyr Ala Gln Lys Lys Phe
        355                 360                 365

Lys Pro Phe Gly Thr Lys Arg Ala Ser Glu Asp Gly Ala Ala Ala Lys
    370                 375                 380

Ala Arg Glu Lys Leu Met Thr Gln Leu Ala Lys Val Leu Asp Lys Val
385                 390                 395                 400

Val Thr Gln Ala Ala His Ser Pro Leu Asp Gly Ile Trp Glu Thr Arg
                405                 410                 415

Pro Glu Ala Lys Leu Arg Ala Met Ile Met Ala Leu Glu His Glu Trp
            420                 425                 430

Ile Phe Leu Arg Pro Gly Pro Cys His Asn Ala Ala Glu Glu Val Ile
        435                 440                 445

Lys Cys Asp Cys Thr Gly Gly His Ala Ile Leu Trp Ala Leu Ile Asp
    450                 455                 460

Glu Ala Arg Gly Ala Leu Glu His Lys Glu Phe Tyr Ala Val Thr Arg
465                 470                 475                 480

Ala His Thr His Asp Cys Glu Lys Gln Lys Leu Gly Gly Arg Leu Ala
                485                 490                 495

Gly Phe Leu Asp Leu Leu Ile Ala Gln Asp Val Pro Leu Asp Asp Ala
            500                 505                 510

Pro Ala Ala Arg Lys Ile Lys Thr Leu Leu Glu Ala Thr Pro Pro Ala
        515                 520                 525

Pro Cys Tyr Lys Ala Ala Thr Ser Ile Ala Thr Cys Asp Cys Glu Gly
    530                 535                 540
```

```
Lys Phe Asp Lys Leu Trp Ala Ile Ile Asp Ala Thr Arg Ala Gly His
545                 550                 555                 560


Gly Thr Glu Asp Leu Trp Ala Arg Thr Leu Ala Tyr Pro Gln Asn Val
                565                 570                 575


Asn Cys Lys Cys Lys Ala Gly Lys Asp Leu Thr His Arg Leu Ala Asp
            580                 585                 590


Phe Leu Gly Leu Leu Ile Lys Arg Asp Gly Pro Phe Arg Glu Arg Pro
        595                 600                 605


Pro His Lys Val Thr Gly Asp Arg Lys Leu Val Phe Ser Gly Asp Lys
    610                 615                 620


Lys Cys Lys Gly His Gln Tyr Val Ile Leu Ala Lys Ala His Asn Glu
625                 630                 635                 640


Glu Val Val Arg Ala Trp Ile Ser Arg Trp Gly Leu Lys Ser Arg Thr
                645                 650                 655


Asn Lys Ala Gly Tyr Ala Ala Thr Glu Leu Asn Leu Leu Leu Asn Trp
            660                 665                 670


Leu Ser Ile Cys Arg Arg Arg Trp Met Asp Met Leu Thr Val Gln Arg
        675                 680                 685


Asp Thr Pro Tyr Ile Arg Met Lys Thr Gly Arg Leu Val Val Asp Asp
    690                 695                 700


Lys Lys Glu Arg Lys Ala Met
705                 710


<210>  206
<211>  574
<212>  PRT
```

<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 206

Ala Lys Gln Arg Glu Ala Leu Arg Val Ala Leu Glu Arg Gly Ile Val
1 5 10 15

Arg Ala Ser Asn Arg Thr Tyr Thr Leu Val Thr Asn Cys Thr Lys Gly
20 25 30

Gly Pro Leu Pro Glu Gln Cys Arg Met Ile Glu Arg Gly Lys Ala Arg
35 40 45

Ala Met Lys Trp Glu Pro Lys Leu Val Gly Cys Gly Ser Cys Ala Ala
50 55 60

Ala Thr Val Asp Leu Pro Ala Ile Glu Glu Tyr Ala Gln Pro Gly Arg
65 70 75 80

Leu Asp Val Ala Lys Tyr Lys Leu Thr Thr Gln Ile Leu Ala Met Ala
85 90 95

Thr Arg Arg Met Met Val Arg Ala Ala Lys Leu Ser Arg Arg Lys Gly
100 105 110

Gln Trp Pro Ala Lys Val Gln Glu Glu Lys Glu Glu Pro Pro Glu Pro
115 120 125

Lys Lys Met Leu Lys Ala Val Glu Met Arg Pro Val Ala Ile Val Asp
130 135 140

Phe Asn Arg Val Ile Gln Thr Thr Ile Glu His Leu Trp Ala Glu Arg
145 150 155 160

Ala Asn Ala Asp Glu Ala Glu Leu Lys Ala Leu Lys Ala Ala Ala Ala

```
                165                 170                 175

Tyr Phe Gly Pro Ser Leu Lys Ile Arg Ala Arg Gly Pro Pro Lys Ala
            180                 185                 190

Ala Ile Gly Arg Glu Leu Lys Lys Ala His Arg Lys Lys Ala Tyr Ala
        195                 200                 205

Glu Arg Lys Lys Ala Arg Arg Lys Arg Ala Glu Leu Ala Arg Ser Gln
    210                 215                 220

Ala Arg Gly Ala Ala Ala His Ala Ala Ile Arg Glu Arg Asp Ile Pro
225                 230                 235                 240

Pro Met Ala Tyr Glu Arg Thr Gln Gly Arg Asn Asp Val Thr Thr Ile
                245                 250                 255

Pro Ile Ala Ala Ala Ile Lys Ile Ala Ala Thr Arg Gly Ala Arg Pro
            260                 265                 270

Leu Pro Ala Pro Lys Pro Met Lys Trp Gln Cys Ser Leu Tyr Trp Asn
        275                 280                 285

Glu Gly Gln Arg Trp Ile Arg Gly Gly Met Leu Thr Ala Gln Ala Tyr
    290                 295                 300

Ala His Ala Ala Asn Ile His Arg Pro Met Arg Cys Glu Met Trp Gly
305                 310                 315                 320

Val Gly Asn Pro Leu Lys Val Arg Ala Phe Glu Gly Arg Val Ala Asp
                325                 330                 335

Pro Asp Gly Ala Lys Gly Arg Lys Ala Glu Phe Arg Leu Gln Thr Asn
            340                 345                 350

Ala Phe Tyr Val Ser Gly Ala Ala Tyr Arg Asn Lys Lys Phe Lys Pro
```

```
        355                 360                 365

Phe Gly Thr Asp Arg Gly Gly Ile Gly Ser Ala Arg Lys Lys Arg Glu
    370                 375                 380

Arg Leu Met Ala Gln Leu Ala Lys Ile Leu Asp Lys Val Val Ser Gln
385                 390                 395                 400

Ala Ala His Ser Pro Leu Asp Asp Ile Trp His Thr Arg Pro Ala Gln
                405                 410                 415

Lys Leu Arg Ala Met Ile Lys Gln Leu Glu His Glu Trp Met Phe Leu
            420                 425                 430

Arg Pro Gln Ala Pro Thr Val Glu Gly Thr Lys Pro Asp Val Asp Val
        435                 440                 445

Ala Gly Asn Met Gln Arg Gln Ile Lys Ala Leu Met Ala Pro Asp Leu
    450                 455                 460

Pro Pro Ile Glu Lys Gly Ser Pro Ala Lys Arg Phe Thr Gly Asp Lys
465                 470                 475                 480

Arg Lys Lys Gly Glu Arg Ala Val Arg Val Ala Glu Ala His Ser Asp
                485                 490                 495

Glu Val Val Thr Ala Trp Ile Ser Arg Trp Gly Ile Gln Thr Arg Arg
            500                 505                 510

Asn Glu Gly Ser Tyr Ala Ala Gln Glu Leu Glu Leu Leu Leu Asn Trp
        515                 520                 525

Leu Gln Ile Cys Arg Arg Arg Trp Leu Asp Met Thr Ala Ala Gln Arg
    530                 535                 540

Val Ser Pro Tyr Ile Arg Met Lys Ser Gly Arg Met Ile Thr Asp Ala
```

545 550 555 560

Ala Asp Glu Gly Val Ala Pro Ile Pro Leu Val Glu Asn Met
565 570

<210> 207
<211> 743
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 207

Lys Ser Ile Ser Gly Arg Ser Ile Lys His Met Ala Cys Leu Lys Asp
1 5 10 15

Met Leu Lys Ser Glu Ile Thr Glu Ile Glu Glu Lys Gln Lys Lys Glu
20 25 30

Ser Leu Arg Lys Trp Asp Tyr Tyr Ser Lys Phe Ser Asp Glu Ile Leu
35 40 45

Phe Arg Arg Asn Leu Asn Val Ser Ala Asn His Asp Ala Asn Ala Cys
50 55 60

Tyr Gly Cys Asn Pro Cys Ala Phe Leu Lys Glu Val Tyr Gly Phe Arg
65 70 75 80

Ile Glu Arg Arg Asn Asn Glu Arg Ile Ile Ser Tyr Arg Arg Gly Leu
85 90 95

Ala Gly Cys Lys Ser Cys Val Gln Ser Thr Gly Tyr Pro Pro Ile Glu
100 105 110

Phe Val Arg Arg Lys Phe Gly Ala Asp Lys Ala Met Glu Ile Val Arg
115 120 125

```
Glu Val Leu His Arg Arg Asn Trp Gly Ala Leu Ala Arg Asn Ile Gly
    130                 135                 140

Arg Glu Lys Glu Ala Asp Pro Ile Leu Gly Glu Leu Asn Glu Leu Leu
145                 150                 155                 160

Leu Val Asp Ala Arg Pro Tyr Phe Gly Asn Lys Ser Ala Ala Asn Glu
                165                 170                 175

Thr Asn Leu Ala Phe Asn Val Ile Thr Arg Ala Ala Lys Lys Phe Arg
            180                 185                 190

Asp Glu Gly Met Tyr Asp Ile His Lys Gln Leu Asp Ile His Ser Glu
        195                 200                 205

Glu Gly Lys Val Pro Lys Gly Arg Lys Ser Arg Leu Ile Arg Ile Glu
    210                 215                 220

Arg Lys His Lys Ala Ile His Gly Leu Asp Pro Gly Glu Thr Trp Arg
225                 230                 235                 240

Tyr Pro His Cys Gly Lys Gly Glu Lys Tyr Gly Val Trp Leu Asn Arg
                245                 250                 255

Ser Arg Leu Ile His Ile Lys Gly Asn Glu Tyr Arg Cys Leu Thr Ala
            260                 265                 270

Phe Gly Thr Thr Gly Arg Arg Met Ser Leu Asp Val Ala Cys Ser Val
        275                 280                 285

Leu Gly His Pro Leu Val Lys Lys Lys Arg Lys Lys Gly Lys Lys Thr
    290                 295                 300

Val Asp Gly Thr Glu Leu Trp Gln Ile Lys Lys Ala Thr Glu Thr Leu
305                 310                 315                 320
```

```
Pro Glu Asp Pro Ile Asp Cys Thr Phe Tyr Leu Tyr Ala Ala Lys Pro
               325                 330                 335

Thr Lys Asp Pro Phe Ile Leu Lys Val Gly Ser Leu Lys Ala Pro Arg
            340                 345                 350

Trp Lys Lys Leu His Lys Asp Phe Phe Glu Tyr Ser Asp Thr Glu Lys
        355                 360                 365

Thr Gln Gly Gln Glu Lys Gly Lys Arg Val Val Arg Arg Gly Lys Val
    370                 375                 380

Pro Arg Ile Leu Ser Leu Arg Pro Asp Ala Lys Phe Lys Val Ser Ile
385                 390                 395                 400

Trp Asp Asp Pro Tyr Asn Gly Lys Asn Lys Glu Gly Thr Leu Leu Arg
               405                 410                 415

Met Glu Leu Ser Gly Leu Asp Gly Ala Lys Lys Pro Leu Ile Leu Lys
            420                 425                 430

Arg Tyr Gly Glu Pro Asn Thr Lys Pro Lys Asn Phe Val Phe Trp Arg
        435                 440                 445

Pro His Ile Thr Pro His Pro Leu Thr Phe Thr Pro Lys His Asp Phe
    450                 455                 460

Gly Asp Pro Asn Lys Lys Thr Lys Arg Arg Arg Val Phe Asn Arg Glu
465                 470                 475                 480

Tyr Tyr Gly His Leu Asn Asp Leu Ala Lys Met Glu Pro Asn Ala Lys
               485                 490                 495

Phe Phe Glu Asp Arg Glu Val Ser Asn Lys Lys Asn Pro Lys Ala Lys
            500                 505                 510
```

```
Asn Ile Arg Ile Gln Ala Lys Glu Ser Leu Pro Asn Ile Val Ala Lys
        515                 520                 525

Asn Gly Arg Trp Ala Ala Phe Asp Pro Asn Asp Ser Leu Trp Lys Leu
    530                 535                 540

Tyr Leu His Trp Arg Gly Arg Arg Lys Thr Ile Lys Gly Gly Ile Ser
545                 550                 555                 560

Gln Glu Phe Gln Glu Phe Lys Glu Arg Leu Asp Leu Tyr Lys Lys His
                565                 570                 575

Glu Asp Glu Ser Glu Trp Lys Glu Lys Glu Lys Leu Trp Glu Asn His
            580                 585                 590

Glu Lys Glu Trp Lys Lys Thr Leu Glu Ile His Gly Ser Ile Ala Glu
        595                 600                 605

Val Ser Gln Arg Cys Val Met Gln Ser Met Met Gly Pro Leu Asp Gly
    610                 615                 620

Leu Val Gln Lys Lys Asp Tyr Val His Ile Gly Gln Ser Ser Leu Lys
625                 630                 635                 640

Ala Ala Asp Asp Ala Trp Thr Phe Ser Ala Asn Arg Tyr Lys Lys Ala
                645                 650                 655

Thr Gly Pro Lys Trp Gly Lys Ile Ser Val Ser Asn Leu Leu Tyr Asp
            660                 665                 670

Ala Asn Gln Ala Asn Ala Glu Leu Ile Ser Gln Ser Ile Ser Lys Tyr
        675                 680                 685

Leu Ser Lys Gln Lys Asp Asn Gln Gly Cys Glu Gly Arg Lys Met Lys
    690                 695                 700
```

```
Phe Leu Ile Lys Ile Ile Glu Pro Leu Arg Glu Asn Phe Val Lys His
705                 710                 715                 720


Thr Arg Trp Leu His Glu Met Thr Gln Lys Asp Cys Glu Val Arg Ala
                725                 730                 735


Gln Phe Ser Arg Val Ser Met
            740


<210>  208
<211>  769
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  208

Phe Pro Ser Asp Val Gly Ala Asp Ala Leu Lys His Val Arg Met Leu
1               5                   10                  15


Gln Pro Arg Leu Thr Asp Glu Val Arg Lys Val Ala Leu Thr Arg Ala
            20                  25                  30


Pro Ser Asp Arg Pro Ala Leu Ala Arg Phe Ala Ala Val Ala Gln Asp
        35                  40                  45


Gly Leu Ala Phe Val Arg His Leu Asn Val Ser Ala Asn His Asp Ser
    50                  55                  60


Asn Cys Thr Phe Pro Arg Asp Pro Arg Asp Pro Arg Arg Gly Pro Cys
65                  70                  75                  80


Glu Pro Asn Pro Cys Ala Phe Leu Arg Glu Val Trp Gly Phe Arg Ile
                85                  90                  95


Val Ala Arg Gly Asn Glu Arg Ala Leu Ser Tyr Arg Arg Gly Leu Ala
```

```
            100                 105                 110

Gly Cys Lys Ser Cys Val Gln Ser Thr Gly Phe Pro Ser Val Pro Phe
        115                 120                 125

His Arg Ile Gly Ala Asp Asp Cys Met Arg Lys Leu His Glu Ile Leu
    130                 135                 140

Lys Ala Arg Asn Trp Arg Leu Leu Ala Arg Asn Ile Gly Arg Glu Arg
145                 150                 155                 160

Glu Ala Asp Pro Leu Leu Thr Glu Leu Ser Glu Tyr Leu Leu Val Asp
                165                 170                 175

Ala Arg Thr Tyr Pro Asp Gly Ala Ala Pro Asn Ser Gly Arg Leu Ala
            180                 185                 190

Glu Asn Val Ile Lys Arg Ala Ala Lys Lys Phe Arg Asp Glu Gly Met
        195                 200                 205

Arg Asp Ile His Ala Gln Leu Arg Val His Ser Arg Glu Gly Lys Val
    210                 215                 220

Pro Lys Gly Arg Leu Gln Arg Leu Arg Arg Ile Glu Arg Lys His Arg
225                 230                 235                 240

Ala Ile His Ala Leu Asp Pro Gly Pro Ser Trp Glu Ala Glu Gly Ser
                245                 250                 255

Ala Arg Ala Glu Val Gln Gly Val Ala Val Tyr Arg Ser Gln Leu Leu
            260                 265                 270

Arg Val Gly His His Thr Gln Gln Ile Glu Pro Val Gly Ile Val Ala
        275                 280                 285

Arg Thr Leu Phe Gly Val Gly Arg Thr Asp Leu Asp Val Ala Val Ser
```

```
    290                 295                 300

Val Leu Gly Ala Pro Leu Thr Lys Arg Lys Lys Gly Ser Lys Thr Leu
305                 310                 315                 320

Glu Ser Thr Glu Asp Phe Arg Ile Ala Lys Ala Arg Glu Thr Arg Ala
                325                 330                 335

Glu Asp Lys Ile Glu Val Ala Phe Val Leu Tyr Pro Thr Ala Ser Leu
            340                 345                 350

Leu Arg Asp Glu Ile Pro Lys Asp Ala Phe Pro Ala Met Arg Ile Asp
        355                 360                 365

Arg Phe Leu Leu Lys Val Gly Ser Val Gln Ala Asp Arg Glu Ile Leu
    370                 375                 380

Leu Gln Asp Asp Tyr Tyr Arg Phe Gly Asp Ala Glu Val Lys Ala Gly
385                 390                 395                 400

Lys Asn Lys Gly Arg Thr Val Thr Arg Pro Val Lys Val Pro Arg Leu
                405                 410                 415

Gln Ala Leu Arg Pro Asp Ala Lys Phe Arg Val Asn Val Trp Ala Asp
            420                 425                 430

Pro Phe Gly Ala Gly Asp Ser Pro Gly Thr Leu Leu Arg Leu Glu Val
        435                 440                 445

Ser Gly Val Thr Arg Arg Ser Gln Pro Leu Arg Leu Leu Arg Tyr Gly
    450                 455                 460

Gln Pro Ser Thr Gln Pro Ala Asn Phe Leu Cys Trp Arg Pro His Arg
465                 470                 475                 480

Val Pro Asp Pro Met Thr Phe Thr Pro Arg Gln Lys Phe Gly Glu Arg
```

```
                485                 490                 495

Arg Lys Asn Arg Arg Thr Arg Arg Pro Arg Val Phe Glu Arg Leu Tyr
            500                 505                 510

Gln Val His Ile Lys His Leu Ala His Leu Glu Pro Asn Arg Lys Trp
        515                 520                 525

Phe Glu Glu Ala Arg Val Ser Ala Gln Lys Trp Ala Lys Ala Arg Ala
    530                 535                 540

Ile Arg Arg Lys Gly Ala Glu Asp Ile Pro Val Val Ala Pro Pro Ala
545                 550                 555                 560

Lys Arg Arg Trp Ala Ala Leu Gln Pro Asn Ala Glu Leu Trp Asp Leu
                565                 570                 575

Tyr Ala His Asp Arg Glu Ala Arg Lys Arg Phe Arg Gly Gly Arg Ala
            580                 585                 590

Ala Glu Gly Glu Glu Phe Lys Pro Arg Leu Asn Leu Tyr Leu Ala His
        595                 600                 605

Glu Pro Glu Ala Glu Trp Glu Ser Lys Arg Asp Arg Trp Glu Arg Tyr
    610                 615                 620

Glu Lys Lys Trp Thr Ala Val Leu Glu Glu His Ser Arg Met Cys Ala
625                 630                 635                 640

Val Ala Asp Arg Thr Leu Pro Gln Phe Leu Ser Asp Pro Leu Gly Ala
                645                 650                 655

Arg Met Asp Asp Lys Asp Tyr Ala Phe Val Gly Lys Ser Ala Leu Ala
            660                 665                 670

Val Ala Glu Ala Phe Val Glu Glu Gly Thr Val Glu Arg Ala Gln Gly
```

675 680 685

Asn Cys Ser Ile Thr Ala Lys Lys Lys Phe Ala Ser Asn Ala Ser Arg
690 695 700

Lys Arg Leu Ser Val Ala Asn Leu Leu Asp Val Ser Asp Lys Ala Asp
705 710 715 720

Arg Ala Leu Val Phe Gln Ala Val Arg Gln Tyr Val Gln Arg Gln Ala
725 730 735

Glu Asn Gly Gly Val Glu Gly Arg Arg Met Ala Phe Leu Arg Lys Leu
740 745 750

Leu Ala Pro Leu Arg Gln Asn Phe Val Cys His Thr Arg Trp Leu His
755 760 765

Met

<210> 209
<211> 564
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 209

Ala Ala Arg Lys Lys Lys Arg Gly Lys Ile Gly Ile Thr Val Lys Ala
1 5 10 15

Lys Glu Lys Ser Pro Pro Ala Ala Gly Pro Phe Met Ala Arg Lys Leu
20 25 30

Val Asn Val Ala Ala Asn Val Asp Gly Val Glu Val His Leu Cys Val
35 40 45

```
Glu Cys Glu Ala Asp Ala His Gly Ser Ala Ser Ala Arg Leu Leu Gly
    50                  55                  60

Gly Cys Arg Ser Cys Thr Gly Ser Ile Gly Ala Glu Gly Arg Leu Met
65                  70                  75                  80

Gly Ser Val Asp Val Asp Arg Glu Arg Val Ile Ala Glu Pro Val His
                85                  90                  95

Thr Glu Thr Glu Arg Leu Gly Pro Asp Val Lys Ala Phe Glu Ala Gly
            100                 105                 110

Thr Ala Glu Ser Lys Tyr Ala Ile Gln Arg Gly Leu Glu Tyr Trp Gly
        115                 120                 125

Val Asp Leu Ile Ser Arg Asn Arg Ala Arg Thr Val Arg Lys Met Glu
    130                 135                 140

Glu Ala Asp Arg Pro Glu Ser Ser Thr Met Glu Lys Thr Ser Trp Asp
145                 150                 155                 160

Glu Ile Ala Ile Lys Thr Tyr Ser Gln Ala Tyr His Ala Ser Glu Asn
                165                 170                 175

His Leu Phe Trp Glu Arg Gln Arg Arg Val Arg Gln His Ala Leu Ala
            180                 185                 190

Leu Phe Arg Arg Ala Arg Glu Arg Asn Arg Gly Glu Ser Pro Leu Gln
        195                 200                 205

Ser Thr Gln Arg Pro Ala Pro Leu Val Leu Ala Ala Leu His Ala Glu
    210                 215                 220

Ala Ala Ala Ile Ser Gly Arg Ala Arg Ala Glu Tyr Val Leu Arg Gly
225                 230                 235                 240
```

```
Pro Ser Ala Asn Val Arg Ala Ala Ala Ala Asp Ile Asp Ala Lys Pro
                245                 250                 255


Leu Gly His Tyr Lys Thr Pro Ser Pro Lys Val Ala Arg Gly Phe Pro
            260                 265                 270


Val Lys Arg Asp Leu Leu Arg Ala Arg His Arg Ile Val Gly Leu Ser
        275                 280                 285


Arg Ala Tyr Phe Lys Pro Ser Asp Val Val Arg Gly Thr Ser Asp Ala
    290                 295                 300


Ile Ala His Val Ala Gly Arg Asn Ile Gly Val Ala Gly Gly Lys Pro
305                 310                 315                 320


Lys Glu Ile Glu Lys Thr Phe Thr Leu Pro Phe Val Ala Tyr Trp Glu
                325                 330                 335


Asp Val Asp Arg Val Val His Cys Ser Ser Phe Lys Ala Asp Gly Pro
            340                 345                 350


Trp Val Arg Asp Gln Arg Ile Lys Ile Arg Gly Val Ser Ser Ala Val
        355                 360                 365


Gly Thr Phe Ser Leu Tyr Gly Leu Asp Val Ala Trp Ser Lys Pro Thr
    370                 375                 380


Ser Phe Tyr Ile Arg Cys Ser Asp Ile Arg Lys Lys Phe His Pro Lys
385                 390                 395                 400


Gly Phe Gly Pro Met Lys His Trp Arg Gln Trp Ala Lys Glu Leu Asp
                405                 410                 415


Arg Leu Thr Glu Gln Arg Ala Ser Cys Val Val Arg Ala Leu Gln Asp
            420                 425                 430
```

```
Asp Glu Glu Leu Leu Gln Thr Met Glu Arg Gly Gln Arg Tyr Tyr Asp
        435                 440                 445


Val Phe Ser Cys Ala Ala Thr His Ala Thr Arg Gly Glu Ala Asp Pro
    450                 455                 460


Ser Gly Gly Cys Ser Arg Cys Glu Leu Val Ser Cys Gly Val Ala His
465                 470                 475                 480


Lys Val Thr Lys Lys Ala Lys Gly Asp Thr Gly Ile Glu Ala Val Ala
                485                 490                 495


Val Ala Gly Cys Ser Leu Cys Glu Ser Lys Leu Val Gly Pro Ser Lys
            500                 505                 510


Pro Arg Val His Arg Gln Met Ala Ala Leu Arg Gln Ser His Ala Leu
        515                 520                 525


Asn Tyr Leu Arg Arg Leu Gln Arg Glu Trp Glu Ala Leu Glu Ala Val
    530                 535                 540


Gln Ala Pro Thr Pro Tyr Leu Arg Phe Lys Tyr Ala Arg His Leu Glu
545                 550                 555                 560


Val Arg Ser Met



<210>  210
<211>  565
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  210

Ala Ala Lys Lys Lys Lys Gln Arg Gly Lys Ile Gly Ile Ser Val Lys
```

```
1               5                   10                  15

Pro Lys Glu Gly Ser Ala Pro Pro Ala Asp Gly Pro Phe Met Ala Arg
            20                  25                  30

Lys Leu Val Asn Val Ala Ala Asn Val Asp Gly Val Glu Val Asn Leu
        35                  40                  45

Cys Ile Glu Cys Glu Ala Asp Ala His Gly Ser Ala Pro Ala Arg Leu
    50                  55                  60

Leu Gly Gly Cys Lys Ser Cys Thr Gly Ser Ile Gly Ala Glu Gly Arg
65                  70                  75                  80

Leu Met Gly Ser Val Asp Val Asp Arg Ala Asp Ala Ile Ala Lys Pro
                85                  90                  95

Val Asn Thr Glu Thr Glu Lys Leu Gly Pro Asp Val Gln Ala Phe Glu
            100                 105                 110

Ala Gly Thr Ala Glu Thr Lys Tyr Ala Leu Gln Arg Gly Leu Glu Tyr
        115                 120                 125

Trp Gly Val Asp Leu Ile Ser Arg Asn Arg Ser Arg Thr Val Arg Arg
    130                 135                 140

Thr Glu Glu Gly Gln Pro Glu Ser Ala Thr Met Glu Lys Thr Ser Trp
145                 150                 155                 160

Asp Glu Ile Ala Ile Lys Ser Tyr Thr Arg Ala Tyr His Ala Ser Glu
                165                 170                 175

Asn His Leu Phe Trp Glu Arg Gln Arg Arg Val Arg Gln His Ala Leu
            180                 185                 190

Ala Leu Phe Lys Arg Ala Lys Glu Arg Asn Arg Gly Asp Ser Thr Leu
```

```
        195                 200                 205

Pro Arg Glu Pro Gly His Gly Leu Val Ala Ile Ala Ala Leu Ala Cys
    210                 215                 220

Glu Ala Tyr Ala Val Gly Gly Arg Asn Leu Ala Glu Thr Val Val Arg
225                 230                 235                 240

Gly Pro Thr Phe Gly Thr Ala Arg Ala Val Arg Asp Val Glu Ile Ala
                245                 250                 255

Ser Leu Gly Arg Tyr Lys Thr Pro Ser Pro Lys Val Ala His Gly Ser
            260                 265                 270

Pro Val Lys Arg Asp Phe Leu Arg Ala Arg His Arg Ile Val Gly Leu
        275                 280                 285

Ala Arg Ala Tyr Tyr Arg Pro Ser Asp Val Val Arg Gly Thr Ser Asp
    290                 295                 300

Ala Ile Ala His Val Ala Gly Arg Asn Ile Gly Val Ala Gly Gly Lys
305                 310                 315                 320

Pro Arg Ala Val Glu Ala Val Phe Thr Leu Pro Phe Val Ala Tyr Trp
                325                 330                 335

Glu Asp Val Asp Arg Val Val His Cys Ser Ser Phe Gln Val Ser Ala
            340                 345                 350

Pro Trp Asn Arg Asp Gln Arg Met Lys Ile Ala Gly Val Thr Thr Ala
        355                 360                 365

Ala Gly Thr Phe Ser Leu His Gly Gly Glu Leu Lys Trp Ala Lys Pro
    370                 375                 380

Thr Ser Phe Tyr Ile Arg Cys Ser Asp Thr Arg Arg Lys Phe Arg Pro
```

385 390 395 400

Lys Gly Phe Gly Pro Met Lys Arg Trp Arg Gln Trp Ala Lys Asp Leu
405 410 415

Asp Arg Leu Val Glu Gln Arg Ala Ser Cys Val Val Arg Ala Leu Gln
420 425 430

Asp Asp Ala Ala Leu Leu Glu Thr Met Glu Arg Gly Gln Arg Tyr Tyr
435 440 445

Asp Val Phe Ala Cys Ala Val Thr His Ala Thr Arg Gly Glu Ala Asp
450 455 460

Arg Leu Ala Gly Cys Ser Arg Cys Ala Leu Thr Pro Cys Gln Glu Ala
465 470 475 480

His Arg Val Thr Thr Lys Pro Arg Gly Asp Ala Gly Val Glu Gln Val
485 490 495

Gln Thr Ser Asp Cys Ser Leu Cys Glu Gly Lys Leu Val Gly Pro Ser
500 505 510

Lys Pro Arg Leu His Arg Thr Leu Thr Leu Leu Arg Gln Glu His Gly
515 520 525

Leu Asn Tyr Leu Arg Arg Leu Gln Arg Glu Trp Glu Ser Leu Glu Ala
530 535 540

Val Gln Val Pro Thr Pro Tyr Leu Arg Phe Lys Tyr Ala Arg His Leu
545 550 555 560

Glu Val Arg Ser Met
565

<210> 211

<211> 499
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 211

Thr Asp Ser Gln Ser Glu Ser Val Pro Glu Val Val Tyr Ala Leu Thr
1 5 10 15

Gly Gly Glu Val Pro Gly Arg Val Pro Pro Asp Gly Gly Ser Ala Glu
20 25 30

Gly Ala Arg Asn Ala Pro Thr Gly Leu Arg Lys Gln Arg Gly Lys Ile
35 40 45

Lys Ile Ser Ala Lys Pro Ser Lys Pro Gly Ser Pro Ala Ser Ser Leu
50 55 60

Ala Arg Thr Leu Val Asn Glu Ala Ala Asn Val Asp Gly Val Gln Ser
65 70 75 80

Ser Gly Cys Ala Thr Cys Arg Met Arg Ala Asn Gly Ser Ala Pro Arg
85 90 95

Ala Leu Pro Ile Gly Cys Val Ala Cys Ala Ser Ser Ile Gly Arg Ala
100 105 110

Pro Gln Glu Glu Thr Val Cys Ala Leu Pro Thr Thr Gln Gly Pro Asp
115 120 125

Val Arg Leu Leu Glu Gly Gly His Ala Leu Arg Lys Tyr Asp Ile Gln
130 135 140

Arg Ala Leu Glu Tyr Trp Gly Val Asp Leu Ile Gly Arg Asn Leu Asp
145 150 155 160

```
Arg Gln Ala Gly Arg Gly Met Glu Pro Ala Glu Gly Ala Thr Ala Thr
                165                 170                 175

Met Lys Arg Val Ser Met Asp Glu Leu Ala Val Leu Asp Phe Gly Lys
            180                 185                 190

Ser Tyr Tyr Ala Ser Glu Gln His Leu Phe Ala Ala Arg Gln Arg Arg
        195                 200                 205

Val Arg Gln His Ala Lys Ala Leu Lys Ile Arg Ala Lys His Ala Asn
    210                 215                 220

Arg Ser Gly Ser Val Lys Arg Ala Leu Asp Arg Ser Arg Lys Gln Val
225                 230                 235                 240

Thr Ala Leu Ala Arg Glu Phe Phe Lys Pro Ser Asp Val Val Arg Gly
                245                 250                 255

Asp Ser Asp Ala Leu Ala His Val Val Gly Arg Asn Leu Gly Val Ser
            260                 265                 270

Arg His Pro Ala Arg Glu Ile Pro Gln Thr Phe Thr Leu Pro Leu Cys
        275                 280                 285

Ala Tyr Trp Glu Asp Val Asp Arg Val Ile Ser Cys Ser Ser Leu Leu
    290                 295                 300

Ala Gly Glu Pro Phe Ala Arg Asp Gln Glu Ile Arg Ile Glu Gly Val
305                 310                 315                 320

Ser Ser Ala Leu Gly Ser Leu Arg Leu Tyr Arg Gly Ala Ile Glu Trp
                325                 330                 335

His Lys Pro Thr Ser Leu Tyr Ile Arg Cys Ser Asp Thr Arg Arg Lys
            340                 345                 350
```

```
Phe Arg Pro Arg Gly Gly Leu Lys Lys Arg Trp Arg Gln Trp Ala Lys
        355                 360                 365


Asp Leu Asp Arg Leu Val Glu Gln Arg Ala Cys Cys Ile Val Arg Ser
    370                 375                 380


Leu Gln Ala Asp Val Glu Leu Leu Gln Thr Met Glu Arg Ala Gln Arg
385                 390                 395                 400


Phe Tyr Asp Val His Asp Cys Ala Ala Thr His Val Gly Pro Val Ala
                405                 410                 415


Val Arg Cys Ser Pro Cys Ala Gly Lys Gln Phe Asp Trp Asp Arg Tyr
            420                 425                 430


Arg Leu Leu Ala Ala Leu Arg Gln Glu His Ala Leu Asn Tyr Leu Arg
        435                 440                 445


Arg Leu Gln Arg Glu Trp Glu Ser Leu Glu Ala Gln Gln Val Lys Met
    450                 455                 460


Pro Tyr Leu Arg Phe Lys Tyr Ala Arg Lys Leu Glu Val Ser Gly Pro
465                 470                 475                 480


Leu Ile Gly Leu Glu Val Arg Arg Glu Pro Ser Met Gly Thr Ala Ile
                485                 490                 495


Ala Glu Met
```

<210> 212
<211> 358
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 212

```
Ala Gly Thr Ala Gly Arg Arg His Gly Ser Leu Gly Ala Arg Arg Ser
1               5                   10                  15


Ile Asn Ile Ala Gly Val Thr Asp Arg His Gly Arg Trp Gly Cys Glu
            20                  25                  30


Ser Cys Val Tyr Thr Arg Asp Gln Ala Gly Asn Arg Ala Arg Cys Ala
        35                  40                  45


Pro Cys Asp Gln Ser Thr Tyr Ala Pro Asp Val Gln Glu Val Thr Ile
    50                  55                  60


Gly Gln Arg Gln Ala Lys Tyr Thr Ile Phe Leu Thr Leu Gln Ser Phe
65                  70                  75                  80


Ser Trp Thr Asn Thr Met Arg Asn Asn Lys Arg Ala Ala Ala Gly Arg
                85                  90                  95


Ser Lys Arg Thr Thr Gly Lys Arg Ile Gly Gln Leu Ala Glu Ile Lys
            100                 105                 110


Ile Thr Gly Val Gly Leu Ala His Ala His Asn Val Ile Gln Arg Ser
        115                 120                 125


Leu Gln His Asn Ile Thr Lys Met Trp Arg Ala Glu Lys Gly Lys Ser
    130                 135                 140


Lys Arg Val Ala Arg Leu Lys Lys Ala Lys Gln Leu Thr Lys Arg Arg
145                 150                 155                 160


Ala Tyr Phe Arg Arg Arg Met Ser Arg Gln Ser Arg Gly Asn Gly Phe
                165                 170                 175


Phe Arg Thr Gly Lys Gly Gly Ile His Ala Val Ala Pro Val Lys Ile
```

```
            180                 185                 190

Gly Leu Asp Val Gly Met Ile Ala Ser Gly Ser Ser Glu Pro Ala Asp
        195                 200                 205

Glu Gln Thr Val Thr Leu Asp Ala Ile Trp Lys Gly Arg Lys Lys Lys
    210                 215                 220

Ile Arg Leu Ile Gly Ala Lys Gly Glu Leu Ala Val Ala Ala Cys Arg
225                 230                 235                 240

Phe Arg Glu Gln Gln Thr Lys Gly Asp Lys Cys Ile Pro Leu Ile Leu
                245                 250                 255

Gln Asp Gly Glu Val Arg Trp Asn Gln Asn Asn Trp Gln Cys His Pro
            260                 265                 270

Lys Lys Leu Val Pro Leu Cys Gly Leu Glu Val Ser Arg Lys Phe Val
        275                 280                 285

Ser Gln Ala Asp Arg Leu Ala Gln Asn Lys Val Ala Ser Pro Leu Ala
    290                 295                 300

Ala Arg Phe Asp Lys Thr Ser Val Lys Gly Thr Leu Val Glu Ser Asp
305                 310                 315                 320

Phe Ala Ala Val Leu Val Asn Val Thr Ser Ile Tyr Gln Gln Cys His
                325                 330                 335

Ala Met Leu Leu Arg Ser Gln Glu Pro Thr Pro Ser Leu Arg Val Gln
            340                 345                 350

Arg Thr Ile Thr Ser Met
        355
```

<210> 213

<211> 369
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 213

```
Gly Val Arg Phe Ser Pro Ala Gln Ser Gln Val Phe Phe Arg Thr Val
1               5                  10                  15


Ile Pro Gln Ser Val Glu Ala Arg Phe Ala Ile Asn Met Ala Ala Ile
            20                  25                  30


His Asp Ala Ala Gly Ala Phe Gly Cys Ser Val Cys Arg Phe Glu Asp
        35                  40                  45


Arg Thr Pro Arg Asn Ala Lys Ala Val His Gly Cys Ser Pro Cys Thr
    50                  55                  60


Arg Ser Thr Asn Arg Pro Asp Val Phe Val Leu Pro Val Gly Ala Ile
65                  70                  75                  80


Lys Ala Lys Tyr Asp Val Phe Met Arg Leu Leu Gly Phe Asn Trp Thr
                85                  90                  95


His Leu Asn Arg Arg Gln Ala Lys Arg Val Thr Val Arg Asp Arg Ile
            100                 105                 110


Gly Gln Leu Asp Glu Leu Ala Ile Ser Met Leu Thr Gly Lys Ala Lys
        115                 120                 125


Ala Val Leu Lys Lys Ser Ile Cys His Asn Val Asp Lys Ser Phe Lys
    130                 135                 140


Ala Met Arg Gly Ser Leu Lys Lys Leu His Arg Lys Ala Ser Lys Thr
145                 150                 155                 160
```

```
Gly Lys Ser Gln Leu Arg Ala Lys Leu Ser Asp Leu Arg Glu Arg Thr
                165                 170                 175

Asn Thr Thr Gln Glu Gly Ser His Val Glu Gly Asp Ser Asp Val Ala
            180                 185                 190

Leu Asn Lys Ile Gly Leu Asp Val Gly Leu Val Gly Lys Pro Asp Tyr
        195                 200                 205

Pro Ser Glu Glu Ser Val Glu Val Val Val Cys Leu Tyr Phe Val Gly
    210                 215                 220

Lys Val Leu Ile Leu Asp Ala Gln Gly Arg Ile Arg Asp Met Arg Ala
225                 230                 235                 240

Lys Gln Tyr Asp Gly Phe Lys Ile Pro Ile Ile Gln Arg Gly Gln Leu
                245                 250                 255

Thr Val Leu Ser Val Lys Asp Leu Gly Lys Trp Ser Leu Val Arg Gln
            260                 265                 270

Asp Tyr Val Leu Ala Gly Asp Leu Arg Phe Glu Pro Lys Ile Ser Lys
        275                 280                 285

Asp Arg Lys Tyr Ala Glu Cys Val Lys Arg Ile Ala Leu Ile Thr Leu
    290                 295                 300

Gln Ala Ser Leu Gly Phe Lys Glu Arg Ile Pro Tyr Tyr Val Thr Lys
305                 310                 315                 320

Gln Val Glu Ile Lys Asn Ala Ser His Ile Ala Phe Val Thr Glu Ala
                325                 330                 335

Ile Gln Asn Cys Ala Glu Asn Phe Arg Glu Met Thr Glu Tyr Leu Met
            340                 345                 350
```

Lys Tyr Gln Glu Lys Ser Pro Asp Leu Lys Val Leu Leu Thr Gln Leu
355 360 365

Met

<210> 214
<211> 486
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 214

Arg Ala Val Val Gly Lys Val Phe Leu Glu Gln Ala Arg Arg Ala Leu
1 5 10 15

Asn Leu Ala Thr Asn Phe Gly Thr Asn His Arg Thr Gly Cys Asn Gly
20 25 30

Cys Tyr Val Thr Pro Gly Lys Leu Ser Ile Pro Gln Asp Gly Glu Lys
35 40 45

Asn Ala Ala Gly Cys Thr Ser Cys Leu Met Lys Ala Thr Ala Ser Tyr
50 55 60

Val Ser Tyr Pro Lys Pro Leu Gly Glu Lys Val Ala Lys Tyr Ser Thr
65 70 75 80

Leu Asp Ala Leu Lys Gly Phe Pro Trp Tyr Ser Leu Arg Leu Asn Leu
85 90 95

Arg Pro Asn Tyr Arg Gly Lys Pro Ile Asn Gly Val Gln Glu Val Ala
100 105 110

Pro Val Ser Lys Phe Arg Leu Ala Glu Glu Val Ile Gln Ala Val Gln

```
        115                 120                 125

Arg Tyr His Phe Thr Glu Leu Glu Gln Ser Phe Pro Gly Gly Arg Arg
    130                 135                 140

Arg Leu Arg Glu Leu Arg Ala Phe Tyr Thr Lys Glu Tyr Arg Arg Ala
145                 150                 155                 160

Pro Glu Gln Arg Gln His Val Val Asn Gly Asp Arg Asn Ile Val Val
                165                 170                 175

Val Thr Val Leu His Glu Leu Gly Phe Ser Val Gly Met Phe Asn Glu
            180                 185                 190

Val Glu Leu Leu Pro Lys Thr Pro Ile Glu Cys Ala Val Asn Val Phe
        195                 200                 205

Ile Arg Gly Asn Arg Val Leu Leu Glu Val Arg Lys Pro Gln Phe Asp
    210                 215                 220

Lys Glu Arg Leu Leu Val Glu Ser Leu Trp Lys Lys Asp Ser Arg Arg
225                 230                 235                 240

His Thr Ala Lys Trp Thr Pro Pro Asn Asn Glu Gly Arg Ile Phe Thr
                245                 250                 255

Ala Glu Gly Trp Lys Asp Phe Gln Leu Pro Leu Leu Leu Gly Ser Thr
            260                 265                 270

Ser Arg Ser Leu Arg Ala Ile Glu Lys Glu Gly Phe Val Gln Leu Ala
        275                 280                 285

Pro Gly Arg Asp Pro Asp Tyr Asn Asn Thr Ile Asp Glu Gln His Ser
    290                 295                 300

Gly Arg Pro Phe Leu Pro Leu Tyr Leu Tyr Leu Gln Gly Thr Ile Ser
```

305 310 315 320

Gln Glu Tyr Cys Val Phe Ala Gly Thr Trp Val Ile Pro Phe Gln Asp
325 330 335

Gly Ile Ser Pro Tyr Ser Thr Lys Asp Thr Phe Gln Pro Asp Leu Lys
340 345 350

Arg Lys Ala Tyr Ser Leu Leu Leu Asp Ala Val Lys His Arg Leu Gly
355 360 365

Asn Lys Val Ala Ser Gly Leu Gln Tyr Gly Arg Phe Pro Ala Ile Glu
370 375 380

Glu Leu Lys Arg Leu Val Arg Met His Gly Ala Thr Arg Lys Ile Pro
385 390 395 400

Arg Gly Glu Lys Asp Leu Leu Lys Lys Gly Asp Pro Asp Thr Pro Glu
405 410 415

Trp Trp Leu Leu Glu Gln Tyr Pro Glu Phe Trp Arg Leu Cys Asp Ala
420 425 430

Ala Ala Lys Arg Val Ser Gln Asn Val Gly Leu Leu Leu Ser Leu Lys
435 440 445

Lys Gln Pro Leu Trp Gln Arg Arg Trp Leu Glu Ser Arg Thr Arg Asn
450 455 460

Glu Pro Leu Asp Asn Leu Pro Leu Ser Met Ala Leu Thr Leu His Leu
465 470 475 480

Thr Asn Glu Glu Ala Leu
485

<210> 215

<211> 400
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 215

Ala Ala Val Tyr Ser Lys Phe Tyr Ile Glu Asn His Phe Lys Met Gly
1 5 10 15

Ile Pro Glu Thr Leu Ser Arg Ile Arg Gly Pro Ser Ile Ile Gln Gly
20 25 30

Phe Ser Val Asn Glu Asn Tyr Ile Asn Ile Ala Gly Val Gly Asp Arg
35 40 45

Asp Phe Ile Phe Gly Cys Lys Lys Cys Lys Tyr Thr Arg Gly Lys Pro
50 55 60

Ser Ser Lys Lys Ile Asn Lys Cys His Pro Cys Lys Arg Ser Thr Tyr
65 70 75 80

Pro Glu Pro Val Ile Asp Val Arg Gly Ser Ile Ser Glu Phe Lys Tyr
85 90 95

Lys Ile Tyr Asn Lys Leu Lys Gln Glu Pro Asn Gln Ser Ile Lys Gln
100 105 110

Asn Thr Lys Gly Arg Met Asn Pro Ser Asp His Thr Ser Ser Asn Asp
115 120 125

Gly Ile Ile Ile Asn Gly Ile Asp Asn Arg Ile Ala Tyr Asn Val Ile
130 135 140

Phe Ser Ser Tyr Lys His Leu Met Glu Lys Gln Ile Asn Leu Leu Arg
145 150 155 160

```
Asp Thr Thr Lys Arg Lys Ala Arg Gln Ile Lys Lys Tyr Asn Asn Ser
                165                 170                 175

Gly Lys Lys Lys His Ser Leu Arg Ser Gln Thr Lys Gly Asn Leu Lys
            180                 185                 190

Asn Arg Tyr His Met Leu Gly Met Phe Lys Lys Gly Ser Leu Thr Ile
        195                 200                 205

Thr Asn Glu Gly Asp Phe Ile Thr Ala Val Arg Lys Val Gly Leu Asp
    210                 215                 220

Ile Ser Leu Tyr Lys Asn Glu Ser Leu Asn Lys Gln Glu Val Glu Thr
225                 230                 235                 240

Glu Leu Cys Leu Asn Ile Lys Trp Gly Arg Thr Lys Ser Tyr Thr Val
                245                 250                 255

Ser Gly Tyr Ile Pro Leu Pro Ile Asn Ile Asp Trp Lys Leu Tyr Leu
            260                 265                 270

Phe Glu Lys Glu Thr Gly Leu Thr Leu Arg Leu Phe Gly Asn Lys Tyr
        275                 280                 285

Lys Ile Gln Ser Lys Lys Phe Leu Ile Ala Gln Leu Phe Lys Pro Lys
    290                 295                 300

Arg Pro Pro Cys Ala Asp Pro Val Val Lys Lys Ala Gln Lys Trp Ser
305                 310                 315                 320

Ala Leu Asn Ala His Val Gln Gln Met Ala Gly Leu Phe Ser Asp Ser
                325                 330                 335

His Leu Leu Lys Arg Glu Leu Lys Asn Arg Met His Lys Gln Leu Asp
            340                 345                 350
```

```
Phe Lys Ser Leu Trp Val Gly Thr Glu Asp Tyr Ile Lys Trp Phe Glu
        355                 360                 365


Glu Leu Ser Arg Ser Tyr Val Glu Gly Ala Glu Lys Ser Leu Glu Phe
    370                 375                 380


Phe Arg Gln Asp Tyr Phe Cys Phe Asn Tyr Thr Lys Gln Thr Thr Met
385                 390                 395                 400


<210>  216
<211>  666
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence

<400>  216

Pro Gln Gln Gln Arg Asp Leu Met Leu Met Ala Ala Asn Tyr Asp Gln
1               5                   10                  15


Asp Tyr Gly Asn Gly Cys Gly Pro Cys Thr Val Val Ala Ser Ala Ala
            20                  25                  30


Tyr Arg Pro Asp Pro Gln Ala Gln His Gly Cys Lys Arg His Leu Arg
        35                  40                  45


Thr Leu Gly Ala Ser Ala Val Thr His Val Gly Leu Gly Asp Arg Thr
    50                  55                  60


Ala Thr Ile Thr Ala Leu His Arg Leu Arg Gly Pro Ala Ala Leu Ala
65                  70                  75                  80


Ala Arg Ala Arg Ala Ala Gln Ala Ala Ser Ala Pro Met Thr Pro Asp
                85                  90                  95


Thr Asp Ala Pro Asp Asp Arg Arg Arg Leu Glu Ala Ile Asp Ala Asp
```

```
            100                 105                 110

Asp Val Val Leu Val Gly Ala His Arg Ala Leu Trp Ser Ala Val Arg
        115                 120                 125

Arg Trp Ala Asp Asp Arg Arg Ala Ala Leu Arg Arg Arg Leu His Ser
    130                 135                 140

Glu Arg Glu Trp Leu Leu Lys Asp Gln Ile Arg Trp Ala Glu Leu Tyr
145                 150                 155                 160

Thr Leu Ile Glu Ala Ser Gly Thr Pro Pro Gln Gly Arg Trp Arg Asn
                165                 170                 175

Thr Leu Gly Ala Leu Arg Gly Gln Ser Arg Trp Arg Arg Val Leu Ala
            180                 185                 190

Pro Thr Met Arg Ala Thr Cys Ala Glu Thr His Ala Glu Leu Trp Asp
        195                 200                 205

Ala Leu Ala Glu Leu Val Pro Glu Met Ala Lys Asp Arg Arg Gly Leu
    210                 215                 220

Leu Arg Pro Pro Val Glu Ala Asp Ala Leu Trp Arg Ala Pro Met Ile
225                 230                 235                 240

Val Glu Gly Trp Arg Gly Gly His Ser Val Val Val Asp Ala Val Ala
                245                 250                 255

Pro Pro Leu Asp Leu Pro Gln Pro Cys Ala Trp Thr Ala Val Arg Leu
            260                 265                 270

Ser Gly Asp Pro Arg Gln Arg Trp Gly Leu His Leu Ala Val Pro Pro
        275                 280                 285

Leu Gly Gln Val Gln Pro Pro Asp Pro Leu Lys Ala Thr Leu Ala Val
```

```
    290                 295                 300

Ser Met Arg His Arg Gly Gly Val Arg Val Arg Thr Leu Gln Ala Met
305                 310                 315                 320

Ala Val Asp Ala Asp Ala Pro Met Gln Arg His Leu Gln Val Pro Leu
                325                 330                 335

Thr Leu Gln Arg Gly Gly Gly Leu Gln Trp Gly Ile His Ser Arg Gly
            340                 345                 350

Val Arg Arg Arg Glu Ala Arg Ser Met Ala Ser Trp Glu Gly Pro Pro
        355                 360                 365

Ile Trp Thr Gly Leu Gln Leu Val Asn Arg Trp Lys Gly Gln Gly Ser
    370                 375                 380

Ala Leu Leu Ala Pro Asp Arg Pro Pro Asp Thr Pro Pro Tyr Ala Pro
385                 390                 395                 400

Asp Ala Ala Val Ala Pro Ala Gln Pro Asp Thr Lys Arg Ala Arg Arg
                405                 410                 415

Thr Leu Lys Glu Ala Cys Thr Val Cys Arg Cys Ala Pro Gly His Met
            420                 425                 430

Arg Gln Leu Gln Val Thr Leu Thr Gly Asp Gly Thr Trp Arg Arg Phe
        435                 440                 445

Arg Leu Arg Ala Pro Gln Gly Ala Lys Arg Lys Ala Glu Val Leu Lys
    450                 455                 460

Val Ala Thr Gln His Asp Glu Arg Ile Ala Asn Tyr Thr Ala Trp Tyr
465                 470                 475                 480

Leu Lys Arg Pro Glu His Ala Ala Gly Cys Asp Thr Cys Asp Gly Asp
```

485 490 495

Ser Arg Leu Asp Gly Ala Cys Arg Gly Cys Arg Pro Leu Leu Val Gly
500 505 510

Asp Gln Cys Phe Arg Arg Tyr Leu Asp Lys Ile Glu Ala Asp Arg Asp
515 520 525

Asp Gly Leu Ala Gln Ile Lys Pro Lys Ala Gln Glu Ala Val Ala Ala
530 535 540

Met Ala Ala Lys Arg Asp Ala Arg Ala Gln Lys Val Ala Ala Arg Ala
545 550 555 560

Ala Lys Leu Ser Glu Ala Thr Gly Gln Arg Thr Ala Ala Thr Arg Asp
565 570 575

Ala Ser His Glu Ala Arg Ala Gln Lys Glu Leu Glu Ala Val Ala Thr
580 585 590

Glu Gly Thr Thr Val Arg His Asp Ala Ala Ala Val Ser Ala Phe Gly
595 600 605

Ser Trp Val Ala Arg Lys Gly Asp Glu Tyr Arg His Gln Val Gly Val
610 615 620

Leu Ala Asn Arg Leu Glu His Gly Leu Arg Leu Gln Glu Leu Met Ala
625 630 635 640

Pro Asp Ser Val Val Ala Asp Gln Gln Arg Ala Ser Gly His Ala Arg
645 650 655

Val Gly Tyr Arg Tyr Val Leu Thr Ala Met
660 665

<210> 217

<211> 560
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 217

```
Ala Val Ala His Pro Val Gly Arg Gly Asn Ala Gly Ser Pro Gly Ala
1               5                   10                  15


Arg Gly Pro Glu Glu Leu Pro Arg Gln Leu Val Asn Arg Ala Ser Asn
            20                  25                  30


Val Thr Arg Pro Ala Thr Tyr Gly Cys Ala Pro Cys Arg His Val Arg
        35                  40                  45


Leu Ser Ile Pro Lys Pro Val Leu Thr Gly Cys Arg Ala Cys Glu Gln
    50                  55                  60


Thr Thr His Pro Ala Pro Lys Arg Ala Val Arg Gly Gly Ala Asp Ala
65                  70                  75                  80


Ala Lys Tyr Asp Leu Ala Ala Phe Phe Ala Gly Trp Ala Ala Asp Leu
                85                  90                  95


Glu Gly Arg Asn Arg Arg Arg Gln Val His Ala Pro Leu Asp Pro Gln
            100                 105                 110


Pro Asp Pro Asn His Glu Pro Ala Val Thr Leu Gln Lys Ile Asp Leu
        115                 120                 125


Ala Glu Val Ser Ile Glu Glu Phe Gln Arg Val Leu Ala Arg Ser Val
    130                 135                 140


Lys His Arg His Asp Gly Arg Ala Ser Arg Glu Arg Glu Lys Ala Arg
145                 150                 155                 160
```

```
Ala Tyr Ala Gln Val Ala Lys Lys Arg Arg Asn Ser His Ala His Gly
                165                 170                 175

Ala Arg Thr Arg Arg Ala Val Arg Arg Gln Thr Arg Ala Val Arg Arg
            180                 185                 190

Ala His Arg Met Gly Ala Asn Ser Gly Glu Ile Leu Val Ala Ser Gly
        195                 200                 205

Ala Glu Asp Pro Val Pro Glu Ala Ile Asp His Ala Ala Gln Leu Arg
    210                 215                 220

Arg Arg Ile Arg Ala Cys Ala Arg Asp Leu Glu Gly Leu Arg His Leu
225                 230                 235                 240

Ser Arg Arg Tyr Leu Lys Thr Leu Glu Lys Pro Cys Arg Arg Pro Arg
                245                 250                 255

Ala Pro Asp Leu Gly Arg Ala Arg Cys His Ala Leu Val Glu Ser Leu
            260                 265                 270

Gln Ala Ala Glu Arg Glu Leu Glu Glu Leu Arg Arg Cys Asp Ser Pro
        275                 280                 285

Asp Thr Ala Met Arg Arg Leu Asp Ala Val Leu Ala Ala Ala Ala Ser
    290                 295                 300

Thr Asp Ala Thr Phe Ala Thr Gly Trp Thr Val Val Gly Met Asp Leu
305                 310                 315                 320

Gly Val Ala Pro Arg Gly Ser Ala Ala Pro Glu Val Ser Pro Met Glu
                325                 330                 335

Met Ala Ile Ser Val Phe Trp Arg Lys Gly Ser Arg Arg Val Ile Val
            340                 345                 350
```

```
Ser Lys Pro Ile Ala Gly Met Pro Ile Arg Arg His Glu Leu Ile Arg
        355                 360                 365

Leu Glu Gly Leu Gly Thr Leu Arg Leu Asp Gly Asn His Tyr Thr Gly
    370                 375                 380

Ala Gly Val Thr Lys Gly Arg Gly Leu Ser Glu Gly Thr Glu Pro Asp
385                 390                 395                 400

Phe Arg Glu Lys Ser Pro Ser Thr Leu Gly Phe Thr Leu Ser Asp Tyr
                405                 410                 415

Arg His Glu Ser Arg Trp Arg Pro Tyr Gly Ala Lys Gln Gly Lys Thr
            420                 425                 430

Ala Arg Gln Phe Phe Ala Ala Met Ser Arg Glu Leu Arg Ala Leu Val
        435                 440                 445

Glu His Gln Val Leu Ala Pro Met Gly Pro Pro Leu Leu Glu Ala His
    450                 455                 460

Glu Arg Arg Phe Glu Thr Leu Leu Lys Gly Gln Asp Asn Lys Ser Ile
465                 470                 475                 480

His Ala Gly Gly Gly Gly Arg Tyr Val Trp Arg Gly Pro Pro Asp Ser
                485                 490                 495

Lys Lys Arg Pro Ala Ala Asp Gly Asp Trp Phe Arg Phe Gly Arg Gly
            500                 505                 510

His Ala Asp His Arg Gly Trp Ala Asn Lys Arg His Glu Leu Ala Ala
        515                 520                 525

Asn Tyr Leu Gln Ser Ala Phe Arg Leu Trp Ser Thr Leu Ala Glu Ala
    530                 535                 540
```

Gln Glu Pro Thr Pro Tyr Ala Arg Tyr Lys Tyr Thr Arg Val Thr Met
545 550 555 560

<210> 218
<211> 404
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 218

Trp Asp Phe Leu Thr Leu Gln Val Tyr Glu Arg His Thr Ser Pro Glu
1 5 10 15

Val Cys Val Ala Gly Asn Ser Thr Lys Cys Ala Ser Gly Thr Arg Lys
20 25 30

Ser Asp His Thr His Gly Val Gly Val Lys Leu Gly Ala Gln Glu Ile
35 40 45

Asn Val Ser Ala Asn Asp Asp Arg Asp His Glu Val Gly Cys Asn Ile
50 55 60

Cys Val Ile Ser Arg Val Ser Leu Asp Ile Lys Gly Trp Arg Tyr Gly
65 70 75 80

Cys Glu Ser Cys Val Gln Ser Thr Pro Glu Trp Arg Ser Ile Val Arg
85 90 95

Phe Asp Arg Asn His Lys Glu Ala Lys Gly Glu Cys Leu Ser Arg Phe
100 105 110

Glu Tyr Trp Gly Ala Gln Ser Ile Ala Arg Ser Leu Lys Arg Asn Lys
115 120 125

Leu Met Gly Gly Val Asn Leu Asp Glu Leu Ala Ile Val Gln Asn Glu

```
    130                 135                 140

Asn Val Val Lys Thr Ser Leu Lys His Leu Phe Asp Lys Arg Lys Asp
145                 150                 155                 160

Arg Ile Gln Ala Asn Leu Lys Ala Val Lys Val Arg Met Arg Glu Arg
                165                 170                 175

Arg Lys Ser Gly Arg Gln Arg Lys Ala Leu Arg Arg Gln Cys Arg Lys
            180                 185                 190

Leu Lys Arg Tyr Leu Arg Ser Tyr Asp Pro Ser Asp Ile Lys Glu Gly
        195                 200                 205

Asn Ser Cys Ser Ala Phe Thr Lys Leu Gly Leu Asp Ile Gly Ile Ser
    210                 215                 220

Pro Asn Lys Pro Pro Lys Ile Glu Pro Lys Val Glu Val Val Phe Ser
225                 230                 235                 240

Leu Phe Tyr Gln Gly Ala Cys Asp Lys Ile Val Thr Val Ser Ser Pro
                245                 250                 255

Glu Ser Pro Leu Pro Arg Ser Trp Lys Ile Lys Ile Asp Gly Ile Arg
            260                 265                 270

Ala Leu Tyr Val Lys Ser Thr Lys Val Lys Phe Gly Gly Arg Thr Phe
        275                 280                 285

Arg Ala Gly Gln Arg Asn Asn Arg Arg Lys Val Arg Pro Pro Asn Val
    290                 295                 300

Lys Lys Gly Lys Arg Lys Gly Ser Arg Ser Gln Phe Phe Asn Lys Phe
305                 310                 315                 320

Ala Val Gly Leu Asp Ala Val Ser Gln Gln Leu Pro Ile Ala Ser Val
```

325 330 335

Gln Gly Leu Trp Gly Arg Ala Glu Thr Lys Lys Ala Gln Thr Ile Cys
340 345 350

Leu Lys Gln Leu Glu Ser Asn Lys Pro Leu Lys Glu Ser Gln Arg Cys
355 360 365

Leu Phe Leu Ala Asp Asn Trp Val Val Arg Val Cys Gly Phe Leu Arg
370 375 380

Ala Leu Ser Gln Arg Gln Gly Pro Thr Pro Tyr Ile Arg Tyr Arg Tyr
385 390 395 400

Arg Cys Asn Met

<210> 219
<211> 392
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 219

Ala Arg Asn Val Gly Gln Arg Asn Ala Ser Arg Gln Ser Lys Arg Glu
1 5 10 15

Ser Ala Lys Ala Arg Ser Arg Arg Val Thr Gly Gly His Ala Ser Val
20 25 30

Thr Gln Gly Val Ala Leu Ile Asn Ala Ala Ala Asn Ala Asp Arg Asp
35 40 45

His Thr Thr Gly Cys Glu Pro Cys Thr Trp Glu Arg Val Asn Leu Pro
50 55 60

```
Leu Gln Glu Val Ile His Gly Cys Asp Ser Cys Thr Lys Ser Ser Pro
65                  70                  75                  80

Phe Trp Arg Asp Ile Lys Val Val Asn Lys Gly Tyr Arg Glu Ala Lys
                85                  90                  95

Glu Glu Ile Met Arg Ile Ala Ser Gly Ile Ser Ala Asp His Leu Ser
            100                 105                 110

Arg Ala Leu Ser His Asn Lys Val Met Gly Arg Leu Asn Leu Asp Glu
        115                 120                 125

Val Cys Ile Leu Asp Phe Arg Thr Val Leu Asp Thr Ser Leu Lys His
    130                 135                 140

Leu Thr Asp Ser Arg Ser Asn Gly Ile Lys Glu His Ile Arg Ala Val
145                 150                 155                 160

His Arg Lys Ile Arg Met Arg Arg Lys Ser Gly Lys Thr Ala Arg Ala
                165                 170                 175

Leu Arg Lys Gln Tyr Phe Ala Leu Arg Arg Gln Trp Lys Ala Gly His
            180                 185                 190

Lys Pro Asn Ser Ile Arg Glu Gly Asn Ser Leu Thr Ala Leu Arg Ala
        195                 200                 205

Val Gly Phe Asp Val Gly Val Ser Glu Gly Thr Glu Pro Met Pro Ala
    210                 215                 220

Pro Gln Thr Glu Val Val Leu Ser Val Phe Tyr Lys Gly Ser Ala Thr
225                 230                 235                 240

Arg Ile Leu Arg Ile Ser Ser Pro His Pro Ile Ala Lys Arg Ser Trp
                245                 250                 255
```

Lys Val Lys Ile Ala Gly Ile Lys Ala Leu Lys Leu Ile Arg Arg Glu
260 265 270

His Asp Phe Ser Phe Gly Arg Glu Thr Tyr Asn Ala Ser Gln Arg Ala
275 280 285

Glu Lys Arg Lys Phe Ser Pro His Ala Ala Arg Lys Asp Phe Phe Asn
290 295 300

Ser Phe Ala Val Gln Leu Asp Arg Leu Ala Gln Gln Leu Cys Val Ser
305 310 315 320

Ser Val Glu Asn Leu Trp Val Thr Glu Pro Gln Gln Lys Leu Leu Thr
325 330 335

Leu Ala Lys Asp Thr Ala Pro Tyr Gly Ile Arg Glu Gly Ala Arg Phe
340 345 350

Ala Asp Thr Arg Ala Arg Leu Ala Trp Asn Trp Val Phe Arg Val Cys
355 360 365

Gly Phe Thr Arg Ala Leu His Gln Glu Gln Glu Pro Thr Pro Tyr Cys
370 375 380

Arg Phe Thr Trp Arg Ser Lys Met
385 390

<210> 220
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 220
ctacgccgat tatcttctga caactttcgc aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 221
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 221
gtgcccgcat tttttacctt acaccgcttg cgaaagttgt cagaagataa tcggcgtag 59

<210> 222
<211> 90
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 222
tttatatgtt tctcctggag ataacgcaat cgtgacaact ttcgcaagcg gtgtaaggta 60

gcaggcttcc gaattccgcg tttttacggc 90

<210> 223
<211> 90
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 223
gccgtaaaaa cgcggaattc ggaagcctgc taccttacac cgcttgcgaa agttgtcacg 60

attgcgttat ctccaggaga aacatataaa 90

<210> 224
<211> 56
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 224
gatcttcagc tatacattat tgcaccaaca ctaaggcaga gtatgtttac ctggac 56

<210> 225
<211> 56
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 225
gatcttcagc tttgtattac tggaaggatg cttgcttgag gtgtaaaaac ctggac 56

<210> 226
<211> 5
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 226
ttttt 5

<210> 227
<211> 6
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 227
tttttt 6

<210> 228
<211> 7
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 228
tttttt 7

<210> 229
<211> 8
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 229
tttttttt 8

<210> 230
<211> 9
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 230
ttttttttt 9

<210> 231
<211> 10
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 231
tttttttttt 10

<210> 232
<211> 11
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 232
tttttttttt t 11

<210> 233
<211> 12
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 233
tttttttttt tt 12

<210> 234
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 234
gccggggtgg tgcccatcct ggtcgagctg gacggcgacg taaacggcca caagc 55

<210> 235
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 235
gccggggtgg tgcccatcct ggtcgagctg gacggcgacg tgctcggcca caagc 55

<210> 236
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 236
gccggggtgg tgcccatcct ggtcgagctg gacggcgagc taaacggcca caagc 55

<210> 237
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 237
gccggggtgg tgcccatcct ggtcgagctg gacggcctcg taaacggcca caagc 55

<210> 238
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 238
gccggggtgg tgcccatcct ggtcgagctg gacgcggacg taaacggcca caagc 55

<210> 239
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 239
gccggggtgg tgcccatcct ggtcgagctg gagcgcgacg taaacggcca caagc 55

<210> 240
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 240
gccggggtgg tgcccatcct ggtcgagctg ctcggcgacg taaacggcca caagc 55

<210> 241
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 241
gccggggtgg tgcccatcct ggtcgagcac gacggcgacg taaacggcca caagc 55

<210> 242
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 242
gccggggtgg tgcccatcct ggtcgacgtg gacggcgacg taaacggcca caagc 55

<210> 243
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 243
gccggggtgg tgcccatcct ggtcctgctg gacggcgacg taaacggcca caagc 55

<210> 244
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 244
gccggggtgg tgcccatcct ggaggagctg gacggcgacg taaacggcca caagc 55

<210> 245
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 245
gccggggtgg tgcccatcct cctcgagctg gacggcgacg taaacggcca caagc 55

<210> 246
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 246
gtgttaatac aaaggtacag gaacaaagaa tttg 34

<210> 247
<211> 18
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 247
caaagagaag cctcggcc 18

<210> 248
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 248
tttattcaag gcaatcacta tcagctgtgg aacacccagg taaactaaca caact 55

<210> 249
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 249
tttattcaag gcaatcacta tcagctgtgg aacacccagg tgctctaaca caact 55

<210> 250
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 250
tttattcaag gcaatcacta tcagctgtgg aacacccacc taaactaaca caact 55

<210> 251
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 251
tttattcaag gcaatcacta tcagctgtgg aacaccgtgg taaactaaca caact 55

<210> 252
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 252
tttattcaag gcaatcacta tcagctgtgg aacaggcagg taaactaaca caact 55

<210> 253
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 253
tttattcaag gcaatcacta tcagctgtgg aagtcccagg taaactaaca caact 55

<210> 254
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 254
tttattcaag gcaatcacta tcagctgtgg ttcacccagg taaactaaca caact 55

<210> 255
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 255
tttattcaag gcaatcacta tcagctgtcc aacacccagg taaactaaca caact 55

<210> 256
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 256
tttattcaag gcaatcacta tcagctcagg aacacccagg taaactaaca caact 55

<210> 257
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 257
tttattcaag gcaatcacta tcaggagtgg aacacccagg taaactaaca caact 55

<210> 258
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 258
tttattcaag gcaatcacta tctcctgtgg aacacccagg taaactaaca caact 55

<210> 259
<211> 55
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 259
tttattcaag gcaatcacta agagctgtgg aacacccagg taaactaaca caact 55

<210> 260
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 260
ctacgccgat tatcttctga caactttcgc aagcggtgta aggcgaaaaa tgcgggcac 59

<210> 261
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 261
ctacgccgat tatcttctga caactttcgc aagcggtgta aaataaaaaa tgcgggcac 59

<210> 262
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 262
ctacgccgat tatcttctga caactttcgc aagcggtgtg gggtaaaaaa tgcgggcac 59

<210> 263
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 263
ctacgccgat tatcttctga caactttcgc aagcggtaca aggtaaaaaa tgcgggcac 59

<210> 264
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 264
ctacgccgat tatcttctga caactttcgc aagcgacgta aggtaaaaaa tgcgggcac 59

<210> 265
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 265
ctacgccgat tatcttctga caactttcgc aagtagtgta aggtaaaaaa tgcgggcac 59

<210> 266
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 266
ctacgccgat tatcttctga caactttcgc agacggtgta aggtaaaaaa tgcgggcac 59

<210> 267
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 267
ctacgccgat tatcttctga caactttcgt gagcggtgta aggtaaaaaa tgcgggcac 59

<210> 268
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 268
ctacgccgat tatcttctga caacttttac aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 269
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 269
ctacgccgat tatcttctga caactcccgc aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 270
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 270
ctacgccgat tatcttctga caatcttcgc aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 271
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 271
ctacgccgat tatcttctga cggctttcgc aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 272
<211> 59
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 272
ctacgccgat tatcttctgg taactttcgc aagcggtgta aggtaaaaaa tgcgggcac 59

<210> 273
<211> 49
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 273
tatcttctga caactttcgc aagcggtgta aggtaaaaaa tgcgggcac 49

<210> 274
<211> 44
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 274
tctgacaact ttcgcaagcg gtgtaaggta aaaaatgcgg gcac 44

<210> 275
<211> 39
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 275
caactttcgc aagcggtgta aggtaaaaaa tgcgggcac 39

<210> 276
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 276
ttcgcaagcg gtgtaaggta aaaaatgcgg gcac 34

<210> 277
<211> 54
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 277
ctacgccgat tatcttctga caactttcgc aagcggtgta aggtaaaaaa tgcg 54

<210> 278
<211> 49
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 278
ctacgccgat tatcttctga caactttcgc aagcggtgta aggtaaaaa 49

<210> 279
<211> 40
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 279
ctacgccgat tatcttctga caactttcgc aagcggtgta 40

<210> 280
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 280
ctacgccgat tatcttctga caactttcgc aagcg 35

<210> 281
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 281
ctacgccgat tatcttctga caactttcgc 30

<210> 282
<211> 25
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 282
ctacgccgat tatcttctga caact 25

<210> 283
<211> 20
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 283
ctacgccgat tatcttctga 20

<210> 284
<211> 34
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 284
caactttcgc aagcggtgta aggtaaaaaa tgcg 34

<210> 285
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 285
atggaatgtg gcgaacgctt tcaacgaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 286
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 286
atggaatgtg gcgaacgctt agttggaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 287
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 287
atggaatgtg gcgaagcgaa agttggaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 288

<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 288
atggaatgtg cgcttgcgaa agttggaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 289
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 289
atggatacac cgcttgcgaa agttggaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 290
<211> 63
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 290
taccttacac cgcttgcgaa agttggaaac aactttcgca agcggtgtaa ggtaaaaaat 60

gcg 63

<210> 291
<211> 40
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 291
gttttatctt ctgctggtgg ttcgttcggt atttttaatg 40

<210> 292
<211> 40
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 292
cattaaaaat accgaacgaa ccaccagcag aagataaaac 40

<210> 293
<211> 43
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 293
gaccatttgc gaaatgtatc taatggtcaa actaaatcta ctc 43

<210> 294
<211> 43
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 294
gagtagattt agtttgacca ttagatacat ttcgcaaatg gtc 43

<210> 295
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 295
cttgcagaac ccggatagac gaatgaagga atgcaac 37

<210> 296
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 296
cttgcaggcc ttgaatagag gagttaagga atgcaac 37

<210> 297
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 297
gttgcacagt gctaattaga gaaactagga atgcaac 37

<210> 298
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 298
ctagcatatt cagaacaaag ggattaagga atgcaac 37

<210> 299
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 299
ctttcatatt cagaaactag gggttaagga ctgcaac 37

<210> 300
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 300
gttgcatccc tacgtcgtga gcaccggtga gtgcaac 37

<210> 301
<211> 31
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 301
ggaaaggaat cccctgaagg aaacgagggg g 31

<210> 302
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 302
gtgtccatca atcagatttg cgttggccgg tgcaat 36

<210> 303
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 303
gtttcagcgc acgaattaac gagatgagag atgcaac 37

<210> 304
<211> 500
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 304

Lys Glu Pro Leu Asn Ile Gly Lys Thr Ala Lys Ala Val Phe Lys Glu
1 5 10 15

Ile Asp Pro Thr Ser Leu Asn Arg Ala Ala Asn Tyr Asp Ala Ser Ile
20 25 30

Glu Leu Asn Cys Lys Glu Cys Lys Phe Lys Pro Phe Lys Asn Val Lys
35 40 45

Arg Tyr Glu Phe Asn Phe Tyr Asn Asn Trp Tyr Arg Cys Asn Pro Asn
50 55 60

Ser Cys Leu Gln Ser Thr Tyr Lys Ala Gln Val Arg Lys Val Glu Ile
65 70 75 80

Gly Tyr Glu Lys Leu Lys Asn Glu Ile Leu Thr Gln Met Gln Tyr Tyr
85 90 95

Pro Trp Phe Gly Arg Leu Tyr Gln Asn Phe Phe His Asp Glu Arg Asp
100 105 110

Lys Met Thr Ser Leu Asp Glu Ile Gln Val Ile Gly Val Gln Asn Lys
115 120 125

Val Phe Phe Asn Thr Val Glu Lys Ala Trp Arg Glu Ile Ile Lys Lys

```
    130                 135                 140

Arg Phe Lys Asp Asn Lys Glu Thr Met Glu Thr Ile Pro Glu Leu Lys
145                 150                 155                 160

His Ala Ala Gly His Gly Lys Arg Lys Leu Ser Asn Lys Ser Leu Leu
                165                 170                 175

Arg Arg Arg Phe Ala Phe Val Gln Lys Ser Phe Lys Phe Val Asp Asn
            180                 185                 190

Ser Asp Val Ser Tyr Arg Ser Phe Ser Asn Asn Ile Ala Cys Val Leu
        195                 200                 205

Pro Ser Arg Ile Gly Val Asp Leu Gly Gly Val Ile Ser Arg Asn Pro
    210                 215                 220

Lys Arg Glu Tyr Ile Pro Gln Glu Ile Ser Phe Asn Ala Phe Trp Lys
225                 230                 235                 240

Gln His Glu Gly Leu Lys Lys Gly Arg Asn Ile Glu Ile Gln Ser Val
                245                 250                 255

Gln Tyr Lys Gly Glu Thr Val Lys Arg Ile Glu Ala Asp Thr Gly Glu
            260                 265                 270

Asp Lys Ala Trp Gly Lys Asn Arg Gln Arg Arg Phe Thr Ser Leu Ile
        275                 280                 285

Leu Lys Leu Val Pro Lys Gln Gly Gly Lys Lys Val Trp Lys Tyr Pro
    290                 295                 300

Glu Lys Arg Asn Glu Gly Asn Tyr Glu Tyr Phe Pro Ile Pro Ile Glu
305                 310                 315                 320

Phe Ile Leu Asp Ser Gly Glu Thr Ser Ile Arg Phe Gly Gly Asp Glu
```

325 330 335

Gly Glu Ala Gly Lys Gln Lys His Leu Val Ile Pro Phe Asn Asp Ser
340 345 350

Lys Ala Thr Pro Leu Ala Ser Gln Gln Thr Leu Leu Glu Asn Ser Arg
355 360 365

Phe Asn Ala Glu Val Lys Ser Cys Ile Gly Leu Ala Ile Tyr Ala Asn
370 375 380

Tyr Phe Tyr Gly Tyr Ala Arg Asn Tyr Val Ile Ser Ser Ile Tyr His
385 390 395 400

Lys Asn Ser Lys Asn Gly Gln Ala Ile Thr Ala Ile Tyr Leu Glu Ser
405 410 415

Ile Ala His Asn Tyr Val Lys Ala Ile Glu Arg Gln Leu Gln Asn Leu
420 425 430

Leu Leu Asn Leu Arg Asp Phe Ser Phe Met Glu Ser His Lys Lys Glu
435 440 445

Leu Lys Lys Tyr Phe Gly Gly Asp Leu Glu Gly Thr Gly Gly Ala Gln
450 455 460

Lys Arg Arg Glu Lys Glu Glu Lys Ile Glu Lys Glu Ile Glu Gln Ser
465 470 475 480

Tyr Leu Pro Arg Leu Ile Arg Leu Ser Leu Thr Lys Met Val Thr Lys
485 490 495

Gln Val Glu Met
500

<210> 305

<211> 507
<212> PRT
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 305

Glu Leu Ile Val Asn Glu Asn Lys Asp Pro Leu Asn Ile Gly Lys Thr
1 5 10 15

Ala Lys Ala Val Phe Lys Glu Ile Asp Pro Thr Ser Ile Asn Arg Ala
20 25 30

Ala Asn Tyr Asp Ala Ser Ile Glu Leu Ala Cys Lys Glu Cys Lys Phe
35 40 45

Lys Pro Phe Asn Asn Thr Lys Arg His Asp Phe Ser Phe Tyr Ser Asn
50 55 60

Trp His Arg Cys Ser Pro Asn Ser Cys Leu Gln Ser Thr Tyr Arg Ala
65 70 75 80

Lys Ile Arg Lys Thr Glu Ile Gly Tyr Glu Lys Leu Lys Asn Glu Ile
85 90 95

Leu Asn Gln Met Gln Tyr Tyr Pro Trp Phe Gly Arg Leu Tyr Gln Asn
100 105 110

Phe Phe Asn Asp Gln Arg Asp Lys Met Thr Ser Leu Asp Glu Ile Gln
115 120 125

Val Thr Gly Val Gln Asn Lys Ile Phe Phe Asn Thr Val Glu Lys Ala
130 135 140

Trp Arg Glu Ile Ile Lys Lys Arg Phe Arg Asp Asn Lys Glu Thr Met
145 150 155 160

```
Arg Thr Ile Pro Asp Leu Lys Asn Lys Ser Gly His Gly Ser Arg Lys
                165                 170                 175

Leu Ser Asn Lys Ser Leu Leu Arg Arg Arg Phe Ala Phe Ala Gln Lys
            180                 185                 190

Ser Phe Lys Leu Val Asp Asn Ser Asp Val Ser Tyr Arg Ala Phe Ser
        195                 200                 205

Asn Asn Val Ala Cys Val Leu Pro Ser Lys Ile Gly Val Asp Ile Gly
    210                 215                 220

Gly Ile Ile Asn Lys Asp Leu Lys Arg Glu Tyr Ile Pro Gln Glu Ile
225                 230                 235                 240

Thr Phe Asn Val Phe Trp Lys Gln His Asp Gly Leu Lys Lys Gly Arg
                245                 250                 255

Asn Ile Glu Ile His Ser Val Gln Tyr Lys Gly Glu Ile Val Lys Arg
            260                 265                 270

Ile Glu Ala Asp Thr Gly Glu Asp Lys Ala Trp Gly Lys Asn Arg Gln
        275                 280                 285

Arg Arg Phe Thr Ser Leu Ile Leu Lys Ile Thr Pro Lys Gln Gly Gly
    290                 295                 300

Lys Lys Ile Trp Lys Phe Pro Glu Lys Lys Asn Ala Ser Asp Tyr Glu
305                 310                 315                 320

Tyr Phe Pro Ile Pro Ile Glu Phe Ile Leu Asp Asn Gly Asp Ala Ser
                325                 330                 335

Ile Lys Phe Gly Gly Glu Glu Gly Glu Val Gly Lys Gln Lys His Leu
            340                 345                 350
```

```
Leu Ile Pro Phe Asn Asp Ser Lys Ala Thr Pro Leu Ser Ser Lys Gln
        355                 360                 365


Met Leu Leu Glu Thr Ser Arg Phe Asn Ala Glu Val Lys Ser Thr Ile
    370                 375                 380


Gly Leu Ala Leu Tyr Ala Asn Tyr Phe Val Ser Tyr Ala Arg Asn Tyr
385                 390                 395                 400


Val Ile Lys Ser Thr Tyr His Lys Asn Ser Lys Lys Gly Gln Ile Val
                405                 410                 415


Thr Glu Ile Tyr Leu Glu Ser Ile Ser Gln Asn Phe Val Arg Ala Ile
            420                 425                 430


Gln Arg Gln Leu Gln Ser Leu Met Leu Asn Leu Lys Asp Trp Gly Phe
        435                 440                 445


Met Gln Thr His Lys Lys Glu Leu Lys Lys Tyr Phe Gly Ser Asp Leu
    450                 455                 460


Glu Gly Ser Lys Gly Gly Gln Lys Arg Arg Glu Lys Glu Glu Lys Ile
465                 470                 475                 480


Glu Lys Glu Ile Glu Ala Ser Tyr Leu Pro Arg Leu Ile Arg Leu Ser
                485                 490                 495


Leu Thr Lys Ser Val Thr Lys Ala Glu Glu Met
            500                 505


<210>  306
<211>  529
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Synthetic sequence
```

<400> 306

```
Pro Glu Glu Lys Thr Ser Lys Leu Lys Pro Asn Ser Ile Asn Leu Ala
1               5                  10                  15

Ala Asn Tyr Asp Ala Asn Glu Lys Phe Asn Cys Lys Glu Cys Lys Phe
            20                  25                  30

His Pro Phe Lys Asn Lys Lys Arg Tyr Glu Phe Asn Phe Tyr Asn Asn
        35                  40                  45

Leu His Gly Cys Lys Ser Cys Thr Lys Ser Thr Asn Asn Pro Ala Val
    50                  55                  60

Lys Arg Ile Glu Ile Gly Tyr Gln Lys Leu Lys Phe Glu Ile Lys Asn
65                  70                  75                  80

Gln Met Glu Ala Tyr Pro Trp Phe Gly Arg Leu Arg Ile Asn Phe Tyr
                85                  90                  95

Ser Asp Glu Lys Arg Lys Met Ser Glu Leu Asn Glu Met Gln Val Thr
            100                 105                 110

Gly Val Lys Asn Lys Ile Phe Phe Asp Ala Ile Glu Cys Ala Trp Arg
        115                 120                 125

Glu Ile Leu Lys Lys Arg Phe Arg Glu Ser Lys Glu Thr Leu Ile Thr
    130                 135                 140

Ile Pro Lys Leu Lys Asn Lys Ala Gly His Gly Ala Arg Lys His Arg
145                 150                 155                 160

Asn Lys Lys Leu Leu Ile Arg Arg Arg Ala Phe Met Lys Lys Asn Phe
                165                 170                 175

His Phe Leu Asp Asn Asp Ser Ile Ser Tyr Arg Ser Phe Ala Asn Asn
```

```
            180                 185                 190

Ile Ala Cys Val Leu Pro Ser Lys Val Gly Val Asp Ile Gly Gly Ile
        195                 200                 205

Ile Ser Pro Asp Val Gly Lys Asp Ile Lys Pro Val Asp Ile Ser Leu
    210                 215                 220

Asn Leu Met Trp Ala Ser Lys Glu Gly Ile Lys Ser Gly Arg Lys Val
225                 230                 235                 240

Glu Ile Tyr Ser Thr Gln Tyr Asp Gly Asn Met Val Lys Lys Ile Glu
                245                 250                 255

Ala Glu Thr Gly Glu Asp Lys Ser Trp Gly Lys Asn Arg Lys Arg Arg
            260                 265                 270

Gln Thr Ser Leu Leu Leu Ser Ile Pro Lys Pro Ser Lys Gln Val Gln
        275                 280                 285

Glu Phe Asp Phe Lys Glu Trp Pro Arg Tyr Lys Asp Ile Glu Lys Lys
    290                 295                 300

Val Gln Trp Arg Gly Phe Pro Ile Lys Ile Ile Phe Asp Ser Asn His
305                 310                 315                 320

Asn Ser Ile Glu Phe Gly Thr Tyr Gln Gly Gly Lys Gln Lys Val Leu
                325                 330                 335

Pro Ile Pro Phe Asn Asp Ser Lys Thr Thr Pro Leu Gly Ser Lys Met
            340                 345                 350

Asn Lys Leu Glu Lys Leu Arg Phe Asn Ser Lys Ile Lys Ser Arg Leu
        355                 360                 365

Gly Ser Ala Ile Ala Ala Asn Lys Phe Leu Glu Ala Ala Arg Thr Tyr
```

370 375 380

Cys Val Asp Ser Leu Tyr His Glu Val Ser Ser Ala Asn Ala Ile Gly
385 390 395 400

Lys Gly Lys Ile Phe Ile Glu Tyr Tyr Leu Glu Ile Leu Ser Gln Asn
405 410 415

Tyr Ile Glu Ala Ala Gln Lys Gln Leu Gln Arg Phe Ile Glu Ser Ile
420 425 430

Glu Gln Trp Phe Val Ala Asp Pro Phe Gln Gly Arg Leu Lys Gln Tyr
435 440 445

Phe Lys Asp Asp Leu Lys Arg Ala Lys Cys Phe Leu Cys Ala Asn Arg
450 455 460

Glu Val Gln Thr Thr Cys Tyr Ala Ala Val Lys Leu His Lys Ser Cys
465 470 475 480

Ala Glu Lys Val Lys Asp Lys Asn Lys Glu Leu Ala Ile Lys Glu Arg
485 490 495

Asn Asn Lys Glu Asp Ala Val Ile Lys Glu Val Glu Ala Ser Asn Tyr
500 505 510

Pro Arg Val Ile Arg Leu Lys Leu Thr Lys Thr Ile Thr Asn Lys Ala
515 520 525

Met

<210> 307
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 307
cttttagaca gtttaaattc taaagggtat aaaac 35

<210> 308
<211> 36
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 308
gtcgaaatgc ccgcgcgggg gcgtcgtacc cgcgac 36

<210> 309
<211> 37
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 309
gttgcagcgg ccgacggagc gcgagcgtgg atgccac 37

<210> 310
<211> 35
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 310
ctttagactt ctccggaagt cgaattaatg gaaac 35

<210> 311
<211> 28
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 311
gggcgccccg cgcgagcggg ggttgaag 28

<210> 312
<211> 136
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 312
gaaggatgct tgcttgaggt gtagttgtca ttccttcatt cgtctattcg ggttctgcaa 60

ctatacatta ttgcaccaac actaaggcag agtatggttg cattccttca ttcgtctatt 120

cgggttctgc aacggg 136

<210> 313
<211> 102
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 313
agaatgcttg cttgaggtgt agttgcattc cttcattcgt ctattcgggt aattgcacca 60

acactaaggc agagtatggt tgcattcctt cattcgtcta gg 102

<210> 314
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 314
cgatgcttgc ttgaggtgta gttgcattgc accaacacta aggcagagta tggttgcatt 60

ccttcattcg tctag 75

<210> 315
<211> 90
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 315
gatgcttgct tgaggtgtag ttgcattcct tcattctgca ccaacactaa ggcagagtat 60

ggttgcattc cttttcgggt tctgcaacgg 90

<210> 316
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 316
gcttgcttga ggtgtagttg cattccttca ttccacctac actaaggcag agtatggttg 60

cattccttca ttc 73

<210> 317
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 317
gcttgcttga ggtgtagttg cattccttca ttccacctac actaaggcag agtatggttg 60

cattccttca ttc 73

<210> 318
<211> 63
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 318
gcttgcttga ggtgtagttg cattcgcaac actaaggcag agtatggttg cattccttca 60

ttc 63

<210> 319
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 319
cttgcttgag gtgtagttgc cgacactaag gcagagtatg gttgcattat tcgggttctg 60

caacgg 66

<210> 320
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 320
cttgcttgag gtgtagttgc attccttcat tcaaacacta aggcagagta tggttgcatt 60

ccttcattc 69

<210> 321
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 321

ttgcttgagg tgtagttgca ttccttcatt ctaacactaa ggcagagtat ggttgcattc 60

cttcattcgt cta 73

<210> 322
<211> 58
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 322
ttgcttgagg tgtagttgca tccacactaa ggcagagtat ggttgcattc cttcattc 58

<210> 323
<211> 67
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 323
tgcttaaggt gtagttgcat tccttcattc caacactaag gcagagtatg gttgcattcc 60

ttcattc 67

<210> 324
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 324
tgcttgaggt gtagttgcat tccttcattc cacactaagg cagagtatgg ttgcattcct 60

tcattc 66

<210> 325
<211> 72
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 325
tgcttgaggt gtagttgcat tccttcattc aacactaagg cagagtatgg ttgcattcct 60

tcattcgtct at 72

<210> 326
<211> 64
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 326
cttgaggtgt agttgcattc cttcattcaa cactaaggca gagtatggtt gcattccttc 60

attc 64

<210> 327
<211> 59
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 327
cttgaggtgt agttgcattc cttaacacta aggcagagta tggttgcatt ccttcattc 59

<210> 328
<211> 63
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 328
ttgaggtgta gttgcattcc ttcattcaac actaaggcag agtatggttg cattccttca 60

ttc 63

<210> 329
<211> 62
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 329
tgaggtgtag ttgcattcct tcattcaaca ctaaggcaga gtatggttgc attccttcat 60

tc 62

<210> 330
<211> 61
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 330
tgaggtgtag ttgcattcct tcgttcacac taaggcagag tatggttgca ttccttcatt 60

c 61

<210> 331
<211> 61
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 331
tgaggtgtag ttgcattcct tcattcacac taaggcagag tatggttgca ttccttcatt 60

c 61

<210> 332
<211> 61
<212> DNA

<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 332
ctacgccgat tatcttctga caactttcgc aagcggtgta aggtaaaaaa tgcgggcacc 60

c 61

<210> 333
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 333
ggaatgcaac taccttacac cgcttgcgaa 30

<210> 334
<211> 140
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 334
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt cggaaagtaa 120

ccctcgaaac aaattcattt 140

<210> 335
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 335

gacgaatgaa ggaatgcaac taccttacac cgcttgcgaa 40

<210> 336
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 336
gacgaatgaa ggaatgcaac ccttacaccg cttgcgaaag 40

<210> 337
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 337
gacgaatgaa ggaatgcaac ttacaccgct tgcgaaagtt 40

<210> 338
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 338
gacgaatgaa ggaatgcaac acaccgcttg cgaaagttgt 40

<210> 339
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 339

gacgaatgaa ggaatgcaac cgtcgccgtc cagctcgacc a 41

<210> 340
<211> 40
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 340
gacgaatgaa ggaatgcaac gatcgttacg ctaactatga 40

<210> 341
<211> 180
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 341
ttcactgata aagtggagaa ccgcttcacc aaaagctgtc ccttagggga ttagaacttg 60

agtgaaggtg ggctgcttgc atcagcctaa tgtcgagaag tgctttcttc ggaaagtaac 120

cctcgaaaca aattcatttg aaagaatgaa ggaatgcaac acttgacact taatgctcaa 180

<210> 342
<211> 44
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 342
gggtaatttc tactaagtgt agatacttga cacttaatgc tcaa 44

<210> 343
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 343
gacgaatgaa ggaatgcaac taccttacac cgcttgcgaa agttg 45

<210> 344
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 344
gacgaatgaa ggaatgcaac taccttacac cgcttgcg 38

<210> 345
<211> 36
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 345
gacgaatgaa ggaatgcaac taccttacac cgcttg 36

<210> 346
<211> 34
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 346
gacgaatgaa ggaatgcaac taccttacac cgct 34

<210> 347
<211> 32
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 347
gacgaatgaa ggaatgcaac taccttacac cg 32

<210> 348
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 348
gacgaatgaa ggaatgcaac taccttacac 30

<210> 349
<211> 57
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 349
gttgcagaac ccgaatagac gaatgaagga atgcaactac cttacaccgc ttgcgaa 57

<210> 350
<211> 37
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 350
gaatgaagga atgcaactac cttacaccgc ttgcgaa 37

<210> 351
<211> 35
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 351
atgaaggaat gcaactacct tacaccgctt gcgaa 35

<210> 352
<211> 179
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 352
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt cggaaagtaa 120

ccctcgaaac aaattcattt ttcctctcca attctgcaca aaaaaaggtg agtccttat 179

<210> 353
<211> 110
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 353
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt 110

<210> 354
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 354
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gg 72

<210> 355
<211> 136
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 355
ttcactgata aagtggagaa ccgcttcacc aaaagctgtc ccttagggga ttagaacttg 60

agtgaaggtg ggctgcttgc atcagcctaa tgtcgagaag tgctttcttc ggaaagtaac 120

cctcgaaaca aattca 136

<210> 356
<211> 234
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 356
ttcacacttc actgataaag tggagaaccg cttcaccaaa agctgtccct taggggatta 60

gaacttgagt gaaggtgggc tgcttgcatc agcctaatgt cgagaagtgc tttcttcgga 120

aagtaaccct cgaaacaaat tcatttttcc tctccaattc tgcacaaaaa aaggtgagtc 180

cttataaacc ggcgtgcaga acgccggctc acctttttttc ttcattcgat ttta 234

<210> 357
<211> 181
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 357
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt cggaaagtaa 120

ccctcgaaac aaattcattt gaaagaatga aggaatgcaa ctaccttaca ccgcttgcga 180

a 181

<210> 358
<211> 222
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 358
cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 60

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt cggaaagtaa 120

ccctcgaaac aaattcattt ttcctctcca attctgcaca agaaagttgc agaacccgaa 180

tagacgaatg aaggaatgca actaccttac accgcttgcg aa 222

<210> 359
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 359
gacgaatgaa ggaatgcaac taccgaacga accaccagca gaaga 45

<210> 360
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 360
gacgaatgaa ggaatgcaac tcttctgctg gtggttcgtt cggta 45

<210> 361
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 361
gacgaatgaa ggaatgcaac gtttgaccat tagatacatt tcg 43

<210> 362
<211> 43
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 362
gacgaatgaa ggaatgcaac cgaaatgtat ctaatggtca aac 43

<210> 363
<211> 7580
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 363
gcaaccgcac ctgtggcgcc ggtgatgccg gccacgatgc gtccggcgta gaggatcgag 60

atctcgatcc cgcgaaatta atacgactca ctatagggag accacaacgg tttccctcta 120

gtgccggctc cggagagctc tttaattaag cggccgccct gcaggactcg agttctagaa 180

ataattttgt ttaactttaa gaaggagata tacatatgaa atcttctcac catcaccatc 240

accatcacca tcaccatggt tcttctatga aaatcgaaga aggtaaactg gtaatctgga 300

ttaacggcga taaaggctat aacggtctcg ctgaagtcgg taagaaattc gagaaagata 360

ccggaattaa agtcaccgtt gagcatccgg ataaactgga agagaaattc ccacaggttg 420

cggcaactgg cgatggccct gacattatct tctgggcaca cgaccgcttt ggtggctacg 480

ctcaatctgg cctgttggct gaaatcaccc cggacaaagc gttccaggac aagctgtatc 540

cgtttacctg ggatgccgta cgttacaacg gcaagctgat tgcttacccg atcgctgttg 600

aagcgttatc gctgatttat aacaaagatc tgctgccgaa cccgccaaaa acctgggaag 660

agatcccggc gctggataaa gaactgaaag cgaaaggtaa gagcgcgctg atgttcaacc 720

tgcaagaacc gtacttcacc tggccgctga ttgctgctga cgggggttat gcgttcaagt 780

atgaaaacgg caagtacgac attaaagacg tgggcgtgga taacgctggc gcgaaagcgg 840

gtctgacctt cctggttgac ctgattaaaa acaaacacat gaatgcagac accgattact 900

ccatcgcaga agctgccttt aataaaggcg aaacagcgat gaccatcaac ggcccgtggg 960

catggtccaa catcgacacc agcaaagtga attatggtgt aacggtactg ccgaccttca 1020

agggtcaacc atccaaaccg ttcgttggcg tgctgagcgc aggtattaac gccgccagtc 1080

cgaacaaaga gctggcaaaa gagttcctcg aaaactatct gctgactgat gaaggtctgg 1140

aagcggttaa taaagacaaa ccgctgggtg ccgtagcgct gaagtcttac gaggaagagt 1200

tggcgaaaga tccacgtatt gccgccacta tggaaaacgc ccagaaaggt gaaatcatgc 1260

cgaacatccc gcagatgtcc gctttctggt atgccgtgcg tactgcggtg atcaacgccg 1320

ccagcggtcg tcagactgtc gatgaagccc tgaaagacgc gcagactaat tcgagctcga 1380

acaacaacaa caataacaat aacaacaacc tcgggatcga ggaaaacctg tacttccaat 1440

ccaatgcaat ggaagaaagc attattaccg gtgtgaaatt caaactgcgc atcgataaag 1500

aaaccaccaa aaaactgaac gagtacttcg atgaatatgg caaagcaatt aacttcgccg 1560

tgaagatcat tcagaaagaa ctggcagatg atcgttttgc aggtaaagca aaactggacc 1620

agaataaaaa cccgatcctg gatgaaaacg gcaaaaaaat ctatgaattc ccggatgaat 1680

tttgcagctg tggtaaacag gttaacaagt acgttaacaa caaaccgttt tgccaagagt 1740

gctataaaat ccgctttacc gaaaatggta ttcgcaaacg tatgtatagc gccaaaggtc 1800

gtaaagccga acataaaatc aatatcctga acagcaccaa caagatcagc aaaacccatt 1860

ttaactatgc cattcgcgaa gccttcattc tggataaaag catcaaaaag cagcgcaaaa 1920

aacgtaatga acgtctgcgt gaaagtaaaa aacgtctgca gcagtttatc gatatgcgtg 1980

atggtaaacg tgaaatttgc ccgaccatta aaggtcagaa agtggatcgt tttattcatc 2040

cgagctggat caccaaagat aaaaagctgg aagattttcg cggttatacc ctgagcatta 2100

tcaacagcaa aattaagatt ctggatcgca acatcaaacg cgaagaaaaa agcctgaaag 2160

aaaaaggcca gatcatcttt aaagccaaac gtctgatgct ggataaatcc attcgttttg 2220

ttggtgatcg caaagtgctg tttacaatta gtaaaaccct gccgaaagag tatgaactgg 2280

atctgccgag caaagaaaaa cggctgaatt ggctgaaaga gaagatcgag attatcaaga 2340

accagaaacc gaaatatgcc tatctgctgc gcaaaaacat tgagagcgaa aaaaaaccga 2400

actatgagta ctatctgcag tacaccctgg aaattaaacc ggaactgaaa gatttttatg 2460

atggtgccat tggtattgac cgtggcatta atcatattgc cgtttgcacc tttattagca 2520

acgatggtaa agttacccct ccgaaatttt tcagcagcgg tgaaattctg cgtctgaaaa 2580

atctgcagaa agagcgtgat cgctttctgc tgcgtaaaca caacaaaaat cgcaaaaaag 2640

gcaacatgcg cgtgatcgaa aacaaaatca atctgatcct gcaccgttat agcaagcaga 2700

ttgttgatat ggccaaaaag ctgaatgcca gcattgtttt tgaagaactg ggtcgtattg 2760

gtaaaagccg caccaaaatg aaaaaaagcc agcgttataa actgagcctg ttcatcttca 2820

agaaactgag cgatctggtt gattacaaaa gccgtcgtga aggtattcgt gttacctatg 2880

ttccgcctga atataccagc aaagaatgta gccattgcgg tgaaaaagtt aatacccagc 2940

gtccgtttaa tggcaactat agcctgttta aatgcaacaa atgtggcatc cagctgaaca 3000

gcgattataa tgcaagcatc aacattgcga aaaagggcct gaaaattccg aatagcacct 3060

aataacattg gaagtggata acggatccgc gatcgcggcg cgccacctgg tggccggccg 3120

gtaccacgcg tgcgcgctga tccggctgct aacaaagccc gaaaggaagc tgagttggct 3180

gctgccaccg ctgagcaata actagcataa ccccttgggg cctctaaacg ggtcttgagg 3240

ggtttttgc tgaaaggagg aactatatcc ggatatccac aggacgggtg tggtcgccat 3300

gatcgcgtag tcgatagtgg ctccaagtag cgaagcgagc aggactgggc ggcggccaaa 3360

gcggtcggac agtgctccga gaacgggtgc gcatagaaat tgcatcaacg catatagcgc 3420

tagcagcacg ccatagtgac tggcgatgct gtcggaatgg acgatatccc gcaagaggcc 3480

cggcagtacc ggcataacca agcctatgcc tacagcatcc agggtgacgg tgccgaggat 3540

gacgatgagc gcattgttag atttcataca cggtgcctga ctgcgttagc aatttaactg 3600

tgataaacta ccgcattaaa gcttatcgat gataagctgt caaacatgag aattcttgaa 3660

gacgaaaggg cctcgtgata cgcctatttt tataggttaa tgtcatgata ataatggttt 3720

cttagacgtc aggtggcact tttcggggaa atgtgcgcgg aacccctatt tgtttatttt 3780

tctaaataca ttcaaatatg tatccgctca tgagacaata accctgataa atgcttcaat 3840

aacattgaaa aaggaagagt atgagtattc aacatttccg tgtcgccctt attccctttt 3900

ttgcggcatt ttgccttcct gtttttgctc acccagaaac gctggtgaaa gtaaaagatg 3960

ctgaagatca gttgggtgca cgagtgggtt acatcgaact ggatctcaac agcggtaaga 4020

tccttgagag ttttcgcccc gaagaacgtt ttccaatgat gagcactttt aaagttctgc 4080

tatgtggcgc ggtattatcc cgtgttgacg ccgggcaaga gcaactcggt cgccgcatac 4140

actattctca gaatgacttg gttgagtact caccagtcac agaaaagcat cttacggatg 4200

gcatgacagt aagagaatta tgcagtgctg ccataaccat gagtgataac actgcggcca 4260

acttacttct gacaacgatc ggaggaccga aggagctaac cgcttttttg cacaacatgg 4320

gggatcatgt aactcgcctt gatcgttggg aaccggagct gaatgaagcc ataccaaacg 4380

acgagcgtga caccacgatg cctgcagcaa tggcaacaac gttgcgcaaa ctattaactg 4440

gcgaactact tactctagct tcccggcaac aattaataga ctggatggag gcggataaag 4500

ttgcaggacc acttctgcgc tcggcccttc cggctggctg gtttattgct gataaatctg 4560

gagccggtga gcgtgggtct cgcggtatca ttgcagcact ggggccagat ggtaagccct 4620

cccgtatcgt agttatctac acgacgggga gtcaggcaac tatggatgaa cgaaatagac 4680

agatcgctga gataggtgcc tcactgatta agcattggta actgtcagac caagtttact 4740

catatatact ttagattgat ttaaaacttc atttttaatt taaaaggatc taggtgaaga 4800

tccttttga taatctcatg accaaaatcc cttaacgtga gttttcgttc cactgagcgt 4860

cagaccccgt agaaaagatc aaaggatctt cttgagatcc ttttttttctg cgcgtaatct 4920

gctgcttgca aacaaaaaaa ccaccgctac cagcggtggt ttgtttgccg gatcaagagc 4980

taccaactct ttttccgaag gtaactggct tcagcagagc gcagatacca aatactgtcc 5040

ttctagtgta gccgtagtta ggccaccact tcaagaactc tgtagcaccg cctacatacc 5100

tcgctctgct aatcctgtta ccagtggctg ctgccagtgg cgataagtcg tgtcttaccg 5160

ggttggactc aagacgatag ttaccggata aggcgcagcg gtcgggctga acgggggggtt 5220

cgtgcacaca gcccagcttg gagcgaacga cctacaccga actgagatac ctacagcgtg 5280

agctatgaga aagcgccacg cttcccgaag ggagaaaggc ggacaggtat ccggtaagcg 5340

gcagggtcgg aacaggagag cgcacgaggg agcttccagg gggaaacgcc tggtatcttt 5400

atagtcctgt cgggtttcgc cacctctgac ttgagcgtcg atttttgtga tgctcgtcag 5460

gggggcggag cctatggaaa aacgccagca acgcggcctt tttacggttc ctggccttttt 5520

gctggccttt tgctcacatg ttctttcctg cgttatcccc tgattctgtg gataaccgta 5580

ttaccgcctt tgagtgagct gataccgctc gccgcagccg aacgaccgag cgcagcgagt 5640

cagtgagcga ggaagcggaa gagcgcctga tgcggtattt tctccttacg catctgtgcg 5700

gtatttcaca ccgcaatggt gcactctcag tacaatctgc tctgatgccg catagttaag 5760

ccagtataca ctccgctatc gctacgtgac tgggtcatgg ctgcgccccg acacccgcca 5820

acacccgctg acgcgccctg acgggcttgt ctgctcccgg catccgctta cagacaagct 5880

gtgaccgtct ccgggagctg catgtgtcag aggttttcac cgtcatcacc gaaacgcgcg 5940

aggcagctgc ggtaaagctc atcagcgtgg tcgtgaagcg attcacagat gtctgcctgt 6000

tcatccgcgt ccagctcgtt gagtttctcc agaagcgtta atgtctggct tctgataaag 6060

cgggccatgt taagggcggt tttttcctgt ttggtcactg atgcctccgt gtaaggggga 6120

tttctgttca tgggggtaat gataccgatg aaacgagaga ggatgctcac gatacgggtt 6180

actgatgatg aacatgcccg gttactggaa cgttgtgagg gtaaacaact ggcggtatgg 6240

atgcggcggg accagagaaa aatcactcag ggtcaatgcc agcgcttcgt taatacagat 6300

gtaggtgttc cacagggtag ccagcagcat cctgcgatgc agatccggaa cataatggtg 6360

cagggcgctg acttccgcgt ttccagactt tacgaaacac ggaaaccgaa gaccattcat 6420

gttgttgctc aggtcgcaga cgttttgcag cagcagtcgc ttcacgttcg ctcgcgtatc 6480

ggtgattcat tctgctaacc agtaaggcaa ccccgccagc ctagccgggt cctcaacgac 6540

aggagcacga tcatgcgcac ccgtggccag gacccaacgc tgcccgagat gcgccgcgtg 6600

cggctgctgg agatggcgga cgcgatggat atgttctgcc aagggttggt ttgcgcattc 6660

acagttctcc gcaagaattg attggctcca attcttggag tggtgaatcc gttagcgagg 6720

tgccgccggc ttccattcag gtcgaggtgg cccggctcca tgcaccgcga cgcaacgcgg 6780

ggaggcagac aaggtatagg gcggcgccta caatccatgc caacccgttc catgtgctcg 6840

ccgaggcggc ataaatcgcc gtgacgatca gcggtccaat gatcgaagtt aggctggtaa 6900

gagccgcgag cgatccttga agctgtccct gatggtcgtc atctacctgc ctggacagca 6960

tggcctgcaa cgcgggcatc ccgatgccgc cggaagcgag aagaatcata atggggaagg 7020

ccatccagcc tcgcgtcgcg aacgccagca agacgtagcc cagcgcgtcg gccgccatgc 7080

cggcgataat ggcctgcttc tcgccgaaac gtttggtggc gggaccagtg acgaaggctt 7140

gagcgagggc gtgcaagatt ccgaataccg caagcgacag gccgatcatc gtcgcgctcc 7200

agcgaaagcg gtcctcgccg aaaatgaccc agagcgctgc cggcacctgt cctacgagtt 7260

gcatgataaa gaagacagtc ataagtgcgg cgacgatagt catgccccgc gcccaccgga 7320

aggagctgac tgggttgaag gctctcaagg gcatcggtcg acgctctccc ttatgcgact 7380

cctgcattag gaagcagccc agtagtaggt tgaggccgtt gagcaccgcc gccgcaagga 7440

atggtgcatg caaggagatg gcgcccaaca gtcccccggc cacggggcct gccaccatac 7500

ccacgccgaa acaagcgctc atgagcccga agtggcgagc ccgatcttcc ccatcggtga 7560

tgtcggcgat ataggcgcca 7580

<210> 364
<211> 4715
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 364
atcgttgata gagttatttt accactccct atcagtgata gagaaaagaa ttcaaaagat 60

ctaaagagga gaaaggatct atggaagaaa gcattattac cggtgtgaaa ttcaaactgc 120

gcatcgataa agaaaccacc aaaaaactga acgagtactt cgatgaatat ggcaaagcaa 180

ttaacttcgc cgtgaagatc attcagaaag aactggcaga tgatcgtttt gcaggtaaag 240

caaaactgga ccagaataaa aacccgatcc tggatgaaaa cggcaaaaaa atctatgaat 300

tcccggatga attttgcagc tgtggtaaac aggttaacaa gtacgttaac aacaaaccgt 360

tttgccaaga gtgctataaa atccgcttta ccgaaaatgg tattcgcaaa cgtatgtata 420

gcgccaaagg tcgtaaagcc gaacataaaa tcaatatcct gaacagcacc aacaagatca 480

gcaaaaccca ttttaactat gccattcgcg aagccttcat tctggataaa agcatcaaaa 540

agcagcgcaa aaaacgtaat gaacgtctgc gtgaaagtaa aaaacgtctg cagcagttta 600

tcgatatgcg tgatggtaaa cgtgaaattt gcccgaccat taaaggtcag aaagtggatc 660

gttttattca tccgagctgg atcaccaaag ataaaaagct ggaagatttt cgcggttata 720

ccctgagcat tatcaacagc aaaattaaga ttctggatcg caacatcaaa cgcgaagaaa 780

aaagcctgaa agaaaaaggc cagatcatct ttaaagccaa acgtctgatg ctggataaat 840

ccattcgttt tgttggtgat cgcaaagtgc tgtttacaat tagtaaaacc ctgccgaaag 900

agtatgaact ggatctgccg agcaaagaaa aacggctgaa ttggctgaaa gagaagatcg 960

agattatcaa gaaccagaaa ccgaaatatg cctatctgct gcgcaaaaac attgagagcg 1020

aaaaaaaacc gaactatgag tactatctgc agtacaccct ggaaattaaa ccggaactga 1080

aagatttta tgatggtgcc attggtattg accgtggcat taatcatatt gccgtttgca 1140

cctttattag caacgatggt aaagttaccc ctccgaaatt tttcagcagc ggtgaaattc 1200

tgcgtctgaa aaatctgcag aaagagcgtg atcgctttct gctgcgtaaa cacaacaaaa 1260

atcgcaaaaa aggcaacatg cgcgtgatcg aaaacaaaat caatctgatc ctgcaccgtt 1320

atagcaagca gattgttgat atggccaaaa agctgaatgc cagcattgtt tttgaagaac 1380

tgggtcgtat tggtaaaagc cgcaccaaaa tgaaaaaaag ccagcgttat aaactgagcc 1440

tgttcatctt caagaaactg agcgatctgg ttgattacaa aagccgtcgt gaaggtattc 1500

gtgttaccta tgttccgcct gaatatacca gcaaagaatg tagccattgc ggtgaaaaag 1560

ttaataccca gcgtccgttt aatggcaact atagcctgtt taaatgcaac aaatgtggca 1620

tccagctgaa cagcgattat aatgcaagca tcaacattgc gaaaaagggc ctgaaaattc 1680

cgaatagcac ctaataatgt tggttaagcc acaatatgga atattgttct tatggacagt 1740

attgacttaa attaataatc ttcgaaggct atatgcggaa gatttggcgt tgttgtaacg 1800

caataagggg taaccctgaa aaggtttgaa atcatataaa cctagtttta tttgagttta 1860

ggctcagata aaatgaacag accaatcttt aattccgttc tgatttaaaa aatcagaatc 1920

tctttataaa tagtattaca aaaagtgtac attccaaaat ccgaaagcag aattgacctt 1980

tttaagccta aaaaagccaa atttcaaggc tctttcatac tcagaacaaa gggattaagg 2040

aatgcaacta ccttacaccg cttgcgaaag ttgtcagaag ataatctttc atactcagaa 2100

caaagggatt aaggaatgca actatcttat ccatttcttg acatcaaatt ttcttgcagc 2160

atctgaattg cttaattgct ttccttgctt cagcaggaaa tagccaagat tttccagttc 2220

tgctggcgtt attgcaagca cggggatttt gtgcttgctg tagattttgt tcttcaggac 2280

cttctttttc catgctagag tcacactggc tcaccttcgg gtgggccttt ctgcgtttat 2340

acctagggat atattccgct tcctcgctca ctgactcgct acgctcggtc gttcgactgc 2400

ggcgagcgga aatggcttac gaacggggcg gagatttcct ggaagatgcc aggaagatac 2460

ttaacaggga agtgagaggg ccgcggcaaa gccgtttttc cataggctcc gccccctga 2520

caagcatcac gaaatctgac gctcaaatca gtggtggcga aacccgacag gactataaag 2580

ataccaggcg tttccccctg gcggctccct cgtgcgctct cctgttcctg cctttcggtt 2640

taccggtgtc attccgctgt tatggccgcg tttgtctcat tccacgcctg acactcagtt 2700

ccgggtaggc agttcgctcc aagctggact gtatgcacga acccccccgtt cagtccgacc 2760

gctgcgcctt atccggtaac tatcgtcttg agtccaaccc ggaaagacat gcaaaagcac 2820

cactggcagc agccactggt aattgattta gaggagttag tcttgaagtc atgcgccggt 2880

taaggctaaa ctgaaaggac aagttttggt gactgcgctc ctccaagcca gttacctcgg 2940

ttcaaagagt tggtagctca gagaaccttc gaaaaaccgc cctgcaaggc ggtttttttcg 3000

ttttcagagc aagagattac gcgcagacca aaacgatctc aagaagatca tcttattaat 3060

cagataaaat atttctagat ttcagtgcaa tttatctctt caaatgtagc acctgaagtc 3120

agccccatac gatataagtt gttactagtg cttggattct caccaataaa aaacgcccgg 3180

cggcaaccga gcgttctgaa caaatccaga tggagttctg aggtcattac tggatctatc 3240

aacaggagtc caagcgagct cgatatcaaa ttacgccccg ccctgccact catcgcagta 3300

ctgttgtaat tcattaagca ttctgccgac atggaagcca tcacaaacgg catgatgaac 3360

ctgaatcgcc agcggcatca gcaccttgtc gccttgcgta taatatttgc ccatggtgaa 3420

aacgggggcg aagaagttgt ccatattggc cacgtttaaa tcaaaactgg tgaaactcac 3480

ccagggattg gctgagacga aaaacatatt ctcaataaac cctttaggga aataggccag 3540

gttttcaccg taacacgcca catcttgcga atatatgtgt agaaactgcc ggaaatcgtc 3600

gtggtattca ctccagagcg atgaaaacgt ttcagtttgc tcatggaaaa cggtgtaaca 3660

agggtgaaca ctatcccata tcaccagctc accgtctttc attgccatac gaaattccgg 3720

atgagcattc atcaggcggg caagaatgtg aataaaggcc ggataaaact tgtgcttatt 3780

tttctttacg gtctttaaaa aggccgtaat atccagctga acggtctggt tataggtaca 3840

ttgagcaact gactgaaatg cctcaaaatg ttctttacga tgccattggg atatatcaac 3900

ggtggtatat ccagtgattt ttttctccat tttagcttcc ttagctcctg aaaatctcga 3960

taactcaaaa aatacgcccg gtagtgatct tatttcatta tggtgaaagt tggaacctct 4020

tacgtgccga tcaacgtctc attttcgcca gatatcgacg tcttaagacc cactttcaca 4080

tttaagttgt ttttctaatc cgcatatgat caattcaagg ccgaataaga aggctggctc 4140

tgcaccttgg tgatcaaata attcgatagc ttgtcgtaat aatggcggca tactatcagt 4200

agtaggtgtt tccctttctt ctttagcgac ttgatgctct tgatcttcca atacgcaacc 4260

taaagtaaaa tgccccacag cgctgagtgc atataatgca ttctctagtg aaaaaccttg 4320

ttggcataaa aaggctaatt gattttcgag agtttcatac tgtttttctg taggccgtgt 4380

acctaaatgt acttttgctc catcgcgatg acttagtaaa gcacatctaa aacttttagc 4440

gttattacgt aaaaaatctt gccagctttc cccttctaaa gggcaaaagt gagtatggtg 4500

cctatctaac atctcaatgg ctaaggcgtc gagcaaagcc cgcttatttt ttacatgcca 4560

atacaatgta ggctgctcta cacctagctt ctgggcgagt ttacgggttg ttaaaccttc 4620

gattccgacc tcattaagca gctctaatgc gctgttaatc actttacttt tatctaatct 4680

agacatcatt aattcctaat ttttgttgac actct 4715

<210> 365
<211> 4670
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 365
taattcctaa tttttgttga cactctatcg ttgatagagt tattttacca ctccctatca 60

gtgatagaga aaagaattca aaagatctaa agaggagaaa ggatctatga aatctcacca 120

tcaccatcac catgaaaacc tgtacttcca atccaatatt ggaagtggaa tggccaaaaa 180

caccattacc aaaacactga aactgcgtat tgtgcgtccg tataatagcg cagaagtgga 240

aaaaattgtt gccgacgaaa aaaacaaccg cgaaaaaatc gcactggaaa agaacaaaga 300

caaagtgaaa gaagcctgca gcaaacatct gaaagttgca gcatattgta ccacacaggt 360

tgaacgtaat gcatgcctgt tttgtaaagc acgtaaactg gatgacaaat tctaccaaaa 420

actgcgtggt cagtttccgg atgcagtttt ttggcaagaa atcagcgaaa tttttcgcca 480

gctgcagaaa caggcagcag aaatctataa tcagagcctg atcgaactgt actacgagat 540

ttttatcaaa ggcaaaggta ttgcaaatgc cagcagcgtt gaacattatc tgagtgatgt 600

ttgttatacc cgtgcagcag aactgtttaa aaacgcagca attgcaagcg gtctgcgtag 660

caaaatcaaa agcaattttc gtctgaaaga actgaaaaac atgaaaagtg gtctgccgac 720

caccaaaagc gataattttc cgattccgct ggttaaacag aaaggtggtc agtataccgg 780

ttttgaaatt agcaatcata atagcgactt catcatcaag attccgtttg gtcgttggca 840

ggtcaaaaaa gagattgata aatatcgtcc gtgggagaaa tttgactttg aacaggttca 900

gaaaagcccg aaaccgatta gcctgctgct gagcacccag cgtcgtaaac gtaataaagg 960

ttggagcaaa gatgaaggca ccgaagccga aatcaaaaaa gttatgaatg gcgattatca 1020

gaccagctac attgaagtta aacgtggcag caaaatcggt gaaaaaagcg catggatgct 1080

gaatctgagc attgatgttc cgaaaattga taaaggtgtg gatccgagca ttattggtgg 1140

tattgatgtt ggtgttaaat caccgctggt ttgcgcaatt aacaatgcat ttagccgtta 1200

tagcatcagc gataacgacc tgtttcactt caacaagaaa atgtttgcac gtcgtcgtat 1260

cctgctgaaa aaaaaccgtc ataaacgtgc aggtcatggt gcaaaaaaca aactgaaacc 1320

gatcaccatt ctgaccgaaa aaagtgaacg ttttcgcaaa aagctgattg aacgttgggc 1380

atgtgaaatc gcggatttct tcattaaaaa caaagttggc accgtgcaga tggaaaatct 1440

ggaaagcatg aaacgtaaag aggacagcta ttttaacatt cgcctgcgtg gcttttggcc 1500

gtatgcagaa atgcagaaca aaatcgaatt caaactgaag cagtatggca tcgaaattcg 1560

taaagttgca ccgaataata ccagcaaaac ctgtagcaaa tgtggccatc tgaacaacta 1620

tttcaacttc gagtaccgca agaaaaacaa attcccgcac tttaaatgcg aaaaatgcaa 1680

cttcaaagaa aacgccgatt ataatgcagc cctgaatatt tcaaacccga aactgaaaag 1740

caccaaagag gaaccgtaaa tatttatact ttattatcct tcattgacaa aaatgagaat 1800

gttatcccag ataacatttg atgtacacag attcacactt cactgataaa gtggagaacc 1860

gcttcaccaa aagctgtccc ttaggggatt agaacttgag tgaaggtggg ctgcttgcat 1920

cagcctaatg tcgagaagtg ctttcttcgg aaagtaaccc tcgaaacaaa ttcatttttc 1980

ctctccaatt ctgcacaaaa aaaggtgagt ccttataaac cggcgtgcag aacgccggct 2040

caccttttt cttcattcga ttttatgctt aaaagccgta aaaacgcgga attcggcgcc 2100

gttgcagaac ccgaatagac gaatgaagga atgcaactac cttacaccgc ttgcgaaagt 2160

tgtcagaaga taatcttgca gaacccgaat agacgaatga aggaatgcaa tcttgacaga 2220

gcccgattgc gttatctcca ggagaaacat ataaaagcat caaccgctga tcggactaga 2280

gtcacactgg ctcaccttcg ggtgggcctt tctgcgttta tacctaggga tatattccgc 2340

ttcctcgctc actgactcgc tacgctcggt cgttcgactg cggcgagcgg aaatggctta 2400

cgaacggggc ggagatttcc tggaagatgc caggaagata cttaacaggg aagtgagagg 2460

gccgcggcaa agccgttttt ccataggctc cgccccctg acaagcatca cgaaatctga 2520

cgctcaaatc agtggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 2580

ggcggctccc tcgtgcgctc tcctgttcct gcctttcggt ttaccggtgt cattccgctg 2640

ttatggccgc gtttgtctca ttccacgcct gacactcagt tccgggtagg cagttcgctc 2700

caagctggac tgtatgcacg aaccccccgt tcagtccgac cgctgcgcct tatccggtaa 2760

ctatcgtctt gagtccaacc cggaaagaca tgcaaaagca ccactggcag cagccactgg 2820

taattgattt agaggagtta gtcttgaagt catgcgccgg ttaaggctaa actgaaagga 2880

caagttttgg tgactgcgct cctccaagcc agttacctcg gttcaaagag ttggtagctc 2940

agagaacctt cgaaaaaccg ccctgcaagg cggtttttc gttttcagag caagagatta 3000

cgcgcagacc aaaacgatct caagaagatc atcttattaa tcagataaaa tatttctaga 3060

tttcagtgca atttatctct tcaaatgtag cacctgaagt cagccccata cgatataagt 3120

tgttactagt gcttggattc tcaccaataa aaaacgcccg gcggcaaccg agcgttctga 3180

acaaatccag atggagttct gaggtcatta ctggatctat caacaggagt ccaagcgagc 3240

tcgatatcaa attacgcccc gccctgccac tcatcgcagt actgttgtaa ttcattaagc 3300

attctgccga catggaagcc atcacaaacg gcatgatgaa cctgaatcgc cagcggcatc 3360

agcaccttgt cgccttgcgt ataatatttg cccatggtga aaacgggggc gaagaagttg 3420

tccatattgg ccacgtttaa atcaaaactg gtgaaactca cccagggatt ggctgagacg 3480

aaaaacatat tctcaataaa ccctttaggg aaataggcca ggttttcacc gtaacacgcc 3540

acatcttgcg aatatatgtg tagaaactgc cggaaatcgt cgtggtattc actccagagc 3600

gatgaaaacg tttcagtttg ctcatggaaa acggtgtaac aagggtgaac actatcccat 3660

atcaccagct caccgtcttt cattgccata cgaaattccg gatgagcatt catcaggcgg 3720

gcaagaatgt gaataaaggc cggataaaac ttgtgcttat ttttctttac ggtctttaaa 3780

aaggccgtaa tatccagctg aacggtctgg ttataggtac attgagcaac tgactgaaat 3840

gcctcaaaat gttctttacg atgccattgg gatatatcaa cggtggtata tccagtgatt 3900

tttttctcca ttttagcttc cttagctcct gaaaatctcg ataactcaaa aaatacgccc 3960

ggtagtgatc ttatttcatt atggtgaaag ttggaacctc ttacgtgccg atcaacgtct 4020

cattttcgcc agatatcgac gtcttaagac ccactttcac atttaagttg tttttctaat 4080

ccgcatatga tcaattcaag gccgaataag aaggctggct ctgcaccttg gtgatcaaat 4140

aattcgatag cttgtcgtaa taatggcggc atactatcag tagtaggtgt ttccctttct 4200

tctttagcga cttgatgctc ttgatcttcc aatacgcaac ctaaagtaaa atgccccaca 4260

gcgctgagtg catataatgc attctctagt gaaaaacctt gttggcataa aaaggctaat 4320

tgattttcga gagtttcata ctgtttttct gtaggccgtg tacctaaatg tacttttgat 4380

ccatcgcgat gacttagtaa agcacatcta aaacttttag cgttattacg taaaaaatct 4440

tgccagcttt ccccttctaa agggcaaaag tgagtatggt gcctatctaa catctcaatg 4500

gctaaggcgt cgagcaaagc ccgcttattt tttacatgcc aatacaatgt aggctgctct 4560

acacctagct tctgggcgag tttacgggtt gttaaacctt cgattccgac ctcattaagc 4620

agctctaatg cgctgttaat cactttactt ttatctaatc tagacatcat 4670

<210> 366

<211> 4607
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 366
ttacttttat ctaatctaga catcattaat tcctaatttt tgttgacact ctatcgttga 60

tagagttatt ttaccactcc ctatcagtga tagagaaaag aattcaaaag atctaaagag 120

gagaaaggat ctatggccaa aaacaccatt accaaaacac tgaaactgcg tattgtgcgt 180

ccgtataata gcgcagaagt ggaaaaaatt gttgccgacg aaaaaaacaa ccgcgaaaaa 240

atcgcactgg aaaagaacaa agacaaagtg aaagaagcct gcagcaaaca tctgaaagtt 300

gcagcatatt gtaccacaca ggttgaacgt aatgcatgcc tgttttgtaa agcacgtaaa 360

ctggatgaca aattctacca aaaactgcgt ggtcagtttc cggatgcagt tttttggcaa 420

gaaatcagcg aaatttttcg ccagctgcag aaacaggcag cagaaatcta taatcagagc 480

ctgatcgaac tgtactacga gatttttatc aaaggcaaag gtattgcaaa tgccagcagc 540

gttgaacatt atctgagtga tgtttgttat acccgtgcag cagaactgtt taaaaacgca 600

gcaattgcaa gcggtctgcg tagcaaaatc aaaagcaatt ttcgtctgaa agaactgaaa 660

aacatgaaaa gtggtctgcc gaccaccaaa agcgataatt ttccgattcc gctggttaaa 720

cagaaaggtg gtcagtatac cggttttgaa attagcaatc ataatagcga cttcatcatc 780

aagattccgt ttggtcgttg gcaggtcaaa aaagagattg ataaatatcg tccgtgggag 840

aaatttgact ttgaacaggt tcagaaaagc ccgaaaccga ttagcctgct gctgagcacc 900

cagcgtcgta aacgtaataa aggttggagc aaagatgaag gcaccgaagc cgaaatcaaa 960

aaagttatga atggcgatta tcagaccagc tacattgaag ttaaacgtgg cagcaaaatc 1020

ggtgaaaaaa gcgcatggat gctgaatctg agcattgatg ttccgaaaat tgataaaggt 1080

gtggatccga gcattattgg tggtattgat gttggtgtta aatcaccgct ggtttgcgca 1140

attaacaatg catttagccg ttatagcatc agcgataacg acctgtttca cttcaacaag 1200

aaaatgtttg cacgtcgtcg tatcctgctg aaaaaaaacc gtcataaacg tgcaggtcat 1260

ggtgcaaaaa acaaactgaa accgatcacc attctgaccg aaaaaagtga acgttttcgc 1320

aaaaagctga ttgaacgttg ggcatgtgaa atcgcggatt tcttcattaa aaacaaagtt 1380

ggcaccgtgc agatggaaaa tctggaaagc atgaaacgta aagaggacag ctattttaac 1440

attcgcctgc gtggcttttg gccgtatgca gaaatgcaga acaaaatcga attcaaactg 1500

aagcagtatg gcatcgaaat tcgtaaagtt gcaccgaata ataccagcaa aacctgtagc 1560

aaatgtggcc atctgaacaa ctatttcaac ttcgagtacc gcaagaaaaa caaattcccg 1620

cactttaaat gcgaaaaatg caacttcaaa gaaaacgccg attataatgc agccctgaat 1680

atttcaaacc cgaaactgaa aagcaccaaa gaggaaccgt aaatatttat actttattat 1740

ccttcattga caaaaatgag aatgttatcc cagataacat ttgatgtaca cagattcaca 1800

cttcactgat aaagtggaga accgcttcac caaaagctgt cccttagggg attagaactt 1860

gagtgaaggt gggctgcttg catcagccta atgtcgagaa gtgctttctt cggaaagtaa 1920

ccctcgaaac aaattcattt ttcctctcca attctgcaca aaaaaaggtg agtccttata 1980

aaccggcgtg cagaacgccg gctcaccttt tttcttcatt cgattttatg cttaaaagcc 2040

gtaaaaacgc ggaattcggc gccgttgcag aacccgaata gacgaatgaa ggaatgcaac 2100

taccttacac cgcttgcgaa agttgtcaga agataatctt gcagaacccg aatagacgaa 2160

tgaaggaatg caatcttgac agagcccgat tgcgttatct ccaggagaaa catataaaag 2220

catcaaccgc tgatcggact agagtcacac tggctcacct tcgggtgggc ctttctgcgt 2280

ttatacctag ggatatattc cgcttcctcg ctcactgact cgctacgctc ggtcgttcga 2340

ctgcggcgag cggaaatggc ttacgaacgg ggcggagatt tcctggaaga tgccaggaag 2400

atacttaaca gggaagtgag agggccgcgg caaagccgtt tttccatagg ctccgccccc 2460

ctgacaagca tcacgaaatc tgacgctcaa atcagtggtg gcgaaacccg acaggactat 2520

aaagatacca ggcgtttccc cctggcggct ccctcgtgcg ctctcctgtt cctgcctttc 2580

ggtttaccgg tgtcattccg ctgttatggc cgcgtttgtc tcattccacg cctgacactc 2640

agttccgggt aggcagttcg ctccaagctg gactgtatgc acgaaccccc cgttcagtcc 2700

gaccgctgcg ccttatccgg taactatcgt cttgagtcca acccggaaag acatgcaaaa 2760

gcaccactgg cagcagccac tggtaattga tttagaggag ttagtcttga agtcatgcgc 2820

cggttaaggc taaactgaaa ggacaagttt tggtgactgc gctcctccaa gccagttacc 2880

tcggttcaaa gagttggtag ctcagagaac cttcgaaaaa ccgccctgca aggcggtttt 2940

ttcgttttca gagcaagaga ttacgcgcag accaaaacga tctcaagaag atcatcttat 3000

taatcagata aaatatttct agatttcagt gcaatttatc tcttcaaatg tagcacctga 3060

agtcagcccc atacgatata agttgttact agtgcttgga ttctcaccaa taaaaaacgc 3120

ccggcggcaa ccgagcgttc tgaacaaatc cagatggagt tctgaggtca ttactggatc 3180

tatcaacagg agtccaagcg agctcgatat caaattacgc cccgccctgc cactcatcgc 3240

agtactgttg taattcatta agcattctgc cgacatggaa gccatcacaa acggcatgat 3300

gaacctgaat cgccagcggc atcagcacct tgtcgccttg cgtataatat ttgcccatgg 3360

tgaaaacggg ggcgaagaag ttgtccatat tggccacgtt taaatcaaaa ctggtgaaac 3420

tcacccaggg attggctgag acgaaaaaca tattctcaat aaacccttta gggaaatagg 3480

ccaggttttc accgtaacac gccacatctt gcgaatatat gtgtagaaac tgccggaaat 3540

cgtcgtggta ttcactccag agcgatgaaa acgtttcagt ttgctcatgg aaaacggtgt 3600

aacaagggtg aacactatcc catatcacca gctcaccgtc tttcattgcc atacgaaatt 3660

ccggatgagc attcatcagg cgggcaagaa tgtgaataaa ggccggataa aacttgtgct 3720

tatttttctt tacggtcttt aaaaaggccg taatatccag ctgaacggtc tggttatagg 3780

tacattgagc aactgactga aatgcctcaa aatgttcttt acgatgccat tgggatatat 3840

caacggtggt atatccagtg atttttttct ccattttagc ttccttagct cctgaaaatc 3900

tcgataactc aaaaaatacg cccggtagtg atcttatttc attatggtga aagttggaac 3960

ctcttacgtg ccgatcaacg tctcattttc gccagatatc gacgtcttaa gacccacttt 4020

cacatttaag ttgtttttct aatccgcata tgatcaattc aaggccgaat aagaaggctg 4080

gctctgcacc ttggtgatca aataattcga tagcttgtcg taataatggc ggcatactat 4140

cagtagtagg tgtttccctt tcttctttag cgacttgatg ctcttgatct tccaatacgc 4200

aacctaaagt aaaatgcccc acagcgctga gtgcatataa tgcattctct agtgaaaaac 4260

cttgttggca taaaaaggct aattgatttt cgagagtttc atactgtttt tctgtaggcc 4320

gtgtacctaa atgtactttt gctccatcgc gatgacttag taaagcacat ctaaaacttt 4380

tagcgttatt acgtaaaaaa tcttgccagc tttccccttc taaagggcaa aagtgagtat 4440

ggtgcctatc taacatctca atggctaagg cgtcgagcaa agcccgctta ttttttacat 4500

gccaatacaa tgtaggctgc tctacaccta gcttctgggc gagtttacgg gttgttaaac 4560

cttcgattcc gacctcatta agcagctcta atgcgctgtt aatcact 4607

<210> 367
<211> 7556
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 367
acccacgccg aaacaagcgc tcatgagccc gaagtggcga gcccgatctt ccccatcggt 60

gatgtcggcg atataggcgc cagcaaccgc acctgtggcg ccggtgatgc cggccacgat 120

gcgtccggcg tagaggatcg agatctcgat cccgcgaaat taatacgact cactataggg 180

agaccacaac ggtttccctc tagtgccggc tccggagagc tctttaatta agcggccgcc 240

ctgcaggact cgagttctag aaataatttt gtttaacttt aagaaggaga tatacatatg 300

aaatcttctc accatcacca tcaccatcac catcaccatg gttcttctat gaaaatcgaa 360

gaaggtaaac tggtaatctg gattaacggc gataaaggct ataacggtct cgctgaagtc 420

ggtaagaaat tcgagaaaga taccggaatt aaagtcaccg ttgagcatcc ggataaactg 480

gaagagaaat tcccacaggt tgcggcaact ggcgatggcc ctgacattat cttctgggca 540

cacgaccgct ttggtggcta cgctcaatct ggcctgttgg ctgaaatcac cccggacaaa 600

gcgttccagg acaagctgta tccgtttacc tgggatgccg tacgttacaa cggcaagctg 660

attgcttacc cgatcgctgt tgaagcgtta tcgctgattt ataacaaaga tctgctgccg 720

aacccgccaa aaacctggga agagatcccg gcgctggata aagaactgaa agcgaaaggt 780

aagagcgcgc tgatgttcaa cctgcaagaa ccgtacttca cctggccgct gattgctgct 840

gacgggggtt atgcgttcaa gtatgaaaac ggcaagtacg acattaaaga cgtgggcgtg 900

gataacgctg gcgcgaaagc gggtctgacc ttcctggttg acctgattaa aaacaaacac 960

atgaatgcag acaccgatta ctccatcgca gaagctgcct ttaataaagg cgaaacagcg 1020

atgaccatca acggcccgtg ggcatggtcc aacatcgaca ccagcaaagt gaattatggt 1080

gtaacggtac tgccgacctt caagggtcaa ccatccaaac cgttcgttgg cgtgctgagc 1140

gcaggtatta acgccgccag tccgaacaaa gagctggcaa aagagttcct cgaaaactat 1200

ctgctgactg atgaaggtct ggaagcggtt aataaagaca aaccgctggg tgccgtagcg 1260

ctgaagtctt acgaggaaga gttggcgaaa gatccacgta ttgccgccac tatggaaaac 1320

gcccagaaag gtgaaatcat gccgaacatc ccgcagatgt ccgctttctg gtatgccgtg 1380

cgtactgcgg tgatcaacgc cgccagcggt cgtcagactg tcgatgaagc cctgaaagac 1440

gcgcagacta attcgagctc gaacaacaac aacaataaca ataacaacaa cctcgggatc 1500

gaggaaaacc tgtacttcca atccaatgca atggccaaaa acaccattac caaaacactg 1560

aaactgcgta ttgtgcgtcc gtataatagc gcagaagtgg aaaaaattgt tgccgacgaa 1620

aaaaacaacc gcgaaaaaat cgcactggaa aagaacaaag acaaagtgaa agaagcctgc 1680

agcaaacatc tgaaagttgc agcatattgt accacacagg ttgaacgtaa tgcatgcctg 1740

ttttgtaaag cacgtaaact ggatgacaaa ttctaccaaa aactgcgtgg tcagtttccg 1800

gatgcagttt tttggcaaga aatcagcgaa atttttcgcc agctgcagaa acaggcagca 1860

gaaatctata atcagagcct gatcgaactg tactacgaga tttttatcaa aggcaaaggt 1920

attgcaaatg ccagcagcgt tgaacattat ctgagtgatg tttgttatac ccgtgcagca 1980

gaactgttta aaaacgcagc aattgcaagc ggtctgcgta gcaaaatcaa aagcaatttt 2040

cgtctgaaag aactgaaaaa catgaaaagt ggtctgccga ccaccaaaag cgataatttt 2100

ccgattccgc tggttaaaca gaaaggtggt cagtataccg gttttgaaat tagcaatcat 2160

aatagcgact tcatcatcaa gattccgttt ggtcgttggc aggtcaaaaa agagattgat 2220

aaatatcgtc cgtgggagaa atttgacttt gaacaggttc agaaaagccc gaaaccgatt 2280

agcctgctgc tgagcaccca gcgtcgtaaa cgtaataaag gttggagcaa agatgaaggc 2340

accgaagccg aaatcaaaaa agttatgaat ggcgattatc agaccagcta cattgaagtt 2400

aaacgtggca gcaaaatctg tgaaaaaagc gcatggatgc tgaatctgag cattgatgtt 2460

ccgaaaattg ataaaggtgt ggatccgagc attattggtg gtattgatgt tggtgttaaa 2520

tcaccgctgg tttgcgcaat taacaatgca tttagccgtt atagcatcag cgataacgac 2580

ctgtttcact tcaacaagaa aatgtttgca cgtcgtcgta tcctgctgaa aaaaaaccgt 2640

cataaacgtg caggtcatgg tgcaaaaaac aaactgaaac cgatcaccat tctgaccgaa 2700

aaaagtgaac gttttcgcaa aaagctgatt gaacgttggg catgtgaaat cgcggatttc 2760

ttcattaaaa acaaagttgg caccgtgcag atggaaaatc tggaaagcat gaaacgtaaa 2820

gaggacagct attttaacat tcgcctgcgt ggcttttggc cgtatgcaga aatgcagaac 2880

aaaatcgaat tcaaactgaa gcagtatggc atcgaaattc gtaaagttgc accgaataat 2940

accagcaaaa cctgtagcaa atgtggccat ctgaacaact atttcaactt cgagtaccgc 3000

aagaaaaaca aattcccgca ctttaaatgc gaaaaatgca acttcaaaga aaacgccgat 3060

tataatgcag ccctgaatat ttcaaacccg aaactgaaaa gcaccaaaga ggaaccgtaa 3120

taacattgga agtggataac ggatccgcga tcgcggcgcg ccacctggtg gccggccggt 3180

accacgcgtg cgcgctgatc cggctgctaa caaagcccga aaggaagctg agttggctgc 3240

tgccaccgct gagcaataac tagcataacc ccttggggcc tctaaacggg tcttgagggg 3300

ttttttgctg aaaggaggaa ctatatccgg atatccacag gacgggtgtg gtcgccatga 3360

tcgcgtagtc gatagtggct ccaagtagcg aagcgagcag gactgggcgg cggccaaagc 3420

ggtcggacag tgctccgaga acgggtgcgc atagaaattg catcaacgca tatagcgcta 3480

gcagcacgcc atagtgactg gcgatgctgt cggaatggac gatatcccgc aagaggcccg 3540

gcagtaccgg cataaccaag cctatgccta cagcatccag ggtgacggtg ccgaggatga 3600

cgatgagcgc attgttagat ttcatacacg gtgcctgact gcgttagcaa tttaactgtg 3660

ataaactacc gcattaaagc ttatcgatga taagctgtca aacatgagaa ttcttgaaga 3720

cgaaagggcc tcgtgatacg cctattttta taggttaatg tcatgataat aatggtttct 3780

tagacgtcag gtggcacttt tcggggaaat gtgcgcggaa cccctatttg tttatttttc 3840

taaatacatt caaatatgta tccgctcatg agacaataac cctgataaat gcttcaataa 3900

cattgaaaaa ggaagagtat gagtattcaa catttccgtg tcgcccttat tccctttttt 3960

gcggcatttt gccttcctgt ttttgctcac ccagaaacgc tggtgaaagt aaaagatgct 4020

gaagatcagt tgggtgcacg agtgggttac atcgaactgg atctcaacag cggtaagatc 4080

cttgagagtt ttcgccccga agaacgtttt ccaatgatga gcacttttaa agttctgcta 4140

tgtggcgcgg tattatcccg tgttgacgcc gggcaagagc aactcggtcg ccgcatacac 4200

tattctcaga atgacttggt tgagtactca ccagtcacag aaaagcatct tacggatggc 4260

atgacagtaa gagaattatg cagtgctgcc ataaccatga gtgataacac tgcggccaac 4320

ttacttctga caacgatcgg aggaccgaag gagctaaccg ctttttgca caacatgggg 4380

gatcatgtaa ctcgccttga tcgttgggaa ccggagctga atgaagccat accaaacgac 4440

gagcgtgaca ccacgatgcc tgcagcaatg gcaacaacgt tgcgcaaact attaactggc 4500

gaactactta ctctagcttc ccggcaacaa ttaatagact ggatggaggc ggataaagtt 4560

gcaggaccac ttctgcgctc ggcccttccg gctggctggt ttattgctga taaatctgga 4620

gccggtgagc gtgggtctcg cggtatcatt gcagcactgg ggccagatgg taagccctcc 4680

cgtatcgtag ttatctacac gacggggagt caggcaacta tggatgaacg aaatagacag 4740

atcgctgaga taggtgcctc actgattaag cattggtaac tgtcagacca agtttactca 4800

tatatacttt agattgattt aaaacttcat ttttaattta aaaggatcta ggtgaagatc 4860

ctttttgata atctcatgac caaaatccct taacgtgagt tttcgttcca ctgagcgtca 4920

gaccccgtag aaaagatcaa aggatcttct tgagatcctt tttttctgcg cgtaatctgc 4980

tgcttgcaaa caaaaaaacc accgctacca gcggtggttt gtttgccgga tcaagagcta 5040

ccaactcttt ttccgaaggt aactggcttc agcagagcgc agataccaaa tactgtcctt 5100

ctagtgtagc cgtagttagg ccaccacttc aagaactctg tagcaccgcc tacatacctc 5160

gctctgctaa tcctgttacc agtggctgct gccagtggcg ataagtcgtg tcttaccggg 5220

ttggactcaa gacgatagtt accggataag gcgcagcggt cgggctgaac gggggttcg 5280

tgcacacagc ccagcttgga gcgaacgacc tacaccgaac tgagatacct acagcgtgag 5340

ctatgagaaa gcgccacgct tcccgaaggg agaaaggcgg acaggtatcc ggtaagcggc 5400

agggtcggaa caggagagcg cacgagggag cttccagggg gaaacgcctg gtatctttat 5460

agtcctgtcg ggtttcgcca cctctgactt gagcgtcgat ttttgtgatg ctcgtcaggg 5520

gggcggagcc tatggaaaaa cgccagcaac gcggcctttt tacggttcct ggccttttgc 5580

tggccttttg ctcacatgtt ctttcctgcg ttatcccctg attctgtgga taaccgtatt 5640

accgcctttg agtgagctga taccgctcgc cgcagccgaa cgaccgagcg cagcgagtca 5700

gtgagcgagg aagcggaaga gcgcctgatg cggtattttc tccttacgca tctgtgcggt 5760

atttcacacc gcaatggtgc actctcagta caatctgctc tgatgccgca tagttaagcc 5820

agtatacact ccgctatcgc tacgtgactg ggtcatggct gcgccccgac acccgccaac 5880

acccgctgac gcgccctgac gggcttgtct gctcccggca tccgcttaca gacaagctgt 5940

gaccgtctcc gggagctgca tgtgtcagag gttttcaccg tcatcaccga aacgcgcgag 6000

gcagctgcgg taaagctcat cagcgtggtc gtgaagcgat tcacagatgt ctgcctgttc 6060

atccgcgtcc agctcgttga gtttctccag aagcgttaat gtctggcttc tgataaagcg 6120

ggccatgtta agggcggttt tttcctgttt ggtcactgat gcctccgtgt aaggggggatt 6180

tctgttcatg ggggtaatga taccgatgaa acgagagagg atgctcacga tacgggttac 6240

tgatgatgaa catgcccggt tactggaacg ttgtgagggt aaacaactgg cggtatggat 6300

gcggcgggac cagagaaaaa tcactcaggg tcaatgccag cgcttcgtta atacagatgt 6360

aggtgttcca cagggtagcc agcagcatcc tgcgatgcag atccggaaca taatggtgca 6420

gggcgctgac ttccgcgttt ccagacttta cgaaacacgg aaaccgaaga ccattcatgt 6480

tgttgctcag gtcgcagacg ttttgcagca gcagtcgctt cacgttcgct cgcgtatcgg 6540

tgattcattc tgctaaccag taaggcaacc ccgccagcct agccgggtcc tcaacgacag 6600

gagcacgatc atgcgcaccc gtggccagga cccaacgctg cccgagatgc gccgcgtgcg 6660

gctgctggag atggcggacg cgatggatat gttctgccaa gggttggttt gcgcattcac 6720

agttctccgc aagaattgat tggctccaat tcttggagtg gtgaatccgt tagcgaggtg 6780

ccgccggctt ccattcaggt cgaggtggcc cggctccatg caccgcgacg caacgcgggg 6840

aggcagacaa ggtatagggc ggcgcctaca atccatgcca acccgttcca tgtgctcgcc 6900

gaggcggcat aaatcgccgt gacgatcagc ggtccaatga tcgaagttag gctggtaaga 6960

gccgcgagcg atccttgaag ctgtccctga tggtcgtcat ctacctgcct ggacagcatg 7020

gcctgcaacg cgggcatccc gatgccgccg gaagcgagaa gaatcataat ggggaaggcc 7080

atccagcctc gcgtcgcgaa cgccagcaag acgtagccca gcgcgtcggc cgccatgccg 7140

gcgataatgg cctgcttctc gccgaaacgt ttggtggcgg gaccagtgac gaaggcttga 7200

gcgagggcgt gcaagattcc gaataccgca agcgacaggc cgatcatcgt cgcgctccag 7260

cgaaagcggt cctcgccgaa aatgacccag agcgctgccg gcacctgtcc tacgagttgc 7320

atgataaaga agacagtcat aagtgcggcg acgatagtca tgccccgcgc ccaccggaag 7380

gagctgactg ggttgaaggc tctcaagggc atcggtcgac gctctccctt atgcgactcc 7440

tgcattagga agcagcccag tagtaggttg aggccgttga gcaccgccgc cgcaaggaat 7500

ggtgcatgca aggagatggc gcccaacagt cccccggcca cggggcctgc caccat 7556

<210> 368
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 368
ttcatttgag cattaaatgt caagttctgc 30

<210> 369
<211> 30
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 369
ttcatttgag cattaagtgt caagttctgc 30

<210> 370
<211> 21
<212> DNA
<213> Artificial sequence

<220>
<223> Synthetic sequence

<400> 370
aaactcgtaa ttcacagttc a 21

<210> 371
<211> 10
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 371
tatatatata 10

<210> 372
<211> 6
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 372
tatata 6

<210> 373
<211> 5
<212> DNA
<213> Artificial Sequence

<220>
<223> Synthetic sequence

<400> 373
tatat 5